ribavirin has been researched along with Chronic Hepatitis C in 5975 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 113 (1.89) | 18.2507 |
| 2000's | 2339 (39.15) | 29.6817 |
| 2010's | 3306 (55.33) | 24.3611 |
| 2020's | 217 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| Elazar, M; Glenn, JS; Korba, BE; Lui, P; Rossignol, JF | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kim, M; Lee, HW; Li, X; Yang, S; Yoon, YS | 1 |
| Batey, R; Ferencz, S | 1 |
| Ball, L; Brooks, L; Gish, R; Sulkowski, MS; Wasserman, R | 1 |
| Kryczka, W | 1 |
| Jasonek, J; Kacprzak-Bergman, I; Zaleska, I | 1 |
| Ahmed, OA; Dabbous, H; Elsayed, MH; Elserafy, M; Elshafie, A; Ezzat, H; Farid, A; Hassan, M; Hassany, M; Naguib, GG; Safwat, E; Shaker, MK; Shazly, YE; Sherief, AF | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW | 1 |
| Al-Judaibi, B; Carleton, BC; Drögemöller, BI; Ford, JA; Kim, RB; Lee, SS; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJ; Schwarz, UI; Tam, E; Trueman, JN; Wright, GEB; Yoshida, EM | 1 |
| Álvares-DA-Silva, MR; Dihl, RR; Librelotto, CS; Simon, D; Souza, AP | 1 |
| Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G | 1 |
| Chiappini, E; de Martino, M; Galli, L; Motisi, MA; Parigi, S; Tamborino, A | 1 |
| Adianti, M; Aoki-Utsubo, C; Hafid, AF; Hotta, H; Permanasari, AA; Tumewu, L; Wahyuni, TS; Widyawaruyanti, A | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Li, X; Lou, L | 1 |
| Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA | 1 |
| Baré, PC; Cairo, FM; Cocco, PA; Massenzio, NE; Picchio, GR; Villamil, FG | 1 |
| Christensen, PB; Søholm, J; Øvrehus, A | 1 |
| Carrilho, FJ; Cunha-Silva, M; Lima, RGR; Lourenço, MS; Mazo, DF; Oliveira, AIN; Oliveira, CP; Pessoa, MG; Sevá-Pereira, T; Souza, EO; Zitelli, PMY | 1 |
| Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S | 1 |
| Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW | 1 |
| Nguyen, MH; Wong, YJ | 1 |
| Chen, J; Gao, H; Guan, Y; Hua, R; Huang, Y; Jiang, Y; Kong, F; Li, C; Li, G; Ma, H; Mao, X; Meng, C; Niu, J; Tan, Y; Wang, J; Wang, Z; Wen, X; Wu, Q; Xin, Y; Xiong, Q; Xu, B; Zhang, X; Zhang, Y; Zhao, L | 1 |
| Al-Judaibi, B; Carleton, BC; Chang, WC; Crotty, P; Drögemöller, BI; Farivar, JF; Ford, JA; Kim, RB; Lee, SS; Li, KH; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJD; Schwarz, UI; Tam, E; Trueman, JN; Walston, LL; Wright, GEB; Yoshida, EM | 1 |
| Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| AlBayati, SM; Faraj, OA | 1 |
| Boscarino, JA; Daida, YG; Gordon, SC; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Trudeau, S; Zhang, J | 1 |
| Al-Karim, S; Bazarah, S; Hamed, MH; Pushparaj, PN; Qadri, I; Rehman, S | 1 |
| Kao, JH; Liu, CH; Liu, CJ | 1 |
| Christensen, PB; Dröse, S; Hansen, JF; Holm, DK; Madsen, LW; Røge, BT; Øvrehus, A | 1 |
| Ahn, SB; An, J; Jun, DW; Ko, MJ; Lee, J; Park, DA; Yim, SY; Yoo, JJ | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Al-Dhamin, Z; An, J; Cui, L; Han, T; Hou, Y; Li, L; Li, W; Liang, J; Liu, L; Nan, Y; Xue, N; Zhang, L; Zhao, W | 1 |
| A Wahsh, E; Ahmed, M; Ahmed, S; Elsayed, A; Esamat, G; Gomaa, A; Hassan, E; Ramadan, A | 1 |
| Guo, M; Ke, L; Liu, J; You, R | 1 |
| Azzari, C; Bartolini, E; Indolfi, G; Moriondo, M; Resti, M; Ricci, S; Rubino, C; Stinco, M; Trapani, S; Veronese, P | 1 |
| Ebell, M; Elshafie, S; Trivedi-Kapoor, R | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Lu, CL; Wang, YK; Wang, YW | 1 |
| Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A | 1 |
| Belyavtsev, AN; Dedova, AV; Kuprianov, VV; Nikolaeva, LI; Samokhvalov, EI; Sapronov, GV; Shastina, NS; Shevchenko, NG; Stuchinskaya, MD | 1 |
| Akbulut, A; Akıncı, E; Bal, T; Barut, Ş; Batırel, A; Baykam, N; Çabalak, M; Can, G; Çelebi, G; Çuvalcı Öztoprak, N; Duygu, F; Erben, N; Esen Yıldız, İ; Esen, Ş; Gül, HC; Günal, Ö; Gündüz, A; Güner, R; Hızel, K; İnan, D; İnce, N; Karaali, R; Karabay, O; Karsen, H; Kaya, S; Köksal, İ; Kömür, S; Köse, Ş; Kumbasar Karaosmanoğlu, H; Kurtaran, B; Namıduru, M; Önlen, Y; Sarı, ND; Sarıgül Yıldırım, F; Şenateş, E; Şener, A; Sırmatel, F; Sünnetçioğlu, M; Tabak, F; Tosun, S; Türker, K; User, Ü; Yamazhan, T; Yörük, G; Zerdali, E | 1 |
| Joshita, S; Okumura, T; Ota, M; Sugiura, A; Umemura, T | 1 |
| Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE | 1 |
| Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D | 1 |
| Bergersen, BM; Dalgard, O; Finbråten, AK; Hagen, K; Lagging, M; Leiva, RA; Mikkelsen, Y; Roberts, RS; Rosseland, CM; Sandvei, PK; Simonsen, Ø; Singh, R; Young, L | 1 |
| Abdelghafour, R; AbdelRazek, W; Dabees, H; Said, M; Shousha, HI | 1 |
| Biliotti, E; Calvani, R; Capuani, G; Giampaoli, O; Miccheli, A; Sciubba, F; Spagnoli, M; Taliani, G; Tomassini, A | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Chang, CC; Chang, YS; Chen, JH; Chen, SC; Chou, SM; Hsu, HC; Kuo, TT; Lin, TM; Shen, YC; Yeh, HJ | 1 |
| Gapon, MN; Grushko, IP; Romanova, EB; Tverdokhlebova, TI; Vodyanitskaya, SY | 1 |
| Cordie, A; Esmat, G; Kamel, AM; Sabry, N | 1 |
| Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J | 1 |
| Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK | 1 |
| Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS | 1 |
| Poddar, U; Umesh Reddy, DV | 1 |
| Amendola Pires, M; Barbosa, ENP; Brandão Mello, CE; Campos, LB; de Almeida, NAA; de Barros, JJF; de Paula, VS; de Santana, CG; Horta, MAP | 1 |
| Abdel-Rahman, YO; Abdel-Razik, W; Dabbous, HM; Elakel, W; Elmakhzangy, H; Elshafaey, A; Esmat, G; Ismail, SA; Omar, H; Saeed, R; Salama, R; Waked, I; Ziada, DH | 1 |
| Ammar, I; Doss, W; El Raziky, M; El-Sayed, M; Elakel, W; Elsaeed, K; Elserafy, M; Elshazly, Y; Fayad, T; Hassany, M; Korany, M; Mahrous, M; Mehrez, M; Saad, Y; Salama, R; Zaki, A | 1 |
| Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ | 1 |
| Berak, H; Brzdęk, M; Citko, J; Dybowska, D; Flisiak, R; Garlicki, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Lorenc, B; Mazur, W; Parfieniuk-Kowerda, A; Piekarska, A; Tomasiewicz, K; Tronina, O; Zarębska-Michaluk, D | 1 |
| Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H | 1 |
| Cheng, ML; Li, H; Qin, YJ; Zhou, XN | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E | 1 |
| Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N | 1 |
| Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME | 1 |
| Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L | 1 |
| Hussain, N; Iqbal, M; Mahnoor, M; Maqsood, Q; Sumrin, A; Wajid, A; Younas, S | 1 |
| Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ | 1 |
| Dong, G; Jiang, J; Li, J; Li, X; Long, S; Su, M; Wei, Y; Zhou, Y | 1 |
| Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M | 1 |
| Li, H; Liu, Z; Ma, C; Wang, J; Wang, X; Wang, Y; Xu, X | 1 |
| Daryani, N; Imam, U; Mumtaz, F; Parkash, A | 1 |
| Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA | 1 |
| Fried, MW; Hassan, MA; Hinestrosa, F; Jacobson, IM; Kort, JJ; Larsen, L; Lok, AS; Lu, W; Michael, LC; Morelli, G; Nelson, DR; Pearlman, BL; Peter, JA; Reddy, KR; Shiffman, ML; Sulkowski, MS; Vainorius, M; Wang, GP; Willner, I | 1 |
| Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ | 1 |
| Merat, S | 1 |
| Aguiar, BF; Bittar, C; Campos, GRF; Marques, NN; Martinelli, ALC; Molina, BF; Pereira, LRL; Rahal, P; Rodrigues, JPV; Souza, FF | 1 |
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| El-Shabrawi, M; Hassanin, F | 2 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
| Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A | 1 |
| Alvarez, M; Bartlett, S; Binka, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Janjua, NZ; Krajden, M; Pearce, ME; Ramji, A; Rossi, C; Samji, H; Tyndall, M; Wong, J; Wong, S; Yoshida, EM; Yu, A | 1 |
| Amin, J; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Read, P; Shaw, D | 1 |
| Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T | 1 |
| Attia, D; Doss, W; Ebeid, B; El Raziky, M; El Serafy, M; El-Khayat, H; Esmat, G; Fouad, Y; Gomaa, A; Hasseb, A; Kamal, EM; Mahmoud, H; Sameh, Y | 1 |
| Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR | 1 |
| Ahn, SB; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, MY; Kim, SG; Kim, W; Lee, SW; Park, SJ; Shim, JJ; Sohn, JH; Suk, KT | 1 |
| Aguilar, P; Aldámiz-Echevarría, T; Andrade, RJ; Carnicer, F; Carrión, JA; Chimeno-Hernández, S; Delgado, M; Escarda, A; Espinosa, N; Estébanez, Á; Gallego, A; García-Buey, L; Hernández-Guerra, M; Hijona, L; Izquierdo, S; Jou, A; Lorente, S; Magaz, M; Manuel Sousa, J; Manzanares, A; Martín-Granizo, I; Mateos-Muñoz, B; Menéndez, F; Morán-Sánchez, S; Morano, L; Moreno-Planas, JM; Morillas, RM; Polo-Lorduy, B; Pulido, F; Rico, M; Rincón, D; Rodríguez, M; Rubín, Á; Salmerón, J; Sampedro, B; Sánchez Antolín, G; Vergara, M; Von-Wichmann, MÁ; Zozaya, JM | 1 |
| Abd El-Wahab, EW; Helmy, SH; Nagaty, A | 1 |
| Carvalho, L; Daniels, E; Eveson, L; Foxton, M; Nelson, M; Pillai, S; Sellers, P; Whyte, R | 1 |
| Chang, PH; Chen, YT; Chien, CH; Chien, RN; Hu, CC; Hua, MC; Lin, CL; Lin, ST; Weng, CH | 1 |
| Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C | 1 |
| Abdelkawy, KS; Ebaid, NF; El-Haggar, SM; El-Magd, MA; Elbarbry, FA; Ziada, DH | 1 |
| Chaikledkaew, U; Due, OT; Genuino, AJM; Sobhonslidsuk, A; Thakkinstian, A | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Chou, SW; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A | 1 |
| Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T | 1 |
| Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S | 1 |
| Attia, FM; Badr, RE; Hassan, AA; Hassan, AM; Saleh, MH; Soliman, AB | 1 |
| Cui, LY; Liu, LD; Nan, YM; Zhao, W | 1 |
| Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C | 1 |
| Pawlotsky, JM | 10 |
| Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M | 1 |
| Akhan, S; Ergun, NC; Köse, Ş; Onlen, Y; Tatar, B; Turken, M; Yılmaz, Y | 1 |
| Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
| David, J; Delahooke, T; Dustan, S; Iliffe, M; Kurmoo, F; Lai, FY; May, S; Patel, A; Stephenson, I; Tang, JW; Wiselka, M | 1 |
| Cazarim, MS; Chachá, SGF; Martinelli, ALC; Pereira, LRL; Rodrigues, JPV | 1 |
| Aleman, S; Björkström, NK; Carlsson, T; Falconer, K; Gorin, JB; Malone, DFG; Sandberg, JK; Strunz, B | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Abbasy, M; Abdu Allah, AM; Elimam, H; Elnaidany, N; Essa, A; Mohamed Ibraheem, KI; Nada, A; Sabry, A; Shehab-Eldeen, S | 1 |
| Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG | 1 |
| Sirinawasatien, A; Techasirioangkun, T | 1 |
| Aghemo, A; Colapietro, F | 1 |
| Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V | 1 |
| Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S | 1 |
| Alston-Smith, B; Anthony, DD; Balagopal, A; Cohen, DE; Morse, GD; Quinn, J; Santana-Bagur, JL; Smeaton, LM; Sulkowski, MS; Talal, AH; Venuto, CS; Vu, V; Wyles, DL | 1 |
| Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chuang, WL; Dai, CY; Hsu, WF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yu, ML | 1 |
| Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX | 1 |
| Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN | 1 |
| Bartenschlager, R; Boldanova, T; Bracht, T; Broering, R; Brown, RJP; Brüggemann, Y; Engelmann, M; Friesland, M; Heim, MH; Kinast, V; Pietschmann, T; Plociennikowska, A; Sitek, B; Steinmann, E; Todt, D; Vieyres, G; Vondran, FWR; Zhang, Y | 1 |
| Che, D; Lu, Y; Wu, B; Zhou, H | 1 |
| Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM | 1 |
| Abu Raya, M; Baruch, Y; Khoury, J; Klein, A; Saadi, T; Sabo, E; Yaccob, A | 1 |
| Bernhard, B; Stickel, F | 1 |
| Alhaddad, O; Elsabaawy, D; Elsabaawy, M; Elshazly, H; Khalil, F; Rady, M; Sabry, A; Shebl, N; Wahb, A | 1 |
| Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL | 1 |
| Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G | 1 |
| Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M | 1 |
| Day, J; Le, HM; Le, PT; Nghiem, NM; Nguyen, DT; Rahman, M; Tran, TTT; Vo, QM | 1 |
| Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N | 1 |
| Hsu, EK; Jolley, CD; Jonas, MM; Leung, DH; Liu, L; Lobritto, SJ; Molleston, JP; Narkewicz, MR; Rosenthal, P; Wen, J; Yao, BB; Zha, J | 1 |
| Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S | 1 |
| Batista, AD; da Silva Sacerdote, AB; de Barros Barreto, S; Filgueira, NA; Lopes, EP | 2 |
| Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA | 1 |
| Jalota, A; Lerma, EV; Lindner, BK; Thomas, B | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Białkowska-Warzecha, J; Błaszczyk, J; Jabkowski, M; Jędrzejczak-Pospiech, K; Poliwczak, AR; Woźny, J | 1 |
| Ahmed, H; Elsadek, HM; Elsayed, IA; Gendia, MA; Gouda, TM; Lbrahim, NF; Magdy, MM; Sadek, AMEM; Shafeik, H; Shendi, AM; Yousif, MM; Zahran, MH; Zaki, AM | 1 |
| Abdurakhmanov, DT; Burnevich, EZ; Filatova, AL; Karpov, VV; Milovanova, SY; Moiseev, SV; Nikulkina, EN; Rozina, TP; Severov, MV; Tanashuk, EL | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lai, WT; Lee, HC; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S | 1 |
| Nordien, R; Sonderup, MW; Spearman, CW | 1 |
| Attia, A; Baudoin, M; Boyer, S; Kouanfack, C; Lacombe, K; Lemoine, M; Moh, R; Nishimwe, ML; Rouveau, N; Seydi, M; Sylla, B; Woode, ME | 1 |
| Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A | 1 |
| Calise, SJ; Chan, EKL | 1 |
| Fagundes, RN; Ferreira, LEVVC; Pace, FHL | 1 |
| Colak Ergun, N; Kose, S; Tatar, B; Turken, M | 1 |
| Abuelhassan, WB; Ally, R; Gasim, GI; Menezes, C | 1 |
| Cázares-Cortazar, A; Chapararro-Sánchez, A; de la Luz Martínez-Rodríguez, M; Gaytán-Martínez, J; Mata-Marín, JA; Mauss, S; Ocaña-Mondragón, A; Uribe-Noguez, LA; Villavicencio-Ferrel, PE | 1 |
| Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH | 1 |
| Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S; Weiland, O | 1 |
| Bellón, JM; Berenguer, J; Carrero, A; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; Hernández-Quero, J; Hontañón, V; Jiménez-Sousa, MA; Martínez, E; Navarro, J; Pérez-Latorre, L; Quereda, C; Resino, S; Santos, I; Sanz, J; Téllez, MJ; von Wichmann, MA | 1 |
| Anees, M; Doss, W; El Akel, W; Eletreby, R; Esmat, G; Hashem, A; Hassany, M; Helmy, A; Khalaf, N; Kobtan, A; Mansour, S; Naguib, M | 1 |
| Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
| Al-Attiyah, R; Al-Nakib, W; Essa, S; Siddique, I | 1 |
| Gandjour, A | 1 |
| Liu, Y | 1 |
| Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL | 1 |
| Chien, RN; Chuang, WL; Hsu, CW; Hsu, SJ; Huang, YW; Kuo, HT; Lin, HH; Lo, GH; Peng, CY; Qin, A; Su, CW; Su, WW; Tseng, KC; Yang, SS; Yu, ML | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S | 1 |
| Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Al-Tawashi, AS; Alaa, AM; Awwad, MA; El-Derany, MO; Eltobgy, MM; Gharib, MM; Kasem, MH; Mostafa, AM; Moubarak, AS; Omar, HM; Saafan, HA | 1 |
| Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH | 1 |
| Doretto, P; Ermacora, A; Fumagalli, S; Gattei, V; Mauro, E; Mazzaro, C; Toffolutti, F; Tonizzo, M | 1 |
| Bebek-Ivankovic, H; Bevanda, M; Grgic, S; Nikolic, J; Soldo-Coric, L; Susak, B | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ | 1 |
| Farooq, MO; Malik, K; Mengal, FUA; Salim, A | 1 |
| Choi, IS; Kim, KM; Shim, SG | 1 |
| Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T | 1 |
| Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YK; Wang, YW | 1 |
| Kottilil, S; Masur, H; Meissner, EG; Orr, C; Xu, W | 1 |
| Balázs, I; Feldbacher, N; Horvath, A; Kollroser, M; Leber, B; Nusshold, C; Posch, A; Rechberger, GN; Sattler, W; Spindelböck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS | 1 |
| Aniszewska, M; Kowalik-Mikołajewska, B; Lewandowski, Z; Marczyńska, M; Pluta, M; Pokorska-Śpiewak, M | 1 |
| Abdallah, OE; Abdel Hammed, OM; Elharrif, MG; Elwan, AW; Mahfouz, MK; Maksoud H A, A; Ragab AboZaid, OA | 1 |
| Bugajska, J; Inglot, M; Janocha-Litwin, J; Malyszczak, K; Marciniak, D; Pawlak, D; Pawlowski, T; Zalewska, M | 1 |
| Bourliere, M; Buti, M; Chokkalingam, A; Colombo, M; Esteban, R; Gaggar, A; Henry, L; Mangia, A; Manns, M; Muir, A; Nader, F; Papatheodoridis, GV; Racila, A; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Atta, AM; Atta, MLBS; Isabel Schinoni, M; Jesus, LS; Oliveira, IS; Silva, JPCG | 1 |
| Batista, AD; Carvalho, BT; Filgueira, NA; Lacerda, C; Lacerda, HR; Lima, K; Lima, MS; Lopes, EP; Medeiros, TB; Melo, CRL; Santos, JC; Silva, IPL | 1 |
| Cole, JL; Stark, JE | 1 |
| Peker, BO; Sarıtaş Yüksel, E; Şener, AG; Topal, F | 1 |
| Han, QY; He, S; Liu, ZW; Wang, XY | 1 |
| Adenugba, A; Geissler, EK; Hornung, M; Junger, H; Kupke, P; Lang, H; Marquardt, JU; Peschel, G; Schlitt, HJ; Weigand, K; Werner, JM; Zimmermann, T | 1 |
| Abd El-Maksoud, E; Hegazy, MGA; Maher, AM; Salem, AM | 1 |
| Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML | 1 |
| Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I | 1 |
| Sarrazin, C | 1 |
| Chuma, M; Fukuda, H; Hara, K; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Tanaka, K; Yamanaka, T | 1 |
| Kamimura, H; Kamimura, K; Terai, S; Tsuchiya, A | 1 |
| El-Sayed, EM; Hassanien, KS; Helal, GK; Ismail, RS; Zakarya, ZM | 1 |
| Zarębska-Michaluk, D | 1 |
| Huang, JC; Muo, CH; Su, FH; Wu, CM; Wu, MM; Yeh, CC | 1 |
| Khedhiri, M; Triki, H | 1 |
| Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M | 1 |
| AbdAllah, M; Abdel-Razek, W; Alalfy, M; Alboraie, M; Ammar, I; Doss, W; El Akel, W; El-Bendary, M; El-Sayed, MH; El-Serafy, M; Elbaz, T; Esmat, G; Gomaa, A; Hassany, M; Hefny, Z; Kamal, E; Okasha, A; Shaaban, E | 1 |
| Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K | 1 |
| Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U | 1 |
| Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N | 1 |
| Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R | 1 |
| Miyasaka, A; Suzuki, A; Takikawa, Y; Yoshida, Y | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Ahmed, M; Gomaa, AA; Mansey, AE; Rabea, HM; Wahsh, EA | 1 |
| Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT | 1 |
| Barbaliscia, S; Bruzzone, B; Cassol, C; Caudai, C; Ceccherini-Silberstein, F; Coppola, N; Cuomo, N; Di Maio, VC; Micheli, V; Monno, L; Montagnani, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C; Paglicci, L; Paolucci, S; Rossetti, B; Santantonio, T; Zanelli, G; Zazzi, M | 1 |
| Chemych, MD; Lishnevska, AG | 1 |
| Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y | 1 |
| Andreone, P; Cusi, MG; De Luca, A; Di Donato, R; Furlini, G; Galli, C; Galli, S; Gandolfo, C; Grandini, E; Guarneri, V; Loggi, E; Margotti, M; Mercinelli, S; Raffaelli, CS; Re, MC; Rossetti, B; Savellini, GG; Vitale, G; Vukotic, R | 1 |
| Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C | 1 |
| Bukh, J; Christensen, PB; Fahnøe, U; Madsen, LW; Pedersen, MS; Øvrehus, A | 1 |
| Baumert, TF; Berg, T; Brants, L; Buggisch, P; Discher, T; Friebe, A; Fromm, G; Kemper, J; Lieb, K; Link, R; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Sarkar, S; Schaefer, M; Schläpfer, T; Spengler, U; Weidenbach, H; Zeuzem, S | 1 |
| Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Krzyzanski, W; Perez-Ruixo, JJ; Vermeulen, A; Woot de Trixhe, X | 1 |
| Al Abosy, R; Allen, TM; Chung, RT; Comstock, DE; Fidler, S; Fox, J; Frater, J; Gerdemann, U; Haining, WN; Kim, AY; Lauer, GM; Martin, GE; Sen, DR; Tonnerre, P; Tully, DC; Weiss, SA; Wolski, D; Yates, KB | 1 |
| Boglione, L; Cardellino, CS; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
| Everson, GT; Kiser, JJ; Langness, JA; Nguyen, M; Wieland, A | 1 |
| Baiguera, C; Garcia-Fraile Fraile, LJ; Puoti, M; Rossotti, R | 1 |
| Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D | 1 |
| Baeg, JY; Cho, J; Chung, JW; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, JW; Kim, YS; Seo, SY | 1 |
| Hao, X; Li, H; Li, Y; Ma, Y; Wang, J; Xiao, Y; Xu, B; Yang, L | 1 |
| Buzas, C; Ciobanu, L; Tantau, M | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G | 2 |
| Arefiev, Y; Budhathoki, N; Gayam, V; Guss, D; Khalid, M; Khan, A; Mansour, M; Mohanty, SR; Mukhtar, O; Rangaraju, AM; Sherigar, JM; Siddiqui, I | 1 |
| Cheng, K; Chevaliez, S; Cloherty, G; Cohen, DE; Dawson, GJ; Feld, JJ; Hackett, J; Herman, C; Maasoumy, B; Pawlotsky, JM; Rockstroh, JK; Sarrazin, C; Wedemeyer, H | 1 |
| Bansal, A; Dutta, U; Goyal, O; Grover, R; Kishore, H; Malhi, NS; Nanda, V; Saluja, H; Sehgal, A; Sidhu, JS; Sidhu, S; Sidhu, SS; Singh, G; Singh, R | 1 |
| El Sayed, MH; Giaquinto, C; Gonzalez-Peralta, RP; Indolfi, G; Thorne, C | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N | 1 |
| Angarano, G; Bruno, G; Milella, M; Saracino, A | 1 |
| Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Tsai, YS; Wang, SC; Yeh, ML; Yu, ML | 1 |
| Abraham, GM; Spooner, LM | 2 |
| Almawi, WY; Ghazoueni, E; Loueslati, BY; Mouelhi, L; Rabia, NA; Sghaier, I | 1 |
| Barocas, JA; Beiser, M; Gaeta, JM; León, C; Linas, BP; O'Connell, JJ | 1 |
| Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM | 1 |
| Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S | 1 |
| Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N | 1 |
| Agarwal, K; Aguilar, H; Asatryan, A; Dore, GJ; Felizarta, F; Gane, E; Gordon, SC; Hassanein, T; Kort, J; Kwo, PY; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Muir, AJ; Ng, TI; Overcash, JS; Poordad, F; Sulkowski, MS; Wang, S; Wyles, DL | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Degasperi, E | 1 |
| Gray, E; Norris, S; O'Leary, A; Pasta, DJ | 1 |
| Alavian, SM; Behnava, B; Dolatimehr, F; Gholami-Fesharaki, M; Karimi-Sari, H; Rezaee-Zavareh, MS; Sharafi, H | 1 |
| Bruno, S; Maisonneuve, P | 1 |
| Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K | 1 |
| Álvarez, B; Benito, JM; Cabello, A; García, M; García-Samaniego, J; Górgolas, M; Madejón, A; Martín-Carbonero, L; Rallón, N | 1 |
| Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Carmona-Soria, I; Caunedo-Alvarez, A; Cordero-Ruiz, P; Flores-Cucho, A; Quezada-Pacheco, RH; Rodríguez-Téllez, M; Romero-Gómez, M; Vilches-Arenas, Á | 1 |
| Chan, HL; Lo, AO; Wong, GL; Wong, VW | 1 |
| El Raziky, M; Elakel, W; Eletreby, R; Esmat, G | 1 |
| Darwish, NHE; Elberry, MH; Mousa, SA | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S; Yoshida, K | 1 |
| Everson, GT; Jackson, WE | 1 |
| Ali, A; Idrees, M; Rafique, S; Saleem, K; Wahid, B | 1 |
| Abdel Baki, A; El Raziky, M; Mansour, SA; Shahin, RMH; Zayed, NA | 1 |
| Chen, LC; Xie, Q | 1 |
| Aghemo, A; Alberti, A; Antinori, A; Ascione, A; Bruno, R; Bruno, S; Chirianni, A; Craxì, A; Gaeta, GB; Giannini, EG; Marzioni, M; Merli, M; Messina, V; Montilla, S; Pani, L; Perno, CF; Petta, S; Puoti, M; Raimondo, G; Rendina, M; Russo, P; Silberstein, FC; Villa, E; Zignego, AL | 1 |
| Brainard, DM; Davis, MN; Dvory-Sobol, H; Etzkorn, K; Gane, EJ; Hinestrosa, F; Huang, KC; McHutchison, JG; McNally, J; Morelli, G; Osinusi, A; Shiffman, ML; Stedman, CAM; Sulkowski, MS; Thompson, AJ | 1 |
| Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A | 1 |
| Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C | 1 |
| Arnon, R; Balistreri, WF; Brainard, DM; Gonzalez-Peralta, RP; Hardikar, W; Jonas, MM; Kanwar, B; Kersey, K; Kirby, B; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, KB; Shao, J; Svarovskaia, E; Wirth, S | 1 |
| Abdelhafez, AT; Cusato, J; D'Avolio, A; De Nicolo, A; Di Perri, G; El Desoky, ES; Hussein, AM; Kamel, SI | 1 |
| Fujikawa, T; Iwabuchi, S; Matsui, K; Nagata, M; Nakano, M; Nakazaki, H; Shimizu, H; Takatsuka, K; Tanemura, H; Watanabe, T | 1 |
| Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Tsai, YS; Yeh, ML; Yu, ML | 1 |
| De Meyer, S; Thys, K; Van Remoortere, P; Vandebosch, A; Verloes, R; Vijgen, L | 1 |
| Czarny, P; Jabłkowski, M; Karwowski, B; Majchrzak, K; Merecz-Sadowska, A; Śliwiński, T; Szemraj, J | 1 |
| Beumont, M; Bourgeois, S; Corbett, C; Da Silva, MH; DeJesus, E; Diago, M; Ferenci, P; Fevery, B; Gane, EJ; George, J; Hinrichsen, H; Janczewska, E; Jessner, W; Kalmeijer, R; Lenz, O; Nikitin, I; Reesink, H; Shukla, U | 1 |
| Harada, S; Iida, T; Koshino, K; Masuda, K; Matsuyama, T; Nakamura, T; Nobori, S; Ushigome, H; Yoshimura, N | 1 |
| Enomoto, M; Kawada, N; Murakami, Y | 1 |
| Ahmad, W; Alam, SE; Asif, M; Hussain Jaffery, SS; Sajjad, SF | 1 |
| Andriulli, A; Guarino, M; Morisco, F | 1 |
| Alavian, SM; Rezaee-Zavareh, MS | 1 |
| Caloska-Ivanova, V; Curakova, E; Dimitrova-Genadieva, M; Joksimovic, N; Kiprijanovska, S; Serafimoski, V; Todorovska, B; Trajkovska, M; Zafirova-Ivanovska, B | 1 |
| Peterson, D; Van Ermen, A | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Huang, CF; Huang, CI; Huang, JF; Lin, TY; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Ashraf, M; Bukhsh, A; Gul, A; Khiljee, S; Omer, MO; Rafique, G | 1 |
| Cho, NH; Choi, JY; Choi, MS; Kim, BG; Kim, DH; Kim, W; Kim, Y; Kwon, EK; Lee, JW; Lee, WW; Min, CK; Shin, HM | 1 |
| Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K | 1 |
| Amin, J; Applegate, TL; Backmund, M; Bourgeois, S; Bruggmann, P; Bruneau, J; Conway, B; Cunningham, EB; Dalgard, O; Dore, GJ; Dunlop, A; Foster, GR; Grebely, J; Hajarizadeh, B; Hellard, M; Marks, PS; Midgard, H; Quiene, S; Robaeys, G; Shaw, D; Staehelin, C; Swan, T; Weltman, M | 1 |
| Kaabi, SA; Singh, R; Soofi, ME; Thandassery, RB; Tharian, B | 1 |
| Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H | 1 |
| Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A | 1 |
| Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L | 1 |
| Aggarwal, R; Bhargava, R; Goel, A; Rai, P | 1 |
| Berry, K; Chang, M; Green, PK; Hettinger, BD; Hum, J; Ioannou, GN; Jou, JH; Lundblad, J | 1 |
| Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Lin, KH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Bredi, E; Covini, G | 1 |
| Abdel Alem, S; Abdellatif, Z; Adel, E; Elsharkawy, A; Esmat, G; Fouad, R; Hussein, MS; Musa, S; Nagy, A; Yosry, A | 1 |
| Afdhal, NH; Curry, MP; Iriana, S | 1 |
| Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z | 1 |
| Lin, HC; Su, CW; Yang, YY | 1 |
| Balslev, U; Belard, E; Dalgard, O; Färkkilâ, M; Hallager, S; Heggelund, L; Karlsen, L; Krarup, H; Lagging, M; Lund Laursen, A; Madsen, LG; Noraberg, G; Skalshøi Kjær, M; Thorup Røge, B; Weiland, O; Weis, N; Øvrehus, A | 1 |
| Donato, FM; Fabrizi, F; Messa, P | 1 |
| Amrose, P; Anand, S; Kumar, MS; McFall, AM; Mehta, SH; Ramasamy, B; Solomon, SS; Srikrishnan, AK; Sulkowski, MS; Thomas, DL | 1 |
| Guo, H; Li, Z; Liu, Z; Qi, W; Sun, D; Wang, H; Wang, J; Wang, S; Wang, X; Zhang, Y; Zhao, P; Zhou, C; Zhu, L | 1 |
| Bhattacharjee, S; Bhushan, A; Chinnaswamy, S; Ghosh, S | 1 |
| Antón, MD; Ferrando, I; Latorre, P; Moreno Osset, E; Pascual, A; Polanco, A | 1 |
| Adlin Nadia, Z; Tan, SS | 1 |
| Agrati, C; Bordoni, V; Casetti, R; Ciccosanti, F; Cimini, E; D'Offizi, G; Fimia, G; Lionetti, R; Martini, F; Montalbano, M; Refolo, G; Sacchi, A; Taibi, C; Tumino, N; Turchi, F | 1 |
| Abdolrahimi, F; Davari, M; Dizaji, SP; Fateh, A; Fateh, R; Gharibzadeh, S; Ghazanfari, M; Jamnani, FR; Sakhaee, F; Siadat, SD; Vaziri, F | 1 |
| Abdel-Razik, A; El-Wakeel, N; Eldars, W; Elgamal, A; Elkashef, W; Elzehery, R; Farag, R; Mousa, N; Shabana, W | 1 |
| Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 3 |
| Asim, M; Jamil, A; Majeed, A; Rashid, A; Razak, S; Wahid, M | 1 |
| Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M | 1 |
| Kim, HJ; Lee, HW; Oh, IS; Won, JW | 1 |
| Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP | 1 |
| Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM | 1 |
| Ardévol, M; López, D; Masnou, H; Morillas, RM | 1 |
| Asli, E; Davari, M; Fateh, A; Gharibzadeh, S; Jamnani, FR; Sadeghi, S; Siadat, SD; Vaziri, F | 1 |
| Kim, HB; Lee, YJ; Myung, SK; Park, BJ | 1 |
| Bian, DD; Chen, Y; Duan, C; Duan, ZP; Jiang, YY; Liu, M; Liu, S; Wang, T; Wang, Z; Zhang, JY; Zheng, SJ; Zhou, HY | 1 |
| Alves, K; Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R | 1 |
| Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB | 1 |
| Feld, JJ; Jacobson, I; Pawlotsky, JM; Poordad, F; Sulkowski, M; Tatsch, F | 1 |
| Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T | 1 |
| Crisan, D; Grigorescu, M; Grigorescu, MD; Radu, C; Suciu, A | 1 |
| Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A | 1 |
| Kim, HJ; Lee, HW; Won, JW; Yoo, KY | 1 |
| Larijani, MS; Mohajel, N; Nikbin, M; Sadat, SM | 1 |
| Abaci, N; Akyuz, F; Akyuz, U; Besisik, F; Cakiris, A; Ciftci, S; Demir, K; Kaymakoglu, S; Keskin, F; Ustek, D | 1 |
| Arends, JE; Bijmolen, M; Blokzijl, H; Burger, DM; de Kanter, CTMM; de Knegt, RJ; Dofferhoff, ASM; Drenth, JPH; Lieveld, FI; Maan, R; Smolders, EJ; van der Valk, M; van Erpecum, KJ; van Tilborg, M | 1 |
| Kanda, T; Moriyama, M | 1 |
| Bodeau, S; Brochot, E; Domange, B; Duverlie, G; Garçon, L; Handala, L; Helle, F; Nguyen-Khac, E; Ouled-Haddou, H | 1 |
| Caraceni, P; Carrai, P; Donato, MF; Fagiuoli, S; Filì, D; Gianstefani, A; Martini, S; Mazzarelli, C; Melazzini, M; Montilla, S; Pani, L; Petraglia, S; Rendina, M; Russo, P; Trotta, MP; Visco-Comandini, U | 1 |
| Huang, JW; Liao, HT; Tan, P; Yuan, KF | 1 |
| Comstock, E; Kottilil, S; Kumar, NS; Mathur, P; McSweegan, E; Mercer, N | 1 |
| Ballard, C; Cachay, ER; Colwell, B; Hicks, C; Mathews, WC; Torriani, F | 1 |
| Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX | 1 |
| Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS | 1 |
| Azzari, C; Cananzi, M; D'Antiga, L; Indolfi, G; Nebbia, G; Resti, M; Ricci, S; Serranti, D; Stagi, S | 1 |
| Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM | 1 |
| Bair, MJ; Chen, HL; Cheng, CH; Lee, YK; Lin, CC; Lin, IT; Wong, MW; Wu, CH | 1 |
| Feroz, F; Sajid, M; Talat, H; Wahid, Z | 1 |
| Atta, AM; Cabral, MS; Oliveira, IS; Pereira, AB; Santos, PL; Santos, TPS; Schinoni, MI; Sousa-Atta, MLB | 1 |
| Abd El-Wahab, EW; Nagaty, A | 1 |
| Ardèvol, M; Carrión, JA; Gallego, A; González-Colominas, E; Lens, S; Londoño, MC; López, D; Mariño, Z; Mojal, S; Morillas, RM; Pagès, N; Solà, R; Torras, X | 1 |
| Chen, M; Fan, H; Huang, P; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F | 1 |
| Hayashi, Y; Imoto, S; Kato, A; Kim, CW; Kim, KI; Kim, SK; Kim, SR; Kobayashi, M; Kudo, M; Morimoto, E; Ohtani, A; Saijo, Y; Seo, K; Yano, Y | 1 |
| Buechel, D; Choi, M; DeNardo, Z; Stiller, M | 1 |
| Barner, A; Early, J; Gottfried, S; Gumpert, R; Libaridian, L; Morrison, V; Santamaria, A; Shipton, L; Sokol, R | 1 |
| Aburawash, A; Elsisi, GH; Waked, E | 1 |
| Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F | 1 |
| Kim, DY | 2 |
| Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH | 1 |
| Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E | 1 |
| Chen, SC; Chiou, SS; Chuang, WL; Dai, CY; Hsieh, MY; Hsu, WY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, PC; Lin, ZY; Yeh, ML; Yu, ML; Zeng, YS | 1 |
| Arai, M; Chiba, T; Imazeki, F; Kanda, T; Mikata, R; Nakamoto, S; Nakamura, M; Shirasawa, H; Tawada, A; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Lagging, M; Waldenström, J | 1 |
| Bhardwaj, N; Brainard, D; Chang, S; Chodavarapu, K; Feld, JJ; Mangia, A; Martin, R; McNally, J; Miller, MD; Mo, H; Murrell, B; Osinusi, A; Ragonnet-Cronin, M; Sulkowski, M; Svarovskaia, ES; Wertheim, JO | 1 |
| Backhus, J; Dikopoulos, N; Groß, MJ; Härter, G; Ludwig, L; Seufferlein, T; Zizer, E | 1 |
| Brandão-Mello, CE; Brito, JDU; Campos, AF; Ferreira, PRA; Gonzalez, MP; Grando, AV; Lopes, MIBF; Martinelli, ALC; Mazo, DFC; Mendes-Corrêa, MC; Nastri, ACS; Pessôa, MG; Reuter, T | 1 |
| Figlerowicz, M; Kaczmarek, M; Kemnitz, P; Mania, A; Mazur-Melewska, K; Sikora, J; Służewski, W; Żeromski, J | 1 |
| Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P | 1 |
| Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA | 1 |
| Abdo, AA; Al-Ashgar, HI; Alalwan, AA; AlBekairy, AM; Alblawi, MA; Alghamdi, A; Alghamdi, H; Alhamoudi, W; Aljumah, A; Alquaiz, M; Alsohaibani, F; Alswat, KA; AlTamimi, W; Altraif, IH; Altraif, S; Babatin, MA; Handoo, FA; Loustaud-Ratti, V; Marquett, P; Murtaza, S; Peedikayil, M; Sanai, F | 1 |
| Al-Zoairy, R; Beinhardt, S; Datz, C; Ferenci, P; Graziadei, I; Gschwantler, M; Hofer, H; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Trauner, M; Zoller, H | 1 |
| Casado, J; Gila, A; Jiménez-Ruiz, SM; Muñoz de Rueda, P; Muñoz-Gámez, JA; Pavón-Castillero, EJ; Quiles, R; Ruiz-Extremera, A; Salmerón, J | 1 |
| Andini, R; Atripaldi, L; Durante-Mangoni, E; Maiello, C; Mattucci, I; Vitrone, M; Zampino, R | 1 |
| Ahmad, I; Anwar, A; Aziz, H; Irfan, J; Mukhtar, M; Ovais, M; Raza, A | 1 |
| Clark, A; Dusheiko, G; Fathi, H; Hill, NR | 1 |
| Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kuo, FY; Lin, JT; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Wu, CK; Yen, YH | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| Barbosa, MED; Carrilho, FJ; de Campos Mazo, DF; de Oliveira, CPMS; Farias, AQ; Pessoa, MG; Zaninotto, AL | 1 |
| Abou-Samra, AB; Butt, AA; Shaikh, OS; Yan, P | 1 |
| Hamano, G; Ito, T; Kawada, N; Kubo, S; Takemura, S; Tamori, A; Tanaka, S | 1 |
| Cornberg, M; Deterding, K; Kirschner, J; Manns, MP; Mix, C; Port, K; Schlevogt, B; Siederdissen, CHZ; Sollik, L; Wedemeyer, H | 1 |
| Abdulla, NA; Amin, MA; El Maksoud, NA; Halim, MH; Kamel, A; Moussa, SM; Ragab, HM | 1 |
| AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M | 1 |
| Gonzalez-Peralta, R; Henry, L; Hunt, S; Murray, K; Rosenthal, P; Schwarz, KB; Stepanova, M; Wirth, S; Younossi, ZM | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Kinh, N; Lai, CL; Lai, W; Lim, YS; Stepanova, M; Younossi, ZM; Yuen, MF | 1 |
| Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H | 1 |
| Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A | 1 |
| Chen, PC; King, YC; Lai, CH; Liu, CY; Yang, YH | 1 |
| Birkemose, I; Christensen, PB; Ernst, A; Holm, DK; Krarup, H; Mössner, B; Øvrehus, ALH | 1 |
| Fiel, MI; Putra, J; Schiano, TD | 1 |
| Albillos, A; García González, M; Gea Rodríguez, F; Rodríguez de Santiago, E; Tavío Hernández, E; Téllez Villajos, L; Velázquez Kennedy, K | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, C | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Wu, CK; Ye, YH | 1 |
| Chen, C; Hartigan-O'Connor, DJ; Khalili, M; Lanier, LL; Lu, D; Manos, MM; McCune, JM; Méndez-Lagares, G; Monto, A; Ryan, JC; Segal, MR; Shen, H; Terrault, N | 1 |
| Maughan, A; Ogbuagu, O | 1 |
| Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F | 1 |
| Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM | 1 |
| Alavi, M; Dore, GJ; Law, MG | 1 |
| de Avila, L; Doyle, J; Stepanova, M; Thompson, A; Younossi, I; Younossi, ZM | 1 |
| Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Amador, C; Carmena, J; Flores, J; Galindo, MJ; García-Deltoro, M; Masiá, M; Mínguez, C; Montero, M; Ortega, E; Reus, S | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K | 1 |
| Abd El Rehim, AY; Alamrani, MA; Alezzi, ZMM; Fathallah, WF; Othman, FH | 1 |
| Lomonosova, E; Tavis, JE | 1 |
| Aslam, R; Khaliq, S; Manzoor, S; Naeemi, H; Naz, S; Raza, SM; Shahzad, MA | 1 |
| Chen, CY; Chen, MY; Chen, Q; Kao, JH; Peng, CY; Tang, H; Wu, JJ; Yu, ML | 1 |
| Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C | 1 |
| Abd El Latif, Y; Alboraie, M; Doss, W; El Kassas, M; El Tahan, A; El-Serafy, M; Elakel, W; Elsaeed, K; ElShazly, Y; Esmat, G; Ezzat, S; Korany, M; Nabeel, MM; Omran, D | 1 |
| Buggisch, P; Corbett, C; Fevery, B; Horban, A; Jessner, W; Lawitz, E; Lee, SS; Lenz, O; Moreno, C; Shukla, U; Verbinnen, T; Zoulim, F | 1 |
| Scott, LJ | 1 |
| Brainard, DM; Cheng, J; Dou, X; Duan, Z; Gao, ZL; German, P; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, D; Jiang, J; Kersey, K; Knox, SJ; Li, J; Li, L; Li, W; Lin, F; Massetto, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Niu, JQ; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, JC; Yang, Y; Zhang, LL | 1 |
| Bair, MJ; Chen, HL; Cheng, CH; Lee, YK; Lin, CC; Lin, IT; Wu, CH | 1 |
| Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A | 1 |
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Hoan, NX; Meyer, CG; Song, LH; Tong, HV; Velavan, TP | 1 |
| Deng, XZ; Ding, WL; Li, GT; Wang, LJ; Xiao, W; Zhang, GQ; Zhang, JH; Zhou, ZX; Zhu, DY; Zhu, YM | 1 |
| Álvarez, H; Castro-Iglesias, A; Delgado, M; Grandal, M; Mariño, A; Mena, A; Pérez, AB; Pernas, B; Poveda, E; Tabernilla, A; Valcarce, N | 1 |
| Bittermann, T; Weinberg, E | 1 |
| Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Imnadze, T; Mikadze, I; Vashakidze, E | 1 |
| Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J | 1 |
| Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J | 1 |
| Aghemo, A; Baldanti, F; Borghi, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Lampertico, P; Lunghi, G; Novazzi, F; Paolucci, S; Perbellini, R | 1 |
| Caroprese, M; Coppola, N; De Pascalis, S; Guerrera, B; Iovinella, V; Macera, M; Masarone, M; Minichini, C; Occhiello, L; Starace, M; Vitrone, M | 1 |
| Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T | 1 |
| Anani, M; Attia, FM; F, GM; M, H; Saleh, RM | 1 |
| Cheon, GJ; Cho, YS; Jang, JY; Jeong, SW; Jun, BG; Kim, BS; Kim, HS; Kim, SG; Kim, YD; Kim, YS; Lee, SH; Lee, WC; Lee, YN; Park, EJ | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M | 1 |
| Kaplan, DE | 1 |
| Berthillon, P; Bordes, I; Chemin, I; Crouy, S; Larrat, S; Leroy, V; Maynard, M; Petit, MA; Pradat, P; Scholtès, C; Trépo, C; Virlogeux, V; Zoulim, F | 1 |
| El-Raziky, M; Elsharkawy, A; Fouad, A; Khairy, M; Salama, A; Tantawy, O | 1 |
| Cherian, R; Driscoll, C; Genther, K; Goode, MB; Lee, H; Lewis, S; Luketic, VA; Martin, K; Matherly, S; Patel, V; Puri, P; Sanyal, AJ; Siddiqui, MS; Smith, P; Sterling, RK; Stravitz, RT | 1 |
| Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE | 1 |
| Otori, K; Tanaka, Y; Yokomori, H | 1 |
| Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M | 1 |
| Aghemo, A; Cresseri, D; Donato, FM; Fabrizi, F; Fraquelli, M; Lampertico, P; Messa, P; Moroni, G; Passerini, P | 1 |
| Kanda, T; Matsuoka, S; Moriyama, M | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Masumoto, A; Miyazaki, M; Motomura, K; Tanaka, K; Yada, M | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A | 1 |
| Chang, F; Duan, CA; Jin, X; Lu, Y | 1 |
| Jang, H; Jin, YJ; Kim, CW; Kim, L; Yoon, CH | 1 |
| Fan, H; Feng, Y; Huang, P; Liu, M; Xia, X; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y | 1 |
| Alavian, SE; Alavian, SM; Behnava, B; Keshvari, M; Pouryasin, A; Pouryasin, M; Sharafi, H; Shirmast, P | 1 |
| Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T | 1 |
| ElBasiony, M; Hassan, AA; Mikhail, NNH; Shiha, G; Soliman, R | 1 |
| Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T | 1 |
| Cheung, CYS; Cooper, SE; Liu, HY | 1 |
| Gupta, E; Kataria, A; Nayak, SL; Sarin, SK | 1 |
| Cervino, L; Hynicka, LM | 1 |
| Furqan, S; Jabeen, S; Rashid, O | 1 |
| Balart, L; Barr, E; Ghalib, R; Hanna, GJ; Hwang, P; Luketic, V; Nguyen, BY; Pearlman, B; Ravendhran, N; Robertson, M; Talwani, R; Vierling, J; Zamor, PJ | 1 |
| Zeuzem, S | 16 |
| Atsumi, T; Fujieda, Y; Nakai, M; Nakamura, H; Yasuda, S | 1 |
| Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M | 1 |
| Fazylov, VC; Guryanova, SV; Manapova, ER | 1 |
| Du, Y; Hou, W; Huo, Z; Qiao, K; Trieu, C | 1 |
| Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM | 1 |
| Abdallah, F; El Tarabily, M; Ibrahim, M; Mohamed, G | 1 |
| Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Bogomolov, PO; Chen, X; Enejosa, JV; Isakov, V; Maevskaya, MV; Ogurtsov, P; Paduta, D; Pasechnikov, V; Shulman, NS; Viani, RM; Znoyko, O | 1 |
| Ananyan, S; Gemilyan, M; Hakobyan, G | 1 |
| Boscarino, JA; Daida, YG; Gordon, SC; Holmberg, SD; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Xing, J; Zhong, Y | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T | 1 |
| Agarwal, K; Cannon, MD; Carey, I; Childs, K; Considine, A; Dusheiko, G; Manini, MA; Mazzarelli, C; Suddle, A | 1 |
| Zhang, DZ; Zhang, QF | 1 |
| Zhang, DZ; Zhang, QY; Zhu, F | 1 |
| Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL | 1 |
| Alavian, SM; Sharafi, H | 1 |
| Kamiya, K; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M; Waki, Y | 1 |
| Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ | 1 |
| Hindi, NN; Saleh, MI | 1 |
| Abd El Latif, Y; Doss, W; El Kassas, M; El Shazly, Y; El Tahan, A; Elbadry, M; Esmat, G; Farid, AM; Fontanet, A; Funk, AL; Sherief, A; Shimakawa, Y; Vasiliu, A; Youssef, N | 1 |
| Höner Zu Siederdissen, C; Maasoumy, B | 1 |
| Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Auckle, R; Che, WL; Li, HL; Liu, L; Mohammed, AQ; Xu, SL; Zhao, DD | 1 |
| Alami, NN; Allam, N; Esmat, G; Fouad, R; Hall, C; Hassany, M; Kopecky-Bromberg, S; Mobashery, N; Mohey, M; Qaqish, RB; Shiha, G; Soliman, R; Waked, I | 1 |
| Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY | 1 |
| Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
| Alper, CJ; Clements, K; Greenwood, BC; Hydery, T; Jeffrey, PL; Kouris, G; Lavitas, P; Lenz, K; Price, M | 1 |
| Kim, SM; Song, IH | 1 |
| Blatt, CR; Carneiro, JMM; Chachá, SGF; Farias, MR; Feltrin, AA; Gomes, LO; Martinelli, ALC; Noblat, LACB; Pereira, LRL; Rodrigues, JPV; Rosa, JAD; Silveira, MPT; Teixeira, MR; Vecchi, MD | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM | 1 |
| Barone, CR; Bonamigo, RR; Boza, JC; Oliveira, FB; Pires, GC; Rossi, SD; Silva, M | 1 |
| But, DYK; Chan, CW; Chan, HLY; Chan, JMC; Cheung, WI; Chow, WH; Fan, TTT; Fung, JYY; Hui, AJ; Hui, YT; Kung, KN; Lai, KB; Lai, LSW; Lai, MS; Lam, BCY; Lam, JTW; Lam, K; Lao, WC; Lau, JYL; Leung, NWY; Li, MKK; Liu, K; Liu, SD; Loo, CK; Lui, TKL; Luk, WF; Ma, YK; Mak, WY; Ng, ACY; Shan, EHS; Tong, RKN; Tsang, OTY; Tsang, SWC; Wong, GLH; Wong, VWS; Yuen, MF | 1 |
| Arand, M | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Abdel Wahed, WY; Ahmed, EI; Ahmed, TI; Hassan, EA | 1 |
| Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA | 1 |
| Brainard, DM; Camus, G; Chayama, K; De-Oertel, S; Enomoto, H; Ide, T; Ikeda, F; Izumi, N; Jiang, D; Kakizaki, S; Kawakami, Y; Kurosaki, M; McHutchison, JG; McNabb, BL; Mizokami, M; Mochida, S; Stamm, LM; Takaguchi, K; Takehara, T; Tanaka, Y; Toyoda, H; Ueno, Y; Yatsuhashi, H | 1 |
| Asante-Appiah, E; Barr, E; Black, T; Brunhofer, J; Galloway, A; Haber, B; Hwang, P; Lahser, F; Palcza, J; Robertson, M; Wahl, J | 1 |
| Feng, L; Gong, F; Hu, S; Huang, H; Sun, B; Yuan, F; Zheng, F | 1 |
| Gao, B; Su, Y; Tong, Z; Wang, W; Zhang, C; Zhang, H; Zhang, L; Zhong, J | 1 |
| Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A | 1 |
| Husic-Selimovic, A; Jahic, E; Merhemic, Z; Prohic, D; Sofic, A | 1 |
| Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N | 1 |
| Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S | 1 |
| Feist, C; Galle, PR; Grambihler, A; Münzel, T; Ostad, MA; Schattenberg, JM; Schmidt, FP; Schnorbus, B; Sprinzl, MF; Wenz, T; Zimmermann, T | 1 |
| Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I | 1 |
| Abdellatif, Z; Anwar, I; Bekheet, N; El-Nahaas, SM; Elhossary, W; Elsharkawy, A; Esmat, G; Fouad, R; Khairy, M; Maher, RM | 1 |
| Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M | 1 |
| Keam, SJ; Markham, A | 1 |
| Cabello, V; Juampérez, J; Julio, E; Mercadal-Hally, M; Quintero, J; Rodrigo, C; Segarra, Ó; Soler-Palacín, P | 1 |
| Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM | 1 |
| Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP | 1 |
| Bischoff, J; Rockstroh, JK | 1 |
| Minowa, K; Suzuki, M; Tajiri, H | 1 |
| Abdel-Aziz, EM; Abdel-Malek, MO; Hashim, AA; Hetta, HF; Mekky, MA; Morsy, KH; Osman, HA | 1 |
| Gruenhage, F; Hahn, D; Kaiser, R; Lammert, F; Meyer, MR; Stokes, CS | 1 |
| Aurora, R; Kanda, T; Kato, N; Meyer, K; Moriyama, M; Ray, R; Ray, RB; Sasaki, R; Yokosuka, O | 1 |
| Yeon, JE | 1 |
| Jacobson, IM | 2 |
| Abd-Elsalam, S; Badawi, R; Elfert, A; Elkhouly, RA; Elnawasany, S; Hawash, N; Kobtan, A; Mansour, L; Selim, A; Soliman, S; Yousef, M | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Chang, CH; Chen, DS; Chen, PJ; Hong, CM; Huang, YJ; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Su, TH; Sun, HY; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S | 1 |
| Aggarwal, M; Bhari, N; Gupta, M | 1 |
| Chen, DZ; Chen, KD; Li, LJ; Ou, HL; Su, JW; Wu, XX; Xu, XW; Yao, HP; Yu, HY | 1 |
| Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M | 1 |
| Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES | 1 |
| Budimir, J; Dušek, D; Jugović, D; Krajcar, N; Kurelac, I; Papić, N; Vince, A | 1 |
| Anton, MD; Badia, E; Bonacci, M; Calleja, JL; Carmona, I; Carrión, JA; Castellote, J; Castro Urda, JL; de la Vega, J; Diago, M; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; Gallego, A; García Buey, L; García, ND; García-Samaniego, J; Gea, F; Hernández-Conde, M; Llerena, S; Menéndez, F; Molina, E; Montoliu, S; Moreno-Palomares, JJ; Moreno-Planas, JM; Morillas, RM; Pascasio, JM; Perelló, C; Piqueras Alcol, B; Romero-Gómez, M; Rosales-Zabal, JM; Salmeron, FJ; Sánchez Ruano, JJ; Souto-Rodríguez, R | 1 |
| El-Tantawy, WH; Temraz, A | 1 |
| Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M | 1 |
| Lee, TY; Yang, SS | 1 |
| Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC | 1 |
| Fukaya, Y; Hirosawa, T; Imai, M; Isoda, N; Kurata, H; Miura, K; Morimoto, N; Murayama, K; Murohisa, T; Nomoto, H; Numao, N; Okamura, Y; Ozawa, I; Sato, T; Tahara, T; Takaoka, Y; Tano, S; Tsukui, M; Watanabe, S; Yamamoto, H; Yoshizumi, H | 1 |
| Asaoka, Y; Enooku, K; Fujiwara, N; Koike, K; Minami, T; Nakagawa, H; Nakagomi, R; Nishibatake Kinoshita, M; Sato, M; Shiina, S; Tateishi, R; Uchino, K; Wake, T | 1 |
| Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M | 1 |
| Bair, MJ; Chen, CH; Chen, CK; Chen, CP; Cheng, CH; Cheng, CY; Cheng, SH; Zou, H | 1 |
| Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB | 1 |
| Abhilash, VB; Asati, PK; Behera, MK; Dixit, VK; Jain, AK; Nath, P; Shukla, SK | 1 |
| Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R | 1 |
| Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB | 1 |
| Aartun, J; Kottilil, S; Masur, H; Meissner, EG; Orr, C | 1 |
| Avril, E; Bouscaillou, J; Butsashvili, M; Etienne, A; Gamezardashvili, A; Inaridze, I; Kamkamidze, G; Kharshiladze, D; Kikvidze, T; Labartkava, K; Le Pluart, D; Luhmann, N | 1 |
| Applegate, TL; Bruggmann, P; Bruneau, J; Castro, E; Conway, B; Cooper, C; Crawford, S; Cunningham, EB; Dalgard, O; Daulouede, JP; Dore, GJ; Dunlop, A; Erratt, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacombe, K; Marks, P; Matthews, GV; Moriggia, A; Petoumenos, K; Powis, J; Schmid, P; Shaw, D; Stedman, C | 1 |
| De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F | 1 |
| Agnieszka, P; Andrzej, H; Hanna, B; Iwona, BO; Kamila, CC; Karol, P; Kosińska, J; Marek, R; Pollak, A; Płoski, R; Tomasz, L | 1 |
| Khaliq, S; Raza, SM | 1 |
| Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA | 1 |
| Asim, M; Khan, A; Rashid, A | 1 |
| Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC | 1 |
| Bamberger, T; Graziadei, I; Gschwantler, M; Katalinic, N; Maieron, A; Stauber, R | 1 |
| Ceccherini-Silberstein, F; Cento, V; Craxì, A; Di Maio, VC; Perno, CF | 1 |
| Abou-Samra, AB; Butt, AA; Freiberg, MS; Shaikh, OS; Shuaib, A; Yan, P | 1 |
| Acero, D; Alsius, M; Buxó, M; Ferri, MJ; López, C; Queralt, X; Serra, I | 1 |
| Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML | 1 |
| Choi, HY; Chung, W; Jang, ES; Jeong, SH; Ki, M; Kim, KA | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Bair, MJ; Chen, HL; Cheng, CH; Chu, CY; Lee, YK; Lin, IT; Wu, CH | 1 |
| Back, DJ; Burger, DM; Colbers, A; de Knegt, RJ; Drenth, JPH; El-Sherif, O; Honkoop, P; Smolders, EJ; van Seyen, M; van Wijngaarden, P; Wouthuyzen-Bakker, M | 1 |
| Fattehi, MR; Ghorbani, M; Hojati, SA; Maserat, E; Safarpour, A | 1 |
| Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lin, MT; Lu, SN; Sou, FM; Tsai, MC; Wang, JH; Wu, CK; Yen, YH | 1 |
| Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S | 1 |
| Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH | 1 |
| Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM | 1 |
| Izumi, T; Kawagishi, N; Kimura, M; Kudo, Y; Maehara, O; Miyoshi, H; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Nishida, M; Ogawa, K; Ohara, M; Sakamoto, N; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS; Teng, W | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Chou, SW; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Wu, SJ; Yang, HC | 1 |
| Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R | 1 |
| Abou El-Khier, NT; Abousamra, NK; Arafa, MM; Eladl, E; Elhammady, D; Esmael, ME; Shahin, D; Shaker, G; Sharaf-Eldeen, O | 1 |
| Ibrahim, MM; Shahid, I | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lu, SN; Wang, JH; Yen, YH | 1 |
| Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SHH; Sulaiman, AS; Zulkifly, S | 1 |
| Elgouhary, SM; Mowafy, MA; Said-Ahmed, KE | 1 |
| Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R | 1 |
| Barker, L; Jiles, RB; White, JZ; Yin, S | 1 |
| Chan, HL; Cheung, D; Chim, AM; Chung, C; Fung, JY; Hui, YT; Loo, CK; Wong, GL; Wong, VW | 1 |
| El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE | 1 |
| Boyacıoğlu, AS; Çolak, T; Dağlı, Ü; Haberal, M; Hilmioğlu, F; Öcal, S; Özer Etik, D; Selçuk, H; Suna, N | 1 |
| Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S | 1 |
| Akarca, US; Akdogan, M; Akhan, S; Aladag, M; Ataseven, H; Cakaloglu, Y; Cavus, B; Demir, M; Erol, C; Ersoz, G; Gunduz, F; Gunsar, F; Idilman, R; Iliaz, R; Karasu, Z; Kaymakoglu, S; Kiyici, M; Koklu, H; Koksal, AS; Koksal, İ; Ozgenel, M; Sahin, M; Tabak, F; Turan, İ | 1 |
| Berger, F; Boesecke, C; Buendgens, L; Christensen, S; Hüppe, D; Ingiliz, P; Lutz, T; Mauss, S; Schewe, K; Simon, KG; Tacke, F | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Brandão, ABM; Cantisani, GPC; Costabeber, AM; Fleck Junior, AM; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Meine, MH; Mucenic, M; Rossato, G; Sacco, FKR; Schlindwein, ES; Zanotelli, ML | 1 |
| Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z | 1 |
| Ferrentino, N; Lidofsky, SD; Strader, DB; VanOpdorp, JR | 1 |
| Frydecka, D; Hadryś, T; Inglot, M; Małyszczak, K; Pawłowski, T | 1 |
| Farias, MR; Foppa, AA; Gomes, LO; Rosa, JAD; Rover, MRM; Teixeira, MR | 1 |
| Ding, X; Fan, Z; Liu, J; Liu, S; Wang, F | 1 |
| Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q | 1 |
| Cho, M; Han, SY; Heo, J; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Pyeon, SI; Song, GA; Woo, HY | 1 |
| Cooper, CL; Crawley, A; Doyle, MA; Galanakis, C; Mulvihill, E | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH | 2 |
| Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K | 1 |
| Aldir, I; Bana E Costa, T; Carvalho, A; Chagas, C; Correia, JM; Falcão, F; Farinha, H; Lebre, L; Lopes, C; Mansinho, K; Marques, S; Miranda, AC; Mirco, A; Peixe, P; Perez, R; Viegas, E | 1 |
| Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H | 1 |
| Chang, YK; Chen, KH; Chen, KT; Tseng, YT | 1 |
| Birerdinc, A; Curry, MP; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Stepanova, M; Weinstein, AA; Younossi, ZM | 1 |
| Ahn, YH; Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Lee, MJ; Park, H | 1 |
| Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P | 1 |
| Cunningham, HE; Grgic, T; Lachiewicz, AM; Shea, TC | 1 |
| Abou-Samra, AB; Aslam, S; Butt, AA; Shaikh, OS; Yan, P | 1 |
| Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K | 1 |
| Cascio, A; Cervo, A; Colomba, C; Di Carlo, P; Firenze, A; Saporito, L; Tolomeo, M; Trizzino, M | 1 |
| Graf, C; Herrmann, E; Mücke, MM; Mücke, VT; Vermehren, J; Zeuzem, S | 1 |
| El-Kosasy, AM; Hussein, LA; Magdy, N; Youssef, AA | 1 |
| Choi, JW; Ko, SY; Seo, HY; Seo, MS; Yoon, SY | 1 |
| Chen, CH; Chien, RN; Hsieh, SY; Hu, TH; Hung, CH; Lin, CL; Lin, CY; Lu, SN; Sheen, IS; Tung, SY | 1 |
| Bani Melhim, S; Saleh, MI | 1 |
| Chen, SC; Hung, HC; Lee, YT; Liao, HH; Tsao, SM | 1 |
| Skorokhodova, N; Tsarova, O; Zhyvytsia, D | 1 |
| Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM | 1 |
| Barr, E; Burnevich, E; Buti, M; Feld, JJ; Foster, GR; Gane, E; Hanna, GJ; Jackson, B; Katchman, H; Klopfer, S; Lahser, F; Lawitz, E; Platt, HL; Rabinovitz, M; Robertson, MN; Shaughnessy, M; Tomasiewicz, K; Yeh, WW | 1 |
| Borba, HHL; Ferreira, VL; Minowa, E; Pontarolo, R; Rochau, U; Siebert, U; Sroczynski, G; Wiens, A | 1 |
| Bermúdez, C; Cheinquer, H; Coelho Borges, S; de Araujo, A; de Maman, Í; Fleck, A; Gadano, A; Garrastazul, P; Haddad, L; Kliemann, D; Marciano, S; Mendizabal, M; Nader, LA; Piñero, F; Ridruejo, E; Silva, M; Wolff, FH | 1 |
| Ahmed, NS; Aref, AM; Helal, TEA; Mahmoud, HA; Radwan, NA; Wahib, AA; Zaki, AM | 1 |
| Angelico, M; Antonucci, F; Armenia, D; Bellocchi, MC; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Ciancio Manuelli, M; De Leonardis, F; Lenci, I; Manzia, TM; Milana, M; Perno, CF; Sforza, D; Sorbo, MC; Tisone, G | 1 |
| Abdelrazik, M; Aboushady, M; Alwassief, A; Elbahrawy, A; Elmestikawy, A; Shahba, H; Ziada, D | 1 |
| Chi, X; Gao, X; Li, Y; Lv, J; Niu, J; Sun, H; Wang, X; Wu, R; Yu, G | 1 |
| Fukui, N; Kamimura, K; Kawai, H; Mizuno, K; Sakai, N; Sakamaki, A; Someya, T; Sugai, T; Takamura, M; Terai, S; Tominaga, K; Watanabe, H; Yamagiwa, S | 1 |
| Boscarino, JA; Daida, YG; Gordon, SC; Li, J; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Trudeau, S; Wu, KH; Zhang, T | 1 |
| Baicus, C; Constantinescu, I; Diculescu, M; Dumitru, R; Gavrila, D; Istratescu, D; Manuc, M; Manuc, T; Oproiu, A; Preda, CM; Sandra, I; Tieranu, C; Vasilescu, C; Voiosu, T | 1 |
| Amiot, X; Arotcarena, R; Cadranel, JF; Causse, X; Garioud, A; Halfon, P; Heng, R; Lucidarme, D; Medmoun, M; Mokhtari, C; Ollivier-Hourmand, I; Pariente, A; Pulwermacher, P; Rémy, AJ; Renou, C; Rosa-Hézode, I; Zanditenas, D; Zougmoré, H | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Igarashi, A; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S | 1 |
| Wahid, B | 1 |
| Frosi, A; Frosi, G; Meloni, MF | 1 |
| Chen, H; Gao, SS; Li, HW; Qiu, H; Sun, ZL; Wang, JM; Wang, ZR | 1 |
| Amory, C; Gardenier, D; Weiss, JJ; Woody, A | 1 |
| Amin, J; Artenie, AA; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dore, GJ; Erratt, A; Feld, JJ; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Quiene, S; Read, P; Stedman, C | 1 |
| Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S | 1 |
| Bourlière, M; Bronowicki, JP; Chimienti, F; Cleophax, S; Doffoel, M; Lang, JP; Pujol, JF; Salvetat, N; Schwan, R; Van der Laan, S; Vire, B; Weissmann, D | 1 |
| A, M; Abd-Elsamie, E; Badawy, ER; ElMelegy, TT; Hassaballa, AE; Kamal-ElDin, TM; Mekky, MA; Zahran, AM | 1 |
| Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Díez, C; Fanciulli, C; Garcia-Broncano, P; Jiménez-Sousa, MA; Medrano, LM; Miralles, P; Pérez-Latorre, L; Resino, S | 1 |
| Gao, XH; Jing, P | 1 |
| Chi, X; Gao, X; Jiang, J; Jiang, T; Niu, J; Pan, Y; Wang, M; Wang, X; Wu, R; Yan, H | 1 |
| Gaballah, AH; Ghazy, AA; Mostafa, H; Osman, EM; Rashwan, EA; Tawfik, S | 1 |
| Afendy, A; Gaggar, A; Jacobson, IM; Lalezari, J; Lawitz, EJ; Muir, AJ; Myers, RP; Nader, F; Racila, A; Reddy, KR; Ruane, PJ; Schwabe, C; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Djauzi, S; Gani, RA; Harimurti, K; Ibrahim, F; Imannuel, S; Kurniawan, J; Nafrialdi, N | 1 |
| Campo-Cerecedo, F; Grueiro, MC; Monteagudo, B; Vilas-Sueiro, A | 1 |
| Fazylov, VKh; Manapova, ÉR; Sozinova, IuM; Tkacheva, SV | 1 |
| Albrecht, JK; Barnard, RJ; Brass, CA; Chaudhri, E; Davis, MN; Gordon, SC; Hazuda, DJ; Howe, AY; Howe, JA; Jacobson, IM; Kwo, PY; Lawitz, EJ; McCone, J; Ogert, RA; Pedicone, LD; Pound, D; Qiu, P; Ralston, R; Ravendhran, N; Rossaro, L; Schiff, ER; Vierling, JM | 1 |
| Araújo Ramos, AL; Hoffmann, L; Ramos, JA; Rondinelli, E; Silva, R; Souza, EV; Tanuri, A; Urményi, TP; Villela-Nogueira, CA | 1 |
| Blum, R; Kessebohm, K; Pfaundler, N; Stickel, F; Stieger, M | 1 |
| Arisawa, T; George, J; Hayashi, N; Saito, T; Shiroeda, H; Toshikuni, N; Tsuchishima, M; Tsutsumi, M | 1 |
| Al Meshari, K; Al-Ashgar, H; Al-Mdani, A; Al-Qahtani, A; Al-Shoail, G; Aleid, H; Bzeizi, KI; Mousa, D; Saadeh, M; Sanai, FM | 1 |
| Gara, N; Ghany, MG | 1 |
| Agarwal, K; Carey, I; Joshi, D | 1 |
| Abe, H; Hirose, K; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Nagashima, A; Seki, K; Togashi, T; Yoshida, T | 1 |
| Bismuth, M; Blanc, P; Christophorou, D; Daurès, JP; Duny, Y; Flori, N; Funakoshi, N; Valats, JC | 1 |
| Chou, R; Cottrell, EB; Fu, R; Hartung, D; Rahman, B; Wasson, N | 1 |
| An, D; Barnard, RJ; Bhanja, S; Gane, EJ; Gress, J; Hwang, P; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A | 1 |
| Bernstein, B; Cohen, DE; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R | 1 |
| Balistreri, WF; Barton, BA; Cheng, I; Gonzalez-Peralta, RP; Haber, BA; Jonas, MM; Lobritto, SJ; Mellman, W; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Njoku, D; Rosenthal, P; Schwarz, KB; Talor, MV | 1 |
| Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ | 1 |
| Corvino, SM; Grotto, RM; Padovani, JL; Pardini, MI; Silva, GF; Zeminian, LB | 1 |
| Amaral, KM; Costi, C; da Fré, NN; da Silva, CM; Fiegenbaum, M; Grandi, T; Niel, C; Picon, PD; Rossetti, ML | 1 |
| Ahmed, A; Doss, W; Saad, Y; Saleh, DA | 1 |
| Andreone, P; Brandao-Mello, CE; Craxi, A; Di Bisceglie, AM; Freilich, B; Hooper, G; Jensen, DM; Marcellin, P; Messinger, D; Olveira Martín, A; Rajender Reddy, K; Tatsch, F; Teuber, G; Wat, C | 1 |
| Ahn, SM; Byun, KS; Choi, DJ; Jung, YK; Kim, JH; Kim, JW; Kim, YS; Kwon, OS; Park, SJ; Yang, JW; Yeon, JE | 1 |
| Heller, T; Tana, MM | 1 |
| Cacoub, P; Saadoun, D; Terrier, B | 1 |
| Feld, JJ; Ghany, MG; Hara, K; Haynes-Williams, V; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Rotman, Y; Zhao, X | 1 |
| Bani-Sadr, F; Carrieri, P; Dabis, F; Loko, MA; Marchou, B; Morlat, P; Neau, D; Pambrun, E; Salmon, D; Winnock, M | 1 |
| Eshach Adiv, O; Kori, M; Rosen, I; Shaoul, R; Yerushalmi, B; Zion, N | 1 |
| Abd-Eldaem, AA; Ahmad, YK; Azmy, MK; Badr, GA; El-Dahshan, T; Houssein, MA | 1 |
| Al-Ahdal, MN; Al-Ashgar, HI; Al-Qahtani, A; Al-Thawadi, S; Helmy, A; Khalaf, N; Khan, MQ; Sanai, FM | 1 |
| Cioe, PA; Friedmann, PD; Promrat, K; Stein, MD | 1 |
| Mensa, FJ; Zeuzem, S | 1 |
| Antón Ródenas, G; Martínez Pascual, C; Ortiz Sánchez, ML; Pons Miñano, JA | 1 |
| Grudinin, M; Komissarov, A; Kozlov, V; Samusenko, I; Stelmakh, V | 1 |
| Abdo, AA; Al-hamoudi, W; Alfaleh, A; Alfaleh, FZ; Ali, SM; Alswat, K; Bedewi, MA; El-sharkawy, M; Hadad, Q; Helmy, A; Omar, M; Shalaby, A | 1 |
| Angulo, J; Biel, F; Labbé, P; López-Lastra, M; Miquel, JF; Pavez, C; Pino, K; Soza, A | 1 |
| Andreone, P; Brown, KK; Cammarata, S; Chuang, WL; Feutren, G; Flisiak, R; Foster, GR; George, J; Gould, M; Jacobson, IM; Komolmit, P; Lee, CM; Messina, I; Pianko, S; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Sola, R; Sood, A; Tanwandee, T; Thongsawat, S; Yin, Y; Zeuzem, S | 1 |
| Anzai, K; Eguchi, Y; Hirai, M; Isoda, H; Iwane, S; Izumi, N; Kawaguchi, Y; Kimura, S; Kurose, K; Mizuta, T; Nakashita, S; Oeda, S; Ozaki, I; Takahashi, H | 1 |
| Alshuth, U; Berger, F; Heyne, R; Hueppe, D; John, C; Mauss, S; Moog, G; Pape, S; Pfeiffer-Vornkahl, H; Schober, A | 1 |
| Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA | 1 |
| Arnholm, B; Björkman, P; Hellstrand, K; Lagging, M; Lindh, M; Nilsson, S; Norkrans, G; Wahlberg, T; Wallmark, E; Weiland, O; Wejstål, R; Westin, J; Widell, A | 1 |
| Andreoletti, M; Borroni, G; Cazzaniga, M; Ceriani, R; Guerzoni, P; Omazzi, B; Pich, MG; Prada, A; Salerno, F; Spinzi, G; Terreni, N | 1 |
| Colle, I; Degre, D; Moreno, C; Van Vlierberghe, H | 1 |
| Jia, JD; Rakhda, MI; Wang, TI; Zhao, XY | 1 |
| Cornberg, M; Manns, MP | 2 |
| Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT | 1 |
| Burney, T; Dusheiko, G | 2 |
| Afdhal, N; Albanis, E; An, D; Anderson, JK; Bernstein, DE; Berrey, MM; Crespo, I; Davis, MN; DeMicco, M; Dvory-Sobol, H; Gordon, SC; Hassanein, T; Hindes, RG; Hyland, RH; Jacobson, IM; Kowdley, KV; Lawitz, E; Nelson, DR; Symonds, WT; Vierling, JM | 1 |
| Aghemo, A; Colombo, M; Cremonesi, E; Degasperi, E; Mantovani, S; Mele, D; Mondelli, MU; Oliviero, B; Rumi, MG; Tinelli, C; Varchetta, S | 1 |
| Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D | 1 |
| Asselah, T; Böcher, WO; Bourlière, M; Bronowicki, JP; Datsenko, Y; Kukolj, G; Larrey, D; Mauss, S; Nehmiz, G; Pawlotsky, JM; Pol, S; Scherer, J; Shafran, SD; Steinmann, GG; Stern, JO; Sulkowski, MS | 1 |
| Carifa, A; Eley, T; Falk, P; Fridell, R; Gardiner, D; Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Wang, C; Yu, F; Zhou, N | 1 |
| Chan, CH; Gilliver, RS; Hansen, RD; Jones, BE | 1 |
| Coffin, CS; Fritzler, MJ; Myers, RP; Stinton, LM | 1 |
| Fernández-Rodríguez, A; Jiménez-Sousa, MÁ; Resino, S | 1 |
| Al-Shamma, S; Allen, H; Hovell, C; Hydes, T; Sharer, NM; Williams, EJ | 1 |
| Bruha, R; Dusek, L; Kreidlova, M; Marecek, Z; Petrtyl, J; Urbanek, P | 1 |
| Fischer, L; Logge, C; Nashan, B; Sterneck, M; Vettorazzi, E | 1 |
| Cao, H; Gao, ZL; Guo, XY; Xie, DY; Xie, JQ; Zhang, XH; Zhao, ZX | 1 |
| Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC | 1 |
| Akin, MS; Atabay, A; Dogan, UB; Yalaki, S | 1 |
| Cacopardo, B; Nunnari, G; Pinzone, MR | 1 |
| Hickman, M; Martin, NK; Miners, A; Vickerman, P | 1 |
| Mazana, JS | 1 |
| Bota, S; Neghină, AM; Popescu, A; Şirli, R; Sporea, I; Străin, M | 1 |
| Berg, T; Däumer, M; Dietz, J; Fitting, D; Füller, C; Herrmann, E; Lengauer, T; Mihm, U; Sarrazin, C; Schelhorn, SE; Susser, S; Teuber, G; Wedemeyer, H; Welker, MW; Zeuzem, S | 1 |
| Aboalam, H; Ahmed, WH; Eldin, AS; Furusyo, N; Hayashi, J; Murata, M; Ogawa, E; Zaky, S | 1 |
| Arama, V; Popescu, C; Popescu, GA | 1 |
| Abdel-Rahman, M; El-Akel, W; El-Beshlawy, M; El-Raziky, M; Esmat, G; Saad, Y; Said, M; Zayed, N | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 4 |
| Aizawa, N; Enomoto, H; Higuchi, K; Hongo, Y; Jyomura, H; Kim, SR; Kudo, M; Nishida, N; Nishiguchi, S; Nishikawa, H; Okazaki, K; Osaki, Y; Seki, T; Tsuda, Y | 1 |
| Cheng, J; Gao, YJ; Li, MH; Lu, Y; Qiu, GH; Shen, G; Wu, Y; Xie, Y; Xu, D; Yang, M; Zhang, L; Zhang, YL; Zhuang, LW | 1 |
| Anty, R; Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Pop, S; Tran, A; Trucchi, R; Tsilika, K | 1 |
| Cahn, P; Gun, A; Laufer, N; Ojeda, D; Quarleri, J; Sede, M | 1 |
| Chuang, WL; Dai, CY; Yu, ML | 1 |
| Angus, P; Arasteh, K; Asselah, T; Böcher, WO; Bronowicki, JP; Gane, E; Heim, M; Kukolj, G; Larrey, D; Lohse, AW; Mensa, FJ; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, YC; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML | 1 |
| Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Rallón, N; Resino, S; Restrepo, C; Soriano, V | 2 |
| Alemán, R; Castellano, G; García-Samaniego, J; González-Portela, C; Granados, R; Jorge Juan, M; Pérez, R; Romero, M; Suárez, D | 1 |
| Geng, JX; Zhang, JM; Zhang, Q | 1 |
| Capuron, L; de la Torre, R; Giménez, D; Gratacòs, M; Langohr, K; Martín-Santos, R; Moreno-España, J; Navinés, R; Solà, R; Udina, M | 1 |
| Bruggmann, P; Brunner, N; Falcato, L; Rosemann, T; Senn, O | 1 |
| Casado, JL; Dronda, F; Hermida, JM; Moreno, A; Moreno, S; Navas, E; Pérez-Elías, MJ; Quereda, C; Royuela, A; Serrano-Villar, S | 1 |
| Boonstra, A; De Knegt, RJ; Groothuismink, ZM; Janssen, HL; Koning, L; Roomer, R; Spaan, M | 1 |
| de Jong, YP; Jacobson, IM; Jesudian, AB | 1 |
| Dixit, V; Fabrizi, F; Messa, P | 1 |
| Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Aoki, Y; Hiramine, S; Imamura, M; Ito, K; Kanto, T; Kimura, T; Kirikae, I; Korenaga, M; Masaki, N; Matsui, T; Mizokami, M; Murata, K; Saito, H; Sugiyama, M; Yoshio, S | 1 |
| Jung, YK; Kim, JH | 1 |
| Byun, KS; Han, KH; Heo, NY; Kim, KM; Lee, HC; Lee, KS; Lee, YS; Lim, YS; Paik, SW; Suh, DJ; Yoon, SK | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Apica, B; Chen, EY; Czul, F; Dubin, P; Lee, WM; Martin, P; Sclair, SN | 1 |
| Chen, Y; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Yang, C; Zeng, X; Zhang, P; Zhu, Q | 1 |
| Bazin-Karra, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Longuet, M; Musset, L; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM | 1 |
| Abeleira, M; Diz, P; Eirea, M; Feijoo, J; Limeres, J; Ocampo, A; Ramos, I | 1 |
| Drenth, JP | 2 |
| Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z | 1 |
| Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM | 1 |
| Idrees, M; Rehman, HU; Ullah, S | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Ting, TT; Tseng, TC | 1 |
| Beckstead, S; Beking, D; Finch, S; Knorr, T; Lynch, C; MacKenzie, M; Mayer, D; Melles, B; Newman, AI; Shore, R | 1 |
| Inglot, M; Malyszczak, K; Pawlowski, T; Radkowski, M; Szymczak, A; Zalewska, M | 1 |
| Brass, CA; Bronowicki, JP; Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Poordad, F | 1 |
| Gómez, S; Marcoval, J; Martín, C; Notario, J | 1 |
| Aghemo, A; Colombo, M; Degasperi, E; Lampertico, P; Viganò, M | 1 |
| Cheong, JY; Cho, SW; Han, S; Hwang, SG; Jang, JW; Jeong, SH; Jin, YJ; Kim, JH; Kim, YS; Lee, CK; Lee, JI; Lee, JS; Lee, JW; Park, CK; Park, SH; Park, YM; Rim, KS; Sohn, JH; Yang, JM; Yim, HJ | 1 |
| Chang, B; Li, B; Sun, Y; Teng, G; Zhang, W; Zhao, J | 1 |
| Bojovic, K; Delic, D; Jevtovic, DJ; Katanic, N; Milosevic, I; Pesic, I; Simonovic, J; Svirtlih, N | 1 |
| Fontana, RJ; Rangnekar, AS | 1 |
| Beumont, M; Ceulemans, H; De Meyer, S; Dierynck, I; Foster, GR; Ghys, A; Lin, TI; Picchio, G; Van Baelen, B | 1 |
| Abbassi, MM; Ali-Eldin, ZA; Ibrahim, WA; Mohamed, AA; Sabry, NA | 1 |
| Hsu, YA; Hung, DZ; Liao, WL; Lim, YP; Lin, CY; Peng, CY; Tien, N; Tsai, FJ; Tsai, KH; Wan, L | 1 |
| Cooper, CL; Kelly, EM | 1 |
| Baron, J; Biedroń-Machura, M; Błońska-Fajfrowska, B; Musialik, J; Pierzchała, W; Sozańska, E; Zbroszczyk, M | 1 |
| Arena, U; Corti, G; Laffi, G; Leoncini, L; Marra, F; Milani, S; Monti, M; Pellegrini, E; Pinzani, M; Renzo, S; Stasi, C; Triboli, E; Zignego, AL | 1 |
| Durantel, D; Levrero, M; Testoni, B | 1 |
| Schmutz, JL; Trechot, P | 1 |
| An, CM; Dai, EH; Jia, YH; Kong, L; Li, YS; Nan, YM; Su, SS; Sun, DX; Zhang, YG; Zhao, SX; Zheng, HW | 1 |
| Gong, WJ; Ma, XH; Sun, YX; Teng, ZL; Zhang, SQ | 1 |
| Coton, T; Diallo, I | 1 |
| Akyuz, F; Badur, S; Baran, B; Demir, K; Ermis, F; Gulluoglu, M; Kaymakoglu, S; Simsek, BP; Uyanikoglu, A | 1 |
| Christian, A; Gallimore, AM; Godkin, A; Hills, RK; Jones, E; Pembroke, T; Wang, EC | 1 |
| Bukh, J; Carlsen, TH; Christensen, PB; Jensen, TB; Krarup, H; Laursen, AL; Pedersen, J; Schønning, K; Weis, N | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Hisanaga, Y; Kanamori, A; Kiriyama, S; Kitabatake, S; Kumada, T; Murakami, Y; Tada, T; Tanikawa, M; Toyoda, H | 1 |
| Abdel-Rahman, M; El Raziky, M; El-Akel, W; El-Sayed, M; Elsharkawy, A; Esmat, G; Ghoneim, H; Khattab, H | 1 |
| Chen, PJ; Chu, YT; Kuo, RN; Lai, MS; Liu, CJ; Shau, WY | 1 |
| Aravena, E; González, MZ; Iturriaga, H; Pinto, A; Roblero, JP | 1 |
| Akin, MS; Dogan, UB; Yalaki, S | 2 |
| Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Okada, K; Shimizu, M; Takayama, K; Toyoda, K | 1 |
| Perelson, AS; Rong, L | 1 |
| Adda, N; Adiwijaya, B; Bsharat, M; Dieterich, DT; Garg, V; Gharakhanian, S; Girard, PM; Henshaw, J; Mahnke, L; McCallister, S; Rockstroh, JK; Rubin, RA; Sherman, KE; Soriano, V; Sulkowski, MS | 1 |
| Bukatman, R; Gordon, P; Kramer, D; Krug, P; Mermelstein, P | 1 |
| Auriemma, F; Caporaso, N; Donnarumma, L; Gaeta, L; Gentile, I; Granata, R; Guarino, M; Loperto, I; Morisco, F; Stroffolini, T | 1 |
| Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Iio, S; Imai, Y; Inada, M; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Bajaj, JS; Forton, DM | 1 |
| Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M | 1 |
| Chan, MW; Chou, JL; Huang, HB; Tseng, CW; Tseng, KC; Wu, SF | 1 |
| Asch, SM; Chan, K; Clark, JA; Gifford, AL; Groessl, EJ; Hanchate, AD; Ho, SB; Lai, MN; Wong, JB | 1 |
| Geier, A; Rau, M | 1 |
| Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G | 1 |
| Asselah, T | 6 |
| Hsu, SH; Wang, SN; Yeh, ML | 1 |
| Albrecht, JK; Bacon, BR; Brass, CA; Bronowicki, JP; Burroughs, MH; Davis, M; Deng, W; Dutko, FJ; Esteban, R; Gordon, SC; Lawitz, EJ; Poordad, F; Rajender Reddy, K; Sniukiene, V; Sulkowski, MS; Yoshida, EM | 1 |
| Beinhardt, S; Dulic, M; Ferenci, P; Gschwantler, M; Hofer, H; Holzmann, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strassl, R | 1 |
| Abbas, SM; El-Feky, HM; Hegab, MF; Lashin, AH; Metwally, MA; Shaheen, YA | 1 |
| Barreiro, P; Camacho, A; Caruz, A; Cifuentes, C; Di Lello, FA; García-Rey, S; Macias, J; Neukam, K; Pineda, JA; Rallon, NI; Rivero, A; Rivero-Juarez, A; Soriano, V | 1 |
| Abdelli, N; Ben Abdallah, H; Bizid, S; Bouali, R; Kilani, I; Mohamed, G | 1 |
| Akahane, T; Igarashi, T; Ishii, M; Iwata, T; Kakazu, E; Kato, T; Kimura, O; Kisara, N; Kobayashi, T; Kondo, Y; Miura, M; Miyazaki, Y; Morosawa, T; Nakayama, H; Ninomiya, M; Obara, N; Sasaki, K; Shimosegawa, T; Ueno, Y | 1 |
| Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A | 1 |
| Sharma, P | 1 |
| Airoldi, A; Belli, LS; Bitetto, D; Burra, P; Cmet, S; Colpanij, M; Cussigh, A; De Feo, T; De Martin, E; Donato, MF; Fabris, C; Fagiuoli, S; Falleti, E; Gambato, M; Mantovani, M; Pasulo, L; Piccolo, G; Rigamonti, C; Toniutto, P; Viganò, R | 1 |
| Aggarwal, J; Bayliss, M; Donepudi, M; Goss, T; Martin, M; Vera-Llonch, M; Younossi, Z | 1 |
| Glavaš, S; Gornjaković, S; Mehmedović, A; Mesihović, R; Papović, V; Saray, A; Vanis, N; Vukobrat-Bijedić, Z | 1 |
| Chan, JM; Fung, J; Lai, CL; Liu, K; Seto, WK; Tsang, OT; Wong, DK; Yuen, MF | 1 |
| Aoki, K; Kumada, H; Ohtsuki, M; Sakurai, Y; Sueki, H; Torii, H; Yamada, I | 1 |
| Belleli, D; Davis, AK; Kemp, W; McCarthy, P; Northcott, MJ; Ong, WL; Street, A; Tran, H; Walsh, M | 1 |
| Baldo, V; Carlotto, A; Del Bianco, T; Fabris, P; Floreani, A; Giordani, MT; Grasso, A; Malfatti, F; Miotti, MA; Tramarin, A | 1 |
| Annicchiarico, EB; D'Aversa, F; Gasbarrini, A; Pompili, M; Ponziani, FR; Siciliano, M | 1 |
| Chang, KC; Chen, TC; Chien, YS; Hu, TH; Hung, CH; Lee, CT; Lin, MT; Shen, CH; Tsai, MC; Tseng, PL; Yen, YH | 1 |
| Ahlén, G; Diepolder, H; Fons, M; Frelin, L; Jung, MC; Levander, S; Mathiesen, I; Sällberg, M; Sardesai, NY; Vahlne, A; Weiland, O | 1 |
| Barnard, RJ; Cheney, CA; Dinubile, MJ; Graham, DJ; Hazuda, DJ; Himmelberger, AL; Hwang, PM; McHale, CM; Mobashery, N; Newhard, W; Nickle, D; Reeves, JD; Rivera, AA; Strizki, J | 1 |
| Naggie, S; Osinusi, A | 1 |
| Cooper, C; Fainboim, H; Greaves, W; Howe, AY; Mak, C; Mallolas, J; Pol, S; Rivero, A; Sklar, P; Slim, J; Sulkowski, M; Thompson, S; Wahl, J; Wenning, L | 1 |
| Abe, H; Aida, Y; Aizawa, Y; Ika, M; Ishiguro, H; Itagaki, M; Kato, K; Miyazaki, T; Seki, N; Shimada, N; Sutoh, S; Tsubota, A; Yoshizawa, K | 1 |
| Akuta, N; Arase, Y; Fukushima, T; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Taylor, DR | 1 |
| Christensen, P; Dalgard, O; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Norkrans, G; Rauning Buhl, M; Rembeck, K; Westin, J | 1 |
| Benhamou, Y; Beumont, M; De Backer, K; De Meyer, S; Ghys, A; Lebray, P; Luo, D; Moussalli, J; Picchio, GR; Ratziu, V | 1 |
| Kanda, T; Miyamura, T; Nakamoto, S; Nakamura, M; Wu, S; Yokosuka, O | 1 |
| Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Plaza, Z; Poveda, E; Soriano, V; Treviño, A; Vispo, E | 1 |
| Abrams, GA; Ahmad, A; Bourlière, M; Bronowicki, JP; Cohen, D; Eley, T; Fried, MW; He, B; Hézode, C; Hindes, R; Hughes, E; Larrey, D; Martorell, CT; Massoud, O; McPhee, F; Mendez, P; Morris, DW; Pol, S; Ratziu, V; Reddy, KR; Reilly, B; Rustgi, VK; Thuluvath, PJ; Younes, Z | 1 |
| Albrecht, JK; Bacon, B; Bárcena, R; Brass, CA; Deng, W; Esteban-Mur, R; Gordon, SC; Hadziyannis, SJ; Häussinger, D; Jacobson, IM; Manns, MP; Marcellin, P; Morgan, TR; Norkrans, G; Pedicone, LD; Pockros, PJ; Poynard, T; Schiff, ER; Schmidt, WN; Shaikh, OS; Shiffman, ML; Smith, CI | 1 |
| Andrei, A; Füller, C; Köberle, V; Kronenberger, B; Perner, D; Piiper, A; Sarrazin, C; Susser, S; Waidmann, O; Zeuzem, S | 1 |
| Bonner, JE; Esserman, DA; Evon, DM; Fried, MW; Golin, CE; Rao, T | 1 |
| George, PM; Mitchell, JA | 1 |
| Bregigeon, S; Colson, P; Poizot-Martin, I; Solas, C; Tamalet, C; Tourres, C | 1 |
| Hsiao, CC; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JC; Wang, JH; Yen, YH | 1 |
| Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Medrano, J; Miralles, P; Rallón, N; Resino, S; Soriano, V | 1 |
| Abdel-Aziz, AO; Alam El-Din, HM; Bahnassy, AA; Eldahshan, DH; Mohamed, WS; Shousha, HI; Zayed, N; Zekri, AR | 1 |
| Borovicka, J; Gerlach, TJ; Helbling, B; Moradpour, D; Pache, I; Stickel, F; Worni, M | 1 |
| Amano, K; Arinaga, T; Fujimoto, Y; Ide, T; Ishii, K; Kuhara, K; Kumashiro, R; Kuwahara, R; Miyajima, I; Morita, Y; Murashima, S; Ogata, K; Sakai, K; Sata, M; Shirachi, M; Uchimura, N | 1 |
| Bell, S; Holmes, J; Thompson, A | 1 |
| Chen, DS; Chen, MY; Chen, PJ; Chen, TC; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Baumgarten, A; Boesecke, C; Grzeszczuk, A; Mandorfer, M; Meyer-Olson, D; Neukam, K; Payer, BA; Peck-Radosavljevic, M; Pineda, JA; Puoti, M; Reiberger, T; Rivero, A; Rockstroh, JK; Trauner, M; Zangerle, R | 1 |
| Kang, EJ; Kweon, YO; Lee, HS; Lee, YL; Park, HW; Park, SY; Tak, WY; Yang, HM | 1 |
| Brown, J; Paladino, JA; Turner, SJ | 1 |
| Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL | 1 |
| Kumada, T; Murakami, Y; Tada, T; Toyoda, H | 1 |
| Chen, JY; Chen, WT; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Sheen, IS | 1 |
| Beinhardt, S; Datz, C; Ferenci, P; Hofer, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M | 1 |
| Han, H; Hoofnagle, JH; Liang, TJ; Noureddin, M; Park, YJ; Rotman, Y; Witthaus, M | 1 |
| Kawada, A; Oiso, N; Sato, M | 1 |
| Gwinn, M; Hu, DJ; Zhang, L | 1 |
| Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kakinuma, S; Kurosaki, M; Muraoka, M; Nakagawa, M; Nakanishi, H; Nishimura, T; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Watanabe, M; Yasui, Y | 1 |
| Akuta, N; Hara, T; Hosaka, T; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Ahmed, Wu; Alam, SE; Arif, A; Sajjad, SF; Waquar, J | 1 |
| Berenguer, M; Calleja, JL; Molina, E; Romero-Gómez, M | 1 |
| Battegay, M; Beniowski, M; Grint, D; Jevtovic, D; Kirk, O; Lundgren, JD; Mocroft, A; Peters, L; Pradier, C; Rockstroh, JK; Schwarze-Zander, C; Soriano, V | 1 |
| Ikeda, F; Iwasaki, Y; Matsushita, H; Miyake, Y; Moritou, Y; Nanba, S; Nouso, K; Onishi, H; Seki, H; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F | 1 |
| Ehleben, C; Pearlman, BL | 3 |
| Amendola Pires, MM; Barcaui, HS; Barroso, PF; Brandão-Mello, CE; May, SB; Tavares, GC | 1 |
| Berki, T; Halasz, M; Hegedus, G; Hunyady, B; Miseta, A; Palinkas, L; Par, A; Par, G; Szekeres-Bartho, J; Szereday, L; Vincze, A | 1 |
| El Raziky, M; Nassar, YH; Nour, ZA; Shaker, OG | 1 |
| Deraz, DM; Elbaz, TM; Shehab, HM | 1 |
| Banerjee, S; Gakkhar, S; Keval, R | 1 |
| Alraies, MC; Alraiyes, AH; Alsabbagh, ME; Eisa, N | 1 |
| Abbasi, A; Bhutto, AR; Butt, N; Dhillo, AK; Munir, SM | 1 |
| Beumont-Mauviel, M; Buti, M; De Smedt, G; Dore, GJ; Ferenci, P; Flisiak, R; Fried, MW; Gilles, L; Jacobson, I; Lenz, O; Manns, M; Marcellin, P; Nikitin, I; Peeters, M; Poordad, F; Scott, J; Sekar, V; Sherman, M; Zeuzem, S | 1 |
| Amanzada, A; Mihm, S; Ramadori, G | 1 |
| Everson, GT; Reddy, KR | 1 |
| Blum, HE | 3 |
| Everhart, JE; Wright, E | 1 |
| Berki, T; Fehér, J; Fráter, E; Gervain, J; Haragh, A; Hunyady, B; Kisfali, P; Lengyel, G; Melegh, B; Nemes, Z; Pálinkás, L; Papp, M; Pár, A; Pár, G; Péterfi, Z; Schuller, J; Szalay, F; Szinku, Z; Tornai, I; Tusnádi, A; Varga, M; Várszegi, D; Vincze, A | 1 |
| Cai, QX; Hong, CX; Lin, CS; Zhang, XH; Zhao, ZX | 1 |
| Abe, H; Aida, Y; Aizawa, Y; Ika, M; Ishiguro, H; Shimada, N; Tsubota, A; Yoshizawa, K | 1 |
| Brochot, E; Duverlie, G; Guillemard, C; Mathurin, P; Nguyen-Khac, E; Plantier, JC; Riachi, G; Vabret, A | 1 |
| Chang, CY; Chang, SY; Chen, CY; Hung, DZ; Liao, WL; Lim, YP; Peng, CY; Tien, N; Tsai, FJ; Wan, L | 1 |
| Aghemo, A; Colombo, M | 3 |
| Ahmed, DS; Barua, R; Chowdhury, MS; Ishaque, SM; Masud, H; Parveen, S; Rahman, MA; Rahman, MZ | 1 |
| Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S | 1 |
| Aziz, S; Mirza, T; Sohail, S | 1 |
| Boglione, L; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G | 1 |
| Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S | 1 |
| Aghemo, A; Lampertico, P | 1 |
| Han, J; Hoop, RS; Jacobson, IM; Korner, EJ; Lafleur, J; Martin, P; Pandya, P; Talal, AH | 1 |
| Mishra, A; Younossi, Z | 1 |
| Ferenci, P; Rutter, K | 1 |
| Cheng, G; Corsa, AC; Delaney, WE; Kim, CU; Krawczyk, S; Mo, H; Pakdaman, R; Peng, B; Qi, X; Robinson, M; Shen, M; Sheng, XC; Tay, C; Tian, Y; Wang, Y; Yang, C; Yang, H | 1 |
| Halota, W; Pawłowska, M; Pilarczyk, M; Wiśniewska-Ligier, M; Woźniakowska-Gęsicka, T | 1 |
| Andréjak, M; Bodeau, S; Brochot, E; Castelain, S; Durand-Maugard, C; Duverlie, G; François, C; Helle, F; Lemaire-Hurtel, AS; Nguyen-Khac, E | 1 |
| Gane, EJ; Lawitz, E | 1 |
| Hsu, CS | 1 |
| Kuboki, M; Nishiguchi, S; Omata, M; Sakai, Y; Sakamoto, W; Steinmann, G; Tsuda, Y; Tsunematsu, S; Urano, Y | 1 |
| Arakawa, Y; Higuchi, T; Matsumura, H; Moriyama, M; Nakamura, H; Nirei, K; Ogawa, M; Tanaka, N | 1 |
| Arnaud, C; Berthillon, P; Chemin, I; Maynard, M; Petit, MA; Pradat, P; Spaziante, M; Taliani, G; Trépo, C | 1 |
| Igarashi, K; Katsumi, T; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sato, C; Shao, L; Soga, T; Sugimoto, M; Tomita, K; Tomita, M; Ueno, Y; Watanabe, H | 1 |
| Ahn, SM; Choi, DJ; Jung, YK; Kim, JH; Kim, JS; Kim, YS; Kwon, OS | 1 |
| Gong, GZ; Jiang, YF; Liu, D; Liu, SF; Peng, ML; Xiao, XQ; Zhang, M | 1 |
| Abate, ML; Andriulli, A; Andriulli, N; Angelico, M; Barone, M; Brancaccio, G; Calvaruso, V; Cozzolongo, R; Craxi, A; D'Andrea, G; Di Marco, V; Fasano, M; Fattovich, G; Felder, M; Gaeta, GB; Gatti, P; Gioffreda, D; Ippolito, AM; Margaglione, M; Mazzella, G; Milella, M; Morisco, F; Santantonio, T; Smedile, A; Tundo, P; Valvano, MR | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Tanaka, Y; Thuy, le TT; Uchida-Kobayashi, S | 1 |
| Flisiak, R; Jaroszewicz, J; Lapinski, TW; Panasiuk, A; Parfieniuk-Kowerda, A; Rogalska-Plonska, M; Swiderska, M | 1 |
| Blázquez-Pérez, A; Mar, J; San Miguel, R | 1 |
| Arakawa, T; Hige, S; Karino, T; Kimura, M; Kuwata, Y; Nakajima, T; Ohmura, T; Ozeki, I; Sato, T; Toyota, J | 1 |
| Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Goto, S; Hayashi, N; Kato, M; Komada, Y; Seto, C | 1 |
| Cao, YG; Hou, HR; Jin, X; Kang, Y; Liang, SQ; Liu, JP; Shang, J | 1 |
| Cai, RT; Shen, L; Yang, YF; Zhang, YC; Zhao, W | 1 |
| Tacke, F; Zimmermann, HW | 1 |
| Lee, TH; Patel, K; Tillmann, HL | 1 |
| Chen, LY; Lei, XZ; Li, YX; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Yang, M; Yang, YJ | 1 |
| Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S | 2 |
| Baur, K; Cerny, A; Dufour, JF; Frei, P; Geier, A; Gerlach, T; Heim, M; Held, U; Kofmehl, R; Leucht, AK; Manser, CN; Mertens, J; Moradpour, D; Müllhaupt, B; Negro, F; Rau, M; Schmitt, J | 1 |
| Cai, Z; Deng, H; Ji, F | 1 |
| Anderson, RT; Baran, RW; Dietz, B; Erickson, P; Gooch, K; Revicki, DA | 1 |
| Boucher, CA; Broekman, MM; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Lamers, MH; Reesink, HW; van Hoek, B | 1 |
| Arends, JE; Dutilh, JC | 1 |
| Feigelstock, DA; Mihalik, KB | 1 |
| Chiba, M; Dohmen, T; Goto, T; Kamada, K; Kanata, R; Minami, S; Miura, K; Ohnishi, H; Ohshima, S; Sakai, T; Sato, W; Shibuya, T; Sugimoto, Y | 1 |
| Hu, KQ; Zhang, YY | 1 |
| Bau, S; Ferguson, J; Saab, S; Zhou, K | 1 |
| Karasawa, T; Saito, T; Soga, T; Sugimoto, M; Ueno, Y | 1 |
| Armienta-Sarabia, R; Cordero-Pérez, P; Hernández-Gómez, ME; Malé-Velázquez, R; Marín-López, E; Muñoz-Espinosa, LE; Núñez-Camarena, Jde J; Olivera-Martínez, MA; Sánchez-Avila, JF; Torres-González, L | 1 |
| Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC | 1 |
| Galle, PR; Knapstein, J; Zimmermann, T | 1 |
| Harrison, SA; Torres, DM | 1 |
| Alsaran, K; Molhem, A; Sabry, A | 1 |
| Pol, S | 2 |
| Albrecht, JK; Brass, CA; Clark, PJ; Gordon, SC; Jazwinski, AB; Lawitz, EJ; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS; Thompson, AJ | 1 |
| Cabezas, J; Crespo, J; Luis Calleja, J; Selmo, J | 1 |
| Forns, X; Solà, R | 1 |
| Planas, R; Tural, C | 1 |
| Macías, J; Rivero, A | 1 |
| García, F; Poveda, E | 1 |
| Pineda, JA | 1 |
| Aizawa, N; Enomoto, H; Iijima, H; Ikeda, N; Imanishi, H; Iwata, K; Iwata, Y; Nishiguchi, S; Saito, M; Sakai, Y; Takashima, T; Tanaka, H | 1 |
| Camacho, A; López-Cortés, LF; Marquez, M; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rivero-Juarez, A; Téllez, F | 1 |
| Fabri, M; Kiralj, K; Mikić, SS; Preveden, T; Ruzić, M; Vukadinov, T | 1 |
| Brahm, J; Torres, C; Venegas, M | 1 |
| Aparicio, E; Clotet, B; Franco, S; Martinez, MA; Parera, M; Tural, C | 1 |
| Agúndez, JA; Fernández-Pérez, C; García-Martín, E; Ladero, JM; Maestro, ML; Martínez, C; Ortega, L; Suárez, A; Vidaurreta, M | 1 |
| Wang, P; Wang, X; Xu, DH; Yan, SS; Yin, J; Zhang, PJ | 1 |
| Bichoupan, K; Dieterich, DT; Shankar, H | 1 |
| Ashraf, J; Azam, S; Imran, M; Khalid, M; Khaliq, HM; Manzoor, S; Tariq, M | 1 |
| Baklan, Z; Kotar, T; Lesnicar, G; Maticic, M; Meglic Volkar, J; Poljak, M; Prah, J; Rajter, M; Selic Kurincic, T | 1 |
| Blotner, S; Brennan, BJ; Grippo, JF; Magnusson, MO; Martin, P; Nieforth, K; Solsky, J; Wang, K; Wat, C; Wilkins, JJ | 1 |
| Inao, M; Mochida, S; Nakayama, N; Sugawara, K | 1 |
| Cao, ZH; Chen, XY; Du, XF; Guo, DD; Liu, YL; Lu, JF; Ma, LN; Zhang, YH | 1 |
| Chang, SC; Chung, YC; Hung, CT; Lee, HM; Li, SF; Pai, LW; Yang, SS | 1 |
| Hézode, C | 4 |
| Agarwal, K; Barnabas, A | 1 |
| Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Ohnishi, H; Okada, K; Shimizu, M; Takayama, K; Toyoda, K | 1 |
| Abdou, MM; Kishk, RM; Mandour, MF; Matsuura, K; Nemr, NA; Ragheb, MM; Tanaka, Y; Watanabe, T | 1 |
| Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J | 1 |
| Faheem, S; Kazmi, SY; Khalid, SR; Tanveer, A | 1 |
| Brulotte, N; Hahn, H; Lee, M | 1 |
| Ahmed, QL; Ashraf, J; Ashraf, W; Aziz, H; Imran, M; Khalid, M; Manzoor, S; Tariq, M | 1 |
| Genda, T; Hirano, K; Ichida, T; Iijima, K; Ishikawa, S; Kanemitsu, Y; Kikuchi, T; Narita, Y; Sato, S; Tsuzura, H; Wada, R | 1 |
| Albrecht, JK; Bacon, B; Balart, L; Bourliere, M; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, M; Davis, MN; Felizarta, F; Helmond, FA; Kwo, P; Manns, MP; McCone, J; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Schiff, E; Shiffman, ML; Sings, HL; Sulkowski, MS; Vierling, JM | 1 |
| Amanzada, A; Cameron, S; Goralczyk, AD | 1 |
| Aghemo, A; Bitetto, D; Bruno, R; Caraceni, P; Ciancio, A; Coco, B; Marzioni, M; Petta, S; Rendina, M; Valenti, L | 1 |
| Calleja, JL; Crespo, J; Diago, M; García-Samaniego, J; Planas, R; Romero-Gómez, M; Rubio-Terrés, C; Solà, R; Turnes, J; Ventayol, P | 1 |
| Chen, XY; He, ZM; Hua, W; Ma, LN | 1 |
| Barnard, RJ; Bhanja, S; Bourque, M; DiNubile, MJ; Gane, EJ; Hwang, PM; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A; Strizki, J; Zhou, A | 1 |
| Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Au, JS; Pockros, PJ | 1 |
| Beste, LA; Green, PK; Ioannou, GN; Scott, JD; Yang, Y | 1 |
| Ancuta, I; Aronsohn, A; Caruntu, F; Cheinquer, H; Coppola, C; Delic, D; Digiacomo, A; Dusheiko, GM; Korner, E; Lengyel, G; Marcellin, P; Orlandini, A; Pruthi, J; Schmitz, M; Silva, GF; Tallarico, L; Tatsch, F | 1 |
| Pockros, PJ; You, DM | 1 |
| Alessio, L; Capoluongo, N; Coppola, N; De Pascalis, S; Macera, M; Minichini, C; Paradiso, L; Pisaturo, M; Sagnelli, C; Sagnelli, E; Stanzione, M | 1 |
| Lam, TT; Markov, PV; Pybus, OG; Rose, R | 1 |
| Carpio-Pedroza, JC; Cruz-Rivera, M; Escobar-Gutiérrez, A; Fonseca-Coronado, S; Larouche, A; Martinez-Guarneros, A; Ruiz-Tovar, K; Soudeyns, H; Vazquez-Chacon, CA; Yamasaki, LH | 1 |
| Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Chen, X; Guo, X; Ruan, P; Yang, G; Yuan, J; Zhang, M; Zhou, B | 1 |
| Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM | 1 |
| Grigorian, ÉG; Sarkisiants, NK | 1 |
| Cao, Q; Ding, GQ; Kang, Y; Liu, JP; Shang, J; Wei, JF; Xiao, EH | 1 |
| Deguchi, H; Higashi, K; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawaguchi, M; Kawashima, A; Maekita, T; Mori, Y; Moribata, K; Shingaki, N; Tamai, H; Tsukuda, H; Ueda, K | 1 |
| Bon, D; Cai, SY; Haagmans, B; Herrmann, E; Kottilil, S; Lee, YJ; Lempicki, R; Masur, H; Nelson, A; Osinusi, A; Polis, M; Poonia, S; Shivakumar, B; Sneller, M; Wood, B | 1 |
| Abdo, AA; Al-Ahdal, MN; Al-Ashgar, HI; Al-Qahtani, AA; Alhamlan, FS; Elhefnawi, M; Khalaf, NZ; Sanai, FM; Zaid, A | 1 |
| Chang, KC; Chen, CH; Hu, TH; Huang, CM; Hung, CH; Kuo, YH; Lee, CM; Liang, CM; Lu, SN; Tsai, MC; Wang, JH; Yen, YH | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ | 1 |
| Ackefors, M; Gjertsen, H; Nyström, J; Sönnerborg, A; Weiland, O; Wernerson, A | 1 |
| Alberti, A; Bruno, R; Calvaruso, V; Covolo, L; Craxì, A; Di Marco, V; Donato, F; Fattovich, G; Ferrari, C; Gaeta, GB; Levrero, M; Mondelli, M; Mussini, C; Puoti, M; Raimondo, G; Santantonio, T; Suter, F | 1 |
| Benanti, F; Cacopardo, B; Nunnari, G; Pinzone, MR | 1 |
| Chen, L; Chen, X; Liu, C; Lu, Y; Xu, Q; Yang, L; Yang, Z; Zhuang, L | 1 |
| Mingote-Adán, C; Solís-Herruzo, JA; Solis-Muñoz, P | 1 |
| Jiangrong, W; Jing, L; Yingying, L | 1 |
| Berg, T; Beumont-Mauviel, M; De Smedt, G; Ferenci, P; Foster, GR; Fried, MW; Gane, E; Hezode, C; Hirschfield, GM; Jacobson, I; Lenz, O; Nikitin, I; Peeters, M; Pockros, PJ; Poordad, F; Scott, J; Sekar, V; Sinha, R; Zeuzem, S | 1 |
| Bieber, B; Gillespie, B; Goodkin, DA; Jadoul, M; Robinson, BM | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E | 1 |
| Chayama, K; Karino, Y; Kawakami, Y; Kumada, H; Suzuki, F; Toyota, J | 1 |
| Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S | 1 |
| Gong, G; Luo, H; Wang, H; Xiao, S; Zhou, H | 1 |
| Abdurakhmanov, D; Colombo, M; DeMasi, R; Fernández, I; Ferreira, PA; Hill, A; Iraqi, W; Läuffer, JM; Lonjon-Domanec, I; Moreno, C; Strasser, SI; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H | 1 |
| Hou, XJ; Wang, J; Xu, JH; Yu, YY | 1 |
| Beinhardt, S; Datz, C; Ferenci, P; Gschwantler, M; Hofer, H; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Strassl, R; Trauner, M | 1 |
| Aslam, S; Bremer, B; Cobb, B; Cornberg, M; Halfon, P; Luk, K; Maasoumy, B; Manns, MP; Wedemeyer, H | 1 |
| Abdo, S; Attia, D; El Akel, W; El Raziky, M; Elsharkawy, A; Esmat, G; Khatab, H; Shaker, O | 1 |
| Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT | 1 |
| Doyle, JS; Hellard, ME | 1 |
| Mahale, P; Okhuysen, PC; Torres, HA | 1 |
| Abe-Sandes, K; Angelo, AL; Cavalcante, LN; Lemaire, DC; Lyra, AC; Lyra, LG; Machado, TB; Malta, F; Pinho, JR | 1 |
| Rodríguez-Torres, M | 1 |
| Anagnostou, O; Andreadis, I; Deutsch, M; Kalafateli, M; Ketikoglou, I; Manolakopoulos, S; Mela, M; Papatheodoridis, G; Pectasides, D; Schini, M; Striki, A; Triantos, C | 1 |
| Chen, PJ; Chen, YC; Cheng, SN; Chu, HC; Hsieh, TY; Lin, JA; Shih, YL | 1 |
| Chen, CY; Chien, RN; Fang, CC; Fang, YJ; Hsu, CW; Huang, YH; Hung, CH; Lee, CM; Lu, SN; Peng, CY; Tsai, TJ; Tseng, KC; Tung, SY; Yeh, CT | 1 |
| Almerighi, C; Angelico, M; Bandiera, F; Biliotti, E; Di Candilo, F; Di Masi, F; Forte, P; Francioso, S; Gentile, S; Lionetti, R; Longo, MA; Montalbano, M; Nosotti, L; Parruti, G; Piccolo, P; Piras, MR; Ponti, ML; Renzi, S; Riccobelli, F; Salso, A; Santopaolo, F; Taliani, G; Zaru, S | 1 |
| Al Badawy, N; El Zowalaty, M; Husseiny, MI; Ibrahim, S; Mohtady, H; Omar, AR; Sadeq, R | 1 |
| Bitetto, D; Ceriani, E; Cmet, S; Cussigh, A; Dissegna, D; Fabris, C; Falleti, E; Fattovich, G; Ieluzzi, D; Lenisa, I; Pirisi, M; Rostello, A; Toniutto, P | 1 |
| Baragli, F; Corti, G; Salomoni, E | 1 |
| Gazdag, G; Horváth, G; Szabó, O; Takács, R; Ungvari, GS | 1 |
| Ahmed, A; Nguyen, MH; Wantuck, JM | 1 |
| Brandão-Mello, CE; de Araújo Ramos, AL; de França, PH; de Jesus Dominici, A; de Mattos, AA; de Souza Leite Pinho, M; Ferreira, LE; Garcia, CE; Garcia, RF; Moreira, S; Nader, LA; Ramos, JA; Rondinelli, E; Tovo, CV; Villela-Nogueira, CA | 1 |
| Adler, M; Assene, C; de Galocsy, C; Delwaide, J; Lasser, L; Michielsen, P; Mulkay, JP; Nkuize, M | 1 |
| Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM | 2 |
| Brost, S; Ganten, TM; Koschny, R; Schirmacher, P; Stremmel, W; Sykora, J; Walczak, H; Zimmermann, A | 1 |
| Alberti, A; Colombo, M; Craxì, A; Rizzetto, M | 1 |
| Fernández-Alonso, R; González-Diéguez, ML; Junceda-Moreno, J; Pérez-Carro, G; Rodríguez-García, M | 1 |
| Henry, L; Hunt, S; Mir, HM; Singer, ME; Younossi, ZM | 1 |
| Barreiro, P; Camacho, A; Labarga, P; Macias, J; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juarez, A; Soriano, V; Torre-Cisneros, J | 1 |
| Applegate, T; Cherepanov, V; Dore, GJ; Feld, JJ; Grebely, J; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Sherker, A; Yeung, B | 1 |
| Chauhan, R; Chen, AY; Jacobson, IM; Michalak, TI; Talal, AH; Zeremski, M | 1 |
| Ando, K; El-Shamy, A; Fujinami, A; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Takashi, H; Tanaka, Y; Yano, Y | 1 |
| El-Shamy, A; Fujinami, A; Hasegawa, Y; Hatae, T; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Tanaka, Y | 1 |
| El-Shamy, A; Fujinami, A; Fujioka, H; Hasegawa, Y; Hatae, T; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Tanaka, Y; Yano, Y | 1 |
| Hörl, WH; Schmidt, A | 1 |
| Ide, T; Kato, K; Kondoh, M; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H; Tsubota, A | 1 |
| Alam, S; Alexander, GJ; Bargery, C; Dearden, J; Forton, D; Foster, GR; Freshwater, D; Mills, PR; Moreea, S; Ryder, S; Shoeb, D; Vila, X; Weatherall, A; White, E | 1 |
| Coskun, A; Karaoglu, AO; Yukselen, O; Yukselen, V | 1 |
| Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y | 1 |
| Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Toon, CD; Tsochatzis, E | 1 |
| Casado, JL; Martí-Belda, P; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Kajiwara, E; Murata, M; Ogawa, E; Okada, K; Satoh, T; Takahashi, K; Toyoda, K | 1 |
| Aghemo, A; Clark, PJ; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Muir, AJ; Patel, K; Rumi, MG; Thompson, AJ; Urban, TJ; Vock, DM | 1 |
| Khokhar, N; Niazi, TK; Qureshi, MO | 1 |
| Benini, F; Cinquegrana, A; Fasoli, M; Furba, P; Giacò, E; Lanzini, A; Pigozzi, MG; Zanini, B | 1 |
| Bibert, S; Bochud, PY; Covolo, L; Donato, F; Fattovich, G; Lagging, M; Negro, F | 1 |
| Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Agarwal, K; Bertelsen, K; Brown, RS; Buti, M; De Masi, R; De Meyer, S; Hézode, C; Horsmans, Y; Janczewska, E; Luo, D; Nyberg, L; Paraná, R; Rizzetto, M; Sievert, W; Witek, J; Zeuzem, S | 1 |
| Aghemo, A; D'Ambrosio, R; Fabrizi, F; Martin, P; Messa, P; Moroni, G; Passerini, P | 1 |
| Fukui, H; Hagiwara, H; Hamasaki, T; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Inui, Y; Ito, T; Kasahara, A; Katayama, K; Kato, M; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Alashinnawy, HA; Alwakeel, HR; Kandil, HM; Matarese, LE; Omar, NA; Rewisha, EA; Taha, AA; Zaghla, HE | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML | 1 |
| Matsuura, K; Tanaka, Y; Watanabe, T | 1 |
| Goh, C | 1 |
| Aichelburg, MC; Breitenecker, F; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Puoti, M; Reiberger, T; Rieger, A; Trauner, M; Zangerle, R | 1 |
| Alshuth, U; Berg, T; Böhm, S; Herrmann, E; Mihm, U; Sarrazin, C; Teuber, G; Wedemeyer, H; Welker, MW; Zeuzem, S | 1 |
| Cai, WP; Hu, FY; Lan, Y; Liu, B; Tang, XP; Xu, M | 1 |
| Gane, E; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Dusheiko, G; Ferenci, P | 1 |
| Ahlenstiel, G; Booth, DR; Douglas, MW; George, J; Leung, R; Liddle, C; O'Connor, KS; Parnell, G; Patrick, E; Read, SA; Stewart, GJ; Suppiah, V; van der Poorten, D; Yang, JY | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Kanto, T; Miyagi, T; Miyazaki, M; Morishita, N; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y | 1 |
| Doucette, K; Emokpare, D; Harris, P; Hawkins, K; Kaita, K; McHattie, J; Minuk, GY; O'Brien, M; Pinette, G; Uhanova, J; Wong, S; Worobetz, L | 1 |
| Brew, IF; Butt, C; Wright, N | 1 |
| Joshita, S; Katsuyama, Y; Kimura, T; Komatsu, M; Matsumoto, A; Morita, S; Nozawa, Y; Ota, M; Shibata, S; Tanaka, E; Umemura, T; Yoshizawa, K | 1 |
| Girón-Gonzalez, JA; Lopez-Cortes, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A | 1 |
| Bonner, JE; Esserman, DA; Evon, DM; Golin, CE | 1 |
| Enomoto, N; Maekawa, S | 3 |
| Alonso, S; Bárcena, R; Calleja, JL; Casanovas, T; Fernández-Rodríguez, CM; González, JM; Jorquera, F; Martín-Martín, L; Masnou, H; Miquel-Planas, M; Morillas, RM; Navarro, JM; Planas, R; Poyato, A; Romero-Gomez, M; Salmerón, J; Solà, R | 1 |
| Albrecht, J; Brass, C; Bronowicki, JP; Colvard, LY; Davis, M; Deng, W; Flamm, S; Galati, J; Gordon, SC; Helmond, FA; Howe, AY; Jacobson, I; Lawitz, E; Luketic, V; Marcellin, P; McCone, J; Muir, AJ; Pedicone, LD; Poordad, F; Treitel, M; Vierling, JM; Wahl, J; Yoshida, EM | 1 |
| Abe, H; Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiraga, N; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Ochi, H; Ohishi, W; Ono, A; Takahashi, S; Tsuge, M; Urabe, A; Yokoyama, S | 1 |
| Guner, R; Tufan, ZK | 1 |
| Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Traynor, K | 2 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Goujard, C; Hessamfar, M; Krastinova, E; Perronne, C; Pol, S; Yazdanpanah, Y | 1 |
| Bayliss, MS; Crosby, RD; L'Italien, G; Mathias, S; Sapra, S | 1 |
| Cybula, M; Szemraj, J | 1 |
| Andreone, P; Coate, B; DeMasi, R; Diago, M; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Lonjon-Domanec, I; Negro, F; Picchio, G; Pol, S; Roberts, S; Serfaty, L; Witek, J; Younossi, Z; Zeuzem, S | 1 |
| Ahadi-Barzoki, M; Dashti-Khavidaki, S; Karimzadeh, I; Khalili, H; Nasiri-Toosi, M; Ravi, S | 1 |
| Koff, RS | 2 |
| Djordjević, J; Kostić, V; Radović, J; Vujić, S | 1 |
| Alavian, SM; Behnava, B; Hajarizadeh, B; Keshvari, M; Pouryasin, A; Sharafi, H | 1 |
| Ferenci, P; Stättermayer, AF | 2 |
| Fehér, J; Fráter, E; Gervain, J; Haragh, A; Hunyady, B; Kisfali, P; Lengyel, G; Melegh, B; Nemes, Z; Papp, M; Pár, A; Pár, G; Péterfi, Z; Schuller, J; Szalay, F; Szereday, L; Szinku, Z; Tornai, I; Tusnádi, A; Varga, M; Várszegi, D; Vincze, A | 1 |
| Berry, L; Irving, W | 1 |
| Iqbal, M; Nomani, AZ; Qureshi, MS; Rasheed, K | 1 |
| Bodeau, S; Brochot, E; Duverlie, G; Nguyen-Khac, E | 1 |
| Eder, E; Ferenci, P; Hofer, H; Scherzer, TM | 1 |
| Gupta, AC; Hissar, S; Midha, V; Sarin, SK; Sood, A; Sukriti, S; Trehanpati, N | 1 |
| Aguilar-Noriega, D; Alvarez-Lajonchere, L; Amador-Cañizares, Y; Armas, A; Castellanos, M; Cinza-Estévez, Z; Dausá, M; Dubuisson, J; Dueñas-Carrera, S; González, Y; Guerra, I; Martínez-Donato, G; Núñez, M; Pérez Aguiar, A; Raíces, I; Revé, I; Valenzuela, C; Vasallo, C; Wychowski, C | 1 |
| Aghemo, A; Colombo, M; Falconer, K; Lunghi, G; Sarrazin, C; Susser, S; Vermehren, J; Weiland, O; Zeuzem, S | 1 |
| Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M | 1 |
| Bernstein, B; Cohen, DE; Everson, GT; Foster, GR; Khatri, A; Kowdley, KV; Kwo, P; Larsen, L; Lawitz, E; Liossis, G; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Xie, W; Zeuzem, S | 1 |
| Abraham, GM; Gammal, RS; Spooner, LM | 1 |
| Bakulin, IG; Kiseleva, AV | 1 |
| Arora, SK; Chawla, Y; Rana, D | 1 |
| Markulin, A; Morović, M; Patrk, I; Patrk, J | 1 |
| Abad-Molina, C; Gutierrez-Valencia, A; Jimenez-Jimenez, L; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Ahlén, G; Bode, JG; Brass, A; Brenndörfer, ED; Karthe, J; Sällberg, M | 1 |
| Bourlière, M; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, EJ; Li, J; Lok, AS; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Serfaty, L; Wind-Rotolo, M; Yu, F | 1 |
| Chayama, K; Kawakami, Y; Yokoyama, S | 1 |
| Chayama, K; Hernandez, D; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Monikowski, A; Osaki, Y; Toyota, J; Ueland, J; Watanabe, H; Yokosuka, O; Yu, F; Zhou, N | 1 |
| Chayama, K; Hayashi, N; Hu, W; Hughes, EA; Ikeda, K; Ishikawa, H; Kumada, H; McPhee, F; Miyagoshi, H; Mochida, S; Suzuki, F; Toyota, J | 1 |
| Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O | 1 |
| Lebano, R; Masarone, M; Persico, M; Romano, M; Rosato, V | 1 |
| Aggarwal, V; Cameron, BA; Lloyd, AR; Martinez, D; Nguyen, N; Palmer, C; Simar, D; Zekry, A | 1 |
| Criado-Illana, MT; García-López, L; Hidalgo-Collazos, P; Marín-Ventura, L; Sánchez, R | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Honda, Y; Imamura, M; Inaba, T; Kanai, A; Kawaoka, T; Kosaka, K; Matsui, H; McPhee, F; Miki, D; Murakami, E; Ochi, H; Ono, A; Takahashi, S; Tsuge, M | 1 |
| Baldini, A; Coate, B; DeMasi, R; Luo, D; Mrus, J; Witek, J; Zeuzem, S | 1 |
| Dou, XG | 2 |
| Alvarez, H; de la Llana, FG; Domingo, P; Genebat, M; Guardiola, JM; Hernández-Quero, J; Leal, M; Lluch, JF; Marín, J; Mariño, A; Martínez, L; Martínez-Madrid, O; Martínez-Pérez, MA; Ruiz-Mateos, E; Sánchez-Villegas, J; Vera, F | 1 |
| Abdel-Hady, M; Bansal, S; Barnes, E; Brown, M; Davies, P; Davison, SM; Kelly, DA; Mieli-Vergani, G; Mulla, S; Tizzard, SA | 1 |
| Dillon, JF; Heron, T; Miller, MH | 1 |
| Galmozzi, E; Lampertico, P | 1 |
| Aghemo, A; Galmozzi, E | 1 |
| Brainard, DM; Habersetzer, F; Herring, RW; Kanwar, B; Lawitz, E; Massetto, B; McHutchison, JG; Mo, H; Pang, PS; Pol, S; Rodriguez-Torres, M; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Trenkle, JD; Wyles, DL; Zhu, Y | 1 |
| Adams-Huet, B; Bedimo, R; Holodniy, M; Jain, MK; Kushner, LE; Li, X; Terekhova, D | 1 |
| Aspinall, E; Barclay, ST; Dillon, JF; Dusheiko, G; Goldberg, D; Hayes, P; Hutchinson, SJ; Innes, H; Mills, PR | 1 |
| Carrion, AF; Gutierrez, J; Martin, P | 1 |
| Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M | 1 |
| Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P | 1 |
| Aggarwal, J; Donepudi, M; Goss, TF; Suthoff, E; Vera-Llonch, M; Younossi, Z | 1 |
| Buccoliero, G; Massa, P; Pisconti, S; Resta, F; Urbano, T | 1 |
| Thomas, DL | 1 |
| Ridruejo, E | 2 |
| Ascione, A; Ciancio, A; Craxì, A; Deodato, B; Golotta, C; Iannacone, C; Piccinino, F | 1 |
| Enomoto, M; Fujii, H; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Nakaya, M; Sakaguchi, H; Tamori, A | 1 |
| Fu, JJ; Jiang, D; Kong, WJ; Pan, XC; Wei, L | 1 |
| Awad, T; Gluud, C; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K | 1 |
| Awad, T; Brok, J; Gluud, C; Gluud, LL; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K | 1 |
| Yang, HS; Zhang, CY; Zhang, HM; Zhang, Q | 1 |
| Booth, CL; Bridge, SH; Dusheiko, G; Garcia-Diaz, A; Haque, T; Irish, D; Jacobs, M; Labbett, W; Macartney, MJ; McCormick, AL; Rosenberg, W; Smith, C; Tanwar, S; Trembling, P; Velazquez, C | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Arslan, F; Aslan, F; Ceylan, B; Fincanci, M; Özgüneş, N; Yardimci, C | 1 |
| Aoki, T; Harada, N; Hasegawa, K; Ishizawa, T; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Togashi, J; Yamashiki, N | 1 |
| Ackrill, A; Badman, E; Bernaards, C; Chan, A; Chen, YC; Kulkarni, R; Moreira, S; Smith, PF; Thommes, J; Zhu, Y | 1 |
| Brogan, AJ; Deniz, B; Miller, JD; Rubin, J; Talbird, SE; Thompson, JR | 1 |
| Baranyi, A; Kapfhammer, HP; Meinitzer, A; Putz-Bankuti, C; Rothenhäusler, HB; Stauber, R | 1 |
| Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Delang, L; Neyts, J; Verpaalen, B | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Tsai, PC; Wang, LY; Yang, HL; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Goyal, O; Hissar, S; Khanna, P; Midha, V; Sharma, SK; Sood, A | 1 |
| Hidaka, H; Jiang, W; Kitagawa, H; Koizumi, W; Nakazawa, T | 1 |
| Cong, X; Feng, B; Jin, Q; Kang, Y; Kong, FY; Liu, YY; Rao, HY; Shang, J; Wei, L; Xie, Q; Yang, RF; Zhang, HY | 1 |
| Shiffman, ML | 11 |
| Goto, S; Hayashi, N; Izumi, N; Kato, M; Ki, R; Komada, Y; Kumada, H; Okanoue, T; Seto, C; Tsubouchi, H; Yatsuhashi, H | 2 |
| Angelico, M; Antonucci, G; Belli, L; Bertuzzo, V; Bitetto, D; Bringiotti, R; Burra, P; Colombo, M; Colpani, M; De Martin, E; De Ruvo, N; Di Benedetto, F; Di Leo, A; Di Paolo, D; Donato, MF; Ettorre, GM; Fagiuoli, S; Fornasiere, E; Gasbarrini, A; Gerunda, GE; Giannelli, V; Giusto, M; Iemmolo, RM; Lupo, L; Marino, M; Memeo, V; Merli, M; Miglioresi, L; Montalti, R; Morelli, MC; Pasulo, L; Pinna, AD; Pompili, M; Ponziani, FR; Rendina, M; Rigamonti, C; Rossi, G; Senzolo, M; Tisone, G; Toniutto, P; Vero, V; Viganò, R; Visco-Comandini, U; Zappimbulso, M | 1 |
| Dong, RQ; Han, R; Zhao, CY; Zhen, Z; Zhou, DF; Zhou, JY | 1 |
| Barin, B; Barnes, D; Curry, M; Dove, L; Johl, J; Millis, M; Peters, M; Poordad, F; Reddy, KR; Regenstein, F; Roland, M; Schiano, T; Schiff, E; Shaikh, O; Shetty, K; Stock, P; Terrault, N | 1 |
| Chen, SC; Chou, WW; Chuang, WL; Dai, CY; Hsi, E; Huang, CF; Huang, JF; Juo, SH; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML | 1 |
| Mandorfer, M | 1 |
| Choudhuri, G; Khan, AJ; Mohindra, S; Negi, TS; Parmar, D; Saraswat, VA | 1 |
| Aziz, H; Gill, ML; Gill, U; Raza, A | 1 |
| Liu, T; Liu, X; Sha, K; Wang, Y; Yang, F; Yang, L; Zhang, L | 1 |
| Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kubo, M; Miki, D; Ochi, H | 1 |
| Azuma, T; Bai, F; Hatazawa, Y; Hayakumo, T; Hayashi, Y; Hirano, H; Hotta, H; Imoto, S; Kim, SR; Miki, A; Minami, A; Momose, K; Rinonce, HT; Saito, M; Seo, Y; Sugano, M; Tani, S; Widasari, DI; Yano, Y; Yoon, S | 1 |
| Bailly, F; Chiarello, P; Gagnieu, MC; Hatu, G; Livrozet, JM; Maynard, M; Miailhes, P; Parant, F; Pourcelot, E; Pradat, P; Zoulim, F | 1 |
| Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, T; Stättermayer, AF | 1 |
| Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS | 1 |
| Agathon, D; Bataille, V; Carreno, V; Di Bisceglie, AM; Fich, A; Flisiak, R; Habersetzer, F; Hennequi, M; Honnet, G; Inchauspé, G; Janczweska-Kazek, E; Limacher, JM; Mazur, W; Romero-Gomez, M; Stanciu, C; Tanasescu, C; Toh, ML; Wedemeyer, H; Zerr, P | 1 |
| de Almeida, PR; de Mattos, AA; Tovo, CV | 1 |
| Chen, PJ; Liu, CJ | 1 |
| Al-Bawardy, B; Canterbury, K; Charlton, MR; Colby, CL; Gross, JB; Kim, WR; Larson, JJ; Poterucha, JJ; Therneau, TM; Warner, J | 1 |
| Sogni, P | 1 |
| Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Assoumou, SA; Barter, DM; DiLorenzo, M; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
| Appourchaux, K; Asselah, T; Bedossa, P; Bièche, I; Broët, P; De Muynck, S; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Valla, D; Vidaud, M | 1 |
| Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M | 1 |
| Andriulli, A; Cozzolongo, R; Fontana, R; Iacobellis, A; Ippolito, A; Minerva, N; Niro, GA; Palmieri, O; Valvano, MR | 1 |
| Andriulli, A; Margaglione, M; Palmieri, O; Valvano, MR | 1 |
| Casado-Caballero, F; Escobar-Jimenez, F; Gonzalez-Calvin, JL; Hernandez-Quero, J; Martin-Rodriguez, JL; Redondo-Cerezo, E | 1 |
| Hagan, LM; Schinazi, RF; Sulkowski, MS | 1 |
| Altincatal, A; Cho, K; Gagnon, DR; Grotzinger, KM; Hermos, JA; Lawler, EV; Quach, L; Weber, HC | 1 |
| Bonfim Freitas, F; da Silva Conde, SR; da Silva Graça, E; de Almeida Lins, PA; Demachki, S; Ferreira de Araújo, MT; Fonseca Filgueiras, NK; Ishak, R; Rosário Vallinoto, AC; Silva Dos Santos, BT; Soares Monteiro, JC | 1 |
| Alfaro, I; Lens, S | 1 |
| Arama, V; Brisc, C; Caruntu, F; Gheorghe, L; Goldis, A; Iacob, S; Motoc, A; Preotescu, L; Rednic, N; Rugina, S; Simionov, I; Stefan, I | 1 |
| Dulic, M; Dulic-Lakovic, E; Graninger, W; Gschwantler, M; Rieder, F; Schwarzer, R; Steininger, C | 1 |
| Mano, S; Mizokami, M; Nishida, N; Nishino, J; Sugiyama, M; Tokunaga, K | 1 |
| Amin, M; Hayashi, Y; Hendrayana, A; Hotta, H; Kurniawan, H; Lusida, MI; Mustika, S; Setiawan, PB; Utsumi, T; Wahyuni, RM; Wibawa, ID; Wibowo, BP; Yamani, LN; Yano, Y | 1 |
| Druyts, E; Mills, EJ; Thorlund, K | 1 |
| Aguilera, I; Gómez-Bravo, MA; Núñez-Roldán, A; Sousa, JM | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Dusheiko, G; Esteban, R; Hezode, C; Hunt, SL; Nader, F; Reesink, HW; Stepanova, M; Weiland, O; Younossi, ZM; Zeuzem, S | 1 |
| Müllhaupt, B; Rampini, SK; Schaffstein, S | 1 |
| Aimitsu, S; Aisaka, Y; Chayama, K; Hayes, CN; Kawakami, H; Kawakami, Y; Kira, S; Kitamoto, M; Kohno, H; Moriya, T; Nakanishi, T; Nonaka, M; Takahashi, S; Tsuji, K; Yamashina, K; Yokoyama, S | 1 |
| Hagiwara, H; Harada, N; Hayashi, N; Hikita, H; Hiramatsu, N; Imai, Y; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Mita, E; Miyagi, T; Miyazaki, M; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H | 1 |
| Baykal, T; Bernstein, B; Bourlière, M; DaSilva-Tillmann, B; Desmond, P; Di Bisceglie, AM; Hassanein, T; Jacobson, IM; Jensen, DM; Larsen, L; Marinho, RT; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Tam, E; Varunok, P; Wedemeyer, H; Xiong, J; Zeuzem, S | 1 |
| An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| Aguilar, H; Bernstein, B; Coakley, E; Crawford, D; DaSilva-Tillmann, B; Feld, JJ; Kowdley, KV; Larsen, L; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Sigal, S; Weiland, O; Xiong, J | 1 |
| Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M | 1 |
| Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S | 1 |
| Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S | 1 |
| Barrero Alor, F; Casado Monge, PG; Jiménez Macías, FM; Pujol de la Llave, E; Ramos Lora, M; Ruíz-Frutos, C | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Ghisetti, V | 1 |
| Angelillo, IF; Coppola, N; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Deraz, D; Elattar, I; Elbaz, T; Hafez, A; Shehab, H | 1 |
| Akahoshi, T; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Maehara, Y; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 1 |
| Muir, AJ | 2 |
| Pavri, TM; Reddy, KR; Sinese, L; Wirjosemito, A | 1 |
| Barrou, B; Lemoinne, S; Thabut, D | 1 |
| Kao, JH; Liu, CH | 3 |
| Dybowska, D; Halota, W; Kozielewicz, D | 2 |
| Bacon, BR; Bronowicki, JP; Bruno, S; Deng, W; DiNubile, MJ; Dutko, FJ; Esteban, R; Flamm, SL; Helmond, FA; Koury, KJ; Kwo, PY; Manns, MP; Pedicone, LD; Poordad, F; Vierling, JM; Wahl, J; Zeuzem, S | 1 |
| Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Lee, CY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML | 1 |
| Aghemo, A; Cappellini, MD; Colancecco, A; Colombo, M; Monico, S; Porretti, L; Prati, G; Ronzoni, L; Rumi, MG | 1 |
| Abrignani, S; Almasio, P; Ascione, A; Bonino, F; Brunetto, MR; Colombatto, P; Houghton, M; Maina, AM; Mondelli, M; Muratori, L; Pinzello, G; Rappuoli, R; Romagnoli, V; Rosa, D; Rumi, MG | 1 |
| Enomoto, N; Fujiwara, K; Izumi, N; Joh, T; Kurosaki, M; Kusakabe, A; Matsuura, K; Mizokami, M; Nojiri, S; Orito, E; Sakamoto, N; Shinkai, N; Tanaka, Y; Watanabe, T; Yatsuhashi, H | 1 |
| Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Pinilla, J; Plaza, Z; Soriano, V; Vispo, E | 1 |
| Berg, T; Bremer, B; Cornberg, M; Filmann, N; Herrmann, E; Lunemann, S; Manns, MP; Markova, AA; Mihm, U; Sarrazin, C; Schlaphoff, V; Wedemeyer, H; Zeuzem, S | 1 |
| Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A | 1 |
| Jang, JY; Jeong, SW; Jung, HJ; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, YN | 1 |
| Bagnarelli, P; Capobianchi, MR; Ferreri, ML; Galli, C; Garbuglia, AR; Monachetti, A; Sabatini, R | 1 |
| Bourgeois, S; De Galocsy, C; Horsmans, Y; Lasser, L; Mulkay, JP; Tomasovic, S; Van Vlierberghe, H | 1 |
| Bair, MJ; Chen, HL; Chen, MJ; Lin, CC; Lin, IT; Shih, SC; Wang, HY; Wang, TE; Wu, CH | 1 |
| Konstantinov, DIu; Konstantinova, EA; Popova, LL; Strebkova, EA; Suzdal'tsev, AA | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Ray, K | 2 |
| Chusri, P; Kumthip, K; Maneekarn, N; Nelson, KE; O'Brien, A; Pantip, C; Thongsawat, S | 2 |
| Grewal, P; Kim, B; Thung, SN; Trivedi, A | 1 |
| Akkarathamrongsin, S; Payungporn, S; Poovorawan, K; Poovorawan, Y; Prapunwattana, P; Tangkijvanich, P; Thong, VD | 2 |
| Abdel-Aty, EF; Abdel-Ghaffar, AY; Abdel-Ghaffar, TY; Allam, AA; Behairy, BE; Ehsan, NA; El Naghi, S; El-Araby, HA; El-Guindi, MA; El-Hennawy, AM; El-Karaksy, H; El-Raziky, MS; El-Sebaie, H; Helmy, H; Sira, MM | 1 |
| Antón, J; de Juan, J; Faraco, I; García-Guerrero, J; Marco, A; Portilla, J; Pozo, E; Saiz de la Hoya, P | 1 |
| Amaral, KM; Costi, C; Fiegenbaum, M; Fré, NN; Grandi, T; Gregianini, TS; Niel, C; Picon, PD; Rossetti, ML; Silva, CM | 1 |
| Kashiwagi, Y; Kawashima, H; Nagao, R; Nishimata, S; Suzuki, S; Tsutsumi, N | 1 |
| Broekman, M; Drenth, JP; Gluud, C; Lamers, MH | 2 |
| Braddock, M; Chen, YP; He, JP; Li, LF; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH | 1 |
| Ghany, MG; Liang, TJ | 1 |
| Brainard, DM; Dusheiko, GM; Esteban, R; Ferenci, P; Flisiak, R; Hézode, C; Hyland, RH; Illeperuma, A; Mangia, A; McHutchison, JG; Reesink, HW; Salupere, R; Subramanian, GM; Svarovskaia, E; Symonds, WT; Weiland, O; Zeuzem, S | 1 |
| Baruch, Y; Bernstein, D; Bhandari, BR; Box, TD; Caruntu, FA; Chulanov, V; Cohen, D; Cooper, C; Enayati, P; Ferenci, P; Gervain, J; Green, S; Hassanein, T; Janczewska, E; King, M; Lalezari, J; Luo, Y; Marinho, RT; Moreno, C; Nyberg, A; Planas, R; Podsadecki, T; Reddy, KR; Rizzardini, G; Sepe, T; Tam, E; Tsai, N; Xie, W; Younes, Z | 1 |
| Chayama, K; Imamura, M | 3 |
| Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M | 1 |
| Francis, J; Gordon, CE | 1 |
| Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inui, Y; Kaneko, A; Kasahara, A; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Suzuki, K; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yamada, R; Yoshida, Y; Yoshihara, H | 1 |
| Chapman, R; Costella, A; De Angelis, D; Griffiths, J; Harris, HE; Harris, RJ; Ramsay, M; Thomas, B | 1 |
| Linas, BP; Pho, MT | 1 |
| Adda, N; Bengtsson, L; Bzowej, NH; DeMasi, R; Dusheiko, GM; Flamm, SL; Fried, MW; George, S; Kieffer, TL; Muir, AJ; Nelson, DR; Reddy, KR; Sullivan, JC; Wright, CI | 1 |
| An, J; Deng, H; Feng, Y; Ji, F; Li, Z; Xiao, S; Zhang, Y | 1 |
| Angeli, E; Caputo, A; Cattelan, AM; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| Dixit, NM; Garaigorta, U; Padmanabhan, P | 1 |
| James, P; Win, LL; Wong, DK | 1 |
| Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E | 1 |
| Choi, YW; Huh, KC; Kang, YW; Kim, SM; Kim, YS; Lee, KO; Lee, TH | 1 |
| Alavian, SM; Keshvari, M; Sharafi, H | 1 |
| Barrett, L; Kottilil, S; Masur, H; Odigie, M; Osinusi, A; Polis, MA; Suffredini, AF; Townsend, K; Wang, H | 1 |
| Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N | 1 |
| Ahmed, DS; Chowdhury, MS; Huda, MN; Mahmuduzzaman, M; Perveen, S; Rahman, MA; Rahman, MZ; Raihan, MA | 1 |
| Mutimer, D | 1 |
| Chan, J | 1 |
| Alexander, P; James, A; Long, AG; Shiffman, ML | 1 |
| Bel Hadj, N; Ben Nejma, H; Cheikh, M; Ennaifer, R; Hefaiedh, R; Romdhane, H | 1 |
| Abe, H; Aizawa, Y; Atsukawa, M; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Nakagawa, A; Sakamoto, C; Shimada, N; Tsubota, A | 1 |
| Takehara, T | 4 |
| Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH | 1 |
| Beumont, M; De Meyer, S; Dierynck, I; Ghys, A; Luo, D; Picchio, G | 1 |
| Alavian, SM; Bokharaei-Salim, F; Keyvani, H; Monavari, SH; Sadeghi, F; Salehi-Vaziri, M; Salimi, S; Vahabpour, R | 1 |
| Alves, K; Asmal, M; DeSouza, C; Di Bisceglie, AM; Gane, E; George, S; Jacobson, IM; Kauffman, R; Kieffer, T; Koziel, MJ; Nelson, D; Sulkowski, M; Zhang, EZ | 1 |
| Böcher, WO; Hennecke, N; Kayser, A; Kukolj, G; Lohmann, V; Martin, B; Neumann-Haefelin, C; Thimme, R | 1 |
| Abdelsalam, MS; Althaf, MM; Nadri, Q; Rashwan, M | 1 |
| Beumont-Mauviel, M; Buti, M; de Araujo, ES; De La Rosa, G; Horsmans, Y; Janczewska, E; Kalmeijer, R; Lenz, O; Manns, M; Marcellin, P; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, J; Sinha, R; Villamil, F | 1 |
| Beumont-Mauviel, M; Craxi, A; De La Rosa, G; Dore, GJ; Foster, GR; Fried, MW; Jacobson, IM; Kalmeijer, R; Lenz, O; Moroz, L; Ouwerkerk-Mahadevan, S; Peeters, M; Radu, M; Rafalsky, VV; Scott, J; Sinha, R | 1 |
| Enomoto, N; Ito, K; Izumi, N; Koike, K; Komatsu, M; Masaki, N; Masaki, T; Mizokami, M; Murata, K; Nakamuta, M; Shimada, N; Sugiyama, M; Tanaka, Y; Tsubota, A; Watanabe, S; Yoneda, M | 1 |
| Cao, GW; Lin, J; Wu, JF; Zhang, HW; Zhang, Q | 1 |
| Bukowska-Ośko, I; Cortes, KC; Laskus, T; Opoka-Kegler, J; Pawełczyk, A; Perlejewski, K; Radkowski, M | 1 |
| Chernova, O; Ignatova, T; Moiseev, S; Novikov, P | 1 |
| de la Vega, J; López-Larrea, C; López-Rodríguez, R; López-Vázquez, A; Martínez-Borra, J; Martínez-Camblor, P; Pérez-Álvarez, R; Pérez-López, R; Prieto, J; Rodrigo, L; Sanz-Cameno, P; Vidal-Castiñeira, JR | 1 |
| Chen, TW; Chu, HC; Fan, HL; Hsieh, CB; Hsieh, TY; Hsu, KF | 1 |
| Joshita, S; Kamijo, A; Katsuyama, Y; Kimura, T; Kiyosawa, K; Kobayashi, M; Komatsu, M; Maruyama, A; Matsumoto, A; Mori, H; Morita, S; Nozawa, Y; Ota, M; Shibata, S; Takamatsu, M; Tanaka, E; Umemura, T; Wada, S; Yoshizawa, K | 1 |
| Abe, H; Akamatsu, S; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Miki, D; Murakami, E; Ochi, H; Tsuge, M | 1 |
| Duvic, M; Kyvernitakis, A; Mahale, P; Torres, HA | 1 |
| Galati, G; Gallo, P; Menna, P; Minotti, G; Picardi, A; Salvatorelli, E; Vespasiani Gentilucci, U | 1 |
| Einecke, D | 1 |
| Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K | 1 |
| Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, D; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H | 1 |
| Atta, HA; Kamel, M; Kishk, R; Metwally, L; Nemr, N; Ragheb, M | 1 |
| Abdurakmonov, D; Abrao Ferreira, P; Colombo, M; DeMasi, R; Fernández, I; Hill, A; Iraqi, W; Lonjon-Domanec, I; Moreno, C; Strasser, S; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H | 1 |
| Acero Fernández, D; Ferri Iglesias, MJ; Figa Francesch, M; Hombrados Verde, M; López Nuñez, C; Louvriex Freire, R; Virolés Torrent, S | 1 |
| Boldrini, B; Caini, P; Fabbrizzi, A; Fognani, E; Gragnani, L; Laffi, G; Monti, M; Piluso, A; Ranieri, J; Triboli, E; Urraro, T; Zignego, AL | 1 |
| Aghemo, A; Andriulli, A; Angelico, M; Brancaccio, G; Calvaruso, V; Craxi, A; Di Marco, V; Di Paolo, D; Gavrila, C; Grassi, E; Ippolito, AM; Nardi, A; Squadrito, G; Valvano, MR | 1 |
| Abdi, AM; Boglione, L; Cardellino, CS; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G | 1 |
| Honda, M; Kaneko, S; Lemon, SM; Murai, K; Murakami, S; Okada, H; Sakai, Y; Shimakami, T; Shiomoto, T; Shirasaki, T; Takabatake, R; Tokumaru, A; Yamashita, T | 1 |
| Hu, H; Liu, F; Ren, H; Wang, X; Wei, F | 1 |
| Cacoub, P; Saadoun, D | 2 |
| Chen, TH; Liao, WL; Lim, YP; Lin, WY; Peng, CY; Tsai, FJ; Wan, L | 1 |
| Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC | 1 |
| Korr, M | 1 |
| Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D | 1 |
| Kekez, AJ | 2 |
| Duvnjak, M; Kurelac, I; Vince, A | 1 |
| Hrstić, I; Ostojić, R | 1 |
| Begovac, J | 2 |
| Smolić, M; Smolić, R; Vcev, A | 1 |
| Almasio, PL; Andreone, P; Azzola, E; Benedetti, A; Borghesio, E; Borgia, G; Carosi, G; Carrara, M; Coppola, C; Koch, M; Masocco, M; Mazzotta, F; Mele, A; Milella, M; Nardone, G; Rizzetto, M; Romano, M; Rosina, F; Sagnelli, E; Tosti, ME; Zignego, AL | 1 |
| Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Rogalska-Taranta, M; Wedemeyer, H | 1 |
| Ginba, H; Ide, T; Izumi, N; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H | 2 |
| Aroucha, DC; Cavalcanti, Mdo S; do Carmo, RF; Dutra, RA; Moura, P; Pereira, LB; Pereira, LM; Vasconcelos, LR | 1 |
| Bharali, R; Chowdhury, SJ; Gumma, PK; Kar, P; Karra, VK | 1 |
| Lin, JA; Shih, YL | 1 |
| Lim, TH; Pearlman, BL | 1 |
| Allen, TM; Park, SH; Rehermann, B; Tully, DC; Veerapu, NS | 1 |
| Kared, H; Klein, MB; Saeed, S; Shoukry, NH | 1 |
| Corchado, S; Girón-González, JA; López-Cortés, LF; Márquez-Coello, M; Rivero, A; Rivero-Juárez, A; Torres-Cornejo, A | 1 |
| Berak, H; Bukowska-Ośko, I; Cortés, KC; Horban, A; Laskus, T; Maroszek, K; Pawełczyk, A; Perlejewski, K; Płoski, R; Radkowski, M; Zagordi, O | 1 |
| An, J; Heo, NY; Kim, KM; Lee, D; Lee, HC; Lee, W; Lee, YS; Lim, YS; Oh, M; Shim, JH; Suh, DJ | 1 |
| Jouan, L; Lamarre, D; Rigsby, H; Rodrigue-Gervais, IG; Willems, B | 1 |
| Cornella, S; Shah, NL; Stine, JG | 1 |
| Bessone, F; Bronowicki, JP; Cohen, D; Eley, T; Gadano, A; He, B; Hernandez, D; Hughes, E; Martorell, CT; McPhee, F; Mendez, P; Pol, S; Ratziu, V; Terg, R; Thuluvath, PJ; Younes, Z; Yu, F | 1 |
| Bourhis, F; Cure, S; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Dixit, V; Fabrizi, F; Martin, P; Messa, P | 2 |
| Aghemo, A; Colombo, M; Ferraris Fusarini, C; Garlaschi, MC; Lunghi, G; Maiavacca, R; Matinato, C; Novembrino, C; Ramondetta, M; Ronchi, M; Torresani, E | 1 |
| Ahmad, A; Chan, P; Freeman, J; Hillson, J; Horga, MA; Hruska, M; Kansra, V; Lopez-Talavera, JC; Wang, X | 2 |
| Galle, PR; Knapstein, J; Wörns, MA; Zimmermann, T | 1 |
| Alavi, M; Baker, D; Balcomb, A; Doong, N; Dore, GJ; Erratt, A; Grebely, J; Hallinan, R; Hill, S; Keats, J; Marks, P; Richmond, D; Siriragavan, S; Smart, J | 1 |
| Aherfi, S; Borentain, P; Botta-Fridlund, D; Bregigeon, S; Brouqui, P; Colson, P; Dhiver, C; Gérolami, R; Mokhtari, S; Moreau, J; Motte, A; Poizot-Martin, I; Portal, I; Ravaux, I; Ruiz, JM; Solas, C; Stein, A; Tamalet, C | 1 |
| Ahmed, A; Assem, N; Doss, W; El Kassas, M; El Raziky, M; Elsharkawy, A; Esmat, G; Hassany, M; Sabry, D | 1 |
| Arora, S; Everson, G; Flisiak, R; George, J; Ghalib, R; Gordon, SC; Gray, T; Greenbloom, S; Hassanein, T; Hillson, J; Horga, MA; Jacobson, IM; Jeffers, L; Kowdley, KV; Lawitz, E; Lopez-Talavera, JC; Lueth, S; Muir, AJ; Rodriguez-Torres, M; Rustgi, V; Shemanski, L; Shiffman, ML; Srinivasan, S; Vargas, HE; Vierling, JM; Xu, D; Zeuzem, S | 1 |
| Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
| Bruno, R; Bruno, S; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A | 1 |
| Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawaguchi, M; Kawashima, A; Maekita, T; Mori, Y; Moribata, K; Shingaki, N; Tamai, H; Ueda, K; Wada, Y | 1 |
| Arotçarena, R; Causse, X; Denis, J; Hagège, H; Henrion, J; Lesgourgues, B; Nalet, B; Pariente, A; Rémy, AJ | 1 |
| Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Martínez, P; Miguel Benito, J; Miralles, P; Rallón, N; Resino, S; Soriano, V | 1 |
| Andruszkiewicz, A; Bartoszewicz, K; Duczkowska, M; Jurczyk, K; Karpińska, E; Laurans, Ł; Parczewski, M; Socha, Ł; Sławiński, J; Wawrzynowicz-Syczewska, M; Zeair, S | 1 |
| Antón, JJ; de la Hoya, PS; Faraco, I; Hoyos, C; Juan, Jd; Marco, A; Pozo, E; Yllobre, C | 1 |
| Beumont, M; Callewaert, K; Corregidor, A; DeJesus, E; Fevery, B; Ghalib, R; Gitlin, N; Jacobson, IM; Lambrecht, T; Lawitz, E; Lim, JK; Lindsay, KL; Ouwerkerk-Mahadevan, S; Pearlman, B; Picchio, G; Pockros, PJ; Rabinovitz, M; Rodriguez-Torres, M; Scott, JD; Sulkowski, MS; Symonds, WT; Younossi, ZM | 1 |
| Bourlière, M; Bräu, N; Brunetto, MR; Esmat, G; Everson, GT; Fried, MW; Ghesquiere, W; Hernandez, D; Hézode, C; Hirschfield, GM; Hughes, EA; Kwo, PY; Lawitz, EJ; Liu, Z; McPhee, F; Noviello, S; Pockros, PJ; Pol, S; Rodriguez-Torres, M; Rustgi, VK; Schnittman, S; Serfaty, L; Shafran, SD; Sievert, W; Sulkowski, M; Tatum, HA; Thuluvath, PJ; Vierling, JM; Waked, I; Weiland, O; Weis, N; Wind-Rotolo, M; Yin, PD; Zeuzem, S | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inada, M; Inui, Y; Ito, T; Kasahara, A; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H | 1 |
| Devine, S; Kattan, M; Muir, A; Thompson, A | 1 |
| Abbassi, MM; Aref, AM; EzzEl-Arab, MA; Hamed, WA; Mohamed, AA | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Masuda, H; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K | 1 |
| Aimitsu, S; Aisaka, Y; Chayama, K; Hayes, CN; Imamura, M; Kawakami, H; Kawakami, Y; Kira, S; Kitamoto, M; Kohno, H; Moriya, T; Nakanishi, T; Nonaka, M; Takahashi, S; Tsuji, K; Yamashina, K; Yokoyama, S | 1 |
| Maldonado, AM; Martín-Álvarez, A; Muñoz-de-Rueda, P; Quer, J; Quiles-Pérez, R; Salmerón, J | 1 |
| Deghedy, A; El-Fatah Fahmy Hanno, A; Mohiedeen, KM; Sayed, R | 1 |
| Manos, MM; Murphy, RC; Pauly, MP; Price, JC; Shvachko, VA | 1 |
| Berdeaux, G; Bianic, F; Cure, S; de Knegt, RJ; Lamotte, M; van Agthoven, M; van der Kolk, A; Vellopoulou, A | 1 |
| Kraus, MR; Schäfer, A; Scheurlen, M | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Soriano, V | 1 |
| Dan, YY; Elbasha, EH; Ferrante, SA; Hsu, TY | 1 |
| Abd El Aziz, G; El Raziky, M; Rashad, A; Shaker, O | 1 |
| Hayashi, N; Izumi, N; Mobashery, N | 1 |
| Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K | 1 |
| Bardadin, K; Berak, H; Horban, A; Kołakowska-Rządzka, A; Laskus, T; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M | 1 |
| Chang, KC; Chang, ML; Chen, TH; Cheng, ML; Chiu, CT; Hu, TH; Lin, CH; Lin, WR; Pang, JH; Shiao, MS; Sung, CM; Tsou, YK; Yeh, CT | 1 |
| Abradelo, M; Agüero, F; Aguilera, V; Antela, A; Barcena, R; Bernal, C; Castells, L; de la Rosa, G; Del Campo, S; Esteban-Mur, JI; Fernandez, JR; González-García, J; Laguno, M; Manzardo, C; Miro, JM; Montero, JL; Olivares, S; Perez, I; Rimola, A; Rodriguez, M; Salcedo, M; Suarez, F; Valdivieso, A; Xiol, X | 1 |
| Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM | 1 |
| Caro-Pérez, N; Coto-Llerena, M; Crespo, G; Fernández-Carrillo, C; Forns, X; Gambato, M; González, P; Mensa, L; Navasa, M; Pérez-del-Pulgar, S | 1 |
| Al Bouzidi, A; El Baaj, M; Hadri, L; Moudden, MK; Ouarssani, A; Ziadi, T | 1 |
| Abdou, AG; Asaad, NY; Ehsan, N; El-Sabaawy, MM; Elkholy, S; Elnaidany, NF; Eltahmody, M | 1 |
| Adachi, K; Hayashi, M; Ishii, T; Kumano, R; Kumon, D; Sato, A; Yamada, T; Yamauchi, M | 1 |
| Eslick, GD; Kitson, MT; Roberts, SK; Sarrazin, C; Toniutto, P | 1 |
| Bazin-Kara, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Musset, L; Peltier, J; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM | 1 |
| Aboulker, JP; Aumaitre, H; Batisse, D; Bertucci, I; Braun, J; Chevaliez, S; Cotte, L; de Truchis, P; Gervais, A; Lacombe, K; Lascoux-Combe, C; Michelet, C; Molina, JM; Morlat, P; Neau, D; Rosa, I; Sogni, P; Valantin, MA; Vincent, C; Vittecoq, D | 1 |
| Rockstroh, JK | 2 |
| Asselah, T; Bruno, S; Craxi, A | 1 |
| Ebrahimi, M; Haqshenas, G; KayvanJoo, AH | 1 |
| Bai, CH; Chong, LW; Lai, HW; Liao, CS; Lin, YM; Pu, CY; Su, HC; Tsai, PJ; Tsai, YS; Tsao, CW; Young, KC | 1 |
| Alshuth, U; Hueppe, D; Jordan, S; Lohse, AW; Lueth, S; Mauss, S; Pfeiffer-Vornkahl, H; Roeder, C; Schulze Zur Wiesch, J; Stoll, S; Zehnter, E | 1 |
| Andreone, P; Conti, F; Vitale, G | 1 |
| Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C | 1 |
| Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX | 1 |
| Cifuentes, C; Di Lello, FA; Gómez-Mateos, J; Guelfo, JR; Macías, J; Mira, JA; Neukam, K; Palomares, JC; Parra-Sánchez, M; Pineda, JA; Real, LM | 1 |
| Beumont, M; Cerri, K; Evon, DM; Fu, M; Gilles, L; Peeters, M; Rosa, K; Scott, J; Zeuzem, S | 1 |
| Lutchman, GA; Nguyen, MH; Nguyen, NH; Vutien, P; Wong, CR; Yee, BE; Zhang, B | 1 |
| Jiang, D; Li, J; Li, XG; Li, Z; Liu, Y; Wang, M; Wu, S; Zhang, H; Zhang, Y; Zhang, Z; Zheng, W; Zhou, R | 1 |
| Chiang, CH; Lai, FJ | 1 |
| Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ | 1 |
| Brussman, K; Nadir, A; Smith, ZM | 1 |
| De La Rosa, G; Dieterich, D; Gutiérrez, F; Jenkins, A; Jessner, W; Klein, MB; Lenz, O; Orkin, C; Ouwerkerk-Mahadevan, S; Peeters, M; Reynes, J; Rockstroh, JK; Shukla, U; Tambuyzer, L | 1 |
| Allen, S; Barclay, S; Bhattacharyya, D; Dillon, JF; Fox, R; Fraser, A; Goldberg, DJ; Hayes, PC; Hutchinson, SJ; Innes, HA; Kennedy, N; McDonald, SA; Mills, PR | 1 |
| Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Jiao, J; Liu, W; Qu, C; Zheng, Z; Zhu, J | 1 |
| Imran, M; Manzoor, S; Parvaiz, F | 1 |
| Kang, Y; Shang, J; Zeng, Y | 1 |
| Kottilil, S; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Naggie, S; Osinusi, A; Patel, K; Qin, J; Remaley, AT; Sampson, M; Sims, Z; Sturdevant, D; Subramanian, M | 1 |
| Du, S; Gong, Y; Kong, W; Li, C; Li, J; Mao, W; Qu, Y; Rao, H; Tian, S; Yang, J; Zhang, W | 1 |
| Boghdadi, G; Seleem, WM | 1 |
| Blanchard, E; Samaras, K; Vickers, CR | 1 |
| Martel-Laferrière, V | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Lang, G; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Briz, V; Carrero, A; Diez, C; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F | 1 |
| Cai, L; Chen, Y; Liao, R; Liu, X; Lu, Q; Wang, X; Yang, X; Yang, Z; Zhang, L | 1 |
| Amanzada, A; Cameron, S; Goralczyk, AD; Mihm, S; Moriconi, F; Reinhardt, L | 1 |
| Peltekian, KM | 1 |
| Yau, AH; Yoshida, EM | 1 |
| Congly, SE; Lee, SS | 1 |
| Saab, S; Younossi, ZM | 1 |
| Ahn, SH; Baatarkhuu, O; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Moon, C; Park, JY | 1 |
| Fabiani, F; Focà, A; Liberto, MC; Marascio, N; Nucara, S; Perrotti, N; Quirino, A; Strazzulla, A; Torti, C; Trapasso, F; Zicca, E | 1 |
| Abu Shanab, A; Carr, MJ; Chin, JL; Collison, M; Connell, J; Coughlan, S; Hall, WW; Mac Nicholas, R; McCormick, PA; Merriman, RB; Segurado, R | 1 |
| Berak, H; Eng, S; Feld, JJ; Foster, GR; Hooper, GJ; Jablkowski, M; Jacobson, IM; Jensen, DM; Kulkarni, R; Le Pogam, S; Lim, CY; Nájera, I; Navarro, MT; Perez-Gomez, HR; Pol, S; Scalori, A; Shahdad, S; Shulman, NS; Tam, E; Tavel, JA; Vierling, JM; Yetzer, ES; Yoshida, EM | 1 |
| Druyts, E; Lorenzi, M; Mills, EJ; Thorlund, K; Toor, K | 1 |
| Gonzalez-Peralta, R; Jonas, MM; Lobritto, S; Molleston, JP; Murray, KF; Pavlovic, V; Rosenthal, P; Schwarz, KB; Warne, C; Wat, C; Wen, J | 1 |
| Badri, P; Bennett, M; Campbell, A; Hu, Y; Kapoor, M; Lawitz, E; Pilot-Matias, T; Poordad, F; Rodrigues, L; Rodriguez-Torres, M; Sullivan, G; Vilchez, RA | 1 |
| Bock, JA; Fairley, KJ; Inverso, NA; Maeng, DD; Pitcavage, JM; Smith, RE; Williams, MS | 1 |
| Broder, MS; Chang, E; L'Italien, G; Sapra, S | 1 |
| Halota, W; Junik, R; Kozielewicz, D | 1 |
| Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Gallivan, JP; Mantry, P; Mensa, FJ; Soriano, V; Stern, JO; Taunk, J; Vinisko, R; Zeuzem, S | 1 |
| Balart, LA; Behorquez, HE; Bohorquez, HE; Bruce, D; Carmody, I; Chandra, PK; Cohen, AJ; Dash, S; Gunduz, F; Hazari, S; Kurt, R; Loss, G; Panigrahi, R; Poat, B; Wu, T | 1 |
| Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Imamura, M; Kan, H; Kawaoka, T; Morio, R; Sasaki, T | 1 |
| Baum, U; Böker, KH; Buggisch, P; Busch, HW; Cornberg, M; Hardtke, S; Heidrich, B; Hinrichsen, H; Klinker, H; Link, R; Maasoumy, B; Manns, MP; Möller, B; Naumann, U; Petersen, J; Teuber, G; Wedemeyer, H; Wiegand, SB; Zehnter, E | 1 |
| De Silva, S; Foster, GR | 1 |
| De Knegt, RJ; Hansen, B; Janssen, HL; Orlent, H | 1 |
| Brunetto, MR; Cohen, D; Cooney, E; de Lédinghen, V; Dore, GJ; Fung, SK; George, J; Ghesquiere, W; Hagens, P; Harley, H; Hernandez, D; Hézode, C; Hughes, EA; Larrey, D; Lawitz, E; Lee, SS; McPhee, F; Noviello, S; Pol, S; Ramji, A; Shafran, SD; Strasser, SI; Taliani, G; Tatum, HA; Tran, A; Weis, N; Zaltron, S | 1 |
| Arenas, J; Babudieri, S; Bollani, S; Bruno, S; Calleja, JL; Calvaruso, V; Caremani, M; Ceccherini Silberstein, F; Chemello, L; Ciancio, A; Colletta, C; Craxì, A; Crespo, J; Forns, X; Gea, F; Larrubia, JR; Magni, C; Maisonneuve, P; Mangia, A; Marenco, S; Moretti, A; Pascasio, JM; Perez-Alvarez, R; Piovesan, S; Zignego, AL | 1 |
| Dong, ZX; Guo, SM; Xiang, XG; Xie, Q; Zhao, GD; Zhou, HJ; Zhuang, Y | 1 |
| Dillon, JF; Miller, MH; Paterson, JC | 1 |
| Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT | 1 |
| Barakat, F; Cattie, JE; Cherner, M; Franklin, D; Grant, I; Hassanein, T; Heaton, RK; Letendre, SL; Perry, W; Umlauf, A; Woods, SP | 1 |
| Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D | 1 |
| Ishihara, T; Kaneko, K; Mizushima, T | 1 |
| Hazama, T; Hitobe, Y; Ikeda, F; Iwasaki, Y; Miyake, K; Namba, S; Nouso, K; Shiraha, H; Takaki, A; Yamamoto, K; Yamasaki, N | 1 |
| Akamatsu, N; Aoki, T; Hasegawa, K; Izumi, N; Kaneko, J; Kokudo, N; Kurosaki, M; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T | 1 |
| Lagging, M; Nyström, K; Waldenström, J | 1 |
| Rojas, Á; Romero-Gómez, M | 1 |
| Stirnimann, G | 1 |
| Baxter, L; Cooper, K; Frampton, GK; Hartwell, D; Loveman, E | 1 |
| Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A | 1 |
| Aghemo, A; Berardinelli, L; D'Ambrosio, R; Fabrizi, F; Martin, P; Messa, P; Pallotti, F | 1 |
| Beumont-Mauviel, M; De La Rosa, G; Forns, X; Fried, MW; Fu, M; Jacobson, IM; Jessner, W; Kalmeijer, R; Lenz, O; Manns, MP; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, JA; Sinha, R; Zeuzem, S | 1 |
| Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X | 1 |
| Agarwal, K; Cohen, D; Podsadecki, T; Poordad, F; Xie, W; Younes, Z | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Carrero, A; Diez, C; García-Alvarez, M; García-Broncano, P; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez-Morón, S | 1 |
| Ghanbari, R; Heidari, Z; Shahzamani, K; Tahamsebifar, A | 1 |
| Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K | 1 |
| Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R | 1 |
| Badri, P; Brown, R; Burton, JR; Coakley, E; Forns, X; Gordon, F; Kwo, PY; Levitsky, J; Mantry, PS; Pilot-Matias, T; Setze, C; Te, HS; Terrault, NA; Vargas, HE; Vilchez, RA; Xie, W | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Chen, DS; Chen, PJ; Chung, CS; Kao, JH; Liang, CC; Lin, CK; Liu, CH; Liu, CJ; Su, TH; Yang, HC | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Deroń, Z; Jabłonowska, E; Piekarska, A; Sidorkiewicz, M; Skubała, A; Wójcik, K | 1 |
| Berg, T; Hamdi, N; Herrmann, E; Lange, C; Müller, T; Perner, D; Sarrazin, C; Susser, S; Zeuzem, S | 1 |
| Kawano, A; Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N | 1 |
| Costa e Silva, FV; Jardim, FN; Mosegui, GB; Peregrino, AA; Rodrigues, MP; Vianna, CM | 1 |
| Antolović-Požgain, A; Barbić, J; Bošnjak, Z; Perić, M; Roksandić-Križan, I; Ružman, N; Šarkanj, B; Vuković, D | 1 |
| Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F | 1 |
| Asch, SM; Barnett, PG; Dally, SK; Gidwani, R; Goldhaber-Fiebert, JD; Lo, J; Owens, DK | 1 |
| Feray, C; Hézode, C; Pawlotsky, JM; Ruiz, I | 1 |
| Ferenci, P | 9 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kouno, M; Kudo, M; Minami, Y; Takita, M; Ueshima, K; Yada, N | 1 |
| Arizumi, T; Hagiwara, S; Inoue, T; Kudo, M; Minami, T; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Bielsa Marsol, I; Carrascosa Carrillo, JM; Ferrándiz Foraster, C; López Escartin, D; Masnou Ridaura, H; Morillas Cunill, R; Plana Pla, A; Planas Vilà, R; Toro Montecinos, M; Vilavella Rius, M | 1 |
| Beumont, M; Buelens, A; Ceulemans, H; De Meyer, S; Fevery, B; Lenz, O; Peeters, M; Picchio, G; Tambuyzer, L; Verbinnen, T; Vijgen, L | 1 |
| Bagaglio, S; Della Torre, L; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C | 1 |
| Ain, D; Doehle, B; Jiang, D; Kersey, K; Kirby, BJ; Knox, SJ; Massetto, B; McHutchison, JG; Meshrekey, R; Mikhail, S; Riad, J; Ruane, PJ; Soliman, M; Stryker, R; Symonds, WT; Wolfe, PR | 1 |
| Becerro González, I; Carrascosa de Lome, R; de Argila, D; García-Buey, L; Martín Domínguez, V; Villar, K | 1 |
| Mangia, A; Piazzolla, V | 1 |
| Chang, KC; Chen, CH; Chen, HH; Hu, TH; Huang, CC; Huang, CM; Hung, HC; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Wu, CK; Wu, YY; Yen, YH | 1 |
| Chen, X; Wei, L; Wu, H; Yan, H; Zhang, S; Zhang, Y; Zhao, Y | 1 |
| Ali, K; Aziz, H; Gill, ML; Irfan, J; Khattak, JZ; Raza, A | 1 |
| Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E | 1 |
| Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J | 1 |
| Bernabucci, V; Cammà, C; Cerami, C; Ciancio, A; Critelli, R; Karampatou, A; Petta, S; Rizzetto, M; Sagnelli, C; Strona, S; Todesca, P; Turco, L; Villa, E | 1 |
| Maliakkal, B; Soota, K | 1 |
| Andreone, P; Dammers, E; Fu, M; George, J; Horban, A; Jessner, W; Kurland, D; Lenz, O; Ouwerkerk-Mahadevan, S; Reddy, KR; Scott, J; Stanciu, C; Verbinnen, T; Villamil, FG; Weiland, O; Zeuzem, S; Zoulim, F | 1 |
| Dusheiko, G | 1 |
| Aihara, Y; Fukuba, R; Fukui, H; Kawaratani, H; Kaya, D; Kubo, T; Mitoro, A; Morioka, C; Noguchi, R; Yoshiji, H | 1 |
| Andreone, P; Gamal, N; Vukotic, R | 1 |
| Arbuckle, R; Beumont, M; Brohan, E; Fu, M; Gilles, L; Jessner, W; Panter, C; Scott, J | 1 |
| Artuk, C; Eyigün, CP; Gül, HC; Kıratlı, K; Kozan, S; Oztuna, A; Tunca, Y | 1 |
| Cohen, S; Cooney, E; DeMicco, M; Ghalib, R; Hanson, J; Hughes, E; Lawitz, E; Martorell, C; Ravendhran, N; Rustgi, V; Tatum, H; Thuluvath, PJ; Treitel, M; Zamparo, J; Zhao, J | 1 |
| Guo, L; Han, Y; Zhu, J | 1 |
| Jones, B; Warren, E; Wright, A | 1 |
| Aoki, Y; Hashimoto, S; Imamura, M; Izumi, N; Kage, M; Kang, JH; Kanto, T; Kimura, T; Korenaga, M; Kurosaki, M; Masaki, N; Mizokami, M; Murata, K; Naito, S; Nomura, H; Sugiyama, M; Takeda, T; Yamagiwa, Y; Yatsuhashi, H; Yoshio, S | 1 |
| Beste, LA; Green, PK; Ioannou, GN | 1 |
| Chen, CH; Chiu, YC; Hu, TH; Hung, CH; Kuo, MT; Lee, CM; Lu, SN; Wang, JH | 1 |
| Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S | 1 |
| Benjamin, S; Botfield, MC; Dimova, RB; Penney, MS; Talal, AH; Zeremski, M | 1 |
| Chan, J; Mohammad, RA; Smith, MA | 1 |
| Burnevich, ÉZ; Tikhonova, NIu | 1 |
| Chen, TC; Chen, YH; Lin, CY; Lin, SY; Lin, WR; Lu, PL; Yang, YH | 1 |
| Bodeau, S; Brochot, E; Duverlie, G | 1 |
| Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, DE; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H | 1 |
| Jensen, DM; Welch, NM | 1 |
| Ansaldi, C; Benali, S; Bourlière, M; Le Folgoc, G; Lecomte, L; Riso, A | 1 |
| Abdel-Razek, W; Waked, I | 1 |
| Bargach, T; Chatioui, S; Elasri, F; Iferkhass, S; Khoyaali, A; Oubaaz, A; Reda, K | 1 |
| Benanti, F; Cacopardo, B; D'Agata, V; Nunnari, G; Pinzone, MR; Rapisarda, L; Spartà, D; Zanghì, AM | 1 |
| Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C | 1 |
| Andreoni, M; Angelico, M; Antonucci, FP; Aragri, M; Babudieri, S; Ceccherini-Silberstein, F; Cento, V; De Leonardis, F; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gasbarrini, A; Landonio, S; Lenci, I; Magni, CF; Mancon, A; Manunta, A; Micheli, V; Mura, MS; Nicolini, LA; Nosotti, L; Parruti, G; Pellicelli, A; Perno, CF; Rizzardini, G; Sarrecchia, C; Siciliano, M; Taliani, G; Tontodonati, M; Vecchiet, J | 1 |
| Kagawa, K; Katayama, Y; Kuniyoshi, T; Suzuki, K; Takada, H; Tamano, M | 1 |
| Celik, B; Gumuslu, S; Kose, S; Seyman, D; Yalcin, AD; Yalcin, AN | 1 |
| Abel, L; Albert, ML; Barthe, Y; Bronowicki, JP; Carrat, F; Casrouge, A; Dorival, C; Fontaine, H; Fontanet, A; Gayat, E; Hézode, C; Lagaye, S; Mallet, V; Mottez, E; Pol, S; Sultanik, P; Theodorou, I | 1 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Maasoumy, B; Manns, MP; Mix, C; Port, K; Sollik, L; Wedemeyer, H | 1 |
| Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT | 1 |
| Ehleben, C; Pearlman, BL; Perrys, M | 1 |
| An, J; Ni, W; Qiao, J | 1 |
| Agarwal, K; Asselah, T; Bourlière, M; Calinas, F; Crespo, J; Datsenko, Y; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; Garcia, M; Kukolj, G; Maevskaya, M; Morano, LE; Moreno, C; Nishiguchi, S; Omata, M; Ouzan, D; Quinson, AM; Sarrazin, C; Scherer, J; Schuchmann, M; Stern, JO; Zehnter, E; Zeuzem, S | 1 |
| Aboulker, JP; Barrail-Tran, A; Chevaliez, S; Cotte, L; Fournier, I; Lacombe, K; Molina, JM; Taburet, AM; Valantin, MA; Vincent, C | 1 |
| Kawasaki, Y; Masaki, N; Sato, I; Shimbo, T | 1 |
| Ferenci, P; Ferenci-Förster, D; Hagmann, M; Kienbacher, C; Miehsler, W; Moser, G; Reichhold, D; Scherzer, TM; Staufer, K | 1 |
| Diego, R; Giampaolo, Q; Marco, R; Sara, B; Vasilij Benatti, S | 1 |
| Bonino, F; Brunetto, MR; Colombatto, P; Iannazzo, S; Oliveri, F; Ricco, G | 1 |
| Bradrick, SS; Goldstein, DB; Lu, YF; Urban, TJ | 1 |
| Andreone, P; Gamal, N; Vitale, G | 1 |
| Modi, R; Saab, S | 1 |
| Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Abd El-Wahab, EW; Mikheal, A; Shatat, HZ; Sidkey, F | 1 |
| Feld, JJ; Krahn, M; Tu, HA; Wong, T; Wong, WWL | 1 |
| Antinori, S; Calvi, E; Cheli, S; Clementi, E; D'Avolio, A; De Nicolò, A; Falvella, FS; Magni, C; Mazzali, C; Milazzo, L; Peri, AM | 1 |
| Bernhardt, P; Duvoux, C; Firpi, RJ; Grazi, GL; Levy, G; Mulhaupt, B; Pageaux, G; Rauer, B; Renner, EL; Schirm, F; Villamil, F | 1 |
| Foster, GR | 5 |
| Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ | 1 |
| Devaki, P; Jencks, D; McCormack, SA; Nguyen, MH; Nguyen, NH; Vutien, P; Yee, BE | 1 |
| Beumont, M; Bourgeois, S; Fevery, B; Francque, S; Grange, JD; Hezode, C; Jessner, W; Lenz, O; Marcellin, P; Moreno, C; Ouwerkerk-Mahadevan, S; Peeters, M; Samuel, D; Shukla, U; Zoulim, F | 1 |
| Becker, B; Berden, FA; Burger, DM; Colbers, AP; de Kanter, CT; de Knegt, RJ; Dofferhoff, AS; Drenth, JP; Grintjes-Huisman, KJ; Koning, L; Rockstroh, JK; Roukens, MM; Wasmuth, JC | 1 |
| Pawlowska, M | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Araki, Y; Ikeda, F; Iwasaki, Y; Kobashi, H; Miyake, Y; Okamoto, R; Takaki, A; Taniguchi, H; Yamamoto, K | 1 |
| Do, D; Nambudiri, V; Shuster, M | 1 |
| Henry, L; Younossi, Z | 1 |
| Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM | 2 |
| Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT | 1 |
| Okubo, A; Tamaki, K | 1 |
| Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS | 1 |
| Afdhal, N; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F | 1 |
| Angelico, M; Antonucci, FP; Armenia, D; Babudieri, S; Bellocchi, MC; Bertoli, A; Cacciatore, P; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Di Maio, VC; Fortuna, S; Manunta, A; Navarra, P; Neumann, AU; Parruti, G; Perno, CF; Tontodonati, M; Trave, F; Valenti, F; Vecchiet, J | 1 |
| Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA | 1 |
| Anderson, PL; Baouchi-Mokrane, F; Burton, JR; D'Argenio, DZ; Everson, GT; Hammond, KP; Kiser, JJ; Rower, JE; Urban, TJ; Wu, LS | 1 |
| Ray, G | 1 |
| Ackefors, M; Castedal, M; Dahlgard, O; Gjertsen, H; Verbaan, H; Weiland, O; Wernerson, A | 1 |
| Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L | 1 |
| Devrajani, BR; Hayat, AS; Rajput, MI; Shaikh, N; Shaikh, S; Waryah, AM | 1 |
| Di Bisceglie, AM; Fan, X; Lin, J; Wang, W; Xu, Y | 1 |
| Buti, M; Cloherty, G; De Meyer, S; Dierynck, I; Ghys, A; Janssen, K; Luo, D; Picchio, G; Sarrazin, C; Witek, J | 1 |
| Akuta, N; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Boglione, L; Cardellino, CS; Cariti, G; D'Avolio, A; De Nicolò, A; Di Perri, G; Ghisetti, V; Ruggiero, T | 1 |
| Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX | 1 |
| Kim, AY; Naggie, S | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Gatto, A | 1 |
| Guo, Q; Islam, MS; Li, JS; Li, ZQ; Ping, Y; Wang, F; Wang, LP; Wang, M; Yue, DL; Zhang, TF; Zhang, Y; Zhang, Z | 1 |
| Barreira, P; Cadinha, S; da Silva, JP; Malheiro, D | 1 |
| Hisanaga, Y; Ito, T; Kanamori, A; Kiriyama, S; Kitabatake, S; Kumada, T; Tada, T; Tanikawa, M; Toyoda, H | 1 |
| Gale, SE; Klibanov, OM; Santevecchi, B | 1 |
| Adler, M; Bourgeois, S; Brixko, C; Deltenre, P; Delwaide, J; Henrion, J; Langlet, P; Moreno, C; Mulkay, JP; Nevens, F | 1 |
| Angeli, E; Caputo, A; Carosi, G; Cattelan, AM; Giralda, M; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| Ahn, JH; Baek, YH; Han, SY; Jo, YM; Kim, SY; Kim, WJ; Lee, JY; Lee, SW | 1 |
| Chen, J; Chen, Y; Ling, Q; Min, N; Shang, B; Ye, Q; Zhong, J; Zhou, H; Zhuo, Y | 1 |
| Chen, MH; Chou, CT; Huang, DF; Huang, YH; Lin, HY; Tsai, CY | 1 |
| Bernstein, D; Brunetto, M; de Ledinghen, V; Elkhashab, M; Everson, G; Hennicken, D; Heo, J; Hézode, C; Hughes, E; Jensen, D; Kugelmas, M; Luketic, V; Mauss, S; McPhee, F; Mendez, P; Noviello, S; Pol, S; Serfaty, L; Sherman, KE; Tran, A; Vierling, J; Younes, ZH; Zeuzem, S | 1 |
| Azam, S; Imran, M; Manzoor, S; Resham, S | 1 |
| Ghani, E; Hussain, AB; Rathore, MA | 1 |
| Endo, M; Fujita, T; Fujiwara, K; Iijima, S; Iio, E; Ito, K; Joh, T; Kusakabe, A; Matsuura, K; Miyaki, T; Nojiri, S; Onomoto, K; Shinkai, N; Tanaka, Y; Watanabe, T | 1 |
| Afzal, S; Idrees, M; Khubaib, B; Saleem, S; Wasim, M | 1 |
| Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R | 1 |
| Burnevich, EZ | 1 |
| Choi, DJ; Jung, YK; Kim, EJ; Kim, JH; Kim, YS; Kwon, OS; Lee, HN; Lee, JJ; Park, SY; Shin, SK | 1 |
| Ali, FT; Ali, MA; Elgizawy, MM; Elsawy, AM | 1 |
| Hedrick, KT; Just, SM; Kahn, DR | 1 |
| Angarano, G; Bartolomeo, N; Bruno, G; Fasano, M; Ladisa, N; Maggi, P; Monno, L; Saracino, A; Volpe, A | 1 |
| Abe, H; Aizawa, Y; Atsukawa, M; Fukuda, T; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A | 1 |
| Füessl, HS | 2 |
| Jäger-Becker, D | 1 |
| Chida, T; Kageyama, F; Kawamura, K; Kawata, K; Kobayashi, Y; Nagasawa, M; Noritake, H; Sasada, Y; Suda, T; Watanabe, S | 1 |
| Chepa-Lotrea, X; Fryzek, N; Ghany, M; Keane, M; Kim, YJ; Liang, TJ; Rehermann, B; Serti, E | 1 |
| Cerri, K; Kuwabara, H; Mahlich, J; Treur, M; Westerhout, K; Yatsuhashi, H | 1 |
| Fujinaiga, H; Koike, K | 1 |
| Akuta, N; Kumada, H | 1 |
| Hiramatsu, N; Oze, T; Takehara, T | 1 |
| Izumi, N; Suzuki, S | 1 |
| Mochida, S | 1 |
| Joshita, S; Tanaka, E | 1 |
| Benito, JM; Berenguer, J; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Pineda-Tenor, D; Rallón, N; Resino, S; Retana, D; Soriano, V | 1 |
| Chi, B; Li, M; Liu, DW; Wang, J; Wu, XX; Zheng, H | 1 |
| Gaytán-Martínez, JE; Huerta García, G; Mata-Marín, JA; Sandoval-Ramirez, JL | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Oze, T; Takehara, T; Tatsumi, T | 1 |
| Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F | 1 |
| Aghasadeghi, MR; Fateh, A; Ghazanfari, M; Hadizade Tasbiti, AR; Keyvani, H; Mollaie, HR; Monavari, SH; Yari, S | 1 |
| Arabzadeh, SA; Ebrahimi, S; Fazlalipour, M; Iranmanesh, Z; Mollaie, HR; Zahedi, MJ | 1 |
| Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH | 1 |
| Afdhal, NH; Campbell, FM; Dusheiko, GM; Elkashab, M; Giannini, EG; Iyengar, M; Muir, AJ; Reddy, KR; Romero-Gómez, M; Sigal, SH; Theodore, D; Vasey, SY; Vijayaraghavan, S | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 3 |
| Asabe, S; Funyu, J; Hashimoto, Y; Hosoda, Y; Inao, M; Koshima, Y; Mochida, S; Nakayama, N; Nishikawa, K; Omori-Mizuno, Y; Tanaka, M; Tomita, K; Yakabi, K | 1 |
| Liffmann, DK; Rein, DB; Smith, BD; Ward, JW; Wittenborn, JS | 1 |
| Curto, J; Di Yacovo, S; Ferrer, E; Imaz, A; Podzamczer, D; Saumoy, M; Van den Eynde, E; Vila, A | 1 |
| Häggblom, A; Nowak, P; Nyström, J; Stenkvist, J; Weiland, O | 1 |
| Butterton, JR; Feng, HP; Hulskotte, EG; Khalilieh, S; Wenning, LA | 1 |
| Andriulli, A; Angelico, M; Di Marco, V; Fasano, M; Fattovich, G; Felder, M; Gaeta, GB; Gatti, P; Granata, R; Ippolito, AM; Mazzella, G; Milella, M; Morisco, F; Santantonio, T; Smedile, A; Valvano, MR | 1 |
| Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Muraki, Y; Nuta, J; Shimizu, R; Shingaki, N; Takifuji, K; Tamai, H; Yamaue, H | 1 |
| Faisal, N; Lilly, LB; Marquez, M; Mumtaz, K; Renner, EL | 1 |
| El-Maraghy, SA; Motawi, TK; Senousy, MA; Shaker, OG | 1 |
| Ben-Marzouk-Hidalgo, OJ; Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
| Enjoji, M; Fujimori, N; Fukuizumi, K; Fukushima, N; Harada, N; Haraguchi, K; Kato, M; Kawabe, K; Kohjima, M; Kotoh, K; Koyama, S; Kurokawa, M; Murata, Y; Nakamura, T; Nakamuta, M; Sasaki, Y; Shimonaka, Y; Sumida, Y; Yoshimoto, T | 1 |
| Amemiya, F; Enomoto, N; Fukasawa, M; Inoue, T; Komatsu, N; Maekawa, S; Miura, M; Moriishi, K; Muraoka, M; Nakayama, Y; Sakamoto, M; Sato, M; Sato, T; Suzuki, Y; Takano, S; Tatsumi, A; Uetake, T; Yamaguchi, T; Yamashita, A | 1 |
| Carlsson, T; Hörnfeld, E; Lindahl, K; Parke, Å; Schvarcz, R; Ståhle, L; Weiland, O | 1 |
| Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 2 |
| Akiyama, MJ; Cheung, R; Ha, NB; Li, J; Nguyen, MH; Piotrowski, JI; Roytman, MM; Tsai, N; Vo, KP; Vu, VD; Vutien, P; Wantuck, J | 1 |
| Abd-Elaati, BM; Ehsan, NA; El-Araby, HA; Konsowa, HA; Sira, AM | 1 |
| Cai, WP; Gao, QS; Gao, YQ; Jiao, YM; Li, HJ; Li, LH; Weng, WJ; Wu, H; Zhu, WJ | 1 |
| Güneş, P; Yaşar, B; Yaşar, Ş | 1 |
| Albandea Moreno, C; Bautista Galán, C; Ruiz Arredondo, J; Serrato, AR | 1 |
| Oni, O; Pandya, P; Rzouq, F | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, WY; Lin, YH; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML | 1 |
| Wedemeyer, H | 1 |
| Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA | 1 |
| Aguilar, H; Cohen, DE; Felizarta, F; Galen, E; King, M; Kowdley, KV; Lalezari, J; McGovern, B; Polepally, AR; Rustgi, V; Sullivan, JG; Varunok, P | 1 |
| Appourchaux, K; Asselah, T; Bièche, I; Boyer, N; Carrat, F; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Vidaud, M | 1 |
| Flamm, S; Lawitz, E; McHutchison, JG; Morelli, G; Pang, PS; Pockros, P; Svarovskaia, E; Wyles, D; Yang, JC; Younes, Z; Zhu, Y | 1 |
| Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S | 1 |
| Demuth, D; Forssen, U; Grotzinger, K; Irving, WL; Rizzetto, M; Roughley, A; Theodore, D | 1 |
| Bennett, M; Brainard, D; Doehle, B; Gane, EJ; Hassanein, T; Jacobson, IM; Kanwar, B; Liu, L; McHutchison, JG; Mo, H; Nahass, RG; Pol, S; Subramanian, GM; Sulkowski, MS; Symonds, WT | 1 |
| Alter, HJ; Ascierto, ML; Bedognetti, D; Bozzano, F; De Maria, A; DeGiorgi, V; Marenco, S; Marincola, FM; Marras, F; Matsuura, K; Moretta, L; Picciotto, A; Schechterly, C; Sommariva, M; Wang, E; Zhao, Y | 1 |
| Abe, H; Aida, Y; Aizawa, Y; Furihata, T; Ishiguro, H; Itagaki, M; Seki, N; Shimada, N; Sugita, T; Sutoh, S; Tsubota, A | 1 |
| Chen, HB; Huang, P; Su, J; Wang, J; Xu, Y; Yu, RB; Zhang, Y; Zhang, YY | 1 |
| Akgöllü, E; Akkız, H; Bekar, A; Kuran, S; Sandıkçı, M; Ülger, Y; Üsküdar, O; Yalınbaş Kaya, B; Yıldırım, S | 1 |
| Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Bartolini, B; Capobianchi, MR; D'Offizi, G; Garbuglia, AR; Gianpiero, D; Giombini, E; Hughes, EA; Ippolito, G; Lionetti, R; McPhee, F; Montalbano, M; Sias, C; Taibi, C; Zhou, N | 1 |
| Chi, X; Jiang, J; Liu, Y; Lv, J; Niu, J; Pan, Y; Sun, B; Sun, H; Tu, Z; Wang, X; Wu, R; Zhong, J | 1 |
| Ahn, SB; Choe, WH; Chung, JI; Jun, DW; Jung, KS; Kim, DY; Kim, JK; Kim, SG; Kim, W; Lee, SH; Park, SY; Seo, YS; Shim, JJ; Shin, HP | 1 |
| Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J | 1 |
| Chang, LC; Chen, LW; Chien, CH; Chien, RN; Hu, CC; Lin, CL; Liu, CJ | 1 |
| Gattei, V; Mauro, E; Mazzaro, C; Panarello, G; Pozzato, G | 1 |
| Cammà, C; Carosi, G; Craxì, A; Cure, S; Guerra, I | 1 |
| Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawanaka, H; Kimura, Y; Maehara, Y; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Takeishi, K; Tsujita, E; Uchiyama, H; Yamashita, YI; Yoshizumi, T | 1 |
| Barr, E; Buti, M; Calleja, JL; DiNubile, MJ; Forns, X; Gilbert, C; Gordon, SC; Hofer, H; Howe, AY; Lawitz, E; Palcza, J; Robertson, MN; Wahl, J; Zuckerman, E | 2 |
| Kitson, MT; Roberts, SK; Sarrazin, C; Toniutto, P | 1 |
| Belsey, J; Ladha, I; Mehnert, A; Pascoe, K; Treur, M; Westerhout, K | 1 |
| El Sabaawy, D; El-Bahrawy, H; El-Haggar, S; El-Said, H; Waked, I | 1 |
| Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J | 1 |
| Liu, C; Pang, Q; Qu, K; Zhang, JY | 1 |
| Fazylov, VKh; Manapova, ÉR; Tkacheva, SV | 1 |
| Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; Calleja, JL; Forns, X; García-Pagán, JC; García-Retortillo, M; Lens, S; Rincón, D; Sanchez-Tapias, JM | 1 |
| Brown, A; Habibi, MS; Selvapatt, N | 1 |
| Furusyo, N; Hayashi, J; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Takayama, K | 1 |
| Cariani, E; Ferrari, C; Missale, G; Roli, L; Trenti, T; Villa, E | 1 |
| Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M | 1 |
| Ali, E; El Sherbini, A; Mostafa, S | 1 |
| Abravanel, F; Alain, S; André-Garnier, E; Baazia, Y; Besse, B; Bouvet, D; Bouvier-Alias, M; Brochot, E; Caporossi, A; David-Tchouda, S; Duverlie, G; Fleury, H; Gaudy-Graffin, C; Gouriou, S; Gozlan, J; Guivarch, M; Haïm-Boukobza, S; Halfon, P; Hantz, S; Henquell, C; Lada, O; Lagathu, G; Larrat, S; LeGuillou-Guillemette, H; Mackiewicz, V; Margier, J; Maylin, S; Mirand, A; Mohamed, S; Morand, P; Mourez, T; Pawlotsky, JM; Pivert, A; Plantier, JC; Pronier, C; Ramière, C; Roque-Afonso, AM; Scholtes, C; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S; Velay, A | 1 |
| Ho, S; Mehnert, A; Pacou, M; Pettré, S; Pisini, M; Taieb, V; Ustianowski, A; Van Sanden, S | 1 |
| Aksoz, S; Ay, N; Baysal, B; Danis, R; Kaya, S | 1 |
| Abo Youssef, H; Darwish, RK; El-Karaksy, HM; Mandour, IA; Mogahed, EA; Rady, NH; Sharaf, SA | 1 |
| Doehle, B; Doss, W; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Jiang, D; Kersey, K; Khairy, M; Knox, SJ; Massetto, B; McHutchison, JG; Samir, W; Shiha, G; Soliman, R | 1 |
| Colombo, M | 2 |
| Al Marzooqi, SH; Feld, JJ | 1 |
| Cozzolongo, R; Giannuzzi, V; Lanzilotta, E; Leandro, G; Porcelli, P | 1 |
| Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J | 1 |
| Hajiaghamohammadi, A; Kazemifar, AM; Miroliaee, A; Nazem, M; Samimi, R | 1 |
| Broquetas, T; Calleja, JL; Campillo, A; Carrión, JA; de la Revilla, J; Forns, X; Lens, S; Londoño, MC; Mariño, Z; Perello, C; Sánchez-Tapias, JM; Urbano-Ispizua, Á | 1 |
| Dzwonek, AB; Wiśniewska-Ligier, M; Woźniakowska-GĘsicka, T | 1 |
| Elarbi, B; Hicham, E; Mimoun, Z; Nadia, K; Nadia, T; Reda, TM; Saâd, E; Saâd, M | 1 |
| Egawa, H; Hashimoto, E; Kogiso, T; Kotera, Y; Omori, A; Shiratori, K; Taniai, M; Tokushige, K; Yamamoto, M | 1 |
| Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S | 1 |
| Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Shimada, N; Tsubota, A | 1 |
| Chu, PS; Ebinuma, H; Hibi, T; Kanai, T; Nakamoto, N; Saito, H; Shiba, S; Sugiyama, K; Taniki, N; Usui, S; Wakayama, Y; Wakita, T; Yamagishi, Y; Yamaguchi, A | 1 |
| Beebe, A; Gicquelais, RE; Haselow, DT; Patil, N; Quattlebaum, T; Smith, NH; Zohoori, N | 1 |
| Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M | 1 |
| Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P | 1 |
| Burridge, A; Fialho, R; File, A; Keller, M; Pereira, M; Tibble, J; Whale, R | 1 |
| Abdelatty, S; El Akel, W; El Raziky, M; Elsharkawy, A; Gamal Eldeen, H; Mabrouk, M; Said, SE; Tantawy, O | 1 |
| Bárcena, R; Berenguer, M; Buti, M; Calleja, JL; Crespo, J; Fernández, I; González, O; López, J; Pérez, F | 1 |
| Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD | 1 |
| Frankova, S; Hejda, V; Jirsa, M; Merta, D; Neroldova, M; Senkerikova, R; Sperl, J; Spicak, J; Viklicky, O; Volfova, M | 1 |
| Asselah, T; Cacoub, P; Carrat, F; Lapidus, N; Pol, S; Ratziu, V; Serfaty, L; Souberbielle, JC; Terrier, B; Thibault, V | 1 |
| Arenas, MD; Caramelo, C; Carnicer, F; Espinosa, M; Fabrizi, F; Hernàndez, J | 1 |
| Ikeda, H; Kamijo-Ikemori, A; Kimura, K; Matsui, K; Okuse, C; Shibagaki, Y; Sugaya, T; Yasuda, T | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A | 1 |
| Abo Taleb, ME; Aref, WM; El Hawary, MS; Fathy, MM; Makhlouf, MM; Nabih, MI | 1 |
| Araki, Y; Hashimoto, N; Ishii, Y; Iwasaki, Y; Okamoto, R; Yamamoto, K | 1 |
| Afdhal, NH; Rourke, M; Sethi, N; Sethi, S; Tapper, EB; Vong, A | 1 |
| Celikel, ÇA; Fincanci, M; Gucin, Z; Mert, A; Midilli, K; Osme, A; Ozaras, R; Ozbay, G; Ozturk, R; Senturk, H; Tabak, F; Tahan, V; Tozun, N; Yenice, N | 1 |
| Abd Elalim, MH; Mohamed, NA; Motawae, IA; Nagib, AN; Zaky, DZ | 1 |
| Bahnasy, K; El Gohary, E; Fouad, A; Ghoraba, D; Hafez, T; Hassan, H; Kamal, SM; Kassim, S; Nabegh, L | 1 |
| Mondelli, MU | 1 |
| Connelly, SM; Fleischer, R; Harrington, PR; Lewis, LL; Murray, J | 2 |
| Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S | 1 |
| Athanasakis, K; Ferrante, SA; Hill, M; Kyriopoulos, II; Kyriopoulos, J; Petrakis, I; Retsa, MP | 1 |
| Bell, SJ; Bonanzinga, S; Bowden, DS; Congiu, M; Desmond, PV; Holmes, JA; Iser, DM; Kia, YH; Nguyen, T; Sandhu, MK; Sievert, W; Thompson, AJ; Visvanathan, K | 1 |
| Böker, KH; Cordes, HJ; Cornberg, M; Gonnermann, A; Hardtke, S; Heidrich, B; Klinker, H; Koch, A; Kraus, MR; Manns, MP; Möller, B; Naumann, U; Roggel, C; Rössle, M; Schuchmann, M; Stoehr, A; Trein, A; Wedemeyer, H | 1 |
| Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH | 1 |
| Hunt, S; Lam, B; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G | 1 |
| Brito, C; Pereira, T; Resende, C; Ventura, F | 1 |
| Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ | 1 |
| Alessandrini, A; Alicino, C; Bruzzone, B; Del Puente, F; Di Biagio, A; Icardi, G; Mazzarello, G; Prinapori, R; Signori, A; Sticchi, L; Viscoli, C | 1 |
| Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M | 1 |
| Donato, MF; Durantel, D; Fresquet, J; Helle, F; Lebossé, F; Levrero, M; Negro, F; Testoni, B; Zoulim, F | 1 |
| Alavian, SM; Behnava, B; Keshvari, M; Mehrnoush, L; Salimi, S; Sharafi, H | 1 |
| Kanto, T; Korenaga, M; Masaki, N; Mizokami, M; Murata, K; Shimbo, T; Yamagiwa, Y | 1 |
| Buggisch, P; Eißing, C; Hartl, J; Jordan, S; Lohse, AW; Lüth, S; Petersen, J; Schulze Zur Wiesch, J; Stoehr, A; Wehmeyer, MH | 1 |
| Chang, WT; Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hou, NJ; Huang, CF; Huang, CI; Huang, JF; Lin, PC; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML | 1 |
| Abdel-Hamid, AH; Ghanem, HZ; Hassan, HA; Sadik, NA; Shaker, OG | 1 |
| Bruneau, J; Deterding, K; Dore, GJ; Doyle, JS; Grebely, J; Hellard, ME; Kim, AY; Lloyd, AR; Manns, MP; Matthews, G; McGovern, BH; Morris, MD; Page, K; Rice, TM; Sacks-Davis, R; Spelman, T; Wedemeyer, H | 1 |
| Burger, DM; de Kanter, CT; Deenen, MJ; Dofferhoff, AS; Drenth, JP; Fleuren, HW; Gisolf, EH; Grintjes-Huisman, KJ; Koopmans, PP; van der Ven, AJ | 1 |
| Aziz, H; Irfan, J; Raza, A | 1 |
| Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V | 1 |
| Adinolfi, LE; Alessio, L; Boemio, A; Coppola, N; Grandone, A; Marrone, A; Minichini, C; Pisaturo, M; Sagnelli, E; Stanzione, M; Starace, M; Zampino, R | 1 |
| Chen, W; Krahn, M | 1 |
| Altman, RB; Gong, L; Klein, TE; Muir, AJ; Shuldiner, SR | 1 |
| Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y | 1 |
| Calabrese, LH; Vassilopoulos, D | 1 |
| Collado, A; de los Santos-Gil, I; Girón-González, JA; López-Cortés, LF; Macías, J; Merino, D; Mira, JA; Neukam, K; Ojeda-Burgos, G; Pérez-Pérez, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A | 1 |
| Eccles, J; Fialho, R; File, A; Haq, I; Keller, M; Pereira, M; Rolt, M; Tibble, J; Whale, R | 1 |
| Avila, C; Chuang, WL; Flisiak, R; Foster, GR; Hézode, C; Li, B; Naoumov, NV; Pawlotsky, JM; Peng, CY; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Wedemeyer, H; Wong, KA; Zhang, W | 1 |
| Arain, A; Bastens, B; Bourgeois, S; Bruckers, L; Buntinx, F; d'Heygere, F; de Galocsy, C; Deltenre, P; Francque, S; George, C; Henrion, J; Janssens, F; Laleman, W; Mathei, C; Moreno, C; Nevens, F; Robaeys, G; Van Overbeke, L; Van Vlierberghe, H; Verrando, R | 1 |
| Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Yang, HC; Yang, SS; Yu, ML | 2 |
| Song, ZZ | 1 |
| Aristizabal, P; Carlin, AF; Paulson, MS; Schooley, RT; Song, Q; Stamm, LM; Wang, H; Wyles, DL | 1 |
| Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D | 1 |
| E Behairy, B; Hussein, ME; Khedr, MA; Marei, AM; Nage, SA; Zakaria, HM | 1 |
| Almeida, AJ; Brandão-Mello, CE; Coelho, HS; Costa, MM; Costa, VD; Delvaux, N; Esberard, EB; Flores, PP; Lampe, E; Villar, LM; Villela-Nogueira, CA | 1 |
| Castro-Iglesias, A; Cid, P; Macías, J; Martínez-Marcos, F; Mena, A; Merchante, N; Merino, MD; Monje-Agudo, P; Neukam, K; Ortega-González, E; Pernas, B; Pineda, JA; Real, LM; Rivero, A; Rivero-Juárez, A | 1 |
| Dimovski, A; Dzekova-Vidimliski, P; Matevska-Geshkovska, N; Mena, S; Nikolov, IG; Rostaing, L; Sikole, A | 1 |
| Lee, BS; Rou, WS | 1 |
| Kim, HJ; Lee, HW; Lee, YJ; Park, SJ; Yang, SY; Yoo, KY | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA | 1 |
| De Oliveira, JA; Martins, EC; Pereira, R; Reis, TM; Silva, MC | 1 |
| Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V | 1 |
| Carter, ME; Gundlapalli, AV; Haroldsen, C; LaFleur, J; Nelson, RE | 1 |
| Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R | 1 |
| Azam, S; Imran, M; Manzoor, S; Naseem, S; Resham, S; Saalim, M | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M | 1 |
| Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG | 1 |
| Fushimi, S; Igawa, T; Ikeda, F; Matsuo, R; Nakatsukasa, H; Nouso, K; Yoshino, T | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
| Berger, KL; Kukolj, G; Quinson, AM; Ranga, M; Scherer, J; Sha, N; Stern, JO | 1 |
| Bura, M; Kowala-Piaskowska, AE; Kuśnierczyk, P; Mozer-Lisewska, I; Pauli, A; Piasecki, E; Rozpłochowski, B; Żeromski, J; Zwolińska, K | 1 |
| Capobianchi, MR; Castiglione, F; D'Offizi, G; Garbuglia, AR; Lapa, D; Lionetti, R; Montalbano, M; Paci, P; Taibi, C; Visco-Comandini, U | 2 |
| Ballestri, S; Bertolotti, M; Lonardo, A; Marrazzo, A; Romagnoli, D | 1 |
| Besma, YL; Brochot, E; Gazouani, E; Morel, V; Mouelhi, L; Sghaier, I | 1 |
| Bae, SH; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, YS; Lee, HC; Lee, SS; Lee, YJ | 1 |
| El Agheb, MO; Grange, JD | 1 |
| Alexander, PC; James, AM; Long, AG; Shiffman, ML | 1 |
| Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F | 1 |
| Ambrosioni, J; Bernasconi, E; Bregenzer, A; Cavassini, M; Kovari, H; Ledergerber, B; Müller, D; Rauch, A; Rotger, M; Russmann, S; Speck, RF; Stöckle, M; Velli, P | 1 |
| Aung, AT; Aung, K; Naing, C; Sitt, T | 1 |
| Gissel, C; Götz, G; Mahlich, J; Repp, H | 1 |
| Hagiwara, H; Hamasaki, T; Harada, N; Hayashi, N; Hijioka, T; Hikita, H; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Irishio, K; Ito, T; Katayama, K; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oze, T; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yamada, Y; Yoshida, Y; Yoshihara, H | 1 |
| Baskič, D; Djurdjevič, P; Jovanovič, D; Mijailovič, Z; Mitrovkič, S; Popovič, S; Vukovič, VR | 1 |
| Altus, R; Colman, A; Dan, YY; Fragomelli, V; Galhenage, S; Guan, R; Jones, T; Lee, YM; Leembruggen, N; Lim, SG; Luman, W; Mason, S; Mollison, L; Morales, B; Nazareth, S; Pham, T; Piratvisuth, T; Sendall, C; Sukeepaisarnjaroen, W; Sutedja, D; Tan, SS; Tanwandee, T; Teo, EK; Than, YM; Totten, L; Wigg, A | 1 |
| Alshuth, U; Baumgarten, A; Böker, K; Hofmann, WP; Hüppe, D; Lutz, T; Manns, MP; Mauss, S; Moog, G; Pfeiffer-Vornkahl, H; Schober, A; Schott, E; Wedemeyer, H | 1 |
| Chen, G; Chen, H; Chen, X; Dou, X; Feng, Y; Gao, Z; Gong, G; Hou, J; Li, J; Niu, J; Rao, H; Shang, J; Wei, L; Wu, Y; Xie, Q; Xu, X; Yang, R; You, H; Zhang, D; Zhao, P | 1 |
| Abdurakhmanov, D; Bao, W; Brass, C; Buggisch, P; Calistru, P; Flisiak, R; Gould, M; Griffel, LH; Heo, J; Hsu, SJ; Makara, M; Mazur, W; Mazzella, G; Merz, M; Mutimer, D; Naoumov, NV; Nault, B; Samuel, D; Stanciu, C; Thongsawat, S; Van Kính, N; Vierling, JM; Zeuzem, S | 1 |
| Bastian, ND; Griffin, PM; Zhang, S | 1 |
| Antoni, C; Eisenbach, C; Galle, PR; Pathil, A; Schattenberg, JM; Sprinzl, MF; Stein, K; Steinebrunner, N; Stremmel, W; Wörns, MA; Zimmerer, T; Zimmermann, T | 1 |
| Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM | 1 |
| Ando, S; Imai, Y; Inao, M; Kouyama, J; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Uchida, Y | 1 |
| Agarwal, K; Barnes, E; Brainard, DM; Brown, A; Cooper, C; Forton, D; Foster, GR; George, J; Han, B; Lin, M; Massetto, B; McHutchison, JG; Nahass, RG; Pianko, S; Subramanian, GM | 1 |
| Berenguer, M; Everson, G; Ferenci, P; Forns, X; Fried, MW; Lopez-Talavera, JC; Lovell, S; Pedrosa, M; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H | 1 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D | 1 |
| Boor, PP; de Jonge, J; de Ruiter, PE; Ijzermans, JN; Kwekkeboom, J; Metselaar, HJ; Tilanus, HW; van der Laan, LJ | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E | 1 |
| Fukushima, K; Ishido, M; Kobayashi, H; Komada, Y; Nakayama, M; Yoshizawa, K | 1 |
| Chen, YC; Hwang, SJ; Li, CY; Lin, LC; Wu, CP | 1 |
| Barcińska, D; Bereszyńska, I; Czubała, K; Dziechciowska, K; Januszkiewicz-Lewandowska, D; Kałużna, EM; Mozer-Lisewska, I; Nowak, JS; Rembowska, J; Świątek-Kościelna, B; Wysocka-Leszczyńska, J; Wysocki, J | 1 |
| Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L | 1 |
| Haj-Sheykholeslami, A; Hemmati, K; Keshvari, M; Mohammadzadehparjikolaei, F; Pouryasin, A; Sharafi, H | 1 |
| Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H | 1 |
| Abdel-Hamid, M; Amr, KS; Esmail, MA; Ghazawy, ER; Hassuna, NA | 1 |
| Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM | 1 |
| Gonzalez-Peralta, RP; Jonas, MM; Lobritto, SJ; Mogul, D; Molleston, JP; Murray, KF; Pavlovic, V; Rosenthal, P; Schwarz, KB; Thompson, B; Warne, C; Wat, C; Wen, J | 1 |
| Antón, JJ; Caylà, JA; de Juan, J; Faraco, I; Marco, A; Saíz de la Hoya, P; Trujols, J | 1 |
| Bartels, DJ; Garg, V; Haseltine, EL; Kieffer, TL; Kimko, H; Luo, H; Tolsma, J | 1 |
| Araki, Y; Fujioka, S; Hashimoto, N; Ikeda, F; Iwasaki, Y; Nanba, S; Seki, H; Takaguchi, K; Takaki, A; Yamamoto, K | 1 |
| Baba, N; Ikeda, F; Iwasaki, Y; Miyake, Y; Moritou, Y; Nagano, T; Nanba, S; Nouso, K; Ohnishi, H; Seki, H; Senoh, T; Takaguchi, K; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T | 1 |
| Aghemo, A; Bruno, R | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Feld, JJ | 3 |
| Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K | 1 |
| Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M | 1 |
| Bjøro, K; Dalgard, O; Marcellin, P; Martinot-Peignoux, M; Ring-Larsen, H; Verbaan, H | 1 |
| Craxì, A; Feld, JJ; Forton, D; Manns, MP; Negro, F; Sulkowski, MS | 1 |
| Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M | 1 |
| Hirashima, N; Imamura, J; Iwase, H; Shimada, M; Sugiura, W; Watanabe, T; Yokomaku, Y | 1 |
| Bellanti, F; Lauletta, G; Lipsi, MR; Natalicchio, MI; Sansonno, D; Serviddio, G; Vendemiale, G; Villani, R | 1 |
| Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J | 1 |
| Braillon, A | 1 |
| Komolmit, P; Poovorawan, Y; Sukeepaisarnjaroen, W; Suksawatamnuay, S; Tangkijvanich, P; Thaimai, P; Thanapirom, K; Treeprasertsuk, S; Wasitthankasem, R | 1 |
| Cockerham-Colas, L; Heo, M; Litwin, AH; Reynoso, S; Roose, RJ; Soloway, IJ; Tenore, C | 1 |
| Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM | 1 |
| Badshah, MB; Kwo, PY | 1 |
| Buclin, T; Chtioui, H | 1 |
| Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Park, YN | 1 |
| Khatri, A; Menon, R | 1 |
| Brown, A; Gendrano, IN; Howe, A; Hwang, P; Lagging, M; Mantry, PS; Mobashery, N; Ramji, A; Robertson, M; Vierling, JM; Wahl, J; Weilert, F; Zhang, B | 1 |
| Huo, N; Li, MR; Shao, CP; Xi, HL; Xu, XY; Yu, M; Zhang, RW | 1 |
| Boonstra, A; de Knegt, RJ; Janssen, HL; Spaan, M; van Oord, GW | 1 |
| Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
| Cheng, PN; Hsu, SJ; Huang, CF; Lai, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, CW; Su, WW; Tsai, WL; Tseng, KC; Wang, CH; Yang, CC; Yu, ML | 1 |
| Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D | 1 |
| Dimitrova, D; Fredlund, P; Gray, T; Hillson, J; Shemanski, L; Srinivasan, S | 1 |
| Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S | 1 |
| Asada, W; Hashimoto, S; Ichino, N; Kan, T; Kato, M; Kawabe, N; Kurashita, T; Murao, M; Nakano, T; Nakaoka, K; Nishikawa, T; Ohki, M; Osakabe, K; Shibata, A; Shimazaki, H; Sugiyama, H; Takagawa, Y; Takamura, T; Yoshioka, K | 1 |
| Augustyniak, K; Berak, H; Dobracka, B; Dobracki, W; Dudziak, M; Flisiak, R; Horban, A; Janczewska, E; Jurczyk, K; Kozielewicz, D; Kryczka, W; Lapinski, T; Librant-Suska, M; Lojewski, W; Musialik, J; Olszok, I; Pisula, A; Postawa-Klosińska, B; Ruszala, A; Wroblewski, J; Zarebska-Michaluk, D | 1 |
| Hayashi, N; Howe, AY; Kumada, H; Ludmerer, SW; Mobashery, N; Nakamuta, M; Takase, A; Takehara, T | 1 |
| A, Y; E, F; GM, Sel-D; H, AG; M, A; MM, B; MM, el-S; U, Y | 1 |
| Abrignani, S; Aghemo, A; Balistreri, F; Bianco, A; Cheroni, C; Colombo, M; D'Ambrosio, R; De Francesco, R; Donnici, L; Neddermann, P; Pagani, M; Rumi, MG; Soffredini, R; Zanoni, V | 1 |
| Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Alshuth, U; Bert, F; Hüppe, D; Krauth, C; Mauss, S; Pfeiffer-Vornkahl, H; Rossol, S; Stahmeyer, JT | 1 |
| Kozlov, VK; Nekrasova, AN; Stelmah, VV | 1 |
| Buti, M; Esteban, R | 5 |
| Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G | 1 |
| Akpo, EI; Kleintjens, J; Sbarigia, U; Wan, G | 1 |
| Alsiö, Å; Färkkilä, M; Holmström, L; Jungnelius, R; Lagging, M; Langeland, N; Lund, K; Mørch, K; Nieminen, U; Norkrans, G; Nuutinen, H; Pedersen, C; Rauning Buhl, M; Rembeck, K; Rubensson, A; Torell, E; Waldenström, J; Westin, J | 1 |
| Cui, X; Jia, J; Kong, Y | 1 |
| García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Vázquez-Morón, S | 1 |
| Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
| Cao, LL; Chen, DW; Dong, Y; Gan, Y; Han, J; Wang, FC; Wang, FS; Wang, LM; Wang, P; Xu, ZQ; Yan, JG; Zeng, QL; Zhang, HF; Zhang, XX; Zhang, Z; Zhu, SS | 1 |
| Alavi, M; Balcomb, AC; Bath, N; Day, CA; Dore, GJ; Dunlop, AJ; Grebely, J; Haber, PS; Micallef, M; Phung, N; Treloar, C; Weltman, MD | 1 |
| Al-Assi, MT; Banyai, T; Beumont-Mauviel, M; Bifano, M; Boparai, N; Bourlière, M; Bronowicki, JP; Buti, M; Cheung, K; Gadano, A; Gea, F; Hézode, C; Hughes, EA; Loustaud-Ratti, V; Makara, M; McPhee, F; Noviello, S; Olveira, A; Ouwerkerk-Mahadevan, S; Petersen, J; Picchio, G; Pol, S; Pruitt, R; Thabut, D; Zeuzem, S | 1 |
| Gusev, DA; Kozlov, KV; Shakhmanov, DM; Shishkin, MK; Sukachev, VS; Zhabrov, SS; Zhdanov, KV | 1 |
| Belsey, J; Duchesne, I; Mehnert, A; Pisini, M; Van Sanden, S | 1 |
| Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F | 1 |
| Akiyama, T; Eguchi, Y; Ide, Y; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kumagai, T; Mizuta, T; Otsuka, T; Ozaki, I; Yanagita, K; Yasutake, T | 1 |
| Aggarwal, A; Ahmed, A; Chao, DT; Jayasekera, CR; Perumpail, RB; Pham, EA; Wong, RJ | 1 |
| Huo, N; Li, M; Shao, C; Xu, X; Zhang, R | 1 |
| Ehsan, N; El-Fert, A; El-Said, H; Ezzat, S; Kohla, MA; Taha, H | 1 |
| Desta, T; Eley, T; Everson, GT; Gardiner, DF; Gitlin, N; Grasela, DM; Hassanein, T; Hawkins, T; Hinestrosa, F; Huang, SP; Lawitz, E; Levin, JM; McPhee, F; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Younossi, Z | 1 |
| Bloom, AK; Chung, RT; Gustafson, JL; Hashemi, N; Kim, AY; Lin, MV; Lundquist, AL; Sise, ME; Steele, D; Thadhani, R; Thiim, M; Williams, WW; Wisocky, J | 1 |
| Bernstein, DE; Bourgeois, S; Elkhashab, M; Feld, JJ; Fu, B; Horsmans, Y; Howieson, K; Larsen, L; Moreno, C; Pangerl, A; Polepally, AR; Poordad, F; Reindollar, RW; Shulman, NS; Tam, E; Trinh, R; Younes, Z | 1 |
| Cooper, C; Doyle, MA | 1 |
| Durant, J; Girard, PM; González-García, J; Grinsztejn, B; Horban, A; Janssen, K; Lathouwers, E; Montes, ML; Nelson, M; Ortega-Gonzalez, E; Ouwerkerk-Mahadevan, S; Rivero, A; Sasadeusz, J; Witek, J; Zakharova, N | 1 |
| Calabuig, M; Hernández-Boluda, JC; Navarro, D; Piñana, JL; Serra, MÁ; Solano, C | 1 |
| Ahmadi, W; El Ghannam, MT; El Khashab, MN; El-Ahwany, EG; El-Refaiy, M; Nagy, FM; Shaker, ZA; Zada, SK; Zoheiry, MK | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Kitai, S; Kitano, M; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Algendy, D; Amin, M; Elbadry, A; Esmat, S; Fawzi, M; Foda, A; Gabal, S; Kamal, M; Naga, M; Rashed, L; Sabry, D | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Bedimo, R; Bhattacharya, D; Brown, TT; Evans, C; Hollabaugh, K; Kang, M; McComsey, G; Overton, ET; Taiwo, B; Tebas, P | 1 |
| Aldámiz-Echevarria, T; Benito, JM; Berenguer, J; Diez, C; Fernández-Rodríguez, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Soriano, V | 1 |
| Hasson, H; Lazzarin, A; Merli, M; Messina, E; Salpietro, S; Uberti-Foppa, C | 1 |
| Clark, S; Cooke, GS; Gellissen, R; Irving, W; Main, J; Padam, P; Thomson, E | 1 |
| Dybowska, D; Karwowska, K; Kozielewicz, D; Wietlicka-Piszcz, M | 1 |
| Cloherty, G; De Locht, P; De Meyer, S; Fevery, B; Gilles, L; Lenz, O; Perner, D; Picchio, G; Sarrazin, C; Susser, S | 1 |
| Kwon, JH | 1 |
| Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S | 1 |
| Ryder, SD; Thiagarajan, P | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, CL | 1 |
| Ogawa, E | 1 |
| Fu, J; Huang, Y; Wu, S; Yang, Y; Yin, S | 1 |
| Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ | 1 |
| Choe, WH; Hwang, Y; Kim, JH; Kim, W; Kwon, SY; Yu, HM | 1 |
| Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E | 1 |
| Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K | 1 |
| Mantry, PS; Pathak, L | 1 |
| An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L | 1 |
| Asselah, T; Bourlière, M; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; García-Samaniego, J; Maevskaya, M; Mantry, P; Oliveira, C; Quinson, AM; Sha, N; Stern, JO; Warner, N; Wright, D; Wright, M; Yoshida, EM | 1 |
| Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y | 1 |
| Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawashima, A; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Niwa, T; Shingaki, N; Tamai, H | 1 |
| Bo, Q; Brass, C; Griffel, L; Orsenigo, R; Wang, J | 1 |
| Antonov, K; Boyanova, Y; Caloska-Ivanova, V; Dimovski, A; Dumitrascu, D; Dzekova-Vidimliski, P; Joksimovic, N; Mateva, L; Matevska-Geshkovska, N; Nikolov, IG; Nikolova, N; Romanciuc, G; Rostaing, L; Sikole, A | 1 |
| Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P | 2 |
| Daher, S; Shalit, M; Tal, Y; Toker, O | 1 |
| Aabakken, L; Dalgard, O; Grimstad, T; Isaksen, K; Karlsen, L; Sandvei, PK | 1 |
| Chen, H; Chen, M; Huang, P; Li, J; Peng, Z; Su, J; Wang, J; Xu, Y; Yu, R; Yue, M; Zhang, Y | 1 |
| Bukowska-Ośko, I; Cortes, KC; Inglot, M; Jabłońska, J; Laskus, T; Osowska, S; Pawełczyk, A; Pawłowski, T; Perlejewski, K; Radkowski, M; Ząbek, P; Zalewska, M | 1 |
| Furuta, N; Ishida, H; Ito, H; Katano, Y; Nakamura, M; Nakayama, J; Seishima, M; Shirakami, Y; Suetsugu, A; Tauchi, R | 1 |
| Delgado, M; López-Cortés, LF; Macías, J; Ojeda-Burgos, G; Pineda, JA; Recio, E; Ríos, MJ; Rivero-Juárez, A; Téllez, F | 1 |
| Busuttil, RW; Cheng, EY; Holt, CD; Saab, S | 1 |
| Ahmed, II; Anand, N; Ilyas, F; Singh, H | 1 |
| Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S | 1 |
| Farnik, H; Herrmann, E; Lange, CM; Luhne, S; Sarrazin, C; Vermehren, J; Welker, MW; Welzel, T; Zeuzem, S | 1 |
| Akamatsu, N; Arita, J; Hasegawa, K; Kaneko, J; Kokudo, N; Maki, H; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Tsukada, K | 1 |
| Chen, TM; Huang, PT; Lin, CC; Wen, CF | 1 |
| Anzai, K; Eguchi, Y; Fujimoto, K; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kuwashiro, T; Mizuta, T; Nakashita, S; Oeda, S; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H | 1 |
| Burger, J; Dranitsaris, G; Fraser, I; Lubbe, M; Sonderup, M; Stander, T | 1 |
| Husa, P | 1 |
| Abenavoli, L; Camera, S; Claar, E; Coppola, C; Coppola, N; De Luna, A; Federico, A; Gentile, I; Granata, R; Masarone, M; Morisco, F; Persico, M; Precone, D; Rosato, V; Salomone-Megna, A; Tartaglione, MT | 1 |
| Chen, G; Chen, H; Chen, X; Dou, X; Feng, Y; Gao, Z; Gong, G; Hou, J; Li, J; Niu, J; Rao, H; Shang, J; Wei, L; Xie, Q; Xu, X; Yang, R; You, H; Zhang, D | 1 |
| Mahmoud, M; Morsy, KH; Zaghloul, A | 1 |
| Fan, Z; Hu, Z; Jin, R; Liang, S; Liu, Y; Nie, W; Qiu, L | 1 |
| Bijani, B; Ghanei, L; Kazemifar, AM | 1 |
| Boyer-Darrigand, N; D'alteroche, L; Dao, MT; Ducancelle, A; Fouchard-Hubert, I; Larrey, D; Le Guillou-Guillemette, H; Loustaud-Ratti, V; Lunel-Fabiani, F; Picard, N; Saulnier, P; Veillon, P | 1 |
| D'Ambrosio, R; Galmozzi, E | 1 |
| Abuelhassan, W; Blackard, JT; Bowyer, SM; Mahlangu, J; Mahomed, A; Prabdial-Sing, N; Puren, AJ; Vermeulen, M | 1 |
| Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y | 1 |
| Adeyi, O; Chen, L; Cotler, SJ; Deneke, MG; Duarte-Rojo, A; Feld, JJ; Fischer, SE; Malespin, M; McGilvray, ID; Selzner, N; Zita, D | 1 |
| Atta, AM; Atta, ML; Carvalho, LP; Oliveira, IS; Paraná, R; Schinoni, MI | 1 |
| Artigas, F; Egmond, E; Gimenez, D; Gómez-Gil, E; Grande, I; Gratacós, M; Kapczinski, F; Langohr, K; Martín-Santos, R; Navinés, R; Oriolo, G; Solà, R; Udina, M; Valdés, M; Vieta, E | 1 |
| Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Calvaruso, V; Craxì, A | 1 |
| Boccaccio, V; Bruno, S; Maisonneuve, P; Russo, ML | 1 |
| Nelson, DR; Peter, J | 1 |
| Serfaty, L | 2 |
| Ghany, M; Keane, M; Liang, TJ; O'Keefe, AC; Park, H; Rehermann, B; Rivera, E; Serti, E | 1 |
| Dore, GJ; Martinello, M | 1 |
| Cope, R; Faulds, S; Glowa, T; McMahon, D; Prasad, R | 1 |
| Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ | 1 |
| Chi, X; Gao, X; Jiang, J; Kong, F; Lv, J; Mei, R; Niu, J; Pan, Y; Sun, B; Sun, H; Wang, X; Wu, R; Xu, H; Yu, G; Zhong, J | 1 |
| Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H | 1 |
| Andersohn, F; Claes, AK; Kulp, W; Mahlich, J; Rockstroh, JK | 1 |
| Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R | 1 |
| Craft, ZN; Kamal, KM; Koerner, PH; Miller, RT; Trombatt, WD | 1 |
| Salman, AG | 1 |
| Waltschew, A | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Asatryan, A; Fu, B; Jackson, DF; Kort, J; Landis, CS; Lin, CW; Ng, TI; Poordad, F; Yao, B | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Yen, YH | 2 |
| Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM | 1 |
| Cooke, GS; Hill, A; Riley, RD; Saleem, J; Simmons, B | 1 |
| Akhan, S; Aynioglu, A; Sargin Altunok, E; Sayan, M | 1 |
| Hoofnagle, JH | 3 |
| Rivero, A; Rivero-Juárez, A | 1 |
| Chi, X; Gao, X; Hua, R; Jiang, J; Kong, F; Lv, J; Niu, J; Pan, Y; Sun, B; Sun, H; Wang, X; Wu, R; Xu, H; Yu, G; Zhong, J | 1 |
| Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E | 1 |
| Henry, L; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Brooks, S; Miyoshi, Y; Murakami, J; Shimizu, T; Suzuki, M; Tajiri, H; Takano, T; Tanaka, Y | 1 |
| Cheng, N; Ford, R; Norvell, JP; Parekh, S; Pillai, AA; Spivey, JR; Wedd, J; Young, N | 1 |
| Brainard, DM; Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Han, L; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mathias, A; Mo, H; Peng, CY; Sheen, IS; Wang, HY; Yang, JC | 1 |
| Aldamiz-Echevarria, T; Benito, JM; Berenguer, J; Carrero, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Restrepo, C; Soriano, V; Vazquez-Morón, S | 1 |
| Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Nishimura, T | 1 |
| Hiramatsu, N; Oze, T | 1 |
| Izumi, N; Kurosaki, M; Suzuki, S | 1 |
| Bailey, R; Cooper, C; Drolet, M; Elkashab, M; Farley, J; Feinman, SV; Marotta, P; Peltekian, K; Poliquin, M; Rampakakis, E; Witt-Sullivan, H | 1 |
| Dolar, E; Gülten, M; Gürel, S; Kiyici, M; Nak, SG; Pekgöz, M | 1 |
| Glisic, S; Jovanovic-Cupic, S; Krajnovic, M; Mandusic, V; Nozic, D; Petrovic, N; Stanojevic, M | 1 |
| Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK | 1 |
| Applegate, T; Dore, GJ; Grebely, J; Haber, P; Hellard, M; Iser, D; Lloyd, A; Maire, L; Martinello, M; Matthews, GV; Petoumenos, K; Sasadeusz, J; Shaw, D; Thompson, A; Yeung, B | 1 |
| Arends, JE; Burger, DM; Friederich, P; Koek, GH; Lieveld, FI; Siersema, PD; van Erpecum, KJ; van Meer, S; van Nieuwkerk, KM; van Vlerken, LG | 1 |
| Blanchet, M; Labonté, P; Le, QT; Seidah, NG | 1 |
| Andrade, A; Bushman, L; Fuchs, EJ; Hendrix, CW; Kiser, JJ; Radebaugh, C; Ray, ML; Sulkowski, M | 1 |
| Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM | 1 |
| Li, J; Li, Z; Ping, Y; Shi, X; Wang, M; Yu, Z; Yue, D; Zhang, B; Zhang, Y; Zhang, Z | 1 |
| Andrade, LE; Calise, SJ; Chan, EK; Keppeke, GD | 1 |
| Kishk, R; Mandour, M; Nemr, N | 1 |
| Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O | 1 |
| Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S | 1 |
| Adachi, K; Ishii, T; Kumon, D; Matsumoto, N; Noguchi, Y; Okuse, C; Sato, A; Tamura, T | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Kunimoto, H; Saitoh, S; Sezaki, H; Sorin, Y; Suzuki, F; Suzuki, Y | 1 |
| Abd El-Maksoud, M; Amin, M; El-Bendary, M; Neamatallah, MA | 1 |
| Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM | 1 |
| Al-Ansari, NL; El-Derany, MO; El-Mesallamy, HO; Hamdy, NM | 1 |
| Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB | 1 |
| Grigg, N; Purcell, D; Santiago-Rolón, A; Toro, DH | 1 |
| Hellard, M; Higgs, P; Wright, C | 1 |
| Stepanova, M; Younossi, Z | 1 |
| D'Argenio, DZ; Jimmerson, LC; Kiser, JJ; MacBrayne, CE; Wu, LS | 1 |
| Chayama, K; Fujimoto, G; Howe, AY; Karino, Y; Kumada, H; Ludmerer, SW; Mobashery, N; Mochida, S; Nakamura, K; Suzuki, F | 1 |
| Horn, M; Horvath, A; Jurse, P; Leber, B; Lemesch, S; Posch, A; Schmerböck, B; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A; Tawdrous, M; Wuensch, G; Zettel, G | 1 |
| Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Lu, MY; Wang, SC; Yeh, ML; Yu, ML | 1 |
| Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E | 1 |
| Abe-Sandes, K; Carrilho, FJ; de Castro Lyra, A; de Mello Malta, F; de Seixas Santos Nastri, AC; Diniz, MA; Dos Santos, SE; Pinho, JR; Yoshino, A | 1 |
| Amorosa, VK; Dou, D; Kang, M; Kottilil, S; Lee, YJ; Matining, R; Osinusi, A; Peters, MG; Petersen, T; Umbleja, T; Wang, C; Zhang, X | 1 |
| Camacho, A; Cuenca, F; Frias, M; Gonzalez, R; Gordon, A; Manzanares-Martín, B; Peña, J; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Rodriguez-Cano, D | 1 |
| Abdel Aziz, RA; Ahmed, SH; Al Akel, W; Al Sayed Taha, A; El Kazaz, AY; Esmat, GE; Mostafa, A; Rashed, LA; Sabry, D | 1 |
| Hagiwara, H; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Imai, Y; Inada, M; Ito, T; Kaneko, A; Katayama, K; Mita, E; Morishita, N; Oshita, M; Oze, T; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yakushijin, T; Yamada, R; Yamada, Y; Yoshida, Y | 1 |
| Asselah, T; Bakalos, G; Flisiak, R; Messinger, D; Romero-Gomez, M; Shiffman, ML; Thompson, AJ | 1 |
| Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J | 1 |
| Bała, A; Białkowska-Warzecha, JE; Broncel, M; Jabłkowski, MS; Poliwczak, AR | 1 |
| Bae, SH; Chen, X; Chuang, WL; Garimella, T; Gong, G; Jia, J; Jia, Z; Li, Y; Lin, S; Lu, W; McPhee, F; Mo, L; Niu, J; Torbeyns, A; Treitel, M; Wei, L; Xie, Q; Xie, W; Xu, M; Yang, YF; Yin, PD; Zhang, M | 1 |
| Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H | 1 |
| Poovorawan, K; Poovorawan, Y; Tangkijvanich, P; Thong, VD; Vongpunsawad, S; Wasitthankasem, R | 1 |
| Bronte, F; Calvaruso, V; D'Ambrosio, R; Di Marco, V; Forni, G; Lanza, AG; Poggiali, E; Saracco, G | 1 |
| Kurmanova, GM; Kurmanova, KB; Sadykova, ShS | 1 |
| Ahlers, S; Bakalos, G; Coppola, C; Derbala, M; Ferenci, P; Foster, GR; Hassanein, T; Orlandini, A; Reddy, KR; Shiffman, ML; Tallarico, L | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Abdurakhmanov, D; Baruch, Y; Bruck, R; Diago, M; Ferenci, P; Flisiak, R; Gadano, A; Hughes, EA; Jacobson, I; Janczewska, E; Knysz, B; Kopit, J; Lueth, S; McPhee, F; Michener, T; Noviello, S; Safadi, R; Shafran, S; Thabut, D; Thompson, AJ; Yin, PD; Zarebska-Michaluk, D; Zeuzem, S; Zignego, AL | 1 |
| Hong, L; Huddleston, L; Poerzgen, P; Ramkissoon, R; Roytman, M; Seto, T; Trujillo, R; Tsai, N; Wong, L; Wu, C | 1 |
| Bruden, DJ; Gove, JE; Homan, CE; Livingston, SE; McMahon, BJ; Plotnik, JN; Simons, BC; Spradling, PR; Townshend-Bulson, LJ | 1 |
| Banerjee, D; Reddy, KR | 1 |
| Cannizzaro, M; Cottone, M; Madonia, G; Madonia, S; Orlando, E; Stagno, B | 1 |
| Komiyama, T; Tamura, Y; Tanaka, Y; Yokomori, H | 1 |
| Bo, Q; Chen, X; Duan, Z; Feng, B; Hou, J; Jia, J; Li, J; Li, R; Liu, Y; Niu, J; Ren, H; Shang, J; Wang, FS; Wang, G; Wei, L; Yang, X; Zhuang, H | 1 |
| Bae, WK; Choi, JW; Kim, JG; Kim, JW; Kim, KA; Lee, JS; Paik, WH; Song, TJ | 1 |
| Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML | 1 |
| Gilbert, J; Jha, LK | 1 |
| Diago, M; Peño, L; Plana, L; Urquijo, JJ | 1 |
| Boucher, CM; Forest, CP; Walsh, A | 1 |
| Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
| Badia, E; Sáez-Royuela, F | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Arai, M; Haga, Y; Imazeki, F; Kanda, T; Mikami, S; Nakamoto, S; Nakamura, M; Ogasawara, S; Sasaki, R; Tawada, A; Yasui, S; Yokosuka, O | 1 |
| Warpakowski, A | 1 |
| Chen, XH; Gao, L; Geng, JB; Hao, KY; Li, P; Wang, J; Wang, M; Wang, MR; Wang, SM; Xie, F; Xiong, X; Yang, ZG; Zhang, X; Zheng, WK | 1 |
| Cai, WP; Chen, XJ; He, Y; Hu, FY; Ke, YC; Lan, Y; Li, LH; Tang, XP | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Al-Ansari, NL; El-Mesallamy, HO; Hamdy, NM; Rizk, HH | 1 |
| Albrecht, JK; Alonso, E; Ciocca, M; Gonzalez, T; Goodman, Z; Haber, B; Jackson, B; Lacaille, F; Lang, T; Noviello, S; Pedreira, A; Rodriguez-Baez, N; Yang, Z | 1 |
| Ding, SX; Gao, GS; Hu, AR; Hu, YR; Ma, JB; Shen, Q | 1 |
| Choi, HS; Chun, HJ; Jung, CH; Kim, TH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY | 1 |
| Aschenbrenner, DS | 1 |
| Goto, H; Hayashi, K; Hirai, T; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Tachi, Y | 1 |
| Abdelsalam, A; Hammad, L; Rashed, L; Sabry, D; Salman, T | 1 |
| Angus, P; Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Kadus, W; Mantry, P; Mensa, FJ; Pockros, PJ; Soriano, V; Stern, JO; Vinisko, R; Wright, D; Zeuzem, S | 1 |
| Feld, JJ; Götte, M | 1 |
| Bulja, D; Husic-Selimovic, A; Huskic, J; Sofic, A | 1 |
| Banjac, V; Miskovic, M; Zivlak-Radulovic, N | 1 |
| Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Mensing, S; Podsadecki, T | 1 |
| Botta, D; Gaudy-Marqueste, C; Grob, JJ; Lorcy, S; Mancini, J; Oulies, V; Portal, I; Quiles, N; Richard, MA | 1 |
| Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Christensen, P; Dalgard, O; Färkkilä, M; Krarup, H; Lagging, M; Lindahl, K; Nilsson, S; Norkrans, G; Norrgren, H; Nyström, K; Rauning Buhl, M; Stenmark, S; Waldenström, J; Westin, J | 1 |
| Huy Ho, NA; Paparoupa, M; Schuppert, F | 1 |
| Bocquier, A; Carrieri, MP; Dabis, F; Esterle, L; Marcellin, F; Miailhes, P; Poizot-Martin, I; Protopopescu, C; Salmon-Ceron, D; Spire, B; Wittkop, L | 1 |
| Chen, YZ; Xie, X; Zhang, L | 1 |
| Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK | 1 |
| Saleem, A | 1 |
| Bane, A; Kassa, E; Kefene, H | 1 |
| Choi, WS; Jeong, JY; Kim, OZ; Min, JH; Pyo, JY; Sohn, JH; Song, JS | 1 |
| Ivanova, AL; Tarasova, LV | 1 |
| Aghasadeghi, MR; Bahiraei, N; Daneshvar, M; Javadi, F; Larijani, MS; Nikbin, M; Rad, LN; Rahimi, P; Sadat, SM; Siadat, SD; Zabihollahi, R | 1 |
| Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC | 1 |
| Baik, SJ; Kim, HI; Kim, TH; Rhie, JY | 1 |
| Cammà, C; Damele, F; Marcellusi, A; Mennini, FS; Taliani, G; Viti, R | 1 |
| Brainard, DM; Byrne, S; Copans, A; Dvory-Sobol, H; Fuchs, M; Guyer, W; Ho, SB; Kaplan, DE; Le, H; Monto, A; Moon, S; Morgan, TR; Peyton, A; Rossaro, L; Roy, A; Shaikh, O; Zhu, Y | 1 |
| Cheng, Y; Ding, N; Jin, X; Qing, S; Wang, J; Xin, S; Yan, T; Zhao, P | 1 |
| Dudina, KR; Kalininа, OV; Kozina, AN; Yushchuk, ND; Znoyko, OO | 1 |
| Acharya, SK; Das, P; Gupta, SD; Kalra, N; Kavimandan, A; Nayak, B; Panda, SK; Thakur, B; Vasudevan, S | 1 |
| Cotler, SJ; Dahari, H; Halfon, P | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Ridler, C | 1 |
| Almeida, PR; Barros, IC; Casagrande, L; Dresch, KF; Feltrin, AA; Mattos, AA; Onofrio, FQ; Tovo, CV | 1 |
| Neumaier, J | 1 |
| Flemming, JA; Lowe, CE | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK | 1 |
| Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Arientová, S; Beran, O; Boštík, P; Chalupa, P; Davidová, A; Holub, M; Kapla, J; Kondělková, K; Plíšek, S | 1 |
| Biasi, L; Casari, S; Castelli, F; Chirico, C; Festa, E; Izzo, I; Salemme, M; Villanacci, V; Zanotti, P | 1 |
| Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E | 1 |
| Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S | 1 |
| Assy, N; Dong, Y; Flisiak, R; Gadano, A; Kao, JH; Kawazoe, S; Kumada, H; Lee, KS; Portsmouth, S; Srinivasan, S; Xu, D; Znoyko, O; Zwirtes, R | 1 |
| Abdul-Kareem, S; Eid, Y; El-Sayed, M; Hamza, I; Marzaban, R | 1 |
| Gouttenoire, J; Moradpour, D; Szkolnicka, D | 1 |
| Arain, SR; Umer, TP | 1 |
| Bogomolov, P; Cooney, E; Critelli, L; Olveira, A; Pol, S; Reesink, HW; Santagostino, E; Srinivasan, S; van Erpecum, K; Xu, D | 1 |
| Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Aquilante, CL; Baouchi-Mokrane, F; Hodara, A; Jimmerson, LC; Kiser, JJ; Kottilil, S; Langness, JA; Meissner, EG; Sims, Z; Truesdale, A; Urban, TJ | 1 |
| Battimelli, C; Durante-Mangoni, E; Falco, E; Iossa, D; Molaro, R; Pafundi, PC; Parrella, A; Sodano, G; Utili, R | 1 |
| Alem, SA; Asem, N; El-Sayed, M; Elsharkawy, A; Esmat, G; Fouad, R; Hassan, E; Ismail, A; Yosry, A | 1 |
| Aarnoutse, RE; Burger, DM; de Kanter, CT; Kan, R; Smolders, EJ; Touw, DJ; van Luin, M | 1 |
| Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X | 1 |
| Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Ali, OE; Elagawy, WA; Mohamed, AA; Moustfa, Z; Sayed, GA; Sayed, O | 1 |
| Bayer, J; Gardner, EM; Johnson, S; Langness, J; Rogers, M; Rowan, SE; Smith, L | 1 |
| Cariani, E; Pecoraro, V; Trenti, T; Villa, E | 1 |
| Bakulin, I; Chulanov, V; Isakov, V; Kersey, K; Knox, SJ; Massetto, B; Svarovskaia, E; Zhdanov, K; Zhu, Y | 1 |
| Khoury, J; Saadi, T | 1 |
| Akutagawa, M; Ide, K; Kawasaki, Y; Masaki, N; Yamada, H | 1 |
| Ceccherini-Silberstein, F; Craxì, A; Perno, CF; Petta, S; Viganò, M | 1 |
| Geier, A; Kuhn, S; Kuntzen, D; Kuntzen, T; Müllhaupt, B; Seifert, B | 1 |
| Agarwal, K; Brown, A; Cheung, MCM; Foster, GR; Gelson, WTH; Hudson, BE; Irving, WL; MacDonald, DC; McLauchlan, J; Mutimer, DJ; Verma, S; Walker, AJ | 1 |
| Arai, M; Haga, Y; Kanda, T; Katsuno, T; Nakamoto, S; Nakamura, M; Ohta, Y; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Kao, JT; Tsai, SM; Tsai, YF | 1 |
| Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME | 1 |
| Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S | 1 |
| Fagundes, RN; Ferreira, LE; Pace, FH | 1 |
| Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C | 1 |
| Pham, YH; Rosenthal, P | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM | 1 |
| Buggisch, P; Cornberg, M; Günther, R; John, C; Klinker, H; Lutz, T; Mauss, S; Niederau, C; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Tacke, F | 1 |
| Fu, N; Meng, P; Nan, Y; Niu, X; Qiao, L; Su, S; Wang, R; Zhang, Y; Zhao, S | 1 |
| Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V | 1 |
| Chen, GF; Chen, J; Hu, JH; Ji, D; Lau, G; Li, B; Liu, JL; Lu, L; Niu, XX; Shao, Q; Wang, C; Wang, YD; Wu, V; You, SL; Zhao, J | 1 |
| Bugianesi, E; Saracco, GM; Vanni, E | 1 |
| Afdhal, N; Bräu, N; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; Patel, K; Reau, N; Roberts, SK; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H | 1 |
| Hsu, YC; Kor, CT; Su, PY; Su, WW; Wu, SS; Yen, HH | 1 |
| Chen, Y; Gao, F; Hu, C; Huang, Y; Liu, J; Qiu, R; Shi, K; Sun, L; Wang, X; Yuan, G; Zhou, Y | 1 |
| Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K | 1 |
| Abenavoli, L; Brkic, S; Lendak, D; Pete, M; Preveden, T; Ruzic, M | 1 |
| Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H | 1 |
| D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M | 1 |
| Choi, JW; Hong, SH; Jang, JW; Kim, DY; Kim, I; Kim, W; Lee, D; Lee, JI; Paik, YH; Yoon, KT | 1 |
| Etschmaier, A; Ferenci, P; Ferlitsch, A; Ferlitsch, M; Hametner, S; Hofer, H; Horvatits, T; Maieron, A; Paternostro, R; Peck-Radosavljevic, M; Quehenberger, P; Reiberger, T; Rutter, K; Salzl, P; Trauner, M | 1 |
| Fujikawa, H; Hasegawa, H; Matsuoka, S; Moriyama, M; Ochiai, T; Watanabe, Y | 1 |
| De Almeida, PR; De Leon, LB; De Mattos, AA; Feltrin, AA; Kliemann, DA; Pacheco, LS; Tovo, CV | 1 |
| Casato, M; Ceccotti, G; Colantuono, S; De Santis, A; Del Padre, M; Fiorilli, M; Fognani, E; Gianni, E; Gragnani, L; Mitrevski, M; Monti, M; Perez, M; Petraccia, L; Pulsoni, A; Stasi, C; Urraro, T; Visentini, M; Zignego, AL | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Axten, D; Dalton, J; Foster, GR; Gardner, H; Kunkel, J; Lewis, H; Tippett, A; Wilkinson, M; Wynne, S | 1 |
| Kapol, N; Lochid-Amnuay, S; Teerawattananon, Y | 1 |
| Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB | 1 |
| Appolo, B; Bloom, R; Patel, N; Sawinski, D | 1 |
| Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, do Y; Kim, HS; Kim, JK; Kim, MN; Kim, SU; Park, JY | 1 |
| Asselah, T; Bakalos, G; Esmat, G; Goulis, I; Messinger, D; Sanai, FM; Waked, I | 1 |
| Kukhareva, EI; Ogurtsov, PP | 1 |
| Abdelli, N; Ben Abdallah, H; Bizid, S; Bouali, R; Ghazouani, E; Mrabet, A; Ouedrani, A | 1 |
| Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM | 2 |
| Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Ng, KJ; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
| Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsi, E; Hsieh, MH; Hsieh, MY; Hsieh, TJ; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Lu, MY; Tsai, PC; Tsai, YS; Yeh, ML; Yu, ML | 1 |
| Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K | 1 |
| Guo, P; Li, G; Sun, X; Wu, D | 1 |
| Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J | 1 |
| Abdel-Hameed, EA; Abdelwahab, SF; Ahmed, SH; Daef, EA; El-Feky, MA; El-Mokhtar, MA; Hetta, HF; Hossain, M; Khalil, NK; Medhat, A; Mehta, M; Mekky, MA; Mohamed, WA; Rouster, SD; Shata, MT; Sherman, KE | 1 |
| Keating, GM | 1 |
| Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y | 1 |
| Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Alric, L; Anty, R; Beaulieux, F; Botta-Fridlund, D; Bouix, C; Canva, V; Carrieri, MP; Conti, F; D'Alteroche, L; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fontaine, H; Lebray, P; Leroy, V; Maynard, M; Métivier, S; Pageaux, GP; Paul, C; Petrov-Sanchez, V; Pradat, P; Roche, B; Roque-Afonso, AM; Samuel, D; Vilotitch, A; Wellems, C | 1 |
| Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Liu, WL | 1 |
| Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A | 1 |
| Bae, SH; Cho, SB; Jang, ES; Jeong, SH; Kim, IH; Kim, YS; Lee, HC; Lee, YJ; Ok, KS | 1 |
| Duguet, A; Ethgen, O; Jeanblanc, G; Juday, T; Misurski, D; Sanchez Gonzalez, Y | 1 |
| Berden, FA; Blokzijl, H; de Knegt, RJ; den Hollander, J; Drenth, JP; Friederich, P; Kievit, W; Kuiken, SD; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Vonderen, MG; Willemse, SB | 1 |
| Abdo, AM; Helmy, S; Yakoot, M; Yousry, A | 1 |
| Boglione, L; Cusato, J; D'Avolio, A; Di Perri, G | 1 |
| Berg, T; Ferenci, P; Gschwantler, M; Herzer, K; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, J; Spengler, U; van der Valk, M; Wedemeyer, H; Weiland, O; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Arns, CW; Bastos, JC; Caserta, LC; Miotto, N; Padilla, MA; Vigani, AG | 1 |
| Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D | 1 |
| He, QF; Zhang, DZ; Zhang, QF | 1 |
| Chadwick, PW; Heymann, WR | 1 |
| Alric, L; Billaud, E; Bourcier, V; Bourliere, M; Bronowicki, JP; Carrat, F; Causse, X; Chazouilleres, O; D'Alteroche, L; Diallo, A; Dorival, C; Fontaine, H; Fouchard-Hubert, I; Geist, C; Gournay, J; Guyader, D; Habersetzer, F; Hezode, C; Larrey, D; Ledinghen, VD; Loustaud-Ratti, V; Lucier, S; Marcellin, P; Mathurin, P; Metivier, S; Minello, A; Petrov-Sanchez, V; Pol, S; Riachi, G; Rosa, I; Saillard, E; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Chawla, Y; Dhiman, RK; Duseja, A; Mehta, M; Satsangi, S; Taneja, S | 1 |
| Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X | 1 |
| Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B | 1 |
| Furusyo, N; Hayashi, J; Hotta, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Uchiumi, T | 1 |
| Azzari, C; Cananzi, M; D'Antiga, L; Grisotto, L; Indolfi, G; Maccabruni, A; Nebbia, G; Resti, M; Zaramella, M | 1 |
| Carter, W; Connelly, S; Struble, K | 1 |
| El-Karaksy, HM; El-Mougy, FA; Mandour, IA; Mogahed, EA; Rady, NH; Sharaf, SA | 1 |
| Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR | 1 |
| Forton, DM | 1 |
| Abagiu, AO; Aramă, V; Bădărău, IA; Barbu, EC; Bojincă, M; Chiţu-Tișu, CE; Ion, DA; Lazăr, M; Olariu, CM; Olteanu, D | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| De Meyer, S; Fevery, B; Janssen, K; Jessner, W; Lenz, O; Peeters, M; Verbinnen, T; Witek, J | 1 |
| Colston, EM; Hruska, MW; Kishnani, N; Narasimhan, P; Srinivasan, S; Wind-Rotolo, MM; Xu, D; Zwirtes, R | 1 |
| Aghasadeghi, M; Fateh, A; Irani, S; Jamnani, FR; Sadat, SM; Sakhaee, F; Sedighimehr, P; Siadat, SD; Vaziri, F | 1 |
| Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL | 1 |
| Alric, L; Kamar, N; Rostaing, L | 1 |
| Barr, E; Black, S; Buti, M; Dutko, FJ; Gane, EJ; Gress, J; Haber, B; Kwo, P; Lin, L; Lupinacci, L; Pearlman, B; Peng, CY; Robertson, M; Serfaty, L; Shafran, S; Stryszak, P; Vierling, JM; Wahl, J | 1 |
| Dinu, S; Oprea, C; Oprişan, G; Ruta, S; Sultana, C; Teleman, MD; Voiculescu, M | 1 |
| Greig, SL | 1 |
| Alavian, SM; Behnava, B; Craig, JC; Keshvari, M; Pouryasin, A; Sharafi, H | 1 |
| Amrani, A; Dayal, S; Jain, VK; Verma, P | 1 |
| Beck, KR; Khalili, M; Kim, N | 1 |
| Brooks-Rooney, C; Dan, YY; Eguchi, Y; Kawada, N; Lim, YS; Mondelli, MU; Negro, F; Tanaka, A; Younossi, ZM; Yu, ML | 1 |
| Arenas, J; Cheinquer, H; Dong, Y; Flisiak, R; Nikitin, I; Rana, K; Shiffman, M; Srinivasan, S | 1 |
| Shi, KQ; Wang, BQ; Wang, YL | 1 |
| Borba, HH; Fernandez-Llimos, F; Pedroso, ML; Perlin, CM; Pontarolo, R; Steimbach, LM; Tonin, FS; Wiens, A | 1 |
| Chida, T; Ito, M; Nakashima, K; Suzuki, T | 1 |
| Boyd, S; Harrington, PR; Komatsu, TE; Naeger, LK; O'Rear, JJ; Sherwat, A; Tracy, L | 1 |
| Chen, H; Chen, X; Huang, P; Liu, J; Liu, Q; Wang, G; Wang, Y; Xu, T; Yao, Y; Yu, R; Zhang, Y; Zhou, H | 1 |
| Berry, K; Green, PK; Ioannou, GN; Su, F | 1 |
| Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A | 1 |
| Kaur, K; Mahajan, R; Mehta, V; Midha, V; Narang, V; Sharma, S; Singh, D; Sood, A; Wander, P | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Akuschevich, L; Brown, RS; Di Bisceglie, AM; Everson, GT; Fried, MW; Galati, JS; Kuo, A; Kwo, PY; Lim, JK; Lok, AS; Manns, MP; Morelli, G; Nelson, DR; Pockros, PJ; Reddy, KR; Sulkowski, MS; Terrault, NA; Vainorius, M | 1 |
| Antosik, D; Barcińska, D; Bereszyńska, I; Januszkiewicz-Lewandowska, D; Kałużna, E; Mozer-Lisewska, I; Nowak, J; Rembowska, J; Strauss, E; Świątek-Kościelna, B; Wysocki, J | 1 |
| Darwish, T; Ghoneum, M; Medhat, E; Salama, H; Shaheen, M; Zekri, AN | 1 |
| Abdo, A; Al-Hamoudi, W; Albarrag, A; Alhetheel, A; Alswat, K; Shakoor, Z | 1 |
| Bodeau, S; Brochot, E; Diouf, M; Duverlie, G; Lemouel, JP; Nguyen-Khac, E | 1 |
| Gul, A; Mahmood, S; Saif, T | 1 |
| Cao, Y; Huo, N; Lu, H; Wu, C; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
| Ashby, CR; Jankovich, RD; Jodlowski, TZ; Puglisi, GM; Smith, SM | 1 |
| Aikata, H; Amano, H; Arataki, K; Chayama, K; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Kawakami, Y; Kawaoka, T; Kohno, H; Makokha, GN; Morio, K; Moriya, T; Nagaoki, Y; Nakahara, T; Nakamura, T; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K | 1 |
| Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R | 1 |
| Albanes, D; Freedman, ND; Horst, R; Howell, CD; Loftfield, E; Morgan, TR; O'Brien, TR; Pfeiffer, RM; Prokunina-Olsson, L; Weinstein, SJ | 1 |
| Alexandru, DO; Kamal, AM; Kamal, KC; MitruŢ, P; Niculescu, M; Tica, AA; Tica, OS | 1 |
| Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S | 1 |
| Bertino, G; Caraci, F; Chisari, G; Drago, F; Greco, C; Malaguarnera, G; Malaguarnera, M; Motta, M; Nunnari, G; Vacante, M; Vecchio, M | 1 |
| Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM | 1 |
| Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF | 1 |
| Chang, JJ; Chen, CK; Chen, LW; Chen, SW; Chien, RN; Lee, TS; Liu, CJ; Wang, LJ; Yen, CL | 1 |
| Bräu, N; Dieterich, DT; Miller, TR; Rivera-Mindt, M; Stivala, A; Weiss, JJ | 1 |
| Buti, M; Calleja, JL; Corbett, C; Crespo, J; Diago, M; Fevery, B; Jessner, W; Kalmeijer, R; Kurland, D; Lens, S; Ortega, E; Pascasio, JM; Planas, R; Rodríguez, FG; Romero-Gómez, M | 1 |
| Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M | 1 |
| Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M | 1 |
| Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E | 1 |
| Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J | 1 |
| Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM | 1 |
| Clayton, CW; Jimmerson, LC; Kiser, JJ; Kottilil, S; MaWhinney, S; Meissner, EG; Sims, Z | 1 |
| Chen, W; Dang, P; Feng, J; Ma, Y; Wang, L; Xi, W; Yu, Y | 1 |
| Agostinacchio, E; Arleo, A; Carraturo, I; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Miscio, M; Palmieri, V; Piazzolla, V; Potenza, D; Santoro, R; Sarrazin, C; Spinzi, G; Susser, S | 1 |
| Elbasha, E; Greaves, W; Nwankwo, C; Roth, D | 1 |
| Afzal, S; Ali, M; Hassan, A; Idrees, M; Khalil, AT; Ovais, M; Shinwari, ZK; Zia, A | 1 |
| Baraldi, C; Barisani, A; Dika, E; Fanti, PA; Patrizi, A; Vaccari, S | 1 |
| Hu, P; Ren, H | 1 |
| Amano, N; Genda, T; Hirano, K; Ichida, T; Iijima, K; Kanemitsu, Y; Murata, A; Nagahara, A; Narita, Y; Sato, S; Shimada, Y; Tsuzura, H; Wada, R; Watanabe, S | 1 |
| Hayashi, Y; Imoto, S; Kim, CW; Kim, SK; Kim, SR | 1 |
| Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U | 1 |
| Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB | 1 |
| Bai, X; Calleja, JL; Forns, X; Garcia-Samaniego, J; Kaste, R; Manns, M; Sarrazin, C; Stern, JO; Wu, J | 1 |
| Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH | 1 |
| Asahina, Y; Asano, Y; Azuma, S; Iijima, S; Itsui, Y; Izumi, N; Kakinuma, S; Kaneko, S; Kawai-Kitahata, F; Miyoshi, M; Murakawa, M; Nagata, H; Nakagawa, M; Nitta, S; Otani, S; Tanaka, Y; Tohda, S; Tsuchiya, K; Tsunoda, T; Watanabe, M | 1 |
| Chen, Y; Jiang, X; Song, Y; Tao, T | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J | 1 |
| Lange, CM; Mücke, MM; Mücke, VT; Zeuzem, S | 1 |
| Alvares-Lajonchere, L; Amador, Y; Camacho, H; Campaña, JR; Dueñas, S; Estevez, ZC; Fernández, JR; Gao, Y; Guillen, IA; Han, J; Martinez-Donato, G; Novoa, LI; Palenzuela Gardón, D; Zhang, X; Zhang, Z | 1 |
| Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J | 1 |
| Abdelaziz, AO; Doss, W; El Akel, W; El Demerdash, T; El Raziky, M; El Serafy, M; El Shazly, Y; Elsharkawy, A; Esmat, G; Fouad, R; Gaballah, A; Hassany, M; Makhlouf, MA; Motawea, I; Said, M; Seif, S; Shiha, G; Thursz, M; Waked, I; Yosry, A | 1 |
| Jin, YJ; Lee, JW; Lee, SH; Shin, JY | 1 |
| Cammà, C; D'Offizi, G; DeMasi, R; Janssen, K; Lionetti, R; Palma, M; Schlag, M; Taibi, C; Weber, K; Witek, J | 1 |
| Aherfi, S; Brouqui, P; Colson, P; Dhiver, C; Meddeb, L; Menard, A; Mokhtari, S; Ravaux, I; Stein, A; Tissot-Dupont, H | 1 |
| Berg, T; Böker, KH; Cornberg, M; Günther, R; Hüppe, D; Link, R; Manns, MP; Mauss, S; Niederau, C; Petersen, J; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Serfert, Y | 1 |
| Beck, R; Berg, CP; Dietz, J; Klag, T; Lauer, UM; Malek, NP; Sarrazin, C; Schwarz, JM; Werner, CR | 1 |
| Frydecka, D; Małyszczak, K; Pawlak, D; Pawłowski, T | 1 |
| Chan, SF; Ho, LY; Lo, KC; Lo, KY; Lo, MW; Mak, SK; Sin, HK; Wong, AKM; Wong, PN; Wong, YY | 1 |
| Cartabellotta, F; Di Marco, V | 1 |
| Baldanti, F; Ludovisi, S; Mondelli, MU; Paolucci, S; Premoli, M | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Yeh, ML; Yu, ML | 1 |
| Boyd, SD; Harrington, PR; Komatsu, TE; Murray, J; Sherwat, A; Tracy, L; Viswanathan, P | 1 |
| Miyoshi, Y; Suzuki, M; Tajiri, H; Takano, T | 1 |
| Andreoni, M; Angelico, M; Antonucci, F; Aragri, M; Babudieri, S; Barbaliscia, S; Bellocchi, MC; Bertoli, A; Brancaccio, G; Calvaruso, V; Caporaso, N; Ceccherini-Silberstein, F; Cento, V; Cozzolongo, R; Craxì, A; Di Biagio, A; Di Maio, VC; Francioso, S; Gianserra, L; Grieco, A; Landonio, S; Lenci, I; Loggi, E; Magni, CF; Masetti, C; Mastroianni, CM; Melis, M; Merli, M; Micheli, V; Morisco, F; Pace Palitti, V; Paoloni, M; Parruti, G; Pasquazzi, C; Pellicelli, AM; Perno, CF; Picciotto, A; Puoti, M; Rizzardini, G; Romagnoli, D; Rossi, P; Santopaolo, F; Sarmati, L; Siciliano, M; Taliani, G; Tarquini, P; Teti, E; Vecchiet, J; Verucchi, G; Vullo, V | 1 |
| Barros, C; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jusdado, JJ; Mallolas, J; Montero, M; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rodríguez-Castellano, E; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Tural, C; Von Wichmann, MA | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S | 1 |
| Hmwe, SS; Ide, T; Inoue, T; Kato, K; Kumada, T; Shimada, N; Takaguchi, K; Tanaka, Y; Torimura, T; Toyoda, H; Tsubota, A; Wakita, T | 1 |
| Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K | 1 |
| Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T | 1 |
| Asatryan, A; Bernstein, DE; Felizarta, F; Flamm, SL; Fried, MW; Gordon, SC; Kort, J; Landis, CS; Lin, CW; Liu, R; Lovell, SS; Mensa, FJ; Ng, TI; Poordad, F; Reindollar, RW; Sulkowski, MS | 1 |
| Abdalla, AF; Alsayed, MAEL; Barakat, T; Fathy, A; Mabood, SAE; Megahed, A; Salem, N; Zalata, KR | 1 |
| Alvarez, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Islam, N; Janjua, NZ; Krajden, M; Ramji, A; Samji, H; Tyndall, M; Wong, J; Yoshida, EM | 1 |
| Kumakawa, M; Matsumoto, N; Matsumura, H; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamagami, H | 1 |
| Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T | 1 |
| Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, Z | 1 |
| Economides, MP; Shigle, TL; Torres, HA | 1 |
| Jiang, JF; Liu, X; Shi, J; Sun, J | 1 |
| Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A | 1 |
| Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y | 1 |
| Abe, M; Hiasa, Y; Hirooka, M; Horiike, N; Joko, K; Kisaka, Y; Michitaka, K; Nakanishi, S; Nonaka, T; Tada, F; Tanaka, Y; Tokumoto, Y; Watanabe, T; Yamauchi, K | 1 |
| Ascione, T; Borgia, G; Buonomo, AR; Calò, F; Coppola, N; De Pascalis, S; de Stefano, G; Di Caprio, G; Federico, A; Filippini, P; Gaeta, GB; Gentile, I; Martini, S; Messina, V; Minichini, C; Persico, M; Rinaldi, L; Sangiovanni, V; Stanzione, M; Starace, M; Stornaiuolo, G; Zampino, R | 1 |
| Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J | 1 |
| Ariaudo, A; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Mornese Pinna, S | 1 |
| Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F | 1 |
| Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H | 1 |
| Arastéh, K; Bourgeois, S; Buggisch, P; Francque, S; Hoeben, E; Horsmans, Y; Jacquemyn, B; Kakuda, TN; Luo, D; Moreno, C; Nevens, F; Orlent, H; Schattenberg, JM; Van Remoortere, P; Van Vlierberghe, H; Vandebosch, A; Verloes, R; Vijgen, L | 1 |
| Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J | 1 |
| Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY | 1 |
| Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J | 1 |
| Efinger, M; Herrmann, E; Lange, CM; von Wagner, M; Welsch, C; Welzel, TM; Zeuzem, S | 1 |
| Arias, A; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Esposito, I; Requena, S; Soriano, V; Treviño, A | 1 |
| Ezzat, W; Fouad, R; Heiba, A; Khairy, M; Khorshied, M; Sheta, MM; Zachariah, K | 1 |
| Afendy, M; Cable, R; Esteban, R; Henry, L; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Ackerman, P; Berenguer, J; Cheinquer, H; Côté, P; Dieterich, D; Eley, T; Fessel, WJ; Gadano, A; Hernandez, D; Hughes, E; Lazzarin, A; Liu, Z; Matthews, G; McPhee, F; Mendez, P; Molina, JM; Moreno, C; Noviello, S; Pineda, JA; Pulido, F; Rivero, A; Rockstroh, J; Sulkowski, MS; Zakharova, N | 1 |
| Bach, TA; Zaiken, K | 1 |
| Ide, K; Iketani, R; Kawasaki, Y; Masaki, N | 1 |
| Brito-Zerón, P; Cacoub, P; Casato, M; Ferri, C; Lamprecht, P; Mangia, A; Ramos-Casals, M; Retamozo, S; Saadoun, D; Tzioufas, AG; Younossi, ZM; Zignego, AL | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Chang, TT; Ho, YC; Hsieh, YH; Tseng, CW; Tseng, KC; Tseng, LH; Wu, SF | 1 |
| Bui, E; di Biase, L; Fasano, A; Freitas, ME; Picillo, M | 1 |
| Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
| Buzzetti, E; Davidson, BR; Gurusamy, KS; Kalafateli, M; Thorburn, D; Tsochatzis, E | 1 |
| Almarzooqi, S; Emery, JS; Feld, JJ; Janssen, HLA; Kowgier, M; Kuczynski, M; La, D; Shah, H; Wong, D | 1 |
| Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T | 1 |
| Chuang, WL; Dai, CY; Hsieh, MY; Huang, JF; Yu, ML | 4 |
| Goto, H; Hayashi, K; Honda, T; Ishigami, M; Katano, Y; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K | 1 |
| Enquist, R; Glaumann, H; Hollander, A; Lindahl, K; Lindh, G; Mattsson, L; Quist, A; Schvarcz, R; Weiland, O | 1 |
| Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yang, YH; Yu, ML | 1 |
| Pol, S; Soriano, V | 1 |
| Banasch, M; Ellrichmann, M; Emminghaus, R; Goetze, O; Schmidt, WE | 1 |
| Niederau, C | 4 |
| Kaden, T; Niederau, C | 1 |
| Dev, A; Dinh, T; George, J; Guirgis, M; Lee, A; Yan, KK; Zekry, A | 1 |
| Borkowska, A; Drózdz, W; Dybowska, D; Halota, W; Kozielewicz, D; Ziółkowska-Kochan, M | 1 |
| Jendryczka, E; Pawłowska, M; Pilarczyk, M | 1 |
| Pawłowska, M | 4 |
| El-Shamy, A; Hotta, H; Imoto, S; Kim, SR; Nagano-Fujii, M; Sasase, N | 1 |
| El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kawada, N; Kim, KI; Kim, SR; Kudo, M; Mita, K; Sasase, N; Shouji, I; Taniguchi, M | 1 |
| Cvetković, RS; Keam, SJ | 2 |
| Akue-Goeh, P; Howaizi, M; Maurer-Chagrin, F | 1 |
| Andriulli, A; Iacobellis, A; Ippolito, A; Leandro, G; Mangia, A; Zeuzem, S | 1 |
| Andreone, P; Ballardini, G; Berardi, S; Bernardi, M; Bianchi, FB; Biselli, M; Bolondi, L; Cescon, M; Colecchia, A; D'Errico, A; Del Gaudio, M; Ercolani, G; Gramenzi, A; Grazi, GL; Grigioni, W; Lenzi, M; Lodato, F; Lorenzini, S; Mazzella, G; Morelli, MC; Pinna, AD; Piscaglia, F; Ravaioli, M; Roda, E; Sama, C; Tame, MR; Vivarelli, M | 1 |
| Clemente, G; Del Rio, JM; Gisbert, JP; Marin, M; Moreno-Otero, R; Nunez, O; Pivel, JP; Trapero-Marugan, M | 1 |
| Bodenheimer, HC; Joyce, MA; Kadam, JS; Lake-Bakaar, G; Leonard, J; Lin, A | 1 |
| Mangini, C; Pereira, GH | 1 |
| Genné, D; Golay, A; Negro, F; Overbeck, K | 1 |
| Cheng, D; Chu, Y; Liu, E; Xue, X; Yang, H; Yu, H; Zhao, S | 1 |
| Hauser, P; Huckans, M; Loftis, J; Mitchell, A; Ruimy, S | 1 |
| Agreda, M; Cuenca, F; Devesa, MJ; Díaz-Rubio, M; Ladero, JM; López-Alonso, G; Ortega, L; Suárez, A | 2 |
| Jensen, DM; Martin, P | 1 |
| Pedersen, C; Pedersen, CR | 1 |
| Collado, A; Crespo, M; Esteban, JI; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Van den Eynde, E | 1 |
| Becheanu, G; Gheorghe, L; Herlea, V; Hrehoret, D; Iacob, S; Popescu, I | 1 |
| Berenguer, M | 1 |
| Bolewska, B; Czajka, A; Juszczyk, J; Moczko, J | 1 |
| Adamek, A; Adamek, J; Bereszyńska, I; Juszczyk, J | 1 |
| Kiciak, SG; Krzowska-Firych, J; Modrzewska, R | 1 |
| Barreiro, P; López-Cortes, LF; Maida, I; Martín-Carbonero, L; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rodríguez-Nóvoa, S; Santos, I; Soriano, V; Vispo, E | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Driss, H; Goderel, I; Lapidus, N; Lunel-Fabiani, F; Morand, P; Perronne, C; Pol, S; Rosenthal, E; Simon, A | 1 |
| Chang, SC; Ko, WS; Peng, CY; Wu, SS; Yang, SS | 1 |
| Laguno, M; Mallolas, J | 1 |
| Pearlman, BL | 3 |
| Paik, SW | 1 |
| Benini, MC; Biagini, MR; Capanni, M; Colagrande, S; Lorefice, E; Milani, S; Salvadori, E; Surrenti, C; Tozzi, A | 1 |
| Crosbie, O; Fanning, LJ; Kenny-Walsh, E; Levis, J; Moreau, I | 1 |
| Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Salmon-Céron, D | 1 |
| Aleman, S; Birk, M; Carlsson, T; Davidsdottir, L; Hagen, K; Hultcrantz, R; Oksanen, A; Rahbin, N; Syed, E; Weiland, O | 1 |
| Kami, M; Komatsu, T; Miura, Y; Toda, N; Yotsuya, R | 1 |
| Fujita, N; Hayashi, H; Iwasa, M; Kaito, M; Kobayashi, Y; Motonishi, S; Sugimoto, R; Takei, Y; Takeo, M; Tanaka, H; Tomosugi, N | 1 |
| Cacopardo, B; Cappellani, A; Cappello, E; La Medica, G; Nigro, L; Nunnari, G; Palermo, F; Russo, R | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 4 |
| Akhan, SC; Kalender, B; Ruzgar, M | 1 |
| Gambarin-Gelwan, M; Jacobson, IM | 2 |
| Bruno, R; De Luca, A; García-Samaniego, J; González, M; Losada, E; Mariño, A; Martín-Carbonero, L; Núñez, M; Puoti, M; Quinzan, G; Soriano, V | 1 |
| Bruggmann, P; Dober, S; Falcato, L; Helbling, B; Keiser, O; Meili, D; Negro, F | 1 |
| Arakawa, T; Atsumi, H; Goto, H; Hayashi, K; Hisanaga, Y; Honda, T; Kanamori, A; Katano, Y; Kiriyama, S; Kumada, T; Nakano, S; Sone, Y; Tanikawa, M; Toyoda, H | 1 |
| Andrade, LJ; Atta, AM; D'Almeida Junior, A; Paraná, R | 1 |
| Burton, JR; Castelblanco, N; Golden-Mason, L; Im, K; Klarquist, J; Rosen, HR; Smyk-Pearson, S; Terrault, N | 1 |
| Jiménez-Rivera, J; Marxuach-Cuétara, A; Ortiz-Lasanta, G; Purcell-Arevalo, D; Ríos-Bedoya, CF; Rodríguez-Torres, M | 1 |
| Hwang, Y; Lin, E | 1 |
| Cheng, C; Fung, J; Hung, I; Lai, CL; Wong, D; Young, J; Yuen, MF | 1 |
| Bigard, MA; Bronowicki, JP; Cadranel, JF; Canva, V; Cortot, A; Gueant, JL; Nousbaum, JB; Oussalah, A; Peyrin-Biroulet, L; Roblin, X; Seddik, M; Sogni, P | 1 |
| Enomoto, M; Hino, M; Kawada, N; Ohnishi, M; Tamori, A; Yamane, T | 1 |
| Borelli, S; Borgia, F; Borgia, G; Borrelli, F; Cerini, R; de Caterina, M; Di Taranto, MD; Fortunato, G; Gentile, I; Reynaud, L; Sacchetti, L; Simone, M; Viola, C | 1 |
| Bain, VG; Benhamou, Y; Cronin, PW; Flisiak, R; Grigorescu, M; Kaita, K; McHutchison, JG; Pianko, S; Pulkstenis, E; Rehak, V; Shouval, D; Subramanian, GM; Yoshida, EM; Zeuzem, S | 1 |
| Alsiö, A; Buhl, MR; Christensen, P; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Leutscher, P; Mørch, K; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Al-Ansari, M; Dickson, G; Weilert, F | 1 |
| Ferenci, P; Formann, E; Gschwantler, M; Gurguta, C; Jessner, W; Watkins-Riedel, T; Wrba, F | 1 |
| Bojunga, J; Bücker, A; Herrmann, E; Hofmann, WP; Kronenberger, B; Mihm, U; Sarrazin, C; Stamm, B; von Wagner, M; Zeuzem, S | 1 |
| Bronowicki, JP; Cadranel, JF; Denis, J; Larrey, D; Perronne, C; Tran, A; Trépo, C | 1 |
| Marcellin, P; Pol, S | 1 |
| De Lédinghen, V; Lang, JP; Poynard, T; Ratziu, V; Rosenthal, E; Wartelle-Bladou, C | 1 |
| Angelico, F; Angelico, M; Bandiera, F; Barlattani, A; Demelia, L; Forlini, G; Francioso, S; Gentile, S; Grieco, A; Guarascio, P; Koehler-Horst, B; Piccolo, P; Pilleri, G; Ponti, L; Rossi, Z; Soccorsi, F; Sorbello, O; Tarquini, P; Vecchia, RD; Zaru, S | 1 |
| de Aguiar, MC; do Carmo, MA; Grossmann, Sde M; Teixeira, R | 1 |
| Chang, CY; Chang, FY; Chu, CJ; Hung, TH; Hwang, SJ; Lee, CY; Lee, FY; Lee, SD; Lin, HC; Lu, RH; Yang, PL; Yu, MI | 1 |
| Kato, M; Miura, H; Ryu, T; Saito, T; Yamada, H | 1 |
| Bodenheimer, HC; Bonkovsky, HL; Monto, A; Rossi, SJ; Sulkowski, MS; Tice, AD; Yapp, RG | 1 |
| Anderson, F; Bailey, RJ; Bain, VG; Cooper, CL; Krajden, M; Marotta, P; Yoshida, EM | 1 |
| Białkowska, J; Dworniak, D; Jabłkowski, M; Pawełczyk, A; Pawełczyk, T; Rabe-Jabłońska, J; Strzelecki, D | 2 |
| Abate, ML; Bo, S; Bugianesi, E; Cassader, M; Ciancio, A; Ciccone, G; Gambino, R; Giordanino, C; Olivero, A; Pellicano, R; Rizzetto, M; Saracco, G; Smedile, A | 1 |
| Gładysz, A; Inglot, M; Machaj, A; Molin, I; Rymer, W; Zalewska, M | 1 |
| Correale, M; Cozzolongo, R; Frisullo, S; Guerra, V; Iacovazzi, PA; Lanzillotta, E | 1 |
| Back-Madruga, C; Bieliauskas, LA; Fontana, RJ; Kronfol, Z; Lindsay, KL; Lok, AS; Padmanabhan, L; Stoddard, AM | 1 |
| Jensen, DM; Mishra, P | 1 |
| Jagodziński, PP; Juszczyk, J; Kmieciak, D; Migdalski, P; Trzeciak, WH | 1 |
| Smith, JP | 1 |
| Crawford, V; Dalton, J; Foster, GR; Hekker, M; Jolly, F; Marley, R; Sims, E; Tippet, A; Turton, J; Wilkinson, M | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Goderel, I; Larrat, S; Lunel-Fabiani, F; Martha, B; Morand, P; Payan, C; Perronne, C; Piroth, L; Pol, S | 1 |
| Husa, P; Husová, L; Slesinger, P; Stroblová, H; Svobodník, A | 1 |
| Kristian, P; Pellová, A; Porubcin, S; Schréter, I | 1 |
| Cacoub, P; Klatzmann, D; Landau, DA; Rosenzwajg, M; Saadoun, D; Trébeden-Negre, H | 1 |
| Baloch, GH; Ghori, R; Jaffri, M; Masood, N; Memon, A; Memon, I; Memon, KI; Memon, S | 1 |
| Berg, T; Hinrichsen, H; Hueppe, D; Manns, MP; Mauss, S; Moeller, B; Sarrazin, C; Wedemeyer, H; Zehnter, E; Zeuzem, S | 1 |
| DeVoss, A; Hart, J; Jensen, DM; Mishra, P; Pai, R | 1 |
| Bellati, G; Bellia, V; Bruno, S; Ceriani, R; Colloredo, G; Corradi, C; Del Poggio, P; Fornaciari, G; Parravicini, P; Pioltelli, P; Pozzpi, M; Ramella, G; Roffi, L; Rossini, A | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Holzmann, H; Kerschner, H; Rutter, K; Scherzer, TM; Schöniger-Hekele, M; Steindl-Munda, P | 1 |
| Calogero, A; Cammalleri, L; Di Fazio, I; Gargante, MP; Malaguarnera, M; Pennisi, G; Rampello, L; Ranno, S; Risino, C; Vicari, E | 1 |
| Angarano, G; Di Tullio, R; Fazio, V; Fornabaio, C; Saracino, A; Scotto, G; Tartaglia, A | 2 |
| Blanco, Cdel V; Federico, A; Loguercio, C; Masarone, M; Persico, M; Torella, R | 1 |
| Raimondo, G; Saitta, C | 1 |
| Gasiorowski, J; Inglot, M; Szymczak, A | 1 |
| Cornberg, M; Hadem, J; Hauptmann, C; Manns, MP; Süttmann, U; Wedemeyer, H | 1 |
| Choi, P; Jung, EU; Kang, MJ; Kim, JH; Lee, SH; Lee, YJ; Park, ET; Park, SJ; Park, SW; Seol, SY | 1 |
| Kaya, S | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 4 |
| Deutch, M; Dourakis, S; Ioannidou, P; Karafoulidou, A; Katsarou, O; Kouraba, A; Nomikou, E; Terpos, E; Theodosiades, G; Tsevrenis, B | 1 |
| Castro, G; Figueiredo, JF; Martinelli, Ade L; Ramalho, LN; Zucoloto, S | 1 |
| Marcellin, P; Nelson, DR; Zeuzem, S | 1 |
| Khan, F; Peltekian, KM; Peterson, TC | 1 |
| Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S | 1 |
| Bugawan, T; Erlich, H; Im, K; Li, J; Liang, TJ; Rhodes, SL; Rosen, HR; Wahed, AS; Yang, H; Yee, LJ | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Azim, J; McCurdy, H; Moseley, RH | 1 |
| Ichijo, T; Joshita, S; Kiyosawa, K; Komatsu, M; Matsumoto, A; Shirakawa, H; Tanaka, E; Tanaka, N; Umemura, T; Yoshizawa, K | 1 |
| Jiménez-Nácher, I; Morello, J; Rodríguez-Novoa, S; Soriano, V | 1 |
| Becheanu, G; Cotruta, B; Cotruta, C; Gheorghe, C; Gheorghe, L; Trifu, V | 1 |
| Bacosi, D; Baldelli, F; Belfiori, B; Chiodera, A; Ciliegi, P; Francisci, D; Tosti, A | 1 |
| Alsiö, A; Dhillon, AP; Ferrari, C; Hellstrand, K; Islam, S; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Westin, J; Ydreborg, M; Zeuzem, S | 1 |
| Farooqi, JI; Farooqi, RJ | 1 |
| Anikina, OV; Kovalenko, SN; Romantsov, MG; Sologub, TV | 1 |
| Araújo, FM; Oliveira, GC; Redondo, RA; Rodrigues, NB; Sonoda, IV; Teixeira, R | 1 |
| Cortina, B; del Olmo, JA; Lluch, P; Lluch, S; Mauricio, MD; Rodrigo, JM; Segarra, G; Serra, MA; Vila, JM | 1 |
| Chang, ML; Hsu, CW; Tsao, ML; Yeh, CT | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Katamura, Y; Kawamura, Y; Kobayashi, M; Kumada, H; Nomura, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Hashemi, N; Herrine, SK; Navarro, VJ; Rossi, S | 1 |
| Ishikawa, T | 1 |
| Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M; Varastet, M | 1 |
| Davison, SM; Kelly, DA | 1 |
| Chang, CS; Chang, SC; Chen, CY; Chuang, JY; Hsieh, YY; Kao, JH; Lu, YT; Yang, SS; Yeh, HZ | 1 |
| Fehér, J; Hagymási, K | 1 |
| Ackermann, O; Grigorian, N; Herrmann, E; Hofmann, WP; Lengauer, T; Mihm, U; Sarrazin, C; Welker, MW; Welsch, C; Zeuzem, S | 1 |
| Caturelli, E; Dell'Isola, S; Ghittoni, G; Ialungo, AM; Roselli, P; Starnini, G | 1 |
| Broers, B; Frei, M; Fried, R; Herold, M; Huber, M; Isler, M; Kölliker, C; Monnat, M; Oppliger, R; Schmid, P; Schönbucher, P; Seidenberg, A | 1 |
| Antonini, T; Canfora, ML; Castaing, D; Delvart, V; Duclos-Vallee, JC; Roche, B; Roque-Afonso, AM; Saliba, F; Samuel, D; Sebagh, M | 1 |
| Boumis, E; Capone, A; Drapeau, CM; Noto, P; Petrosillo, N; Remotti, D | 1 |
| Jones, TL; Reeves, GE; Tran, HA | 1 |
| Bergmann, JF; De Knegt, RJ; Janssen, HL | 1 |
| Deuter, C; Doycheva, D; Stuebiger, N; Zierhut, M | 1 |
| Azhar, M; Jamall, IS; Jamall, S; Yusuf, S | 1 |
| Arnsten, JH; Gourevitch, MN; Harris, KA; Kaswan, D; Litwin, AH; Nahvi, S; Soloway, IJ; Tenore, PL; Zamor, PJ | 1 |
| Nerrienet, E; Njouom, R; Pasquier, C; Rousset, D; Sartre, MT; Tchendjou, P; Timba, I | 1 |
| Kearney, KR; Navarro, VJ; Thornton, JJ | 1 |
| Lin, CC; Yin, MC | 1 |
| Dai, Y; Ishii, K; Mohri, K; Motegi, E; Uesawa, Y | 1 |
| Bonet, L; Cifuentes, C; Gatell, JM; Laguno, M; Laufer, N; Mallolas, J; Murillas, J; Perez, I; Veloso, S; Vidal, F | 1 |
| Galizio, C; Johnson, K; Sargent, LA; Ubogu, EE | 1 |
| Bogomolov, BP; Gromova, NI | 2 |
| Curto, TM; Desanto, JL; Everson, GT; Hoefs, JC; Morgan, TR; Shiffman, ML; Sterling, RK; Wagner, DA; Wright, EC | 1 |
| Burke, V; Cheng, W; Connelly, C; Flexman, J; Jamil, KM; Kontorinis, N; Leedman, PJ; McInerney, M; Metcalf, C; Nazareth, S; Tarquinio, L | 1 |
| Herrmann, E; Hofmann, WP; Sarrazin, C; Zeuzem, S | 1 |
| Alvarez-Lajonchere, L; Amador-Cañizares, Y; Dueñas-Carrera, S; González-Horta, EE; Guerra, I; Martínez-Donato, G; Pérez, A; Rodríguez-Alonso, I; Triana, J | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Lok, AS; Naishadham, D; Sterling, RK; Su, GL | 1 |
| Couzigou, P; Kharlov, N; Mascarell, V; Payen, JL; Pillard, F; Rivière, D | 1 |
| Agostinacchio, E; Andriulli, A; Bacca, D; Carretta, V; Cozzolongo, R; Mangia, A; Minerva, N; Petruzzellis, D; Ricci, GL; Romano, M; Scotto, G; Sogari, F; Vinelli, F | 1 |
| Adams, O; Emmelkamp, J; Häussinger, D; Kupfer, B; Oette, M; Rockstroh, J; Sagir, A; Vogel, M | 1 |
| Akahane, T; Fukushima, K; Inoue, J; Ishii, M; Iwasaki, T; Kakazu, E; Kobayashi, T; Kogure, T; Kondo, Y; Mano, Y; Matsuda, Y; Miyazaki, Y; Nagasaki, F; Okamoto, H; Onodera, H; Shimosegawa, T; Ueno, Y; Yamamoto, T | 1 |
| Bassa, A; Blanco, JL; Bonet, L; Calvo, M; Cifuentes, C; Gatell, JM; Laguno, M; Larrousse, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Milinkovic, A; Murillas, J; Payeras, A; Pérez, I; Sánchez-Tapias, JM; Tural, C; Veloso, S; Vidal, F; Villalonga, C | 1 |
| Amorosa, VK; Dorey-Stein, Z; Gross, R; Kostman, JR; Lo Re, V; Localio, AR; O'Flynn, R; Teal, V | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Diago, M | 2 |
| Nelson, DR; Reddy, KR; Zeuzem, S | 1 |
| Hasegawa, I; Joh, T; Kurbanov, F; Matsuura, K; Mizokami, M; Nojiri, S; Ohno, T; Sugauchi, F; Tanaka, Y; Tokuda, H | 1 |
| Antaki, N; Marcellin, P | 1 |
| Hino, T; Ide, T; Kuhara, K; Kuwahara, R; Miyajima, I; Ogata, K; Sata, M | 1 |
| Hegedüs, G; Hunyady, B; Miseta, A; Pár, A; Pár, G; Roth, E; Vincze, A | 1 |
| Chae, HB; Kang, YW; Kim, AN; Kim, HS; Kim, JI; Kim, SB; Kim, SH; Lee, BS; Lee, HIe; Lee, HY; Lee, TH; Nam, SW; Park, BC; Park, JY; Song, IH | 1 |
| Chang, SH; Choe, WH; Han, HS; Kim, BK; Ko, SY; Kwon, SY; Lee, CH | 1 |
| Aoki, C; Goforth, J; Martinez, F; Prosser, C; Rossaro, L; Yuk, J | 1 |
| Hartwell, D; Shepherd, J | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 2 |
| El-Gohary, Y; Elfert, A; Keeffe, EB; Rossignol, JF | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Chen, SI; Hsu, SJ; Hung, PH; Kao, JH; Lai, MY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Tsai, HB | 1 |
| Benanti, F; Cacopardo, B; Caltabiano, E; Cappellani, A; Nunnari, G; Onorante, A; Russo, R | 1 |
| Afendy, A; Bakshi, A; Baranova, A; Chan, JP; Chang, SY; Collantes, R; Iverson, AA; Manyam, G; Santini, CD; Sigua, CL; Stepanova, M; Younossi, ZM | 1 |
| Ando, M; Araki, Y; Ikeda, H; Iwasaki, Y; Kobashi, H; Osawa, T; Sakaguchi, K; Shiratori, Y; Tanioka, D; Yamamoto, K | 1 |
| Florianu, AI; Makashova, VV | 1 |
| Ankoma-Sey, V; Hamzeh, FM; Jeffers, LJ; Martin, P; Rodriguez-Torres, M; Rossaro, L; Sheikh, MY | 1 |
| Ferenci, P; Hofer, H; Novacek, G; Scherzer, TM; Schumacher, S; Staufer, K; Steindl-Munda, P; Vogelsang, H | 1 |
| Elgouhari, HM; Feldstein, AE; Hanouneh, I; Zein, CO; Zein, NN | 1 |
| Idrees, M; Riazuddin, S | 1 |
| Antonietti, CL; Brandão-Mello, CE; Campos-de-Magalhães, M; da Silva, ML; de Almeida, AJ; de Oliveira, RV; do Espírito-Santo, MP; Lampe, E; Yoshida, CF | 1 |
| Lake-Bakaar, G | 1 |
| McHutchison, JG; Patel, K; Tillmann, HL | 1 |
| Kronenberger, B; Zeuzem, S | 2 |
| Audin-Mamlouk, H; Bismuth, M; Garrigues, V; Hilleret, MN; Mourad, G; Pageaux, GP; Zarski, JP | 1 |
| Benhamou, Y; Kaita, KD; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Torbenson, M; Yoshida, EM; Zeuzem, S | 1 |
| Bojunga, J; Friedrich-Rust, M; Theobald, J; Zeuzem, S | 1 |
| Aghemo, A; Colombo, M; Prati, GM; Rumi, MG | 1 |
| Guy, CS; MacParland, SA; Michalak, TI; Pham, TN | 1 |
| Akiyama, T; Ario, K; Eguchi, Y; Hisatomi, A; Kawaguchi, Y; Kuwashiro, T; Mizuta, T; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H; Yoshimura, T | 1 |
| Macías, J; Mira, JA; Neukam, K; Pineda, JA | 1 |
| Błoñska-Fajfrowska, B; Hartleb, M; Musialik, J; Petelenz, M | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Alicante, S; Amante, A; Amato, F; Caserta, C; Fiorillo, MT; Foti, G; Gutamo, G; Mariano, A; Marra, M; Mele, A; Messineo, A; Pendino, GM; Polito, I; Surace, M; Surace, P; Vacalebre, C | 1 |
| Amrani, N; Benaïssa, A; Kabbaj, N; Mohammadi, M; Sentissi, S | 1 |
| Alberti, A | 1 |
| Craxì, A; Tarantino, G | 1 |
| Heathcote, J | 2 |
| Asselah, T; Benhamou, Y; Marcellin, P | 1 |
| Aslam, M; Hussain, T; Khan, DA; Khan, SA; Nadeem, A | 1 |
| Albrecht, J; Bedossa, P; Berg, T; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Mukhopadhyay, P; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R | 1 |
| Abbati, G; Belussi, F; Bonetto, S; Boninsegna, S; Borghi, A; Carbonieri, A; Corradini, E; Fagiuoli, S; Fattovich, G; Felder, M; Ferrara, F; Ferrari, C; Guido, M; Massari, M; Minola, E; Orlandini, A; Pietrangelo, A; Pozzato, G; Rizzo, G; Rossi, E; Rovere, P; Sardini, C; Tagliazucchi, M; Toniutto, P; Vegetti, A; Ventura, P; Zeneroli, ML | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Arribas, JR; Fraile, JM; González, JJ; Montes, ML | 1 |
| Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K | 1 |
| Ben-Ari, Z; Braun, M; Cohen, M; Cohen-Ezra, O; Katz, L; Manhaim, V; Rotman, Y; Tur-Kaspa, R | 1 |
| Ishibashi, H; Miyagi, Y; Nomura, H; Tanimoto, H | 1 |
| Kitagawa, C; Kiuchi, K; Miyashiro, M | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Cammà, C; Petta, S | 1 |
| Borrego, L; Guillermo, N; Hernández Santana, J; Jorge, M | 1 |
| Kreek, MJ; Piccolo, P; Talal, AH | 1 |
| Chan, PK; Li, CS; Tang, JW | 1 |
| Aikata, H; Chayama, K; Imamura, M; Kawakami, Y; Kawaoka, T; Mori, N; Saneto, H; Takahashi, S; Takaki, S | 1 |
| Alberdi-Leniz, A; Alvarez-Rubio, L; Banos, F; Lastra, CF; Marino, EL; Miro, S; Modamio, P | 1 |
| Aoyagi, Y; Enjoji, M; Fujino, T; Fukuizumi, K; Harada, N; Miyahara, T; Nakamuta, M; Nakashima, M; Sakai, H; Takemoto, R; Yoshimoto, T | 1 |
| Comar, C; Dal Maso, L; De Re, V; Festini, G; Mazzaro, C; Pozzato, G; Spina, M; Tirelli, U | 1 |
| Abruzzese, G; Alpert, S; Kaul, V; Mehta, N; Murthy, UK; Teitelbaum, C | 1 |
| Cannon, NA; Di Bisceglie, AM; Donlin, MJ; Lyra, AC; Mayes, LM; Tavis, JE | 1 |
| El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, SR; Kitai, S; Kudo, M; Mita, K; Muramatsu, A; Sasase, N; Taniguchi, M | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 2 |
| Caroleo, B; De Sarro, G; Gallelli, L; Guadagnino, V; Staltari, O | 1 |
| De Clercq, E | 2 |
| Higaki, K; Ide, T; Karashima, T; Maeyama, Y; Narita, K; Okamura, S; Sakai, T; Sata, M; Sumie, H; Yoshikai, H | 1 |
| Guindi, M; Kirby, M; O'Connor, C; Roberts, EA; Yap, J | 1 |
| Carbonell, J; Crespo, M; Curran, A; Esteban, JI; Esteban, R; Falco, V; Imaz, A; Jardi, R; Ocaña, I; Pahissa, A; Ribera, E; Rodríguez-Frias, F; Van den Eynde, E; Villar del Saz, S | 1 |
| Higashi, M; Ishibashi, H; Miyagi, Y; Nomura, H; Tanimoto, H | 1 |
| Belle, SH; Brown, RS; Hoofnagle, JH; Howell, CD; Wahed, AS | 1 |
| Cotter, MA; Petersen, MJ; Squires, SM | 1 |
| Bain, VG; Neumann, AU; Patel, K; Pulkstenis, E; Subramanian, GM; Yoshida, EM | 1 |
| Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK | 1 |
| Bacon, BR; Ghalib, R; Gitlin, N; Hassanein, T; Joshi, S; Kwo, P; Mendes, F; Morelli, G; Rothstein, K; Shiffman, ML | 1 |
| Allen, SA; Chew, KW; Feller, E; Rich, JD; Taylor, LE | 1 |
| Bartalesi, F; Bartoloni, A; Biliotti, E; Camiciottoli, G; Corti, G; Maluccio, NM; Taliani, G | 1 |
| Fujita, N; Hara, N; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Miyachi, H; Takei, Y; Takeo, M; Tanaka, H | 1 |
| Chokshi, S; Cooksley, H; Farmakiotis, D; Michalak, TI; Naoumov, NV; Pachiadakis, I; Sarrazin, C; Zeuzem, S | 1 |
| de Man, RA; Dietvorst, MH; van Wijngaarden, P | 1 |
| Bailey, RJ; Bain, VG; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, K; Sherman, M; Usaty, C; Witt-Sullivan, H; Yoshida, EM | 1 |
| Archimandritis, A; Elefsiniotis, J; Koskinas, J; Kostopoulos, P; Kotsiou, S; Kountouras, D; Savvas, S; Schina, M; Sidiropoulos, J; Zacharakis, G | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Hsu, CS; Kao, JH; Lai, MY; Liu, CH; Liu, CJ | 1 |
| De Angelis, D; Grieve, RD; Grishchenko, M; Irving, WL; Ryder, SD; Sweeting, MJ; Thomson, BJ | 1 |
| Knight, V; Sievert, W | 1 |
| Chuang, WL; Yu, ML | 1 |
| Ishida, C; Kato-Motozaki, Y; Komai, K; Kusunoki, S; Takahashi, K; Ueda, M; Yamada, M | 1 |
| Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I | 1 |
| Bellou, A; Bibashi, E; Gigi, E; Raptopoulou-Gigi, M; Sinakos, E; Sykia, A | 1 |
| Alain, S; Denis, F; Loustaud-Ratti, V; Marquet, P; Rousseau, A | 1 |
| Koike, K | 2 |
| Enomoto, N; Sakamoto, M | 2 |
| Jeong, S; Kim, CH; Kim, HG; Kim, YS; Kwon, KS; Lee, DH; Lee, JI; Lee, JW; Park, BD; Shin, YW | 1 |
| Barraud, H; Bronowicki, JP; Nani, A | 1 |
| Basso, M; Blanchi, S; Giannini, EG; Picciotto, A; Savarino, V; Torre, F | 1 |
| Bortolotti, F | 1 |
| Celiento, M; De Rosa, A; Ripa, C; Schiano, A; Tambaro, O; Tarantino, L | 1 |
| Bellón, JM; Berenguer, J; Esteban, H; González-García, J; Hernando, A; López-Aldeguer, J; Mallolas, J; Miralles, P; Montes, ML; Ortega, E; Quereda, C; Santos, I; Sanz, J; Tural, C; Von-Wichmann, MA | 1 |
| Nikolaou, A; Telakis, E | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Bani-Sadr, F | 1 |
| Andreone, P; Brandão-Mello, CE; Craxi, A; Di Bisceglie, A; Freilich, B; Jensen, DM; Marcellin, P; Martin, AO; Messinger, D; Reddy, KR; Teuber, G; Thommes, JA; Tietz, A | 1 |
| de Carvalho Filho, RJ; Ferrari, MV; Ferraz, ML; Freire, FC; Narciso-Schiavon, JL; Scanhola, GQ; Schiavon, Lde L; Silva, AE; Suarez, MM | 1 |
| Elefsiniotis, I; Konstantinou, E; Mihas, C; Saroglou, G; Vezali, E | 1 |
| Chrissafidou, A; Musch, E | 1 |
| Amorosa, VK; Kovarik, CL; Lin, J; Lott, JP | 1 |
| Korobowicz, E; Modrzewska, R; Tomasiewicz, K | 1 |
| Bassendine, MF; Donaldson, P; Neely, D; Price, DA; Schmid, ML; Sheridan, DA; Toms, GL | 1 |
| Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Niro, GA; Siciliano, M; Valvano, MR | 1 |
| Fartoux, L; Poupon, R; Serfaty, L | 1 |
| Ballardini, G; Bianchi, FB; Ferri, S; Granito, A; Lenzi, M; Menichella, R; Muratori, L; Muratori, P; Pappas, G; Quarneti, C | 1 |
| Drenth, JP; Heijdra, YF; Slavenburg, S | 1 |
| Asjø, B; Myrmel, H; Ulvestad, E | 1 |
| Alam, J; Everson, GT; Gordon, SC; Jacobson, IM; Kauffman, R; McHutchison, JG; McNair, L; Muir, AJ; Sulkowski, M | 1 |
| Alam, J; Bengtsson, L; Bourlière, M; Bronowicki, JP; Dusheiko, G; Ferenci, P; Forestier, N; George, S; Gharakhanian, S; Goeser, T; Hézode, C; Kauffman, RS; Kieffer, T; Kwong, A; McNair, L; Pawlotsky, JM; Pol, S; Zeuzem, S | 1 |
| Malgarini, RB; Pimpinella, G | 1 |
| Amiot, X; Ancel, D; Chaslin-Ferbus, D; Garioud, A; Girot, R; Grange, JD; Hagege, I; Pol, S | 1 |
| Marks, K; Talal, AH; Wan, DW; Yantiss, RK | 1 |
| Schildgen, O | 1 |
| Danis, D; Fejdiova, K; Gazdik, F; Gazdikova, K; Kajaba, I; Kratky, A; Laktis, K; Okruhlica, L; Pijak, MR; Wsolova, L | 1 |
| Babany, G; Gagnieu, MC; Jourdil, JF; Marquet, P; Sauvage, FL; Stanke-Labesque, F | 1 |
| Dimitroulopoulos, D; Elefsiniotis, IS; Koutsounas, S; Mariolis-Sapsakos, T; Mihas, C; Paraskevas, E; Pavlidis, C; Saroglou, G; Vezali, E | 1 |
| Bräu, N; Fishbein, D; Stivala, A; Swan, T; Weiss, JJ | 1 |
| Abbas, FA; Ayyub, MA; El-Moursy, SA; Khazindar, AM | 1 |
| Itha, S; Radha Krishna, Y | 1 |
| Blanc, F; Clot, J; Corbeau, P; Perney, P; Portalès, P; Psomas, C; Rigole, H; Turriere, C | 1 |
| Ferenci, P; Rizzetto, M; Shiffman, ML; Zeuzem, S | 1 |
| Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Perronne, C; Pol, S | 1 |
| Bashirova, A; Bonkovsky, HL; Carrington, M; Chanock, SJ; Chung, RT; Crenshaw, AT; Di Bisceglie, AM; Dotrang, M; Fontana, RJ; Ghany, MG; Gretch, DR; Hutchinson, AA; Lee, WM; Lindsay, KL; Morgan, TR; Naishadham, D; O'Brien, TR; Pfeiffer, RM; Sterling, RK; Welzel, TM; Wright, EC | 1 |
| Arora, S; Douglass, JM; Dunkelberg, JC; Qualls, C; Yu, S | 1 |
| Haruna, Y; Kashiwagi, T; Katayama, K; Kishida, Y; Naitoh, M | 1 |
| Furusyo, N; Hayashi, J; Maeda, S; Ogawa, E; Takeoka, H; Toyoda, K | 1 |
| Weiland, O | 2 |
| Hueppe, D; Jacobson, I; Kwo, P; Marotta, P; Zehnter, E | 1 |
| Aronsohn, A; Reau, N | 1 |
| De Compadri, P; Garattini, L; Koleva, D; Mangia, A; Motterlini Stat Sci, N | 1 |
| Berg, T; Böcker, U; Bugert, P; Gundt, J; Haas, SL; Singer, MV; Weiss, C; Witt, H | 1 |
| Bocket, L; Canva, V; Castelain, S; Deltenre, P; Dharancy, S; Duverlie, G; El Nady, M; François, C; Henrion, J; Hollebecque, A; Lazrek, M; Louvet, A; Mathurin, P; Wartel, F | 1 |
| Arends, JE; Baak, LC; Boland, GJ; Hoepelman, AI; Simons, CP; Stuart, JC; van Baarle, D; van der Ende, ME; van Erpecum, KJ | 1 |
| Couzigou, VP; DeLedinghen, V; Foucher, J; Gaundong Mbéthé, GL | 1 |
| Etani, Y; Fujisawa, T; Inui, A; Kagimoto, S; Kiyohara, Y; Shimizu, T; Suzuki, M; Tajiri, H | 1 |
| Barbare, JC; Cadranel, JF; Capron, D; Cazier, A; Dumouchel, P; Jouannaud, V; Rochette, J | 1 |
| Conti, CM; Dalessandro, M; Falasca, K; Mancino, P; Manzoli, L; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Aidelsburger, P; Manns, MP; McHutchison, JG; Rossol, S; Siebert, U; Sroczynski, G; Wasem, J; Wong, JB | 1 |
| Reiser, M; Timm, J | 1 |
| Coffin, CS; Terrault, NA | 1 |
| Adler, M; Brenard, R; D'Heygere, F; Delwaide, J; Henrion, J; Horsmans, Y; Langlet, P; Lasser, L; Laureys, A; Michielsen, P; Mulkay, JP; Nevens, F; Van Vlierberghe, H | 1 |
| Amano, K; Fujimoto, M; Katsumura, N; Kimura, K; Kojima, T; Moriwaki, H; Nagaki, M; Naiki, T; Ninomiya, M; Sakai, T; Sano, C; Shimizu, M; Sugihara, JI; Tomita, E | 1 |
| Bukh, J; Christensen, PB; Clausen, MR; Hansen, N; Krarup, H; Kromann-Andersen, H; Laursen, AL; Lunding, S; Møller, A; Obel, N; Schlichting, P; Weis, N | 1 |
| Hadziyannis, SJ; Messinger, D; Popescu, M; Reddy, KR | 1 |
| Berg, T; Biermer, M | 1 |
| Arakawa, T; Fujiwara, Y; Hosomi, S; Kamata, N; Morimoto, K; Ohira, M; Oshitani, N; Sogawa, M; Suekane, T; Tamori, A; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H | 1 |
| Angelico, F; Angelico, M; Carbone, M; Del Ben, M; Feole, K; Francioso, S; Pignatelli, P; Violi, F | 1 |
| Gaglio, PJ | 1 |
| Cheng, DX; Chu, YL; Liu, EQ; Xue, X; Zhao, SH | 1 |
| Gluud, LL; Iorio, A; Marchesini, E | 1 |
| Brodanová, M; Brůha, R; Dusek, L; Janousová, E; Marecek, Z; Petrtýl, J; Subhanová, I; Urbánek, P | 1 |
| Akuta, N; Chayama, K; Hashimoto, H; Itoh, Y; Izumi, N; Kumada, H; Minami, M; Okanoue, T; Onji, M; Takehara, T; Tanaka, E; Toyota, J; Yasui, K; Yoshioka, K | 1 |
| Halota, W; Juszczyk, J | 1 |
| Jabłońska, J; Kozłowska, J | 1 |
| Bressler, B; Grippo, JF; Heathcote, EJ; Wang, K | 1 |
| Doizaki, M; Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Shimizu, J; Toyoda, H; Urano, F; Yoshioka, K | 1 |
| Breilh, D; Castéra, L; Couzigou, P; de Lédinghen, V; Djabarouti, S; Foucher, J; Merrouche, W; Saux, MC; Trimoulet, P | 1 |
| Benito-Martínez, S; González-Mateos, F; Larrubia, JR; Miquel-Plaza, J; Parra, T; Sanz-de-Villalobos, E | 1 |
| Belle, SH; Brown, RS; Dove, LM; Hoofnagle, JH; Ramcharran, D; Rosen, RC; Wahed, AS | 1 |
| Bartkowiak, J; Ciechowicz, J; Durys, B; Józwiak, B; Kosciuk, N; Majda-Stanislawska, E; Majewska, E; Piekarska, A; Sidorkiewicz, M | 1 |
| Armendáriz-Borunda, J; Bautista López, CA; Lugo-Baruqui, A | 1 |
| Gilani, N; Panetta, JD | 1 |
| Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Igura, T; Imai, Y; Imanaka, K; Inoue, Y; Inui, Y; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kiso, S; Mita, E; Mochizuki, K; Nagase, T; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Igura, T; Imai, Y; Imanaka, K; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Kurokawa, M; Mita, E; Mochizuki, K; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Firbas, C; Hinrichsen, H; Hofmann, WP; Jilma, B; Klade, CS; Manns, MP; Schiefke, I; Schlaphoff, V; Schuller, E; Stauber, RE; Tauber, E; Thursz, M; Wedemeyer, H; Wiegand, J; Zeuzem, S | 1 |
| Andriulli, A; Iacobellis, A | 1 |
| Akin, H; Atug, O; Sari, M; Tozun, N; Yilmaz, Y | 1 |
| Alba, LM; Bulchandani, D; Nachnani, JS; Pandya, PK; Rao, GA | 1 |
| Alvarez-Pellicer, J; Bellón, JM; Berenguer, J; González-García, J; López-Aldeguer, J; Mallolas, J; Martín, PM; Quereda, C; Sanz, J; Tural, C; Von-Wichmann, MA | 1 |
| Asaka, M; Chuma, M; Hige, S; Nagasaka, A; Nakanishi, M; Ogawa, K; Yamamoto, Y | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Donato, MF; Monico, S; Prati, GM; Rumi, MG | 1 |
| Alvarez-Uria, G; Day, JN; Nasir, AJ; Russell, SK; Vilar, FJ | 1 |
| Hwang, JM; Jeong, SH; Kang, HM; Kim, JW; Park, MJ | 1 |
| Jackson, D; O'Brien, L; Sgorbini, M | 1 |
| Afdhal, NH; Benhamou, Y; Chun, E; Halliman, DG; Heise, J; Nelson, DR; Pockros, PJ; Shiffman, ML | 1 |
| Gomes, R; Lee, C; Manka, C; Reviere, R | 1 |
| Adinolfi, LE; Durante-Mangoni, E; Portella, G; Ruggiero, G; Utili, R; Zampino, R | 1 |
| Bacin, F; Glatre, F; Viennet, A | 1 |
| Gschwantler, M; Ordubadi, P | 1 |
| Andreoni, M; Angeli, E; Carbone, R; Cargnel, A; Giorgi, R; Gubertini, G; Mainini, A; Orani, A; Rizzardini, G; Schiavini, M; Uberti-Foppa, C | 1 |
| Elefsiniotis, IS; Mihas, C; Saroglou, G; Vezali, E | 1 |
| Coppola, N; Iodice, V; Macera, M; Piccinino, F; Sagnelli, E; Stanzione, M; Tonsiello, G | 1 |
| Albrecht, JK; Bacon, BR; Brass, CA; Davis, MN; Galati, JS; Galler, GW; Ghalib, RH; Koury, K; Lawitz, EJ; Lee, WM; McCone, J; McHutchison, JG; Muir, AJ; Mukhopadhyay, P; Noviello, S; Nyberg, LM; Pedicone, LD; Schiff, ER; Shiffman, ML; Sulkowski, MS | 1 |
| Abdel-Hamid, M; Bedossa, P; El Makhzangy, H; Elraziky, M; Esmat, G; Fontanet, A; Gad, RR; Mohamed, MK; Pol, S; Refai, R; Rekacewicz, C; Said, M; Shouman, S; Vignier, N; Zalata, K | 1 |
| Abellán Galiana, P; Aguilera Sancho-Tello, V; Berenguer Haym, M; Merino Torres, JF; Pérez-Lázaro, A; Piñón Sellés, F | 1 |
| Forde, KA; Reddy, KR | 1 |
| Mauss, S; Schaefer, M | 1 |
| Chan, HL; Cheng, AY; Wong, VW | 1 |
| Alavian, SM; Tabatabaei, SV | 2 |
| Blanc, F; Buchler, M; Cacoub, P; Coppéré, B; Ghillani, P; Karras, A; Pérard, L; Plaisier, E; Rosenzwajg, M; Saadoun, D; Sellam, J; Sène, D; Terrier, B | 1 |
| Kao, JH | 1 |
| Adinolfi, LE; Durante-Mangoni, E; Marrone, A; Merola, A; Restivo, L; Ruggiero, G; Salzillo, M; Tripodi, MF; Zampino, R | 1 |
| Tsantrizos, YS | 1 |
| Durantel, D | 1 |
| Khan, AA; Sarwar, S | 1 |
| Behnam, SE; Fife, DJ; Hindiyeh, R; Jeffes, EW; Wu, JJ | 1 |
| de Silva, K; Jones, BE; Napoli, J; Pang, SH | 1 |
| Andriulli, A; Attanasio, M; Bronte, F; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Licata, A | 1 |
| Alavian, SM; Ayyub, M; Tabatabaei, SV | 1 |
| Bedossa, P; Boyer, N; Cardoso, AC; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Nicolas-Chanoine, MH; Ripault, MP; Stern, C; Valla, D; Vidaud, M; Voitot, H | 1 |
| Chung, RT; Hamzeh, FM; Jensen, DM; Rodriguez-Torres, M; Sulkowski, MS | 1 |
| Kato, M; Matsumoto, S; Yamaguchi, T; Yuki, N | 1 |
| Cheng, WS; Crawford, DH; Depamphilis, JK; Desmond, PV; Dore, GJ; Marks, PS; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, MD; Yoshihara, M | 1 |
| Babany, G; Canva-Delcambre, V; Deltenre, P; Deuffic-Burban, S; Dharancy, S; Lonjon-Domanec, I; Louvet, A; Mathurin, P; Roudot-Thoraval, F | 1 |
| Fukui, H; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Hohsui, A; Imai, Y; Inada, M; Inoue, A; Inoue, Y; Ishida, H; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Yakushijin, T; Yoshihara, H | 1 |
| Attia, JR; Gibson, R; Malcolm Reeves, GE; Tran, HA | 1 |
| Gerner, P; Jenke, AC; Moser, S; Orth, V; Wirth, S; Zilbauer, M | 1 |
| Hinokio, Y; Imai, J; Ishigaki, Y; Katagiri, H; Kudo, H; Ogihara, T; Oka, Y; Shimosegawa, T; Ueno, Y; Yamada, T; Yamagiwa, Y | 1 |
| Akahoshi, T; Ikejiri, K; Korenaga, D; Saku, M; Takenaka, K; Tomikawa, M | 1 |
| Cheng, DX; Chu, YL; Liu, EQ; Waqar, AB; Xue, X; Yang, HJ; Yang, PH; Yu, Q; Zhao, SH | 1 |
| Folwaczny, C; Janssen, G; Loeschke, K; Lorenz, R; Martin, G; Schaefer, M; Schmidt, F; Soyka, M | 1 |
| Anselmo, M; De Leo, P; Fabris, P; Grasso, A; Malfatti, F; Martines, H; Menardo, G; Toscanini, F | 1 |
| Guadagnino, V | 1 |
| Alaeus, A; Blom, KG; Falconer, K; Gonzalez, VD; Laursen, AL; Mørn, B; Reichard, O; Sandberg, JK; Weis, N | 1 |
| Lo, GH | 1 |
| Gallefoss, F; Kristensen, Ø; Opsal, A; Rysstad, O; Skeie, K; Sundøy, A; Vederhus, JK; Øye, I | 1 |
| Bae, SH; Byun, KS; Choi, JY; Han, KH; Kwon, JH; Lee, HC; Lee, KS; Lim, YS; Paik, SW; Yoon, SK | 1 |
| Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML | 3 |
| Al-Saran, K; Sabry, A; Shaheen, N; Yehia, A | 1 |
| Hayashi, M; Kataoka, Y; Koguchi, H; Tachikawa, K; Tanaka, H | 1 |
| Davis, C; Olerud, J; Shinohara, MM | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Naishadham, D; Shiffman, ML; Wright, EC | 1 |
| An, JW; Brady, DE; Harrison, SA; Lawitz, E; Torres, DM; Ward, JA | 1 |
| O'Brien, TR | 1 |
| Hiasa, Y; Hige, S; Hino, K; Honda, M; Imamura, M; Ito, K; Ito, Y; Izumi, N; Koike, A; Korenaga, M; Kurosaki, M; Masaki, N; Matsuura, K; Mita, E; Mizokami, M; Mochida, S; Murawaki, Y; Nakagawa, M; Nishida, N; Nishiguchi, S; Sakai, A; Sakaida, I; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, E; Tanaka, Y; Tokunaga, K; Yano, K | 1 |
| Abate, ML; Ahlenstiel, G; Bahlo, M; Bassendine, M; Berg, T; Booth, DR; Dore, GJ; Fragomeli, V; George, J; Moldovan, M; Müller, T; Powell, E; Riordan, S; Sheridan, D; Smedile, A; Spengler, U; Stewart, GJ; Suppiah, V; Weltman, M | 1 |
| Arora, A; Kuzniar, TJ; Vargas, L | 1 |
| Dinya, E; Schaff, Z; Tulassay, Z; Werling, K | 1 |
| Battezzati, PM; Benetti, A; Capsoni, F; Gershwin, ME; Giorgini, A; Lleó, A; Malinverno, F; Ongari, AM; Podda, M; Rossaro, L; Selmi, C; Zuin, M | 1 |
| Herrmann, E; Hofmann, WP; Lengauer, T; Mihm, U; Polta, A; Sarrazin, C; Welsch, C; Zeuzem, S | 1 |
| Borgia, G; Borrelli, F; Cerini, R; D'Agostino, E; D'Onofrio, M; Gentile, I; Paesano, L; Piazza, M; Viola, C | 1 |
| Lanford, RE; Lemon, SM; Shimakami, T | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Donato, MF; Prati, GM; Rumi, MG; Russo, A; Soffredini, R | 1 |
| Arponen, S; Collado, A; Delgado, M; Gil, Ide L; González-Serrano, M; Gutiérrez-Valencia, A; López-Ruz, MA; Macías, J; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortosa, M | 1 |
| Hung, CH; Lin, MC; Tsai, MC | 1 |
| Ansaldi, F; Borro, P; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
| Almasio, PL; Amoruso, DC; Caporaso, N; Medda, E; Morisco, F; Paris, B; Stanzione, M; Stroffolini, T; Villa, E; Zuin, M | 1 |
| Ferrari, C; Freedman, LS; Gorfine, M; Lukasiewicz, E; Neumann, AU; Pawlotsky, JM; Schalm, SW; Zeuzem, S | 1 |
| Dore, GJ; French, R; Grebely, J; Haber, PS; Hellard, M; Kaldor, JM; Lloyd, AR; Marks, P; Matthews, GV; McCaughan, G; Petoumenos, K; Rawlinson, W; van Beek, I; White, P; Yeung, B | 1 |
| Bae, SH; Choi, JY; Jang, JW; Jeong, SW; Kim, JD; Lee, SW; Song, MJ; Woo, HY; Yoon, SK; You, CR | 1 |
| Ha, CY; Ju, K; Jung, WT; Kim, TH; Lee, OJ; Min, HJ; Shin, MK | 1 |
| Barlow, LL; Chung, RT; Corey, KE; Kane, E; Munroe, C; Zheng, H | 1 |
| Babany, G; Gagnieu, MC; Loustaud-Ratti, V; Marquet, P; Stanke-Labesque, F | 1 |
| Belle, SH; Evon, DM; Fontana, RJ; Fried, MW; Ramcharran, D; Terrault, NA | 1 |
| Pradat, P; Trepo, C | 1 |
| Berg, T; Boland, GJ; de Vries, RA; Drenth, JP; Halangk, J; Kok, KF; van Herwaarden, AE; van Oijen, MG; van Soest, H | 1 |
| Aghemo, A; Colombo, M; Coppola, A; Mancuso, ME; Mannucci, PM; Puoti, M; Rumi, MG; Santagostino, E | 1 |
| Aslan, V; Naz, H | 1 |
| Aghemo, A; Colombo, M; Rumi, MG | 2 |
| Alonso López, S; Fernández Rodríguez, CM | 1 |
| Chaparro, M; Gisbert, JP; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Angeletti, C; Antonucci, G; Girardi, E; Longo, MA; Vairo, F | 1 |
| Iijima, M; Sato, M; Sueki, H | 1 |
| Chang, JJ; Chen, LW; Chien, RN; Lin, CL; Liu, CJ; Yen, CL | 1 |
| Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G | 1 |
| Brok, J; Gluud, C; Gluud, LL | 6 |
| Callender, ME; Cash, WJ; McDougall, NI; Patterson, K | 1 |
| Chaudhari, S; Lingisetty, CS; Proper, S; Satapathy, SK; Williams, S | 1 |
| Basso, M; Bazzica, M; Contini, P; Giannini, EG; Marenco, S; Picciotto, A; Savarino, V | 1 |
| Aketa, H; Chiba, M; Ikezawa, K; Iwahashi, K; Kanno, T; Katayama, K; Kita, H; Maeda, K; Matsuura, T; Michida, T; Mizuno, T; Naito, M; Nishio, A; Onishi, Y; Ono, A; Yumiba, T | 1 |
| Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R | 1 |
| Alonso-Arias, R; Díaz-Peña, R; Fernández-Suárez, J; López-Larrea, C; López-Vázquez, A; Martínez-Borra, J; Melón, S; Pérez, R; Prieto, J; Rodrigo, L; Vidal-Castiñeira, JR | 1 |
| Alaeus, A; Björkström, NK; Blom, KG; Falconer, K; Gonzalez, VD; Ljunggren, HG; Sandberg, JK; Weiland, O | 1 |
| Basso, M; Giannini, EG; Picciotto, A; Savarino, V | 3 |
| Aalyson, M; Afdhal, N; Alam, J; Bengtsson, L; Bonkovsky, HL; Chandorkar, G; Gharakhanian, S; Gordon, SC; Harding, M; Kauffman, R; Lawitz, E; Lee, WM; McHutchison, JG; McNair, L; Poordad, F; Rustgi, VK | 1 |
| Ascione, A; De Luca, M; Di Costanzo, GG; Fontanella, L; Lampasi, F; Lanza, AG; Leandro, G; Marino-Marsilia, G; Picciotto, FP; Tartaglione, MT | 1 |
| Alric, L; Baazia, Y; Bouviers-Alias, M; Chaix, ML; Colson, P; Coppere, H; D'Alteroche, L; Doffoël, M; Fontaine, H; Foucher, J; Gassin, M; Gaudy, C; Hézode, C; Izopet, J; Legrand-Abravanel, F; Leguillou-Guillemette, H; Lunel-Fabiani, F; Nousbaum, JB; Payan, C; Poinard, T; Poynard, T; Pozzetto, B; Ravaux, I; Roche, B; Roque-Afonso, AM; Roulot, D; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S | 1 |
| Ben Mami, N; Ben Yahia, A; Bouzgarrou, N; Chouchane, L; Gabbouj, S; Hassen, E; Mahfoudh, W; Schvoerer, E; Triki, H | 1 |
| Dabrowska, MM; Flisiak, R; Panasiuk, A | 1 |
| Hsu, CS; Kao, JH | 3 |
| Broglio, KR; Hahn, KM; Hortobagyi, GN; Kau, SC; Morrow, PKH; Tarrand, JJ; Taylor, SH; Theriault, RL | 1 |
| Angelico, M; Baiocchi, L; Carbone, M; Lenci, I | 1 |
| Askar, M; Avery, R; Corey, R; Eghtesad, B; Fung, J; Lopez, R; Miller, C; Pidwell, D; Thomas, D; Zein, NN | 1 |
| Alberti, A; Bonisegna, S; Bortoletto, G; Franceschini, L; Marcolongo, M; Martines, D; Mirandola, S; Noventa, F; Plebani, M; Realdon, S; Scribano, L | 1 |
| Guturu, P; Jaganmohan, S; Kuo, YF; Mummadi, R; Singal, AK; Singh, A; Sood, GK | 1 |
| Butt, AA; Justice, AC; McGinnis, KA; Skanderson, M | 1 |
| Dieterich, DT; Manns, MP; Rizzetto, M | 1 |
| Kumada, T; Toyoda, H | 1 |
| Calvieri, S; Carboni, V; Carlomagno, V; Giancristoforo, S; Maiani, E; Mattozzi, C; Richetta, AG | 1 |
| Keicher, C; Kraus, MR; Rieger, P; Schäfer, A; Scheurlen, M; Seufert, J; Weissbrich, B | 1 |
| Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS | 1 |
| Aguilar Reina, J | 1 |
| Cabanillas, M; de la Santa, E; Domper, F; Galván, MD; Hernández, A; León, A; López, B; Lorente, R; Olmedo, J; Patón, R; Rodríguez, E | 1 |
| Anand, N; Borozan, I; Chen, L; Edwards, AM; Feld, J; Fischer, S; Guindi, M; Heathcote, J; McGilvray, ID; Sun, J | 1 |
| Hofmann, WP; Peveling-Oberhag, J; Zeuzem, S | 1 |
| Garcia, G; Garcia, RT; Keeffe, EB; Levitt, BS; Li, J; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, NH; Trinh, HN; Vutien, P | 1 |
| El Monaiery, M; El Naghy, S; El Sebaie, H; Ghaffar, AY; Ghaffar, TY | 1 |
| Berezovskaya, S; Bini, EJ; Choy-Shan, A; Sedlis, SP; Zinn, A | 1 |
| Wei, L | 1 |
| Li, MH; Xie, Y | 2 |
| Chen, XY; Zhang, YH | 1 |
| Chen, LJ; Li, MH; Lu, Y; Qiu, GH; Xie, Y; Xu, DZ | 1 |
| Chun, E; Gish, RG; Gitlin, N; Halliman, DG; Heise, J; Marcellin, P; Rodriguez-Torres, M | 1 |
| Anagnostou, O; Dimitroulopoulos, D; Manolakopoulos, S; Paraskevas, E; Petroulaki, E; Tsaklakidou, D; Tsamakidis, K; Tzourmakliotis, D; Xinopoulos, D | 1 |
| Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y | 1 |
| Chan, AH; Ensom, MH; Partovi, N | 1 |
| Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E | 1 |
| Chen, SC; Chu, PY; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, YY; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Imeryuz, N; Yilmaz, Y; Yonal, O | 1 |
| Jovanović, M; Konstantinović, L; Kostić, V; Popović, L; Vrbić, M | 1 |
| Falasca, K; Gorgoretti, V; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Higami, K; Ishii, K; Kogame, M; Morita, T; Sano, M; Sawa, M; Shinohara, M; Sumino, Y | 1 |
| Banasch, M; Ellrichmann, M; Meier, JJ; Schmidt, WE; Schrader, H; Vollmer, K | 1 |
| Borum, ML; Igiehon, E; Shafa, S | 1 |
| Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H | 1 |
| Atripaldi, L; D'Antonio, A; Esposito, C; Perrella, A; Perrella, O; Sbreglia, C | 1 |
| Fischler, B; Friman, S; Gerdén, B; Josephson, F; Karlström, O; Lagging, M; Sangfelt, P; Schvarz, R; Uhnoo, I; Weiland, O; Wejstål, R | 1 |
| Afendy, A; Baranova, A; Birerdinc, A; Manyam, G; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Garcia, RT; Levitt, B; Nguyen, H; Nguyen, K; Nguyen, MH; Nguyen, NH; Trinh, H; VuTien, P | 1 |
| Fukuhara, T; Ikegami, T; Kato, M; Kotoh, K; Maehara, Y; Shimoda, S; Soejima, Y; Taketomi, A; Yoshizumi, T | 1 |
| Chuang, WL; Wu, KT; Yang, JF; Yu, ML | 1 |
| Bihl, F; Negro, F | 1 |
| Andreone, P; Anticoli, S; Balsano, C; Bernardi, M; Cursaro, C; Furlini, G; Galli, S; Gramenzi, A; Loggi, E; Margotti, M; Salerno, M; Spaziani, A | 1 |
| Parkinson, E | 1 |
| Atluri, D; Iduru, S; Mullen, K; Veluru, C | 1 |
| Berenguer, J; Catalán, P; Cosín, J; López, JC; Miralles, P; Resino, S; Vargas, A | 1 |
| Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM | 1 |
| Chin, HS; Kim, ET; Kim, LH; Lee, JI | 1 |
| Burke, JD; Fish, EN | 1 |
| Kaneko, J; Kokudo, N; Makuuchi, M; Sugawara, Y; Tamura, S; Yamashiki, N | 1 |
| Craxì, A | 2 |
| Drenth, JP; Slavenburg, S; van Oijen, MG; Weggelaar, I | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, MN; Park, JY; Yoon, KT | 1 |
| Fan, Y; Mao, Q; Tan, WT; Wang, XH; Zhou, YQ; Zhu, Y | 1 |
| Ebinuma, H; Hibi, T; Inoue, M; Ojiro, K; Saito, H; Tada, S; Wakabayashi, K | 1 |
| Elfert, A; Keeffe, EB; Rossignol, JF | 1 |
| Battegay, M; Beckmann, JS; Berg, T; Bergmann, S; Bernasconi, E; Bochud, M; Bochud, PY; Borovicka, J; Cai, T; Cerny, A; Colombo, S; Descombes, P; Di Iulio, J; Dufour, JF; Furrer, H; Günthard, HF; Heim, M; Hirschel, B; Kutalik, Z; Malinverni, R; Moradpour, D; Mueller, T; Müllhaupt, B; Negro, F; Rauch, A; Telenti, A; Witteck, A | 1 |
| Hibi, T; Hokari, R; Ikeda, M; Kato, N; Miura, S; Nakamura, M; Saito, H | 1 |
| El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Kudo, M; Mita, K; Nagai, T; Nagano-Fujii, M; Nagata, Y; Sasase, N; Shoji, I; Taniguchi, M | 1 |
| El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Kudo, M; Mita, K; Sasase, N; Shoji, I; Taniguchi, M | 1 |
| Chung, H; Hagiwara, S; Hayaishi, S; Inoue, T; Ishikawa, E; Kudo, M; Minami, Y; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N | 1 |
| Chung, H; Hagiwara, S; Hatanaka, K; Hayaishi, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N | 1 |
| Cho, EY; Choi, CS; Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, CS; Lee, S; Lee, SO; Lee, ST | 1 |
| Akiyama, M; Ichikawa, T; Miuma, S; Miyaaki, H; Motoyoshi, Y; Nakao, K; Ozawa, E; Shibata, H; Takeshita, S; Taura, N | 1 |
| Asselah, T; Boyer, N; Cardoso, AC; Castelnau, C; El Ray, A; Giuily, N; Leclere, L; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Ripault, MP; Stern, C | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Féray, C | 1 |
| Awad, T; Gluud, LL; Iorio, A; Marchesini, E | 1 |
| Duffin, RP; Ichim, TE; Joyce, JA; Levin, NW; Tullis, RH | 1 |
| Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Madejón, A; Medrano, J; Morello, J; Rodríguez-Novoa, S; Soriano, V | 1 |
| Barreiro, P; Labarga, P; Martín-Carbonero, L; Medrano, J; Morello, J; Pinilla, J; Rodríguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Azuma, S; Enomoto, N; Itsui, Y; Kakinuma, S; Mogushi, K; Nagaie, S; Nakagawa, M; Sakamoto, N; Tanaka, H; Ueyama, M; Watanabe, M | 1 |
| Arakawa, T; Fujimori, M; Hiramatsu, T; Hisanaga, Y; Hosokawa, T; Kanamori, A; Kiriyama, S; Kumada, T; Tada, T; Takagi, M; Tanikawa, M; Toyoda, H | 2 |
| Antinori, S; Caramma, I; Cesari, M; Galli, M; Mazzali, C; Milazzo, L; Olivetti, M | 1 |
| Bortolotti, F; Brugiolo, A; Carli, M; Cesaro, S; Guido, M; Petris, MG | 1 |
| Chu, CJ; Lee, SD | 1 |
| Dessouki, O; Kamiya, Y; Nagahama, H; Okada, S; Sasaki, Y; Suzu, S; Tanaka, M | 1 |
| Rockstroh, JK; Vogel, M | 1 |
| Bjoro, K; Dalgard, O; Ring-Larsen, H; Verbaan, H | 1 |
| Baumgarten, A; Dikopoulos, N; Goelz, J; Heyne, R; Hueppe, D; John, C; Mauss, S; Moeller, B; Moog, G; Simon, KG; Teuber, G; Witthoeft, T; Wollschlaeger, S | 1 |
| Bono, A; Cabibi, D; Cammà, C; Craxí, A; Di Marco, V; Licata, G; Marchesini, G; Petta, S; Porcasi, R; Scazzone, C; Tripodo, C | 1 |
| Jain, MK; Zoellner, C | 1 |
| Borg, BB; Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Loomba, R; Lutchman, G; Modi, AA; Neumann, AU; Rivera, E; Rotman, Y; Soza, A | 1 |
| Cheng, W; Flexman, JP; Hammond, T; Lee, S; Price, P; Watson, MW | 1 |
| Halevy, S; Horev, A | 1 |
| Amorosa, VK; Bruno, C; Dorey-Stein, Z; Ferrara, T; Hoffman-Terry, M; Kostman, JR; Lo Re, V; Mounzer, K; Slim, J | 1 |
| Andreoli, A; Arcuri, P; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Mazzoni, E; Mecenate, F; Nosotti, L; Paffetti, A; Pellicelli, AM; Picardi, A; Romano, M; Soccorsi, F | 1 |
| Bouraoui, R; Chebil, A; El Matri, L; Kort, F; Youssef, NB | 1 |
| Albrecht, J; Bertelsen, AH; Brass, C; Fellay, J; Ge, D; Goldstein, DB; Gumbs, CE; Little, LD; McHutchison, JG; Muir, AJ; Qiu, P; Shianna, KV; Sulkowski, M; Thompson, AJ; Urban, TJ; Warner, A; Watson, M | 1 |
| Mac Nicholas, R; Norris, S | 1 |
| Lao, XQ; Li, JH; McCarthy, JJ; McHutchison, JG; Muir, AJ; Patel, K; Suchindran, S; Thompson, A; Tillmann, HL | 1 |
| Abdo, A; Abu El-Asrar, AM; Al Otaibi, M; Al-Muammar, AM; Al-Mudhaiyan, TM | 1 |
| Bengsch, B; Thimme, R | 1 |
| Alsiö, A; Askarieh, G; Ferrari, C; Hellstrand, K; Lagging, M; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Pugnale, P; Schalm, SW; Söderholm, J; Westin, J; Zeuzem, S | 1 |
| Bailly, F; Trepo, C | 1 |
| Albrecht, JK; Alonso, E; Bortolotti, F; Brass, C; Broue, P; Calzado, MA; Ciocca, M; Galoppo, M; Gonzalez, T; Goodman, Z; Huber, WD; Hunter, B; Jara, P; Kerkar, N; Kullmer, U; Lacaille, F; Lachaux, A; Lang, T; Neigut, D; Noviello, S; Pedreira, A; Pollack, H; Ramakrishna, J; Ribes-Koninckx, C; Rodriguez-Baez, N; Shelton, M; Sniukiene, V; Valle-Segarra, AD; Wirth, S; Xu, CR; Zancan, L; Zheng, H | 1 |
| Bielawski, KP; Izycka-Swieszewska, E; Romanowski, T; Sikorska, K; Stalke, P | 1 |
| Araújo, DV; Araújo, GT; Fonseca, MC | 1 |
| Bronowicki, JP; Diago, M; Nelson, DR; Pappas, SC; Rodriguez-Torres, M; Shiffman, ML; Tietz, A; Zeuzem, S | 1 |
| Heathcote, EJ; Mazzulli, T; Pattullo, V; Ravindran, NC; Wong, DK | 1 |
| Hagen, K; Rosenberg, P | 1 |
| Dhillon, AP; Hellstrand, K; Lagging, M; Westin, J | 1 |
| Kao, JH; Wang, CC | 1 |
| Hrstić, I; Ostojić, R; Vucelić, B | 1 |
| Begovac, J; Romih, V | 1 |
| Colić Cvrlje, V; Filipec Kanizaj, T; Mrzljak, A; Ostojić, R | 1 |
| Jaklin Kekez, A | 1 |
| Bartkowiak, J; Grek, M; Jozwiak, B; Majda-Stanislawska, E; Piekarska, A; Sidorkiewicz, M | 1 |
| Azevedo, RS; Carrilho, FJ; Gonçalves, L; Malta, Fde M; Medeiros-Filho, JE; Pinho, JR; Silva, LC | 1 |
| Perez, V | 1 |
| Ciocca, M; Cuarterolo, M; Ramonet, M | 1 |
| Colombato, L; Descalzi, V; Gadano, A | 1 |
| Galdame, O; Manero, E; Reggiardo, V | 1 |
| Galdame, O; Jorge, A; Sordá, J | 1 |
| González Ballerga, E; Levi, D; Reggiardo, V | 1 |
| Bain, VG; Balshaw, R; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, KM; Sherman, M; Usaty, C; Yoshida, EM | 1 |
| Broussolle, C; Faurie, P; Sève, P; Trepo, C; Zoulim, F | 1 |
| Florholmen, J; Goll, R; Gutteberg, T; Konopski, Z; Kristiansen, MG; Kvamme, JM; Paulssen, EJ; Steigen, SE; Sørbye, SW | 1 |
| Amer, A; Bener, A; Derbala, M; Rashid, A; Shebl, FM | 1 |
| Andriulli, A; Bacca, D; Carretta, V; Copetti, M; Cozzolongo, R; Dalgard, O; Mangia, A; Minerva, N; Mottola, L; Piazzolla, V; Ring-Larsen, H; Verbaan, H | 1 |
| Dai, Y; Ishii, K; Mohri, K; Motege, E; Uesawa, Y | 1 |
| Negro, F | 1 |
| Ali, A; Eslam, M; Hamdy, L; Khattab, M; Sharwae, MA; Shatat, M | 1 |
| Chen, TM; Chen, YP; Chow, KC; Huang, PT; Tung, JN; Wen, CF | 1 |
| Cañete, N; Crespo, M; Jou, A; Mira, JA; Pahissa, A; Pineda, JA; Podzamczer, D; Solà, R; Tiraboschi, JM; Tural, C; Van den Eynde, E | 1 |
| Feld, JJ; Ghany, MG; Hara, K; Haynes-Williams, V; Heller, T; Hoofnagle, JH; Ko, M; Koh, C; Leff, RD; Liang, TJ; Lutchman, GA; Meek, C; Neumann, AU; Pfeiffer, JK; Rivera, M; Rotman, Y | 1 |
| Cardona-Meléndez, GM; DebRoy, S; Diaz, E; Kang, M; Kribs-Zaleta, C; Medina-Rios, L; Mubayi, A | 1 |
| de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Pérez-Daga, JA; Rodrigo-López, JM; Sáez-Gómez, AB | 1 |
| Chironna, M; Conteduca, V; Dammacco, F; De Re, V; Gatti, P; Lauletta, G; Mariggiò, MA; Russi, S; Sansonno, D; Sansonno, S; Tucci, FA | 1 |
| Bruggmann, P; Dampz, M; Falcato, L; Gerlach, T; Kravecz, L | 1 |
| Cheveau, A; Larrat, S; Leroy, V; Levast, M; Morand, P; Nicod, S; Plages, A; Seigneurin, JM; Thelu, MA; Zarski, JP | 1 |
| El-Azm, AR; El-Demellawy, M; Salem, ML | 1 |
| Beld, MG; Gelderblom, HC | 1 |
| Baysoy, G; Demir, H; Temizel, IN; Uslu, N; Yuce, A | 1 |
| Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M | 1 |
| Ackermann, G; Waizmann, M | 1 |
| Dzyublyk, I; Humphries, JE; Kromminga, A; Miroshnichenko, V; Moroz, L; Popovych, O; van Hoogdalem, EJ; Wilkes, MM; Yegorova, T; Zaytsev, I | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Ishigami, M; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K | 1 |
| Adda, N; Afdhal, NH; Bsharat, M; Di Bisceglie, AM; Garg, J; George, S; Heathcote, EJ; Jacobson, IM; Kauffman, RS; Manns, MP; McHutchison, JG; Muir, AJ; Reesink, HW; Terrault, NA; Zeuzem, S | 1 |
| Cheong, HR; Cho, M; Heo, J; Kang, DH; Kim, DU; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
| Aguirrebengoa, K; Barreiro, P; Guardiola, JM; Labarga, P; Miralles, C; Miralles, P; Morello, J; Portu, J; Rodriguez-Novoa, S; Rubio, R; Soriano, V; Vispo, E | 1 |
| Flisiak, I; Flisiak, R; Jaroszewicz, J; Rogalska, M | 1 |
| Alsiö, Å; Buhl, MR; Christensen, PB; Färkkilä, M; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Sangfelt, P; Westin, J | 1 |
| Colucci, G; Hadziyannis, SJ; Ishida, H; Lin, A; Sarrazin, C; Shiffman, ML; Zeuzem, S | 1 |
| Antonaci, S; Napoli, N; Simone, O; Tortorella, C; Zaccaro, B | 1 |
| Shouval, D | 2 |
| Furusyo, N; Hayashi, J; Kainuma, M; Murata, M; Ogawa, E; Otaguro, S; Sawayama, Y; Taniai, H; Toyoda, K | 1 |
| Doo, EC; Jacobson, IM; Murray, JS; Perrillo, RP; Peters, MG; Ross, DB; Wong, JB | 1 |
| Dejaco, C; Donnerer, J; Ferenci, P; Hofer, H; Kessler, H; Sator, K; Sator, M; Scherzer, TM; Staufer, K | 1 |
| Bourgois, A; Fischler, B; Gardovska, D; Kelly, D; Porta, G; Silveira, T; Sokal, EM; Stéphenne, X | 1 |
| Cheng, W; Fernandez, S; Flexman, JP; Hammond, T; Lee, S; Price, P; Watson, MW | 2 |
| Bader, TF; Bird, PC; Fazili, J; Lackey, CL; Mallonee, S; Mesiya, SA; Sachdev, AK; Schmidt, RD; Tierney, WM | 1 |
| Chang, HH; Chen, IM; Shih, CC; Wang, BY; Yang, AH | 1 |
| Cross, TJ; Harrison, PM; Hughes, S; Nolan, J; Quaglia, A | 1 |
| Elkady, A; Hasegawa, I; Khan, A; Kurbanov, F; Matsuura, K; Mizokami, M; Ohno, T; Sugauchi, F; Tanaka, Y; Tokuda, H | 1 |
| Zucker, DM | 1 |
| Bárcena, R; Blesa, C; Casado, JL; Fortún, J; Mateos, ML; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Honda, M; Horimoto, K; Kaneko, S; Mizokami, M; Mizukoshi, E; Nakamoto, Y; Nakamura, M; Sakai, A; Sakai, Y; Shirasaki, T; Tanaka, Y; Tokunaga, K; Yamashita, T | 1 |
| Blanc, F; Cacoub, P; Coppéré, B; Karras, A; Musset, L; Perard, L; Piette, JC; Resche Rigon, M; Rosenzwajg, M; Saadoun, D; Schoindre, Y; Sene, D; Terrier, B | 1 |
| Kaur, A; Kaushal, S; Midha, V; Mittal, R; Puri, S; Singla, D; Sobti, P; Sood, A; Sood, N | 1 |
| Cozma, A; Orāşan, O; Pârvu, A; Petrov, L; Rednic, N; Sâmpelean, D | 1 |
| Ahlenstiel, G; Baumgarten, A; Bickel, M; Buggisch, P; Fenske, S; Gölz, J; Hintsche, B; John, C; Khaykin, P; Klinker, H; Lutz, T; Mayr, C; Rockstroh, JK; Schürmann, D; Staszewski, S; Stephan, C; Trein, A; Vogel, M | 1 |
| Imazeki, F; Omata, M; Yokosuka, O | 1 |
| Angelo, AL; Bendicho, MT; Carneiro, VL; Cavalcante, LN; Freire, SM; Lemaire, DC; Lyra, AC; Lyra, LG; Mendes, CM; Santana, N; Souza, SL | 1 |
| de Carvalho-Mello, IM; de Queiróz, AT; Jardim, AC; Maracaja-Coutinho, V; Matioli, SR; Rahal, P | 1 |
| Corcoy, R; Enríquez, J; Rigla, M; Torras, X; Vinagre, I | 1 |
| Chanu, P; Frey, N; Goggin, T; Grippo, J; Jacqmin, P; Jonsson, EN; Jorga, K; Jumbe, NL; Lavielle, M; Snoeck, E | 1 |
| Herrine, SK; Santos, C | 1 |
| Berg, J; Biesenbach, G; Bodlaj, G; Hubmann, R; Saleh, K; Stojakovic, T | 1 |
| Poordad, F; Zeuzem, S | 1 |
| Chao, YC; Chen, CH; Chen, CL; Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Hu, TH; Huang, JF; Hung, CH; Kao, JH; Kuo, HT; Lai, MY; Lee, CM; Liao, LY; Lin, ZY; Liu, CH; Liu, CJ; Lu, SN; Su, TH; Tung, SY; Wang, JH; Wu, SS; Yang, SS; Yu, ML | 1 |
| Schwarz, KB | 1 |
| Kremen', NV; Romantsov, MG; Sologub, TV | 1 |
| Alonso, N; Martínez-Arconada, MJ; Martínez-Cáceres, EM; Morillas, RM; Planas, R; Sanmartí, AM; Soldevila, B | 1 |
| Piccolo, P | 1 |
| Alsaran, K; Sabry, A; Shaheen, N | 1 |
| Berzsenyi, MD; Roberts, SK | 1 |
| Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Chan, JM; Chan, KH; Cheung, KW; Chow, DA; Kan, YM; Kwan, WK; Lai, TS; Li, FT; Li, MK; Li, RS; Lo, FH; Ng, FH; Tsang, OT; Yeung, YW; Zee, JS | 1 |
| Frampton, CM; Gane, EJ; Gibson, M; Keogh, GF; Lockhart, MM; Murphy, MP; Orr, DW; Smith, RA; Taylor, KM; Weilert, F | 1 |
| Fuchsteiner, H; Hackl, F; Luger, C; Maieron, A; Metz-Gercek, S; Mittermayer, H; Schöfl, R; Ziachehabi, A | 1 |
| Kabieszová, L; Kloudová, A; Kůrková, J; Mrázek, J; Orságová, I; Petrousová, L; Pospísek, M; Roznovský, L | 1 |
| Behrens, R; Enninger, A; Gerner, P; Hilbich, J; Kliemann, G; Walther, F; Wenzl, TG; Wirth, S | 1 |
| Bernardini, C; Di Biagio, A; Mikulska, M; Nicco, E; Rosso, R; Viscoli, C | 1 |
| Molina, JM; Palmer, P; Rachline, A; Simon, F | 1 |
| Boesecke, C; Rockstroh, JK; Vogel, M; Wasmuth, JC | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Ciancio, A; Rizzetto, M | 1 |
| Andreone, P; Bernardi, M; Cannoletta, F; Cursaro, C; Di Donato, R; Fortini, C; Gramenzi, A; Grandini, E; Loggi, E; Riili, A; Scuteri, A | 1 |
| Cho, MS; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tung, WC; Wang, JH | 1 |
| Arends, JE; Baak, BC; Boonstra, A; Claassen, MA; Hoepelman, AI; Nanlohy, NM; van Baarle, D; van den Berg, CH; van Erpecum, KJ | 1 |
| Ettorre, A; Harrison, RJ; Khakoo, SI; Little, AM | 1 |
| Rustgi, VK | 2 |
| Candolo Martinelli, AL; Carneiro, FP; Carneiro, MV; Figueiredo, JF; Passos, AD; Ramalho, LN; Secaf, M; Souza, FF; Teixeira, AC; Villanova, MG; Zucoloto, S | 1 |
| Ando, K; Fukuda, K; Hayashi, Y; Hong, HS; Hotta, H; Imoto, S; Kim, SR; Kudo, M; Lee, YH; Mita, K; Nagano-Fujii, M; Nakajima, T; Nakashima, K; Shoji, I | 1 |
| Cooper, C | 2 |
| Byrnes-Blake, K; de la Torre, A; Flamm, S; Fontana, D; Freeman, J; Gordon, SC; Gray, T; Hausman, D; Hunder, NN; Lawitz, E; Lopez-Talavera, JC; Marotta, P; Muir, AJ; Shiffman, ML; Vierling, JM; Yoffe, B; Zaman, A | 1 |
| Bonkovsky, HL; De Santo, JL; Di Bisceglie, AM; Dienstag, JL; Ghany, MG; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Snow, KK | 1 |
| Aydin, I; Ferenci, P; Hofer, H; Mueller, C; Neumueller-Guber, S; Scherzer, TM; Staufer, K; Steindl-Munda, P; Wrba, F | 1 |
| Albrecht, JK; Brass, CA; Dhaliwal, S; Goteti, VS; Harrison, SA; Hu, KQ; Koury, K; McHutchison, JG; Noviello, S; Patel, K; Rossaro, L; Sulkowski, MS; Tillmann, H; Torres, DM | 1 |
| Deng, L; El-Shamy, A; Fukuda, K; Haga, H; Hotta, H; Imai, Y; Ishii, R; Ito, J; Kawata, S; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sanjo, M; Shoji, I; Togashi, H; Watanabe, H | 1 |
| Díaz-García, F; Fernández-Gutiérrez-Del-Alamo, C; Girón-González, JA; Marín-Serrano, E; Martín-Herrera, L; Rodríguez-Ramos, C | 1 |
| Angelico, M; Baiocchi, L; Carbone, M; Conti, RL; Cucchiarelli, S; De Leonardis, F; Delle Monache, M; Di Paolo, D; Lenci, I; Nosotti, L | 1 |
| Fehér, J; Lengyel, G | 3 |
| Caruntu, F; Ceausu, E; Csiki, IE; Gheorghe, L; Iacob, S; Pascu, O; Simionov, I; Vadan, R | 1 |
| Arakawa, T; Goto, H; Hayashi, K; Honda, T; Katano, Y; Kumada, T; Tada, T; Toyoda, H | 1 |
| Chan, HL; Farrell, GC; Teoh, NC | 1 |
| Bate, JP; Colman, AJ; Frost, PJ; Harley, HA; Shaw, DR | 1 |
| Bacon, BR; Cianciara, J; Cronin, PW; Grigorescu, M; Lawitz, EJ; Lurie, Y; McHutchison, JG; Muir, AJ; Pulkstenis, E; Rodriguez-Torres, M; Rustgi, VK; Subramanian, GM; Sulkowski, MS; Tice, AD; Zeuzem, S | 1 |
| Bain, VG; Benhamou, Y; Chuang, WL; Cronin, PW; Flisiak, R; Kryczka, W; Lawitz, EJ; Lee, CM; McHutchison, JG; Nelson, DR; Patel, K; Pianko, S; Pulkstenis, E; Rasenack, JW; Rodriguez-Torres, M; Subramanian, GM | 1 |
| Farnik, H; Herrmann, E; Kronenberger, B; Lange, CM; Sarrazin, C; Zeuzem, S | 1 |
| Fan, YM; Li, TM; Liu, XQ; Zhou, BT | 1 |
| Belkahla, N; Chaabouni, H; Chouaib, S; Hariz, FB; Kchir, H; Maamouri, N; Mami, NB; Ouerghi, H | 1 |
| Chung, YH; Jeong, SH; Jin, YJ; Kim, GM; Lee, HC; Lee, YS; Lim, YS; Park, YK; Suh, DJ; Yun, GJ | 1 |
| Jang, JY; Jeon, SR; Jeong, SW; Kim, BS; Kim, SK; Kim, YS; Lee, YN; Lim, JH; Roh, MO; Ryu, YS | 1 |
| Hanson, B; Lambot, F; Sztern, B | 1 |
| Carvalho Filho, RJ; Ferrari, MV; Ferraz, ML; Freire, FC; Narciso-Schiavon, JL; Scanhola, GQ; Schiavon, Lde L; Silva, AE; Suarez, MM | 1 |
| Gómez-Domínguez, E; González-Moreno, L; Jones, EA; Mendoza, J; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Abdo, AA; Alajlan, A; Binamer, Y; Hamadah, I; Sanai, FM | 1 |
| Chan, PK; Tam, JS; Tully, DC; Zhang, T; Zhou, DX | 1 |
| Mendes-Corrêa, M; Núñez, M | 1 |
| Browne, JA; Crowe, J; Devitt, E; Lawless, MW; Sadlier, D; Walsh, C | 1 |
| Asselah, T; Bieche, I; De Muynck, S; Estrabaud, E; Lapalus, M; Marcellin, P; Saadoun, D; Soumelis, V; Vidaud, M | 1 |
| Abergel, A; Connell, EV; Cooksley, WG; Diago, M; Dieterich, DT; Lai, MY; Lin, A; Pessôa, MG; Shiffman, ML; Swain, MG; Tietz, A; Zeuzem, S | 1 |
| Broering, R; Gerken, G; Jiang, M; Kottilil, S; Lu, M; Schlaak, JF; Trippler, M; Zhang, X | 1 |
| Batista-Neves, S; de Oliveira, IR; Galvão-de Almeida, A; Guindalini, C; Lyra, AC; Miranda-Scippa, A; Paraná, R; Quarantini, LC | 1 |
| Bianchi, C; Hernández, N; Mescia, G; Pollio, C; Quintana, L; Robaina, G | 1 |
| Ramos, EL | 1 |
| Angerami, AF; Gonçales, ES; Gonçales, FL; Gonçales, NS; Moma, CA; Pavan, MH; Tozzo, R; Vigani, AG | 1 |
| Bernasconi, E; Borovicka, J; Cavassini, M; Cerny, A; Chave, JP; Chuard, C; Dufour, F; Dutoit, V; Genné, D; Gonvers, JJ; Heim, MH; Malinverni, R; Monnat, M; Müllhaupt, B; Negro, F; Oneta, C; Troilliet, N | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Nakamura, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Bignulin, S; Bitetto, D; Cmet, S; Cussigh, A; Fabris, C; Falleti, E; Fontanini, E; Fornasiere, E; Fumolo, E; Martinella, R; Pipan, C; Pirisi, M; Toniutto, P | 1 |
| Ardiri, A; Bertino, G; Boemi, PM; Boemi, R; Bruno, CM; Calvagno, GS; Ierna, D; Naimo, S; Neri, S; Ruggeri, IM; Santonocito, MM; Speranza, A; Valenti, M | 1 |
| Fowell, AJ; Nash, KL | 1 |
| El Diasty, A; Saudy, N; Zaki, Mel S | 1 |
| Adams, S; Ostermeier, M | 1 |
| Camacho, A; del Valle, J; Macías, J; Mata, R; Merchante, N; Mira, JA; Neukam, K; Pérez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Benedan, L; Borroni, V; Del Menico, B; Dongiovanni, P; Fargion, S; Fracanzani, AL; Galmozzi, E; Maggioni, P; Rametta, R; Valenti, L | 1 |
| Jung, EU; Kang, HG; Lee, SH; Lee, YJ; Moon, SS; Park, SJ; Seo, JA; Seol, SY | 1 |
| Song, BC | 1 |
| Kenis, G; Koek, GH; Prickaerts, J; Robaeys, G; Steinbusch, HW; van Os, J; Wichers, M | 1 |
| Araújo, ES; Barone, AA; Campos, AF; Mello, ES; Takagaki, T; Yamashiro, J | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Goodman, ZD; Lok, AS; Naishadham, D; Sterling, RK; Su, GL; Wright, EC | 1 |
| Chary, A; Holodniy, M; Kottilil, S; Murphy, AA; Polis, MA; Winters, MA | 1 |
| Balciuniene, L; Blokhina, NP; Buti, M; Esteban, R; Faruqi, R; Feinman, SV; Horban, A; Lurie, Y; Pedicone, LD; Sarrazin, C; Teuber, G; Zakharova, NG | 1 |
| Bech, P; Buhl, MR; Färkkilä, M; Hellstrand, K; Hjerrild, S; Lagging, M; Langeland, N; Leutscher, PD; Mørch, K; Norkrans, G; Pedersen, C | 1 |
| Burbelo, PD; Ching, KH; Iadarola, MJ; Issa, AT; Kottilil, S; Kovacs, JA; Masur, H; Murphy, AA; Polis, MA; Schlaak, JF | 1 |
| McHutchison, J; Naggie, S; Patel, K | 1 |
| Belle, SH; Conjeevaram, HS; Evans, RW; Ramcharran, D; Wahed, AS; Wang, T; Yee, LJ | 1 |
| Beste, LA; Chapko, M; Dominitz, JA; Ioannou, GN; Larson, MS | 1 |
| Albrecht, JK; Anderson, FH; Brass, CA; Chaudhri, E; Davis, MN; Galati, JS; Gordon, SC; Jacobson, IM; Koury, K; Kwo, PY; Lawitz, EJ; McCone, J; Pedicone, LD; Pound, D; Ravendhran, N; Rossaro, L; Rubin, R; Schiff, ER; Vierling, JM | 1 |
| Asano, T; Hatakeyama, H; Hayashi, T; Iwashita, M; Maeda, T; Nishiwaki, S; Saito, K; Tagami, A; Takada, J; Watanabe, N | 1 |
| Bondarenko, AN; Goriacheva, LG; Kovalenko, AL; Kovalenko, SN; Petrov, AIu; Romantsov, MG; Shul'diakov, AA; Sologub, TV; Sukhanov, DS | 1 |
| Aydemir, S; Cakal, B; Engin, H; Gokmen, A; Kiran, S; Oztoprak, N; Tekin, IO; Ustundag, Y | 1 |
| Ceccherini-Silberstein, F; Cento, V; Di Masi, F; Manzoli, L; Mazzotta, E; Mercurio, F; Parruti, G; Perno, CF; Pieri, A; Polilli, E; Sozio, F; Tontodonati, M | 1 |
| Abe, T; Fukuhara, T; Maehara, Y; Matsuura, Y; Motomura, T; Ninomiya, A; Okano, S; Shirabe, K; Soejima, Y; Taketomi, A; Uchiyama, H | 1 |
| Beinhardt, S; Ferenci, P; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Staettermayer, AF | 1 |
| Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Chavanet, P; Duong, M; Duvillard, L; Halfon, P; Petit, JM; Piroth, L | 1 |
| Hattori, T; Inoue, Y; Kodama, EN; Li, S; Matsuura, Y; Tanaka, T; Tani, H; Zhang, J | 1 |
| Archimandritis, AJ; Giannaris, M; Koskinas, J; Malaktari, S; Papakostas, N; Savvas, SP | 1 |
| Nagao, Y; Sata, M | 1 |
| Daruich, J | 1 |
| Galoppo, C; Galoppo, M | 1 |
| Fujishiro, T; Kato, H; Narita, M | 1 |
| Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML | 1 |
| Baur, K; Berg, T; Bibert, S; Bochud, PY; Braun, J; Frei, P; Geier, A; Goetze, O; Iwata, R; Martin, IV; Mertens, JC; Müller, T; Müllhaupt, B; Schmitt, J; Stieger, B; Vergopoulos, A | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Deng, W; Harrison, SA; Herrine, SK; Koury, K; Lee, WM; McCone, J; McHutchison, JG; Noviello, S; Pedicone, LD; Poordad, FF; Reddy, KR; Shiffman, ML; Sulkowski, MS | 1 |
| Beinhardt, S; Datz, C; Dulic-Lakovic, E; Ferenci, P; Hofer, H; Kessler, HH; Krall, C; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Zinober, K | 1 |
| Boland, GJ; Burger, DM; Drenth, JP; Janssen, MP; Siersema, PD; Van Erpecum, KJ; Van Soest, H; Van Vlerken, LG | 1 |
| Berg, T; Bojunga, J; Farnik, H; Hassler, A; Herrmann, E; Lange, CM; Sarrazin, C; von Wagner, M; Zeuzem, S | 1 |
| Bakulin, IG; Sharabanov, AS | 1 |
| Bakulin, IG; Iakovleva, EV; Moliarenko, EV; Sharabanov, AS | 1 |
| Arai, K; Honda, M; Kaneko, S; Nakamura, M; Sakai, A; Sakai, Y; Shimakami, T; Shirasaki, T; Tateno, M; Yamashita, T | 1 |
| Cardot-Leccia, N; Lacour, JP; Montaudié, H; Passeron, T; Sebbag, N | 1 |
| Badley, AD; Cummins, NW; Klein, MB; Rider, DN; Rizza, SA; Saeed, S | 1 |
| Kaur, A; Mehta, V; Midha, V; Mittal, R; Sharma, S; Sood, A; Sood, N; Thara, A | 1 |
| Kaur, A; Midha, V; Mittal, R; Puri, S; Sandhu, JS; Sood, A; Sood, N | 1 |
| Camacho, A; Caruz, A; de la Torre, J; Macías, J; Martínez, A; Mira, JA; Neukam, K; Palomares, JC; Pineda, JA; Rivero, A; Roldán, C; Salas, I | 1 |
| Aghemo, A; Colombo, M; De Nicola, S; Rumi, MG | 1 |
| Barreiro, P; Cuenca, L; Jiménez-Nácher, I; Labarga, P; Madejón, A; Medrano, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA | 1 |
| Barreiro, P; González-Lahoz, J; Labarga, P; Martín-Carbonero, L; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD | 1 |
| Bernard, I; Brochot, E; Canva, V; Castelain, S; Descamps, V; Duverlie, G; François, C; Mathurin, P | 1 |
| Altomare, E; Antonaci, S; Batini, I; Capria, A; Giannelli, G; Grandi, B; Guarducci, I; Marsi, O; Moscato, GA; Pellegrini, G; Pieri, D; Sacco, R | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kurosaki, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Yatsuhashi, H | 1 |
| de Knegt, RJ; Hansen, BE; Janssen, HL; Roomer, R | 1 |
| Pandya, PK; Rao, GA | 1 |
| Ferenci, P; Ferlitsch, A; Gangl, A; Homoncik, M; Peck-Radosavljevic, M; Pramhas, S; Scherzer, T | 1 |
| Amador-Cañizares, Y; Dueñas-Carrera, S | 1 |
| Abate, G; Bertino, G; Boemi, P; Calvagno, GS; Di Pino, A; Giancarlo, C; Ignaccolo, L; Judica, A; Maiorca, D; Mastrosimone, G; Mauceri, B; Misseri, M; Neri, S; Palermo, F; Petralia, A; Rizzotto, A; Vadalà, G | 1 |
| Belotti, C; Brocco, G; Bruno, R; Covolo, L; Cristofori, C; Donato, F; Fattovich, G; Gaeta, GB; Guido, M; Minola, E; Negro, F; Pasino, M; Perini, E; Puoti, M; Raimondo, G; Rossi, L; Santantonio, T | 1 |
| Alejska, M; Błażewicz, J; Figlerowicz, M; Formanowicz, P; Jackowiak, P; Kędziora, P; Malinowska, N | 1 |
| Agostinacchio, E; Andriulli, A; Annicchiarico, B; Bacca, D; Bandiera, F; Barbarini, G; Carretta, V; Cela, M; Mangia, A; Minerva, N; Montalto, G; Mottola, L; Pellicelli, A; Piazzolla, V; Ricci, GL; Romano, M; Russello, M; Scotto, G | 1 |
| Azuma, K; Furusyo, N; Hayashi, J; Kainuma, M; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Satoh, T; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y | 1 |
| Anagnostou, O; Archimandritis, AJ; Deutsch, MJ; Georgiou, E; Karatapanis, S; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Tiniakou, E; Tzourmakliotis, D | 1 |
| Fujioka, T; Honda, M; Koyama, K; Matsuno, H; Ogawa, M; Shimokawa, K; Yoshizaki, T | 1 |
| Cottone, M; D'Amico, G; Fasola, S; Giannuoli, G; Graviano, D; Madonia, S; Malizia, G; Patti, S; Tinè, F | 1 |
| Baumgarten, A; Dikopoulos, N; Goelz, J; Herrmann, A; Heyne, R; Hueppe, D; John, C; Link, R; Mauss, S; Moeller, B; Simon, KG; Spelter, M; Teuber, G; Witthoeft, T; Wollschlaeger, S | 1 |
| Meléndez-Mena, D; Ramírez-Mata, A; Reyes-Leyva, J; Rocha-Gracia, RC; Santos-López, G; Sedeño-Monge, V; Vallejo-Ruiz, V | 1 |
| Fukuhara, T; Gion, T; Ikegami, T; Maehara, Y; Morita, K; Nagata, S; Soejima, Y; Sugimachi, K; Takeishi, K; Taketomi, A; Toshima, T; Umeda, K | 1 |
| Afeltra, A; D'Avola, D; Dicuonzo, G; Galati, G; Gallo, P; Mazzarelli, C; Pellicelli, A; Picardi, A; Rigon, A; Spataro, S; Vespasiani-Gentilucci, U | 1 |
| Kwo, PY; Vinayek, R | 1 |
| Chevaliez, S; Hézode, C | 1 |
| Beyazit, Y; Efe, C; Ozaslan, E; Purnak, T | 1 |
| Bota, S; Curescu, M; Gheorghe, L; Iacob, S; Popescu, A; Sirli, R; Sporea, I | 1 |
| Donnini, D; Franceschi, L; Furlanut, M; Sechi, L; Soardo, G | 1 |
| Clark, PJ; McHutchison, JG; Thompson, AJ | 1 |
| Ghany, MG; Noureddin, M | 2 |
| Ando, N; Arakawa, T; Fujimori, M; Hisanaga, Y; Kanamori, A; Kimura, J; Kiriyama, S; Kumada, T; Niinomi, T; Sakai, K; Tada, T; Tanikawa, M; Toyoda, H; Yasuda, S | 1 |
| Ahmed, F; Albert, C; Brand, M; Brass, C; Brown, R; Fixelle, AM; Herrera, JL; Jacobson, IM; Rustgi, VK; Wasserman, RB | 1 |
| Abdo, AA; Ahmed, LR; Al-hamoudi, W; Al-Husseini, H; Al-Otaibi, MM; Albenmousa, A; Ali, SM; AlQaraawi, AM; AlSheikh, A; Alswat, KA; Hersi, A; Sanai, FM; Syed, M | 1 |
| Bernardinello, E; Bertazzo, A; Cavalletto, L; Chemello, L; Comai, S; Costa, CV; Ragazzi, E | 1 |
| Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM | 1 |
| Parikh, M; Singh, A; Sood, G | 1 |
| Ghany, MG; Seeff, LB | 1 |
| Cadranel, JF; Denis, J; Duprat, C; Faroux, R; Lahmek, P; Morin, T; Nalet, B; Pariente, A; Renou, C | 1 |
| Barreiro, P; Benito, JM; Calvino, A; Caruz, A; Macías, J; McHutchison, J; Medrano, J; Naggie, S; Neukam, K; Pineda, JA; Rallón, N; Resino, S; Rivero, A; Sánchez-Piedra, C; Soriano, V; Vispo, E | 1 |
| Fais, V; Gonçales, ES; Gonçales, FL; Gonçales, NS; Macedo de Oliveira, A; Pavan, MH; Tozzo, R; Vigani, AG | 1 |
| Chen, P; Cheng, D; Liu, E; Lu, S; Wang, Y; Wei, K; Yang, P; Yu, Q; Zhao, S | 1 |
| Branch, AD; Bräu, N; Dieterich, DT; Factor, SH; Fiel, MI; Rodriguez-Torres, M; Slim, J; Sterling, RK; Sulkowski, MS; Talal, AH; Vachon, ML | 1 |
| Dai, CY | 1 |
| Benhamou, Y; Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Halfon, P; Leroy, V; Marcellin, P; Penaranda, G; Pérusat, S; Trimoulet, P | 1 |
| Beumont, M; Carosi, G; De Backer, K; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Luo, D; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L; Van Heeswijk, R | 1 |
| Balistreri, WF; Barton, BA; Gonzalez-Peralta, RP; Goodman, Z; Haber, BA; Jonas, MM; Lobritto, SJ; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Robuck, PR; Rosenthal, P; Rossi, S; Schwarz, KB; Smith, L; Valsamakis, A | 1 |
| El-Ghannam, M; El-Ray, A; Mounir, B; Taha, AA | 1 |
| Adán-Merino, L; Castillo-Grau, P; Gea-Rodríguez, F; Martín-Arranz, E; Olveira-Martín, A; Prados, C; Sáenz, JC; Segura-Cabral, JM | 1 |
| Heller, T; Liang, TJ; Raghuraman, S; Rehermann, B; Veerapu, NS | 1 |
| Casteelen, G; Coutinho, RA; Jansen, PL; Krol, A; Lambers, FA; Lindenburg, CE; Prins, M; Schinkel, J; Urbanus, AT; van den Berg, CH; van Santen, G; Weegink, CJ | 1 |
| Albrecht, J; Berg, T; Boparai, N; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Munteanu, M; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R | 1 |
| Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| He, Q; Li, ZY | 1 |
| Aggelopoulou-Tiga, P; Bassaris, H; Delis, V; Diamanti, H; Dimitroulopoulos, D; Dimopoulou, M; Giannoulis, G; Ionnidou, P; Kaligeros, K; Karatapanis, S; Kardasi, M; Ketikoglou, I; Kountouras, J; Kouroumalis, E; Koutsounas, S; Manolakopoulos, S; Mimidis, K; Nikolaou, A; Papaioannou, C; Perperas, A; Protopapas, A; Thomopoulos, K; Tsianos, E; Tzelas, G | 1 |
| Deng, L; Hotta, H; Ide, Y; Kim, SR; Sasayama, M; Shoji, I | 1 |
| Chung, RT; Di Bisceglie, AM; Hassanein, T; Lentz, E; Poordad, FF; Prabhakar, A; Zhou, X | 1 |
| Abe, H; Akuta, N; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Suzuki, F | 1 |
| Di Lernia, V | 1 |
| Abbey, SE; Links, PS; Sockalingam, S | 1 |
| Afdhal, N; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Howell, CD; Wahed, AS | 1 |
| Andersen, ES; Christensen, PB; Kjær, M; Krarup, H; Lillevang, S; Moessner, BK; Weis, N | 1 |
| Bernsmeier, C; Duong, FH; Filipowicz, M; Heim, MH; Terracciano, L | 1 |
| Bruguera, M; Fernández-Varo, G; Forns, X; González, P; Jiménez, W; Martinez, SM; Navasa, M; Sampson, E; Sánchez-Tapias, JM | 1 |
| Féray, C; Guillouche, P | 1 |
| Bahgat, MM; El-Gammal, NE; Emara, MH; Mohamed, LA | 1 |
| Hegarty, JE; Norris, S; O'Farrelly, C; Ryan, EJ; Tajuddin, T | 1 |
| Andriulli, A; Caruso, N; Iacobellis, A; Niro, GA; Perri, F; Valvano, MR | 1 |
| Brillanti, S; Mazzella, G; Roda, E | 1 |
| Hong, GH; Hu, YJ; Mao, Q; Wang, XH; Zhang, XQ; Zhou, YQ; Zhu, Y | 1 |
| Bereszyńska, I; Elikowski, W; Kurosz, J; Marszałek, A; Małek, M; Mozer-Lisewska, I; Zawilska, K | 1 |
| Al Dweik, NZ; Alkaabi, SR; Almohanadi, M; Amer, AM; Amin, A; Butt, MT; Derbala, MF; John, A; Pasic, F; Sharma, M; Shebl, FM; Yaqoob, R | 1 |
| Albrecht, JK; Boparai, N; Gordon, SC; Hu, KQ; Koury, K; McCone, J; Muir, AJ; Noviello, S; Sulkowski, MS | 1 |
| Xing, WL; Zhao, CY; Zhen, Z; Zhou, DF; Zhou, JY | 1 |
| Barbera, C; Bortolotti, F; Cammà, C; Giacchino, R; Guido, M; Indolfi, G; Marazzi, MG; Resti, M; Verucchi, G; Zancan, L | 1 |
| Bibert, S; Bochud, PY; Dill, MT; Duong, FH; Heim, MH; Papassotiropoulos, A; Roth, V; Terracciano, L; Vogt, JE | 1 |
| Berg, T; Doehring, A; Herrmann, E; Lange, CM; Lötsch, J; Müller, T; Sarrazin, C; Schlecker, C; Susser, S | 1 |
| Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kawaoka, T; Kubo, M; Kumada, H; Maekawa, T; Mitsui, F; Nakamura, Y; Ochi, H; Ohishi, W; Takahashi, S; Tsuge, M; Tsunoda, T | 1 |
| Boland, GJ; Burger, DM; Drenth, JP; Huisman, EJ; Siersema, PD; van Erpecum, KJ; van Soest, H; van Vlerken, LG | 1 |
| Halota, W; Pawłowska, M; Pilarczyk, M | 1 |
| Chiba, T; Egawa, H; Haga, H; Hatano, E; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
| Arai, M; Chiba, T; Fujiwara, K; Imazeki, F; Kanai, F; Kanda, T; Kato, K; Kurihara, T; Mikami, S; Mikata, R; Nakamoto, S; Nishino, T; Sugiura, N; Tada, M; Takada, N; Takashi, M; Tanaka, T; Tawada, A; Tsubota, A; Wu, S; Yokosuka, O; Yonemitsu, Y | 1 |
| Asahina, Y; Enomoto, N; Honda, M; Ito, K; Izumi, N; Kaneko, S; Kurosaki, M; Maekawa, S; Masaki, N; Matsuura, K; Mizokami, M; Nakagawa, M; Nishida, N; Sakai, A; Sakamoto, M; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, Y; Tokunaga, K; Watanabe, M | 1 |
| Abbate, I; Agrati, C; Capobianchi, MR; D'Offizi, G; Martini, F; Rozera, G; Sacchi, A; Vlassi, C | 1 |
| Mederacke, I; Meyer-Olson, D; Wedemeyer, H; Witte, T | 1 |
| Akase, T; Eguchi, Y; Iizuka, T; Ishizuka, H; Yoshiyama, Y | 1 |
| Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kubo, M; Maekawa, T; Miki, D; Mitsui, F; Nakamura, Y; Ochi, H; Takahashi, S; Tsuge, M | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Kerschner, H; Kessler, HH; Rutter, K; Scherzer, TM; Staettermayer, AF; Steindl-Munda, P | 1 |
| Blatt, L; Bradford, W; Forestier, N; Guyader, D; Larrey, D; Marcellin, P; Patat, A; Porter, S; Rouzier, R; Seiwert, SD; Smith, P; Zeuzem, S | 1 |
| Fried, MW; Hadziyannis, SJ; Messinger, D; Shiffman, ML; Zeuzem, S | 1 |
| Fukui, H; Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kaytayama, K; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Antonino, AT; Bechstein, WO; Bibert, S; Bochud, PY; Doehring, A; Farnik, H; Hansmann, ML; Hofmann, WP; Lange, CM; Lehr, HA; Lötsch, J; Moench, C; Moradpour, D; Müllhaupt, B; Pascual, M; Sarrazin, C; Shi, Y; Zeuzem, S | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E | 1 |
| Barone, AA; Cotler, SJ; Dahari, H; de Araujo, ES; Layden, TJ; Melo, CE; Neumann, AU | 1 |
| Browne, JA; Crowe, J; Devitt, EJ; Gallagher, WM; Gaora, PO; Lawless, MW; Power, KA | 1 |
| Delgado-Borrego, A | 1 |
| Borque, MJ; Chaparro, M; García-Buey, L; González-Moreno, L; Mendoza, J; Moreno Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N | 1 |
| Bucurică, S; Costache, R; Ioniţă-Radu, F; Nuţă, P; Stanciu, S | 1 |
| Ferguson, MC | 1 |
| Abdalla, MS; Abdalla, S; Anany, MA; Bader El Din, NG; El Akel, W; El Awady, MK; El Raziky, M; El Zayady, AR; Esmat, G; Helmy, A; Sharada, HM; Tabll, AA; Zayed, N | 1 |
| Ahloulay, M; Albert, ML; Casrouge, A; Decalf, J; Fontanet, A; Lababidi, C; Mallet, V; Mansour, H; Mapes, J; Mottez, E; Pol, S; Vallet-Pichard, A | 1 |
| Morgan, TR; O'Brien, TR | 1 |
| Aleem, AA; El Hadad, H; Essawy, M; Fouad, YM; Gomaa, W; Ibrahim, M; Ibrahim, Y; Shatat, M | 1 |
| Borro, P; Testino, G | 1 |
| Burger, DM; Dofferhoff, TS; Drenth, JP; Huntjens-Fleuren, HW; Koopmans, PP; Richter, C; Slavenburg, S; Verwey-Van Wissen, CP | 1 |
| Alberti, A; Bortoletto, G; Campagnolo, D; Comastri, G; Mirandola, S; Pulvirenti, FR; Severini, L | 1 |
| Gonzalez, SA; Keeffe, EB | 1 |
| Cirulli, ET; Fellay, J; Goldstein, DB; Gumbs, CE; Hitomi, Y; McHutchison, JG; Shianna, KV; Thompson, AJ; Urban, TJ | 1 |
| Afendy, A; Baranova, A; Limongi, D; Liotta, L; Mehta, R; Petricoin, E; Pierobon, M; Stepanova, M; Younossi, ZM | 1 |
| Barton, D; Dore, G; Kronborg, I; Sasadeusz, JJ; Weltman, M; Yoshihara, M | 1 |
| Sanyal, AJ | 1 |
| Asselah, T; Marcellin, P | 3 |
| Al, KS; Derbala, M; John, A; John, AK; Singh, R | 1 |
| Aqel, B; Bini, EJ; Boyd, W; DeComarmond, C; Dieperink, E; Falck-Ytter, Y; Ho, SB; Kulig, CC; Liu, S; McKee, DP; Pedrosa, MC; Smith, CI; Tetrick, L | 1 |
| Kovacs, A; Operskalski, EA | 1 |
| Blum, HE; Grimm, D; Thimme, R | 1 |
| Abe, H; Aimitsu, S; Chayama, K; Hayashida, Y; Hayes, CN; Hiraga, N; Imamura, M; Kao, JH; Kawakami, Y; Kubo, M; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T | 1 |
| Ikegami, T; Masuda, Y; Matsuda, K; Mita, A; Miwa, S; Miyagawa, S; Nakazawa, Y; Ohno, Y; Sano, K; Urata, K | 1 |
| Abu-Mouch, S; Buggisch, P; Chen, R; Cornberg, M; Faruqi, R; Hinrichsen, H; Horban, A; Ilan, Y; Klinker, H; Lurie, Y; Manns, M; Mauss, S; Merican, I; Müller, TH; Pedicone, LD; Rössle, M; Sood, A; Wedemeyer, H; Welsch, C; Zeuzem, S | 1 |
| Mangia, A | 2 |
| Fourcade, L; Gil, JM; Heno, P; Kerebel, S; Paule, P; Roche, NC | 1 |
| Clarke, C; Ferlic-Stark, L; Goodgame, R; Raghavan, R; Rungta, M | 1 |
| Chayama, K; Hayes, CN; Hiasa, Y; Izumi, N; Kumada, H; Matsumoto, A; Moriwaki, H; Nomura, H; Okanoue, T; Oketani, M; Sakisaka, S; Seike, M; Takehara, T; Toyota, J; Ueno, Y; Yoshioka, K; Yotsuyanagi, H | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kamatani, N; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Nakamura, Y; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Khudyakov, Y; Lara, J; Purdy, M; Xia, G | 1 |
| Chang, NC; Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Li, YN; Lin, ZY; Wang, LY; Wu, MS; Yang, JF; Yu, ML | 1 |
| Feld, JJ; Fried, MW; Hu, Z; Li, Q; Liang, TJ; Thomas, E | 1 |
| Aerssens, J; Afdhal, NH; Bollekens, J; Darling, JM; De Wit, M; Fanning, G; Fried, MW; Goldstein, DB; Howell, CD; Hudson, ML; McHutchison, JG; Scholliers, A; Shianna, KV; Talloen, W; Thompson, AJ | 1 |
| Afdhal, NH; Booth, DR; Goldstein, DB; Mangia, A; McHutchison, JG; Murray, JS; Pawlotsky, JM; Shianna, KV; Tanaka, Y; Thomas, DL; Zeuzem, S | 1 |
| Alric, L; Barange, K; Barel, P; Castan, B; Chatelut, E; Combis, JM; Desmorat, H; Dramard, JM; Garipuy, D; Guerin, B; Imbert, Y; Izopet, J; Métivier, S; Meurisse, JJ; Morin, T; Nicot, F; Payen, JL; Peron, JM; Renou, C; Sauné, K; Sire, S; Thebault, S | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kurosaki, M; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A | 1 |
| Jovanović, D; Kuljić-Kapulica, N; Nozić, D; Rajić, R; Ristanović, E; Savić, D | 1 |
| Khoramnia, R; Lohmann, CP; Maier, MM; Salgado, JP; Winkler von Mohrenfels, C | 1 |
| Chen, Y; Chen, Z; He, LL; Lei, BJ; Lei, XZ; Tang, H; Xu, H | 1 |
| Fujise, K; Namiki, Y; Tada, N; Tsubota, A | 1 |
| Borque, MJ; Chaparro, M; González-Moreno, L; Mendoza, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Jia, CH; Lan, L; Liu, BW; Yu, J; Yuan, Y; Zhang, H | 1 |
| Malhotra, R; Morley, AM; O'Sullivan, E; Thaung, C | 1 |
| Ahmed, A; Aziz, AA; El Gohary, I; Ghoraba, D; Hafez, T; Kamal, SM; Mahmoud, S; Metaoei, M; Nabegh, L; Obadan, I | 1 |
| Jahan, S; Khaliq, S; Pervaiz, A | 1 |
| Deng, L; El-Shamy, A; Hotta, H; Ide, YH; Imoto, S; Kim, SR; Sasase, N; Shoji, I | 1 |
| Ciesek, S; Manns, MP | 1 |
| Aoyagi, Y; Ikeda, H; Matsuda, Y; Morita, S; Nomoto, M; Ohkoshi, S; Takahashi, H; Takeuchi, M; Tanaka, Y; Yamagiwa, S; Yano, M | 1 |
| De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R | 1 |
| Adeeb, U; Athar, MA; Aziz, H; Bilal, I; Gil, ML; Raza, A; Waheed, Y | 1 |
| Abdo, AA; Almasio, PL; Cacoub, P; Colombo, M; Eslam, M; Esteban, R; Ferenci, P; Hadziyannis, SJ; Harrison, SA; Ibrahim, N; Khattab, MA; Lee, SS; Manns, MP | 1 |
| Aghemo, A; Colombo, M; Vezali, E | 1 |
| El-Serag, HB; Kanwal, F; Stepanova, M; Younossi, ZM | 1 |
| Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C | 1 |
| Chen, DS; Chen, HC; Chen, PJ; Hsu, CS; Hsu, SJ; Jeng, J; Kao, JH; Lai, MY; Liu, CH; Liu, CJ; Niu, WF; Tseng, TC | 1 |
| Almasio, PL; Calvaruso, V; Mazza, M | 1 |
| Budimir, J; Čajić, V; Dušek, D; Kurelac, I; Papić, N; Vince, A; Židovec Lepej, S | 1 |
| Choi, MS; Gwak, GY; Kil, JS; Kim, J; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Batool, U; Burki, UF; Iqbal, M; Khan, NU; Qureshi, S | 1 |
| Duarte-Rojo, A; Feld, JJ; Heathcote, EJ | 1 |
| Cacoub, P; Carrat, F; Geri, G; Halfon, P; Piroth, L; Pol, S; Poynard, T; Souberbielle, JC; Terrier, B | 1 |
| Abbacchi, A; Adewuyi, SA; Debold, C; Hong, BA; Lisker-Melman, M; North, CS; Pollio, DE | 1 |
| Carmo, RA; Moura, AS; Rocha, MO; Teixeira, AL; Teixeira, MM | 1 |
| Jordá, E; López, V; Molina, I; Monteagudo, C | 1 |
| Goksugur, N; Karabay, O; Ogutlu, A | 1 |
| Berg, T; Doehring, A; Geisslinger, G; Herrmann, E; Hofmann, WP; Lötsch, J; Müller, T; Sarrazin, C; Schlecker, C; Zeuzem, S | 1 |
| Chang, SW; Chen, JY; Kuo, SN; Lin, CY; Lin, YT; Sheen, IS; Shiu, CF; Wang, CM; Wu, J | 1 |
| Grotzinger, K; Poordad, F; Sullivan, J; Theodore, D | 1 |
| Chang, L; Gane, EJ; Horban, A; Nájera, I; Rouzier, R; Sampeur, P; Shulman, NS; Smith, P; Stedman, C; Tran, JQ; Wiercinska-Drapalo, A; Zhang, Y | 1 |
| Canva, V; Castel, H; Corouge, M; Deltenre, P; Dharancy, S; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Wartel, F | 1 |
| Bibert, S; Bochud, PY; Ferrari, C; Haagmans, B; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, S; Soulier, A; Zeuzem, S | 1 |
| Alagbe, O; Felger, JC; Hu, F; Miller, AH; Pace, TW; Raison, CL; Woolwine, BJ | 1 |
| Azuma, S; Hiasa, Y; Hige, S; Itoh, Y; Itsui, Y; Izumi, N; Kakinuma, S; Kurosaki, M; Mizokami, M; Nakagawa, M; Nishida, N; Sakamoto, N; Sekine-Osajima, Y; Tamori, A; Tanaka, E; Tanaka, Y; Tokunaga, K; Ueyama, M; Watanabe, M; Yuki, NS | 1 |
| Diago, M; Urquijo, JJ | 1 |
| Casas Rodrigo, M; Cebollero Agustí, A; Dalmau Obrador, B; Gallach Montero, M; Gavarró Puig, A; Gil Prades, M; Miquel Planas, M; Puig Del Castillo, I; Sánchez Delgado, J; Tomás Tutusaus, R; Vergara Gómez, M | 1 |
| Blacklaws, H; Gardner, A; Usher, K | 1 |
| Chong, VH | 1 |
| Bjøro, K; Dalgard, O; Melum, E; Moghaddam, A; Reinton, N; Ring-Larsen, H; Verbaan, H | 1 |
| Curto, TM; Everhart, JE; Freedman, ND; Lindsay, KL; Sinha, R; Wright, EC | 1 |
| Domínguez López, A; Martínez, RA; Sánchez-Ávila, JF; Sánchez-Muñoz, F; Sixtos-Alonso, MS; Uribe, M; Vargas Vorácková, F | 1 |
| Biesiada, G; Dumnicka, P; Kuśnierz-Cabala, B; Mach, T; Solnica, B | 1 |
| Adachi, H; Aoki, Y; Higami, K; Hige, S; Hino, K; Imamura, M; Ito, K; Kani, S; Masaki, N; Mizokami, M; Mukaide, M; Murata, K; Nomura, H; Orito, E; Saito, H; Sato, Y; Sugiyama, M; Tanaka, Y; Yatsuhashi, H | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Koga, T; Murata, M; Ogawa, E; Toyoda, K | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Gangl, A; Hofer, H; Kundi, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Trauner, M | 1 |
| Backus, LI; Belperio, P; Boothroyd, DB; Halloran, J; Mole, LA; Phillips, BR | 1 |
| Ichijo, T; Joshita, S; Kamijo, A; Katsuyama, Y; Komatsu, M; Matsumoto, A; Ota, M; Tanaka, E; Umemura, T; Yoneda, S; Yoshizawa, K | 1 |
| Cacoub, P; Resche-Rigon, M; Saadoun, D; Semoun, O; Sène, D; Terrier, B | 1 |
| Abdurakhmanov, DT; Baĭzhanova, ZhZh; Ignatova, TM; Nekrasova, TP | 1 |
| Fleischer, M; Fleischer-Stepniewska, K; Gladysz, A; Inglot, M; Staszek-Zurowska, B; Szymczak, A | 1 |
| Adler, M; D'Heygere, F; Decaestecker, J; Delwaide, J; George, C; Laureys, A; Nakad, A; Nevens, F; Van Vlierberghe, H | 1 |
| Barcelo de Brito, S; Campos-de-Magalhães, M; Cecília da Fonseca Salgado, M; Eduardo Brandão-Mello, C; José de Almeida, A; Lúcia Elias Pires, M | 1 |
| Furman, PA; Lam, AM; Murakami, E | 1 |
| Fujiwara, K; Yasui, S; Yokosuka, O | 1 |
| Alric, L; Babany, G; Bouvier-Alias, M; Bronowicki, JP; Charaf-Eddine, M; Chevaliez, S; Costes, B; Couzigou, P; Foucher, J; Hézode, C; Leroy, V; Mallat, A; Mathurin, P; Pawlotsky, JM; Rosa, I; Rouanet, S; Soulier, A; Tran, A | 1 |
| van Erpecum, KJ; van Oijen, MG; van Vlerken, LG | 1 |
| Askarieh, G; Bibert, S; Bochud, PY; Bruno, R; Clément, S; Covolo, L; Donato, F; Fattovich, G; Gaeta, GB; Guido, M; Lagging, M; Malerba, G; Negro, F; Pasino, M; Puoti, M; Raimondo, G; Santantonio, T | 1 |
| Baleriola, C; Chaverot, S; Cheng, W; Crawford, D; Dore, GJ; Dubois, D; McCaughan, G; Rawlinson, WD; Rizkalla, B; Roberts, S; Sievert, W; Stelzer-Braid, S; Thommes, J; Weltman, M; Yoshihara, M | 1 |
| Costas, P; Iturrino, J; Ortiz, A; Romero, CJ; Sánchez, CJ; Torres, EA; Velázquez, V | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; DiNubile, MJ; Goodman, ZD; Jacobson, IM; Manns, MP; McCone, J; Poordad, F; Reddy, KR; Sniukiene, V; Sulkowski, MS | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Burroughs, M; Esteban, R; Goodman, ZD; Gordon, SC; Lawitz, E; Marcellin, P; Poordad, F; Sings, HL; Vierling, JM; Zeuzem, S | 1 |
| Jensen, DM | 1 |
| Boonstra, A; Claassen, MA; de Knegt, RJ; Janssen, HL | 1 |
| Arama, V; Gliga, S; Popescu, C | 1 |
| Honda, M; Kaneko, S; Lemon, SM; Mizukoshi, E; Muramatsu, T; Nakamoto, Y; Nakamura, M; Nishitani, S; Sakai, A; Sakai, Y; Shimakami, T; Shirasaki, T; Suzuki, T; Tagata, Y; Takehana, K; Wakita, T; Yamashita, T; Yi, M | 1 |
| Kowala-Piaskowska, A; Michalak, TI; Mozer-Lisewska, I; Pham, TN | 1 |
| Cielecka-Kuszyk, J; Godzik, P; Komorowski, M; Madaliński, K | 1 |
| Baxter, L; Hartwell, D; Jones, J; Shepherd, J | 2 |
| Chang, SW; Chen, JY; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Lin, TN; Sheen, IS | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Lee, WM; Morgan, TR; Morishima, C; Seeff, LB; Shiffman, ML; Snow, KK; Stoddard, AM; Wright, EC | 1 |
| Bitetto, D; Ceriani, E; Cmet, S; Cussigh, A; Fabris, C; Falleti, E; Fattovich, G; Fornasiere, E; Ieluzzi, D; Pasino, M; Pirisi, M; Toniutto, P | 2 |
| Cheng, W; Crawford, DH; Depamphilis, JK; Dore, GJ; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, M; Yoshihara, M | 1 |
| Janssen, HL; Pan, Q; Tilanus, HW; van der Laan, LJ | 1 |
| Buggisch, P; Hoepner, L; Lohse, AW; Lüth, S; Pudelski, N; Schulze Zur Wiesch, J; Supplieth, M | 1 |
| Chen, JJ; Gao, YQ; Nie, HM | 1 |
| Jang, JY; Jeong, SW; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, YN; Lim, JH; Park, TK | 1 |
| Afif, N; de Vernejoul, MC; Javier, RM; Kuntz, JL; Sibilia, J | 1 |
| Husa, P; Ivanovski, L; Messinger, D; Oltman, M; Rehák, V; Tietz, A; Urbanek, P | 2 |
| Abe, H; Chayama, K; Hashimoto, Y; Hayashida, Y; Hiraga, N; Imamura, M; Kamatani, N; Kubo, M; Mitsui, F; Nakamura, Y; Nelson Hayes, C; Ochi, H; Ohishi, W; Takahashi, S; Tsuge, M; Tsunoda, T | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Abe, H; Akuta, N; Azakami, T; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Kawakami, Y; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Sezaki, H; Suzuki, F; Takahashi, S; Tsuge, M | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E | 1 |
| Bae, SH; Choi, JY; Jeong, SW; Kim, JD; Kwon, JH; Lee, JE; Song, MJ; Yoon, NR; Yoon, SK | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Murata, M; Ogawa, E; Taniai, H; Toyoda, K | 1 |
| Fakharzadeh, E; Jabbari, H; Merat, S; Sharifi, AH; Zamini, H | 1 |
| Abiru, S; Hashimoto, S; Ishibashi, H; Izumi, Y; Komori, A; Migita, K; Miyashita, T; Yasunaga, Y; Yatsuhashi, H | 1 |
| Garcia, GF; Garib, JR; Silva, Fd; Teixeira, R | 1 |
| Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Mira, JA; Neukam, K; Pineda, JA; Pinilla, J; Rallón, N; Rivero, A; Rodriguez-Novoa, S; Soriano, V; Vispo, E | 1 |
| Fukui, H; Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inui, Y; Ishida, H; Ito, T; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Lai, CL; Liu, K; Seto, WK; Tanaka, Y; Yuen, MF | 1 |
| Dicpinigaitis, PV; Weiner, FR | 1 |
| Abdullah, NA; Amr, KS; El-Batae, HE; Elhosary, YA; Ezzat, WM; Raslan, HM | 1 |
| Chang, CS; Lin, HY; Tsai, CY; Yan, SL; Yu, FL | 1 |
| Bergsma, TT; Chen, C; Corey, AE; Devalaraja, M; Gastonguay, MR; Riggs, MM; Rogers, JA; Stein, DS; Subramanian, GM; Sun, H; Yu, J | 1 |
| Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Imai, Y; Imanaka, K; Inui, Y; Ishida, H; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Nagase, T; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Akbar, H; Awan, Z; Butt, S; Hussain, A; Idrees, M; Rehaman, Iu; Sabar, MF; Saleem, S | 1 |
| Carvalho-Filho, RJ; Carvente, CT; El Batah, PN; Ferraz, ML; Narciso-Schiavon, JL; Sampaio, JP; Schiavon, LL; Silva, AE; Silva, GA | 1 |
| Akaike, J; Arakawa, T; Chayama, K; Kamiya, N; Karino, Y; Kumada, H; Kuwata, Y; Ohmura, T; Ozeki, I; Sato, T; Toyota, J; Yamada, I | 1 |
| Isakov, VA; Morozov, SV; Selivestrova, TR; Trufanova, IuM | 1 |
| Risum, M | 1 |
| Hunyady, B | 1 |
| Chiang, BL; Kao, JH; Liang, CC; Lin, YL; Liu, CH; Liu, CJ | 1 |
| Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Tada, T; Toyoda, H | 1 |
| Ackerman, Z; Ben-Dov, IZ; Pappo, O | 1 |
| Del Santo, F; Maratea, D; Messori, A | 1 |
| González, S; Velasco, J | 1 |
| Afzal, S; Akram, M; Ali, M; Butt, A; Butt, S; Hussain, A; Idrees, M; Liaqat, A; Rehman, IU; Saleem, S; Zafar, S | 1 |
| Abbasi, A; Bhutto, AR; Butt, N; Munir, SM | 1 |
| Ahmed, AS; Fathy, A; Hassan, A; Metwally, L | 1 |
| Antinori, S; Bestetti, G; Foschi, A; Galli, M; Longhi, E; Mazzali, C; Milazzo, L; Parravicini, C; Vago, T; Viola, A | 1 |
| Arai, H; Hirokawa, T; Horiuchi, K; Kakizaki, S; Mori, M; Naganuma, A; Ohyama, T; Sato, K; Shimada, Y; Tahara, H; Takagi, H; Tojima, H | 1 |
| Fujita, T; Kawaguchi, T; Kumada, T; Kuroda, M; Matsuda, F; Morimoto, S; Murakami, Y; Onomoto, K; Shimotohno, K; Tanaka, M; Toyoda, H; Uno, K | 1 |
| Arai, M; Azemoto, R; Fujiwara, K; Fukai, K; Imazeki, F; Kanda, T; Kato, K; Kita, K; Koma, Y; Mikami, S; Nakamoto, S; Sunaga, M; Suzuki, N; Takashi, M; Tawada, A; Wu, S; Yokosuka, O; Yonemitsu, Y; Yoshida, Y | 1 |
| Cao, H; Hong, XL; Li, G; Pan, XF; Xu, QH; Zhang, K; Zhao, F; Zhao, ZX | 1 |
| Aftab, M; Afzal, S; Akram, M; Badar, S; Hussain, A; Idrees, M; Ilyas, M; Khubaib, B; Zafar, S | 1 |
| Błońska-Fajfrowska, B; Hartman, M; Klimacka-Nawrot, E; Lichtański, P; Musialik, J; Petelenz, M; Suchecka, W | 1 |
| Masarone, M; Persico, M | 1 |
| Ali, I; Attaullah, S; Idrees, M; Iqbal, A; Khan, J; Khan, S; Khan, SN; Siraj, S; Swati, ZA | 1 |
| Ji, HF | 1 |
| Escolano, C; Gutiérrez, F; López, N; Masiá, M; Robledano, C | 1 |
| Eun, HS; Goh, PG; Kim, ES; Kim, HJ; Kim, MJ; Kim, SH; Kim, YJ; Lee, BS; Lee, ES; Lee, HY; Lee, SY; Moon, HS | 1 |
| Aparcero, R; Del Campo, JA; Eslam, M; Kawaguchi, T; Khattab, MA; Romero-Gomez, M; Sata, M | 1 |
| Al-Ahdal, MN; Al-Qahtani, AA; Rubino, S | 1 |
| Castellano Tortajada, G; Castellanos González, M; Muñoz Gómez, R; Pérez Carreras, M | 1 |
| Anand, BS; Jampana, SC; Singal, AK | 1 |
| Dougherty, KA; Fried, MW; McGowan, CE | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Namikawa, M; Sato, K; Takagi, H; Yamazaki, Y; Yata, Y | 1 |
| Hara, K; Ohira, A; Tanito, M | 1 |
| Antoniazzi, S; Baldo, V; Baldovin, T; Cazzagon, N; Egoue, J; Floreani, A; Furlan, P; Minola, E | 1 |
| Enomoto, N; Hiasa, Y; Hige, S; Hino, K; Honda, M; Itoh, Y; Izumi, N; Kaneko, S; Koike, A; Kurosaki, M; Matsuura, K; Mizokami, M; Mochida, S; Nishida, N; Nishiguchi, S; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, E; Tanaka, Y; Tokunaga, K; Yatsuhashi, H | 1 |
| Carazo, A; Casado, J; de Rueda, PM; Diago, M; Gila, A; León, J; López-Nevot, MÁ; Martín-Casares, A; Moreno-Otero, R; Muñoz, JA; Palomares, P; Pavón, EJ; Quiles, R; Romero-Gómez, M; Ruiz-Extremera, A; Sáenz-López, P; Salmerón, J; Sanz-Cameno, P | 1 |
| Buti, M; Cervoni, JP; Di Martino, V; Ferenci, P; Jensen, DM; Mangia, A; Richou, C; Sanchez-Tapias, JM; Sheppard, F; Thévenot, T | 1 |
| Jabbari, H; Malboobi, MA; Merat, S; Mousavi-Fard, SH; Sabahi, F; Shahzamani, K; Sharifi, H; Yahoo, N | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinnuma, S; Kurosaki, M; Matsuura, K; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A | 1 |
| Canva, V; Castel, H; Colin, M; Deltenre, P; Dharancy, S; Glowacki, F; Hazzan, M; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Noel, C; Ollivier, I; Provôt, F; Stanke, F; Tran, A | 1 |
| Arpurt, JP; Boulay, G; Boutet, O; Daures, JP; Hyrailles-Blanc, V; Karlova, N; Larrey, D; Niang, B; Pageaux, GP; Ribard, D; Salse, A; Vaucher, E | 1 |
| Fischer, K; Fransen van de Putte, DE; Mauser-Bunschoten, EP; Posthouwer, D | 1 |
| Ianna, EA; Jones, TL; Reeves, GE; Tran, HA | 1 |
| Brown, A; Foster, GR; Freshwater, D; Marley, R; Moreea, S; Mutimer, D; Rowe, IA; Sabin, CA; Shoeb, D; Sood, R | 1 |
| Benicky, M; Benova, B; Gombosova, L; Jarcuska, P; Lazurova, I | 1 |
| Arnholm, B; Eilard, A; Hellstrand, K; Lagging, M; Lindh, M; Nilsson, S; Norkrans, G; Söderholm, J; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Berg, T; Möller, B; Möller, JF; Schott, E; Wiedenmann, B | 1 |
| Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Di Stefano, R; Marchesini, G; Petta, S | 1 |
| Crouzet, J; Di Martino, V; Hillon, P; Minello, A; Monnet, E; Thévenot, T | 1 |
| Bukh, J; Christensen, PB; Hansen, N; Kjær, M; Krarup, HB; Laursen, AL; Møller, A; Obel, N; Schlichting, P; Weis, N | 1 |
| Bozzano, F; Costa, P; De Maria, A; Fazio, V; Hirsch, I; Marras, F; Moretta, L; Olive, D; Picciotto, A | 1 |
| Andreone, P; Beumont, M; Boogaerts, G; De Meyer, S; Diago, M; Ferenci, P; Focaccia, R; Foster, GR; Horban, A; Lawitz, E; Luo, D; Müllhaupt, B; Nevens, F; Picchio, G; Pockros, P; Pol, S; Polo, R; Roberts, S; Shouval, D; Terg, R; Van Heeswijk, R; van Hoek, B; Weiland, O; Younossi, Z; Zeuzem, S | 1 |
| Rosen, HR | 1 |
| Beumont, M; Bronowicki, JP; Carosi, G; Foster, GR; Hézode, C; Picchio, G; van Baelen, B; van Heeswijk, R; Verlinden, L; Weiland, O | 1 |
| Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM | 1 |
| Chen, KC; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Kuo, HT; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Clark, PJ; Esteban, R; Fellay, J; Galler, GW; Ge, D; Goldstein, DB; Jacobson, IM; King, JW; Kwo, PY; Lawitz, EJ; McCone, J; McHutchison, JG; Muir, AJ; Naggie, S; Noviello, S; Patel, K; Pedicone, LD; Poordad, F; Shianna, KV; Shiffman, ML; Singh, A; Sulkowski, MS; Thompson, AJ; Tillmann, HL; Urban, TJ; Zhu, M; Zhu, Q | 1 |
| Deltenre, P; Fartoux, L; Henrion, J; Lemoine, M; Louvet, A; Mathurin, P; Moreno, C; Mourad, A; Serfaty, L | 1 |
| Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Ghosh, S; Sharma, BK; Taneja, S; Tohra, SK | 1 |
| Abdel-Aziz, DH; El-Gazayerly, ON; El-Sayed, MH; Sabry, NA | 1 |
| Beam, C; Bonafede, M; Chakravarti, P; Pan, K; Solomon, M; Spiegel, B; Wilson, K | 1 |
| Masuzaki, R; Schuppan, D; Shimada, M; Yoshida, S | 1 |
| Chainuvati, S; Charatcharoenwitthaya, P; Kachintorn, U; Leelakusolvong, S; Limwongse, C; Manatsathit, S; Nimanong, S; Pausawasdi, N; Pithukpakorn, M; Pongprasobchai, S; Prachayakul, V; Tanwandee, T; Udompunturak, S; Vipatakul, N | 1 |
| Agúndez, JA; Carballo, M; Devesa, MJ; Díaz-Rubio, M; Fernández, C; Ladero, JM; Martin, EG; Martínez, C; Suárez, A | 1 |
| Alcaide, N; Aller, R; Almansa, R; Bermejo-Martín, JF; Caro-Patón, A; de la Fuente, C; González, JM; Jiménez-Sousa, MÁ; Largo, P; Ortiz de Lejarazu, R; Ruiz, L; Sánchez-Antolín, G | 1 |
| Bonardi, R; Ciancio, A; Manca, A; Pellicano, R; Rizzetto, M; Tabone, M | 1 |
| Imazeki, F; Kanda, T; Nakamoto, S; Wu, S; Yokosuka, O | 1 |
| Pazgan-Simon, M; Simon, K | 1 |
| Izumi, N; Kurosaki, M | 2 |
| Goto, H; Hayashi, K; Honda, T; Katano, Y; Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Toyoda, H | 1 |
| Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kamatani, N; Kubo, M; Miki, D; Nakamura, Y; Ochi, H; Takahashi, S; Tsuge, M | 1 |
| Athar, MA; Aziz, H; Bilal, I; Irfan, J; Murtaza, S; Raza, A; Waheed, Y | 1 |
| Dillon, JF; El Wahed, Z; Jafferbhoy, H; Miller, MH | 1 |
| Chen, CH; Chuang, TW; Hu, TH; Hung, CH; Kuo, YH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Asselah, T; Chevaliez, S | 1 |
| Burgess, C; Coppel, E; Corey, L; Goldstein, D; Holte, S; McHutchison, J; Scott, J; Urban, T; Wang, C | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsiao, PJ; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Shin, SJ; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Toyoda, H; Yoshioka, K | 1 |
| Da Silva, A; de Juan, J; del Pozo, E; Faraco, I; Marco, A; Saiz de la Hoya, P; Veiras, FM; Yllobre, C | 1 |
| Cabrera, R; Draganov, PV; Limaye, AR | 1 |
| Kandel, C; Kandel, G | 1 |
| Bouvier-Alias, M; Castéra, L; Hézode, C; Leroy, V; Mallat, A; Pawlotsky, JM; Rosa, I; Roudot-Thoraval, F; Roulot, D | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Donato, MF; Prati, GM; Rumi, MG | 1 |
| Brissot, P; Danielou, H; Deugnier, Y; Guillygomarc'h, A; Guyader, D; Lainé, F; Le Dréau, G; Le Lan, C; Moirand, R; Védeilhié, C | 1 |
| El-Serag, HB; Kanwal, F; Kramer, JR; Mei, M; Richardson, P | 1 |
| Chakravarti, A; Chawla, YK; Dogra, G; Kar, P | 1 |
| Elewa, U; Fervenza, FC; Poterucha, JJ; Sandri, AM | 1 |
| Bonkovsky, HL; Chung, RT; Dotrang, M; Everhart, JE; Lok, AS; Morgan, TR; O'Brien, TR; Pfeiffer, RM; Shao, Y; Shiffman, ML; Sninsky, JJ | 1 |
| Aguilera, V; Berenguer, M; Giusto, M; López-Andujar, R; Navarro, L; Ortiz, C; Prieto, M; Rodriguez, M; Rubin, A; San-Juan, F | 1 |
| Corouge, M; Pol, S | 1 |
| Schiff, ER | 1 |
| Burgueño-Montañés, C; Pérez-Álvarez, R | 1 |
| Berg, T; Boecher, WO; Buggisch, P; Dikopoulos, N; Encke, J; Goeser, T; Herrmann, E; Klinker, H; Möller, B; Prinzing, R; Sarrazin, C; Schulte-Frohlinde, E; Schwendy, S; Teuber, G; Thimme, R; Zeuzem, S | 1 |
| Jacobson, IM; Olson, M | 1 |
| Arai, M; Fujiwara, K; Imazeki, F; Kanda, T; Maruoka, D; Yokosuka, O | 1 |
| Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH | 5 |
| Zhang, YH | 1 |
| Bagree, A; Tavakoli-Tabasi, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG | 1 |
| Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Matsuura, K; Mizokami, M; Nakanishi, H; Nishida, N; Sugauchi, F; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tanaka, Y; Tokunaga, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Chung, TL; Herrmann, E; Hofmann, WP; Karey, U; Lötsch, J; Mihm, U; Osbahr, C; Sarrazin, C; Susser, S; Welsch, C; Zeuzem, S | 1 |
| de Knegt, RJ; Heijens, A; Janssen, HL; Roomer, R; Schutten, M; van Vuuren, AJ | 1 |
| Dickensheets, H; Donnelly, RP; O'Brien, TR | 1 |
| Arai, M; Fujiwara, K; Fukai, K; Imazeki, F; Kanda, T; Kato, K; Kimura, M; Mikami, S; Miyauchi, T; Nishino, T; Shimada, N; Sugiura, N; Takada, N; Takashi, M; Tsubota, A; Yokosuka, O; Yonemitsu, Y | 1 |
| Chayama, K; Hayashi, N; Kumada, H; Okanoue, T; Toyota, J; Tsubouchi, H | 2 |
| Belliveau, PP; Foote, BS; Spooner, LM | 1 |
| Brass, C; Brown, RS; Freilich, B; Hu, KQ; Jacobson, IM | 1 |
| Aalaei-Andabili, SH; Alavian, SM | 1 |
| Moreno, V; Valencia, ME | 1 |
| Hagiwara, H; Hayashi, N; Hiramatsu, N; Imai, Y; Inoue, Y; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurashige, N; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshihara, H | 1 |
| Gutierrez-Reyes, G; Hevezi, PA; Kershenobich, D; Lambert, P; Tom, E; Wilson, K; Zlotnik, A | 1 |
| Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M | 1 |
| Ilyas, JA; Vierling, JM | 1 |
| Atsukawa, M; Harimoto, H; Kobayashi, T; Nakatsuka, K; Sakamoto, C; Shimizu, M; Takahashi, H; Tamura, H | 1 |
| Carnauba, D; Damas, C; Diaz, RS; Dos Santos, CV; El-Far, F; Ferraz, ML; Reis, A; Santos, C; Serra, F; Silva, MH; Viana, MV | 1 |
| Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M | 1 |
| Adinolfi, LE; Lonardo, A; Loria, P; Restivo, L; Zampino, R | 1 |
| Higuchi, K; Hirose, S; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Seki, K; Suzuki, Y; Tasaki, K; Yoshida, T | 1 |
| Carrieri, MP; Cohen, J; Salmon-Ceron, D; Winnock, M | 1 |
| Chen, X; Dong, T; Guo, D; Jin, Y; Ma, L; Wei, L; Wu, H; Yan, H; Zhang, Y; Zhao, Y | 1 |
| Ikeda, N; Nishino, R; Unoura, M | 1 |
| Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Katoh, T; Kurosaki, M; Muraoka, M; Nakanishi, H; Nitta, S; Sakamoto, N; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Ahlenstiel, G; Edlich, B; Feld, JJ; Liang, TJ; Noureddin, M; Rehermann, B; Rotman, Y; Serti, E; Stoltzfus, J; Zabaleta Azpiroz, A | 1 |
| Foster, GR; Goldberg, DJ; Hickman, M; Hutchinson, SJ; Martin, NK; Miners, A; Vickerman, P | 1 |
| Goldenberg, D; Kurtz, S; Moisseiev, E | 1 |
| Argiro, L; Botta, D; Bourliere, M; Castellani, P; Dessein, A; Halfon, P; Maor, Y; Oules, V; Ouzan, D; Pénaranda, G; Portal, I; Renou, C; Tran, A; Wartelle, C | 1 |
| Balshaw, R; Cooper, C; Elkashab, M; Harris, P; Lalonde, R; Marrotta, PJ; Myers, RP; Sherman, M; Usaty, C; Witt-Sullivan, H | 1 |
| Berg, T; Bergk, A; Buggisch, P; Chung, TL; Gerlach, T; Herrmann, E; Hinrichsen, H; Klinker, H; Sarrazin, C; Spengler, U; Weich, V; Zeuzem, S | 1 |
| Alekseeva, LA; Bessonova, TV; Goriacheva, LG; Kotiv, MIa; Romantsov, MG; Vasil'eva, DK | 1 |
| Berak, H; Cortés, KC; Fic, M; Horban, A; Ośko, I; Pawełczyk, A; Radkowski, M | 1 |
| Antoniazzi, S; Baldo, V; Baldovin, T; Boemo, DG; Cazzagon, N; Egoue, J; Floreani, A; Minola, E | 1 |
| Clark, PJ; Thompson, AJ | 1 |
| Macías, J; Pineda, JA; Soriano, V; Vispo, E | 1 |
| Kohli, A; Kottilil, S; Masur, H; Migueles, S; Naggie, S; Polis, MA; Shivakumar, B; Sidique, N; Subramanian, GM | 1 |
| Bella, R; Bertino, G; Bruno, CM; Chisari, G; Gargante, MP; Lupo, L; Malaguarnera, M; Motta, M; Neri, S; Pennisi, G; Vacante, M | 1 |
| Angus, P; Arasteh, K; Asselah, T; Boecher, WO; Bronowicki, JP; Gane, E; Haefner, C; Heim, M; Kukolj, G; Larrey, D; Lohse, A; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Desenclos, JC; Deuffic-Burban, S; Dhumeaux, D; Larsen, C; Mathurin, P; Pol, S; Roudot-Thoraval, F; Yazdanpanah, Y | 1 |
| Abate, ML; Ahlenstiel, G; Armstrong, NJ; Bassendine, M; Berg, T; Bochud, PY; Booth, DR; Dore, GJ; Dunn, D; Gaudieri, S; George, J; Hammond, E; Hellard, M; Irving, WL; Mallal, S; Matthews, G; Müller, T; Nattermann, J; Negro, F; O'Connor, KS; Powell, E; Riordan, S; Sheridan, D; Smedile, A; Spengler, U; Stewart, GJ; Suppiah, V; Weltman, M | 1 |
| Aghemo, A; Cheroni, C; Colombo, M; D'Ambrosio, R; De Francesco, R; De Nicola, S; Donato, MF; Galmozzi, E; Prati, GM; Rumi, MG; Soffredini, R; Valenti, L | 1 |
| Kalpaka, A; Klonizakis, P; Paschos, P; Pasvanti, C; Perifanis, V; Sinakos, E; Vlachaki, E | 1 |
| Flisiak, R; Lapiński, TW; Parfieniuk-Kowerda, A; Rogalska-Płońska, M | 1 |
| Almeida, JR; França, AV; Júnior, LJ; Nogueira, JB; Quintans, Jde S; Sena, LC | 1 |
| Hagiwara, H; Hayashi, N; Higashitani, K; Hiramatsu, N; Iio, S; Inoue, M; Kakita, N; Kanto, T; Kasahara, A; Katayama, K; Matsubara, T; Mita, E; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T | 1 |
| Chawla, YK; Dhiman, RK; Duseja, A; Ghosh, S | 1 |
| Asselah, T; Bedossa, P; Bièche, I; Blanluet, M; Boyer, N; Broët, P; De Muynck, S; El Ray, A; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Masliah-Planchon, J; Ripault, MP; Valla, D; Vidaud, D; Vidaud, M; Zhang, Q | 1 |
| Bota, S; Danila, M; Neghina, AM; Popescu, A; Sirli, R; Sporea, I; Strain, M | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Imai, N; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Alvarez-Pellicer, J; Arponen, S; Barquilla, E; Bellón, JM; Berenguer, J; Crespo, M; De Miguel, J; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Mallolas, J; Miralles, P; Quereda, C; Tellez, MJ; von Wichmann, MA | 1 |
| Almeida, C; Cifuentes, C; Claro, E; García-Rey, S; Gilabert, I; Macías, J; Merchante, N; Mira, JA; Neukam, K; Pineda, JA; Vázquez, MJ | 1 |
| Mizokami, M; Sugiyama, M | 1 |
| Arends, JE; Fransen, JH; Hoepelman, AI; van Baarle, D | 1 |
| Feng, IC; Koay, LB; Kuo, HT; Lin, CY; Lin, YM; Sheu, MJ; Sun, CS | 1 |
| Al-Enzi, SA; Alsurayei, SA; Ismail, E; Ismail, WA | 1 |
| Jain, S; Midha, V; Sood, A | 1 |
| Brahm, J; González, K; Venegas, M; Villanueva, RA | 1 |
| Stiefelhagen, P | 1 |
| Abad-Santos, F; Borque, MJ; Hernandez-Bartolome, A; Lopez-Rodriguez, R; Martin-Vilchez, S; Moreno-Otero, R; Muñoz de Rueda, P; Rodrigo, L; Rodriguez-Muñoz, Y; Roman, M; Salmeron, J; Sanz-Cameno, P; Trapero-Marugan, M; Vidal-Castiñeira, JR | 1 |
| Amanzada, A; Blaschke, M; Goralczyk, A; Mihm, S; Moriconi, F; Ramadori, G; Schaefer, IM; van Thiel, D | 1 |
| Bezemer, G; de Knegt, RJ; Drenth, JP; Droogleever Fortuyn, HA; Hansen, BE; Hengeveld, MW; Janssen, HL; Van Gool, AR; Weegink, CJ | 1 |
| Bonner, JE; Esserman, DA; Evon, DM; Fried, MW; Ramcharran, D | 1 |
| Bhagani, S | 1 |
| Chang, KC; Chen, CH; Hung, CH; Kee, KM; Lee, CM; Lin, CY; Lu, SN; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Aractingi, S; Bachmeyer, C; Gombeaud, T; Moguelet, P; Sbidian, E | 1 |
| Datz, C; Dulic-Lakovic, E; Ferenci, P; Hofer, H; Laferl, H; Maieron, A; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M | 1 |
| Chammas, MC; Danilovic, DL; Marui, S; Mendes-Correa, MC; Zambrini, H | 1 |
| Abe, K; Kumagai, I; Miyasaka, A; Suzuki, K | 1 |
| Berg, T; Böhm, S; Buggisch, P; Gerlach, T; Hinrichsen, H; Klinker, H; Möller, B; Neumann, K; Rasenack, J; Sarrazin, C; Spengler, U; Teuber, G; Weich, V; Wiegand, J | 1 |
| Abdallah, DM; Hashad, DI; Salem, PE | 1 |
| Chen, CH; Hu, TH; Huang, CM; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Ichijo, T; Joshita, S; Katsuyama, Y; Matsumoto, A; Ota, M; Tanaka, E; Umemura, T; Yoneda, S; Yoshizawa, K | 1 |
| Azuma, S; Funaoka, Y; Itsui, Y; Kakinuma, S; Kitazume, A; Kiyohashi, K; Murakawa, M; Nakagawa, M; Nishimura-Sakurai, Y; Nitta, S; Onozuka, I; Sakamoto, N; Sekine-Osajima, Y; Ueyama, M; Watanabe, M; Watanabe, T | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A | 1 |
| Afdhal, NH; Alsop, D; Byrnes, V; Hill, E; Lenkinski, R; Lowry, D; Miller, A; Weinstein, C | 1 |
| Afdhal, NH; Fried, M; Goldstein, DB; Gorden, A; Howell, CD; Ibrahim, C; McHutchison, JG; Mitchell, BD; Ryan, KA; Shianna, KV; Shuldiner, AR; Thompson, AJ | 1 |
| Aguirrebengoa, K; Barreiro, P; Benito, JM; Castro, MÁ; Labarga, P; Miralles, C; Miralles, P; Morello, J; Ocampo, A; Pineda, JA; Portu, J; Rallón, NI; Rodríguez-Nóvoa, S; Soriano, V; Tellez, MJ; Vispo, E | 1 |
| Curto, TM; Everson, GT; Hoefs, JC; Lauriski, S; Morgan, TR; Shiffman, ML; Sterling, RK; Stoddard, A; Wagner, DA; Wright, EC | 1 |
| Bull, RA; Dore, GJ; Grebely, J; Hellard, M; Kaldor, J; Lloyd, A; Matthews, GV; Petoumenos, K; Pham, ST; Rawlinson, W; White, PA; Yeung, B | 1 |
| Lok, AS; Sharma, P | 1 |
| Hegarty, J; Iqbal, M; McCormick, PA; O'Farrelly, C; Ryan, EJ; Sarwar, S | 1 |
| Gołabek, V; Kupś-Rzepecka, J; Woźniakowska-Gesicka, T | 1 |
| Adda, N; Berg, T; Dusheiko, G; Ferenci, P; George, S; Heathcote, EJ; Kauffman, RS; Martin, EC; McHutchison, JG; Muir, AJ; Pawlotsky, JM; Poordad, FF; Reesink, HW; Shiffman, ML; Zeuzem, S | 1 |
| Mizokami, M; Nakanishi, M; Sugiyama, M; Tanaka, Y; Wakita, T | 1 |
| Balshaw, R; Elkashab, M; Greenbloom, S; Hilzenrat, N; Lee, SS; Myers, RP; Pluta, H; Ramji, A; Sherman, M; Usaty, C | 1 |
| Brahm, J; Hola, K; Pizarro, C; Smok, G; Venegas, M | 1 |
| Andoh, A; Aomatsu, T; Fujiyama, Y; Imaeda, H; Nishimura, T; Okumura, Y; Osaki, R; Shioya, M; Takeuchi, T | 1 |
| Wang, JB; Xu, Y | 1 |
| Lesesne, SB; Patel, N; Rein, DB; Roblin, DW; Smith, BD; Wagner, LD; Ward, JW; Weinbaum, CM; Wittenborn, JS | 1 |
| Backus, LI; Cheung, R; Hwang, EW; Thomas, IC | 2 |
| Hurter, P; Kauffman, RS; Kwong, AD; Mueller, P | 1 |
| Ahmed, U; Anas, A; Attia, M; Beejay, N; El-Azab, G; Giguere, A; Hassan, MH; Khalowf, M; Khan, A; Nasser, T; Nouh, M; Saleh, A | 1 |
| Delić, D; Jašović-Gašić, M; Marić, NP; Pavlović, Z; Vuković, O | 1 |
| Emara, MH; Radwan, MI | 1 |
| Ando, M; Hirohata, M; Imagawa, A; Miyake, Y; Miyatake, H; Nakatsu, M; Takahara, M; Yamamoto, K | 1 |
| Boninsegna, S; Buda, A; Fabris, P; Fagiuoli, S; Lobello, S; Martines, D; Milan, M; Scribano, L | 1 |
| Goto, H; Hayashi, K; Honda, T; Katano, Y; Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Tada, T; Toyoda, H | 1 |
| Bibert, S; Bochud, PY; Cerny, A; Dollenmaier, G; Dufour, JF; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Morikawa, K; Müllhaupt, B; Negro, F | 1 |
| Arase, Y; Kumada, H | 1 |
| Hayashi, N; Hiramatsu, N; Oze, T | 2 |
| Arase, Y | 2 |
| Hokari, A | 1 |
| Ide, T | 1 |
| Ikeda, F; Iwasaki, Y; Yamamoto, K | 2 |
| Karino, Y; Ozeki, I; Toyota, J | 1 |
| Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 3 |
| Chen, X; Dong, T; Liu, Y; Ma, L; Shi, L; Wei, L; Wu, H; Yan, H; Zhang, Y; Zhao, Y | 1 |
| Abe-Sandes, K; Angelo, AL; Cavalcante, LN; Lemaire, DC; Lyra, AC; Lyra, LG; Machado, TM; Malta, F; Mendes, CM; Pinho, JR | 1 |
| Angeletti, C; Antonucci, G; Ciccosanti, F; Corazzari, M; Daniele, N; Fimia, GM; Iacono, OL; Ippolito, G; Perdomo, AB; Piacentini, M; Pisa, R; Testa, A | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Itoh, A; Katano, Y; Nakano, I | 1 |
| Asselah, T; Bedossa, P; Laouénan, C; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Nicolas-Chanoine, MH; Panhard, X | 1 |
| Heo, J | 1 |
| Choi, BJ; Choi, JS; Choi, SB; Jee, SR; Jung, EU; Kim, JH; Lee, JI; Lee, SH; Lee, YJ; Park, SJ; Seol, SY; Song, YJ | 1 |
| Jeong, SH; Kim, BH; Kim, YJ; Kim, YS; Lee, CK; Lee, JW; Park, CK; Park, SH; Yim, HJ | 1 |
| Chung, WJ; Hwang, JS; Jang, BK; Kim, KH; Kweon, YO; Lee, CH; Lee, HJ; Suh, JI; Tak, WY | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Litman, HJ; Lok, AS; Sterling, RK; Su, G | 1 |
| Andrade, R; Candel, JM; Carazo, A; Diago, M; Gila, A; León, J; Martín, AB; Muñoz-de-Rueda, P; Navarro, JM; Quiles, R; Quintero, D; Ruiz-Extremera, A; Salmerón, J | 1 |
| Chiba, T; Eso, Y; Henmi, S; Kimura, T; Kita, R; Marusawa, H; Nakajima, J; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Ueda, Y | 1 |
| Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Iio, S; Imai, Y; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Song, C; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Bertino, G; Galvano, F; Giordano, M; Li Volti, G; Malaguarnera, M; Motta, M; Neri, S; Pennisi, M; Vacante, M | 1 |
| Battyáni, Z; Hunyady, B; Kovács, B | 1 |
| Alsiö, A; Buhl, MR; Färkkilä, M; Hellstrand, K; Jannesson, A; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Fouad, YM; Helmy, AK; Ibraheem, H; Khalaf, H; Rady, H | 1 |
| Aberle, J; Ferenci, P; Holzmann, H; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Buti, M; Homs, M | 1 |
| Baron, A; Brochot, E; Capron, D; Castelain, S; Coulouarn, C; Descamps, V; Duchaussoy, I; Duverlie, G; François, C; Nguyen-Khac, E | 1 |
| Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kamatani, N; Nakamura, Y; Ochi, H; Uchiyama, T | 1 |
| Alexander, G; Amirthalingam, G; Andrews, N; Costella, A; Harris, HE; Ramsay, ME | 1 |
| Aoyagi, Y; Enjoji, M; Fujino, T; Fukuda, M; Ishibashi, H; Kohjima, M; Nakamuta, M; Satoh, T; Yatsuhashi, H | 1 |
| Boroń-Kaczmarska, A; Jurczyk, K; Karpińska, E; Laurans, L; Parczewski, M; Wawrzynowicz-Syczewska, M | 1 |
| Botfield, M; de Bruijne, J; Kieffer, TL; Molenkamp, R; Reesink, H; Schinkel, J; Shames, B; Sullivan, JC; Weegink, C | 1 |
| Aulakh, VS; Hoefs, JC; Ilagan, BJ | 1 |
| Nehra, V; Rizza, SA; Talwani, R; Temesgen, Z | 1 |
| Côrtes, R; Diaz, RS; Ferreira, PR; Reis, A; Santos, C; Silva, MH; Tenore, Sde B; Vilhena, C | 1 |
| Kim, R; McEwan, P; Townsend, R; Yuan, Y | 1 |
| Cole, SW; Doho, GH; Felger, JC; Hu, F; Miller, AH; Pace, TW; Raison, CL; Woolwine, BJ | 1 |
| Xue, R | 1 |
| Lei, H; Liu, J; Pu, D; Tao, J | 1 |
| Ishibashi, S; Nagasaka, S; Okada, K; Okada, N; Osuga, J; Sato, S; Sugano, K; Yagyu, H; Yamashita, Y | 1 |
| Ferenci, P; Reddy, KR | 1 |
| Bergin, C; Hennessy, M; Hopkins, S; Kennedy, A; Mulcahy, F; Spiers, JP | 1 |
| Di Martino, V; Kantelip, JP; Monnet, E; Montange, D; Muret, P; Piedoux, S; Piroth, L; Royer, B; Thevenot, T | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Kerschner, H; Popow-Kraupp, T; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P | 1 |
| Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL | 1 |
| Ando, K; Fujinami, A; Fukuda, K; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Komaki, T; Kudo, M; Maekawa, Y; Nagata, Y; Nakajima, T; Ohta, M; Ohtani, A; Otono, Y; Saito, J; Sugimoto, K | 1 |
| El-Shamy, A; Fujinami, A; Hasegawa, Y; Hotta, H; Imoto, S; Kasugai, H; Kawada, T; Kim, KI; Kim, SR; Kimura, N; Komaki, T; Konishi, E; Kudo, M; Makino, T; Morikawa, T; Muramatsu, A; Nagata, Y; Nakajima, T; Nakamura, A; Ohta, M; Saito, J; Sakashita, M; Sasase, N; Sasatani, K; Sugano, M; Tanaka, Y; Tsuchida, S | 1 |
| Lim, JK; Porto, AF; Tormey, L | 1 |
| Cibor, D; Ciećko-Michalska, I; Cieśla, A; Janas-Skulina, U; Mach, TH; Owczarek, D; Warunek, W | 1 |
| Benito, JM; Clark, PJ; Goldstein, DB; McHutchison, JG; Morello, J; Naggie, S; Rallon, NI; Rodriguez-Novoa, S; Shianna, KV; Soriano, V; Thompson, AJ; Vispo, E | 1 |
| Jabłonowska, E; Kur, B; Lewkowicz, P; Nocuń, M; Wójcik, K | 1 |
| Ebinuma, H; Hibi, T; Kanai, T; Ojiro, K; Saito, H; Tada, S; Takayama, T; Wakabayashi, K; Yamagishi, Y | 1 |
| Golik, OO; Konstantinov, DIu; Popova, LL; Suzdal'tsev, AA; Vasil'ev, SIu | 1 |
| Gemovic, B; Glisic, S; Jovanovic Cupic, S; Perovic, V; Prljic, J; Vasiljevic, N; Veljkovic, N; Veljkovic, V | 1 |
| Goulis, I; Karatapanis, S; Ketikoglou, I; Lisgos, P; Papastergiou, V; Saitis, I; Skorda, L; Stampori, M; Tsitsopoulos, E; Tsoplou, P; Vasiageorgi, A | 1 |
| Hidaka, H; Koizumi, W; Minamino, T; Nakazawa, T; Ogasawara, S; Okuwaki, Y; Shibuya, A; Takada, J; Takahashi, A; Tanaka, Y; Watanabe, M | 1 |
| Febles, MH; Hernández, LO; López, MJ; Martínez, ER; Román, JL; Sánchez, CG; Suárez, JM; Vanegas, NO | 1 |
| Fujiwara, K; Imazeki, F; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O | 1 |
| Branch, AD; Gutierrez, JA; Parikh, N | 1 |
| Angarano, G; Antonelli, G; Caporaso, N; Cozzolongo, R; Fasano, M; Gaeta, GB; Giannelli, G; Milella, M; Morisco, F; Santantonio, T; Scagnolari, C; Scotto, G; Soldà, A; Trombetti, S | 1 |
| Alegre, SM; Fioravante, M; Lorena, SL; Marin, DM; Pereira, TS; Soares, EC | 1 |
| Chuang, WL; Huang, CF; Yu, ML | 1 |
| Andreone, P; Gitto, S; Karampatou, A; Villa, E | 1 |
| Bihrer, V; Forestier, N; Kronenberger, B; Piiper, A; Waidmann, O; Zeuzem, S | 1 |
| Calle Serrano, B; Cornberg, M; Manns, MP; Markova, AA | 1 |
| Forestier, N; Zeuzem, S | 2 |
| Kwo, PY | 3 |
| Bacon, BR; Khalid, O | 1 |
| Esteban, R; Shiffman, ML | 1 |
| Lin, F; Reddy, KR; Zoulim, F | 1 |
| Clark, V; Nelson, DR | 1 |
| Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C | 1 |
| Roche, B; Samuel, D | 2 |
| Sulkowski, MS | 4 |
| Mangia, A; Mottola, L | 1 |
| Kumar, CK; Sarin, SK | 1 |
| El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M | 2 |
| Fried, MW; McGowan, CE | 1 |
| Armstrong, MJ; Houlihan, DD; Rowe, IA | 1 |
| Fujiwara, K; Funyu, J; Harada, Y; Koshima, Y; Matsui, A; Mochida, S; Nagoshi, S; Nakamura, I; Nishikawa, K; Saito, A; Sekine, C; Shiomi, M; Sotome, N; Takegoshi, S; Tanaka, M; Toshima, K; Yoshida, T | 1 |
| Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M | 1 |
| Antinori, S; Foschi, A; Galli, M; Mazzali, C; Milazzo, L; Ridolfo, A; Viola, A | 1 |
| Abellán, JJ; Aguilera, V; Berenguer, M; López-Labrador, FX; Ortíz-Cantó, C; Prieto, M; Rubín, A | 1 |
| Aghemo, A; Degasperi, E | 1 |
| Buti, M; Esteban, R; Simón-Talero, M | 1 |
| Bruno, R; Cima, S; Fagiuoli, S; Filice, G; Maiocchi, L; Novati, S; Sacchi, P | 1 |
| Aghemo, A; Prati, GM; Rumi, M | 1 |
| Andreone, P; Camerini, R; Ciancio, A; De Rosa, A; Kaiser, S; Mangia, A; McBeath, R; Milella, M; Pol, S; Rizzetto, M; Solà, R; Tsianos, E | 1 |
| González-Escribano, MF; Jimenez-Jimenez, L; López-Cortés, LF; Marquez-Solero, M; Mata, R; Pineda, JA; Rivero, A; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| De Gottardi, A; Geier, A; Gerlach, T; Heim, M; Helbling, B; Hirschi, C; Negro, F; Stickel, F; Terziroli, B; Wehr, K | 1 |
| Alavian, SM; Behnava, B; Tabatabaei, SV | 1 |
| Hamzeh, FM; Jensen, D; Lentz, E; Reau, N; Zhou, X | 1 |
| Gerken, G; Katsounas, A; Kottilil, S; Lempicki, RA; Polis, M; Schlaak, JF; Trippler, M; Wang, B | 1 |
| Chaudhri, E; Chemello, L; Craxi, A; Diago, M; Faruqi, R; Koutsounas, S; Maticic, M; Ogurtsov, P; Pedicone, LD; Tartaglione, MT; Torras, J; Witthoeft, T; Yu, X; Zuckerman, E | 1 |
| Abe, H; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Miki, D; Nakamura, Y; Ochi, H; Ohishi, W; Tsuge, M | 1 |
| Chang, ML; Cheng, JC; Huang, YH; Liang, KH; Lin, CY; Yeh, CT; Yeh, YJ | 1 |
| Barreiro, P; Labarga, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Bali, D; Cullufi, P; Dervishi, E; Durro, V; Velmishi, V | 1 |
| Ahmad, B; Ali, I; Ali, S; Azam, S; Bashir, S | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Tachi, Y; Toyoda, H; Urano, F; Yoshioka, K | 1 |
| Habalová, V; Kristian, P; Schréter, I; Válková, I | 1 |
| Wirth, S | 1 |
| Dimitrova, DI; Eley, T; Everson, GT; Gardiner, DF; Ghalib, R; Grasela, DM; Guo, T; Lawitz, E; Lok, AS; Martorell, C; McPhee, F; Pasquinelli, C; Persson, A; Reindollar, R; Rustgi, V; Wind-Rotolo, M; Zhu, K | 1 |
| Chan, HH; Chen, WC; Hsu, PI; Lai, KH; Lin, CK; Lin, KH; Tsai, WL; Yu, HC | 1 |
| Allende, H; Bes, M; Campos-Varela, I; Castells, L; Charco, R; Esteban, JI; Esteban, R; Rodríguez-Frías, F; Sapisochin, G | 1 |
| Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Tien, HC; Weng, CH; Yen, CL | 1 |
| Bunchorntavakul, C; Rajender Reddy, K; Tan Dat, H; Thu Thuy, PT | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A; Yatsuhashi, H | 1 |
| Bourlière, M; Doffoël, M; Fagnani, F; Marcellin, P; Ouzan, D; Pawlotsky, JM; Pinta, A; Rosenheim, M; Rouanet, S; Salomon, L; Vray, M | 1 |
| Cabibi, D; Colombo, MP; Craxì, A; Guarnotta, C; Petta, S; Pipitone, R; Tripodo, C | 1 |
| Bolcic, F; Laufer, N; Moretti, F; Quarleri, J; Sede, M; Vazquez, M; Westergaard, G | 1 |
| Baroni, GS; Covolo, L; Faraci, MG; Fattovich, G; Guido, M; Ieluzzi, D; Negro, F; Pasino, M; Passigato, N; Pierantonelli, I; Tonon, A | 1 |
| de Moraes, CF; De Pauli, DS; Grotto, RM; Marangon, AV; Moliterno, RA; Pardini, MC; Sell, AM; Silva, GF; Visentainer, JE | 1 |
| Bezemer, G; de Knegt, RJ; Esteban, JI; Ferrari, C; Hansen, BE; Lagging, M; Lurie, Y; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, SW; Van Gool, AR; Verheij-Hart, E; Zeuzem, S | 1 |
| Antoniazzi, S; Bergasa, NV; Floreani, A; Mescoli, C | 1 |
| Bredi, E; Carcamo, WC; Chan, EK; Colombo, M; Covini, G; von Mühlen, CA | 1 |
| Berenguer, J; Cosín, J; Fernández-Rodríguez, A; Guzmán-Fulgencio, M; Jiménez, JL; López, JC; Micheloud, D; Miralles, P; Muñoz-Fernández, MÁ; Resino, S | 1 |
| Benito, JM; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E | 1 |
| Agarwal, K; Austin, A; Brown, A; Dillon, JF; Foster, GR; Fox, R; Fraser, A; Hayes, PC; Leen, C; Mills, PR; Mutimer, DJ; Ramachandran, P; Ryder, SD | 1 |
| Ali, A; Aparcero, R; Del Campo, JA; Eslam, M; Grande, L; Khattab, MA; Mousa, YI; Romero-Gomez, M; Shaker, Y | 1 |
| Hézode, C; Pawlotsky, JM; Sarrazin, C; Zeuzem, S | 1 |
| Bergmann, JF; Boonstra, A; de Knegt, RJ; Haagmans, BL; Hansen, BE; Janssen, HL; Kwadijk-de Gijsel, S; Roomer, R; van Vuuren, AJ | 1 |
| Baur, K; Bischoff Ferrari, HA; Frei, P; Geier, A; Iwata, R; Mertens, JC; Müllhaupt, B; Schmitt, J; Seifert, B; Stieger, B; von Eckardstein, A | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Hsu, SJ; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, SS | 1 |
| Ceauşu, E; Gheorghe, L; Iliescu, L; Mateescu, B; Micu, L; Mocan, T; Pascu, O; Seicean, A; Voiculescu, M | 1 |
| Ausina Ruiz, V; Martró Català, E; Saludes Montoro, V | 1 |
| Arora, SK; Chawla, YK; Dhiman, R; Duseja, A; Rana, D | 1 |
| Campistol, JM; Esforzado, N | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 4 |
| Afendy, A; Baranova, A; Birerdinc, A; Estep, M; Stepanova, M; Younossi, ZM | 1 |
| Clark, PJ; Kelley, RI; Kratz, LE; McHutchison, JG; Millington, DM; Muir, AJ; Patel, K; Subramanian, M; Thompson, AJ; Tolun, AA; Vock, DM | 1 |
| Azuma, T; Deng, L; El-Shamy, A; Fujisawa, T; Hotta, H; Ide, Y; Imoto, S; Kim, SR; Seo, Y; Shoji, I; Tani, S; Yano, Y; Yoon, S | 1 |
| Karatapanis, S; Lisgos, P; Papastergiou, V; Skorda, L | 1 |
| Dalagiorgou, G; Hatzakis, A; Kakkanas, A; Karamitros, T; Katsoulidou, A; Mavromara, P; Sypsa, V | 1 |
| Clark, PJ; Herrmann, E; Katsounas, A; Kottilil, S; Lempicki, R; Masur, H; McHutchison, JG; Muir, AJ; Naggie, S; Osinusi, A; Patel, K; Polis, MA; Schlaak, JF; Shivakumar, B; Thompson, AJ; Trippler, M | 1 |
| Midena, E; Noventa, F; Sebastiani, G; Tempesta, D; Vujosevic, S | 1 |
| Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH; Zhu, PF | 1 |
| Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM | 1 |
| Barili, V; Fasano, M; Ferrari, C; Missale, G; Molinari, A; Orlandini, A; Penna, A; Pilli, M; Ravanetti, L; Santantonio, T; Zerbini, A | 1 |
| Barnes, E; Brown, A; Christian, A; Collier, JD; Foster, GR; Hibbert, L; Humphreys, IS; Klenerman, P; Rahman, M; von Delft, A | 1 |
| Crespo, G; Lens, S | 1 |
| Aoun, O; Bricaire, F; Mellon, G; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Abe, H; Arihiro, K; Chayama, K; Hayes, CN; Hiraga, N; Hyogo, H; Imamura, M; Kimura, Y; Kohno, T; Miki, D; Ochi, H; Ohnishi, M; Takahashi, S; Tanaka, S; Tsuge, M; Zhang, Y | 1 |
| Cipriano, LE; Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Owens, DK | 1 |
| De Martin, E; Di Paolo, D; Donato, MF; Fagiuoli, S; Farcomeni, A; Giannelli, V; Giusto, M; Iemmolo, RM; Merli, M; Miglioresi, L; Morelli, MC; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R | 1 |
| Ahmad, J; Haider, SI | 1 |
| Hayat, AS; Masood, N; Shaikh, N | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, ZY; Shin, SJ; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Neukam, K; Pineda, JA; Rallón, NI; Restrepo, C; Rivero, A; Soriano, V; Vispo, E | 1 |
| Bai, F; Bellistrì, GM; Borghi, F; Carosi, G; Gatti, F; Marchetti, G; Monforte, Ad; Nasta, P; Puoti, M; Tincati, C | 1 |
| Inage, E; Minowa, K; Naritaka, N; Ohtsuka, Y; Saito, N; Shimizu, T; Suzuki, M; Tokita, A; Tsubahara, M | 1 |
| Dybowska, D; Halota, W; Karwowska, K; Kozielewicz, D | 1 |
| Halota, W; Kozielewicz, D | 1 |
| Fujiyama, S; Haraoka, K; Miyase, S; Morishita, Y; Ouchida, Y | 1 |
| Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA | 1 |
| Beumont, M; Carosi, G; DeMasi, R; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Lonjon-Domanec, I; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L | 1 |
| La Mura, V; Persico, M | 1 |
| Peck-Radosavljevic, M; Reiberger, T | 1 |
| Aronson, SJ; de Bruijne, J; Reesink, HW; Schinkel, J; van der Valk, M; Weegink, CJ | 1 |
| Dusheiko, GM; Tanwar, S; Trembling, PM | 2 |
| Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawabe, J; Kawada, N; Kawamura, E; Kobayashi, S; Kotani, K; Morikawa, H; Shiomi, S; Tamori, A; Tominaga, K | 1 |
| Bellis, L; Dell' Unto, O; Elmo, MG; Guarisco, R; Mitidieri Costanza, O; Puoti, C; Spilabotti, L | 1 |
| Albrecht, JK; Deng, W; González-Peralta, RP; Haber, B; Jonas, MM; Kelly, DA; Lachaux, A; Lang, T; Molleston, JP; Murray, KF; Narkewicz, MR; Noviello, S; Pollack, H; Shelton, M; Sinatra, FR; Te, HS; Wirth, S | 1 |
| Ako, S; Hatamaru, K; Henmi, S; Iguchi, E; Inuzuka, T; Ishikawa, T; Kimura, T; Kita, R; Koshikawa, Y; Matsuda, F; Nakajima, J; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Takeda, H | 1 |
| Fan, XH; Liu, LC; Lu, HY; Shan, Y; Wang, LF; Wei, L; Wu, CH; Xu, XY; Yao, Y | 1 |
| Aichelburg, MC; Breitenecker, F; Ferenci, P; Heil, PM; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scherzer, TM; Schuster, C | 1 |
| Domínguez Muñoz, E; Fernández Castroagudín, J; Molina Pérez, E | 1 |
| Abdallah, N; Arastéh, K; Berger, F; Böcher, W; Cerny, A; de Ledinghen, V; Dikopoulos, N; Gerken, G; Gerlach, T; Girlich, B; Heim, MH; Kukolj, G; Larrey, D; Lohse, AW; Marquis, M; Mathurin, P; Scherer, J; Schuchmann, M; Steffgen, J; Stern, JO; Thimme, R; Tran, A; Trautwein, C; Trepo, C; Wu, K; Zarski, JP | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, B; Kim, CJ; Lee, SJ; Park, BR; Park, NH; Shin, JW | 1 |
| Petta, S | 1 |
| Francque, S; Ho, E; Michielsen, P | 1 |
| Hou, J; Li, J; Li, W; Liu, S; Wang, J; Wu, Y; Zeng, Y; Zhang, J; Zhou, B; Zhou, Y | 1 |
| Baiget, M; Del Mar Gutierrez, M; Domingo, P; Fontanet, A; Guardiola, JM; Lamarca, K; Martin, J; Mateo, MG; Muñoz, J; Pacho, C; Salazar, J; Torres, F; Vidal, F | 1 |
| Aikata, H; Chayama, K; Hiraga, N; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Miki, D; Ochi, H; Ohdan, H; Onoe, T; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Allen, S; Bhattacharyya, D; Bramley, P; Carman, B; Delahooke, TE; Dillon, JF; Goldberg, DJ; Hayes, P; Hutchinson, SJ; Innes, HA; Kennedy, N; Mills, PR; Morris, J; Robertson, C; Stanley, AJ | 1 |
| Gupta, R; Kim, S; Taylor, MW | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Perry, CM | 1 |
| Dallmeier, K; Neyts, J; Paeshuyse, J | 1 |
| Deng, L; El-Shamy, A; Hasegawa, Y; Hotta, H; Ide, YH; Imoto, S; Kim, KI; Kim, SR; Ota, M; Shoji, I; Tanaka, Y | 1 |
| Coenen, M; Eisenhardt, M; Glässner, A; Körner, C; Krämer, B; Nattermann, J; Sauerbruch, T; Spengler, U | 1 |
| Abd-Aalhalim, H; Aly, H; Eslam, M; Khattab, MA; Mousa, YI; Samir, F; Shaker, O; Shaker, Y; Shatat, M | 1 |
| Băţagă, S; Boţianu, AM; Demian, S; Georgescu, D; Macarie, I; Oltean, G | 1 |
| Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakamoto, N; Sho, T; Terashita, K | 1 |
| Daniš, D; Gazdík, F; Gazdíková, K; Hučková, D; Kajaba, I; Okruhlica, L | 1 |
| Blotner, SD; Brennan, BJ; Grippo, JF; Hagedorn, CH; Marbury, TC; Morcos, PN; Morrison, R; Sulkowski, M; Wang, K | 1 |
| Fazio, V; Giannini, EG; Marenco, S; Picciotto, A; Pieri, G; Savarino, V | 1 |
| Altus, R; Gordon, DL; Muller, K; Rodgers, A; Waddell, V; Wigg, A; Wundke, R | 1 |
| Barnard, RJ; Caro, L; Gane, E; Hwang, PM; Lee, AW; Manns, MP; Marcellin, P; Rodriguez-Torres, M; Stoehr, A; Wiedmann, RT; Yeh, CT | 1 |
| Chen, XY; Guo, DD; Huang, YX; Ma, LN; Ren, S; Yin, JM; Zheng, YH | 1 |
| Coppola, N; Pasquale, G; Piccinino, F; Pisaturo, MA; Sagnelli, C; Sagnelli, E | 1 |
| Casey, LC; Lee, WM | 1 |
| Saxena, V; Terrault, N | 1 |
| Hino, K; Hoshino, H; Hosoya, N; Kajiyama, Y; Kikuchi, K; Miyakawa, H; Takai, A | 1 |
| Amur, S; Birnkrant, D; Fleischer, R; Hammerstrom, T; Jadhav, PR; Lewis, L; Liu, J; Naeger, L; O'Rear, J; Pacanowski, M; Robertson, S; Seo, S; Soon, G | 1 |
| Gao, SJ; Jia, YH; Nan, YM | 1 |
| García-Ruiz, I; Gómez-Izquierdo, E; Muñoz-Yagüe, MT; Solís-Herruzo, JA; Solís-Muñoz, P; Valverde, AM | 1 |
| Alshuth, U; Christensen, S; Heyne, R; Hüppe, D; Mauss, S; Möller, B; Niederau, C; Pfaff, R; Theilmeier, A; Zehnter, E | 1 |
| Afdhal, N; Albrecht, JK; Clark, PJ; Esteban, R; Fellay, J; Ge, D; Goldstein, DB; Harrison, SA; Kwo, P; McHutchison, JG; Muir, AJ; Naggie, S; Noviello, S; Patel, K; Pedicone, LD; Shianna, K; Sulkowski, MS; Thompson, AJ; Tillmann, HL; Urban, TJ; Vock, DM; Zhu, M; Zhu, Q | 1 |
| Alavian, SM; Nejad, MR | 1 |
| Burnett, D; Cornett, DD; Lindstrom, MJ; Lucey, MR; Rice, JP; Sawyer, J; Striker, R; Tsotsis, H; Voermans, P | 1 |
| Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM | 1 |
| Aleman, S; Duberg, AS; Josephson, F; Lagging, M; Lindh, M; Weiland, O; Wejstål, R | 1 |
| Amrani, N; Barkat, A; Elmachad, M; Kabbaj, N; Laarabi, FZ; Sefiani, A; Tajir, M | 1 |
| Guarascio, P; Pellicelli, AM; Romano, M; Vignally, P | 1 |
| Afdhal, NH; Lai, M | 1 |
| Bae, SH; Jun, DW; Lee, YJ; Tak, WY | 1 |
| Kim, TY | 1 |
| Cho, KB; Chung, WJ; Hwang, JS; Jang, BK; Kim, ES; Kim, YJ; Park, KS | 1 |
| Adda, N; Adiwijaya, B; Bartels, DJ; Beumont, M; De Meyer, S; Dierynck, I; Dorrian, J; Ghys, A; Jacobson, IM; Jiang, M; Kauffman, RS; Kieffer, TL; Kwong, AD; Picchio, G; Sherman, KE; Spanks, J; Sullivan, JC; Tigges, A; Zeuzem, S; Zhang, EZ | 1 |
| Durmaz, O | 1 |
| Chang, MF; Lim, J; Monto, A; Morgan, TR; Pocha, C; Ross, D; Yee, HS | 1 |
| Aghemo, A; Colombo, M; De Nicola, S; Dongiovanni, P; Fargion, S; Ferenci, P; Maggioni, P; Motta, BM; Rumi, MG; Stättermayer, AF; Valenti, L | 1 |
| Inose, K; Kani, S; Matsuura, K; Mizokami, M; Motojuku, N; Orito, E; Tanaka, Y; Wakimoto, Y; Watanabe, T; Yatsuhashi, H | 1 |
| Chevaliez, S; Pawlotsky, JM; Rodriguez, C | 1 |
| Barritt, AS; Fried, MW | 1 |
| Thompson, AJ | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Ito, K; Masaki, N; Miyagi, Y; Mizokami, M; Nomura, H; Tanimoto, H; Yamashita, N | 1 |
| Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M | 1 |
| Badridze, N; Chkhartishvili, N; Dolmazashvili, E; Dvali, N; Dzigua, L; Gatserelia, L; Gochitashivli, N; Karchava, M; Nelson, K; Sharvadze, L; Tsertsvadze, T; Zhamutashvili, M | 1 |
| Amur, S; Pacanowski, M; Zineh, I | 1 |
| Afendy, A; Baranova, A; Birerdinc, A; Estep, M; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Akkarathamrongsin, S; Komolmit, P; Mahachai, V; Poovorawan, K; Poovorawan, Y; Tangkijvanich, P | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Krastinova, E; Perronne, C; Piroth, L; Pol, S; Quertainmont, Y; Rosenthal, E | 1 |
| Heim, MH | 1 |
| Amemiya, F; Enomoto, N; Inoue, T; Kadokura, M; Kanayama, A; Kitamura, T; Komase, K; Komatsu, N; Maekawa, S; Miura, M; Nakayama, Y; Ohmori, T; Okada, S; Sakamoto, M; Shindo, H; Shindo, K; Sueki, R; Takano, S; Yamaguchi, T | 1 |
| Bjøro, K; Dalgard, O; Eskesen, AN; Melum, E; Moghaddam, A; Ring-Larsen, H; Verbaan, H | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Fishbein, D; Funk, E; Hu, Z; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, M; Poonia, S; Schlaak, J; Trippler, M | 1 |
| Igarashi, T; Inoue, J; Kakazu, E; Kimura, O; Kobayashi, K; Kobayashi, T; Kondo, Y; Miura, M; Ninomiya, M; Shimosegawa, T; Tamai, K; Tanaka, Y; Ueno, Y; Yamamoto, T | 1 |
| Amur, S; Ayala, R; Florian, J; Harrington, P; Jadhav, PR; Mishra, P; Murray, J; O'Rear, J; Pacanowski, M; Robertson, S; Singer, M; Soon, G; Zeng, W | 1 |
| Benhamou, Y; Boyer, N; Carenco, C; Guyader, D; Larrey, D; Marcellin, P; Pageaux, GP; Rouzier, R | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Murata, M; Ogawa, E; Okada, K; Taniai, H; Toyoda, K | 1 |
| Baldanti, F; Fiorina, L; Paolucci, S; Papadimitriou, S | 1 |
| Albrecht, JK; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, MH; Deng, W; DiNubile, MJ; Esteban, R; Gottesdiener, KM; Jacobson, IM; Marcellin, P; Pedicone, LD; Poordad, F; Sulkowski, MS; Zeuzem, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Grancini, V; Orsi, E; Prati, GM; Rumi, MG; Soffredini, R | 1 |
| Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F | 1 |
| Dowling, TC; Fossler, MJ; Howell, CD; Jin, R; McHutchison, JG | 1 |
| Erdem, H; Örmeci, N | 1 |
| Blum, HE; Neumann-Haefelin, C; Thimme, R | 1 |
| Alsiö, Å; Askarieh, G; Buhl, MR; Christensen, PB; Färkkilä, M; Haagmans, BL; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Nasic, S; Norkrans, G; Pedersen, C; Rembeck, K; Westin, J | 1 |
| Aziz, H; Gill, ML; Gill, U; Raza, A; Waheed, Y | 1 |
| Künzler-Heule, P; Panfil, EM | 1 |
| Bukh, J; Christensen, PB; Krarup, HB; Krogsgaard, K; Laursen, AL; Madsen, PH; Orholm, M; Pedersen, C; Ring-Larsen, H; Schlichting, P | 1 |
| Dieterich, D; Poordad, F | 1 |
| Bellia, C; Cabibi, D; Cammà, C; Caruso, A; Ciaccio, M; Craxì, A; Di Marco, V; Mazzola, A; Petta, S | 1 |
| Bibert, S; Bochud, PY; Guedj, H; Guedj, J; Lagging, M; Negro, F; Neumann, AU; Westin, J | 1 |
| McCaughan, GW | 1 |
| Dore, GJ | 1 |
| Gold, J; Hellard, ME; Hickman, M; Higgs, P; Jenkinson, R; Martin, NK; Sacks-Davis, R; Stoové, MA; Vickerman, P | 1 |
| Amin, J; Dore, GJ; George, J; Gidding, HF; Haber, PA; Law, MG; Macdonald, GA; Ostapowicz, G; Sasadeusz, JJ; Weltman, M | 1 |
| Baumert, TF; Dill, MT; Duong, FHT; Filipowicz, M; Heim, MH; Makowska, Z; Merkofer, F; Terracciano, L; Tornillo, L | 1 |
| Barut, S; Erkorkmaz, U; Günal, O | 1 |
| Bolcic, F; Cassino, L; Laufer, N; Quarleri, J; Reynoso, R; Torres, C | 1 |
| Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Naishadham, D; Shiffman, ML; Szabo, G; Wright, EC | 1 |
| Alves, A; Cardoso, C; Freire, R; Oliveira, A | 1 |
| Bashir, S; Hamid, S; Mirza, S; Siddiqui, AR; Umar, M | 1 |
| Allwinn, R; Berger, A; Peiffer, KH; Perner, D; Sarrazin, C; Susser, S; Vermehren, J; Zeuzem, S | 1 |
| Adamek, A; Bereszyńska, I; Bura, A; Bura, M; Czajka, A; Hryckiewicz, K; Kowala-Piaskowska, A; Mozer-Lisewska, I | 1 |
| Cheinquer, H; Curescu, M; Dusheiko, GM; Ferenci, P; Horban, A; Jensen, D; Lengyel, G; Mangia, A; Marcellin, P; Ouzan, D; Puoti, M; Rizzetto, M; Rodriguez-Torres, M; Schmitz, M; Shiffman, ML; Tatsch, F | 1 |
| Palmer, M; Rubin, R; Rustgi, V | 1 |
| Amanzada, A; Lindhorst, A; Mihm, S; Moriconi, F; Ramadori, G; Schneider, S; Suermann, T; van Thiel, DH | 1 |
| Dimitroulopoulos, D; Karatapanis, S; Ketikoglou, I; Kostas, N; Lisgos, P; Papastergiou, V; Skorda, L | 1 |
| Cai, Q; Gao, Z; Guo, X; Peng, L; Xie, J; Zhang, X; Zhao, Z | 1 |
| Abrams, GA; Bräu, N; Bronowicki, JP; Diva, U; Everson, GT; Ghalib, RH; Hernandez, D; Hézode, C; Hindes, R; Hughes, EA; Lim, JK; Martorell, C; McPhee, F; Morris, DW; Pol, S; Reindollar, RW; Rustgi, VK; Schnittman, S; Tatum, HA; Thuluvath, PJ; Wind-Rotolo, M; Yin, PD | 1 |
| El Saadany, S; Enaba, M; Ghazy, M; Hasan, A; Ziada, DH | 1 |
| Bailly, F; Zoulim, F | 1 |
| Barreiro, P; Benito, JM; Labarga, P; Rallon, NI; Soriano, V; Vispo, E | 1 |
| Katsounas, A; Kottilil, S; Lempicki, RA; Masur, H; Murphy, AA; Osinusi, A; Polis, M; Rasimas, J; Raza, H; Rosenstein, D; Yang, J | 1 |
| Liu, GW; Ma, SP; Wang, CF; Zhao, WX | 1 |
| Boyer, N; Castelnau, C; Marcellin, P; Martinot-Peignoux, M; Ripault, MP; Stern, C; Valla, D | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Arakaki, RF; Sarasombath, O; Suwantarat, N; Tice, AD | 1 |
| Dieterich, D; Ladd, AM; Martel-Laferriere, V | 1 |
| Chen, YH; Chiou, YL; Ke, T; Ko, WS | 1 |
| Evon, DM; Hoofnagle, JH; Jiang, Z; Sarkar, S; Wahed, AS | 1 |
| Bourlière, M; Le Folgoc, G; Lecomte, L; Wartelle-Bladou, C | 1 |
| Berg, T; Biermer, M; Brodzinski, A; Fülöp, B; Heyne, R; Keller, K; Sarrazin, C; Schlosser, B; van Bömmel, F | 1 |
| Adinolfi, LE; Barillari, M; Costa, G; Marrone, A; Zampino, R | 1 |
| Bani-Sadr, F; Dominguez, S; Garraffo, R; Izopet, J; Pambrun, E; Peytavin, G; Poizot-Martin, I; Salmon, D; Solas, C; Winnock, M | 1 |
| Kishikawa, T; Koike, K; Minami, T; Sato, M; Tateishi, R; Yoshida, H | 1 |
| Campbell, SA; Tirado, CF; Weinrieb, RM; Zickmund, SL; Zook, CL | 1 |
| Fujisaki, S; Goto, H; Hibino, Y; Hirashima, N; Iwase, H; Kamiya, A; Ryuge, N; Saito, M; Shimada, M; Sugiura, W; Tamaki, D; Tsuzuki, T; Yokoi, M; Yokomaku, Y | 1 |
| Barsic, B; Dusek, D; Gorenec, L; Grlgic, I; Kurelac, I; Lepej, SZ; Papic, N; Vince, A | 1 |
| Bartels, DJ; Beumont, M; Daems, B; De Meyer, S; Dierynck, I; Ghys, A; Kieffer, TL; Picchio, G; Sullivan, JC; Van Baelen, B; Zeuzem, S | 1 |
| Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E | 1 |
| Badenhoop, K; Berg, T; Bibert, S; Bochud, PY; Bojunga, J; Burgisser, P; Cerny, A; Dufour, JF; Geier, A; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Müller, T; Negro, F; Regenass, S; Sarrazin, C; Zeuzem, S | 1 |
| Dixit, NM; Krishnan, SM | 1 |
| Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M | 1 |
| Ito, K; Masaki, N; Miyagi, Y; Mizokami, M; Nomura, H; Shibuya, T; Tanimoto, H; Yamashita, N | 1 |
| Al-Osaimi, AM; Brown, RS; Everhart, JE; Everson, GT; Gillespie, BW; Kulik, LM; Lok, AS; Rodrigo, del R; Saab, S; Shiffman, ML; Terrault, NA | 1 |
| Aghemo, A; Colombo, M; Galmozzi, E | 1 |
| El-Dessouki, A; Sadik, NA; Shaker, OG | 1 |
| Chen, YP; Fan, YC; Lin, XF; Liu, WY; Shi, KQ; Zheng, MH | 1 |
| Arndt, S; Braunschweiger, I; Langhans, B; Nattermann, J; Nischalke, HD; Sauerbruch, T; Spengler, U | 1 |
| Atsukawa, M; Fukuda, T; Itokawa, N; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A | 1 |
| Antonaci, S; Antonelli, G; Carducci, A; Giannelli, G; Mazzarelli, C; Monteleone, K; Picardi, A; Pizzigallo, E; Riva, E; Scagnolari, C; Selvaggi, C; Vincenzi, B | 1 |
| Bernabucci, V; Cammà, C; De Maria, N; Di Leo, A; Enea, M; Ferrari, A; Francavilla, A; Gitto, S; Karampatou, A; Lei, B; Losi, L; Rendina, M; Vignoli, P; Villa, E; Vukotic, R | 1 |
| Buti, M; Deltenre, P; Deuffic-Burban, S; Hatzakis, A; Mathurin, P; Moreno, C; Mühlberger, N; Parkes, J; Rosenberg, W; Siebert, U; Stroffolini, T; Zeuzem, S | 1 |
| Burton, MJ; McGuire, BM; Passarella, MJ | 1 |
| Chikazawa, Y; Fujimoto, K; Imura, J; Kimura, S; Nakagawa, M; Okuyama, H; Yamaya, H; Yokoyama, H | 1 |
| Liu, N; Liu, P; Sun, C; Wen, Y | 1 |
| Aspinall, E; Doyle, JS; Hellard, ME; Liew, D; Thompson, AJ | 1 |
| Gao, ZL; Guo, XY; Lin, BL; Wang, GS; Xie, DY; Xie, JQ; Zhang, XH; Zhao, ZX | 1 |
| Fan, XH; Huo, N; Lu, HY; Tian, D; Wang, LF; Wei, L; Wu, CH; Xu, XY; Zheng, YY | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Hiramine, S; Ihara, T; Ikezaki, H; Kainuma, M; Kajiwara, E; Mukae, H; Murata, M; Ogawa, E; Okada, K; Sudoh, M; Taniai, H; Toyoda, K | 1 |
| Naveau, S; Perlemuter, G; Voican, CS | 1 |
| Bourlière, M; Bronowicki, JP; Delasalle, P; Leroy, V; Pageaux, GP; Pariente, A; Pol, S; Serfaty, L; Zoulim, F | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, SS | 1 |
| Azuma, T; El-Shamy, A; Fujisawa, T; Hamano, K; Hayashi, Y; Hirohata, S; Hotta, H; Kato, H; Kawara, A; Kitagaki, K; Kitajima, N; Maeda, T; Miki, A; Nakashima, T; Ouchi, S; Oya, M; Saito, M; Seo, Y; Tani, S; Yamada, H; Yamashita, Y; Yano, Y; Yoon, S; Yu, H | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lin, SC; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, MF; Yen, YH | 1 |
| Houlihan, DD; Mutimer, DJ; Rowe, IA | 1 |
| Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM | 1 |
| Grammatikos, G; Vermehren, J; Zeuzem, S | 1 |
| Baik, SJ; Cho, MS; Kim, TH; Moon, IH; Yoo, K | 1 |
| Jabłonowska, E; Koślińska-Berkan, E; Omulecka, A; Piekarska, A; Szymańska, B; Wójcik, K | 1 |
| Hussain, S; Kazmi, AR; Malik, SA; Mustafa, M; Naeem, M; Qureshi, S | 1 |
| Chary, A; Holodniy, M; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, MA; Winters, MA | 1 |
| Chang, CK; Hsieh, YH; Hung, TH; Lai, NS; Tseng, CW; Tseng, KC; Wu, SF | 1 |
| Dusheiko, G; Wedemeyer, H | 1 |
| Diago, M; Hadziyannis, S; Harrison, SA; Jensen, DM; Marcellin, P; Messinger, D; Reddy, KR; Rizzetto, M; Roberts, SK; Tatsch, F; Weltman, M | 1 |
| Drexler, DM; Grace, JE; Wei, C; Zvyaga, TA | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Schmied, B; Sieghart, W; Trauner, M | 1 |
| Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN | 1 |
| Beaumont, M; Garg, V; Kauffman, RS; van Heeswijk, RP | 1 |
| Azzouz, MM; El Bouchtili, S; Hamzaoui, L; Mahmoudi, M; Siai, K | 1 |
| Haruna, Y; Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H | 1 |
| Brjalin, V; Kuznetsova, T; Priimägi, L; Salupere, R; Tallo, T; Tefanova, V | 1 |
| Aizawa, N; Enomoto, H; Iijima, H; Imanishi, H; Iwata, Y; Kuga, C; Matsuda, F; Nakamura, H; Nishiguchi, S; Saito, M; Shimomura, S; Tanaka, H; Tanaka, Y; Torii, Y; Tsutsui, H | 1 |
| Berak, H; Bukowska-Ośko, I; Caraballo Cortés, K; Fic, M; Horban, A; Laskus, T; Pawełczyk, A; Radkowski, M | 1 |
| Hu, YJ; Li, QR; Tan, ZX; Wang, XH; Xiong, YL; Yuan, J; Zhang, CJ; Zhu, Y | 1 |
| Li, MY; Yuan, XL; Zhang, DZ | 1 |
| Gafter-Gvili, A; Goldvaser, H; Katz, LH; Tur-Kaspa, R | 1 |
| Chang, MH; Fung, HB; Gordon, LA | 1 |
| Hagiwara, H; Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurokawa, M; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshihara, H | 1 |
| Abdallah, el S; Ahmed, R; Ahmed, Sel-D; Darwish, T; Omar, D; Sabry, D; Salama, H | 1 |
| Abe, M; Furukawa, S; Hiasa, Y; Hirooka, M; Kumagi, T; Matsuura, B; Miyake, T; Miyaoka, H; Onji, M; Tokumoto, Y; Ueda, T; Watanabe, T; Yamamoto, S | 1 |
| Huang, P; Xiong, QF; Yang, YF; Zhong, YD | 1 |
| Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A | 1 |
| Araki, M; Kawazoe, T; Lin, Y; Murata, M; Ogawa, M; Okamoto, T; Wakakura, M; Yamamura, T | 1 |
| Cattaneo, D; Cheli, S; Clementi, E; Colella, E; Ferraris, L; Gervasoni, C; Milazzo, L | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kobayashi, T; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Clotet, B; Franco, S; Martinez, MA; Tural, C | 1 |
| Bilasy, SE; Deng, L; El-Akel, W; El-Raziky, M; El-Shamy, A; Esmat, G; Hotta, H; Jiang, DP; Shoji, I | 1 |
| Cohen, J | 2 |
| Frolov, VM; Sotskaia, IaA | 1 |
| Chen, CH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JH | 1 |
| Bociąga-Jasik, M; Cibor, D; Cieśla, A; Głowacki, MK; Mach, T; Owczarek, D; Sanak, M; Sobczyk-Krupiarz, I | 1 |
| Alfaleh, FZ; Alghamdi, AS; Alghamdi, H; Alqutub, A; Alswat, K; Altraif, I; Ismail, M; Sanai, FM; Shah, H | 1 |
| Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA | 1 |
| Lilea, GC; Rogoveanu, I; Streba, CT; Vere, CC | 1 |
| Arai, M; Fujiwara, K; Imazeki, F; Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O | 1 |
| Fleckenstein, JF; Madey, MA; Mahmoudi, TM; Marion, TN; Schechtman, KB; Weintraub, SJ | 1 |
| Sadik, NA; Shaker, OG | 1 |
| Ouzan, D | 1 |
| Andrade, LE; Chan, EK; Ferraz, ML; Granato, C; Keppeke, GD; Nunes, E; Silva, EA | 1 |
| Ding, Y; Jia, Z; Jiang, J; Niu, J; Tian, S | 1 |
| Abe, H; Chayama, K; Hayashida, Y; Kamatani, N; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T | 1 |
| Arnsten, JH; Jefferson, KS; Litwin, AH; Roose, RJ; Soloway, IJ; Stein, MR | 1 |
| Chiba, T; Haga, H; Kawabata, H; Nishida, N; Takahashi, K | 1 |
| Alves, AL; Augusto, F; Cardoso, C; Freire, R; Gonçalves, M; Oliveira, AP; Quintana, C | 1 |
| Kondo, Y; Shimosegawa, T; Ueno, Y | 1 |
| Debbiche, A; Fenniche, S; Kerkeni, N; Marrak, H; Mlika, RB; Mokhtar, I | 1 |
| Chandy, GM; Conjeevaram, H; Jothimani, D | 1 |
| Aziz, S | 1 |
| Devrajani, BR; Kalhoro, M; Shaikh, S | 1 |
| Albrecht, JK; Bacon, BR; Barnard, RO; Bourlière, M; Brass, CA; Burroughs, MH; Flamm, SL; Goteti, V; Hezode, C; Howe, JA; Jacobson, I; Lawitz, E; Niederau, C; Pedicone, LD; Poordad, F; Sherman, M; Sings, HL; Vierling, JM | 1 |
| Dou, XG; Han, F; Zhang, D; Zhang, L | 1 |
| Adams-Huet, B; Attar, N; Jain, MK; Lee, WM; Petersen, T; Yuan, H | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Bronowicki, JP; Burroughs, MH; Harrison, SA; Jacobson, IM; Koury, KJ; Manns, MP; Pedicone, LD; Poordad, F; Rajender Reddy, K; Sings, HL; Sniukiene, V; Sulkowski, MS | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Afridi, MS; Slim, J | 1 |
| Ahola, T; Kaukinen, P | 1 |
| Tai, YK; Tsai, CY; Wu, CS | 1 |
| Cai, L; Dowling, TC; Howell, CD; Jin, R; McHutchison, JG; Tan, M | 1 |
| Jang, JY; Jeong, SW; Kim, BS; Kim, Hi; Kim, HS; Kim, SG; Kim, SH; Kim, YS; Lee, SW; Park, SS; Seo, YR; You, BC | 1 |
| Chung, WJ | 1 |
| Barreiro, P; Soriano, V; Vispo, E | 1 |
| Bijedic, N; Husic-Selimovic, A; Huskic, J; Vukobrat-Bijedic, Z | 1 |
| Aghemo, A; Colombo, M; Degasperi, E; Ferrari, B; Lotta, LA; Peyvandi, F | 1 |
| Abdel-Aziz, A; Besheer, T; Elbendary, A; Gad, Y; Mokbel, T; Mousa, N | 1 |
| Bartalesi, F; Bartoloni, A; Cavallo, A; Corti, G; Pimpinelli, N; Salomoni, E; Taliani, G | 1 |
| Chen, SW; Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Yen, CL | 1 |
| Ampuero, J; Conde, M; Del Campo, JA; García-Lozano, JR; García-Valdecasas, M; González-Escribano, MF; Maraver, M; Millán, R; Rojas, A; Rojas, L; Romero-Gómez, M | 1 |
| Hashimoto, K; Nagao, Y; Sata, M | 1 |
| Iijima, S; Iio, E; Kakuni, M; Kohara, M; Matsuura, K; Mizokami, M; Murakami, S; Shimada, T; Sugauchi, F; Sugiyama, M; Tanaka, Y; Watanabe, T; Yatsuhashi, H | 1 |
| Derbala, MF; Rizk, NM | 1 |
| Abe, H; Agata, R; Aizawa, Y; Fujise, K; Ika, M; Matsudaira, H; Nagatsuma, K; Namiki, Y; Shimada, N; Tada, N; Tsubota, A; Yoshizawa, K; Yumoto, Y | 1 |
| Awad, AB; Awad, T; Doss, W; El-Akel, W; Mabrouk, M; Radwan, A; Zayed, N | 1 |
| Jin, C; Ling, Z; Luo, Y; Mou, X; Xiang, C; Zhang, Q | 1 |
| Boonstra, A; Claassen, MA; de Knegt, RJ; Groothuismink, ZM; Janssen, HL; Turgut, D | 1 |
| Akahoshi, T; Fukuhara, T; Furusyo, N; Hayashi, J; Ikegami, T; Maehara, Y; Motomura, T; Shirabe, K; Soejima, Y; Tomikawa, M; Yoshizumi, T | 1 |
| Haroon, W; Husain, A; Khan, Z; Mirza, SA; Nazir, L; Shaikh, MI | 1 |
| Coelho, HS; Hoffmann, L; Perez, Rde M; Ramos, AL; Ramos, JA; Rondinelli, E; Silva, R; Urményi, TP; Villela-Nogueira, CA | 1 |
| Dumortier, J; Gagnieu, MC; Guillaud, O; Janbon, B; Juillard, L; Leroy, V; Morelon, E | 1 |
| Brjalin, V; Jõeste, E; Lapidus, N; Prikk, K; Salupere, R; Tefanova, V | 1 |
| Andreoli, A; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Furlan, C; Gentilucci, UV; Marignani, M; Mastropietro, C; Mazzoni, E; Mecenate, F; Miglioresi, L; Mitidieri, O; Monarca, R; Nosotti, L; Pellicelli, AM; Picardi, A; Puoti, C; Romano, M; Stroffolini, T; Vignally, P | 1 |
| Fan, XH; Lu, HY; Wang, LF; Wei, L; Wu, CH; Xu, XY; Yao, Y; Zheng, YY | 1 |
| Adda, N; Bartels, DJ; Bengtsson, L; Gritz, L; Jacobson, IM; Kauffman, RS; Kieffer, TL; Luo, D; Picchio, G; Tomaka, F | 1 |
| Cooper, C; Druyts, E; El Khoury, AC; Lester, R; Mills, EJ; Thorlund, K; Yaya, S | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kojima, T; Kumada, T; Kuzuya, T; Matsushita, T; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K | 1 |
| Aoyagi, Y; Enjoji, M; Fujino, T; Fukuizumi, K; Fukushima, N; Harada, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M; Sakamoto, N; Tanaka, Y; Yada, M; Yada, R; Yoshimoto, T | 1 |
| Bochud, PY; Clément, S; Conzelmann, S; Dill, MT; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pascarella, S; Pawlotsky, JM; Rubbia-Brandt, L; Zeuzem, S | 1 |
| Drago, F; Javor, S; Parodi, A | 1 |
| Hung, DZ; Liao, WL; Lim, YP; Peng, CY; Tien, N; Tsai, FJ; Wan, L | 1 |
| Choi, DJ; Ha, MS; Jung, YK; Kim, JH; Kim, JS; Kim, YS; Kwon, OS; Lee, JW; Park, SY; Rim, MY; Yo, IK | 1 |
| Chen, JY; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Sheen, IS | 1 |
| Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Iwakiri, K; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A | 1 |
| Doyle, JS; Hellard, ME; Shiell, AM; Visconti, AJ; Weir, A | 1 |
| Jacobson, IM; Jesudian, AB | 2 |
| Burton, JR; Everson, GT | 1 |
| Button, P; Cheng, WS; Crawford, DH; Dore, GJ; George, J; Kitson, MT; McCaughan, GW; Roberts, SK; Sievert, W; Weltman, MD | 1 |
| Albanis, E; Berrey, MM; Cornpropst, MT; Dejesus, E; Hebner, CM; Jiang, D; Kowdley, KV; Lalezari, J; Lawitz, E; Mader, M; McHutchison, JG; Nelson, DR; Rodriguez-Torres, M; Symonds, WT | 1 |
| Gane, E | 3 |
| Andriulli, A; Bossa, F; Fontana, R; Iacobellis, A; Ippolito, A; Niro, G; Spirito, F; Terracciano, F; Valvano, MR | 1 |
| Chayama, K; Hayes, CN; Kawakami, Y; Ohishi, W | 1 |
| Li, XH; Xie, DY; Xie, JQ; Xu, QH; Zhang, XH | 1 |
| Cheng, J; Li, MH; Lu, Y; Qiu, GH; Shen, G; Xie, Y; Xu, DZ; Yang, M; Zhang, L; Zhang, YL; Zhao, H | 1 |
| Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Leroy, V; Marcellin, P; Pérusat, S; Poynard, T; Trimoulet, P | 1 |
| Becker, PP; Dill, MT; Dufour, JF; Geier, A; Manser, CN; Moradpour, D; Müllhaupt, B; Rau, M; Russmann, S; Schmitt, J; Semela, D; Stickel, F; Weisskopf, M | 1 |
| Benguria, A; Benito, JM; Fiorante, S; Garcia, MI; Lopez-Fernandez, LA; Rallon, NI; Soriano, V | 1 |
| Doyle, JS; Hellard, ME; Thompson, AJ | 1 |
| Sarrazin, C; Vermehren, J | 1 |
| Terrault, N | 2 |
| Aghemo, A; Degasperi, E; Facchetti, F; Galmozzi, E; Lampertico, P | 1 |
| Kumada, T; Tada, T; Toyoda, H | 1 |
| Cheng, ML; Liu, SD; Ren, H; Shu, DY; Yang, QK | 1 |
| Furusyo, N; Hayashi, J; Ogawa, E | 1 |
| Lago, P; Pedroto, I; Salgueiro, P | 1 |
| Izumi, N; Kurosaki, M; Suzuki, S; Tamaki, N | 1 |
| Burra, P; Cescon, M; Donato, MF; Fagiuoli, S; Gasbarrini, A; Iemmolo, RM; Merli, M; Miglioresi, L; Milani, A; Paolo, DD; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R; Zaccaria, R | 1 |
| Abboud, D; Alideeb, S; Antaki, N; Asaad, F; Baroudi, O; Bibert, S; Bochud, PY; Hadad, M; Kebbewar, K; Negro, F; Sabah, H | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Trauner, M | 1 |
| Almeida, C; Benito, JM; Camacho, A; Caruz, A; Di Lello, FA; Herrero, R; Macías, J; Neukam, K; Pineda, JA; Rallón, NI; Rivero, A; Rivero-Juárez, A; Soriano, V | 1 |
| Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S | 1 |
| Berg, T; Böcher, WO; Ehrlich, A; Eisenbach, C; Galle, PR; Gösseringer, R; Günther, R; Kittner, JM; Klass, DM; Neumann, K; Schlaak, JF; Schuchmann, M; Sprinzl, MF; Trautwein, C; Wachtlin, D; Zeuzem, S; Zimmermann, T | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Juo, SH; Kao, JH; Lin, ZY; Liu, CH; Tseng, TC; Wang, LY; Yeh, ML; Yu, ML | 1 |
| Albert, J; Bojunga, J; Dultz, G; Forestier, N; Friedrich-Rust, M; Gaus, A; Gerber, L; Herrmann, E; Poynard, T; Sarrazin, C; Schneider, MD; Zeuzem, S | 1 |
| Enomoto, N; Hashimoto, S; Imazeki, F; Inao, M; Inoue, T; Izumi, N; Kaito, M; Kudo, M; Mochida, S; Nishiguchi, S; Tanaka, A; Tsuchiya, K; Ueda, T; Yatsuhashi, H; Yokosuka, O | 1 |
| Everhart, JE; Wright, EC | 1 |
| González Díaz, P; López Peláez, MV; Téllez Molina, MJ; Vergas García, J | 1 |
| Lange, CM | 1 |
| Hou, W; Lu, W; Ma, P; Song, SD; Wang, L; Yang, JM | 1 |
| Amaral, KM; Artico, S; Gonçalves, CB; Picon, PD | 1 |
| Mangia, A; Mottola, L; Piazzolla, V | 1 |
| Chmura, A; Cieciura, T; Lisik, W; Pacholczyk, M; Tronina, O; Wasiak, D; Łągiewska, B | 1 |
| Aghemo, A; Altamura, AC; Cavallaro, F; Colombo, M; Dell'Osso, B; Palazzo, MC; Prati, G; Rumi, MG | 1 |
| Cresseri, D; Donato, MF; Fabrizi, F; Fogazzi, GB; Martin, P; Messa, P; Passerini, P | 1 |
| Churchill, ND; King, D; Kowala-Piaskowska, A; Lin, DM; Machaj, A; Michalak, TI; Mozer-Lisewska, I; Mulrooney-Cousins, PM; Pazgan-Simon, M; Pham, TN; Reddy, SB; Simon, K; Zalewska, M | 1 |
| Bernstein, B; Cohen, DE; Heckaman, M; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R | 1 |
| Berrey, MM; Ding, X; Gane, EJ; Hindes, RG; Hyland, RH; Stedman, CA; Svarovskaia, E; Symonds, WT | 1 |
| Guo, Z; He, X; Kong, Y; Liang, W; Ling, X; Schroder, PM; Shang, Y; Wang, X | 1 |
| Maasoumy, B; Manns, MP | 1 |
| Chopra, A; Drinnan, T; Klein, PL; Lee, SS | 1 |
| Aghemo, A; Grassi, E | 1 |
| Bourlière, M; Bronowicki, JP; Fontaine, H; Hézode, C; Pol, S; Wendt, A | 1 |
| Han, J; Hoop, R; Jacobson, I; Korner, EJ; LaFleur, J; Martin, P; Pandya, P; Talal, AH | 1 |
| Cheng, ML; Liu, XF; Wang, J; Zeng, AP | 1 |
| Boonstra, A; de Knegt, RJ; Groothuismink, ZM; Hotho, DM; Janssen, HL; Kreefft, K | 1 |
| Asahina, Y; Enomoto, N; Izumi, N; Kurosaki, M; Maekawa, S; Matsuura, K; Mizokami, M; Nakagawa, M; Nishida, N; Sakamoto, M; Sakamoto, N; Tanaka, Y; Tokunaga, K; Watanabe, M | 1 |
| Keicher, C; Kraus, MR; Porst, H; Schäfer, A; Scheurlen, M; Sprinzl, K; Teuber, G; Wollschläger, S | 1 |
| Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Grimaudo, S; Pipitone, RM | 1 |
| Agrati, C; Bonnafous, C; Capobianchi, MR; Cimini, E; D'Offizi, G; Martini, F; Sicard, H; Vlassi, C | 1 |
| Kim, KA | 1 |
| Domagalski, K; Grzybowski, T; Halota, W; Linkowska, K; Pawłowska, M; Pilarczyk, M; Smukalska, E; Tretyn, A | 1 |
| Chazouillères, O; Pascale, A; Serfaty, L | 1 |
| Hige, S; Ikehara, Y; Ito, K; Kage, M; Kuno, A; Matsuda, A; Mizokami, M; Narimatsu, H; Sakamoto, M; Sekiya, S; Tanaka, Y | 1 |
| Choi, DJ; Jeong, SH; Jung, YK; Kim, JH; Kim, JW; Kim, YS; Kwon, OS; Park, SJ; Yang, JW | 1 |
| Kim, R; McEwan, P; Yuan, Y | 1 |
| Hadziyannis, SJ; Sevastianos, V | 1 |
| Chien, RN; Hu, CC | 1 |
| Abdel Aziz, AO; Abdelhafez, TH; Bader El Din, NG; El Awady, MK; El Hosary, Y; El Khayat, H; Salama, M; Tabll, A | 1 |
| Chen, Q; Chen, W; Gu, L; Liang, B; Su, L; Tan, J; Tang, N; Wu, G; Wu, P; Xie, J; Yan, Y | 1 |
| Chuang, WL; Dai, CY; Huang, JF; Yu, ML | 1 |
| Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S | 1 |
| Cai, W; Fu, Y; Guo, P; Hu, F; Qin, A; Tang, X; Xu, M; Yan, D; Yang, Q; Zhou, J | 1 |
| Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Laires, PA | 1 |
| Chen, YC; Cooper, C; Dickson, R; Jensen, D; Kulkarni, R; Lou Munson, M; Najera, I; Pockros, PJ; Ramji, A; Taylor, R; Thommes, J; Tice, A; Tsai, N; Vierling, JM | 1 |
| Asselah, T; Bessone, F; Böcher, WO; Datsenko, Y; Fainboim, H; Ferenci, P; Heo, J; Kukolj, G; Lalezari, J; Leggett, B; Mauss, S; Nehmiz, G; Scherer, J; Steinmann, GG; Stern, JO; Sulkowski, MS | 1 |
| Ali, RM; Arafa, MM; El-Alfy, HA; El-Etreby, S; Eldeek, BS; Farag, RE; Goda, IF; Saudy, NS | 1 |
| Naggie, S | 1 |
| Comee, MK; Malloy, M; Silva, M; Sitole, M; Spooner, L | 1 |
| Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Handberg, A; Macaluso, FS; Marchesini, G; Petta, S | 1 |
| Sönnerborg, A; Stenkvist, J; Weiland, O | 1 |
| Heil, EL; Hynicka, LM | 1 |
| Chen, Y; Guo, LL; He, LL; Lei, BJ; Lei, XZ; Liu, K; Xu, H | 1 |
| Alvarez-Pellicer, J; Barquilla, E; Barros, C; Bellón, JM; Berenguer, J; Carrero, A; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jusdado, JJ; López-Aldeguer, J; Mallolas, J; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Tural, C; Van Den Eynde, E; Von Wichmann, MA | 1 |
| Deng, H; Ji, F; Li, Z; Zhang, S | 1 |
| Szabó, A; Tusnádi, A | 1 |
| Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M | 1 |
| Abdalla, A; Ahlenstiel, G; Dahari, H; Doo, E; Edlich, B; Feld, JJ; Gara, N; Ghany, MG; Guedj, J; Han, H; Heller, T; Hogdal, L; Hoofnagle, JH; Koh, C; Liang, TJ; Noureddin, M; Park, SH; Park, YJ; Perelson, AS; Rehermann, B; Rotman, Y; Sarkar, S; Thomas, E; Titerence, R; Witthaus, M | 1 |
| El Raziky, M; El-Shehaby, A; Fayez, S; Marzouk, S; Shaker, O; Zahra, A | 1 |
| Davis, GL | 6 |
| Brochier, J; Flexman, J; French, MA; Jeffrey, GP; Keane, NM; Lee, S; Macquillan, GC; Price, P | 1 |
| Barbui, A; Bobbio, A; David, E; Fadda, M; Franchello, A; Lavezzo, B; Ottobrelli, A; Rizzetto, M; Salizzoni, M; Smedile, A; Torrani, M; Zamboni, F | 1 |
| Bizollon, T; Trepo, C | 1 |
| Cano, Y; Guyader, D; Poinsignon, Y; Saout, L | 1 |
| Bernard, N; Dupon, M; Fleury, H; Galperine, T; Houghton, M; Lacut, JY; Lafon, ME; Le Bail, B; Legrand, E; Moreau, JF; Neau, D; Pitard, V; Ragnaud, JM; Schvoerer, E; Trimoulet, P | 1 |
| Bruno, R; Filice, G; Puoti, M; Sacchi, P; Soriano, V | 1 |
| Akremi, R; Benhamou, JP; Bourliere, M; Ibrahim, A; Katz, GG; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH; Spircu, T | 1 |
| Gitlin, N | 1 |
| Akbar, HO | 2 |
| Perlemuter, G | 1 |
| Lucidarme, D | 1 |
| Gervais, A | 1 |
| Boyer, N; Marcellin, P | 1 |
| Bernard, O | 1 |
| Cacoub, P | 1 |
| Bronowicki, JP | 1 |
| Zoulim, F | 1 |
| Hilleret, MN; Leroy, V | 1 |
| Bourlière, M; Halfon, P; Portal, I | 1 |
| Couzigou, P | 1 |
| Perronne, C | 1 |
| Larrey, D | 1 |
| Trépo, C | 1 |
| Gournay, J; Richou, C | 1 |
| Durand, F | 1 |
| Bernard, D; Colle, I; De Vos, M; Delanghe, J; Leroux-Roels, G; Praet, M; Van Vlierberghe, H; Verdievel, H | 1 |
| Süoglu, OD | 1 |
| Butterfield, JH; Kalaaji, AN; Kelkar, PS | 1 |
| Buti, M; Cabasés, JM; Guillén, F; San Miguel, R | 1 |
| Chan, KA; Chang, CH; Chen, KY; Lai, MY | 1 |
| Ascione, T; Bruno, R; Campanone, A; De Sena, R; Felaco, FM; Filice, G; Gaeta, GB; Piccinino, F; Precone, DF; Spadaro, A; Stanzione, M; Stornaiuolo, G | 1 |
| Allan, JE; de Boer, WB; Jeffrey, GP; MacQuillan, GC; McCaul, KA; Platten, MA; Reed, WD | 1 |
| Gola, J; Gonciarz, Z; Jurzak, M; Krysiak, R; Mazur, W; Mazurek, U; Szuścik, T; Wilczok, T | 1 |
| Bode, JC; Rothfuss, KS | 1 |
| Iñigo, P; Lasierra, P; Moros, M; Pérez-Calvo, J | 1 |
| Bean, P | 1 |
| Layden, JE; Layden, TJ; Levy-Drummer, RS; Neumann, AU; Poulakos, J; Reddy, KR | 1 |
| Almasio, P; Cappello, M; Cino, N; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A | 1 |
| Andreoni, M; Biglino, A; Carenzi, S; Cariti, G; Ciancio, A; Ciccone, G; Croce, G; Manca, A; Olivero, A; Orsi, PG; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tabone, M; Tappero, G | 1 |
| Carosi, G; Craxi, A; Dhumeaux, D; Diago, M; Fried, MW; Gonçales, FL; Häussinger, D; Hoffman, J; Lin, A; Marinos, G; Reddy, KR; Shiffman, ML; Smith, C; Yu, J | 1 |
| Friedlander, L; Kondaveeti, K; Van Thiel, DH | 1 |
| Albrecht, JK; Dienstag, J; Garaud, JJ; Lee, WM; Lindsay, KL; Mak, C; Manns, M; McHutchison, JG; Patel, K; Poynard, T; Trepo, C | 1 |
| Fehr, J; Kamal, SM; Peters, T; Rasenack, JW; Roesler, B | 1 |
| Samuel, D | 1 |
| Carbone, A; Carella, C; Cioffi, M; Mazziotti, G; Morisco, F; Sorvillo, F | 1 |
| Dupke, S; Gölz, J; Klausen, G; Lichterfeld, M; Mauss, S; Mudar, M; Nischalke, HD; Notheis, G; Rockstroh, JK; Stein, L | 1 |
| Bassit, L; Carrilho, FJ; da Silva, LC; Madruga, CL; Nishiya, A; Ono-Nita, SK; Pinho, JR | 1 |
| Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M | 1 |
| Angelico, M; Araco, A; Bergamini, A; Bolacchi, F; Cepparulo, M; Ombres, D; Rocchi, G; Tisone, G | 1 |
| Blanco, F; Garcia-Benayas, T; Soriano, V | 1 |
| Bowden, S; Dev, AT; McCaw, R; Sievert, W; Sundararajan, V | 1 |
| Doo, E; Everhart, JE; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Park, Y; Promrat, K; Soza, A | 1 |
| Gehring, S; Gerner, P; Lang, T; Wirth, S | 1 |
| Christiansen, L; Der-Petrossian, M; Ferenci, P; Gangl, A; Jessner, W; Maier, H; Steindl-Munda, P | 1 |
| Agesta, N; Díaz-Pérez, JL; Zabala, R | 1 |
| Dorak, MT; Folayan, GO; Kaslow, RA; Niwas, S; Tang, J; van Leeuwen, DJ; Yee, LJ | 1 |
| Bass, EB; Chander, G; Gebo, KA; Herlong, HF; Jenckes, MW; Sulkowski, MS; Torbenson, MS | 1 |
| Aprili, G; Capra, F; de Maria, E; Franchini, M; Gandini, G; Pattacini, C; Rossetti, G; Tagliaferri, A; Veneri, D | 1 |
| Changchien, CS; Chen, CH; Chen, TM; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Alain, S; Denis, F; Karaaslan, H; Le Meur, Y; Liozon, E; Loustaud-Ratti, V; Paraf, F; Vidal, E | 1 |
| Andreone, P; Andriulli, A; Bruno, S; Cammà, C; Caporaso, N; Chiesa, A; Cino, L; Craxì, A; Crosignani, A; Di Marco, V; Freni, M; Gramenzi, AG; Lo Iacono, O; Mangia, A; Morisco, F; Puoti, M; Rumi, MG; Saracco, G; Schepis, F; Spadaro, A | 1 |
| Bürger, E; Meier, V; Mihm, S; Ramadori, G; Saile, B | 1 |
| Hamidah, A; Jamal, R; Yong, JF; Zulkifli, HI | 1 |
| Blanc, F; Dereure, O; Guilhou, JJ; Larrey, D; Raison-Peyron, N | 1 |
| Avenhaus, W; Domschke, W; Menzel, J; Poremba, C; Ullerich, H | 1 |
| Malfertheiner, P | 1 |
| Benhamou, Y; Cacoub, P | 1 |
| Poynard, T | 3 |
| Cacoub, P; Duhaut, P; Ghillani, P; Leger, JM; Lidove, O; Maisonobe, T; Myers, RP; Piette, JC; Servan, J; Thibault, V | 1 |
| Myaing, M; Stein, DF | 1 |
| Bessard, G; Larrat, S; Plages, A; Souvignet, C; Stanke-Labesque, F; Zarski, JP | 1 |
| Pár, A | 1 |
| Emens, LA; Sulkowski, MS | 1 |
| Golzman, G; Hallevy, C; Herishanu, Y; Medvedovsky, M; Vander, T | 1 |
| De Lalla, F; Fabris, P; Giordani, MT; Tositti, G | 1 |
| Yang, G; Yang, X; Zhang, H | 1 |
| Morisada, A; Ogawa, M | 1 |
| Rakov, NE | 1 |
| Bacon, BR | 4 |
| Dantzler, TE; Lawitz, EJ | 1 |
| Dejica, D; Dejica, V; Grigorescu, M; Neculoiu, D; Radu, C | 1 |
| Folwaczny, C; Grunze, H; Heldwein, W; Koenig, A; Loeschke, K; Lorenz, R; Martin, G; Schaefer, M; Schindlbeck, N; Schmidt, F; Soyka, M | 1 |
| Chen, DS; Chen, PJ; Chen, W; Kao, JH; Lai, MY | 2 |
| Allen, SA; Cabral, AM; Osei, AM; Rich, JD; Spaulding, AC; Taylor, LE | 1 |
| Datz, C; Ferenci, P; Gangl, A; Hackl, F; Hofer, H; Jessner, W; Kessler, H; Stauber, R; Watkins-Riedel, T | 1 |
| Boyd, DG; McHutchinson, J; Pockros, PJ; Reddy, R; Reindollar, R; Wilkes, LB; Wright, T | 1 |
| Carenzi, S; Ciancio, A; Olivero, A; Rizzetto, M; Saracco, G | 1 |
| Hadziyannis, S; Koskinas, J; Manesis, E; Merkouraki, P | 1 |
| King, J; Kooragayala, LM; Liang, C; Schulman, JA | 1 |
| Calvo, F; Córdoba, J; Garijo, R; Gobernado, M; Jaén, J; López, L; Martínez, F; Molina, JM; Olaso, V; Siles, MS | 1 |
| Kurth, BM; Manns, MP; McHutchison, JG; Ravens-Sieberer, U; Rossol, S; Siebert, U; Sroczynski, G; Wasem, J; Wong, JB | 1 |
| Adams, P | 1 |
| Bau, I; Beltrán, B; Calvo, F; Córdoba, J; Gobernado, M; López, B; Martínez, B; Molina, JM; Monte, E; Olaso, V; Siles, MS | 1 |
| Okai, T; Sawabu, N; Shirasaki, F | 1 |
| Berg, T; Gerlach, T; Herrmann, E; Hinrichsen, H; Hopf, U; Sarrazin, C; Wiedenmann, B; Zachoval, R; Zeuzem, S | 1 |
| Cheung, R; Cooper, S; Greenberg, HB; He, XS; Ji, X; Li, Q | 1 |
| Ahmed, SN; Albrecht, JK; Baulieux, J; Bismuth, H; Bizollon, T; Chevallier, M; Cohard, M; Ducerf, C; Feray, C; Geffner, M; Lemonnier, C; Reynes, M; Roche, B; Samuel, D; Trepo, C | 1 |
| Changchien, CS; Chen, TM; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lee, JF; Lu, SN; Tung, HD; Wang, JH | 1 |
| Myers, RP; Poynard, T; Thibault, V | 1 |
| Abbati, G; Boccia, S; Castagnetti, E; Distasi, M; Fabris, P; Fattovich, G; Felder, M; Fornaciari, G; Giusti, M; Lomonaco, L; Minola, E; Montanari, R; Pantalena, M; Paternoster, C; Redaelli, A; Rizzo, C; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Tonon, A; Tositti, G; Zagni, I | 1 |
| Crespo, J; Diago, M; Muñoz-Sánchez, M; Pérez, R; Romero-Gómez, M; Sánchez-Tapias, JM | 1 |
| Farrell, GC; George, J; Kumar, D; Liddle, C; Lin, R; Samarasinghe, D; Wallington-Beddoe, C | 1 |
| Buti, M; Cabasés, JM; Guillén-Grima, F; Mar, J; San Miguel, R | 1 |
| Buti, M; Casado, MA; Esteban, R; Fosbrook, L; Medina, M; Wong, JB | 1 |
| Massoud, OI; Mullen, KD; Yousef, WI | 1 |
| Chang, TT; Chen, CY; Cheng, PN; Chow, NH; Hu, SC; Jen, CM; Young, KC | 1 |
| Kuzmic, P; Lake-Bakaar, G; Ruffini, L | 1 |
| Baran, A; Cagatay, T; Guneylioglu, D; Mert, A; Ozaras, R; Ozseker, F; Senturk, H; Tahan, V; Ucisik, AC; Yilmazbayhan, D | 1 |
| Alvarez Delgado, A; Carneros Martín, JA; Fuentes Coronel, A; González San Martín, F | 1 |
| Delahooke, TE; Hayes, PC; Kilpatrick, DC; Koch, C; Turner, ML | 1 |
| Curran, MP; Keating, GM | 1 |
| Chan, AO; Hui, CK; Lai, CL; Sablon, E; Wong, BC; Yuen, MF | 1 |
| Battezzati, PM; Bissoli, F; Borzio, M; Bruno, S; Ceriani, R; Chiesa, A; Crosignani, A; Fargion, S; Fiorelli, G; Fracanzani, AL; Maraschi, A; Morini, L; Orlandi, A; Podda, M | 1 |
| Ivanikov, IO; Pomova, NI; Siutkin, VE | 1 |
| Amaraa, R; Fucikova, T; Mareckova, H; Urbanek, P | 2 |
| Hirose, Y; Izumi, N; Kumada, H; Tsubota, A | 1 |
| Caini, P; Gentilini, P; Giannelli, F; Giannini, C; Gragnani, L; La Villa, G; Laffi, G; Monti, M; Moscarella, S; Romanelli, RG; Solazzo, V; Zignego, AL | 1 |
| Chapman, WC; Crippin, J; Jaramillo, A; Lisker-Melman, M; Mohanakumar, T; Sreenarasimhaiah, J | 1 |
| Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R | 1 |
| Horiike, N; Onji, M | 1 |
| Kaslow, RA; Perez, KA; Tang, J; van Leeuwen, DJ; Yee, LJ | 1 |
| Allan, JE; Jeffrey, GP; MacQuillan, GC; Mamotte, C; Reed, WD | 1 |
| Arribas, JR; Barreiro, P; Castro, A; García-Samaniego, J; González, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Pedreira, J; Pérez-Olmeda, M; Romero, M; Soriano, V | 1 |
| Dupon, M; Fleury, H; Galpérine, T; Lafon, ME; Legrand, E; Moreau, JF; Neau, D; Neau-Cransac, M; Pitard, V; Ragnaud, JM | 1 |
| Dehesa Violante, M | 1 |
| Juárez Navarro, JA | 1 |
| Del Vecchio, C; Durante Mangoni, E; Marrone, A; Ruggiero, G; Saviano, D; Utili, R | 1 |
| Carducci, B; Caruso, A; Cavaliere, AF; De Santis, L; De Santis, M; Lucchese, A; Straface, G | 1 |
| Buti, M; Esteban, R; Lurie, Y; Sánchez-Avila, F; Valdés, A | 1 |
| Iino, S | 3 |
| Forns, X; Martínez-Bauer, E | 1 |
| Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Okamura, T; Sata, M; Seki, R; Tanaka, K | 1 |
| Aprosina, ZG; Ignatova, TM; Il'iankova, AA; Krel', PE; Sekamova, SM; Serov, VV; Tanashchuk, EL | 1 |
| Capra, F; De Maria, E; Franchini, M; Marchiori, L; Thalheimer, U; Vantini, I | 1 |
| Abbate, I; Antonucci, G; Capobianchi, MR; Cappiello, G; Craxi, A; Di Marco, V; Di Stefano, R; Ferraro, D; Ippolito, G; Lo Iacono, O; Longo, R; Solmone, M | 1 |
| Flamm, SL | 1 |
| Andrès, E; Geisler, F; Maloisel, F; Noel, E; Pflumio, F | 1 |
| Benech, H; Bonnet, E; Bouvier-Alias, M; Chêne, G; Goujard, C; Lassalle, R; Morlat, P; Payan, C; Pérusat, S; Pruvost, A; Salmon-Céron, D; Sogni, P; Tréluyer, JM; Zoulim, F | 1 |
| Bianca, S; Ettore, G | 1 |
| Batey, R; Bhathal, P; Bowden, S; De Solom, R; Marinos, G; McDonald, J; Mollison, L; Pianko, S; Reed, W; Sievert, W; Warner, S | 1 |
| Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ | 1 |
| Aggelis, P; Akriviadis, E; Avgerinos, A; Giannoulis, G; Goritsas, K; Hatzakis, A; Hatzis G, G; Kanatakis, S; Ketikoglou, I; Manolakopoulos, S; Paraskevas, E; Raptopoulou, M; Sypsa, V; Tassopoulos, NC; Thomopoulos, K; Tsantoulas, D; Tzathas, C; Vafiadis, I; Vassiliadis, T | 1 |
| Beaugrand, M; Bedossa, P; Bissery, A; Brissot, P; Bronowicki, JP; Buffet, C; Chaumet-Riffaud, P; Daurat, V; Degos, F; Dhumeaux, D; Eugene, C; Gayno, S; Larrey, D; Marcellin, P; Moussalli, J; Myers, RP; Naveau, S; Pol, S; Poynard, T; Riachi, G; Samuel, D; Serfaty, L; Sogni, P | 1 |
| Bekkering, FC; Brouwer, JT; Hansen, BE; Schalm, SW; Vrolijk, JM | 1 |
| Abergel, A; Alleman, I; Arpurt, JP; Bailly, F; Bernard, PH; Blanc, F; Botta-Fridlund, D; Botti, G; Bourlière, M; Caroli-Bosc, F; Chazouillères, O; Couzigou, P; De Lédinghen, V; Debonne, JM; Doll, F; Ducloux, S; Eugène, C; Gauthier, AP; Gérolami, A; Gérolami, V; Gouvernet, J; Grimaud, JC; Halfon, P; Khiri, H; Larrey, D; Mathieu-Chandelier, C; Moreau, X; Ouzan, D; Picon, M; Pol, S; Portal, I; Sogni, P; Thiefin, G; Vetter, D; Zamora, C | 1 |
| Maygers, J; Pande, H; Thuluvath, PJ | 1 |
| Belli, L; Civardi, E; Leveri, M; Marinelli, D; Rossi, L; Silini, EM | 1 |
| Blanco, M; García Flores, MA; Graus, J; Pérez Mota, A; Pérez-Muñoz, C; Rodero, R; Villalgordo, C | 1 |
| Fried, MW; Russo, MW | 2 |
| Aytaman, A; Bini, EJ; Bräu, N; Finch, DA; Stancic, S | 1 |
| Adams, O; Behlen-Wilm, U; Donner, A; Erhardt, A; Häussinger, D; Heintges, T | 1 |
| Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S | 2 |
| Baker, DE | 1 |
| Appleby, TC; Hong, Z; Lau, JY; Walker, MP; Zhong, W | 1 |
| Boeri, E; De Bona, A; Galli, L; Gallotta, G; Lazzarin, A; Morsica, G; Uberti-Foppa, C | 1 |
| Bartenschlager, R; Haagmans, BL; Hansen, BE; Kaul, A; Lohmann, V; Schalm, SW; Vrolijk, JM | 1 |
| Bioulac-Sage, P; Chêne, G; Dupon, M; Lacoste, D; Lafon, ME; Le Bail, B; Neau, D; Ragnaud, JM; Rullier, A; Trimoulet, P; Winnock, M | 1 |
| Cornberg, M; Felten, G; Hüppe, D; Manns, MP; Wedemeyer, H; Wiegand, J | 1 |
| Hrachovec, J; Patel, P | 1 |
| Barreiros, AP; Galle, PR; Gerken, G; Löhr, HF; Schlaak, JF | 1 |
| Akdogan, M; Bozdayi, M; Bozkaya, H; Ersoz, G; Kaymakoglu, S; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Yenice, N | 1 |
| Bendtsen, F; Holten-Andersen, M; Johansen, JS; Krarup, HB; Møller, A; Nøjgaard, C | 1 |
| Aucella, F; Bunnapradist, S; Fabrizi, F; Lunghi, G; Martin, P | 1 |
| Dev, A; McHutchison, JG; Muir, AJ; Patel, K | 1 |
| Doo, E; Everhart, JE; Ghany, MG; Heller, T; Herion, D; Hoofnagle, JH; Khokhar, F; Kleiner, DE; Liang, TJ; Ong, J; Park, Y; Promrat, K; Soza, A | 1 |
| Hoofnagle, JH; Soza, A | 1 |
| Cointault, O; Durand, D; Izopet, J; Kamar, N; Ribes, D; Rostaing, L; Sandres-Saune, K; Selves, J | 1 |
| Smith, C | 1 |
| Guntz, P; Lunel, F; Maniez-Montreuil, M; Payan, C; Picchio, G; Veillon, P | 1 |
| Goldie, SJ; Hammitt, JK; Salomon, JA; Weinstein, MC | 1 |
| Dejica, D; Grigorescu, M; Neculoiu, D; Radu, C; Zaharie, T | 1 |
| Folwaczny, C; Glas, J; König, A; Martin, K; Schaefer, M; Schiemann, U; Schmidt, F; Simperl, C; Török, HP | 1 |
| Juszczyk, J | 2 |
| Arif, A; Bank, L; Gregory, DH; Levine, RA; Mahl, TC; Sanderson, SO; Shah, A; Velu, RP | 1 |
| Aguilar-Reina, J; Barroso, N; González-Escribano, MF; Montes-Cano, MA; Núñez-Roldan, A; Romero-Gómez, M; Sánchez-Muñoz, D; Torres, B | 1 |
| Ahlenstiel, G; Berg, T; Brackmann, HH; Grünhage, F; Hess, L; Iwan, A; Kupfer, B; Sauerbruch, T; Schernick, A; Spengler, U; Woitas, RP | 1 |
| McHutchison, JG; Patel, K | 2 |
| Zhang, F | 1 |
| Desmet, VJ; Roskams, T | 1 |
| Boucher, EJ; Brissot, P; Canva, V; Colimon, R; Deugnier, Y; Guyader, D; Jacquelinet, C; Jacquelinet, S; Turlin, B | 1 |
| Brunner, H; Datz, C; Ferenci, P; Gangl, A; Gschwantler, M; Hackl, F; Hofer, H; Jessner, W; Nachbaur, K; Rosenbeiger, M; Stauber, R; Steindl-Munda, P; Vogel, W | 1 |
| Shobokshi, OA | 2 |
| Al-Jaser, NM; Serebour, FE; Shobokshi, OA; Skakni, LI | 1 |
| Al-Kayyal, BM; Shobokshi, OA; Tantawe, AO | 1 |
| Campanozzi, F; D'Adduzio, A; Fazio, V; Grimaldi, M; Scotto, G | 1 |
| Dieterich, DT; Spivak, JL | 1 |
| Cadranel, JF; Djilloul, A; Pariente, A | 1 |
| Niaz, A | 1 |
| Bagri, AS; Dural, AT; Khaoustov, VI; Shtenberg, KM; Tran, T; Yoffe, B | 1 |
| Tsolakos, A; Zalatimo, N | 1 |
| Keeffe, EB | 3 |
| Dixit, NM; Golia, P; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH | 1 |
| Herrmann, E; Welsch, C; Zeuzem, S | 1 |
| Craxi, A; Licata, A | 1 |
| Ma, QY | 1 |
| Bressler, BL; Guindi, M; Heathcote, J; Tomlinson, G | 1 |
| Albrecht, J; Davis, GL; Harvey, J; Manns, MP; McHutchison, JG; Wong, JB | 1 |
| Heathcote, EJ; Manoharan, P; Moskovitz, DN | 1 |
| Heathcote, J; Liu, LW; Mazzulli, T; Murray, A; Tomlinson, G | 1 |
| Adler, M; Brouwer, JT; Delwaide, J; Hansen, BE; Michielsen, P; Nevens, F; Schalm, SW; Veldt, BJ | 1 |
| Folwaczny, C; Glas, J; König, A; Martin, K; Schaefer, M; Schiemann, U; Schmidt, F; Simperl, C; Török, P | 1 |
| Berkowitz, D; Hartman, C; Rimon, N; Shamir, R | 1 |
| Bourlière, M; Cacoub, P; Chadapaud, S; Halfon, P; Khiri, H; Neumann, AU; Ouzan, D; Rieu, A | 1 |
| Anagnostopoulos, G; Hatzakis, A; Hatzis, G; Kanatakis, S; Ketikoglou, I; Raptopoulou, M; Sidiropoulos, L; Sypsa, V; Tassopoulos, NC; Tsantoulas, D; Vafiadis, I | 1 |
| Kessel, A; Sabo, E; Slobodin, G; Toubi, E; Yeshurun, D; Zuckerman, E | 1 |
| Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S | 1 |
| Cadranel, JF; Dumouchel, P; Gouérou, H; Legrand, MC; Nousbaum, JB; Savary, O | 1 |
| Allison, M; Carithers, RL; Elizaga, M; Gaba, K; Gretch, DR; McElrath, MJ; Morishima, C; Musey, L | 1 |
| Courcambeck, J; Halfon, P; Joly, H; Khiri, H; Ouzan, D; Pénaranda, G; Tran, A | 1 |
| Maier, KP | 2 |
| Degertekin, H; Kilinc, N; Yalcin, K; Yildiz, F | 1 |
| Rodés, J | 1 |
| Berenguer, M; Wright, TL | 2 |
| Fennerty, MB; Keeffe, EB; Zaman, A | 1 |
| Kerl, K; Lübbe, J; Negro, F | 1 |
| Alaeus, A; Fischler, B; Reichard, O; Uhnoo, I; Weiland, O; Wejstål, R | 1 |
| Bajaj, JS; Jeffers, LJ; Molina, E; Regev, A; Schiff, ER | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Erim, Y; Frilling, A; Gerken, G; Karliova, M; Malago, M; Treichel, U | 1 |
| Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C | 1 |
| Cruz, CN; Ferraz, ML; Kirsztajn, GM; Lopes, EP; Silva, AE; Valente, LM | 1 |
| Kaplan, AL; Sidhu-Malik, NK | 1 |
| Fried, MW; Russo, MW; Zacks, SL | 1 |
| Duncan, M; Younossi, Z | 1 |
| García González, N; Prieto Valtueña, J | 1 |
| Abergel, A; Bacq, Y; Blanchi, A; Causse, X; Fouchard-Hubert, I; Loustaud-Ratti, V; Lunel, F; Payan, C; Rifflet, H; Silvain, C; Veillon, P | 1 |
| Benedetti, P; Bertin, T; Boccia, S; Capanni, M; Carlotto, A; Costa, P; Fattovich, G; Felder, M; Ferrara, C; Giusti, M; Lisa Ribero, M; Lomonaco, L; Marin, R; Mazzella, G; Milani, S; Minola, E; Miracolo, A; Pantalena, M; Paternoster, C; Rizzo, C; Rossini, A; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Zagni, I | 1 |
| Belaye, T; Hui, CK; Lau, E; Monto, A; Wright, TL | 1 |
| Jiao, J; Wang, JB | 2 |
| del Mar Alcalde, M; Jiménez, C; Narváez, I; Pérez, B; Soria, A | 1 |
| Barbakadze, G; Butsashvili, M; Jatchvliani, D; Kamkamidze, G; Kiladze, M | 1 |
| Duvnjak, M; Hrabar, D; Pavić, T; Virović, L | 1 |
| Sievert, W | 1 |
| Busuttil, RW; Saab, S | 1 |
| Annese, M; Babudieri, S; Bacca, D; Barbarini, G; Barbaro, G; Belloni, G; Francavilla, R; Fruttaldo, L; Grisorio, B; Hazra, C; Lucchini, A; Matarazzo, F; Rizzo, G; Torre, D | 1 |
| Avataneo, T; Badalamenti, S; Framarin, L; Rosina, F; Salzedo, E; Tappero, G | 1 |
| Buggisch, P; Grossmann, J; Koop, K; Reiser, M; Schmiegel, W; Wursthorn, K | 1 |
| Haagmans, BL; Hansen, BE; Janssen, HL; Kwekkeboom, J; Osterhaus, AD; Schalm, SW; Vrolijk, JM; Zondervan, PE | 1 |
| August-Jörg, BS; Borovicka, J; Dufour, JF; Gonvers, JJ; Henz, S; Hermann, R; Meyenberger, C; Renner, EL; Weitz, M | 1 |
| Blanco, MI; Crespo, J; Diago, M; Enríquez, J; Jiménez, M; Melón, S; Olcoz, JL; Oña, M; Pérez, R; Rodrigo, L; Romero, M; Salmerón, J; Solá, R; Vaquero, P | 1 |
| Adler, M; Bastens, B; Bourgeois, N; Brenard, R; Brouwer, J; Bruckers, L; Colle, I; de Galocsy, C; de Vries, RA; Delwaide, J; Henrion, J; Horsmans, Y; Leroux-Roels, G; Michielsen, P; Nevens, F; Robaeys, G; Van Vlierberghe, H | 1 |
| Castéra, L; Couzigou, P; de Lédinghen, V; Fleury, H; Foucher, J; Trimoulet, P | 1 |
| Dev, A; McHutchison, JG; Muir, A; Patel, K | 1 |
| Albrecht, JK; Davis, GL; Manns, MP; McHutchison, JG; Wong, JB | 1 |
| Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R | 1 |
| García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Arlt, AC; Dennin, RH; Gause, A; Gross, WL; Gutzeit, O; Lamprecht, P; Lerin-Lozano, C; Merz, H; Peters, SO; Solbach, W; Voswinkel, J | 1 |
| Brillanti, S; Levantesi, F; Nigro, G; Roda, E; Vicari, S | 1 |
| Rubin, RA | 1 |
| Cheng, DM; Lagakos, SW | 1 |
| Klinker, H | 1 |
| Chapman, MD; Chester, BP; De Boer, B; Forster, E; Garas, G; Jeffrey, GP; Kontorinis, N; MacQuillan, GC; Speers, D; Young, J | 1 |
| Nierengarten, MB | 1 |
| Everson, GT; Forman, LM; Medeiros, BC; Seligman, PA | 1 |
| Chengyu, P; Fujioka, S; Ikeda, F; Iwasaki, Y; Nakajima, H; Ohnishi, Y; Shimomura, H; Shiratori, Y; Takagi, SJ; Taniguchi, H; Umeoka, F | 1 |
| Anania, FA; Black, M; Fairbanks, KD; Gelrud, LG; Lobis, IF; Maheshwari, A; Mehdi, J; Ryan, MJ; Thuluvath, PJ; Wu, LL | 1 |
| Barcena, R; del Campo, S; Mateos, M; Moraleda, G; Moreno, J | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Asensi, V; Blanch, J; García-Samaniego, J; Guardiola, J; Jiménez-Nácher, I; Morales, D; Núñez, M; Ochoa, A; Pérez-Olmeda, M; Romero, M; Sánchez-Montero, F; Santin, M; Soriano, V | 1 |
| Haagsma, EB; Meijer, K; van der Meer, J | 1 |
| Sánchez Tapias, JM | 1 |
| Alfageme Michavila, I; Lara Lara, I; López Garrido, J; Merino Sánchez, M; Pérez Ronchel, J; Suárez García, E | 1 |
| Dev, A; McHutchison, JG; Patel, K | 1 |
| Primo Vera, J | 1 |
| Bernstein, D | 1 |
| Engler, S; Flechtenmacher, C; Gugler, R; Kallinowski, B; Stremmel, W; Wiedemann, KH | 1 |
| Drouet, E; Hilleret, MN; Thelu, MA; Zarski, JP | 1 |
| Funakoshi, S; Kiribayashi, Y; Maeda, Y; Maruhashi, A; Moriya, T; Murakami, T; Omoda, K; Takano, M | 1 |
| Halota, W; Pawłowska, M | 4 |
| Fehér, J; Fehérvári, I; Görög, D; Kóbori, L; Lengyel, G; Nemes, B; Patonai, A; Perner, F; Sárváry, E; Varga, M | 1 |
| Khokhar, N | 3 |
| Bevilacqua, P; Bozzola, L; Brown, D; de Lalla, F; Dusheiko, G; Fabris, P; Giordani, MT; Tositti, G; Webster, GJ | 1 |
| Bauditz, J; Roske, AE; Schmidt, HH | 1 |
| Carter, DJ; Elpern, DJ; Moore, MM | 1 |
| Hayashi, N; Hiramatsu, N | 1 |
| Goyal, A; Guptan, RC; Hashmi, AZ; Kumar, S; Malhotra, V; Sakhuja, P; Sarin, SK | 1 |
| Alberti, A; Craxi, A; De Carli, C; Giuliani, G; Green, J; Patel, KK; Sullivan, SD; Wintfeld, N | 1 |
| Andriulli, A; Giacobbe, A; Iacobellis, A; Leandro, G; Mangia, A; Minoli, G; Montalto, G; Pazienza, V; Piattelli, M; Piermanni, V; Spinzi, G; Vuturo, O | 1 |
| Sette Júnior, H; Strauss, E | 1 |
| Conca, P; Perrella, A; Perrella, O; Ragucci, P; Sorrentino, P; Tarantino, G | 1 |
| Chen, DS; Chen, GH; Kao, JH; Lai, MY; Yang, SS | 1 |
| Apolinario, A; Clemente, G; Diago, M; García-Monzón, C; Lo Iacono, O; Lorente, R; Majano, PL; Pérez, C | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Castera, L; Dahari, H; Dhumeaux, D; Germanidis, G; Hezode, C; Lonjon, I; Neumann, AU; Pawlotsky, JM | 1 |
| Ahmed, A; Keeffe, EB | 2 |
| Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Sluzewski, W | 1 |
| Bonner, JO; Lyketsos, CG; Onyike, CU; Treisman, GJ | 1 |
| Alam, I; Harb, G; Hu, S; Imperial, J; Klaskala, W; Perrillo, R; Rothstein, KD; Rubin, R | 1 |
| Ackrill, AM; Balan, V; Bernstein, D; Bodenheimer, H; Diago, M; Hadziyannis, SJ; Lin, A; Marcellin, P; Morgan, TR; Pockros, PJ; Ramadori, G; Rizzetto, M; Sette, H; Zeuzem, S | 1 |
| Benoni, G; Corrocher, R; Cuzzolin, L; Gabrielli, GB; Pasino, M; Perfetti, P; Stanzial, AM | 1 |
| Chalupa, P; Husa, P; Husová, L; Penka, M; Smejkal, P | 1 |
| Everson, GT; Fontana, RJ; Shiffman, ML; Tuteja, S; Vargas, HE | 1 |
| Ball, L; Berggren, R; Dieterich, DT; Felizarta, F; Goodman, R; Khalili, M; Slim, J; Smith, C; Sulkowski, MS | 1 |
| Ishida, F; Tanaka, E; Tanaka, N | 1 |
| Baldini, V; Bardella, MT; Casella, G; Perego, D | 1 |
| Boillot, O; Chevallier, P; Dumortier, J; Scoazec, JY | 1 |
| Cooksley, G; Green, J; Hassanein, T; Horta E Vale, A; Lai, MY; Marinos, G; Pastore, G; Smith, C; Sulkowski, M; Trejo-Estrada, R; Wintfeld, N | 1 |
| Bekkering, FC; Bourgeois, N; Brouwer, JT; Delwaide, J; Hansen, BE; Henrion, J; Lefebvre, V; Nevens, F; Schalm, SW; Van Hattum, J; Van Vlierberghe, H; Weegink, CJ | 1 |
| Bahr, MJ; Manns, MP | 1 |
| Rogers, CJ; Romagosa, R; Vincek, V | 1 |
| Dietrich, CG; Gartung, C; Geier, A; Lammert, F; Lorenzen, J; Matern, S; Stolte, C; Wasmuth, HE | 1 |
| Christensen, UB; Krogsgaard, K | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Goodman, ZD; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC | 1 |
| Bonacini, M; Bräu, N; Frost, KR; Giffen, CA; Kostman, JR; Prokupek, D; Rodriguez-Torres, M; Smith, JJ | 1 |
| Chi, CS; Chiu, CC; Fu, LS; Liao, YR; Lin, CC; Yen, CP | 1 |
| Clavien, PA; Egger, HP; Fried, R; Giostra, E; Hadengue, A; Keller, W; Kraehenbuhl, S; Kullak-Ublick, GA; Locher, S; Mentha, G; Morel, P; Negro, F; Vanlemmens, C | 1 |
| Cox, P; Jarrett, M | 1 |
| Homma, M; Inoue, Y; Kohda, Y; Matsuzaki, Y; Mitamura, K; Shibata, M; Tanaka, N | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 2 |
| Allan, JE; English, S; Garas, G; Harnett, GB; Jeffrey, GP; Macquillan, GC; Niu, X; Reed, WD; Speers, D | 1 |
| Kobayashi, K; Niitsuma, H; Satoh, H; Shiina, M; Shimosegawa, T; Ueno, Y | 1 |
| Antela, A; Bárcena, R; Casado, JL; Dronda, F; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C | 1 |
| Benhamou, Y; Bochet, M; Mehri, D; Myers, RP; Poynard, T; Thibault, V | 1 |
| Alatrakchi, N; Autran, B; Benhamou, Y; Di Martino, V; Katlama, C; Poynard, T; Thibault, V | 1 |
| Bottieau, E; Callens, S; Colebunders, R; Michielsen, P | 1 |
| Abbate, I; Antonucci, G; Capobianchi, MR; Cappiello, G; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Girardi, E; Ippolito, G; Lo Iacono, O; Longo, R; Solmone, M | 1 |
| Borghi-Scoazec, G; Claudy, A; Merle, P; Scoazec, JY; Trepo, C | 1 |
| Balestreri, L; Canzonieri, V; Cinelli, R; Dal Maso, L; Di Gennaro, G; Fedele, P; Nasti, G; Tedeschi, R; Tirelli, U | 1 |
| Andreone, P; Bagaglio, S; Bruno, R; De Mitri, MS; Lazzarin, A; Morsica, G | 1 |
| Hivnor, CM; Honig, PJ; Junkins-Hopkins, JM; Yan, AC | 1 |
| Colombo, M; De Filippi, F; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E | 1 |
| Buffet, C | 2 |
| Bain, C; Couzigou, P; Decullier, E; Epstein, A; Goutagny, N; Inchauspe, G; Ligeoix, B; Trepo, C; Vieux, C | 1 |
| Bräu, N | 3 |
| Lobos, IV; Marinho, RT; Moura, MC; Pinto, R; Santos, ML | 1 |
| Ishii, H; Kinoshita, M; Kumagai, N; Saito, H; Takahashi, N; Tsuchimoto, K; Tsunematsu, S | 1 |
| Fontana, RJ; Lok, AS; Marrero, JA; Oberhelman, K; Shehab, TM; Su, GL | 1 |
| Dries, V; Goeser, T; Kasper, HU; Petersen-Benz, C | 1 |
| Asnis, GM; De La Garza, R; Miller, AH; Raison, CL | 1 |
| Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S | 1 |
| Buti, M; Esteban, R; Jardi, R; Mendez, C; Rodriguez-Frias, F; Sauleda, S; Schaper, M; Valdes, A | 1 |
| Brechmann, T; Griga, T; Henke, H; Schmiegel, W; Voigt, E | 1 |
| Contos, MJ; Hofmann, CM; Luketic, VA; Mills, AS; Sanyal, AJ; Shiffman, ML; Sterling, RK | 1 |
| Denk, DM; Ferenci, P; Formann, E; Gangl, A; Jessner, W; Munda-Steindl, P; Stauber, R; Zollner, G | 1 |
| Hrnicek, MJ; Mailliard, ME | 1 |
| Arguedas, M | 1 |
| Peters, T; Rasenack, J; Reincke, M; Schories, M | 1 |
| Basso, M; Delfino, A; Pelli, N; Picciotto, A; Rossol, S; Torre, F | 1 |
| Manjón-Haces, JA; Pérez-Alvarez, R; Pérez-Oliva, N; Vázquez-López, F | 1 |
| Bielawski, KP; Lakomy, EA; Michalska, Z; Sikorska, K; Stalke, P; Witczak-Malinowska, K | 1 |
| Chrapek, M; Kryczka, W; Zarebska-Michaluk, D | 1 |
| Gonciarz, M; Gonciarz, Z; Jurzak, M; Kajdy, M; Mazur, W; Mazurek, U; Wilczok, T | 1 |
| García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Albrecht, J; Bourliere, M; Brass, C; Goeser, T; Harvey, J; Hultcrantz, R; Marcellin, P; Sanchez-Tapias, J; Sarrazin, C; Zeuzem, S | 1 |
| Ferenci, P; Hofer, H; Jessner, W; Osterreicher, C; Penz, M; Steindl-Munda, P; Wrba, F | 1 |
| Bornstein, JD; Killenberg, PG; Muir, AJ | 1 |
| Lehmann, M; Manns, MP; Meyer, MF; Monazahian, M; Tillmann, HL; Wedemeyer, H | 1 |
| Koff, JM; Younossi, Z | 1 |
| Reddy, KR | 2 |
| Bruno, R; Filice, G; Maiocchi, L; Sacchi, P; Zocchetti, C | 1 |
| Fried, MW | 2 |
| Keeffe, EB; Nguyen, MH | 1 |
| Agarwal, K; Dieterich, DT; Kontorinis, N | 1 |
| Everson, GT | 1 |
| Cassidy, W; Howell, CD; Hu, S; Jeffers, LJ; Reddy, KR | 1 |
| Chu, CM; Liaw, YF; Sheen, IS | 1 |
| Breadmore, MC; Theurillat, R; Thormann, W | 1 |
| Altman, RD; Concha, R; Herrera, I; Molina, EG; Schiff, ER | 1 |
| Merican, I; Suresh, RL; Suryati, Y | 1 |
| Gregor, M; Hass, HG; Kaiser, S; Kreysel, C; Nehls, O | 1 |
| Asahina, Y; Hamano, K; Inoue, K; Itakura, J; Izumi, N; Kurosaki, M; Miyake, S; Nishimura, Y; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Buti, M | 1 |
| Bolognini, S; Careddu, GF; Cottoni, F; Deplano, A; Garrucciu, G; Lissia, A; Manzoni, NE; Montesu, MA; Solinas, A; Tocco, A | 1 |
| Gudinaviciene, I; Jonaitis, L; Kupcinskas, L; Petrenkiene, V | 2 |
| Han, KH; Yoon, YH | 1 |
| Bonfissuto, G; Carroccio, A; Di Giovanni, G; Montalto, G; Riili, A; Sesti, R; Soresi, M; Tripi, S | 1 |
| Ascione, A; Caporaso, N; Carbone, A; Fogliano, V; Marmo, R; Morisco, F; Scarpati, S; Stingo, S; Vitaglione, P | 1 |
| Adams, O; Erhardt, A; Haussinger, D; Heintges, T; Kirschberg, O; Sagir, A | 1 |
| Annicchiarico, BE; Siciliano, M | 1 |
| Huang, SB; Liao, BM; Luo, GH | 1 |
| Farrell, GC; Teoh, NC | 1 |
| Husa, P; Husová, L; Penka, M; Smejkal, P | 1 |
| Cholongitas, E; Papatheodoridis, GV | 2 |
| Brouwer, JT; Haagmans, BL; Herscheid, AJ; Janssen, HL; Kusters, JG; Kwekkeboom, J; Schalm, SW; Tang, TJ; Vrolijk, JM | 1 |
| Guardo, P; La Spina, M; Lo Nigro, L; Mirabile, E; Pisana, P; Schilirò, G | 1 |
| Ammassari, A; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Fantoni, M; Marasca, G; Tamburrini, E; Tumbarello, M | 1 |
| Berger, F; Goelz, J; Jacob, B; Mauss, S; Schmutz, G | 1 |
| Douglas, DD; Rodriguez-Luna, H | 1 |
| Heathcote, J; Ramji, A | 1 |
| Kottilil, S; Kovacs, JA; Polis, MA | 1 |
| Bacq, Y; Barbereau, D; Corcia, P; de Toffol, B; Guennoc, AM | 1 |
| Dowling, J; Gordon, A; Jenkins, P; Menahem, S; Mitchell, J; Roberts, SK | 1 |
| Durantel, D; Khattab, E; Ottevaere, I; Sablon, E; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F | 1 |
| Hegenbarth, K; Ille, R; Krause, R; Lahousen, T; Lipp, RW; Little, RR; Schnedl, WJ | 1 |
| Akbar, SM; Horiike, N; Murakami, H; Onji, M; Tsubouchi, E | 1 |
| Cantu, NS; Hepburn, LM; Hepburn, MJ; Lapeer, MG; Lawitz, EJ | 1 |
| Amati, L; Caccavo, D; Cozzolongo, R; Cuppone, R; Jirillo, E; Manghisi, OG; Pellegrino, NM | 1 |
| Cozzolongo, R; Maiellaro, PA; Marino, P | 1 |
| Barnes, E; De Lalla, F; Fabris, P; Giordani, MT; Grasso, A; Tositti, G | 1 |
| Carosi, G; De Pamphilis, J; Dieterich, DT; Duff, F; Gonzalez-García, J; Katlama, C; Lazzarin, A; Lissen, E; Montaner, J; Passe, S; Rockstroh, JK; Rodriguez-Torres, M; Sasadeusz, J; Schrenk, UM; Sette, H; Torriani, FJ | 1 |
| Alston, B; Andersen, J; Bhan, AK; Chung, RT; Colquhoun, D; Harb, G; Koziel, MJ; Liu, T; Nevin, T; Peters, MG; Robbins, GK; Sherman, KE; van der Horst, C; Volberding, P | 1 |
| Artioli, S; Carosi, G; Maggiolo, F; Mignani, E; Paraninfo, G; Pastore, G; Puoti, M; Quinzan, GP; Raise, E; Ravasio, L; Resta, F; Rollo, A; Santantonio, T; Suter, F; Verucchi, G; Zaltron, S; Zanini, B | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Takaki, S; Tsubota, A | 1 |
| Itoh, Y; Okanoue, T | 1 |
| Acharya, SK; Batra, Y; Gupta, SD; Hazari, S; Panda, SK; Singh, R | 1 |
| Baluch, MH; Dhillon, S; Farr, D; George, MM; Li, SD; Mindikoglu, AL; Van Thiel, DH | 1 |
| Bernstein, DE; Cheinquer, H; Cooksley, G; Craxi, A; Foster, GR; Green, J; Hassanein, TI; Jensen, DM; Klaskala, W; Lee, SS; Patel, KK; Pettit, K; Sullivan, SD | 1 |
| Anand, BS; Batash, S; Bini, EJ; Chaudhari, S; Dieterich, DT; Park, J; Pimstone, NR | 1 |
| Cupelli, L; DePamphilis, J; Dieterich, D; Duff, F; Larrey, D; Mauss, S; Passe, S; Solsky, J; Torriani, FJ; Valenti, W | 1 |
| Bargallo, X; Blanco, JL; de Lazzari, E; García-Criado, A; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miquel, R; Murillas, J; Sánchez-Tapias, JM | 1 |
| Campbell, C; Farel, C; Koratich, C; Kottilil, S; Masur, H; McLaughlin, M; Metcalf, JA; Polis, MA; Robinson, MR; Suzman, DL | 1 |
| Chamberlain, AJ; Poon, E | 1 |
| Backmund, M; Heinz, A; Schaefer, M | 1 |
| Aigner, ES | 1 |
| Moriguchi, H; Sato, C | 1 |
| Anwar, M; Hussain, AB; Hussain, S; Hussain, T; Karamat, KA; Kazmi, Y; Tariq, WU | 1 |
| Khalili, M; Proietti, N | 1 |
| Afdhal, NH; Oh, S | 1 |
| Ahmed, F; Jacobson, IM | 1 |
| Fontana, RJ | 2 |
| Ahmed, F; Antignano, L; Bach, N; Brown, RS; Dieterich, DT; Esposito, SP; Gabbaizadeh, D; Geders, J; Jacobson, IM; Klion, F; Lebovics, E; Levendoglu, H; Russo, MW; Tobias, H | 1 |
| Al-Ajmi, M; Al-Khaldi, J; Al-Nakib, B; Asker, H; Hasan, F; Owaid, S; Siddique, I; Varghese, R | 1 |
| Colombo, M; Del Ninno, E; Parravicini, ML; Ronchi, G; Rumi, MG; Russo, A; Soffredini, R | 1 |
| Canva, V; De Maeght, S; Deltenre, P; Dharancy, S; Henrion, J; Louvet, A; Mathurin, P; Paris, JC; Texier, F | 1 |
| Bruno, S; Cammà, C; Camozzi, M; Colombo, M; Craxì, A; Di Bona, D; Di Marco, V; Mondelli, MU; Pinzello, G; Rebucci, C; Rumi, M; Vinci, M | 1 |
| Fried, MW; Hadziyannis, SJ | 1 |
| Fabrizi, F; Martin, P; Poordad, FF | 1 |
| Sterling, RK; Sulkowski, MS | 1 |
| Charlton, M; Wiesner, R | 1 |
| Brillanti, S | 1 |
| Caporaso, N; De Luise, G; Fogliano, V; Marmo, R; Morisco, F; Ritieni, A; Tuccillo, C; Verde, V | 1 |
| Gazdik, F; Hrusovsky, S; Pijak, MR | 1 |
| Brown, GR; Browning, JD; Getachew, Y; Prebis, M; Rogers, T | 1 |
| Enomoto, M; Habu, D; Kohmoto, M; Nishiguchi, S; Seki, S; Shiomi, S; Takeda, T; Tamori, A | 1 |
| Imperial, JC; Keeffe, EB; Lim, JK | 1 |
| Asahina, Y; Izumi, N | 1 |
| Kaneko, S; Nakamoto, Y | 1 |
| Fukuda, A | 1 |
| Hayashi, N; Iyoda, K; Kato, M; Yamamoto, K; Yuki, N | 1 |
| Iyoda, K; Kato, M | 1 |
| Kakumu, S | 2 |
| Kondo, Y; Omata, M; Tateishi, R; Yoshida, H | 1 |
| Izumi, N | 2 |
| Imazeki, F | 1 |
| Yamada, G | 1 |
| Makuuchi, M; Sugawara, Y | 1 |
| Hokari, A; Zeniya, M | 1 |
| Nishiguchi, S; Tamori, A | 1 |
| Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P | 1 |
| Cucurull, E; Espinoza, LR; Menon, Y; Reisin, E | 1 |
| Mauss, S | 2 |
| Santos Gil, I; Sanz Sanz, J | 1 |
| Chebli, JM; Gaburri, AK; Gaburri, PD; Martins Junior, EV | 1 |
| Alegría, S; Brahm, J; Buckel, E; Ceresa, S; Ferrario, M; Smok, G | 1 |
| Rókusz, L | 1 |
| Chaix, ML; Equi-Andrade, C; Fontaine, H; Kreis, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A; Verkarre, V | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 4 |
| Chang, TC; Chang, YC; Liao, SL; Su, DH | 1 |
| Al-Ajmi, M; Al-Khaldi, J; Al-Nakib, B; Asker, H; Hasan, F; Owayed, S; Siddique, I; Varghese, R | 1 |
| Barreiro, P; Camino, N; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martin-Carbonero, L; Núñez, M; Romero, M; Soriano, V | 1 |
| Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Fenu, L; Maida, I; Mura, MS; Puoti, M; Putzolu, V; Rezza, G; Rossi, S; Sassu, S; Viale, P; Zanini, B | 1 |
| Accogli, E; Azzaroli, F; Colecchia, A; Derenzini, M; Festi, D; Giovanelli, S; Lodato, F; Mazzella, G; Miracolo, A; Montagnani, M; Mwangemi, C; Nigro, G; Roda, E; Tamé, M; Trere, D | 1 |
| Blum, HE; Moradpour, D | 3 |
| Guthoff, R; Kirchhoff, A; Kirchhoff, U; Lafrenz, M | 1 |
| Brodin, H; Cave, C; Gabbay, J; Price, A; Shepherd, J; Waugh, N | 1 |
| Davis, GL; Saadeh, S | 1 |
| Ong, JP; Younossi, ZM | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Collantes, R; Gujral, H; Viscomi, C | 1 |
| Vogel, W | 2 |
| Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P | 1 |
| de Moura, MC; Marinho, RT; Pinto, RM; Santos, ML | 1 |
| Hayashi, J; Higashi, M; Ishibashi, H; Kajiwara, E; Kashiwagi, S; Maruyama, T; Matsui, Y; Mukai, T; Nagano, M; Nomura, H; Shimono, J; Tanimoto, H; Yamashita, N | 1 |
| Blanco, JR; Metota, L; Oteo, JA; Rosel, L | 1 |
| Altintas, E; Sezgin, O | 1 |
| Berenguer, J; Berenguer, M; Calvo, F; Carrasco, D; Palau, A; Prieto, M; Rayón, JM | 1 |
| Bogris, P; Elefsiniotis, IS; Magaziotou, I; Mavrogiannis, C; Pantazis, KD | 1 |
| Andriulli, A; Bacca, D; Di Salvo, D; Iacobellis, A; Leandro, G; Maio, G; Mangia, A; Persico, M; Spadaccini, A; Ventrella, F | 1 |
| Abbati, G; Boccia, S; Castagnetti, E; Distasi, M; Fabris, P; Fattovich, G; Felder, M; Fornaciari, G; Giusti, M; Lomonaco, L; Minola, E; Montanari, R; Noventa, F; Pantalena, M; Paternoster, C; Redaelli, A; Ribero, ML; Rizzo, C; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Tomba, A; Tonon, A; Tositti, G; Zagni, I | 1 |
| Białkowska, J; Bolewska, B; Boroń-Kaczmarska, A; Gładysz, A; Halota, W; Inglot, M; Jabłkowski, M; Jabłonska, J; Janas-Skulina, U; Jurczyk, K; Juszczyk, J; Kryczka, W; Kuydowicz, J; Lakomy, EA; Lyczak, A; Mach, T; Michalska, Z; Moczko, J; Modrzewska, R; Nazzal, K; Pabjan, P; Pawłowska, M; Piszko, P; Sikorska, K; Swiqtek, K; Tomasiewicz, K; Topczewska-Staubach, E; Wawrzynowicz-Syczewska, M; Zarqbska-Michaluk, D; Zejc-Bajsarowicz, M | 1 |
| Aspinall, RJ; Pockros, PJ | 1 |
| Dahab, ST; Khuroo, MS | 1 |
| De Sarro, G; Ferraro, M; Gallelli, L; Mauro, GF | 1 |
| Jan, MA; Muhammad, N; Rahman, N | 1 |
| Alberti, A; Boccato, S; Bortoletto, G; Dal Pero, F; Ferrari, A; Gerotto, M; Realdon, S | 1 |
| García-Samper, X; Gongora, J; Kershenobich, D; Poo, JL; Sánchez-Avila, F; Uribe, M | 2 |
| Gładysz, A; Inglot, M | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Bini, EJ; Mehandru, S | 1 |
| Bell, H; Bjøro, K; Dalgard, O; Hellum, KB; Myrvang, B; Raknerud, N; Ritland, S; Skaug, K | 1 |
| Keating, GM; Plosker, GL | 2 |
| Rich, JD; Tashima, KT; Taylor, LE | 1 |
| Herrmann, E; Kronenberger, B; Micol, F; von Wagner, M; Zeuzem, S | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Leitz, G; Mody, SH; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, TL; Younossi, Z | 1 |
| Al-Ahdal, MN; Alashgar, H; Alfaleh, FZ; Algamedi, A; Aljumah, A; Hadad, Q; Kessie, G; Khan, MQ; Khuroo, MS; Mayet, I | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 2 |
| Bajaj, JS; Daniel, J; Franco, J; Ho, S; Knox, JF; McKee, D; Peine, C; Saeian, K; Varma, RR | 1 |
| Bozorg, B; Rifai, MA; Rosenstein, DL | 1 |
| Asnis, GM; De La Garza, R; Henderson, MA; Rego, SA; Reinus, JF | 1 |
| Wilson, MS | 1 |
| Gholam, PM | 1 |
| Brogna, A; Malaguarnera, M; Musumeci, S; Neri, S; Pistone, G; Romano, M | 1 |
| Canepa, J | 1 |
| Diago, M; Farci, P; Gane, E; Gitlin, N; Lamour, F; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Reddy, KR; Shiffman, M; Zeuzem, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y | 1 |
| Kasahara, A | 2 |
| Douglas, SD | 1 |
| Borisov, AS; Broadwell, SD; Capuron, L; Jacobson, IM; Manatunga, AK; Miller, AH; Nemeroff, CB; Raison, CL; Woolwine, BJ | 1 |
| Keeffe, EB; Kowdley, KV | 1 |
| Fredrick, RT; Hassanein, TI | 1 |
| Kowdley, KV | 1 |
| Collantes, RS; Younossi, ZM | 1 |
| Rossi, G | 1 |
| González-Peralta, RP | 1 |
| Bani-Sadr, F; Benzekri, A; Cacoub, P; Carrat, F; Degott, C; Goujard, C; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E; Salmon-Céron, D | 1 |
| Manns, MP; Wedemeyer, H | 1 |
| Abad, MA; Gómez, G; Leal, M; Lissen, E; Molina-Pinelo, S; Sánchez-Quijano, A; Vallejo, A | 1 |
| Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; García Juárez, R; Girón-González, JA; Guerrero, F; Pérez-Guzmán, E | 1 |
| Hsieh, CH; Tasi, TN | 1 |
| Goudeau, A; Gouriou, S; Legrand-Quillien, MC; Nousbaum, JB; Picard, B; Vallet, S | 1 |
| Adair, D; Colby, TV; Gallegos-Orozco, JF; Jablonska, J; Kubicka, J; Laskus, T; Radkowski, M; Rakela, J; Walewska-Zielecka, B; Wilkinson, J | 1 |
| Fujisaki, K; Ido, A; Kubozono, O; Sakashita, H; Sho, Y; Tahara, K; Tsubouchi, H; Yamaguchi, K | 1 |
| Abbas, Z; Hamid, SS; Jafri, W; Tabassum, S | 1 |
| Atsukawa, K; Higashimoto, M; Ishii, H; Saito, H; Takahashi, M | 1 |
| Kraus, MR; Reimer, P; Schäfer, A; Scheurlen, M; Wissmann, S | 1 |
| Altintas, E; Altiparmak, E; Cicek, B; Filik, L; Kilic, M; Odemis, B; Oguz, D; Zengin, N | 1 |
| Ferenci, P; Ferlitsch, A; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Panzer, S; Peck-Radosavljevic, M | 1 |
| Crossey, M; D'Souza, R; Foster, GR; Hayward, C; Main, J; Murray-Lyon, IM; Rosenberg, W | 1 |
| Almasio, PL | 1 |
| Cutler, D; Grace, MJ | 1 |
| Biglia, A; Blanch, J; Blanco, JL; de Pablo, J; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Miró, JM; Murillas, J | 1 |
| Ballesteros, AL; Clotet, B; Côté, H; Fuster, D; Garrabou, G; López, S; Martínez, E; Miró, O; Planas, R; Rey-Joly, C; Salas, A; Tor, J; Tural, C; Videla, S | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Núñez, M; Soriano, V | 1 |
| Arcos, P; Busteros, JI; de Dios García-Díaz, J; García-Sánchez, M | 1 |
| Bassendine, M; Forton, D; Goldin, R; Grant, P; Main, J; Mills, PR; Millson, C; Naoumov, N; Tedder, R; Thomas, HC; Thursz, M; Torok, E; Wright, M | 1 |
| Akriviadis, E; Hatzis, G; Kanatakis, S; Ketikoglou, I; Paraskevas, E; Raptopoulou, M; Sidiropoulos, L; Tsantoulas, D; Vafiadi, I; Vassiliadis, T | 1 |
| Al-Taie, O; Kraus, MR; Schäfer, A; Scheurlen, M | 1 |
| Hsu, S; Pielop, J; Shen, Y | 1 |
| Barry, K; Cleare, AJ; Hotopf, M; Landau, S; Maddock, C; Maulayah, P; Norris, S; Pariante, CM | 1 |
| Bessis, D; Blatìre, V; Girard, C; Guilhou, JJ; Guillot, B | 1 |
| Ghany, M; Lutchman, G | 1 |
| Bruchfeld, A; Lindahl, K; Schvarcz, R; Stahle, L | 1 |
| Byun, KS; Chang, YJ | 1 |
| Balan, V; Bowers, PJ; Burnett, A; Ghalib, R; Goon, BL; Jackson, J; Keeffe, EB; Leitz, GJ; Muir, AJ; Rossaro, L; Schwartz, D; Wu, GY | 1 |
| Eng, SC; Gordon, SC; Kowdley, KV; McHutchison, JG; Patel, K; Rulyak, SJ | 1 |
| Butt, MB; Gill, ML; Khokhar, N | 1 |
| Cholewa, K; Gola, J; Gonciarz, Z; Jurzak, M; Mazur, W; Mazurek, U; Rozek-Kostórkiewicz, J; Sypniewski, D; Wilczok, T | 1 |
| Egger, M; Furrer, H; Rauch, A; Reichen, J | 1 |
| Alaric, L; Bureau, C; Péron, JM; Pey, F; Valmary, S; Vinel, JP; Zabraniechki, L | 1 |
| Dimitropoulou, D; Gogos, CA; Labropoulou-Karatza, C; Siagris, D; Theocharis, GJ; Thomopoulos, KC; Tsamantas, AC | 1 |
| Hu, SL; Jaber, BL | 1 |
| Fujiyama, S; Hamada, A; Saito, H; Sasaki, Y; Uchida, M; Yamasaki, M | 1 |
| Alston-Smith, B; Bassett, R; Brass, C; Fichtenbaum, C; Glesby, MJ; Jacobson, EL; Owens, S; Race, EM; Sherman, KE; Sulkowski, M | 1 |
| Bonder, A; Fuentes, AP; Gallegos-Orozco, JF; García-Sandoval, M; Gutiérrez-Reyes, G; Gutiérrez-Ruíz, MC; Kershenobich, D; Loaeza-del Castillo, A; Olivera, MA; Rodríguez, R; Soto, L | 1 |
| Molleston, JP; Rao, GS | 1 |
| Afdhal, N; Kelleher, TB | 1 |
| Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM | 1 |
| Alain, S; Bezanahary, H; Doffoël-Hantz, V; Fauchais, AL; Liozon, E; Loustaud-Ratti, V; Ramos-Casals, M; Vidal, E | 1 |
| Offner, F; Sagmeister, M; Sprenger, R | 1 |
| Al-Jumah, A; Al-Nasser, M; Al-Traif, I; Handoo, FA | 1 |
| Bianchi, FB; Granito, A; Guidi, M; Lenzi, M; Muratori, L; Muratori, P; Susca, M | 1 |
| Bogdanos, DP; Mieli-Vergani, G; Vergani, D | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Ripault, MP | 1 |
| Ffrench, RA; Freeman, AJ; Lloyd, AR; Marinos, G | 1 |
| Bellis, L; Castellacci, R; Montagnese, F; Puoti, C | 1 |
| Andrejczyn, M; Halota, W; Pawłowska, M | 1 |
| Nitkiewicz, J | 1 |
| Apale, P; Avolio, A; Bellia, V; Bordoni, T; Parravicini, P; Pioltelli, P; Pozzi, M; Redaelli, A; Roffi, L; Santamaria, G; Scalori, A | 1 |
| Brodin, HF; Cave, CB; Gabbay, J; Price, A; Shepherd, J; Waugh, NR | 1 |
| Siebert, U; Sroczynski, G | 1 |
| de Knegt, RJ; Eijkemans, MJ; Habbema, JD; Hansen, BE; Schalm, SW; Stijnen, T; Veldt, BJ | 1 |
| Daniel, S | 1 |
| Mukherjee, S | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Bertisch, B; Huber, M; Meili, D; Oppliger, R; Renner, EL; Schmid, P; Schönbucher, P; Vernazza, P; Weber, R | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Romero, M; Sánchez-Conde, M; Soriano, V | 1 |
| Adamek, A; Adamek, J; Juszczyk, J | 1 |
| Goto, H; Hayashi, K; Honda, T; Katano, Y; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K; Yano, M; Yoshioka, K | 1 |
| Gross, JB | 1 |
| Brito-Zerón, P; Cervera, R; Font, J; Mañá, J; Nardi, N; Ramos-Casals, M; Sánchez-Tapias, JM; Xaubet, A | 1 |
| Karpov, SIu; Krel', PE | 1 |
| Bachmeyer, C; Cadranel, JF; Ducamp-Posak, I; Dumouchel, P; Hammi, R; Thevenot, T | 1 |
| Andrade, RJ; Castillo, J; Corpas, R; Cruz, M; Del Mar Viloria, M; Diago, M; Fernández-Rodríguez, CM; Gila, A; Grande, L; Gutiérrez, ML; López-Serrano, P; Muñoz-De-Rueda, P; Pérez, C; Romero-Gómez, M; Ruiz-Extremera, A; Salmerón, J; Suárez, E; Vázquez, L | 1 |
| Alexander, GJ; Hoare, M; Woodall, T | 1 |
| Chisholm, JA; Gavin, M; Keating, D; Mills, PR; Parks, S; Spence, E; Williams, G | 1 |
| Lagging, M; Lindh, M; Norkrans, G; Wejstål, R; Westin, J | 1 |
| Chung, HV; Farley, JD; Farley, TA; Lim, E; Walters, G; Wong, VK; Yoshida, EM | 1 |
| Boulestin, A; Chatelut, E; Durand, D; Esposito, L; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J; Stébenet, M | 1 |
| Antonaci, A; Antonaci, S; Giannelli, G; Maddalena, G; Napoli, N; Parisi, CV | 1 |
| Angarano, G; Cibelli, DC; Fazio, V; Palumbo, E; Saracino, A; Scotto, G | 1 |
| Ampurdanés, S; Forns, X; Franco, S; Furčić, I; Giménez-Barcons, M; Puig-Basagoiti, F; Saiz, JC; Sánchez-Tapias, JM | 1 |
| Inoue, K; Izumi, N; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K; Yasuhiro, A | 1 |
| Chang, JJ; Chang, LC; Chen, LW; Lee, TS; Liu, CJ; Yen, CL | 1 |
| Antonaci, S; Giannelli, G; Simone, B; Vella, FS | 1 |
| Zein, NN | 2 |
| Ballauff, A; Gerner, P; Jenke, A; Kullmer, U; Lang, T; Pieper-Boustani, H; Wintermeyer, P; Wirth, S | 1 |
| Anatol, P; Danuta, P; Robert, F | 1 |
| Abergel, A; Bacq, Y; Causse, X; Giraudeau, B; Gros, J; Labarriere, D; Loustaud-Ratti, V; Si Ahmed, SN; Silvain, C; Veillon, P | 1 |
| Desurmont, P; Filoche, B; Hamdan-Khalil, R; Khalil, A; Lucidarme, D | 1 |
| Bernard, PH; Foucher, J; Lafon, ME; Ledinghen, VD; Legrand, E; Neau-Cransac, M | 1 |
| Flisiak, R | 1 |
| Jabłonowska, E | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Bouvier-Alias, M; Darthuy, F; Gourlain, K; Hézode, C; Pawlotsky, JM; Pellegrin, B; Rémiré, J; Soulier, A | 1 |
| Castro, A; Castro, M; Diz Dios, P; Eirea, M; Hermida, M; Reforma, NG; Rodríguez, I | 1 |
| Caizzi, M; Carniello, G; Di Gennaro, G; Donada, C; Maso, LD; Mazzaro, C; Pozzato, G; Tirelli, U; Virgolini, L; Zorat, F | 1 |
| Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M | 1 |
| Kumar, R; Kumar, S; Sarin, SK; Sharma, BC; Singh, J | 1 |
| González-Gallego, J; Guerra, J; Jorquera, F; Marin, JJ; Merayo, JA; Monte, MJ; Olcóz, JL; Sanchez-Campos, S | 1 |
| Bernstein, DE; Brown, RS; Herrine, SK; Lentz, E; Ondovik, MS; Te, H | 1 |
| Butterfield, B; Drake, S; Holtzmuller, K; Howard, R; Sjogren, MH; Sjogren, R; Smith, M; Watts, A; Winston, B | 1 |
| Akyuz, F; Besisik, F; Dincer, D; Karaca, C; Okten, A; Sever, MS | 1 |
| Heathcote, J; Main, J | 1 |
| Fukunaga, K; Hada, T; Hara, N; Hayashi, S; Ishikawa, T; Masaki, N; Ohnishi, K; Sawada, K; Takahashi, H; Toda, G; Yamamoto, T; Zeniya, M | 1 |
| Chang, TT; Chang, WY; Chao, YC; Chen, DS; Cheng, PN; Hsieh, TY; Hwang, SJ; Lai, MY; Lee, SD; Liu, CJ; Yu, ML | 1 |
| Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Conte, D; Festi, D; Guadagnino, V; Maio, G; Mangia, A; Minerva, N; Pazienza, V; Persico, M; Piattelli, M; Ricci, GL; Spirito, F | 1 |
| Baldo, V; Bozzola, L; Carlotto, A; de Lalla, F; Fabris, P; Floreani, A; Giordani, MT; Negro, F; Rassu, M; Tramarin, A | 1 |
| Karaman, G; Karaoğlu, AO; Savk, E; Sendur, N; Uslu, G | 1 |
| Assor, P; Bacq, Y; d'Alteroche, L; Gaudy, C; Lefrou, L; Senecal, D | 1 |
| Bruno, R; Ciappina, V; Filice, G; Maiocchi, L; Patruno, S; Sacchi, P; Zocchetti, C | 1 |
| Angeli, E; Cargnel, A; Duca, P; Giorgi, R; Gubertini, G; Mainini, A; Schiavini, M | 1 |
| Egashira, T; Fujiwara, K; Hashimoto, M; Inao, M; Ito, N; Matsui, A; Mishiro, S; Mochida, S; Nagano, M; Nagoshi, S; Naito, M | 1 |
| Borgia, G; Borrelli, F; Cerini, R; Ciampi, R; Gentile, I; Piazza, M; Reynaud, L; Viola, C | 1 |
| Escanhoela, CA; Gonçales, FL; Gonçales, NS; Pavan, MH; Pereira, JS; Silva, Cd | 1 |
| Bruno, C; Cassidy, W; Howell, CD; Jeffers, L; Luo, S; Reddy, KR | 1 |
| Tran, HA | 1 |
| Berg, T; Garkisch, AS; Heinz, A; Hinzpeter, A; Pich, M; Schaefer, M; Schwaiger, M; Uebelhack, R; van Boemmel, F | 1 |
| Colak, H; Kartal, ED; Ozgunes, I; Usluer, G | 1 |
| Borozan, I; Chen, L; Coltescu, C; Edwards, AM; Feld, J; Heathcote, J; McGilvray, ID; Sun, J; Tannis, LL | 1 |
| Aziz, AA; El Tawil, AA; Hakam, SA; He, Q; Ismail, A; Kamal, SM; Madwar, MA; Nakano, T; Rasenack, J; Saleh, WA | 1 |
| Beniowski, M; Borgiel-Marek, H; Fila, A; Filipczyk, P; Janczewska-Kazek, E; Kajdaniuk, D; Kajdaniuk, J; Kos-Kudla, B; Marek, B; Mazurek, U; Niedziolka, D; Nowak, M; Ostrowska, Z; Pakula, D; Sieminska, L; Strzalka, B; Wilczok, T | 1 |
| Aidelsburger, P; Bullinger, M; Greiner, W; Kurth, BM; Ravens-Sieberer, U; Rossol, S; Siebert, U; Sroczynski, G; von der Schulenburg, JM; Wasem, J; Wong, JB | 1 |
| Anatol, P; Bozena, P; Danuta, P; Janusz, D | 1 |
| Chiou, YL; Guo, CH; Hsu, GS; Ko, WS; Yaun, SR; Yeh, MS | 1 |
| Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM | 1 |
| Chemin, I; Guillaud, O; Khattab, E; Mrani, S; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F | 1 |
| Furusyo, N; Hayashi, J; Kubo, N; Murata, M; Nabeshima, S; Nakamuta, M; Takeoka, H; Toyoda, K | 1 |
| Germain, J; Ghany, M; Heller, T; Hoofnagle, JH; Hsu, HH; Jake Liang, T; Lutchman, G; Park, Y; Soza, A | 1 |
| Chang, KM; Ikeda, F; Kaplan, DE; Reddy, KR; Shetty, K; Stadanlick, J; Sugimoto, K; Valiga, M | 1 |
| Gwak, GY; Kang, GH; Kim, KA; Kim, TH; Lee, HS; Lim, YS; Yoon, JH | 1 |
| Biliotti, E; Bresci, S; Capanni, M; Pimpinelli, N; Taliani, G; Tozzi, A | 1 |
| Hauser, P; Loftis, JM; Rifai, MA | 2 |
| Bouzas, E; Naoum, G; Papastathopoulos, K; Tsiodras, S; Vergados, I | 1 |
| Datz, C; Ferenci, P; Gangl, A; Homoncik, M; Jessner, W; Kreil, A; Peck-Radosavljevic, M; Schmid, M | 1 |
| Bacon, BR; Brunt, EM; Di Bisceglie, AM; Harrison, SA; Neuschwander-Tetri, BA; Oliver, DA; Qazi, RA | 1 |
| Chang, TT; Huang, FC; Lin, SC; Shih, MH; Tseng, SH | 1 |
| Andriulli, A; Annese, M; Bacca, D; Carretta, V; Mangia, A; Minerva, N; Persico, M; Ricci, GL; Romano, M; Santoro, R; Scotto, G; Sogari, F; Spirito, F; Vinelli, F; Zechini, F | 1 |
| Fukunaga, K; Hirata, I; Kashiwamura, S; Ohnishi, K; Okamura, H; Saniabadi, A; Sawada, K | 1 |
| D'Souza, R; Foster, GR; Sabin, CA | 1 |
| Bertrand, JJ; Germain, S; Halfon, P; Harafa, A; Larroque, O; Martin, S; Muller, P; Renou, C | 1 |
| Amer, A; Bener, A; Derbala, M; El Ghannam, M; Lopez, AC; Omar, M | 1 |
| Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D | 1 |
| Carosi, G; Chaneac, M; Craxì, A; Dhumeaux, D; Diago, M; Ferenci, P; Fried, MW; Gonçales, FL; Häussinger, D; Marinos, G; Reddy, KR; Shiffman, ML; Smith, CI | 1 |
| Bancila, I; Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Parvulescu, I; Simionov, I; Vadan, R | 1 |
| Bassendine, M; DeAngelis, D; Grieve, R; Main, J; Roberts, J; Rosenberg, W; Sweeting, M; Thomas, H; Wright, M | 1 |
| Motoo, Y; Mouri, H; Ohtsubo, K; Sawabu, N; Watanabe, H; Yamaguchi, Y | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C; Zoulim, F | 1 |
| Hohenberger, W; Meyer, T; Müller, V; Schellerer, V; Schuppan, D; Tannapfel, A; Yedibela, S | 1 |
| Attia, M; Badran, HM; Barakat, E; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Saied, A; Selim, O; Zalata, K | 1 |
| Carnicer, F; García, A; Gutiérrez, A; López, M; Ruiz, F; Zapater, P | 1 |
| Alvarez Delgado, A; Fuertes Martín, A; Pérez García, ML | 1 |
| Ikeda, S; Kaneko, K; Komastu, H; Nakamura, A; Takasu, K; Tojo, K | 1 |
| Kizawa, H; Kondoh, R; Nagane, Y; Terayama, Y; Utsugisawa, K | 1 |
| Sethi, A; Shiffman, ML | 1 |
| Afdhal, NH; Curry, MP | 1 |
| Biggins, SW; Terrault, NA | 1 |
| Alam-Fotias, S; Bui, C; Mansberg, R; Nguyen, D; Shen, L | 1 |
| Everson, GT; Fey, B; Forman, L; Halprin, A; Kugelmas, M; Ray, C; Trotter, J | 1 |
| Carré, D; Coton, T; Delpy, R; Garnotel, E; Guisset, M | 1 |
| Hurst, EA; Mauro, T | 1 |
| Chen, DW; Dong, Y; Jia, WZ; Mao, YL; Tang, HM; Xu, ZQ; Yang, XJ; Zhang, HF; Zhu, SS | 1 |
| Alric, L; Boulestin, A; Izopet, J; Legrand-Abravanel, F; Nicot, F; Sandres-Sauné, K; Vinel, JP | 1 |
| Albrecht, J; Blatt, LM; Conrad, A; Dev, A; Heaton, S; McHutchison, JG; Owens, E; Patel, K; Pianko, S; Pockros, PJ | 1 |
| Buitelaar, M; de Baar, MP; de Mendoza, C; Gonzalez-Lahoz, J; Sánchez-Conde, M; Soriano, V; Timmermans, E | 1 |
| Aceti, A; Antonelli, M; Pasquazzi, C; Persechino, S; Pranteda, G; Teggi, A; Versace, I; Zechini, B | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J | 1 |
| Alberti, A; Almasio, PL; Berrutti, M; Boccato, S; Cattaneo, C; Craxi, A; Demelia, L; Ideo, G; Pellicano, R; Picciotto, A; Rizzetto, M; Sorbello, O; Torre, F; Valenza, M; Venezia, G | 1 |
| Hayashi, Y; Ishii, F; Izawa, S; Kim, KI; Kim, SR; Kimura, N; Kinoshita, K; Mita, K; Muramoto, Y; Nabeshima, S; Nakao, K; Ohtani, A; Sasase, N; Shikata, M; Tanaka, K; Taniguchi, M; Togitani, T | 1 |
| Coelho, HS; de Segadas Soares, JA; Perez, RM; Villela-Nogueira, CA | 1 |
| Casillas-Davila, L; Chirino-Sprung, R; Dehesa-Violante, M; Díaz-Hernandez, M; Juarez-Navarro, A; Navarro, JM; Vera-de-León, L | 1 |
| Ashikaga, T; Ferrentino, N; Gordon, SR; Krawitt, EL; Lidofsky, SD; Ray, MA | 1 |
| Esteban, JI; Ferrari, C; Gianfranco, E; Goulis, I; Hansen, B; Hezode, C; Lagging, M; Lukasiewicz, E; Lurie, Y; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, SW; Soulier, A; Tal, R; Verheij-Hart, E; von Wagner, M; Vrolijk, JM; Zeuzem, S | 1 |
| Berg, T; Bergk, A; Bernsmeier, C; Häussinger, D; Heintges, T; Herrmann, E; Hinrichsen, H; Huber, M; Rasenack, J; von Wagner, M; Zeuzem, S | 1 |
| Bárcena, R; Blesa, C; Fortún, J; García, M; García-Garzón, S; Martín-Dávila, P; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Otón, E; Quereda, C | 1 |
| Ahmad, J; Anand, BS; Awad, J; Aytaman, A; Bini, EJ; Bräu, N; Chang, KM; Cheung, R; Currie, S; Hagedorn, C; Ho, SB; Hu, KQ; Jeffers, L; Johnson, D; King, P; Mendenhall, C; Morgan, TR; Moseley, R; Pedrosa, M; Rossi, S; Sasaki, AW; Schmidt, WN; Shen, H; Simon, F; Strader, D; Waters, B; Wright, TL | 1 |
| Akcan, Y; Kavak, A; Korkmaz, U | 1 |
| Jensen, DM; Marcellin, P | 1 |
| Aoun, E; Ghorra, S; Inati, A; Koussa, S; Sharara, AI; Taha, M; Taher, A | 1 |
| Asahina, Y; Enomoto, N; Izumi, N; Kitamura, T; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Perelson, AS; Ribeiro, RM | 1 |
| Antonaci, S; Bergamini, C; Dentico, P; Fransvea, E; Giannelli, G; Marinosci, F; Maurel, P; Napoli, N | 1 |
| Anderson, F; Friesenhahn, M; Gish, R; Gordon, S; Holodniy, M; Krajden, M; McHutchison, J; Pawlotsky, JM; Perrillo, R; Terrault, NA; Zitron, I | 1 |
| Bläckberg, J; Carlsson, T; Norkrans, G; Reichard, O; Sangfelt, P; Wallmark, E; Weiland, O | 1 |
| Diago, M; Giménez, MD; González, V; Matas, L; Montoliu, S; Morillas, RM; Padilla, E; Pérez, C; Planas, R; Solà, R | 1 |
| Freshwater, DA; Mutimer, DJ; O'Donnell, K; Seyam, MS | 1 |
| Azzaroli, F; Bacchi Reggiani, ML; Brillanti, S; Colecchia, A; Feletti, V; Giovanelli, S; Lodato, F; Mazzella, G; Montagnani, M; Muratori, R; Roda, E; Tamé, MR | 1 |
| Ding, PP; He, Y; Huang, L; Li, H; Zhang, CY; Zheng, YH; Zhou, HY; Zou, W | 1 |
| Diepolder, HM; Franz, M; Kashiwagi, N; Teuber, G; Ulsenheimer, A; Yokoyama, T; Zachoval, R | 1 |
| Fukunaga, K; Morita, M; Murao, S; Nishumi, T; Shibutani, Y; Tani, S; Uchikoga, O; Yagi, N | 1 |
| Kugelmas, M; Ward, RP | 1 |
| Chokshi, S; Cooksley, H; Herrmann, E; Naoumov, NV; Tang, KH; Tatman, N; Williams, R; Zeuzem, S | 1 |
| Fischinger, J; Hass, HG; Kaiser, S; Kreysel, C; Menzel, J | 1 |
| Cheong-Lee, C; Ford, JA; Wong, VK; Yoshida, EM | 1 |
| Castellano, G; Diago, M; Fernández, I; García-Monzón, C; García-Samaniego, J; Iacono, OL; Pérez, C; Romero, M | 1 |
| Arazo, P; Barreiro, P; Berdún, MA; Camino, N; Echevarría, S; García-Samaniego, J; Losada, E; Martín-Carbonero, L; Miralles, C; Núnez, M; Ocampo, A; Ramos, B; Romero, M; Santos, I; Soriano, V | 1 |
| Deutsch, M; Hadziyannis, S; Koskinas, J; Mailis, A; Tolis, G; Tzannos, K; Vassilopoulos, D | 1 |
| Borg, BB; Hoofnagle, JH | 1 |
| Kolor, B | 1 |
| Jeong, SH; Suh, DJ | 1 |
| Changchien, CS; Chen, CL; Chen, WJ; Huang, WS; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Lai, MY | 2 |
| Chang, WY; Chuang, WL; Dai, CY; Yu, ML | 1 |
| Goto, H; Honda, T; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Toyoda, H | 1 |
| Henry, MJ | 1 |
| Covino, M; Gasbarrini, G; Larocca, LM; Pizzolante, F; Pompili, M; Rapaccini, GL | 1 |
| Chen, CH; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Anand, BS; Bini, EJ; Bräu, N; Cheung, RC; Currie, S; Ho, SB; Shen, H; Wright, TL | 1 |
| de Sola-Earle, C; Fernández-Moreno, N; Fernández-Pérez, F; García-Fernández, G; Méndez-Sánchez, I; Moreno-Mejías, P; Navarro-Jarabo, JM; Pérez-Aisa, A; Rivera-Irigoín, R; Sánchez-Cantos, A; Ubiña-Aznar, E; Vera-Rivero, F | 1 |
| Alfonso, V; Campos, RH; Mbayed, VA; Sookoian, S | 1 |
| Alex, P; Bader, T; Centola, M; Dozmorov, I; Gonzales, L; Gurakar, A; Naylor, M; Nguyen, T; Nour, B; Sebastian, A; Wallis, G; Wright, H | 1 |
| Brouwer, JT; Mathot, RA; Orlent, H; Schalm, SW; Van Bommel, EF; Vulto, AG | 1 |
| Adamski, M; Dziecioł, J; Panasiuk, A; Prokopowicz, D | 1 |
| Czarnecki, M; Gładysz, A; Inglot, M; Jańczak, G; Małyszczak, K; Pawłowski, T; Rymer, W | 1 |
| Jeleń, M; Piszko, P; Simon, K; Sulka, A | 1 |
| Dworacki, G; Figlerowicz, M; Kaczmarek, E; Kaczmarek, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W; Zeromski, J | 1 |
| Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W | 3 |
| Simon, K; Szymczak, A | 1 |
| Gładysz, A; Inglot, M; Rymer, W | 1 |
| Alejska, M; Błazewicz, J; Figlerowicz, M; Formanowicz, P; Jackowiak, P; Kedziora, P; Słuzewski, W | 1 |
| Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewska, M; Słuzewski, W | 1 |
| Jankowska, I; Pawłowska, J; Rokitka, M; Socha, J; Sokal, E; Teisseyre, M | 1 |
| Malone, DC; Poordad, FF; Tran, TT | 1 |
| Black, M; Chang, A; Friedenberg, FK; Gautam, M; Horwitz, B; Schmutz, J; Skole, K; Thomas, R | 1 |
| Bárcena, R; Blázquez, J; Foruny, JR; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, S; Muriel, A; Pérez-Elías, MJ; Quereda, C; Rodriguez-Sagrado, MA; Sánchez, J | 1 |
| de Franchis, R; Del Ninno, E; Ferrero Bogetto, S; Rumi, MG; Saibeni, S; Signorelli, C; Vecchi, M; Villa, F | 1 |
| Aghemo, A; Colombo, M; Del Ninno, E; Donato, MF; Monti, V; Rumi, MG | 1 |
| Broissand, C; Fontaine, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A | 1 |
| Gahr, S; Ganslmayer, M; Hahn, EG; Herold, C; Janson, C; Ocker, M; Zopf, S | 1 |
| Conde-Taboada, A; Cruces, MJ; de la Torre, C; Feal, C; Gonzalez-Sixto, B; Mayo, E | 1 |
| Kerl, K; Lübbe, J; Negro, F; Saurat, JH | 1 |
| Bonkovsky, HL; Salek, J | 1 |
| Chen, K; Chiou, CF; Robbins, S; Spiegel, BM; Younossi, ZM | 1 |
| Brok, J; Gluud, C; Gluud, L | 1 |
| Buti, M; Casado, MA; Esteban, R; Fosbrook, L | 1 |
| Figlerowicz, M; Kowala-Piaskowska, A; Machowska, L; Mozer-Lisewska, I; Słuzewski, W | 1 |
| Ding, PP; Gong, GZ; He, Y; Huang, L; Li, H; Yang, X; Zhang, CY; Zheng, YH; Zhou, HY; Zhou, W | 1 |
| Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M | 1 |
| Arapoglu, M; Gulec, SG; Nuhoğ, A; Urganci, N; Vural, S | 1 |
| Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V | 1 |
| Borque, MJ; García-Buey, L; Moreno-Monteagudo, JA; Moreno-Otero, R; Muñoz, C; Quintana, NE; Trapero, M; Vitón, M | 1 |
| Altuna, L; Castiella, A; Fernández, J | 1 |
| Danta, M; Dusheiko, G | 1 |
| Bianchi, FB; Granito, A; Guidi, M; Lenzi, M; Muratori, L; Muratori, P; Pappas, G | 1 |
| Goelz, J; Jessen, H; Klausen, G; Mauss, S; Mutz, A; Rockstroh, JK; Schmutz, G; Schranz, D; Schulz, C; Voigt, E; Weitner, L | 1 |
| Attia, M; Badran, HM; Barakat, EM; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Hamdy, H; Saied, A; Selim, O | 1 |
| Ahmed, F; Aytaman, A; Berman, DH; Bini, EJ; Bodenheimer, HC; Bräu, N; Brodsky, N; Brown, RS; Cerulli, MA; Chait, M; Edlin, BR; Ehrlich, J; Esposito, SP; Gardner, PW; Geders, JM; Gonzalez, SA; Jacobson, IM; Klion, FM; Lebovics, E; Min, AD; Rahmin, MG; Rovner, D; Russo, MW; Spivack, JE; Tobias, H | 1 |
| Albrecht, J; Brass, C; Buti, M; Cianciara, J; Ferenci, P; Horsmans, Y; Ibranyi, E; Noviello, S; Sperl, J; Weiland, O; Zeuzem, S | 1 |
| Gish, RG | 2 |
| Bordens, RW; Cutler, DL; Grace, MJ | 1 |
| Antinori, A; Carioti, J; Caroleo, B; Guadagnino, V; Trotta, MP | 1 |
| Clouston, AD; Jonsson, JR; Lipka, GM; Powell, EE; Purdie, DM; Richardson, MM; Walsh, MJ | 1 |
| Bodaghi, B; Cacoub, P; Cassoux, N; LeHoang, P; Rao, NA; Touitou, V; Tran, TH | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Bonvicini, F; Cursaro, C; Gramenzi, A; Loggi, E; Lorenzini, S | 1 |
| Pialoux, G | 1 |
| Gholam, PM; Rich, JD; Schwartzapfel, B; Taylor, LE | 1 |
| Fukuoka, M; Hata, T; Kudo, M; Kuwano, H; Kuwao, H; Moriyama, K; Naitoh, S; Nomura, M; Tohda, Y | 1 |
| Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P | 1 |
| Butensky, E; Foote, D; Harmatz, P; Pakbaz, Z; Vichinsky, EP; Walters, MC | 1 |
| Adachi, K; Akagi, S; Furuta, K; Ishihara, S; Kinoshita, Y; Kohge, N; Mishiro, T; Miyake, T; Rumi, MA; Sato, S; Uchida, Y | 1 |
| Enomoto, M; Fujiwara, K; Jomura, H; Kawada, N; Mochida, S; Nishiguchi, S; Onishi, S; Saibara, T; Tamori, A | 1 |
| Cornberg, M; Hadem, J; Herrmann, E; Manns, MP; Marschal, O; Reiser, M; Schmidt, HH; Schuppert, F; Steffen, M; Wedemeyer, H | 1 |
| Fukui, K; Ichinose, M; Miyano, M; Tanaka, H; Ueda, H | 1 |
| Kimu, M; Koike, N; Mitsutaka, M; Nakamura, T; Soda, M; Takahashi, H | 1 |
| Hughes, CA; Shafran, SD | 1 |
| Bourlière, M; Halfon, P; Khiri, H; Masseyeff, MF; Ouzan, D; Pénaranda, G | 1 |
| Ando, M; Araki, Y; Hashimoto, N; Ikeda, H; Iwasaki, Y; Kawaguchi, M; Kita, K; Kobashi, H; Kobatake, T; Osawa, T; Sakaguchi, K; Shimoe, T; Shiratori, Y; Takaguchi, K; Tomita, M | 1 |
| Crespo, J; Forns, X; Martínez-Bauer, E; Moreno-Otero, R; Pons, F; Romero-Gómez, M; Sánchez-Tapias, JM; Solá, R; Tesei, N | 1 |
| Fraenkel, L; Garcia-Tsao, G; McGraw, S; Wongcharatrawee, S | 1 |
| Ostojić, R | 1 |
| Duvnjak, M; Lerotić, I; Pavić, T; Tomasić, V; Virović, L | 1 |
| Weekley, D; Yuen, JC | 1 |
| Barcena, R; Blesa, C; Foruny, JR; Garcia-Garzon, S; Garcia-Gonzalez, M; Moreno, A; Moreno-Zamora, A; Oton, E; Ruiz, P | 1 |
| Bruckers, L; Buntinx, F; Matheï, C; Robaeys, G; Van Ranst, M; Van Vlierberghe, H | 1 |
| Bertagnolli, M; Lewis, JH; Srivastava, S | 1 |
| Berg, P; Bock, H; Frick, B; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kellner, HU; Kihn, R; Moog, G; Pfaff, R; Rambow, A; Sarrazin, C; Schöfer, M; Tacke, W; Weber, C; Zeuzem, S | 1 |
| Braga, EL; Freitas, LA; Lyra, AC; Lyra, LG; Moraes, CF; Souza, RM | 1 |
| Bergholz, U; Ferenci, P; Formann, E; Gurguta, C; Kauer, C; Steindl-Munda, P | 1 |
| Bankuti, C; Donnerer, J; Grahovac, M; Kessler, HH; Stadlbauer, V; Stauber, RE; Stelzl, E | 1 |
| Cacciatore, P; Capani, F; Chincoli, C; Cosentino, L; D'Amico, E; di Pasqua, G; Palazzi, C; Pennese, E; Riario-Sforza, G | 1 |
| Bastens, B; Bataille, C; Belaiche, J; Delwaide, J; Gerard, C; Hepatotropes, GL; Maes, B; Reenaers, C; Servais, B; Vaira, D | 1 |
| Honda, T; Kojima, T; Matsushita, T; Takamatsu, J; Yamamoto, K | 1 |
| Bailey, RJ; Bain, VG; Deschenes, M; Heathcote, J; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Simonyi, S; Yoshida, EM | 1 |
| Abbas, Z; Hussainy, A; Jafri, W; Moatter, T | 1 |
| Flisiak, I; Flisiak, R; Jaroszewicz, J; Lapinski, TW; Prokopowiczi, D | 1 |
| Crone, C; Dan, AA; Farmer, DW; Martin, LM; Ong, JP; Robbins, SC; Wise, T; Younossi, ZM | 1 |
| Kessler, CM | 1 |
| Baka-Cwierz, B; Beniowski, M; Berak, H; Bolewska, B; Boroń-Kaczmarska, A; Cianciara, J; Cieśla, A; Dziambor, A; Gasiorowski, J; Gietka, A; Gliwińska, E; Gonciarz, Z; Gładysz, A; Halota, W; Horban, A; Inglot, M; Janas-Skulina, U; Janczewska-Kazek, E; Jaskowska, J; Jurczyk, K; Juszczyk, J; Knysz, B; Kryczka, W; Kuydowicz, J; Lakomy, EA; Logiewa-Bazger, B; Lyczak, A; Mach, T; Mazur, W; Michalska, Z; Modrzewska, R; Nazzal, K; Pabjan, P; Piekarska, A; Piszko, P; Sikorska, K; Sliwińska, M; Swietek, K; Szamotulska, K; Tomasiewicz, K; Topczewska-Staubach, E; Trocha, H; Wasilewski, M; Wawrzynowicz-Syczewska, M; Wrodycki, W; Zarebska-Michaluk, D; Zejc-Bajsarowicz, M | 1 |
| Forestier, N; Friedrich-Rust, M; Zeuzem, S | 1 |
| Elliott, RM; Granath, FN; Hamid, S; Lindström, H; Persson, MA; Siddiqui, AA; Yasmeen, A | 1 |
| Alric, L; Balard, P; Izopet, J; Metivier, S; Peron, JM; Pipy, B; Thebault, S; Vinel, JP | 1 |
| Andersen, J; Bhan, AK; Chung, RT; Graham, CS; Koziel, MJ; Liu, T; Peters, M; Sherman, KE; Wells, A | 1 |
| Bergholz, U; Ferenci, P; Formann, E; Gurguta, C; Hofer, H; Jessner, W; Steindl-Munda, P | 1 |
| Alter, H | 1 |
| Gui Qiang, W; Jian Wu, Y; Shu Chen, L | 1 |
| Hauser, P; Loftis, JM; Matthews, AM | 1 |
| Biasin, M; Clerici, M; Galli, M; Gatti, N; Milazzo, L; Moroni, M; Niero, F; Piacentini, L; Riva, A; Zanone Poma, B | 1 |
| Hara, Y; Hino, K; Kawakami, T; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M | 1 |
| Abe, S; Narita, R; Oto, T; Otsuki, M; Tabaru, A | 1 |
| Changchien, CS; Kee, KM; Lee, CM; Lu, SN; Tung, HD; Wang, JH; Wang, PW | 1 |
| Asselah, T; Blazquez, M; Bonnet, J; Cohen, A; Condat, B; Estampes, B; Marcellin, P; Ngo, Y; O'Toole, D; Zanditenas, D | 1 |
| Bowler, L; Coates, P; Singh, P; Tahrani, A | 1 |
| Linde, R; Reichenbach, J; Strnad-Trojan, N; Trojan, J; Zeuzem, S; Zielen, S | 1 |
| Adachi, Y; Fujita, N; Horiike, S; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Urawa, N; Watanabe, S | 1 |
| Camacho, F; García-Bravo, B; Ruiz de Casas, A | 1 |
| De Kaita, K; Minuk, GY; Renner, E; Wong, S | 1 |
| Basso, M; Delfino, A; Pelli, N; Picciotto, A; Torre, F | 1 |
| Blotner, S; Diago, M; Farci, P; Gane, E; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Rajender Reddy, K; Shiffman, ML; Zeuzem, S | 1 |
| Bianchi, FB; Granito, A; Guidi, M; Muratori, L; Muratori, P; Pappas, G | 1 |
| Chiodo, F; Cristoni, L; Manfredi, R; Marinacci, G; Pavoni, M; Sabbatani, S | 1 |
| Brosig, B; Gieler, U; Holthausen-Markou, S; Schreiber, M; Wölfelschneider, M | 1 |
| Ibrányi, E; Nemes, L | 1 |
| Arora, S; Diago, M; Gane, E; Green, J; O'Brien, C; Patel, K; Pockros, PJ; Reindollar, RW; Shiffman, ML; Tran, A; Wintfeld, N; Zeuzem, S | 1 |
| Batisse, D; Chaix, ML; Dupont, C; Fontaine, H; Piketty, C; Pol, S; Rouveix, E; Rouzioux, C; Serpaggi, J; Vallet-Pichard, A; Viard, JP; Weiss, L | 1 |
| Aghemo, A; D'Ambrosio, R; Rumi, MG | 1 |
| Robert Ding, PH; Seow, EL | 1 |
| Bruchfeld, A; Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R | 2 |
| Chang, CH; Changchien, CS; Chen, WJ; Eng, HL; Hu, TH; Huang, CM; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JH | 1 |
| Azuma, K; Furusyo, N; Hayashi, J; Kajiwara, E; Katoh, M; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y | 1 |
| Borgiel-Marek, H; Janczewska-Kazek, E; Kajdaniuk, D; Marek, B | 1 |
| Kakibuchi, N; Kawakami, T; Kita, K; Murakami, Y; Okita, M; Takaguchi, K; Tomioka, K | 1 |
| Godoy Guerrero, M; Manteca González, R; Palacios Rodríguez, S; Salgado Ordóñez, F | 1 |
| Ariello, M; Conca, P; Mastrolia, M; Tarantino, G | 1 |
| Kakizaki, S; Kanda, D; Mori, M; Sato, K; Sohara, N; Suzuki, H; Takagi, H | 1 |
| Naoumov, NV; Paulon, E | 1 |
| Lawson, A; Ryder, SD | 1 |
| Hoepffner, N; Nikodem, AB; Paul, KA; Teuber, G | 1 |
| Dieterich, DT; Mullen, MP; Patel, MR | 1 |
| Anwar, W; Hussain, AB; Saif, M; Sarwar, M; Tariq, WU | 1 |
| Stadlbauer, V; Stauber, RE | 1 |
| Higashimoto, M; Jokyu, R; Saito, H; Takahashi, M | 1 |
| Herrine, SK; Navarro, VJ; Rossi, S | 1 |
| Baldo, V; Carderi, I; Ferrara, F; Floreani, A; Minola, E; Rizzotto, ER | 1 |
| Choi, MS; Kim, DY; Kim, JH; Koh, KC; Lee, H; Lee, JH; Paik, SW; Rhee, JC; Song, SM; Yoo, BC | 1 |
| Becker, MC; Bresson-Hadni, S; Bronowicki, JP; Di Martino, V; Lunel-Fabiani, F; Miguet, JP; Thevenot, T; Vanlemmens, C | 1 |
| Chambers, T; Di Bisceglie, AM; Fan, X; Strinko, J | 1 |
| Bonora, S; D'Avolio, A; de Requena, DG; Di Perri, G; Ibañez, A; Sciandra, M; Siccardi, M | 1 |
| Böcher, WO; Galle, PR; Hillenbrand, H; Link, R; Löhr, HF; Mudter, J; Rahman, F; Schuchmann, M; Sprinzl, M | 1 |
| Boroń-Kaczmarska, A; Jurczyk, K; Karpińska, E; Morańska, I; Urbanowicz, W; Wawrzynowicz-Syczewska, M | 1 |
| Balestrieri, A; Balestrieri, C; Cauli, C; Chessa, L; Farci, P; Serra, G | 1 |
| Montes-Ramírez, ML; Rodríguez-Zapata, M | 1 |
| Díaz, F; Girón-González, JA; Marín-Serrano, E; Martín-Herrera, L; Rodríguez-Ramos, C | 1 |
| Ahmad, J; Anand, BS; Awad, JA; Aytaman, A; Bini, EJ; Bräu, N; Chang, KM; Cheung, RC; Currie, S; Hagedorn, CH; Ho, SB; Hu, KQ; Jeffers, LJ; Johnson, DP; King, PD; Mendenhall, CL; Morgan, TR; Moseley, RH; Pedrosa, MC; Rossi, SJ; Schmidt, WN; Shen, H; Simon, FR; Waters, B; Wright, TL | 1 |
| Herrmann, E; Mihm, U; Sarrazin, C; Zeuzem, S | 1 |
| de Vries, RA; Kok, KF | 1 |
| Everson, GT; Sieja, KS | 1 |
| Alshuth, U; Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Heintges, T; Kallinowski, B; Klinker, H; Martus, P; Nasser, S; Pape, GR; Rasenack, J; Sarrazin, C; Schmidt, WE; Spengler, U; von Wagner, M; Zeuzem, S | 1 |
| Aceti, A; Bartolozzi, D; Blanc, PL; Capanni, M; Esperti, F; Ferrari, C; Forte, P; Gemignani, G; Guadagnino, V; Mari, T; Marino, N; Messerini, L; Milani, S; Pasquazzi, C; Rosina, F; Stroffolini, T; Tacconi, D; Taliani, G; Toti, M; Zignego, AL | 1 |
| Husa, P; Slesinger, P; Stroblová, H; Svobodník, A | 2 |
| Aiglová, K; Ehrmann, J; Kümpel, P; Palas, J | 1 |
| Altés, J; Baguena, F; Casanova, A; de Castro, ER; Delejido, A; Garcia, MJ; Rota, R; Sala, M; Santin, M; Shaw, E; Valero, S | 1 |
| Ackrill, AM; Ferenci, P; Hadziyannis, SJ; Jensen, DM; Marcellin, P; Morgan, TR; Pockros, PJ; Reddy, KR; Willems, B | 1 |
| Brown, RS | 2 |
| Juszczyk, J; Kmieciak, D; Kruszyna, Ł; Migdalski, P; Trzeciak, WH; Łaciński, M | 1 |
| Asnis, GM; De La Garza, R | 1 |
| Bilusic, M; Hrstic, I; Huic, D; Vucelic, B | 1 |
| Main, J; Thomas, H | 1 |
| Day, C; Desmond, CP; Dudley, F; Mitchell, J; Nguyen, S; Pianko, S; Roberts, SK | 1 |
| Koksal, I | 1 |
| Elefsiniotis, IS; Fotos, NV; Mavrogiannis, C; Moulakakis, A; Pantazis, KD | 1 |
| Foster, GR; Hollander, A; Weiland, O | 1 |
| McHutchison, JG; Muir, AJ; Patel, K | 1 |
| Zoras, C | 1 |
| Fukui, H; Matsumura, Y; Nishiofuku, M; Toyohara, M; Tsujimoto, T; Yamao, J; Yoshiji, H; Yoshikawa, M | 1 |
| Dumitraşcu, DL; Grigorescu, M; Pascu, O; Pojoga, C | 1 |
| Calonje, E; Perera, GK | 1 |
| Fehér, J; Kiss, A; Lengyel, G; Podányi, B; Schaff, Z; Szakonyi, J | 1 |
| Mathew, A; McGarrity, TJ; Peiffer, LP; Rhoades, K | 1 |
| Anand, BS; Bini, EJ; Currie, S; Dieperink, E; Ho, SB; Shen, H; Wright, T | 1 |
| Capelli, P; Corrocher, R; De Franceschi, L; Fattovich, G; Felder, M; Guido, M; Lanza, C; Leandro, G; Olivari, N; Pasino, M; Rugge, M | 1 |
| Lin, F; Wang, HF | 1 |
| Betterle, C; Cozzolongo, R; Fabris, P; Lanzilotta, E; Manghisi, OG; Paola Albergoni, M | 1 |
| Christensen, AF; Mando, OG; Ridruejo, E | 1 |
| Alessio, A; Buonsante, ME; Frider, B; Pellerano, G; Tiscornia, J | 1 |
| Anderson, F; Bain, VG; Balshaw, R; Deschenes, M; Kaita, K; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Simonyi, S; Yoshida, EM | 1 |
| Tulassay, Z; Werling, K | 1 |
| García-Buey, L; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Arakawa, Y; Moriyama, M | 1 |
| Carnero-Fernández, M; Lite-Alvarez, JM; Pineda, JR | 1 |
| Arpurt, JP; Bernard, P; Chousterman, M; Fischer, D; Glibert, A; Grasset, D; Lagier, E; Morin, T; Nalet, B; Pariente, A; Picon, M; Pillon, D; Ramdani, M; Renou, C; Rotily, M; Wartelle-Bladou, C | 1 |
| Abud-Bastida, F; Constantino-Casas, P; García-Contreras, F; Garduño-Espinosa, J; Nevárez-Sida, A | 1 |
| Grieve, R; Main, J; Roberts, J; Thomas, HC; Wright, M | 1 |
| Ahern, M; Cai, FZ; Smith, M | 1 |
| Bernal, Mdel C; Casado, J; De Rueda, PM; Huertas, C; Palacios, A; Rodríguez, L; Ruiz-Extremera, A; Salmerón, J | 1 |
| Halota, W; Palewicz, E; Pawłowska, M | 1 |
| Simon, K | 1 |
| Ruiz-Sancho, A; Soriano, V | 1 |
| Asselah, T; Bedossa, P; Boyer, N; Dargere, D; Marcellin, P; Martinot, M; Paradis, V; Ripault, MP; Valla, D | 1 |
| Amorim, W; Cheinquer, H; Correa, E; Cotrim, H; Crespo, D; Fonseca, J; Gallizi, J; Lacet, C; Martinelli, A; Meirelles, A; Paraná, R; Parise, E; Pessoa, M; Sette, H; Silva, R; Spinelli, V; Tatsch, F | 1 |
| Sette, H; Tatsch, FF; Vianna, D | 1 |
| Ashikaga, T; Gordon, SR; Grace, ND; Krawitt, EL; Moskowitz, S; Palmer, M; Ray, MA; Yarze, JC | 1 |
| Di Martino, V; Le Calvez, S; Massard, J; Munteanu, M; Poynard, T; Ratziu, V; Thabut, D; Thibault, V | 1 |
| Iino, S; Itoh, F; Kobayashi, Y; Koike, K; Nagase, Y; Okuse, C; Suzuki, M; Yasuda, K; Yotsuyanagi, H | 1 |
| Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Giordanino, C; Macor, A; Manca, A; Orsi, PG; Pozzi, M; Prandi, G; Rizzetto, M; Saracco, G; Smedile, A; Tappero, GF | 1 |
| Bordens, R; Cullen, C; Cutler, D; Grace, M; Harvey, J; Jackson, M; Laughlin, M; Poo, J; Silva, M; Wagner, F | 1 |
| Balestrieri, C; Cauli, C; Chessa, L; Farci, P; Lai, ME; Scioscia, R; Serra, G | 1 |
| Kupś, J; Wiśniewska-Ligier, M; Woźniakowska-Gesicka, T | 1 |
| Barreiro, P; Garcia-Samaniego, J; Labarga, P; Martín-Carbonero, L; Nuñez, M; Ramos, B; Romero, M; Simarro, N; Soriano, V | 1 |
| Berg, C; Bernstein, DE; Cooksley, G; Diago, M; Goncales, FL; Graham, P; Jensen, DM; Rasenack, J; Sette, H | 1 |
| Adachi, Y; Fujita, N; Horiike, S; Iwasa, M; Kai, M; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Watanabe, S | 1 |
| Arn, M; Borovicka, J; Criblez, D; Egger, H; Gonvers, JJ; Helbling, B; Meyenberger, C; Meyer-Wyss, B; Müllhaupt, B; Oneta, C; Rammert, C; Renner, EL; Rich, P; Rossi, L | 1 |
| Bernfort, L; Reichard, O; Sennfält, K | 1 |
| Blatt, LM; Seiwert, SD; Wang, T | 1 |
| Baditoiu, L; Danila, M; Laza, A; Popescu, A; Sirli, R; Sporea, I | 1 |
| Borque, MJ; Fernández, MJ; García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Muñoz, C; Quintana, NE; Salvanés, FR; Trapero-Marugán, M | 1 |
| Bagheri, H; Barange, K; Bonnet, E; Claeyssens, S; Guitton, E; Massip, P; Montastruc, JL; Vinel, JP | 1 |
| Alves, VA; Correa-Giannella, ML; Giannella-Neto, D; Machado, MC; Massarollo, PC; Ribeiro, CM; Stefano, JT | 1 |
| Ito, S; Taguchi, N | 1 |
| Abe, H; Aizawa, R; Aizawa, Y; Chuganji, Y; Endou, H; Fujimoto, T; Fujita, Y; Higuchi, T; Iga, D; Ishizuka, H; Itou, Y; Kuroda, H; Matsuda, T; Nakanishi, H; Ohta, K; Tomimatsu, M; Ushiyama, H | 1 |
| Ahmad, I; Alam, A; Butt, AK; Dilshad, A; Khan, AA; Sarwar, S | 1 |
| Arican, N; Gümrah, M; Mehtap, O; Yenice, N | 1 |
| Di Liberto, G; Ducoulombier, D; Fallot, G; Feray, C; Kara, R; Roque-Afonso, AM; Samuel, D | 1 |
| Cassidy, W; Howell, CD; Hu, S; Jeffers, LS; Lee, JS; Reddy, KR | 1 |
| Farci, P; Green, J; Hornberger, J; Patel, KK; Prati, D; Zeuzem, S | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, JF; Lee, LP; Lee, PL; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Chen, CH; Eng, HL; Hu, TH; Hung, CH; Kuo, FY; Lee, CM; Lu, SN; Wang, JH | 1 |
| Andrade, RJ; Camargo, R; Cilvetti, A; Clavijo, E; García-Cortés, M; González, FJ; Lucena, MI; Martos-VanDussen, JV; Rosón, P; Vázquez, L | 1 |
| Bahra, M; Berg, T; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, U; Puhl, G | 1 |
| Daruich, J; Fainboim, H; Frider, B | 1 |
| Elefsiniotis, IS; Kamposioras, K; Ketikoglou, I; Moulakakis, A; Pantazis, KD; Saroglou, G; Tontorova, R; Vezali, E | 1 |
| Berenguer, M; Terrault, NA | 1 |
| Bang, CT; Bodenheimer, HC; Clain, DJ; Gopal, K; Gopal, S; Johnson, TC; Min, AD; Pena-Sahdala, HN; Suwandhi, P; Walfish, A | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC | 1 |
| Furutani, T; Hara, Y; Hino, K; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M; Ren, F; Yamaguchi, Y; Yamashita, S; Yutoku, K | 1 |
| Ariello, M; Conca, P; Sorrentino, P; Tarantino, G | 1 |
| Carrilho, FJ; D'Amico, EA; Farias, AQ; Goncalves, LL; Gonçalves, PL | 1 |
| Fireman, M; Hauser, P; Matthews, AM; Sobel, M; Zucker, B | 1 |
| Amaral, AC; Conceição, RD; de Oliveira, AC; Leite, K; Parise, ER | 1 |
| Stribling, R; Sussman, N; Vierling, JM | 1 |
| Gisbert, JP; Maté, J; Medina, J; Moreno-Otero, R; Nam Cha, SJ; Salcedo-Mora, X | 1 |
| Chao, YC; Chen, DS; Chen, EY; Chen, PJ; Chuang, WL; Dai, CY; Gu, ZJ; Hwang, Y; Lai, MY; Lee, CM; Liao, YT; Shian-Jy Bey, M; Wang, JH; Yu, ML | 1 |
| Cotler, SJ; Layden, TJ; Layden-Almer, JE | 1 |
| Chiba, T; Egawa, H; Ikeda, K; Iwai, A; Marusawa, H; Nabeshima, M; Takada, Y; Uemoto, S | 1 |
| Boillot, O; Chevallier, P; Ducos, E; Dumortier, J; Gagnieu, MC; Scoazec, JY | 1 |
| Carrión, JA; Costa, J; Feliu, A; Forns, X; García-Retortillo, M; González, P; Martínez-Bauer, E; Massaguer, A; Sánchez-Tapias, JM | 1 |
| Barone, A; Brandão, C; Caramori, C; Carrilho, F; Focaccia, R; Patelli, M; Pedroso, M; Pereira, L; Pessoa, M; Silva, A; Tatsch, F | 1 |
| Cornberg, M; Manns, MP; Wedemeyer, H | 4 |
| Dudley, T; Haydon, G; Mutimer, D; O'Donnell, K | 1 |
| Bräu, N; Eldeiry, LS; Greenberg, PD; Naqvi, Z; Rosman, AS | 1 |
| Chung, DJ; Jin, HM; Kim, JH; Kim, K; Kim, N; Lee, J; Lee, KB | 1 |
| Coupoulou, AA; Dimitropoulou, D; Gogos, CA; Karatza, C; Liava, A; Petsas, T; Siagris, D; Syrokosta, I; Thomopoulos, K; Tsamandas, AC; Zolota, V | 1 |
| Fischer, K; Makris, M; Mauser-Bunschoten, EP; Posthouwer, D | 1 |
| Bhagani, S; Johnson, M; Killingley, B; Slapak, G; Yee, TT | 1 |
| Hayashi, K; Hirashima, N; Kato, H; Kato, T; Lau, JY; Mizokami, M; Mizuno, Y; Ogino, M; Ohno, T; Orito, E; Sakakibara, K; Sugihara, K; Suzuki, S; Tanaka, Y; Ueda, R | 1 |
| Arataki, K; Chayama, K; Kumada, H; Ohishi, W; Takahashi, S; Tazuma, S; Toyota, K | 1 |
| Aimitsu, S; Aisaka, Y; Chayama, K; Kawakami, H; Kitamoto, M; Kohno, H | 1 |
| de Filippo, FR; Focareta, R; Forte, G; Piai, G; Scalice, E; Terracciano, F | 1 |
| Aslan, V; Aykin, N; Cevik, F; Demirdal, T; Demirturk, N | 1 |
| Costas, P; Ortiz, A; Torres, EA; Velázquez, V | 1 |
| Aponte, N; Arroyo, J; Chinea, B; De Jesus-Monge, WE; González, H; Guzmán, A; Muñoz, H; Rivera, C; Rodríguez, F; Toro, DH; Torres, EA | 1 |
| Antúnez, I; Aponte, N; Fernández-Carbia, A; Rodríguez-Perez, F; Toro, DH | 1 |
| Müller, C | 1 |
| Arora, N; Goyal, A; Kumar, GT; Sarin, SK; Shukla, DK; Suneetha, PV | 1 |
| Adenwalla, M; Cheong-Lee, C; Ma, PE; Yoshida, EM; Zandieh, I | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Kuo, HT; Lee, LP; Lin, ZY; Tsai, SL; Wang, LY; Yu, ML | 1 |
| Ansaldi, F; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
| Antela, A; Bárcena, R; Celma, ML; Fernández-Muñoz, R; García-Martos, M; López-San Román, A; Moreno, A; Moreno, L; Moreno, S; Pérez-Elías, MJ; Quereda, C | 1 |
| Funada, R; Harada, K; Hasegawa, K; Homma, N; Inoue, M; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T | 2 |
| Arora, N; Blum, HE; Goyal, A; Hermann, E; Hissar, SS; Hofmann, WP; Sarin, SK; Sarrazin, C; Traver, S; Zeuzem, S | 1 |
| Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Clements, BJ; Malibu, Y; Sylvestre, DL | 1 |
| Akimoto, Y; Harada, S; Hirai, M; Hirooka, T; Hotta, H; Ishii, F; Izawa, S; Kim, KI; Kim, SH; Kim, SR; Kimura, N; Kinoshita, K; Kinoshita, M; Motojima, M; Nabeshima, S; Nakao, K; Ohtani, A; Ohzu, M; Sasase, N; Shikata, M; Tanaka, K; Taniguchi, M | 1 |
| Dhillon, AP; Dustin, LB; Ferrari, C; Haagmans, BL; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; Westin, J; Zeuzem, S | 1 |
| Battistin, L; Bernardinello, E; Briani, C; Cavalletto, L; Chemello, L; Ermani, M; Gatta, A; Ruggero, S; Toffanin, E; Zara, G | 1 |
| Cua, IH; George, J; Henriquez, M; Kench, J; Kwan, V | 1 |
| Bottari, S; Hilleret, MN; Leroy, V; Morel, F; Sturm, N; Trocme, C; Zarski, JP | 1 |
| Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS | 1 |
| Boyer, N; Castelnau, C; Comanor, L; Giuily, N; Hendricks, D; Marcellin, P; Martinot-Peignoux, M; Minor, JM; Pham, BN; Ripault, MP | 1 |
| Dolmazashvili, E; Gochitashvili, N; Kakabadze, T; Sharvadze, L; Tsertsvadze, T | 1 |
| Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M | 1 |
| Kobayashi, K; Kobayashi, T; Kondo, Y; Shiina, M; Shimosegawa, T; Ueno, Y | 1 |
| Takahashi, H; Zeniya, M | 1 |
| Elefsiniotis, IS; Ketikoglou, I; Pantazis, KD; Petrocheilou, A; Scarmeas, N; Toutouza, M; Tsianos, EV | 1 |
| Cho, H; Kim, YM; Lee, JS; Lee, MY | 1 |
| Araújo, C; Braga, H; Cruz, M; Cruz, T; Cunha, S; Mello, V; Ney-Oliveira, F; Nuñez, G; Parana, R; Schinoni, MI; Simões, MT | 1 |
| Deschênes, M; Hilzenrat, N; Nudo, CG; Wong, P | 1 |
| Mathew, A; McGarrity, T; Peiffer, LP; Rhoades, K | 1 |
| Banerjee, R; Gupta, R; Lakhtakia, S; Ramakrishna, CH; Reddy, DN; Tandan, M | 1 |
| Gehring, S; Gerner, P; Koeppelmann, S; Kullmer, U; Wintermeyer, P; Wirth, S | 1 |
| Chrysagis, D; Dalekos, GN; Elefsiniotis, I; Gigi, E; Kanatakis, S; Kartalis, G; Ketikoglou, I; Koliouskas, D; Mimidis, K; Papadopoulos, VP; Paraskevas, E; Protopapas, A; Tsianos, E; Tzathas, C | 1 |
| Alberti, A; Diago, M; Marcellin, P; Negro, F; Prati, D; Puoti, C; Roberts, SK; Rosenberg, W; Shiffman, ML; Zeuzem, S | 1 |
| Bernard, PH; Castera, L; Champbenoit, P; Constant, A; Couzigou, P; De Ledinghen, V; Demotes-Mainard, J; Henry, C | 1 |
| Colombo, M; Coppola, A; Linari, S; Mancuso, ME; Mannucci, PM; Rumi, MG; Santagostino, E | 1 |
| Fabris, C; Pirisi, M; Toniutto, P | 1 |
| Ebinuma, H; Hibi, T; Ishii, H; Kashiwazaki, K; Nishida, J; Saito, H; Shiozaki, H; Tada, S; Takahashi, M; Tanaka, S; Tsukada, N | 1 |
| Asselah, T; Bourlière, M; Bouvier-Alias, M; Bronowicki, JP; Chevalier, M; Chevaliez, S; Desmorat, H; Foucher, J; Hézode, C; Lonjon-Domanec, I; Melin, P; Montestruc, F; Ouzan, D; Pawlotsky, JM; Renou, C; Tran, A; Zarski, JP | 1 |
| Rustgi, VK; Shiffman, ML | 1 |
| Alvarez, E; Bañares, R; Catalina, MV; Clemente, G; Lo Iacono, O; Matilla, AM; Nuñez, O; Rincon, D; Ripoll, C; Salcedo, M | 1 |
| Ferenci, P; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Peck-Radosavljevic, M; Schmid, M; Sieghart, W | 1 |
| Chang, KC; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Durante Mangoni, E; Graham, CS; He, Q; Koziel, MJ | 1 |
| Alessandri, A; Franco, V; Giannitrapani, L; Montalto, G; Rappa, F; Soresi, M; Tripi, S; Vuturo, O | 1 |
| Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; Girón-González, JA; Guzmán, EP; Márquez, M; Rodríguez-Iglesias, M | 1 |
| Hagiwara, H; Haruna, Y; Hayashi, N; Hijioka, T; Hiramatsu, N; Ishibashi, K; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kubota, S; Kurashige, N; Mita, E; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tsuda, N; Yakushijin, T; Yoshihara, H | 1 |
| Bodenheimer, HC; Clain, DJ; Homel, P; Kalakuntla, R; Min, AD; Narasimhan, G; Sargios, TN; Theise, ND | 1 |
| Chen, EY; Gu, ZJ; Hwang, Y; Lin, E; Wang, SC | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Lee, CM; Lee, LP; Liaw, YF; Lin, SM; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Fernández-Carbia, A; González-Lassalle, E; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R | 1 |
| Leung, Y; Myers, RP; Schindel, L; Urbanski, SJ | 1 |
| Alexander, J; Kowdley, KV | 1 |
| Agho, K; Byrne, A; Dore, GJ; Hallinan, R | 1 |
| Etani, Y; Hasegawa, Y; Mushiake, S; Ozono, K; Tajiri, H | 1 |
| Chang, CS; Chen, GH; Fu, LS; Kao, JH; Yang, SS; Yeh, HZ | 1 |
| Cacoub, P; Piette, JC; Resche-Rigon, M; Saadoun, D; Thibault, V | 1 |
| Artioli, S; Azzola, E; Basso, M; Blanchi, S; Grasso, A; Pelli, N; Percario, G; Picciotto, A; Torre, F | 1 |
| Dixit, V; Fabrizi, F; Lunghi, G; Martin, P | 1 |
| Lin, WA; Tang, SL; Tarn, YH | 1 |
| Buggisch, P; Clumeck, N; DePamphilis, J; Dieterich, D; Lissen, E; Main, J; Mendes-Correa, M; Montaner, J; Nelson, M; Pessôa, M; Sola, R | 1 |
| Barreiro, P; Garcia-Samaniego, J; Labarga, P; Ruiz-Sancho, A; Soriano, V | 1 |
| Aguilera Sancho-Tell, V; Berenguer Haym, M; Iborra Colomino, M | 1 |
| Dalekos, GN; Gatselis, NK; Georgiadou, SP; Hatzakis, A; Koukoulis, GK; Liaskos, C; Tassopoulos, N; Zachou, K | 1 |
| Alves Couto, C; Costa Faria, L; de Abreu Ferrari, TC; de Melo Couto, OF; de Paula Farah, K; Dias Ribeiro, D | 1 |
| Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; D'Angelo, F; Di Marco, V; Di Stefano, R; Ferraro, D; Porrovecchio, S | 1 |
| Civolani, A; Demelia, L; Murgia, D; Murru, A; Rizzetto, M; Sorbello, O | 1 |
| Abergel, A; Alric, L; Barange, K; Bernard, PH; Bommelaer, G; Bonny, C; Bronowicki, JP; Castera, L; Chevallier, M; Darcha, C; Dhumeaux, D; Dubost, S; Henquell, C; Hezode, C; Lafeuille, H; Leroy, V; Martineau, N; Randl, K; Tran, A; Ughetto, S | 1 |
| Carulli, N | 1 |
| Balzola, F; Bellati, G; Benetti, G; Borzio, M; Colombo, A; Croce, G; Fargion, S; Iamoletti, C; Ramella, G; Rizzetto, M | 1 |
| Duff, F; Jorga, K; Lamb, M; Snoeck, E; Wade, JR | 2 |
| Fan, YM; Li, DM; Li, TS; Li, ZR; Liao, GX; Ma, XJ | 1 |
| Boix-Martínez, V; Clemente-Ricote, G; Marco-Mouriño, A; Núñez-Martínez, O; Portilla-Sogorb, J; Reus-Bañuls, S; Saiz de la Hoya-Zamácola, P; Teixidó i Pérez, N | 1 |
| Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Leandro, G; Perri, F; Siciliano, M | 1 |
| Ballesteros, AL; Clotet, B; Ferrer, MJ; Fumaz, CR; Fuster, D; Gómez, G; Masmitjà, E; Muñoz-Moreno, JA; Paredes, R; Pérez-Alvarez, N; Salas, A; Tural, C | 1 |
| Romero-Gómez, M | 1 |
| McHutchison, JG; Muir, AJ | 1 |
| Dhillon, AP; Ferrari, C; Haagmans, BL; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; von Wagner, M; Westin, J; Zeuzem, S | 1 |
| Del Rio, RA; Post, AB; Singer, ME | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Kahn, JA; Lee, WM; Lok, AS; Morishima, C; Naishadham, D; Seeff, LB; Shiffman, ML | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Itoh, A; Katano, Y; Murayama, M; Nakano, I | 1 |
| Bergholz, U; Ferenci, P; Gurguta, C; Hofer, H; Steindl-Munda, P | 1 |
| Carrilho, FJ; da Silva, LC; de Carvalho Mello, IM; de Mello Malta, F; Medeiros-Filho, JE; Neumann, AU; Pinho, JR | 1 |
| Buenestado-García, J; Egido-García, R; Piñol-Felis, C; Reñé-Espinet, JM; Rubio-Caballero, M; Rubio-Rivas, M | 1 |
| Tural i Llàcher, C | 1 |
| Laursen, AL; Vilstrup, H | 1 |
| Berg, T; Bergk, A; Halangk, J; Hinrichsen, H; Müller, T; Neuhaus, P; Neumann, K; Puhl, G; Schott, E; Tinjala, S; Weich, V; Wiedenmann, B; Witt, H | 1 |
| Hoofnagle, JH; Seeff, LB | 1 |
| Deibler, P; Haasen, C; Reimer, J | 1 |
| Darling, JM; Fried, MW | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Koyama, R; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y | 1 |
| Bonte, D; Capron, D; Castelain, S; Dedeurwaerder, S; Duverlie, G; François, C; Morel, V; Penin, F; Wychowski, C; Zawadzki, P | 1 |
| Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D | 1 |
| Afdhal, NH; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Kleiner, DE; Wahed, AS; Zacks, S | 1 |
| Honda, H; Honda, M; Kaneko, S; Kawamura, T; Tateno, M | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, JH; Lee, KS; Moon, YM; Park, YN | 1 |
| Jiang, HC; Li, SC; Liu, BR; Yang, XH | 1 |
| Back-Madruga, C; Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Gretch, DR; Kulig, CC; Malet, PF; Morgan, TR; Snow, KK; Sterling, RK | 1 |
| Fried, M; Hadziyannis, S; Hamzeh, FM; Morgan, TR; Reddy, KR; Shiffman, ML; Wright, TL; Zeuzem, S | 1 |
| Baker, RD; Baker, SS; Dee, D | 1 |
| Aikaterini, T; Barbara, M; Claudio, I; Daniela, C; Danila, C; Davide, P; Gaetano, B; Giuseppe, A; Luca, I; Luciano, C; Massimo, L; Salvatore, T; Sergio, N; Stefano, C | 1 |
| Ide, T; Kage, M; Maruyama, T; Okamura, T; Sata, M; Seki, R; Uyesaka, N | 1 |
| Manns, MP; Tillmann, H; Trebst, C; Wedemeyer, H; Windhagen, A | 1 |
| Abbott, WG; Naoumov, NV; Rigopoulou, EI; Williams, R | 1 |
| Adachi, Y; Fujita, N; Hasegawa, K; Horiike, S; Iwasa, M; Kaito, M; Kawanishi, S; Kobayashi, Y; Ma, N; Sugimoto, R; Tanaka, H | 1 |
| Dhillon, AP; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; Westin, J; Zeuzem, S | 1 |
| Akamatsu, T; Ichijo, T; Kiyosawa, K; Matsumoto, A; Muto, H; Tanaka, E; Umemura, T; Yoshizawa, K | 1 |
| De Heusden, N; Fischer, K; Mauser-Bunschoten, EP; Posthouwer, D | 1 |
| Asselah, T; Bourlière, M; Boyer, N; Cazals-Hatem, D; El Ray, A; Marcellin, P; Martinot-Peignoux, M; Moucari, R; Oulès, V; Ripault, MP; Valla, D; Vidaud, D | 1 |
| Conde, A; Cruces, M; De La Torre, C; García-Doval, I; González-Sixto, B; Mayo, E; Pardavila, R | 1 |
| Bini, EJ; Bräu, N; Cheung, RC; Currie, SL; Ho, SB; Hu, KQ; Jeffers, L; McCracken, JD; Morgan, T; Schmidt, WN; Shen, H; Wright, TL | 1 |
| Mallet, VO; Pol, S | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC | 1 |
| Andrade, R; de la Mata, M; Diago, M; Granados, R; Muñoz de Rueda, P; Pérez, R; Romero, M; Ruiz-Extremera, A; Salmerón, J; Solá, R | 1 |
| Colledan, M; Montalbano, M; Pasulo, L; Remuzzi, G; Sonzogni, A; Strazzabosco, M | 1 |
| Bardadin, K; Berak, H; Horban, A; Paprocka, H; Stańczak, JJ; Wasilewski, M | 1 |
| Balan, V; Cheruvattath, R; Gautam, M; Rakela, J; Rosati, MJ; Vargas, HE | 1 |
| Bani-Sadr, F; Chakvetadze, C; Lamontagne, F; Le Pendeven, C; Pialoux, G; Vincensini, JP | 1 |
| Bowers, P; Henry, DH; Lamarca, A; Leitz, G; Slim, J | 1 |
| Belle, SH; Brodsky, L; Edenberg, HJ; Howell, C; Li, L; McClintick, JN; Sanda, C; Schaley, J; Stephens, MJ; Tavis, JE; Taylor, MW; Tsukahara, T | 1 |
| Fuchs, M; Ludwig, D; Witthoeft, T | 1 |
| Adachi, K; Iino, S; Ishii, T; Itoh, F; Katakura, Y; Matsumoto, N; Matsunaga, K; Okuse, C; Suzuki, M; Yotsuyanagi, H | 1 |
| Giuliani, R; Manfredi, R; Sabbatani, S | 1 |
| Araújo, E; Barone, AA; Borges, A; Coelho, HS; Corrêa-Giannella, ML; Ferraz, ML; Focaccia, R; Gonçales, FL; Gonçales, N; Lobato, C; Oliveira, U; Paixao, J; Perez, R; Rosa, H; Vigani, A; Vila, R; Weirich, J | 1 |
| Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP | 1 |
| Antinori, A; Armignacco, O; Babudieri, S; Carioti, J; Caroleo, B; Guadagnino, V; Maio, G; Monarca, R; Montesano, F; Trotta, MP | 1 |
| Adams, PC; Bain, VG; Chatterjee, A; Croitoru, K; Heathcote, EJ; Kaita, K; Lee, SS; Peltekian, K; Swain, MG; Teitel, J | 1 |
| Bahnassy, AA; El-Awady, M; El-Din, HM; El-Hefnewi, M; Fouad, I; Khaled, MM; Omar, A; Thakeb, F; Zekri, AR | 1 |
| Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Ocaña, I; Pahissa, A; Ribera, E; Sauleda, S | 1 |
| Brunetto, MR; Fargion, S; Gaeta, GB; Niro, GA; Picciotto, A; Pontisso, P; Raimondo, G; Saitta, C; Smedile, A; Squadrito, G | 1 |
| Bourlière, M; Pol, S | 1 |
| Chang, WY; Chuang, WL; Dai, CY; Lee, CM; Liaw, YF; Lin, SM; Lu, SN; Sheen, IS; Wang, JH; Yu, ML | 1 |
| Delgado-Jimenez, Y; Fernandez-Herrera, J; Fraga, J; Garcia-Diez, A; Goiriz, R; Perez-Gala, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG; Soffredini, R | 1 |
| Gra Oramas, B; Llanio Navarro, R; Ruenes Domech, C; Soler, E; Vilar Gomez, E | 1 |
| Januszkiewicz-Lewandowska, D; Lewandowski, K; Mańkowski, P; Nowak, J; Nowicka, K; Pernak, M; Rembowska, J; Wysocki, J; Zawada, M | 1 |
| Barreiro, P; Benito, JM; de Baar, M; de Mendoza, C; González-Lahoz, J; Martin-Carbonero, L; Rodriguez-Novoa, S; Soriano, V; Zahonero, N | 1 |
| Brok, J; Gluud, C; Gong, Y; Koretz, RL | 1 |
| Luketic, VA; Mihas, AA; Millwala, F; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Berenson, CS; Bhatti, Z | 1 |
| Amore, M; Baldini, A; Beverini, E; Bonino, F; Brunetto, M; Carlini, M; Del Debbio, A; Dell'Osso, L; Ferrari, G; Maggi, L; Maj, M; Manca, E; Pini, S; Rucci, P; Scarallo, V; Semeraro, Q | 1 |
| Kallman, J; Kincaid, J; Younossi, Z | 1 |
| Foster, GR; Freivogel, K; Fried, MW; Hadziyannis, SJ; Messinger, D; Weiland, O | 1 |
| Aszalós, Z; Lengyel, G; Tulassay, Z | 1 |
| Davidson, P; Hartwell, D; Jones, J; Price, A; Shepherd, J; Waugh, N | 1 |
| Campos, NG; Freedberg, KA; Goldie, SJ; Nunes, DP; Salomon, JA; Samet, JH; Servoss, JC | 1 |
| Dong, MH; Kaunitz, JD; Smith, JP | 1 |
| Christodoulou, D; Christou, L; Economou, MS; Filis, S; Tsianos, EV; Vienna, H | 1 |
| Archimandritis, AJ; Hadziyannis, E; Karandreas, N; Kilidireas, C; Koskinas, J; Kountouras, D; Savvas, S | 1 |
| Sallie, R | 1 |
| Cacoub, P; Carrat, F; Fafi-Kremer, S; Lunel, F; Morand, P; Payan, C; Perronne, C; Pivert, A; Pol, S | 1 |
| Honsová, E; Sperl, J; Sticová, E | 1 |
| Attia, JR; Batey, RG; Jones, TL; Tran, HA | 1 |
| Duggan, AE; Duggan, JM | 1 |
| Abramowicz, M | 1 |
| Dalmi, L; Gervain, J; Hunyady, B; Ibrányi, E; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Han, DS; Jeon, YC; Kim, TY; Park, YK; Sohn, JH; Son, BK | 1 |
| Evoli, A; Servidei, S | 1 |
| Assy, N; Embon, O | 1 |
| Leiner, S | 1 |
| Ben Salem, C; Bouraoui, K; Hmouda, H | 1 |
| Andreu, AL; Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Juarez, A; Ocaña, I; Pahissa, A; Quer, J; Ribera, E; Ruiz, I; Sauleda, S | 1 |
| Amoruso, AC; Castellaneta, NM; Di Leo, A; Francavilla, A; Losito, F; Rendina, M; Schena, A; Schena, FP; Stallone, G | 1 |
| Herrmann, E; Hofmann, WP; Kronenberger, B; Lohmann, V; Mihm, U; Polta, A; Sarrazin, C; Schönberger, B; Sonntag, T; Zeuzem, S | 1 |
| Hayashi, N; Hiramatsu, N; Inoue, M; Itose, I; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Miyatake, H; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T; Yakushijin, T | 1 |
| Aberle, JH; Ferenci, P; Gurguta, C; Holzmann, H; Kundi, M; Perstinger, G; Popow-Kraupp, T; Sinzinger, U; Steindl-Munda, P; Weseslindtner, L | 1 |
| Brown, RS; Manns, MP; McHutchison, JG; Reddy, KR; Shiffman, ML; Wong, JB | 1 |
| García-Morán, S; Muñoz Fernández-Lomana, C; Sáez-Royuela, F | 1 |
| Riley, TR; Taheri, MR | 1 |
| Antón, M; Barniol, R; Benítez, A; Casanovas, T; Dalmau, B; Del Olmo, J; Diago, M; Díaz, F; Domínguez, A; Enríquez, J; Eraña, L; Garijo, JM; Gavilán, JC; Huarte, M; Jiménez, E; Montoro, M; Moreno-Otero, R; Muñoz-Sánchez, M; Olcoz, JL; Olveira, A; Orive, M; Pamplona, X; Pérez, R; Planas, R; Portu, J; Romero-Gómez, M; Roset, M; Rota, R; Salmerón, J; Sánchez-Galdón, S; Sánchez-Ruano, J; Sillero, C; Solá, R; Uribarrena, R | 1 |
| Angeletti, C; Antonucci, G; Boumis, E; Capobianchi, MR; Comandini, UV; Girardi, E; Longo, MA; Noto, P; Oliva, A; Solmone, MC; Tocci, G; Vairo, F | 1 |
| Bonkovsky, H; Faris-Young, S; Huntley, B; Lyons, MF; Reddy, KR; Ryan, M; Santoro, J; Sjogren, MH; Sjogren, R; Smith, C | 1 |
| Ahmed, F; Gonzalez, SA; Jacobson, IM; Kadam, JS; Menezes, A | 1 |
| Amaki, S; Arakawa, Y; Kaneko, M; Matsumura, H; Matsuoka, S; Moriyama, M; Nirei, K; Ogawa, M; Tanaka, N; Yamagami, H | 1 |
| Lv, H; Wang, YZ; Yu, SL; Zhang, QG; Zhang, ZH | 1 |
| Brunette, MF; Iber, M; Luckoor, R; Mistler, LA; Rosenberg, SD; Vidaver, RM | 1 |
| Cuadrado Pastor, JM; Jover Díaz, FM; Wikman Jorgensen, PE | 1 |
| Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP | 1 |
| Fleckenstein, J; Krushkal, J; Li, R; Mason, BC; Park, VM; Riely, C | 1 |
| Dahari, H; Haller, I; Licholai, T; Markatou, M; Perelson, AS; Ribeiro, RM; Talal, AH; Zeremski, M | 1 |
| Janssen, HL; Schalm, SW; Veldt, BJ | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP | 1 |
| Ivashkin, VT; Maevskaia, MV; Pablov, ChS; Vedernikova, AV; Zolotarevskiĭ, VB | 1 |
| Batista-Neves, SC; Bressan, RA; Cruz, SC; Miranda-Scippa, A; Paraná, R; Quarantini, LC | 1 |
| Cacayorin, E; Cedron, H; Kato, T; Levi, D; Moon, J; Nishida, S; Pyrsopoulos, N; Schiff, E; Selvaggi, G; Taffaro, M; Tzakis, A; Weppler, D | 1 |
| Fucci, JC; Gleason, OC; Philipsen, MA; Yates, WR | 1 |
| Bachmatov, L; Ben-Ari, Z; Cohen, M; Rotman, Y; Tur-Kaspa, R; Zemel, R | 1 |
| Fischer, J; Metzler, G; Schaller, M | 1 |
| Annicchiarico, BE; Avolio, AW; Bombardieri, G; Grillo, RL; Siciliano, M | 1 |
| Karandikar, NJ; Lee, WM; Pillai, V; Thiele, DL | 1 |
| Behler, CM; Chung, RT; Lin, F; Peters, MG; Robbins, GK; Vittinghoff, E; Volberding, PA | 1 |
| Hayashi, N; Iino, S; Kiyosawa, K; Kuboki, M; Kumada, H; Okuno, T; Omata, M; Sakai, T | 1 |
| Chao, PL; Chen, TM; Ho, KS; Huang, PT; Lin, LF; Liu, CC; Siauw, CP; Tsai, MH; Tung, JN | 1 |
| El-Shamy, A; Hotta, H; Imoto, S; Kim, SR; Nagano-Fujii, M; Sasase, N; Sasayama, M | 1 |
| Cincin, A; Imeryuz, N; Ozdogan, O; Tahan, V; Tozun, N | 1 |
| Anderson, GD; Goharkhay, N; Hankins, GD; Jain, S; Saade, G | 1 |
| Gaudy, C; Le Guillou-Guillemette, H; Lunel, F; Payan, C; Veillon, P | 1 |
| Brok, J; Gluud, C; Gluud, LL; Simin, M; Stimac, D | 1 |
| Asnis, GM; Borisov, AS; Bruno, CJ; Demetrashvili, MF; Evans, DL; Henderson, MA; Miller, AH; Raison, CL; Reinus, JF; Staab, JP; Weinreib, R; Woolwine, BJ; Zajecka, JM | 1 |
| Almasio, PL; Amato, M; Craxí, A; De Lisi, S; Di Marco, V; Ferraro, D; Giordano, C; Lo Iacono, O; Mineo, C; Petta, S; Rodolico, V; Venezia, G | 1 |
| Bartolomé, J; Carreño, V; Castellanos, ME; Castillo, I; López-Alcorocho, JM; Pardo, M; Quiroga, JA; Rodríguez-Iñigo, E | 1 |
| Carreño, V; Desombere, I; Hultgren, C; Leroux-Roels, G; Quiroga, J; Sällberg, M; Van Vlierberghe, H; Weiland, O | 1 |
| Encke, J; Stremmel, W; Weigand, K | 1 |
| Alsiö, A; Ferrari, C; Hellstrand, K; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Verhey-Hart, E; Westin, J; Ydreborg, M; Zeuzem, S | 1 |
| Back-Madruga, C; Bieliauskas, LA; Fontana, RJ; Kronfol, Z; Lindsay, KL; Lok, AS; Padmanabhan, L; Snow, KK; Wright, EC | 1 |
| Pár, A; Szalay, F; Tornai, I | 1 |
| Barreiro, P; Berdún, MA; Galindo, MJ; Hernandez-Burruezo, JJ; Mariño, A; Martin-Carbonero, L; Miralles, C; Núñez, M; Sola, J; Soriano, V | 1 |
| Arora, S; Gish, RG; Murphy, B; Nelson, DR; O'Brien, C; Rajender Reddy, K; Xu, Y | 1 |
| Bramlage, C; Groene, HJ; Koziolek, MJ; Mueller, GA; Scheel, A; Strutz, F | 1 |
| Danehower, S; Ghany, MG; Hoofnagle, JH; Liang, TJ; Lutchman, G; Song, BC; Thomson, M | 1 |
| Farkas, A; Halász, T; Horváth, G; Tolvaj, G | 1 |
| Córdoba López, A; Monterrubio Villar, J | 1 |
| Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B | 1 |
| Asahina, Y; Doi, F; Higaki, M; Hosokawa, T; Izumi, N; Kitamura, T; Kurosaki, M; Matsunaga, K; Miyake, S; Nakanishi, H; Tsuchiya, K; Uchihara, M; Ueda, K; Umeda, N | 1 |
| Hayashi, N; Hiramatsu, N; Inoue, M; Itose, I; Kaimori, A; Kanto, T; Kasahara, A; Kuzushita, N; Miyatake, H; Miyazaki, M; Sakakibara, M; Takehara, T; Yakushijin, T | 1 |
| Benhamou, Y; Bräu, N; Cargnel, A; Hatzakis, A; Mauss, S; Peters, M; Pol, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M | 1 |
| Forţofoiu, C; Genunche, A; Gofiţă, E; Streba, LA; Vere, CC | 1 |
| Hubscher, S; Lai, WK; Mutimer, D; O'Donnell, K; Thorburn, D; Thurairajah, PH; White, A | 1 |
| Gagnieu, MC; Maynard, M; Souvignet, C; Trepo, C | 1 |
| Buntinx, F; De Bie, J; Robaeys, G; Van Ranst, M | 1 |
| Arraes, LC; Crovella, S; Montenegro de Melo, F; Moura, P; Santos Silva, B; Segat, L; Silva Vasconcelos, LR | 1 |
| Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G | 1 |
| Abdelmalek, MF; Liu, C; Valentine, JF | 1 |
| Arduino, RC; Barnett, BJ; Bull, L; Torres, HA | 1 |
| Bethanis, S; Christidou, A; Katsanika, A; Liapi, C; Manolakopoulos, S; Margeli, A; Sklavos, P; Stripeli, F; Theocharis, S; Tzourmakliotis, D; Vogiatzakis, E | 1 |
| Armstrong, EP; Malone, DC; Skrepnek, GH; Yeh, WS | 1 |
| Angus, P; Bowden, S; Gordon, A; McLean, C; Pedersen, J; Roberts, S; Thomson, K | 1 |
| Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K | 1 |
| Biliotti, E; Taliani, G | 1 |
| Fukumoto, K; Kanemasa, K; Sakai, K; Sumida, Y; Yoshida, N | 1 |
| Hollander, A; Jönsson, B; Lidgren, M; Weiland, O | 1 |
| Hubbard, S; Luketic, VA; Price, A; Salvatore, J; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Alston, B; Aweeka, FT; Chung, RT; Kang, M; Lizak, P; Yu, JY | 1 |
| Bouajram, R; Dorn, A; Kim, AI; Saab, S | 1 |
| Asselah, T; Auray-Cartier, V; Denis, J; Herbert, S; Lambare, B; Rautou, PE | 1 |
| Li, SC; Li, XG; Sun, LJ; Wang, GQ; Yu, JW | 1 |
| Bharadwaj, M; Boo, I; Bowden, S; Chin, R; Drummer, H; Fischer, AE; Giourouki, M; Johnson, D; Torresi, J | 1 |
| Karkar, A | 1 |
| Baazia, Y; Bailly, F; Bourcier, V; Bourlière, M; Castera, L; De Ledinghen, V; Deny, P; Fontaine, H; Grando, V; Marcellin, P; Poupon, R; Roudot-Thoraval, F; Roulot, D; Zarski, JP | 1 |
| Bahnassy, AA; El-Din, HM; Esmat, GE; Hafez, MM; Haleem, HA; Sharaby, AF; Sharaf, H; Zakaria, MS; Zekri, AR | 1 |
| Alestig, E; Arnholm, B; Eilard, A; Hellstrand, K; Lagging, M; Lindh, M; Norkrans, G; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Bodaghi, B; Cacoub, P; Cassoux, N; Hoang, PL; Perlemuter, G; Piette, JC; Saadoun, D; Sene, D; Touitou, V | 1 |
| Bárcena, R; del Campo, S; García, M; Garrido, E; Mateos, ML; Moreno, A; Moreno, S; Muriel, A; Quereda, C | 1 |
| Arjal, RR; Burton, JR; Rosen, HR; Villamil, F | 1 |
| Borghi, G; Chemin, I; Chevallier, M; Chevallier, P; Guillaud, O; Menouar, K; Mrani, S; Pradat, P; Trabaud, MA; Trépo, C; Zoulim, F | 1 |
| Camerini, R; Ciancio, A; DE Rosa, A; Rizzetto, M | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Goto, H; Hayashi, K; Honda, T; Ishigami, M; Katano, Y; Kumada, T; Murayama, M; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K | 1 |
| Chang, KO; George, DW | 1 |
| Kalia, H; Lopez, PM; Martin, P | 1 |
| Chen, DS; Chen, PJ; Hsu, CS; Kao, JH; Lai, MY; Liu, CJ | 1 |
| Araújo, ES; Barone, AA; Courtouké, C | 1 |
| Alam, J; Bengtsson, L; Bronowicki, JP; Garg, V; Grange, JD; Horsmans, Y; Marcellin, P; McNair, L; Nevens, F; Purdy, S; Vetter, D | 1 |
| Bräu, N; Clumeck, N; Cooper, DA; Dieterich, DT; Dore, GJ; Godofsky, EW; Lamoglia, RS; Lissen, E; Mendes-Correa, MC; Nelson, MR; Rodriguez-Torres, M; Sulkowski, M; Torriani, FJ; Tural, C; Yetzer, E | 1 |
| Gluud, C; Gluud, LL; Krogsgaard, K | 1 |
| Arenovich, T; Heathcote, J; Khan, K; Missiha, S | 1 |
| Bansal, M; Hissar, S; Kumar, M; Midha, V; Sakhuja, P; Sarin, SK; Sood, A; Sood, N; Suneetha, PV | 1 |
| Annemans, L; Beguin, C; Gerkens, S; Horsmans, Y; Mouchart, M; Nechelput, M; Peraux, B | 1 |
| Ahmed, R; Antonishyn, N; Chui, L; Doucette, K; McDonald, RR; Obarianyk, A; Tandon, P; Webster, D | 1 |
| Chan, HL; Chow, WC; Ren, H; Wee, T | 1 |
| Bolokadze, N; Gochitashvili, N; Sharvadze, L; Tophuria, A; Tsertsvadze, T | 1 |
| Berg, T; Bergk, A; Krüger, D; Plöckinger, U; Weich, V; Wiedenmann, B | 1 |
| Fischer, K; Griffioen, A; Makris, M; Mauser-Bunschoten, EP; Posthouwer, D; Van Veen, JJ; Yee, TT | 1 |
| Brindani, F; Gemignani, F; Marbini, A | 1 |
| Agarwal, K; Emre, S; Fiel, MI; Kontorinis, N; Schiano, TD; Stanca, CM | 1 |
| Benito, JM; Capa, L; Cascajero, A; de Mendoza, C; García-Samaniego, J; González-Lahoz, J; Muñoz, F; Nuñez, M; Romero, M; Soriano, V | 1 |
| Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Blanco, F; Cervantes, M; de los Santos, I; Echeverria, S; Galindo, MJ; García-Samaniego, J; Guardiola, J; Hernandez-Burruezo, JJ; Losada, E; Martin-Carbonero, L; Miralles, C; Nuñez, M; Ocampo, A; San Joaquín, I; Sola, J; Soriano, V | 1 |
| Arizcorreta-Yarza, A; Girón-González, JA; González-Serrano, M; Gutiérrez-Valencia, A; López-Cortés, LF; Macías, J; Mira, JA; Pineda, JA; Santos, I; Torre-Cisneros, J; Valera-Bestard, B; Vergara, S | 1 |
| Capasso, M; Crocè, L; Iolascon, A; La Mura, V; Masutti, F; Moschella, F; Persico, E; Persico, M; Russo, R; Spano, D; Svelto, M; Tiribelli, C; Torella, R | 1 |
| Berg, T; Friebe, A; Gutsche, J; Halangk, J; Heinz, A; Hinzpeter, A; Janssen, G; Kluschke, M; Mohmand, A; Pich, M; Sarkar, R; Schaefer, M; Schwaiger, M; Weich, V; Ziemer, M | 1 |
| Barreiro, P; Casado, R; Castellares, C; Garcia-Gasco, P; Labarga, P; Maida, I; Martin-Carbonero, L; Pinilla, J; Soriano, V; Vispo, ME | 1 |
| Berkan, E; Jozefowicz-Korczynska, M; Piekarska, A; Wojcik, K | 1 |
| Dworacki, G; Figlerowicz, M; Kaczmarek, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W; Zeromski, J | 1 |
| Berak, H; Horban, A; Kołakowska-Rzadzka, A; Krzysztof, B; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M | 1 |
| Hashimoto, Y; Itoh, M; Kanto, H | 1 |
| Altiparmak, E; Biyikoglu, I; Cicek, B; Filik, L; Oguz, D; Yilmaz, B | 1 |
| Halász, T; Horváth, G; Stotz, G; Tolvaj, G | 1 |
| Allegri, L; Buzio, C; Garini, G; Lannuzzella, F; Vaglio, A | 1 |
| Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Peralta, S | 1 |
| Craxì, A; Heathcote, EJ; Marcellin, P | 1 |
| Akyazi, Z; Erhardt, A; Häussinger, D; Heintges, T; Oette, M; Sagir, A | 1 |
| Bani-Sadr, F; Billaud, E; Cacoub, P; Carrat, F; Doll, J; Goderel, I; Penalba, C; Perronne, C; Pol, S; Welker, Y | 1 |
| Buti, M; Casado, MA; Esteban, R | 1 |
| Akazawa, K; Aoyagi, Y; Kobayashi, K; Nakamura, J; Toyabe, S | 1 |
| Clements, BJ; Sylvestre, DL | 1 |
| Akgun, H; Baskol, M; Gursoy, S; Guven, K; Ozbakir, O; Torun, E; Yucesoy, M; Yurci, A | 1 |
| Alpat, SN; Kartal, ED; Ozgunes, I; Usluer, G | 1 |
| Dybowska, D; Halota, W | 1 |
| Herrmann, E; Hofmann, WP; Kronenberger, B; Mihm, U; Piiper, A; Sarrazin, C; von Wagner, M; Zeuzem, S | 1 |
| Abdel-Hamid, M; Abobakr, H; Anwar, M; Bedossa, P; El Hoseiny, M; Esmat, G; Fontanet, A; Gad, RR; Males, S; Mohamed, MK; Pol, S; Rekacewicz, C; Zalata, K | 1 |
| Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Cervantes, M; de Los Santos, I; Echeverría, S; Galindo, MJ; García-Samaniego, J; Guardiola, JM; Hernandez-Burruezo, JJ; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Romero, M; San Joaquín, I; Sola, J; Soriano, V | 1 |
| Janczewska-Kazek, E; Kajdaniuk, D; Magiera, M; Marek, B; Pisula, A; Witor, A | 1 |
| Chamuleau, RA | 1 |
| de Messias-Reason, IJ; Kremsner, PG; Kun, JF; Pedroso, ML; Tena-Tomás, C | 1 |
| Puoti, C | 1 |
| Basile, V; Capone, D; Conca, P; Cuocolo, A; Di Minno, MN; Gentile, A; Tarantino, G; Tarantino, M | 1 |
| Bzowej, N; Carr, C; Gish, RG; Hollinger, FB; Leung, J; Mirro, K; Moore, DH; Phillips, J; Poordad, F; Wakil, A; Yoffe, B | 1 |
| Heger, B; Krook, AL; Nygaard, E; Stokka, D | 1 |
| Deterding, K; Manns, MP; Potthoff, A; Rifai, K; Trautwein, C; Wedemeyer, H | 1 |
| Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K | 1 |
| Berenguer, J; Clotet, B; Montes-Ramírez, M; Planas, R; Quereda, C; Rubio, R; Santín, M; Solà, R; Tural, C | 1 |
| Di Bisceglie, AM; Ghalib, RH; Hamzeh, FM; Rustgi, VK | 1 |
| Alberti, A; Boccato, S; Ferrari, A; Pistis, R; Sebastiani, G | 1 |
| Bergin, C; Farrell, G; Hopkins, S; Kevans, D; Mahmud, N; Norris, S; White, B | 1 |
| Capasso, M; Crocè, L; Iolascon, A; Persico, E; Persico, M; Russo, R; Tiribelli, C | 1 |
| Bárcena, R; Crespo, J; Diago, M; Muñoz-Sánchez, M; Olveira, A; Pérez, R; Romero-Gómez, M; Sánchez-Tapias, JM | 1 |
| Asselah, T; Bieche, I; Boyer, N; Laurendeau, I; Marcellin, P; Martinot-Peignoux, M; Narguet, S; Ripault, MP; Sabbagh, A; Valla, D; Vidaud, M | 1 |
| Jeong, SH | 1 |
| Jee, SR; Jung, EU; Kang, SW; Lee, SH; Lee, YJ; Pae, KI; Park, ET; Park, JH; Park, SJ; Seol, SY | 1 |
| Byun, KS; Choi, DW; Han, WS; Kim, YH; Lee, SJ; Oh, SN; Yeon, JE | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Cursaro, C; Gramenzi, A; Scuteri, A; Serra, C; Vitale, G; Vukotic, R | 1 |
| Ali, S; Cheema, HA; Memon, I; Mirza, R; Shah, U; Thobani, S | 1 |
| Angelico, M; Di Paolo, D; Francioso, S; Galante, A; Lenci, I; Piccolo, P | 1 |
| Bassett, ML | 1 |
| Adachi, Y; Araki, J; Fujita, N; Horiike, S; Iwasa, M; Kaito, M; Kobayashi, Y; Mifuji, R; Sugimoto, R; Tanaka, H; Urawa, N; Yamamoto, M | 1 |
| Adachi, Y; Fujita, N; Hamano, H; Ikoma, J; Imoto, I; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Yamauchi, K | 1 |
| Haga, H; Ishii, R; Ito, J; Kawata, S; Misawa, K; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sanjo, M; Sugahara, K; Suzuki, A; Togashi, H; Watanabe, H | 1 |
| Bergmann, JF; Brouwer, JT; de Knegt, RJ; de Vries, RA; Hansen, BE; Janssen, HL; Schalm, SW; van der Schaar, P; van der Sluys Veer, A; van Hoek, B; Verhey, E; Vrolijk, JM; Vroom, B | 1 |
| Adamski, A; Blessman, D; Gandotra, SD; Htwe, TH; Khardori, NM; Koirala, J; Mushtaq, A; Rao, S; Sangwan, G | 1 |
| Alshuth, U; Gelbmann, CM; Hüppe, D; Lafrenz, M; Link, R; Lohmeyer, J; Mauss, S; Möller, B; Niederau, C; Wiedmann, KH; Witthöft, T | 1 |
| Cam, M; Chen, W; Feld, JJ; Fried, MW; Huang, Y; Liang, TJ; Nanda, S; Pusek, SN; Schweigler, LM; Theodore, D; Zacks, SL | 1 |
| Altan, M; Bektas, H; Bektas, M; Cetinkaya, H; Gören, D | 1 |
| Asim, M; Chakravarti, A; Das, RH; Kar, P; Kumar, D; Malik, A | 1 |
| Baragiotta, AM; Biscontin, MG; Mazzaro, C; Pozzato, G; Spina, M; Tirelli, U; Zorat, F | 1 |
| Aldinucci, A; Biagioli, T; Carpenedo, R; Cozzi, A; Giannini, C; Laffi, G; Moroni, F; Rosselli, M; Zignego, AL | 1 |
| Gatti, P; Lauletta, G; Montrone, M; Sansonno, D; Sansonno, L; Troiani, L; Tucci, FA | 1 |
| Almasio, PL; Cottone, C; D'Angelo, F | 1 |
| Coppola, N; Piccinino, F | 1 |
| Cammalleri, L; Colonna, V; Cristaldi, E; Gargante, MP; Malaguarnera, M; Romano, M; Vacante, M | 1 |
| Abdelaziz, M; Ahmed, IN; El Kamary, SS; Hakem, SA; Hashem, M; Ibrahiem, A; Kamal, SM; Mansour, H; Moniem, M; Moustafa, A; Muhammadi, M; Sayed, K; Shardell, MD | 1 |
| Brew, BJ; Dore, GJ; Kaldor, JM; Koorey, DJ; Krahn, MD; Maruff, P; Thein, HH | 1 |
| Highleyman, L | 1 |
| Benito, JM; Rallón, NI; Soriano, V | 1 |
| Heathcote, EJ | 1 |
| McCaughan, GW; Shackel, NA | 1 |
| Dainichi, T; Enjoji, M; Gondo, H; Urabe, K | 1 |
| Brandt, LR; Cua, IH; George, J; Hui, J; Kench, JG; Negro, F; Poustchi, H | 1 |
| Hino, T; Hisamochi, A; Ide, T; Kawano, H; Korekoda, H; Kuhara, K; Kumashiro, R; Sata, M; Toubaru, T; Tsuruta, O | 1 |
| Buti, M; Esteban, R; Majó, J; Segarra, A; Tovar, JL | 1 |
| Ardevol, M; Castellví, P; Díez-Quevedo, C; Galeras, JA; García, F; Martín-Santos, R; Masnou, H; Miquel, M; Navinés, R; Planas, R; Solà, R; Soler, A | 1 |
| Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S | 1 |
| Llopis González, A; Márquez Peiró, JF; Morales Suárez-Varela, M; Pérez Peiró, C; Valero Alcocer, VE | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG | 1 |
| Hansen, BE; Heathcote, EJ; Hofmann, WP; Janssen, HL; Manns, MP; Reichen, J; Schalm, SW; Veldt, BJ; Wedemeyer, H; Zeuzem, S | 1 |
| Devries, JH; Gelderblom, HC; Hamann, D; Hoekstra, JB; Jansen, PL; Reesink, HW; Schreuder, TC; Weegink, CJ | 1 |
| Barton, BA; González-Peralta, RP; Murray, KF; Robuck, PR; Rodrigue, JR; Schwarz, KB; Shepherd, J | 1 |
| Adang, RP; Cnossen, TT; de Vries, RA; Konings, CJ; Schalm, SW; Tan, AC; van Leusen, R | 1 |
| Cantillano, AL; González-Pardo, G; Jiménez, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Ehleben, C; Pearlman, BL; Saifee, S | 1 |
| Cervello, M; Florena, AM; Giannitrapani, L; Ingrao, S; La Spada, E; Montalto, G; Soresi, M; Vuturo, O | 1 |
| Battegay, E; Mettler, J; Zimmerli, L | 1 |
| Castera, L; Couzigou, P; De Ledinghen, V; Foucher, J | 1 |
| Kryczka, W; Lebensztejn, DM; Zarebska-Michaluk, D | 1 |
| Baik, SK; Chang, SJ; Choi, JW; Kim, HW; Lee, HW; Lee, JI; Lee, KH; Namkung, J; Sohn, JH; Yeh, BI; Yoon, J | 1 |
| Han, Q; Kang, W; Li, H; Liu, Z; Zhang, L; Zhang, N | 1 |
| Lee, WM; Yuan, HJ | 1 |
| Esposito, S; Hamzeh, FM; Rustgi, VK; Shiffman, ML | 1 |
| Abdo, N; Antaki, F; Antaki, N; Ftayeh, M; Hadad, M; Hermes, A; Kebbewar, K | 1 |
| De Angelis, D; Grieve, R; Irving, WL; Kwong, G; Ratib, S; Ryder, SD; Sweeting, M; Thomson, BJ | 1 |
| Deutsch, M; Hadziyannis, SJ | 1 |
| Bain, VG; Balshaw, RF; Cooper, C; Deschenes, M; Heathcote, EJ; Krajden, M; Lee, SS; Peltekian, KM; Powis, J; Sherman, M; Yoshida, EM | 1 |
| Bonura, C; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Giglio, M; Mondelli, MU | 1 |
| Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS | 1 |
| Alcocer, F; Bonet, L; Cordero, M; García-Samaniego, J; López-Serrano, P; Mariño, A; Martin-Carbonero, L; Nuñez, M; Portu, J; Soriano, V | 1 |
| Ansari, S; Bateni, F; Vossogh, P | 1 |
| Bacon, BR; McHutchison, JG | 1 |
| Bacon, BR; McHutchison, JG; Owens, GS | 1 |
| Blanc, D; Carrieri, MP; Dellamonica, P; Marcellin, F; Préau, M; Ravaux, I; Spire, B | 1 |
| Chu, PL; Chung, GB; Liu, CH; Wu, KD; Yang, WS | 1 |
| Gotoh, T; Hiramatsu, K; Joh, T; Kani, S; Matsuura, K; Mizokami, M; Takagi, K; Tanaka, Y; Wakimoto, Y | 1 |
| Kim, HJ | 1 |
| Ahn, CS; Choi, KM; Chung, YH; Hwang, S; Kim, KH; Lee, SG; Lee, YS; Moon, DB; Park, JI; Suh, DJ | 1 |
| Chung, RT; Gale, M; Hoofnagle, JH; Lemon, SM; Liang, TJ; Polyak, SJ | 1 |
| Aucejo, F; Hanouneh, IA; Lopez, R; Miller, C; Quinn, MK; Zein, NN | 1 |
| Martin, P; Poordad, F; Reddy, KR | 1 |
| Cho, BM; Cho, M; Heo, J; Hwang, SY; Kang, DH; Kim, GH; Kim, KY; Kim, TO; Lee, HJ; Lee, SM; Park, CW; Park, KT; Song, GA | 1 |
| Camarena, C; de Guevara, CL; de la Vega, A; Díaz, C; Díez-Dorado, R; Frauca, E; Hierro, L; Jara, P; Larrauri, J; Miños-Bartolo, G; Rueda, M | 1 |
| Abad, FJ; Borrás-Blasco, J; Casterá, E; Jiménez, I; Primo, J; Rosique-Robles, JD | 1 |
| Casassus-Buihle, D; Chauveau, E; Fraudin, A; Oddes, B; Reffet, A; Terrier, F | 1 |
| Cacoub, P; Karras, A; Perard, L; Resche-Rigon, M; Saadoun, D; Sene, D | 1 |
| Aguirrebengoa, K; Asensi, V; Barreiro, P; Cervantes, M; Echeverria, S; Garcia-Samaniego, J; Núñez, M; Ocampo, A; Pascual, A; Soriano, V | 1 |
| Ackrill, A; Bernstein, D; Bodenheimer, H; Dienstag, JL; Govindarajan, S; Hadziyannis, SJ; Marcellin, P; Messinger, D; Rakela, J; Reddy, KR; Schmidt, G | 1 |
| Bemba, G; Kautz, A; Niederau, C | 1 |
| Dalekos, GN; Germenis, A; Liaskos, C; Makaritsis, K; Rigopoulou, EI; Togousidis, E; Zografos, TA | 1 |
| Bai, C; Collantes, R; Fang, Y; Farmer, D; Gujral, H; Gurung, C; Nader, FH; Ong, JP; Ramsey, L; Sjogren, M; Sjogren, R; Srishord, M; Terra, K; Younossi, ZM | 1 |
| Dalmi, L; Gervain, J; Horváth, G; Hunyady, B; Ibrányi, E; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Clemente Ricote, G; Díaz Sánchez, A; Matilla Peña, A; Merino Rodríguez, B; Núñez Martínez, O | 1 |
| Leevy, CB | 1 |
| Iushchuk, ND; Ivanova, LM; Kravchenko, AV; Maksimova, SL; Morgunova, NM; Ol'shanskiĭ, AIa; Serebrovskaia, LV | 1 |
| Dammacco, F; Sansonno, D; Sansonno, L; Troiani, L; Tucci, FA | 1 |
| Herrmann, E; Naoumov, NV; Pachiadakis, I; Paulon, E; Tang, KH; Tatman, N; Zeuzem, S | 1 |
| Carrozzo, M | 1 |
| Casado, J; Diago, M; Gila, A; Lafuente, V; León, J; Palacios, A; Quiles, R; Rodriguez, L; Romero-Gómez, M; Rueda, PM; Ruiz-Extremera, A; Salmerón, J | 1 |
| Gourineni, N; Pothula, VR; Punnam, A; Punnam, SR; Ranganathan, V | 1 |
| Bonkovsky, HL; Dienstag, JL; Everson, GT; Ghany, MG; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC | 1 |
| Cacoub, P; Fois, E; Halfon, P; Landau, DA; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B | 1 |
| Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S | 1 |
| Endo, H; Fujimoto, T; Iga, D; Otsuka, K; Tomimatsu, M | 1 |
| Azuma, K; Enjoji, M; Furusyo, N; Hayashi, J; Kajiwara, E; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y | 1 |
| Karino, Y; Toyota, J | 1 |
| Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N | 1 |
| Aikata, H; Aimitsu, S; Chayama, K; Imamura, M; Ishihara, H; Kawakami, H; Kawakami, Y; Kitamoto, M; Moriya, T; Nakanishi, T; Satoh, K; Takahashi, S; Takaki, S; Tsuji, K | 1 |
| Capuron, L; Majer, M; Miller, AH; Pagnoni, G; Raison, CL; Welberg, LA | 1 |
| Buggisch, P; Cornberg, M; Steffen, M | 1 |
| Dougherty, KA; Evon, DM; Fried, MW; Galanko, JA; Simpson, K; Verma, A | 1 |
| Chen, PJ; Hwang, Y; Lin, CG; Wu, LS; Wu, YJ | 1 |
| Cacoub, P; Delluc, A; Piette, JC; Saadoun, D | 1 |
| Baldo, V; Baldovin, T; Carderi, I; Floreani, A; Minola, E; Rizzotto, ER | 1 |
| Barreales, M; Castellano, G; Fernández, I; Manzano, M; Muñoz, R; Solís Herruzo, JA | 1 |
| Amoruso, D; Caporaso, N; Morisco, F; Stroffolini, T | 1 |
| Abate, ML; Baldi, I; Balzola, F; Ciancio, A; Ciccone, G; Pellicano, R; Puglisi, G; Rizzetto, M; Saracco, G; Smedile, A | 1 |
| Hibi, T; Ikeda, M; Kato, N; Kumagai, N; Nakamura, M; Saito, H; Shimotohno, K; Tada, S | 1 |
| Bilalović, N; Gogov, B; Gornjaković, S; Husić-Selimović, A; Koluder, N; Radović, S; Vukobrat-Bijedić, Z; Zubcević, N | 1 |
| Andreoletti, M; Borroni, G; Casiraghi, MA; Ceriani, R; Guerzoni, P; Omazzi, B; Salerno, F; Terreni, N | 1 |
| Deschênes, M; Hilzenrat, N; Soulellis, C; Turbide, C | 1 |
| Antonaci, A; Antonaci, S; Giannelli, G; Napoli, N | 1 |
| Alonso, S; Andrade, RJ; Barcena, R; Carmona, I; Diago, M; Durán, S; Fernández-Rodríguez, CM; Perez, R; Planas, R; Pons, JA; Romero-Gómez, M; Salmerón, J; Solá, R | 1 |
| Robertson, M | 1 |
| Borque, MJ; Chaparro-Sánchez, M; González-Moreno, L; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugan, M | 1 |
| Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K; Tsukamoto, I | 1 |
| Adla, M; Ahmad, J; Downey, KK | 1 |
| Coelho, KI; Corvino, SM; Henriques, RM; Pardini, MI; Peres, MN; Polônio, RJ; Silva, GF; Silveira, LV | 1 |
| Ferenci, P; Staufer, K | 1 |
| Agud, JM; Apraiz, L; Portu, J; Tarabini-Castellani, P | 1 |
| Bal, C; Doyuk Kartal, E; Erben, N; Nayman Alpat, S; Ozgunes, I; Usluer, G; Yavuz, H | 1 |
| Bolewska, B; Juszczyk, J; Wojtacha, A | 1 |
| Chen, HY; Li, J; Rao, HY; Sun, Y; Wang, H; Wei, L; Zhang, LF; Zhu, LM | 1 |
| Fernández, A; Rodríguez-González, L; Vázquez, S | 1 |
| Cruciani, M; Franchini, M; Lippi, G; Mazzi, R; Mengoli, C; Veneri, D | 1 |
| Carlsson, T; Quist, A; Weiland, O | 1 |
| Hiramatsu, N | 1 |
| Dev, A; McHutchison, JG; Patel, K; Pawlotsky, JM; Rigby, S; Symonds, WT; Ward, CL; Zekry, A | 1 |
| McHutchison, J; Sulkowski, M | 1 |
| Baek, YH; Han, SY; Jang, JS; Kim, JH; Kim, KT; Kim, MJ; Lee, JH; Lee, SW; Roh, MH; Yoon, HA | 1 |
| Choi, JW; Eun, JR; Kim, KO; Lee, HJ; Moon, HJ | 1 |
| Amrani, N; Benaïssa, A; Guedira, MM; Kabbaj, N; Mohammadi, M; Sentissi, S | 1 |
| Arakawa, T; Atsumi, H; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Nakano, S; Sone, Y; Tanikawa, M; Toyoda, H | 1 |
| Bonino, F; Brunetto, MR; Ciccorossi, P; Civitano, L; Coco, B; Colombatto, P; Maina, AM; Oliveri, F; Romagnoli, V | 1 |
| Schafer, DF | 1 |
| Abdel-Hamid, M; Attala, M; El Hoseiny, M; El Makhzangy, H; Esmat, G; Fontanet, A; Gad, RR; Hasan, A; Males, S; Mohamed, MK; Shouman, S; Zalata, K | 1 |
| Bailey, R; Bain, VG; Balshaw, R; Deschênes, M; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Witt-Sullivan, H; Yoshida, EM | 1 |
| Coriat, R; Podevin, P | 1 |
| Drenth, JP; Slavenburg, S | 1 |
| Abe, S; Matsuhashi, T; Narita, R; Oto, T; Otsuki, M; Tabaru, A | 1 |
| Dowling, TC; Hoofnagle, JH; Howell, CD; Jeffers, L; Paul, M; Taylor, M; Terrault, NA; Wahed, AS | 1 |
| Lopukhova, NL | 1 |
| Hsu, EK; Murray, KF | 1 |
| Cooper, CL; Costiniuk, CT; Mills, E | 1 |
| Bugawan, T; Erlich, H; Im, KA; Jeffers, L; Li, J; Liang, TJ; Rhodes, SL; Rosen, HR; Su, X; Tong, X; Wang, J; Yang, H; Yee, LJ | 1 |
| Lübbe, J | 1 |
| Beppu, T; Fuke, H; Ito, K; Shiraki, K; Sugimoto, K; Takei, Y; Tanaka, J; Yamamoto, N; Yoneda, K | 1 |
| Del Olmo, JA; Escudero, A; Montes, F; Rodrigo, JM; Rodríguez, F; Serra, MA | 1 |
| Fan, R; He, J; Jiang, TJ; Xie, YX; Zhang, X; Zhao, M; Zhao, P; Zhou, ZP | 1 |
| Antoniades, CG; Cross, TJ; Harrison, PM | 1 |
| Bergamaschi, V; Borghi, F; Carosi, G; Cologni, G; Gatti, F; Matti, A; Nasta, P; Puoti, M; Ricci, A | 1 |
| Karlström, O; Sönnerborg, A; Weiland, O | 1 |
| Chang, TT; Chen, JS; Cheng, PN; Wei, YL; Young, KC | 1 |
| Foster, G; Mathurin, P | 1 |
| Marcellin, P; Rizzetto, M | 1 |
| Ferenci, P; Lee, SS | 1 |
| Berg, T; Carosi, G | 1 |
| Dusheiko, G; Nelson, D; Reddy, KR | 1 |
| Carriero, D; Dieterich, DT; Fabrizi, F; Martin, P; Park, J; Uriel, AJ | 1 |
| Alain, S; Calès, P; Denis, F; Fauchais, AL; Hubert, IF; Lefebvre, A; Liozon, E; Loustaud-Ratti, V; Lunel, F; Marquet, P; Rousseau, A; Sauvage, FL; Vidal, E | 1 |
| Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero, M | 1 |
| Cebollero, A; Dalmau, B; Gallach, M; Gavarro, A; Gil, M; Masip, M; Miquel, M; Real, J; Rudi, N; Vergara, M | 1 |
| Collado, A; de los Santos, I; del Valle, J; García-García, JA; Girón, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A | 1 |
| Alsiö, A; Buhl, MR; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Aitchison, KJ; Alexander, N; Binder, EB; Bull, SJ; Cassidy, E; Cleare, AJ; Cubells, JF; Hotopf, M; Huezo-Diaz, P; Maddock, C; Miller, AH; Miyazaki, C; Norris, S; Pariante, CM; Ranjith, G | 1 |
| Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Dettori, G; Fenu, L; Maida, I; Manno, D; Mura, MS; Puoti, M; Zanini, B | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Olmo, JD; Ortega, E; Torres-Puente, M | 1 |
| Bailey, RJ; Bain, VG; Cronin, PW; Kaita, KD; Marotta, P; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Swain, MG; Yoshida, EM | 1 |
| Asahina, Y; Enomoto, N; Hirayama, I; Hosokawa, T; Itakura, J; Izumi, N; Komatsu, N; Kurosaki, M; Miyake, S; Nakanishi, H; Sakamoto, N; Sato, M; Tanaka, T; Tasaka, M; Tsuchiya, K; Ueda, K; Umeda, N; Yasui, Y | 1 |
| Elefsiniotis, IS; Ketikoglou, I; Koutsounas, S; Moulakakis, A; Pantazis, KD; Pavlidis, C; Scarmeas, N; Tsianos, EV | 1 |
| Garcia, R; Keeffe, EB; Lam, KD; Nguyen, G; Nguyen, MH; Trinh, HN | 1 |
| Caetano, J; Luxo, C; Martinho, A; Pais, B; Paiva, A; Valente, C | 1 |
| Carson, S; Chan, BK; Chou, R | 1 |
| Al Kaabi, SR; Al Khinji, MA; Al Mohanadi, M; Al-Marri, AD; Amer, AM; Bener, AB; Butt, MT; Derbala, MF; El Dweik, NZ; John, A; Pasic, F; Shebl, FM; Yakoob, R | 1 |
| Bourliere, M | 1 |
| Khunvichai, A; Kieffer, TL; Lawitz, E; McHutchison, JG; McNair, L; Muir, AJ; Rodriguez-Torres, M | 1 |
| Ferenci, P; Gangl, A; Peck-Radosavljevic, M; Rasoul-Rockenschaub, S; Reiberger, T; Rieger, A | 1 |
| Arnold, J; Berg, T; Bergk, A; Boecher, WO; Deterding, K; Forestier, N; Gruengreiff, K; Kaeser, T; Manns, MP; Potthoff, A; Schuchmann, M; Spengler, U; Trautwein, C; Wedemeyer, H; Zeuzem, S | 1 |
| Canbakan, B; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Tahan, V; Ulger, Y; Uraz, S | 1 |
| Alaeus, A; Falconer, K; Gonzalez, VD; Michaëlsson, J; Moll, M; Reichard, O; Sandberg, JK | 1 |
| Coppola, N; Filippini, P; Imparato, M; Martini, S; Piai, G; Piccinino, F; Pisapia, R; Sagnelli, C; Sagnelli, E; Stanzione, M; Tonziello, G | 1 |
| Brown, JL | 1 |
| Braconier, JH; Frydén, A; Norkrans, G; Reichard, O; Sönnerborg, A; Weiland, O | 2 |
| Renner, EL | 2 |
| Bresters, D; Damen, M | 1 |
| Moussalli, J; Opolon, P; Poynard, T | 1 |
| Bordessoule, D; Jaccard, A; Loustaud, V; Rogez, S; Turlure, P | 1 |
| Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V | 1 |
| Bletry, O; Cacoub, P; Cosserat, J; Cretel, E; Durand, JM; Frances, C; Godeau, P; Kaplanski, G; Lunel-Fabiani, F; Soubeyrand, J | 1 |
| Ahmed, SS; Bailly, F; Chevallier, M; Chossegros, P; Habersetzer, F; Haem, J; Trépo, C; Zoulim, F | 1 |
| Emslander, HP; Gössl, C; Hoffmann, RM; Jung, MC; Motz, R; Pape, GR; Zachoval, R | 1 |
| Borghesio, E; Ghisetti, V; Marchiaro, G; Pittaluga, F; Rizzetto, M; Rocca, G; Saracco, G; Sostegni, R | 1 |
| Lee, JH; Roth, WK; Sarrazin, C; Teuber, G; von Wagner, M; Zeuzem, S | 1 |
| Nightingale, SL | 1 |
| Carreño, V; Martín, J; Navas, S; Pardo, M; Quiroga, JA | 1 |
| Borque, MJ; Fernández-Bermejo, M; García-Buey, L; García-Monzón, C; Iacono, LO; Moreno-Monteagudo, JA; Moreno-Otero, R; Sanz, P | 1 |
| Alberti, A; Chemello, L; Crucitti, A; Donada, C; Donadon, V | 1 |
| Frank, H; Jäckel, E; Manns, MP; Schüler, A; Trautwein, C; Wedemeyer, H; Wedemeyer, J | 1 |
| Albrecht, J; Bain, V; Heathcote, J; Ideo, G; Lee, SS; Marcellin, P; Minuk, GS; Niederau, C; Poynard, T; Trepo, C; Zeuzem, S | 1 |
| Albrecht, JK; Cort, S; Goodman, ZD; Gordon, SC; Lee, WM; Ling, MH; McHutchison, JG; Rustgi, VK; Schiff, ER; Shiffman, ML | 1 |
| Albrecht, J; Craxi, A; Davis, GL; Esteban-Mur, R; Gordon, SC; Hoefs, J; Ling, MH; Rustgi, V; Shiffman, ML; Trepo, C; Zeuzem, S | 1 |
| Liang, TJ | 1 |
| Schalm, SW | 1 |
| Hermann, R | 1 |
| Annese, M; Bacca, D; Barbarini, G; Barbaro, G; Bellomo, G; Belloni, G; Di Lorenzo, G; Francavilla, R; Giancaspro, G; Grisorio, B; Rizzo, G; Soldini, M | 1 |
| Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B | 1 |
| Caselmann, WH; Manns, MP; Wedemeyer, H | 1 |
| Ballaré, M; Farina, M; Negro, F; Tappero, G | 1 |
| Pol, S; Zylberberg, H | 1 |
| Ansaldi, F; Icardi, GC; Perasso, A; Testino, G; Venturino, V | 1 |
| Bergmann, JF | 1 |
| Brouwer, JT; Hansen, BE; Niesters, HG; Schalm, SW | 1 |
| Averett, DR; Bard, J; Lim, C; Milovanovic, T; Pai, B; Phan, UT; Tam, RC | 1 |
| Bell, H; Bjøro, K; Gutigard, BG; Harthug, S; Hellum, K; Maeland, A; Myrvang, B; Raknerud, N; Ritland, S; Simmonds, P; Skaug, K; von der Lippe, B | 1 |
| Koretz, RL | 2 |
| Al Ashgar, H; Cattral, MS; Greig, PD; Hemming, AW; Krajden, M; Levy, GA; Lilly, L; Wanless, IR | 1 |
| Glue, P | 1 |
| McHutchison, JG; Poynard, T | 1 |
| Maddrey, WC | 1 |
| Bayliss, MS; Cort, S; Neary, MP; Ware, JE | 1 |
| Dieterich, DT; Purow, JM; Rajapaksa, R | 1 |
| Marcellin, P | 1 |
| Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C | 1 |
| Ochsendorf, F; Röder, C; Stryjek-Kaminska, D; Wolter, M; Zeuzem, S | 1 |
| Andreone, P; Bernardi, M; Cursaro, C; D'Errico, A; Di Giammarino, L; Fiorino, S; Gasbarrini, G; Gramenzi, A; Miniero, R; Sbolli, G | 1 |
| Martin, P; Saab, S | 1 |
| Albrecht, J; Conrad, A; Elliot, M; Gianelli, G; Glue, P; McHutchison, J; Nyberg, L; Zambas, D | 1 |
| Casalino, C; Genchi, C; Mariano, N; Maselli, R; Milella, M; Pastore, G; Pietromatera, G; Santantonio, T | 1 |
| Chapman, RW; Christie, JM | 1 |
| Begemann, F; Jablonowski, H | 1 |
| Berg, T; Dietrich, CF; Lee, JH; Roth, WK; Sarrazin, C; Teuber, G; Zeuzem, S | 1 |
| Fontaine, H; Pol, S | 1 |
| Bellobuono, A; Brouwer, JT; Chemello, L; Chen, DS; Hansen, BE; Hollander, A; Lai, MY; Michielsen, PP; Milella, M; Pastore, G; Schalm, SW; Weiland, O | 1 |
| Bayliss, MS; Davis, GL; Mannocchia, M; Ware, JE | 1 |
| Abergel, A; Berthelot, P; Bourlière, M; Bréchot, C; Combis, JM; Couzigou, P; Larrey, D; Moussalli, J; Pol, S; Poupon, R; Tran, A | 1 |
| Alberti, A; Cavalletto, L; Chemello, L; Gerotto, M; Gretch, DR; Polyak, SJ; Pontisso, P; Sullivan, DG | 1 |
| Frossard, JL | 1 |
| Castaño, G; Chohuela, E; Frider, B; Kien, MC; Neglia, V; Sookoian, S | 1 |
| Sarrazin, C; Zeuzem, S | 1 |
| Lavín, I; Palacios, A; Quintero, D; Rodríguez-Ramos, L; Ruiz-Extremera, A; Salmerón, J; Torres, C | 1 |
| Annese, M; Bacca, D; Barbarini, G; Barbaro, G; Barelli, A; Belloni, G; Calleri, G; Del Poggio, P; Di Lorenzo, G; Ferrari, L; Francavilla, R; Fruttaldo, L; Grisorio, B; Gualandi, G; Mongiò, F; Paiano, A; Poltronieri, I; Rizzo, G; Rocchetto, P; Scotto, G | 1 |
| Silvain, C | 1 |
| García-Buey, L; García-Monzón, C; Ibarrola, N; Lo Iacono, O; Martínez-Salas, E; Moreno-Monteagudo, JA; Moreno-Otero, R; Sáiz, M; Sobrino, F | 1 |
| Berg, T; Hoffmann, RM; Hopf, U; Jung, MC; Leifeld, L; Pape, GR; Prümmer, O; Spengler, U; Teuber, G; Zeuzem, S | 1 |
| Macedo, G; Ribeiro, T | 1 |
| Barbarini, G; Barbaro, G; Di Lorenzo, G; Giancaspro, G; Grisorio, B; Pellicelli, A; Soldini, M | 2 |
| Castro, A; Hermida, M; López Calvo, S; Pedreira, J; Vega, P | 1 |
| McHutchison, JG; Shermock, KM; Singer, ME; Younossi, ZM | 1 |
| Henrion, J | 1 |
| Fischler, B; Glaumann, H; Norkrans, G; Reichard, O; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R | 1 |
| Glaumann, H; Reichard, O; Schvarcz, R; Weiland, O | 1 |
| Rizzetto, M; Saracco, G | 1 |
| Goebel, FD; Jablonowski, H | 1 |
| Albrecht, J; Goodman, Z; Ling, MH; McHutchison, J; Poynard, T | 1 |
| Emmett, C; Gurakar, A; Hulagu, S; Jazzar, A; Karasu, Z; McMillon, G; Wright, H | 1 |
| Forton, DM; Taylor-Robinson, SD; Thomas, HC; Török, ME | 1 |
| Bekkering, FC; Brouwer, JT; Schalm, SW; van Rossum, TG | 1 |
| Civeira, MP; Prieto, J | 1 |
| Barnes, E; Dusheiko, G; Jacobs, R; Webster, G | 1 |
| Bjøro, K; Frøland, SS; Haaland, T; Skaug, K | 1 |
| Bodenheimer, HC; Davis, GL; Fiel, MI; Guido, M; Lewis, JH; Lindsay, KL; Schiano, TD; Seeff, LB; Thung, SN | 1 |
| Lawrence, SP | 1 |
| Böker, KH; Manns, MP | 1 |
| Carucci, P; Chokshi, S; Cramp, ME; Naoumov, NV; Rossol, S; Williams, R | 1 |
| McHutchison, J | 1 |
| Jacobson, I | 1 |
| Dieterich, DT | 1 |
| Berg, T; Kronenberger, B; Lee, JH; Roth, WK; Rüster, B; Sarrazin, C; Zeuzem, S | 1 |
| Moberg, L; Schvarcz, R; Sönnerborg, A | 1 |
| Gordon, SC | 2 |
| Caspary, WF; Dietrich, CF; Lee, JH; Stryjek-Kaminska, D; Teuber, G; Zeuzem, S | 1 |
| Berg, T; Hoffmann, RM; Hopf, U; Lafrenz, M; Leifeld, L; Pape, GR; Spengler, U; Teuber, G; Zeuzem, S | 1 |
| Albrecht, JK; Goodman, Z; Hong, Z; Kato, T; Lai, VC; Lau, JY; Mizokami, M; Orito, E | 1 |
| Fimmel, CJ | 1 |
| Batisse, D; Kazatchkine, MD; Landau, A; Piketty, C | 1 |
| Bode, JC; Steimann, RU | 1 |
| Bertoni, M; Bresci, G; Capria, A; Parisi, G; Scatena, F | 1 |
| Greving, I; Griga, T; Hüppe, D; Mankel, K; Tromm, A | 1 |
| Gross, JB; Kim, WR; Poterucha, JJ | 1 |
| Bérets, O; Cointet, F; Debourdeau, P; Rault, A; Romand, F; Stoll, L; Védrine, L | 1 |
| Gretch, DR; Pawlotsky, JM | 1 |
| Andreone, P; Bernardi, M; Cursaro, C; D'Errico, A; Di Giammarino, L; Fiorino, S; Gasbarrini, G; Gramenzi, A; Grigioni, WF; Miniero, R | 1 |
| Ayi, K; Brugnara, C; Corrocher, R; De Franceschi, L; Fattovich, G; Manzato, F; Noventa, F; Solero, P; Stanzial, AM; Turrini, F | 1 |
| Cotrim, H; Lyra, L; Paraná, R; Portugal, M; Trepo, C; Vitvitski, L | 1 |
| Bain, VG; Gutfreund, KS | 1 |
| Sterneck, M | 1 |
| Criblez, DH | 1 |
| Davis, GL; Pauker, SG; Wong, JB | 1 |
| Buti, M; Esteban, R; Guardi, J; Olive, G; Stalgis, C | 1 |
| Borque, MJ; Carbonell, P; Castro, A; Diago, M; Fernandez-Bermejo, M; García, V; García-Buey, L; García-Monzón, C; Lo Iacono, O; Moreno, JA; Moreno-Otero, R; Pedreira, J; Sanz, P; Vega, P | 1 |
| Datz, C; Ferenci, P; Fickert, P; Gschwantler, M; Hackl, F; Lin, W; Müller, C; Rainer, W; Stauber, R; Steindl-Munda, P; Watkins-Riedel, T | 1 |
| Cacoub, P; Lunel, F | 1 |
| Bacosi, M; Miglioresi, L; Ricci, GL; Russo, F | 1 |
| Arribas, JR; García-Samaniego, J; González, J; Peña, JM; Pérez-Olmeda, M; Soriano, V | 1 |
| Battaglia, AM; Hagmeyer, KO | 1 |
| Paul, A | 1 |
| Denham, C; Khalili, M; Perrillo, R | 1 |
| Burns, DA; Taylor, C; Wiselka, MJ | 1 |
| Abergel, A; Berthelot, P; Bourlière, M; Bréchot, C; Couzigou, P; Nalpas, B; Pol, S; Tran, A; Zarski, JP | 1 |
| Batisse, D; Belec, L; Bloch, F; Duong Van Huyen, JP; Kazatchkine, MD; Landau, A; Petite, JP; Pialoux, G; Piketty, C; Weiss, L | 1 |
| Carmona, I; Herrerías-Esteban, JM; Herrerías-Gutiérrez, JM; Jiménez-Sáenz, M; Piñar, A; Rebollo, J; Rojas, M; Salas, E | 1 |
| Hoepelman, AI | 1 |
| Baum, I; Berenguer, J; Córdoba, J; Gobernado, M; Lòpez Viedma, B; Molina, JM; Olaso, V; Prieto, M; Siles, MS | 1 |
| Al-Faleh, FZ; Al-Humayed, S; Al-Juhani, M; Al-Karawi, M; Al-Otaibi, M; Alahdal, M; Aljumah, A; George, K; Mayet, I; Rezeig, M; Sbeih, F | 1 |
| Foster, GR; Thomas, HC | 1 |
| Chang, MH | 1 |
| Dhumeaux, D; Hezode, C | 1 |
| Albrecht, JK; Ling, MH; Pauker, SG; Poynard, T; Wong, JB | 1 |
| Burroughs, AK; Papatheodoridis, GV; Pastacaldi, S; Teixeira, R | 1 |
| McHutchison, JG; Younossi, Z | 1 |
| Rasenack, JW | 1 |
| Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C | 1 |
| Alberti, A; Belussi, F; Bernardinello, E; Casarin, P; Cavalletto, L; Chemello, L; Donada, C; Gatta, A; Marino, F; Pontisso, P | 1 |
| Colucci, G | 1 |
| Albrecht, JK; Fang, JW; Gordon, SC; McHutchison, JG; Silverman, AL | 1 |
| Chutaputti, A | 1 |
| McHutchison, JG; Pianko, S | 1 |
| Koshy, A; Madda, JP; Marcellin, P; Martinot, M | 2 |
| Bolondi, L; Brillanti, S; Foli, M; Levantesi, F; Masi, L | 1 |
| Clement, RP; Glue, P; Gupta, SK; Jacobs, S; Raffanel, C; Rouzier-Panis, R; Sabo, R; Salfi, M | 1 |
| Cruz, M; Cruz, T; Lyra, L; Paraná, R | 1 |
| Herrmann, E; Neumann, AU; Schmidt, JM; Zeuzem, S | 1 |
| De Bona, A; Finazzi, R; Foppa, CU; Lazzarin, A; Morsica, G; Sitia, G | 1 |
| Bonkovsky, HL; Katz, E; Szabo, G | 1 |
| Herrera, JL; Smith, JR | 1 |
| Cuccorese, G; Miglietta, A; Modeo, ME; Spinazzola, AM; Tursi, A | 1 |
| Cruz, CN; Felipe, M; Ferraz, LG; Figueiredo, VM; Granero, L; Lanzoni, V; Lopes, EP; Oliveira, PM; Silva, AE | 1 |
| Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Preisegger, KH; Schwinger, W; Urban, C | 1 |
| Almasio, P; Cataldo, MG; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A | 1 |
| Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S | 1 |
| Chapman, R; Foster, GR | 1 |
| Glue, P; Gupta, S; Hajian, G; Jen, JF; Zambas, D | 1 |
| Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H | 1 |
| Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T | 1 |
| Contos, MJ; Gabbay, J; Hofmann, CM; Luketic, VA; Rustgi, V; Ryan, MJ; Sanyal, AJ; Shiffman, ML; Sterling, RK; Yoshida, C | 1 |
| Albrecht, J; Dienstag, J; Gordon, SC; McHutchison, JG; Morgan, T; Pianko, S; Poynard, T; Reid, AE; Yao, R | 1 |
| Hoofnagle, JH; Howell, C; Jeffers, L | 1 |
| Fischler, B; Glaumann, H; Norkrans, G; Reichard, O; Sönnerbor, A; Uhnoo, I; Weiland, O; Wejstål, R | 1 |
| Grob, PJ; Negro, F; Renner, EL | 1 |
| García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Romero, M; Soriano, V | 1 |
| Amann, B; Grunze, H; Loeschke, K; Schäfer, M; Schlösser, S; Schmidt, F | 1 |
| Glaser, D | 1 |
| Castellano, G; Fernández, I; Hawkins, F; Muñoz, R; Solís-Herruzo, JA | 1 |
| Diago, M; Enríquez, J; Gallego, A; García-Samaniego, J; Luján, MS; Pérez-Olmeda, T; Soriano, V; Torras, X | 1 |
| Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R | 1 |
| Braun, F; Ramadori, G; Ringe, B; Wietzke, P | 1 |
| Bonis, PA; Cheng, SJ; Lau, J; Pham, NQ; Wong, JB | 1 |
| Schalm, SW; Vrolijk, JM | 1 |
| Colantoni, A; De Maria, N; Harig, J; Idilman, R; Van Thiel, DH | 1 |
| Berg, T; Hopf, U; Kaul, T; Naumann, U; Wiedenmann, B | 1 |
| Hewitson, P; Shepherd, J; Waugh, N | 1 |
| Amati, L; Caradonna, L; Cozzolongo, R; Cuppone, R; Giannuzzi, V; Jirillo, E; Manghisi, OG; Tamborrino, V | 1 |
| Bertoni, M; Bresci, G; Capria, A; Parisi, G | 1 |
| Albillos, A; Calleja, JL; Domper, F; Escartín, P; Martínez, JL; Moreno, R; Rossi, I | 1 |
| Fattovich, G; Krampera, M; Pizzolo, G; Scupoli, MT | 1 |
| Keeffe, EB; Lin, OS | 1 |
| Balija, M; Bingulac-Popovic, J; Drazic, V; Grahovac, B; Grgicevic, D; Hrstic, I; Ostojic, R; Vucelic, B | 1 |
| Baumgarten, R; Berg, T; Hoffmann, RM; Hopf, U; Lafrenz, M; Leifeld, L; Pape, GR; Spengler, U; Teuber, G; Zeuzem, S | 1 |
| Aoki, Y; Cid-Ruzafa, J; Cummings, KJ; Fein, SG; Goodman, SN; Lee, SM; Sulkowski, MS; West, ES | 1 |
| Koff, R | 1 |
| Brown, RS; Russo, MW | 1 |
| Bastani, B; Philipneri, M | 1 |
| Castéra, L; Roulot, D | 1 |
| Kallinowski, B; Pohl, J; Stremmel, W | 1 |
| Ahmed, A; Cheung, R | 1 |
| Brenci, S; Brizzolara, R; Campo, N; Contini, P; Ghio, M; Indiveri, F; Picciotto, A; Puppo, F; Sinelli, N; Torre, F | 1 |
| Brouwer, JT; de Vries, RA; Glue, P; Kauffmann, RH; Schalm, SW; Tan, AC; van Leusen, R; Vroom, B | 1 |
| Barnes, DS; Boparai, N; Brand, E; Carey, WD; Easley, K; Gramlich, T; Hodnick, S; McCullough, AC; Mullen, KD; Younossi, ZM; Zakko, W | 1 |
| Albrecht, JK; Bayliss, MS; Cort, S; McHutchison, JG; Neary, MP; Pianko, S; Ware, JE; Yang, I | 1 |
| Boudjema, H; Cadranel, JF; Caron, C; Cazier, A; Coutarel, P; Delacour, T; Di Martino, V; Dumouchel, P | 1 |
| Bacon, BR; Brunt, EM; Di Bisceglie, AM; Smith-Wilkaitis, N; Thompson, J | 1 |
| Gibson, AW; Kaslow, RA; Kimberly, R; Tang, J; Van Leeuwen, DJ; Yee, LJ | 1 |
| Bhatti, A; Gabbay, R; McGarrity, TJ | 1 |
| Adinolfi, LE; Andreana, A; Durante Mangoni, E | 1 |
| Lagging, LM; Lindh, M; Nenonen, N; Norkrans, G; Wejstål, R; Westin, J | 1 |
| Attias, D; Rowe, JM; Sabo, E; Sahar, D; Streichman, S; Yeshurun, D; Zuckerman, E; Zuckerman, T | 1 |
| Cadorin, L; di Gennaro, G; Nasti, G; Rizzardini, G; Tirelli, U | 1 |
| Berg, T; Hopf, U; Naumann, U; Wiedenmann, B | 1 |
| Agarwal, K; Bassendine, DR; Bassendine, MF; Burt, AD; Craig, W; Gilvarry, E; Hewett, M; Jowett, SL; Smith, BC | 1 |
| Hillon, P | 1 |
| Billaud, G; Maertens, G; Querenghi, F; Trépo, C; Yu, Q; Zoulim, F | 1 |
| Gómez, M; Otero, A; Souto, J; Suárez, FJ; Vázquez-Iglesias, JL | 1 |
| Lam, NP; Layden, TJ; Wiley, TE | 1 |
| Eibl, MM; Eibl, N; Ferenci, P; Gschwantler, M; Schernthaner, G; Weiss, W | 1 |
| Angelico, F; Angelico, M; Bergamini, A; Bolacchi, F; Bongiovanni, B; Carvelli, C; Cepparulo, M; Cerasari, G; Demin, F; Francioso, S; Hurtova, M; Liuti, A; Ombres, D; Rocchi, G; Uccella, I | 1 |
| Bodenheimer, HC; Bodian, C; Esposito, S; Geders, JM; Goldman, IS; Jacobson, IM; Jones, JL; Klion, FM; Lebovics, E; Min, AD; Tobias, H | 1 |
| Bekkering, FC; Brouwer, JT; Hansen, BE; Schalm, SW | 1 |
| Andriulli, A; Attino, V; Bacca, D; Carretta, V; Cela, M; Giangaspero, A; Leandro, G; Mangi, A; Minerva, N; Ventrella, F; Villani, MR | 1 |
| Goeser, T; Kallinowski, B; Liehr, H; Moeller, B; Stremmel, W; Wechsler, JG; Wiese, M | 1 |
| Arnold, JC; Stremmel, W | 1 |
| Campos, R; Castaño, G; Cello, J; Flichman, D; Frider, B; Sookoian, S | 1 |
| Barni, MC; Cadeo, GP; Carosi, G; Cristini, G; Forleo, MA; Gargiulo, F; Paraninfo, G; Puoti, M; Putzolu, V; Quiros-Roldan, E; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B | 1 |
| Bartlett, SE; Chapman, BA; Edgar, CL; Frampton, CM; Jennings, LC; Scahill, SL; Stace, NH | 1 |
| James, JS | 1 |
| Roehr, B | 1 |
| Lee, SS; Sherman, M | 1 |
| McHutchison, JG; Shad, JA | 1 |
| Elez, R; Kronenberger, B; Lee, JH; Piiper, A; Roth, WK; Rüster, B; Weber, S; Zeuzem, S | 1 |
| Meier, V; Ramadori, G | 1 |
| Mullhaupt, B; Renner, EL; Sagmeister, M; Wong, JB | 1 |
| Hayashi, N; Takehara, T | 1 |
| Akremi, R; Asselah, T; Benhamou, JP; Boyer, N; Ibrahim, A; Jacobson-Brown, P; Katz, GG; Le Breton, V; Le Guludec, G; Malkiewicz, IM; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH; Suneja, A | 1 |
| Blendis, LM; Brill, S; Halpern, Z; Ibrahim, A; Katz, GG; Konikoff, FM; Magazinik, S; Malkiewicz, IM; Neuman, MG; Peretz, H; Sapir, D; Shear, NH | 1 |
| Alaimo, G; Almasio, PL; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Peralta, S; Rodolico, V; Vaccaro, A | 1 |
| Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Macor, A; Maggi, G; Olivero, A; Orsi, PG; Rinaldi, E; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tappero, GF; Terreni, N | 1 |
| Capra, F; De Maria, E; Franchini, M; Gandini, G | 1 |
| Datz, C; Ferenci, P; Fickert, P; Gangl, A; Gschwantler, M; Hackl, F; Krejs, GJ; Lin, W; Müller, C; Rainer, W; Stauber, R; Steindl-Munda, P; Watkins-Riedel, T | 1 |
| Chapman, R; Collier, J | 1 |
| Rivero, A; Torre-Cisneros, J | 1 |
| Couzigou, P; De Ledinghen, V; Foucher, J | 1 |
| De Vos, M; Delanghe, JR; Leroux-Roel, G; Van Vlierbergh, H | 1 |
| Carmona-Soria, I; González-Vilches, J; Herreriás-Gutiérrez, JM; Jiménez-Sáenz, M | 1 |
| Andersson, J; Bruchfeld, A; Schvarcz, R; Ståhle, L | 2 |
| Deschênes, M; Mishkin, D | 1 |
| Fickert, P; Hegenbarth, K; Kroisel, PM; Maurer, U; Stauber, RE; Trauner, M | 1 |
| Balestra, V; Brizzolara, R; Campo, N; Giusto, R; Grasso, A; Picciotto, A; Sinelli, N; Torre, F | 1 |
| Contos, MJ; Hofmann, CM; Luketic, VA; Sanyal, AJ; Shiffman, ML; Sterling, RK | 1 |
| Asahina, Y; Hamano, K; Itakura, J; Izumi, N; Kanazawa, N; Miyake, S; Noguchi, O; Sakai, T; Tsuchiya, K; Uchihara, M | 1 |
| Carbonell, P; Cors, R; Diago, M; García, V; Luján, M; Marcaida, G; Tuset, C; Valeros, D | 1 |
| Kato, N; Omata, M; Otsuka, M | 1 |
| Kawabe, T; Toda, G | 1 |
| Tanikawa, K | 1 |
| Hultkrantz, R; Jonsson, D; Reichard, O; Sennfält, K; Wong, JB | 1 |
| Azara, V; Branca, B; Deplano, A; Garrucciu, G; Manzoni, NE; Ogana, G; Solinas, A; Tocco, A | 1 |
| Almar, M; Díaz-Golpe, V; García-Fernández, A; González-Gallego, J; Jorquera, F; Olcóz, JL | 1 |
| Bacon, BR; Britton, RS; Di Bisceglie, AM; Mistry, B; Naeem, M | 1 |
| Ashur, Y; Bishara, A; Eid, A; Galun, E; Ilan, Y; Israeli, E; Jurim, O; Safadi, R | 1 |
| Anagnostopoulos, G; Aroni, K; Kontochristopoulos, GJ; Nakopoulou, L; Tassopoulos, NC | 1 |
| Heathcote, J; Jain, K; Lam, WC; Thai, Q; Waheeb, S | 1 |
| Kiyosawa, K; Sodeyama, T | 1 |
| Bowlus, CL; Leigh, JP; Leistikow, BN; Schenker, M | 1 |
| Cadorin, L; Carbone, A; Di Gennaro, G; Nasti, G; Talamini, R; Tavio, M; Tedeschi, RM; Tirelli, U | 1 |
| Albrecht, JK; Goodman, ZD; Gordon, SC; Koury, K; Ling, M; Manns, MP; McHutchison, JG; Reindollar, R; Rustgi, VK; Shiffman, M | 1 |
| Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Tahan, V | 1 |
| García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Soriano, V | 1 |
| Ferenci, P; Gangl, A; Gschwantler, M; Hofer, H; Jessner, W; Mueller, C; Steindl-Munda, P; Watkins-Riedel, T; Wrba, F | 1 |
| Blum, HE; Cerny, A; Heim, MH; Moradpour, D; Wölk, B | 1 |
| Ahmed, S; Karim, A; Khan, A; Mattana, J; Steinberg, H | 1 |
| Brunner, H; Datz, C; Ferenci, P; Gangl, A; Gschwantler, M; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Munda-Steindl, P; Nachbaur, K; Rosenbeiger, M; Stauber, R; Vogel, W | 1 |
| Altisent, C; Esteban, JI; Esteban, R; Guardia, J; Juárez, A; Puig, L; Ruiz, I; Sauleda, S | 1 |
| Ahmad, J; Demetris, AJ; Dodson, SF; Fung, JJ; Shakil, AO | 1 |
| Airoldi, A; Alberti, AB; Belli, LS; Cernuschi, A; D'Amico, M; de Carlis, L; Forti, D; Minola, E; Pinzello, G; Rondinara, G; Vangeli, M | 1 |
| Csef, H; Faller, H; Kraus, MR; Mörk, H; Schäfer, A; Scheurlen, M | 1 |
| Banner, BF; Bonkovsky, HL; Colker, J; Israel, J; Liu, Q; McNeal, K; Stagias, J; Stefancyk, D; Zucker, GM | 1 |
| Batisse, D; Belec, L; Bloch, F; Bruneval, P; Duong Van Huyen, JP; Jian, R; Kazatchkine, MD; Landau, A; Piketty, C; Weiss, L | 1 |
| Chamuleau, RA; Molenaar, DS; Reesink, HW; Weegink, CJ | 1 |
| Albrecht, JK; Dienstag, JL; Garaud, JJ; Gordon, SC; Ling, MH; McHutchison, JG; Morgan, TR; Shad, JA | 1 |
| Gluud, C; Kjaergard, LL; Krogsgaard, K | 3 |
| Gow, PJ; Mutimer, D | 1 |
| Buti, M; Esteban, R; Martell, M; Morral, S; Sanchez, F; Stalgis, C | 1 |
| Edelstein, MA; Martin, P | 1 |
| Husa, P; Husova, L | 1 |
| Attuil, V; Brengel-Pesce, K; Drouet, E; Leroy, V; Seigneurin, JM; Thelu, MA; Zarski, JP | 1 |
| Di Bisceglie, AM | 1 |
| Donahue, P; Hasan, I; Lebovics, E; Rehman, R; Rigas, B; Wittkowski, KM | 1 |
| Ashur, Y; Granot, E; Shouval, D | 1 |
| Addesa, JA; Navarro, VJ | 1 |
| van Hattum, J; van Soest, H | 1 |
| Adamek, B; Biskupska-Karasińska, M; Bolewska, B; Boroń-Kaczmarska, A; Cianciara, J; Daniluk, J; Dudziak, M; Dziambor, AP; Flieger, J; Gonciarz, Z; Gładysz, A; Juszczyk, J; Kozłowska, J; Kryczka, W; Kuydowicz, J; Lakomy, E; Machniak, M; Mazur, W; Niwicka-Michałowska, A; Piszko, P; Swietek, K; Słomka, M; Trocha, H; Wawrzynowicz-Syczewska, M; Witczak-Malinowska, K; Zaborowski, P; Zarebska-Michaluk, D | 1 |
| Fontana, RJ; Klein, S; Lok, AS; Moyer, CA; Walsh, J; Webster, S | 1 |
| Rosenberg, W; Stein, K; Wong, J | 1 |
| Himelhoch, S | 1 |
| Besancenot, JF; Bielefeld, P; Champigneulle, B; de Boulard, A; Gabreau, T; Hillon, P; Lévêque, L; Makki, H; Sgro, C | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lai, MY | 1 |
| Kumada, H | 1 |
| Santin, M; Shaw, E | 1 |
| Beltrame, A; Costa, AF; Kuchenbecker, R; Picon, PD | 1 |
| Cecil, BD | 1 |
| Braun, F; Meier, V; Ramadori, G; Wietzkebetaraun, P | 1 |
| Koczorek, M | 1 |
| Hwang, SJ | 1 |
| Perry, CM; Scott, LJ | 1 |
| Tossing, G | 1 |
| Germer, JJ; Vidigal, PG; Zein, NN | 1 |
| García-Samaniego, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Romero, M; Soriano, V | 1 |
| Laurence, J | 1 |
| Elkabes, B; Saner, G; Sökücü, S; Süoğlu D, OD | 1 |
| Bell, H; Bjøro, K; Døskeland, B; Hellum, KB; Lund-Tønnesen, S; Maeland, A; Myrvang, B; Raknerud, N; Sandvei, P; Skaug, K | 1 |
| Barange, K; Hrycewycz, N; Izopet, J; Pascal, JP; Payen, JL; Sandres, K | 1 |
| Amarapurkar, A; Amarapurkar, D; Dhorda, M; Kankonkar, S; Kirpalani, A | 1 |
| Lombraña, JL; Pérez-Alvarez, R; Pérez-López, R; Rodrigo, L; Rodríguez, M | 1 |
| Skrivánková, J; Stránský, J | 1 |
| Borque, MJ; Castro, A; De Pedro, A; Fernández-Bermejo, M; García-Buey, L; Lopez, S; Lorenzo, JA; Moreno-Monteagudo, JA; Moreno-Otero, R; Pedreira, JD | 1 |
| Langner, RG; van Leeuwen, DJ; Yee, LJ | 1 |
| Albrecht, JK; Davis, GL; Dienstag, JL; Esteban-Mur, R; Garaud, JJ; Goodman, ZD; Harvey, J; Ling, MH; McHutchison, JG; Morgan, T; Patel, K; Poynard, T | 1 |
| Bica, I; McGovern, B | 1 |
| Adams, G; Jones, A; Kumar, KS; Lee, WM; Malet, PF; Malik, AH; Ostapowicz, G; Wood, M; Yarbrough, K | 1 |
| Colomb, MG; Drouet, C; Dumestre-Perard, C; Dutertre, N; Leroy, V; Ponard, D; Zarski, JP | 1 |
| Akremi, R; Asselah, T; Benali, S; Benhamou, JP; Bourliere, M; Boyer, N; Ibrahim, A; Katz, GG; Le Breton, V; Le Guludec, G; Lecomte, L; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH | 1 |
| Hong, Z; Lau, JY; Tam, RC | 1 |
| Beylot, C; Beylot-Barry, M; Cogrel, O; Couzigou, P; Doutre, MS; Marlière, V | 1 |
| Häussinger, D; Heintges, T; Sagir, A; Wettstein, M | 1 |
| Chou, S; Conrad, AJ; Lentz, JJ; Marousek, G; McHutchison, JG; Rose, SL; Rosen, HR; Taylor, K; Zaman, A | 1 |
| Pockros, PJ | 1 |
| Siboni, A | 1 |
| Blackwell, J | 1 |
| Mollison, L; Olynyk, J; Totten, L; Yusoff, IF | 1 |
| Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Belaich, S; Crickx, B; Descamps, V; Grossin, M; Le Bozec, P; Marcellin, P; Wendling, J | 1 |
| Cozzolongo, R; Cuppone, R; Manghisi, OG | 1 |
| Bellobuono, A; Idéo, G | 1 |
| Carreño, V | 1 |
| Kinnman, N; Lindmarker, P; Schulman, S; von Sydow, M | 1 |
| Forns Bernhardt, X | 1 |
| Buti, M; Esteban-Mur, R; Guardia, J; Olivé, G | 1 |
| García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R | 1 |
| Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H | 1 |
| Kimura, S; Makuuchi, M; Morisawa, Y; Oka, S; Sugawara, Y; Tachikawa, N | 1 |
| Matsushima, T | 1 |
| Baldini, C; Bombardieri, S; Della Rossa, A; Tavoni, A | 1 |
| Hong, Z; Lau, JY; Liang, TJ; Tam, RC | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lafarge, P; Lunel-Fabiani, F | 1 |
| Bernard, PH; Bourlière, M; Canva, V; Capron, D; Chêne, G; Couzigou, P; de Lédinghen, V; Desmorat, H; Fleury, H; Foucher, J; Lévy, S; Mannant, PR; Mion, F; Trimoulet, P; Winnock, M | 1 |
| Haydon, GH; Mutimer, DJ | 1 |
| Barbarini, G; Barbaro, G | 1 |
| Albrecht, J; Goodman, Z; Lindsay, K; Ling, MH; Manns, M; McHutchison, J; Poynard, T; Trepo, C | 1 |
| Arthur, MJ | 1 |
| Brinkley-Laughton, S; Hudson, M; Reindollar, R; Sulkowski, M; Thomas, DL; Yu, J | 1 |
| Esteban, JI; Juárez, A; Sauleda, S | 1 |
| García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R; Trapero Marugán, M | 1 |
| Forns, X | 1 |
| Duncan, D; Sharieff, KA; Younossi, Z | 1 |
| Allende, H; Castro, FJ; Esteban, JI; Esteban, R; Guardia, J; Juárez, A; Martell, M; Moreno, F; Sauleda, S; Viladomiu, L | 1 |
| Desch, S; Klinker, H; Langmann, P; Lingenauber, C; Väth, T; Zilly, M | 1 |
| Herrine, SK | 1 |
| Al-Khalid, J; Al-Mekhaizeem, K; Al-Nakib, B; Al-Shamali, M; Asker, H; Hasan, F; Siddique, I | 1 |
| Chan, PK; Ha, SY; Li, CK; Ling, SC | 1 |
| Bacon, BR; Blatt, LM; Brunt, EM; Cortese, CM; Goodman, ZD; Gordon, SC; Heaton, S; McHutchison, JG; Patel, K; Pianko, S | 1 |
| Amato, G; Caporaso, N; Carella, C; Cioffi, M; Mazziotti, G; Morisco, F; Rotondi, M; Sorvillo, F; Tuccillo, C | 1 |
| Abergel, A; Bernard, PH; Bourlière, M; Chêne, G; Couzigou, P; de Lédinghen, V; Fleury, H; Lévy, S; Portal, I; Rémy, AJ; Szostak, N; Tran, A; Trimoulet, P; Winnock, M | 1 |
| Naoumov, NV | 1 |
| Enomoto, M; Nishiguchi, S | 1 |
| Bausch, J; Bordens, R; Grace, M; Wang, YS; Wyss, DF; Youngster, S | 1 |
| Chou, S; Marousek, GI; Murphy, MD; Rosen, HR | 1 |
| Bondeson, TL; Lindgren, SC; Verbaan, HP; Widell, HE | 1 |
| Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Leandro, G; Mangia, A; Minerva, N; Piattelli, M; Santoro, R; Spirito, F; Ventrella, F | 1 |
| Burtscheidt, W; Gaebel, W; Kornischka, J | 1 |
| Willson, RA | 1 |
| Changchien, CS; Chen, TM; Huang, WS; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Bell, H; Bjøro, K; Dalgard, O; Hellum, KB; Myrvang, B | 1 |
| Abbas, Z; Hamid, S; Tabassum, S | 1 |
| Giostra, E; Mentha, G; Negro, F; Rizzoli, R; Trombetti, A | 1 |
| Becquemont, L; Broly, F; Chazouilleres, O; Funck-Brentano, C; Jaillon, P; Poirier, JM; Poupon, R; Serfaty, L | 1 |
| Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH | 1 |
| Ashton-Prolla, P; Cheinquer, H; Cheinquer, N; Coelho-Borges, S; Krug, L | 1 |
| Nĕmecek, V; Rýzlová, M; Stránský, J; Stríteský, J | 1 |
| Bell, H; Berg, JP; Bjøro, K; Distante, S; Hellum, KB; Myrvang, B; Raknerud, N; Skaug, K | 1 |
987 review(s) available for ribavirin and Chronic Hepatitis C
| Article | Year |
|---|---|
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
[From treating in the dark towards eliminating hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin | 2021 |
Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Treatment Outcome | 2022 |
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides | 2022 |
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Management of Hepatitis C in Children - A New Paradigm.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Ribavirin; Treatment Outcome | 2023 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin | 2023 |
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Paediatric hepatitis C virus infection and its treatment: Present, past, and future.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins | 2019 |
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.
Topics: Antiviral Agents; Benzimidazoles; Databases, Factual; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2019 |
Interferon-Free Hepatitis C Virus Therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Practice Guidelines as Topic; Ribavirin; Sustained Virologic Response | 2020 |
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Patient Selection; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2021 |
Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery.
Topics: Aged; Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin | 2020 |
Hepatitis C virus-related cryoglobulinemic vasculitis.
Topics: Antiviral Agents; Blood Component Removal; Colchicine; Cryoglobulinemia; Female; Glucocorticoids; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis | 2021 |
Treatment failure with DAA therapy: Importance of resistance.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2021 |
Genotype 3-hepatitis C virus' last line of defense.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome | 2021 |
Hepatitis C in Tunisia from 1991 to 2019: A systematic review.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Tunisia | 2021 |
The Challenge of Treating Children With Hepatitis C Virus Infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2017 |
Direct-acting antivirals: the endgame for hepatitis C?
Topics: Antiviral Agents; Disease Eradication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2017 |
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sofosbuvir | 2017 |
Hepatitis C virus management: potential impact of nanotechnology.
Topics: Antiviral Agents; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; MicroRNAs; Nanoparticles; Nanotechnology; Ribavirin; Viral Vaccines | 2017 |
Sofosbuvir and velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Risk Factors; Sofosbuvir; Sustained Virologic Response; Viral Load | 2017 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2017 |
Neurologic Manifestations of Hepatitis C Virus Infection.
Topics: Antiviral Agents; Cerebrovascular Disorders; Electroencephalography; Hepatitis C, Chronic; Humans; Interferons; Magnetic Resonance Imaging; Mental Disorders; Neurocognitive Disorders; Ribavirin | 2017 |
Impact of etiological treatment on prognosis.
Topics: Alcohol Abstinence; Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Portal Pressure; Prognosis; Ribavirin | 2018 |
Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2017 |
Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.
Topics: Adult; Aged; Antiviral Agents; Child; Dietary Supplements; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Vitamin D; Vitamins | 2018 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2017 |
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Patient Selection; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sustained Virologic Response; Viral Load; Vitamin D; Vitamin D Deficiency | 2018 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
[Chronic hepatitis C : Standard treatment and remaining challenges].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Ribavirin; Treatment Outcome | 2018 |
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Observational Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Time Factors; Young Adult | 2018 |
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Ribavirin | 2018 |
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Danoprevir: First Global Approval.
Topics: Antiviral Agents; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Natural products for the management of the hepatitis C virus: a biochemical review.
Topics: Antiviral Agents; Aquatic Organisms; Biological Products; Clinical Trials as Topic; Drug Therapy, Combination; Flavonoids; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Plant Extracts; Ribavirin | 2020 |
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Pakistan; Prevalence; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Viral resistance in HCV infection.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
Topics: Administration, Oral; Animals; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Viral Load | 2018 |
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Viral Load | 2019 |
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2019 |
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Polyethylene Glycols; Retreatment; Ribavirin | 2019 |
What the infectious disease physician needs to know about pegylated interferon and ribavirin.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Infectious Disease Medicine; Interferons; Polyethylene Glycols; Ribavirin | 2013 |
Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Odds Ratio; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.
Topics: Adult; Antiviral Agents; Comparative Effectiveness Research; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Topics: Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Blood Component Removal; Combined Modality Therapy; Cryoglobulinemia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Rituximab | 2013 |
Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
Topics: Antiviral Agents; Azathioprine; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2013 |
The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Oligopeptides; Polyethylene Glycols; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Risk; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load; Viremia | 2013 |
[Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Sarcoidosis | 2013 |
[Interferon treatment of chronic hepatitis C: basic immunobiology and immunopathology of the liver].
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Elasticity Imaging Techniques; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2013 |
Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Odds Ratio; Oligopeptides; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
[Inosine triphosphatase gene polymorphism and ribavirin-related anemia in chronic hepatitis C patients].
Topics: Anemia; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Genetic; Pyrophosphatases; Ribavirin | 2012 |
Emerging therapeutic targets for hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin | 2013 |
Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Odds Ratio; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; Viral Load | 2013 |
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
Topics: Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
Topics: Antiviral Agents; Asian People; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Publication Bias; Ribavirin; Time Factors; Treatment Outcome; White People | 2013 |
[Telaprevir-induced pityriasis rubra pilaris].
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Biopsy; Drug Eruptions; Drug Therapy, Combination; Eosinophilia; Eosinophils; Hepacivirus; Hepatitis C, Chronic; Histamine Antagonists; Humans; Interferon-alpha; Keratinocytes; Lymphocytes; Middle Aged; Oligopeptides; Pityriasis Rubra Pilaris; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin; Viral Nonstructural Proteins | 2013 |
New insights in recurrent HCV infection after liver transplantation.
Topics: Antibodies, Neutralizing; Antiviral Agents; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Viral Envelope Proteins; Virus Internalization | 2013 |
Evolution of cell culture systems for HCV.
Topics: Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Cultivation; Virus Replication | 2013 |
Protease inhibitors for hepatitis C: economic implications.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality of Life; Recombinant Proteins; Ribavirin | 2013 |
Viral hepatitis C gets personal--the value of human genomics to public health.
Topics: Antiviral Agents; Genomics; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Public Health; Ribavirin | 2013 |
Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.
Topics: Anemia; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
Hepatitis C virus: standard-of-care treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2013 |
Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genetic Markers; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Precision Medicine; Protease Inhibitors; Pyrophosphatases; Ribavirin | 2014 |
[Telaprevir in treatment-naïve patients with HCV monoinfection].
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Young Adult | 2013 |
[Telaprevir in HCV-monoinfected patients with failure to prior treatment].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome | 2013 |
[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Drug Eruptions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Medical Futility; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Stevens-Johnson Syndrome; Viral Load | 2013 |
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Topics: Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2013 |
[Telaprevir resistance].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2013 |
[Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Treatment Outcome | 2013 |
The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Ribavirin | 2013 |
Role of viral and host factors in interferon based therapy of hepatitis C virus infection.
Topics: Antiviral Agents; Genetic Markers; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin; Treatment Outcome | 2013 |
Management of anaemia and other treatment complications.
Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin | 2013 |
Treatment of chronic hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention | 2013 |
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients.
Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2014 |
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain | 2013 |
Novel therapeutic approaches for hepatitis C.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin | 2014 |
Simeprevir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides | 2013 |
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.
Topics: Age Factors; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Regression Analysis; Ribavirin | 2014 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2013 |
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Topics: Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2013 |
Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2014 |
Lacrimal gland marginal zone lymphoma: regression after treatment of chronic hepatitis C virus infection: case report and review of the literature.
Topics: Adult; Antiviral Agents; Eye Neoplasms; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lacrimal Apparatus; Lymphoma, B-Cell, Marginal Zone; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Tomography, X-Ray Computed | 2013 |
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
Topics: Antiviral Agents; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2013 |
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
Topics: Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?: a narrative systematic review of the evidence base.
Topics: Antiviral Agents; Delivery of Health Care; Epidemiologic Methods; General Practice; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Primary Health Care; Prisoners; Recombinant Proteins; Ribavirin | 2013 |
HCV F1/F2 patients: treat now or continue to wait.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate | 2014 |
[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polymorphism, Genetic; Prognosis; Proline; Protease Inhibitors; Regulatory Sequences, Nucleic Acid; Ribavirin; Treatment Outcome | 2013 |
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Predictors of hepatitis C treatment response: what's new?
Topics: Age Factors; Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Protease Inhibitors; Ribavirin; Viral Load | 2014 |
[Triple therapy for chronic hepatitis C: practical aspects].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Ribavirin | 2013 |
Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells.
Topics: Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Myeloid Cells; Ribavirin; Treatment Outcome; Viral Load | 2013 |
New antiviral agents for the treatment of hepatitis C: ABT-450.
Topics: Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2014 |
Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2014 |
Safety of direct-acting antivirals in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin | 2014 |
Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2014 |
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2014 |
Hepatitis C virus therapy in the direct acting antiviral era.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate | 2014 |
IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Review article: genetic factors that modify the outcome of viral hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; HLA-DP alpha-Chains; HLA-DP beta-Chains; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Watchful Waiting | 2014 |
Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
Topics: Antiviral Agents; Coinfection; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2014 |
[Future prospects for hepatitis C treatment: without interferon and ribavirin?].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2014 |
[Therapy of chronic hepatitis C].
Topics: Adult; Algorithms; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Polyethylene Glycols; Prognosis; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
The rapid evolution of treatment strategies for hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin | 2013 |
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2014 |
Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Aminoadamantanes for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
[Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Education, Medical, Continuing; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides | 2014 |
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Design; Drug Evaluation, Preclinical; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Molecular Structure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome | 2014 |
Virus-related liver cirrhosis: molecular basis and therapeutic options.
Topics: Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Genotype; Hepacivirus; Hepatic Stellate Cells; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Liver Cirrhosis; Mutation; Regeneration; Ribavirin; Stem Cells; Virus Replication | 2014 |
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Mycophenolic Acid; Randomized Controlled Trials as Topic; Ribavirin | 2014 |
Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
Topics: Genotype; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Safety | 2014 |
[Treatment of viral hepatitis in children].
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
Topics: Adult; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2013 |
[Treatment of non-1 genotype chronic hepatitis C patients].
Topics: Adult; Age Factors; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2013 |
Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
Topics: Dietary Supplements; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Outcome Assessment, Health Care; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vitamin D | 2014 |
Treating hepatitis C in the elderly: the future is near?
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferons; Liver Cirrhosis; Polymorphism, Genetic; Research Design; Ribavirin; Viral Load | 2014 |
Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis.
Topics: Antiviral Agents; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Transplantation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous | 2014 |
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
Topics: Administration, Oral; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2014 |
Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2015 |
Treatment of hepatitis B and C in children.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Egypt; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infant; Interferon-alpha; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C genotype 1.
Topics: Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load | 2014 |
Update on the treatment of hepatitis C genotypes 2-6.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Load | 2014 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins | 2014 |
The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
Topics: Adolescent; Antiviral Agents; Biomarkers; Child; Child Development; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2014 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
Topics: Anemia, Hemolytic; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Heme Oxygenase-1; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Inflammation Mediators; Ribavirin; Treatment Outcome | 2014 |
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prevalence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2015 |
[Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Papilledema; Polyethylene Glycols; Radiography; Ribavirin | 2015 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine | 2015 |
Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Asian People; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2015 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Outcome Assessment; Quality of Life; Ribavirin; Treatment Outcome | 2015 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2015 |
[Outline of HCV treatment].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin | 2015 |
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2015 |
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors | 2014 |
Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Viral Load; White People | 2016 |
Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Young Adult | 2015 |
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Bibliographic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Viral Load | 2015 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2015 |
Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Risk Assessment; Survival Analysis; Treatment Failure | 2015 |
Therapy for hepatitis C genotype 3: moving forward.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Health Care Costs; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2015 |
HCV Treatments and Their Integration Into Rheumatology.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Rheumatic Diseases; Ribavirin; Sialadenitis; Vasculitis | 2015 |
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Extrahepatic morbidity and mortality of chronic hepatitis C.
Topics: Antiviral Agents; Cryoglobulinemia; Glomerulonephritis; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma; Morbidity; Ribavirin; Vasculitis | 2015 |
Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure | 2015 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir | 2015 |
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hemoglobins; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolism, Inborn Errors; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome | 2015 |
The hepatitis C revolution part 1: antiviral treatment options.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
[Clinical Implication of Insulin Resistance in Chronic Hepatitis C Patients].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferons; Ribavirin; Treatment Outcome | 2015 |
[Diabetic retinopathy induced by PEG-IFN-alpha2a plus ribavirin in chronic hepatitis C: a literature review].
Topics: Antiviral Agents; Diabetic Retinopathy; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir | 2016 |
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2016 |
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2016 |
[Possibilities of IFN-free therapy of hepatitis C].
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Why do I treat my patients with mild hepatitis C?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Why I do not treat patients for mild disease.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 2016 |
Is the benefit of treating patients with cirrhosis proven?
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2016 |
News and challenges in the treatment of hepatitis C in liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin | 2016 |
Hepatitis C virus: how to provide the best treatment with what I have.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult | 2016 |
Follow-up of patients with chronic hepatitis C and a sustained viral response.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Antiviral Agents; Coinfection; Drug Users; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sustained Virologic Response; Viral Load; Young Adult | 2016 |
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Topics: Antibodies, Antinuclear; Antiviral Agents; Autoimmunity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunity, Humoral; IMP Dehydrogenase; Interferon-alpha; Protein Conformation; Ribavirin; Self Tolerance; Time Factors; Treatment Outcome | 2016 |
Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin; Treatment Outcome | 2015 |
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nucleotides; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins | 2016 |
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
Topics: Antigens, Viral; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Immunity; Interferon-alpha; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2016 |
Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Complementary Therapies; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis C, Chronic; Humans; Interferons; Medicine, Chinese Traditional; Ribavirin; Treatment Outcome | 2016 |
Pharmacogenetics of ribavirin-induced anemia in HCV patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2016 |
Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Chronic Hepatitis C Infection in Children.
Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2016 |
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin | 2016 |
Daclatasvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Hepatitis C virus: Promising discoveries and new treatments.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; RNA, Viral; Sustained Virologic Response; Viral Load | 2016 |
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Reinventing HCV Treatment: Past and Future Perspectives.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Phosphoproteins; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Serine Proteases; Sustained Virologic Response; Viral Nonstructural Proteins | 2017 |
How much of a problem is resistance in treating hepatitis C?
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Quinoxalines; Ribavirin; Sulfonamides; Transplant Recipients | 2016 |
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
The impact of hepatitis C virus outside the liver: Evidence from Asia.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Costs and Cost Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sustained Virologic Response; Treatment Failure | 2017 |
Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferons; Network Meta-Analysis; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Sustained Virologic Response | 2017 |
Advances in drug development for hepatitis C.
Topics: Antiviral Agents; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Viral Nonstructural Proteins | 2015 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.
Topics: Adult; Antiviral Agents; Disease Management; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Prevalence; Ribavirin; Treatment Outcome | 2016 |
[Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China].
Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2016 |
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Hepatitis C: efficacy and safety in real life.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Randomized Controlled Trials as Topic; Renal Insufficiency; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Management of direct antiviral agent failures.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir | 2016 |
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Autoimmune Diseases; Cryoglobulinemia; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferons; Lymphoma, B-Cell; Ribavirin; Rituximab; Vasculitis | 2017 |
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Network Meta-Analysis; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Hepatitis Vaccines | 2017 |
Management of chronic hepatitis C virus infection in HIV-infected patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2008 |
[Therapy of chronic Hepatitis C in 2008].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
[The role of ribavirin in the treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; Virus Replication | 2008 |
Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Ribavirin in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2008 |
[Thrombocytopenia in HCV infection. Natural interferon as an alternative therapy].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thrombocytopenia | 2007 |
Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
[Goals of treatment, indication, and treatment for chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors.
Topics: Antiviral Agents; Drug Carriers; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2008 |
Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review.
Topics: Antiviral Agents; Autoantibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iodide Peroxidase; Ribavirin; Thyroid Gland; Thyroiditis | 2008 |
[Hepatitis C: which strategy in case of treatment failure ?].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2008 |
[Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Care Team; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hepatitis C: current and future therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin; United States; United States Food and Drug Administration | 2008 |
Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Pharmacists; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2008 |
Expert opinion on the treatment of patients with chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
[Current opportunities for treatment of chronic hepatitis C in patients with HIV co-infection].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Comorbidity; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferons; Poland; Primary Health Care; Randomized Controlled Trials as Topic; Ribavirin; Risk Assessment | 2008 |
[Treatment of chronic hepatitis C virus infection in hemodialysis patients].
Topics: Antiviral Agents; Contraindications; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Prevalence; Recombinant Proteins; Renal Dialysis; Ribavirin; Turkey | 2008 |
Interferon-based therapy for chronic hepatitis C: current and future perspectives.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2008 |
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
Topics: Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Plasma; Ribavirin; Treatment Outcome | 2008 |
Safety of peginterferon in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Secondary Prevention; Treatment Outcome | 2008 |
Management strategies for hepatitis C virus infection in children.
Topics: Adult; Anemia; Antiviral Agents; Child; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2008 |
What is on the horizon for treatment of chronic hepatitis C?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Hepatitis Vaccines; Viral Load | 2008 |
Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Taribavirin for the treatment of chronic hepatitis C.
Topics: Anemia; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hepatitis C, Chronic; Humans; Prodrugs; Ribavirin; Treatment Outcome | 2008 |
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms.
Topics: DNA-Directed RNA Polymerases; Gene Expression Regulation; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon alpha-2; Interferon-alpha; Models, Biological; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2008 |
[Treatment of hepatitis C virus infection: current status and perspectives].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load; Viremia | 2008 |
Ribavirin: current role in the optimal clinical management of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
Peginterferon and ribavirin in HCV: improvement of sustained viral response.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Depression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2008 |
Future treatment options for HCV: double, triple, what is the optimal combination?
Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin | 2008 |
A review of current anti-HCV treatment regimens and possible future strategies.
Topics: Antiviral Agents; Clinical Trials as Topic; DNA-Directed RNA Polymerases; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2009 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?
Topics: Alcoholism; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Retreatment of chronic hepatitis C: who and how?
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Retreatment; Ribavirin; Time Factors | 2009 |
Protease and polymerase inhibitors for the treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2009 |
What future for ribavirin?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins | 2009 |
[Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Visual Acuity; Visual Fields | 2009 |
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
Topics: Antiviral Agents; Drug Discovery; Hepatitis C, Chronic; HIV Protease Inhibitors; IMP Dehydrogenase; Ribavirin | 2009 |
Treatment of chronic hepatitis C in Asia: when East meets West.
Topics: Antiviral Agents; Asia; Asian People; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2009 |
Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
[Cutting edge anti-viral therapy for hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2009 |
[Chronic hepatitis C in children: natural history and prognosis].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Incidence; Interferons; Italy; Prevalence; Prognosis; Ribavirin; Risk Factors; Treatment Outcome; Viremia | 2009 |
Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2009 |
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
The hepatitis C virus enigma.
Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication | 2009 |
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Medication Adherence; Ribavirin | 2009 |
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Efficacy of chronic hepatitis C therapy in community-based trials.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Long-term outcomes after treatment with interferon and ribavirin in HCV patients.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Serine protease inhibitors as anti-hepatitis C virus agents.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors | 2009 |
Management of patients co-infected with HBV and HCV.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Superinfection; Treatment Outcome | 2009 |
Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2009 |
Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Difficulties in treatment of kidney diseases related to HCV infection].
Topics: Antiviral Agents; Cryoglobulinemia; Diet Therapy; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Cytokines - their pathogenic and therapeutic role in chronic viral hepatitis.
Topics: Antiviral Agents; Apoptosis; Cytokines; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Lymphocyte Subsets; Models, Biological; Receptors, Cytokine; Ribavirin; Virus Replication | 2009 |
[Novel treatments for hepatitis C viral infection and the hepatic fibrosis].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Treatment options for hepatitis C and the rationale for low response rates in African Americans.
Topics: Antiviral Agents; Black or African American; Disease Progression; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome; United States; White People | 2009 |
Hepatitis C virus infection and immunomodulatory therapies.
Topics: Antibodies, Monoclonal; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Immunologic Factors; Immunotherapy; Interferons; Nitro Compounds; Ribavirin; Thiazoles; Toll-Like Receptors; Viral Hepatitis Vaccines | 2009 |
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
Topics: Alcoholism; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Depressive Disorder; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Illicit Drugs; Interferon alpha-2; Interferon-alpha; Methadone; Narcotics; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous | 2008 |
Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thalassemia; Treatment Outcome; Young Adult | 2010 |
TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Viral Nonstructural Proteins; Viral Proteins | 2009 |
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
Topics: alpha-Glucosidases; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Indolizines; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin | 2009 |
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
Topics: Adult; Antiviral Agents; Clinical Audit; Drug Therapy, Combination; Evidence-Based Medicine; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Prospective Studies; Ribavirin; Risk Assessment; RNA, Viral; Thyroid Diseases; Time Factors; Treatment Outcome; Viral Load | 2009 |
Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virulence Factors | 2009 |
Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.
Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Treatment Outcome; Virus Replication | 2009 |
Ribavirin therapeutic drug monitoring: why, when and how?
Topics: Antiviral Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Monitoring; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Viral Load | 2010 |
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
[Treatment optimization in chronic hepatitis C virus infection].
Topics: Adult; Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Viremia | 2010 |
Ribavirin monotherapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Viral Load | 2009 |
[HCV entry as a new therapeutic target in chronic hepatitis C].
Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Attachment; Virus Internalization | 2009 |
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Assessment | 2010 |
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin.
Topics: Antiviral Agents; Case Management; Controlled Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2009 |
Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.
Topics: Antiviral Agents; Chemoprevention; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Ribavirin; Secondary Prevention; Treatment Outcome | 2010 |
The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.
Topics: Adult; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Making; Drug Monitoring; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome | 2009 |
Optimizing the treatment of chronic viral hepatitis C.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
Topics: Acute Disease; Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sweden | 2009 |
Treatment of chronic hepatitis C.
Topics: Antiviral Agents; Biopsy, Needle; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2009 |
Antiviral strategies: the present and beyond.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Influenza, Human; Interferon-alpha; Oseltamivir; Ribavirin; Structure-Activity Relationship | 2009 |
Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2009 |
New trends in hepatitis C management.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Global Health; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2010 |
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2010 |
Ribavirin plus interferon versus interferon for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin | 2010 |
Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.
Topics: Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Mannose-Binding Lectins; Models, Biological; Plant Lectins; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Sorption Detoxification; Treatment Outcome; Viral Load; Viremia | 2010 |
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
[Antiviral therapy for chronic hepatitis C: current status and perspectives].
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin; Thiazoles | 2010 |
The treatment of chronic hepatitis C virus infection in HIV co-infection.
Topics: Antiretroviral Therapy, Highly Active; Coinfection; Europe; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2009 |
Role of ribavirin in HCV treatment response: now and in the future.
Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2010 |
Adverse effects of drugs in the treatment of viral hepatitis.
Topics: Antiviral Agents; Drugs, Investigational; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Risk Assessment; Risk Factors | 2010 |
The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus.
Topics: Adjuvants, Immunologic; Antiviral Agents; Dendritic Cells; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Killer Cells, Natural; Protein-Tyrosine Kinases; Ribavirin; T-Lymphocytes, Regulatory; Toll-Like Receptors | 2010 |
Treatment of hepatitis C in 2011: what can we expect?
Topics: Antiviral Agents; Drug Therapy, Combination; Forecasting; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2010 |
Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2010 |
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
[HIV and hepatitis C co-infection].
Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Evidence-Based Medicine; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2010 |
Thymalfasin in the treatment of hepatitis B and C.
Topics: Adjuvants, Immunologic; Antiviral Agents; Europe; Hepacivirus; Hepatitis B; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; Thymalfasin; Thymosin; Viral Vaccines | 2010 |
Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome | 2010 |
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
Topics: Animals; Antiviral Agents; Carboxylic Acids; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Protease Inhibitors; Remission Induction; Ribavirin; Thiophenes; Treatment Outcome | 2010 |
[Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver Neoplasms; Ribavirin | 2010 |
Individualisation of antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Care Team; Precision Medicine; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Management of HIV and hepatitis virus coinfection.
Topics: Animals; Antiretroviral Therapy, Highly Active; Disease Management; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunity, Humoral; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2010 |
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Telaprevir: a new hope in the treatment of chronic hepatitis C?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2010 |
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
Topics: Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serpins; Viral Nonstructural Proteins; Viral Proteins; Viruses | 2010 |
[A case of cardiac sarcoidosis occurring during combination therapy by IFN alpha and ribavirin for chronic hepatitis C].
Topics: Aged; Antiviral Agents; Cardiomyopathies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sarcoidosis | 2010 |
Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
Topics: Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
[Thrombocytopenia in patients with chronic hepatitis C].
Topics: Antiviral Agents; Biomarkers; Disease Progression; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2010 |
Early interferon-based treatment after detection of persistent hepatitis C virus infection: a critical decision.
Topics: Animals; Cost-Benefit Analysis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferons; Precision Medicine; Ribavirin; RNA, Viral | 2010 |
Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Statistics as Topic; Treatment Outcome | 2010 |
IL28B polymorphisms and chronic hepatitis C.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2010 |
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
Topics: Antiviral Agents; Female; Follow-Up Studies; Forecasting; Gene Expression Regulation, Viral; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Polymorphism, Genetic; Precision Medicine; Randomized Controlled Trials as Topic; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2011 |
Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Time Factors; Treatment Outcome | 2011 |
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Risk Factors; Suicide | 2011 |
Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2011 |
Ribavirin for chronic hepatitis C: and the mystery goes on.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Off-Label Use; Ribavirin | 2011 |
Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Heart Failure; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Renal Insufficiency; Ribavirin; Treatment Outcome | 2011 |
[Primary care enlightenment to local inhabitants--cooperation of medical institution and community pharmacy in treatment of chronic hepatitis C].
Topics: Antiviral Agents; Community Networks; Community Pharmacy Services; Critical Pathways; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Nonprescription Drugs; Pharmacies; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin | 2010 |
Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
Topics: Antiviral Agents; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2010 |
Current therapies for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Liver Cirrhosis; Male; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Treatment Outcome | 2011 |
Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Signal Transduction; Standard of Care; Virus Replication | 2011 |
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Prevalence; Randomized Controlled Trials as Topic; Ribavirin | 2011 |
[Genome-wide association studies].
Topics: Antiviral Agents; Chromosomes, Human, Pair 19; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Recombinant Proteins; Ribavirin | 2011 |
Hepatitis C pharmacogenetics: state of the art in 2010.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration; Viral Load | 2011 |
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Peginterferon and ribavirin treatment for hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Drug Therapy, Combination; Fatty Liver; Genetic Variation; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferons; Liver Neoplasms; Ribavirin; Viral Core Proteins; Virus Replication | 2011 |
Hepatitis in 2010: the dawn of a new era in HCV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Liver Neoplasms; Liver Transplantation; Polymorphism, Single Nucleotide; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2011 |
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Therapy Management; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Insulin Resistance; Interferon Type I; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases | 2011 |
Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Mood Disorders; Ribavirin | 2011 |
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure | 2011 |
Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials.
Topics: Adult; Animals; Antiviral Agents; Belgium; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Molecular Structure; Nucleosides; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2009 |
[Chronic hepatitis and occult HCV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Tolerance; Interferon-alpha; Ribavirin; Virus Replication | 2010 |
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Topics: Antiviral Agents; Confidence Intervals; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Risk Assessment; State Medicine; Treatment Outcome; Uncertainty; United Kingdom | 2011 |
[New therapeutic options in chronic hepatitis C virus infection].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cryoglobulinemia; Disease Progression; Drug Resistance, Viral; Female; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2011 |
Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Treatment Outcome; Viral Load | 2011 |
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
Clinical practice. Chronic hepatitis C infection.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B Antibodies; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Ribavirin; Treatment Outcome; Viral Load | 2011 |
[Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Prediction of response to peg-interferon plus ribavirin therapy for chronic hepatitis C].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Consensus Development Conferences as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load | 2011 |
Treatment of hepatitis C-mediated glomerular disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab | 2011 |
New treatments for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational | 2011 |
Role of the nurse practitioner in the management of patients with chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Nurse Practitioners; Nurse's Role; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors | 2011 |
Interferon-lambda and therapy for chronic hepatitis C virus infection.
Topics: Animals; Antiviral Agents; Chromosomes, Human, Pair 19; Drug Therapy, Combination; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Mice; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Transcription Factors; Treatment Outcome; Viral Load | 2011 |
Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
1990-2010: two decades of interferon-based therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2011 |
An overview of emerging therapies for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Metabolic alterations and chronic hepatitis C: treatment strategies.
Topics: Antiviral Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
[Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Host genomics and HCV treatment response.
Topics: Animals; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Treatment Outcome | 2012 |
Host genetics.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2011 |
Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2011 |
[Genome-wide association study on and the clinical application to chronic hepatitis C].
Topics: Anemia, Hemolytic; Antiviral Agents; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin | 2011 |
Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
[Treatment strategy for chronic hepatitis C in Japan].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Japan; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2011 |
[Development of anti viral therapy for chronic hepatitis type C].
Topics: Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Combination therapy of PEG-interferon and ribavirin for chronic hepatitis C in Japan].
Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fatty Alcohols; Female; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Metformin; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Silybin; Silymarin; Thiazoles | 2011 |
[Re-treatment for patients with chronic hepatitis C who previously failed to peginterferon/ribavirin therapy].
Topics: Antiviral Agents; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2011 |
[Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin.
Topics: Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Prognosis; Ribavirin; Th1-Th2 Balance | 2011 |
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia | 2011 |
Telaprevir for the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
[New agents for the treatment of hepatitis C].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins | 2012 |
Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Models, Economic; Quality-Adjusted Life Years; Ribavirin | 2011 |
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Management of chronic hepatitis C infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Classical and emerging roles of vitamin D in hepatitis C virus infection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Osteoporosis; Ribavirin; Vitamin D; Vitamin D Deficiency; Vitamins | 2011 |
Chronic hepatitis C infection in the elderly.
Topics: Age Factors; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prevalence; Ribavirin | 2011 |
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care | 2012 |
Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome | 2012 |
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment | 2012 |
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult | 2012 |
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure | 2012 |
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load | 2012 |
Response-guided and -unguided treatment of chronic hepatitis C.
Topics: Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2012 |
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Topics: Antiviral Agents; Disease Eradication; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2012 |
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Future treatment of patients with HCV cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Hepatitis C virus treatment pre- and post-liver transplantation.
Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
Hepatitis C virus-human immunodeficiency virus coinfection.
Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load | 2012 |
What's new in HCV genotype 2 treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2012 |
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
The future for the treatment of genotype 4 chronic hepatitis C.
Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D | 2012 |
Barriers to hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Refusal; Viral Load | 2012 |
Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Treatment failure with new hepatitis C drugs.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Phenotype; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
[Genetic polymorphisms as new predictive factors for successful treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Antiviral strategies in hepatitis C virus infection.
Topics: Antiviral Agents; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins | 2012 |
[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].
Topics: Algorithms; Antiviral Agents; Drug Resistance, Viral; Forecasting; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Models, Biological; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Proteins | 2011 |
Treatment of hepatitis C in dialysis patients.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2012 |
Telaprevir for the treatment of hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin | 2012 |
Update of old and emerging therapies in chronic hepatitis C.
Topics: Antiviral Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Recombinant Proteins; Ribavirin | 2011 |
[New class of medicines for chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2012 |
Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.
Topics: Alanine Transaminase; Antiviral Agents; Carrier State; Hepatitis C, Chronic; Humans; Interferons; Liver; Ribavirin | 2012 |
Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Neoplasms; North America; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Viral Load | 2012 |
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland.
Topics: Acyltransferases; Adult; Age Distribution; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Distribution; Treatment Outcome | 2012 |
Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2012 |
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Hepatitis C therapy update.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2012 |
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load | 2012 |
Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.
Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Time Factors | 2012 |
Clinical utility of interleukin-28B testing in patients with genotype 1.
Topics: Antiviral Agents; Confidence Intervals; Ethnicity; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2012 |
Recent trends in the treatment of chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
New virologic tools for management of chronic hepatitis B and C.
Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Point-of-Care Systems; Polyethylene Glycols; Proline; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome | 2012 |
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Tract; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Interferons and hepatitis C virus.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Janus Kinases; Ribavirin; Signal Transduction; STAT Transcription Factors | 2012 |
TMC435 for the treatment of chronic hepatitis C.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sulfonamides | 2012 |
Basic answers to complicated questions for the course of chronic hepatitis C treatment.
Topics: Antiviral Agents; Disease Management; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; United States | 2012 |
[Direct antiviral treatment strategies in chronic hepatitis C].
Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Treatment Outcome | 2012 |
[Hepatitis C! Experience in diagnosis and medical treatment. A literature review].
Topics: Adult; Ambulatory Care; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Patient-Centered Care; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Self Care; Sick Role | 2012 |
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Standard of Care; Treatment Outcome | 2012 |
The changing therapeutic landscape for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
Topics: Antiviral Agents; Carrier Proteins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Oligopeptides; Poland; Proline; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Hepatitis C therapy in non-genotype 1 patients: the near future.
Topics: Antioxidants; Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Silybin; Silymarin | 2012 |
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
Topics: Antiviral Agents; Asian People; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Viral Load; White People | 2012 |
Current and emerging antiviral treatments for hepatitis C infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
Topics: Antiviral Agents; Drug Combinations; France; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors | 2012 |
[Chronic hepatitis C: improved cure rates with new approved medications].
Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.
Topics: Abdominal Pain; Antiviral Agents; Colitis, Ischemic; Colonoscopy; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment | 2012 |
Genomic variation-guided management in chronic hepatitis C.
Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Precision Medicine; Pyrophosphatases; Recombinant Proteins; Ribavirin | 2012 |
The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2012 |
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Topics: Age Factors; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors | 2012 |
Telaprevir: pharmacokinetics and drug interactions.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ketoconazole; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins | 2012 |
[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Treatment Outcome | 2012 |
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2012 |
Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
[Boceprevir (Victrelis), oral administration].
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin | 2012 |
New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
Topics: Antibodies, Anti-Idiotypic; Antiviral Agents; Aquaporin 4; Diabetes Mellitus, Type 1; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferon-beta; Middle Aged; Optic Neuritis; Ribavirin | 2012 |
Shortened peginterferon and ribavirin treatment for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; United Kingdom | 2012 |
Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2012 |
Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
Topics: Adult; Antiviral Agents; Black People; Drug Eruptions; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue | 2013 |
A new era in the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
[Treatment of hepatitis C infection: towards eradication of chronic virus].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
Pharmacokinetics of new oral hepatitis C antiviral drugs.
Topics: Administration, Oral; Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2013 |
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Interferon stimulated genes and hepatitis C virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2012 |
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].
Topics: Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Telaprevir for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Boceprevir and treatment of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Management of the transplant recipient with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferons; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Care; Preoperative Care; Proline; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Future perspectives: towards interferon-free regimens for HCV.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2012 |
Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Oligopeptides; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
The role of viral and host genetics in natural history and treatment of chronic HCV infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin; Treatment Outcome | 2012 |
Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.
Topics: Acute Disease; Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin | 2012 |
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Induction Chemotherapy; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
The role of resistance in HCV treatment.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mutation; Oligopeptides; Proline; Protease Inhibitors; Ribavirin | 2012 |
Liver transplantation in the setting of chronic HCV.
Topics: Age Factors; Antiviral Agents; Cytomegalovirus Infections; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Protease Inhibitors; Ribavirin; Risk Factors; Secondary Prevention; Tissue Donors | 2012 |
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Ribavirin; Time Factors; Treatment Outcome; United States; Viral Load | 2013 |
Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome | 2013 |
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin | 2012 |
Optimal treatment with telaprevir for chronic HCV infection.
Topics: Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2013 |
Optimal treatment with boceprevir for chronic HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
How to optimize HCV therapy in genotype 1 patients: management of side-effects.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
How to optimize HCV therapy in genotype 2 patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2013 |
How to optimize HCV therapy in genotype 4 patients.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2013 |
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Interferon free therapy with direct acting antivirals for HCV.
Topics: Antiviral Agents; Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Molecular; Molecular Structure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral | 2013 |
Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2012 |
Glucose abnormalities in hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Ribavirin | 2013 |
Management of hepatitis C virus infection: the basics.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2012 |
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2013 |
Anemia management in patients with chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2013 |
Current treatment for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2001 |
Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2002 |
HCV chronic hepatitis in patients with HIV: clinical management issues.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Ribavirin; Time Factors | 2002 |
[Hepatitis C and alcohol].
Topics: Alanine Transaminase; Alcoholism; Antiviral Agents; Apoptosis; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Odds Ratio; Prevalence; Ribavirin; Risk Factors; Time Factors; Viral Load | 2002 |
[Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; France; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferons; Prevalence; Prisons; Prognosis; Prospective Studies; Recurrence; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders; Time Factors | 2002 |
[Chronic hepatitis C in HIV-HCV coinfected patients].
Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Meta-Analysis as Topic; Pilot Projects; Prevalence; Ribavirin; Risk Factors | 2002 |
[Management of patients with hepatitis C virus infection. Virological tests].
Topics: Acute Disease; Adult; Algorithms; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Biomarkers; Capsid; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Male; Monitoring, Physiologic; Polymerase Chain Reaction; Prognosis; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2002 |
[Treatment of patients with chronic hepatitis C who have not been previously treated].
Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Placebos; Polyethylene Glycols; Prognosis; Ribavirin; RNA, Viral; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
Topics: Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Transaminases; Viral Load | 2002 |
[Treatment of chronic hepatitis C in children].
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors | 2002 |
[Treatment of extrahepatic manifestations associated with hepatitis C virus infection].
Topics: Antiviral Agents; Autoantibodies; Cryoglobulinemia; Drug Therapy, Combination; Fatigue; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Lymphoproliferative Disorders; Male; Middle Aged; Odds Ratio; Porphyria Cutanea Tarda; Pruritus; Ribavirin; Sjogren's Syndrome; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Vascular Diseases | 2002 |
[Treatment of hepatitis C virus-related cirrhosis].
Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
Topics: Amantadine; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Transaminases; Treatment Failure; Viral Load | 2002 |
[Evaluation of response to treatment in chronic hepatitis C].
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Meta-Analysis as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Transaminases; Viremia | 2002 |
[Treatment of chronic hepatitis C in special groups].
Topics: Acute Disease; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Drug Therapy, Combination; Follow-Up Studies; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Renal Dialysis; Ribavirin; Thalassemia; Time Factors | 2002 |
[Quality of life of patients with chronic hepatitis C: effect of treatments].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Surveys and Questionnaires; Time Factors; Viral Load | 2002 |
[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Liver Transplantation; Male; Multicenter Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Time Factors; Transaminases | 2002 |
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine | 2002 |
[Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
Topics: Adult; Alcoholism; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Deficiencies; Liver Transplantation; Male; Obesity; Patient Education as Topic; Ribavirin; Risk Factors; Smoking; Smoking Prevention; Time Factors | 2002 |
[Hepatitis C: therapeutic perspectives].
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Clinical Trials, Phase III as Topic; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Interferon-beta; Interferons; Multicenter Studies as Topic; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Viral Load | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C who never had been treated].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biopsy; Body Weight; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Transaminases; Viral Load | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors | 2002 |
[Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
Topics: Anemia, Hemolytic; Antiviral Agents; Blood Cell Count; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Neutropenia; Prospective Studies; Quality of Life; Retrospective Studies; Ribavirin; Risk Factors; Thrombocytopenia; Time Factors | 2002 |
[Hepatitis C and liver transplantation].
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Pilot Projects; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Tissue Donors; Transaminases | 2002 |
Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2002 |
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin | 2002 |
Treatment of chronic hepatitis C: a systematic review.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Motion - the available treatments for hepatitis C are cost effective: arguments for the motion.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Ontario; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Severity of Illness Index; Treatment Outcome | 2002 |
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure | 2002 |
[Role of interferons in the treatment of hepatitis B and hepatitis C virus infections].
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2002 |
[Do the interferons have an antifibrotic action? The hepatologist's point of view].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterozygote; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Novel mode of action of ribavirin (Rebetol), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses].
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon alpha-2; Interferon-alpha; Mutation; Recombinant Proteins; Ribavirin; RNA Viruses; RNA-Dependent RNA Polymerase | 2002 |
Treatment of chronic hepatitis C in nonresponders to previous therapy.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Therapy of chronic hepatitis C: a critical review.
Topics: Age Factors; Alanine Transaminase; Animals; Blood Coagulation Disorders, Inherited; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Pregnancy; Recurrence; Renal Insufficiency; Ribavirin; Treatment Outcome | 2003 |
[Combination therapy for chronic viral hepatitis C].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Treatment of hepatitis C. Paris 27-28 February 2002].
Topics: Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Paris; Practice Guidelines as Topic; Ribavirin; Transaminases; Treatment Outcome | 2002 |
Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoidosis, Pulmonary | 2003 |
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Topics: Adsorption; Antiviral Agents; Black People; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Treatment of chronic hepatitis C in patients without previous treatment].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2002 |
[Treatment of chronic hepatitis C in patients coinfected with HIV-HCV/HBV].
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
[Antiviral therapy for chronic viral hepatitis B and C].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Half-Life; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Chronic hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Side effects of therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Mental Disorders; Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases | 2003 |
Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Topics: Adult; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load | 2003 |
Hepatitis C virus therapies: current treatments, targets and future perspectives.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
Treatment of HCV-related liver diseases after renal transplantation: modern views.
Topics: Antiviral Agents; Graft Survival; Hepatitis C, Chronic; Humans; Interferon Type I; Kidney Transplantation; Recombinant Proteins; Renal Dialysis; Ribavirin | 2003 |
Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2003 |
Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 2003 |
Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Pegylated interferons in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
The role of the laboratory in the diagnosis and management of chronic hepatitis C patients.
Topics: Acute Disease; Biopsy, Needle; Clinical Laboratory Techniques; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Saudi Arabia; Sensitivity and Specificity | 2003 |
Chronic hepatitis C treatment. Side effects and their management.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Recombinant Proteins; Ribavirin; Risk Assessment; Saudi Arabia; Severity of Illness Index; Treatment Outcome | 2003 |
Hepatis C virus genotype 4.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prognosis; Recombinant Proteins; Ribavirin; Saudi Arabia; Treatment Outcome | 2003 |
Pharmacokinetics of peginterferons.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum Albumin; Serum Albumin, Human | 2003 |
Clinical trial results of peginterferons in combination with ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Therapeutic progresses of hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2003 |
Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease.
Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Ribavirin; Secondary Prevention; Time Factors | 2003 |
Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2003 |
Chronic hepatitis C: updated Swedish consensus.
Topics: Adult; Aged; Antiviral Agents; Consensus; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Rate; Sweden; Treatment Outcome | 2003 |
Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Management of newly diagnosed hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Prognosis; Recombinant Proteins; Ribavirin | 2003 |
Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Recurrence; Retreatment; Ribavirin | 2003 |
Practical management of liver transplant recipients for hepatitis C.
Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome | 2003 |
Combined antiviral options for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2004 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index | 2003 |
[Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature].
Topics: Antiviral Agents; Biopsy, Needle; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2004 |
Guidelines for stopping therapy in chronic hepatitis C.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Guidelines as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2004 |
New therapies for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2004 |
[Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2002 |
[New therapeutic agents for chronic hepatitis C].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors | 2004 |
Update on chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Tests; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Terminology as Topic; Treatment Outcome | 2003 |
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
Topics: Antiviral Agents; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2004 |
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Changing faces-natural course and treatment of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Hepatitis C virus.
Topics: Antiviral Agents; Complementary Therapies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Nurse's Role; Prevalence; Quality of Life; Ribavirin; Risk Factors; Sex Characteristics; Sex Distribution; Sex Factors; United States; Women's Health | 2004 |
Necrolytic acral erythema: response to combination therapy with interferon and ribavirin.
Topics: Acrodermatitis; Antiviral Agents; Child; Drug Therapy, Combination; Erythema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Necrosis; Parenteral Nutrition; Recombinant Proteins; Ribavirin; Skin | 2004 |
Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.
Topics: Alanine Transaminase; Antiviral Agents; Decision Making; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; United States | 2004 |
Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated.
Topics: Alanine Transaminase; Antiviral Agents; Decision Making; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index | 2004 |
Host factors affecting the outcome of treatment of hepatitis C.
Topics: Antiviral Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Integration Host Factors; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Patient Compliance; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Tissue Distribution; Treatment Outcome; Viral Load | 2004 |
Viral factors affecting the outcome of therapy for chronic hepatitis C.
Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9.
Topics: Africa; Antiviral Agents; Asia; Clinical Trials as Topic; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Epidemiology; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2004 |
Management of patients with chronic hepatitis C virus infection and previous nonresponse.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Salvage Therapy; Severity of Illness Index; Treatment Failure; Treatment Outcome; Viral Load | 2004 |
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin.
Topics: Antiviral Agents; Chemotherapy, Adjuvant; Drug Therapy, Combination; Erythropoietin; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferons; Leukemia, Myeloid, Acute; Polychondritis, Relapsing; Prednisone; Ribavirin | 2004 |
[Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Topics: Acute Disease; Antiviral Agents; Forecasting; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Remission, Spontaneous; Ribavirin; RNA, Viral; Viral Load; Viremia | 2004 |
[Treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Management of chronic hepatitis C virus infection: a new era of disease control.
Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2004 |
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin | 2004 |
Natural history of hepatitis C following liver transplantation.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferons; Liver Transplantation; Ribavirin | 2004 |
When to treat patients with chronic hepatitis C.
Topics: Antiviral Agents; Comorbidity; Hepatitis C, Chronic; Humans; Interferons; Patient Selection; Ribavirin | 2004 |
The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells.
Topics: Antigens, CD19; Antiviral Agents; B-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Endotoxins; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2004 |
Therapy of chronic hepatitis C virus infection in HIV co-infected people.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2004 |
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
Topics: Antiviral Agents; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon-alpha; Mental Disorders; Research Design; Ribavirin; Substance-Related Disorders | 2004 |
Treatment of the hepatitis C virus in patients coinfected with HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Antiviral therapy for treatment naïve patients with hepatitis C virus.
Topics: Antiviral Agents; Contraindications; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Treatment of relapsers after combination therapy for chronic hepatitis C.
Topics: Adjuvants, Pharmaceutic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Secondary Prevention | 2004 |
Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2004 |
Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2004 |
Treatment of hepatitis C virus: the first decade.
Topics: Age Factors; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin; Risk Factors; Viral Load | 2004 |
Predictors of response to therapy for chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Predictive Value of Tests; Prognosis; Ribavirin; Treatment Outcome; Viral Load | 2004 |
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Natural history and management of hepatitis C infection after liver transplantation.
Topics: Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
Topics: Adjuvants, Immunologic; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2004 |
Retreatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Retreatment; Ribavirin; RNA, Viral; Treatment Failure | 2004 |
[Combination therapy of interferon plus ribavirin for chronic hepatitis C].
Topics: Antiviral Agents; Biomarkers; Drug Resistance; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
[Differential effects of interferon-based treatments in chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2004 |
[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
[Two-step interferon rebound therapy].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cytokines; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferons; Japan; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Treatment Outcome | 2004 |
[Clinical significance of measuring HCV-RNA levels in patients with chronic hepatitis C by IFN treatment, including combination therapy with ribavirin].
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors; Treatment Outcome | 2004 |
[Effectiveness of long-acting interferon (peginterferon)].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2004 |
[Prevention of adverse effects in ribavirin and interferon combination therapy].
Topics: Abnormalities, Drug-Induced; Anemia; Animals; Antiviral Agents; Cerebral Hemorrhage; Drug Eruptions; Drug Therapy, Combination; Feeding and Eating Disorders; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Tissue Distribution | 2004 |
[Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drug Therapy, Combination; Genotype; Glycine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Iron, Dietary; Liver Neoplasms; Oleanolic Acid; Phlebotomy; Prognosis; Ribavirin; Time Factors | 2004 |
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid | 2004 |
[Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
Topics: Antiviral Agents; Brain Death; Combined Modality Therapy; Drug Therapy, Combination; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Transplantation; Living Donors; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors | 2004 |
[Difference between autoimmune hepatitis (AIH) with and without hepatitis C virus (HCV)].
Topics: Adrenal Cortex Hormones; Antiviral Agents; Autoantibodies; Azathioprine; Disease Susceptibility; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatitis, Autoimmune; HLA-DR4 Antigen; Humans; Immunosuppressive Agents; Interferons; Ribavirin | 2004 |
[Prevalence and clinical course in HBV and HCV dual chronic infection].
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Male; Prevalence; Ribavirin; Superinfection | 2004 |
[Treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hungary; IMP Dehydrogenase; Interferons; Liver Cirrhosis; Liver Transplantation; Nucleosides; Ribavirin; Risk Factors | 2004 |
[Hepatitis C].
Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors | 2004 |
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2004 |
The evolving treatment of chronic hepatitis C: where we stand a decade out.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Virus Replication | 2004 |
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.
Topics: Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials as Topic; Drug Carriers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Compliance; Patient Selection; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2004 |
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinical Trials as Topic; Counseling; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferons; Liver Cirrhosis; Meta-Analysis as Topic; Oligonucleotides, Antisense; Patient Compliance; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; White People | 2004 |
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-11; Neutropenia; Patient Compliance; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
The role of physician extenders in managing patients with chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Neutropenia; Nurse Practitioners; Patient Compliance; Patient Education as Topic; Physician Assistants; Quality of Health Care; Ribavirin; Risk Factors; Social Support; Thrombocytopenia | 2004 |
Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection.
Topics: Animals; Clinical Trials as Topic; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
The management of side-effects during therapy for hepatitis C.
Topics: Antiviral Agents; Depressive Disorder; Drug Carriers; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
[Treatment strategies of acute and chronic hepatitis C].
Topics: Acute Disease; Antiviral Agents; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2002 |
[Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hemorrhagic Fevers, Viral; Hepatitis C, Chronic; Humans; Respiratory Tract Infections; Ribavirin; RNA Viruses; Virus Replication | 2002 |
Treatment of acute and chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Ribavirin | 1997 |
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Molecular Weight; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation.
Topics: Antiviral Agents; Growth Substances; Hematologic Diseases; Hematopoiesis; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; United States | 2005 |
Hematologic side effects of interferon and ribavirin therapy.
Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Topics: Anemia, Hypochromic; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematinics; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Weight-based dosing: which impact on efficacy and safety of therapy?
Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Histidine; Humans; Interferon alpha-2; Interferon-alpha; Isomerism; Models, Molecular; Molecular Weight; Polyethylene Glycols; Protein-Tyrosine Kinases; Recombinant Proteins; Ribavirin; Signal Transduction | 2004 |
Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
[Treatment of chronic hepatitis C].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Children with hepatitis C.
Topics: Age Distribution; Antiviral Agents; Child; Child, Preschool; Disease Progression; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infant; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Distribution | 2005 |
Maintenance therapy for chronic hepatitis C.
Topics: Antiviral Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Long-Term Care; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Viral Load | 2005 |
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin | 2005 |
Treatment of chronic hepatitis c.
Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2004 |
Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response.
Topics: Hepatitis C, Chronic; Humans; Interferons; Retreatment; Ribavirin; Treatment Failure | 2004 |
[Interferons alpha in the treatment of chronic HCV infections].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
[Chronic hepatitis C infection--mechanisms of virus "immune escape"].
Topics: Antibody Formation; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Ribavirin; Risk Factors; Treatment Outcome; Viral Proteins | 2004 |
Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
Topics: Alanine Transaminase; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Technology Assessment, Biomedical | 2005 |
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Soci
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Technology Assessment, Biomedical | 2005 |
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Clinical Enzyme Tests; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; Sex Factors | 2005 |
Chronic hepatitis C treatment patterns in African American patients: an update.
Topics: Antiviral Agents; Black or African American; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.
Topics: Adult; Antiviral Agents; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prednisone; Ribavirin; Sarcoidosis; Skin Diseases | 2005 |
[Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C].
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
[Syndrome of overlap: Chronic hepatitis C/autoimmune hepatitis: fact or fancy?].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Diagnosis, Differential; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferons; Ribavirin; Syndrome | 2005 |
[Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Crohn Disease; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin | 2005 |
[Chance of hepatic fibrosis treatment in chronic hepatitis C].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Caspase Inhibitors; Cell Death; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2004 |
[Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin; Risk Factors | 2004 |
Treatment of hepatitis C.
Topics: Acute Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Maximum Tolerated Dose; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2005 |
[Treatment of hepatitis C virus infection].
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Meta-Analysis as Topic; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Viral Load | 2005 |
[Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients].
Topics: Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain | 2005 |
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Life Style; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Refusal; Viral Load | 2005 |
Use of growth factors with antiviral therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Treatment of recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Recombinant Proteins; Ribavirin; Secondary Prevention; Severity of Illness Index | 2005 |
Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
Topics: Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases | 2005 |
Ribavirin plus interferon versus interferon for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin | 2005 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Transaminases; Treatment Failure; Viral Envelope Proteins; Viral Hepatitis Vaccines | 2005 |
Treatment of chronic hepatitis C in patients with renal disease.
Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin | 2005 |
Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[The adherence in the treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Ribavirin; Treatment Outcome | 2005 |
Current status of hepatitis C virus infection in Korea.
Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Prevalence; Ribavirin; Risk Factors; RNA, Viral; Species Specificity | 2006 |
Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
Topics: Age Factors; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Multivariate Analysis; Mutation; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Treatment Outcome; Viral Nonstructural Proteins; Viremia | 2006 |
Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Ribavirin; Seroepidemiologic Studies; Taiwan | 2006 |
Treatment of chronic hepatitis C in southern Taiwan.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Viral Load | 2006 |
[Molecular virology and treatment of patients with chronic hepatitis C].
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Neoplasms; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
[HCV: immune response and its modifiers in clinical development].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon Type I; Interferon-alpha; Interferons; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2005 |
[Experimental therapy in HCV infection].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrones; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Catalytic; RNA, Small Interfering; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins | 2005 |
[The clinical consequences of changes occurring in HCV population during the first weeks of chronic hepatitis C treatment with interferon and ribavirin].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
[Retreatment strategies for the patients with HCV infection].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2005 |
[Current trends and first clinical studies of therapy for chronic hepatitis C in children using pegylated interferon alpha and ribavirin].
Topics: Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Management of the hematologic complications of hepatitis C therapy.
Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2005 |
Chronic hepatitis C: management of treatment failures.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Viral Load | 2005 |
Ribavirin monotherapy for chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin | 2005 |
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.
Topics: Antiviral Agents; Decision Trees; Drug Therapy, Combination; Economics, Pharmaceutical; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Spain | 2005 |
Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2005 |
New paradigms in the management of HIV and hepatitis C virus coinfection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Treating HCV with ribavirin analogues and ribavirin-like molecules.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Molecular Structure; Ribavirin; Structure-Activity Relationship; Virus Replication | 2006 |
Pegylated IFNs for chronic hepatitis C: an update.
Topics: Animals; Antiviral Agents; Drug Therapy; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Therapeutic Equivalency | 2005 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Sclerosing; Chronic Disease; Drug Therapy, Combination; Fatty Liver; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Hepatolenticular Degeneration; Humans; Immunosuppression Therapy; Interferons; Lamivudine; Liver Cirrhosis, Biliary; Liver Diseases; Organophosphonates; Prednisolone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors | 2005 |
Chronic hepatitis C virus management: 2000-2005 update.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Time Factors; Treatment Outcome | 2006 |
Management of hepatitis C/HIV coinfection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2006 |
[Hepatitis C--treatment of untreated (naive) patients].
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Update on liver disease in hemophilia patients.
Topics: Antiviral Agents; Factor VII; Factor VIIa; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2006 |
Therapy of hepatitis C: from empiricism to eradication.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2006 |
Viral hepatitis.
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
Topics: Antiviral Agents; Comorbidity; Hepatitis C, Chronic; Humans; Interferons; Mental Disorders; Ribavirin; Substance-Related Disorders | 2006 |
Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Cardiomyopathy, Dilated; Drug Administration Schedule; Drug Therapy, Combination; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Remission Induction; Ribavirin; Treatment Failure; Weight Loss | 2006 |
Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin | 2006 |
[Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
Topics: Antiviral Agents; Autoantibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2006 |
Aspects of hepatitis C virus infection relating to liver transplantation.
Topics: Antiviral Agents; Graft Survival; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention | 2006 |
Individualization of antiviral treatment regimens for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2006 |
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors | 2006 |
[High dose repeat therapy in previously treated patients with chronic hepatitis C].
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Novel approaches for therapy of chronic hepatitis C.
Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Erythropoietin; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Protease Inhibitors; Purine-Nucleoside Phosphorylase; Pyrimidine Nucleosides; Ribavirin; Viral Hepatitis Vaccines | 2006 |
Management of patients with chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
Topics: Antiviral Agents; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Complementary treatments of chronic viral hepatitis C].
Topics: Anemia; Antidepressive Agents; Antioxidants; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
[Individualised treatment of chronic hepatitis C].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Practice Guidelines as Topic; Practice Patterns, Physicians'; Ribavirin | 2006 |
Review article: predicting response in hepatitis C virus therapy.
Topics: Antiviral Agents; Fibrosis; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Prognosis; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Assessing evidence from clinical trials in chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2006 |
Evaluating the evidence from clinical trials in chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2006 |
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases | 2006 |
Diagnosis and treatment of chronic hepatitis C infection.
Topics: Antibodies, Viral; Antiviral Agents; Biopsy; Drug Combinations; Hepatitis C, Chronic; Humans; Immunologic Tests; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virology | 2006 |
Systemic sarcoidosis presenting in a tattooed man undergoing treatment for hepatitis C.
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Histiocytes; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Paint; Ribavirin; Sarcoidosis; Skin; Skin Diseases; Tattooing | 2006 |
[New trend in treatment in patients with chronic hepatitis C].
Topics: Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Lymphokines; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Is interferon-beta an alternative treatment for chronic hepatitis C?
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Randomized Controlled Trials as Topic; Ribavirin | 2006 |
Treatment of interferon-alpha for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Chronic hepatitis C--patients "difficult to treat"].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[The expectations for results of clinical trial "IDEAL"].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[HIV and HCV coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Pharmacoeconomics applied to chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2006 |
Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Monitoring; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Patient Selection; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Failure | 2006 |
Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.
Topics: Antiviral Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Paternal Exposure; Pregnancy; Recombinant Proteins; Ribavirin; Spermatozoa | 2005 |
[HCV-HBV infection].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk | 2006 |
[Side effects of interferon therapy for chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Fatigue; Hepatitis C, Chronic; Humans; Interferons; Leukopenia; Mental Disorders; Ribavirin; Thrombocytopenia | 2006 |
Chronic hepatitis C therapy: changing the rules of duration.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Treating hepatitis C infection in liver transplant recipients.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Reoperation; Ribavirin | 2006 |
Treatment of hepatitis C infection.
Topics: Antiviral Agents; Contraindications; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Viral kinetics in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2006 |
Treating viral hepatitis C: efficacy, side effects, and complications.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2006 |
Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature.
Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Seronegativity; HIV Seropositivity; Humans; Interferons; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
Topics: Adenine; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2006 |
[Optimization of the method of treatment of chronic viral hepatitis C with pegylated interferon-alfa and ribavirin].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Secondary Prevention; Treatment Outcome | 2006 |
[Acute hepatitis. Biological hepatic anomalies in asymptomatic persons].
Topics: Acute Disease; Adult; Antiviral Agents; Cholestasis; Chronic Disease; Clinical Enzyme Tests; Diagnosis, Differential; France; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Hepatitis D; Hepatitis D, Chronic; Hepatitis, Viral, Human; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Phosphoric Monoester Hydrolases; Prevalence; Ribavirin; Transaminases | 2006 |
Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Motivation; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2006 |
Antiviral treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2006 |
[Therapy of chronic hepatitis C].
Topics: Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Difficult-to-treat patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Postoperative Complications; Ribavirin; Treatment Outcome | 2006 |
Antiviral treatment of hepatitis C: present status and future prospects.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Pharmacokinetics of ribavirin in patients with hepatitis C virus.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Treatment of chronic hepatitis C--ribavirin plus interferon versus interferon. An analysis of a systematic Cochrane review].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Meta-Analysis as Topic; Ribavirin; Treatment Outcome | 2006 |
Peginterferon and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Optimizing treatment regimens in hepatitis C.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Replication | 2006 |
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome | 2006 |
Improving anti-HCV therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 2006 |
Customizing treatment to patient populations.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2006 |
Hepatology may have problems with putative surrogate outcome measures.
Topics: Antiviral Agents; Bilirubin; Biomarkers; Cholagogues and Choleretics; Gastroenterology; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis, Biliary; Liver Diseases; Outcome Assessment, Health Care; Reproducibility of Results; Ribavirin; Ursodeoxycholic Acid; Viral Load | 2007 |
The effects of HCV infection and management on health-related quality of life.
Topics: Antiviral Agents; Chronic Disease; Depression; Fatigue; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2007 |
[Hepatitis C viral infection and depression].
Topics: Antidepressive Agents; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2007 |
Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2007 |
Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis.
Topics: Adult; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases | 2007 |
Short-duration therapy for hepatitis C: suitable for all?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality of Life; Recombinant Proteins; Ribavirin | 2007 |
Management of chronic hepatitis C.
Topics: Antiviral Agents; Decision Trees; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2007 |
Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2007 |
Treatment of hepatitis C virus infection.
Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Ribavirin; Transaminases | 2007 |
[Retreatment of chronic hepatitis C patients non responder to a previous antiviral treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Risk Factors; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Hepatitis C in dialysis units: the Saudi experience.
Topics: Antiviral Agents; Education, Nursing, Continuing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infection Control; Interferon-alpha; Kidney Failure, Chronic; Prevalence; Renal Dialysis; Ribavirin; Saudi Arabia | 2007 |
Management and therapy of chronic hepatitis C virus infection in HIV-infected individuals.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Patient Compliance; Ribavirin; Treatment Outcome | 2007 |
Review article: the treatment of hepatitis C virus recurrence after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Treatment Outcome | 2007 |
Treatment of HCV in patients with renal failure.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin | 2007 |
Hepatitis C treatment: shorter and better?
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin | 2007 |
[Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago].
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Drug Therapy, Combination; Fibroblasts; Hepatitis B, Chronic; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferon-beta; Interferon-gamma; Interferons; Leukocytes; Lymphocytes; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Terminology as Topic | 2007 |
[PEG IFN alpha-2a in the treatment of chronic hepatitis C in patients with treatment failure].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2007 |
[Recent developments in the treatment of chronic hepatitis B and C].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Adaptive cell immune response against the hepatitis C virus infection].
Topics: Acute Disease; Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Killer Cells, Natural; Mutation; Pan troglodytes; Ribavirin; T-Lymphocytes; T-Lymphocytes, Helper-Inducer; Time Factors; Virus Replication | 2007 |
Antiviral therapy: chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2007 |
Inflammation and repair in viral hepatitis C.
Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors | 2008 |
Future treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin | 2007 |
Nonresponse to treatment for hepatitis C: current management strategies.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Compliance; Polyethylene Glycols; Ribavirin; Treatment Failure | 2008 |
Long-term effects of interferon-based therapy for chronic hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2007 |
Old and emerging therapies in chronic hepatitis C: an update.
Topics: Antiviral Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2008 |
Into the light: strategies for battling hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Making it happen: managed care considerations in vanquishing hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Managed Care Programs; Patient Education as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Rapid virologic response: a new milestone in the management of chronic hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin M; Interferons; Oligonucleotides, Antisense; Rheumatoid Factor; Ribavirin; Rituximab; Signal Transduction | 2008 |
Oral diseases associated with hepatitis C virus infection. Part 2: lichen planus and other diseases.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Lichen Planus, Oral; Mediterranean Region; Mouth Mucosa; Mouth Neoplasms; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2008 |
[Development of antiviral therapy for patients with chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2008 |
[Treatment of the old patients with chronic hepatitis C].
Topics: Aged; Anti-Infective Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin | 2008 |
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure | 2007 |
Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis | 2008 |
Review article: novel therapeutic options for chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligonucleotides, Antisense; Recombinant Proteins; Ribavirin; Thionucleotides; Treatment Outcome | 2008 |
Treatment regimens for patients with chronic hepatitis C.
Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature.
Topics: Adult; Antiviral Agents; Biopsy; Chemical and Drug Induced Liver Injury; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis | 2008 |
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome; Viremia | 2008 |
[Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hepatitis B and C in children.
Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Ribavirin; Treatment Outcome | 2008 |
Current and future management of chronic hepatitis C infection.
Topics: Antiviral Agents; Forecasting; Hepatitis C, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin | 2008 |
Hepatitis C virus therapy to date.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Ribavirin considerations in treatment optimization.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2008 |
Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
[Therapy of chronic hepatitis C: facing a breakthrough?].
Topics: Amantadine; Clinical Trials as Topic; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 1998 |
Hepatitis C treatment.
Topics: Alanine Transaminase; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Retreatment; Ribavirin | 1998 |
Management of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 1998 |
[New antiviral agents in the treatment of chronic hepatitis B and C].
Topics: 2-Aminopurine; Antimetabolites; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Prodrugs; Reverse Transcriptase Inhibitors; Ribavirin | 1998 |
[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 1998 |
[Chronic hepatitis C--therapeutic modalities for interferon failure].
Topics: Amantadine; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 1998 |
[Interactions between the human immunodeficiency virus and hepatitis C virus].
Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prevalence; Ribavirin; Virus Replication | 1998 |
[Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?].
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 1999 |
The clinical pharmacology of ribavirin.
Topics: Absorption; Administration, Oral; Antiviral Agents; Biological Availability; Biological Transport; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intestine, Small; Recombinant Proteins; Ribavirin | 1999 |
Use of high-dose interferon in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Standards of treatment in chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Routes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Recurrence; Ribavirin | 1999 |
Combination therapy for chronic hepatitis C: interferon and ribavirin.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Recurrence; Ribavirin | 1999 |
[Antiviral treatment of hepatitis C virus infection].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 1999 |
Treatment of chronic viral hepatitis.
Topics: Antiviral Agents; Glucocorticoids; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Patient Selection; Prednisone; Reverse Transcriptase Inhibitors; Ribavirin | 1999 |
[Chronic viral hepatitis caused by B and C virus: diagnostic and therapeutic trends].
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral | 1999 |
Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Ribavirin; Treatment Failure; Virus Replication | 1999 |
Treatment of naive patients with chronic hepatitis C.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Remission Induction; Ribavirin; Viral Load | 1999 |
Retreatment of interferon relapse patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin | 1999 |
New treatment strategies in non-responder patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 1999 |
Early predictors of response to treatment in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Viremia | 1999 |
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors | 1999 |
Advances in the treatment of hepatitis C.
Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin | 2000 |
[Therapy of chronic viral hepatitis].
Topics: Antiviral Agents; Germany; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; Hepatitis, Viral, Human; Humans; Interferons; Liver Transplantation; Prognosis; Renal Dialysis; Ribavirin; Risk Factors | 1999 |
Antiviral therapy for chronic hepatitis B and C. Which patients are likely to benefit from which agents?
Topics: Antiviral Agents; Contraindications; Drug Combinations; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Ribavirin | 2000 |
Molecular tools for the treatment of hepatitis C.
Topics: Antiviral Agents; Biomarkers; Drug Resistance, Microbial; Genetic Techniques; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia; Virus Replication | 1998 |
Hepatitis C virus in the transplant setting.
Topics: Antiviral Agents; Combined Modality Therapy; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Failure; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time Factors; Tissue Donors | 1998 |
Chronic viral hepatitis C: management update.
Topics: Antiviral Agents; Canada; Drug Approval; Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin | 2000 |
[Etiology of hepatocellular carcinoma. The problem of the primary disease].
Topics: Carcinoma, Hepatocellular; Cross-Cultural Comparison; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Ribavirin; Risk Factors | 2000 |
[New therapeutic possibilities in chronic hepatitis C].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2000 |
Treatment of autoimmune and extra-hepatic manifestations of HCV infection.
Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Complex Diseases; Interferon-alpha; Kidney; Lichen Planus; Microsomes; Microsomes, Liver; Ribavirin; Sialadenitis; Thyroiditis, Autoimmune | 2000 |
Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2000 |
Treatment strategies for chronic hepatitis C virus infection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Interferons; Iron Overload; Liver Neoplasms; Ribavirin; Treatment Outcome; Ursodeoxycholic Acid | 2000 |
Current therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Resistance; Hepatitis C, Chronic; Humans; Interferons; Monitoring, Physiologic; Recurrence; Ribavirin | 2000 |
Therapeutic options for HCV--management of the infected individual.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Selection; Practice Guidelines as Topic; Ribavirin; Treatment Outcome | 2000 |
Treatment of chronic hepatitis C virus infection in children.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
[Treatment of chronic hepatitis C: present and future].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2000 |
Recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Cytomegalovirus; Drug Therapy, Combination; Flaviviridae; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral | 2000 |
Treatment strategies for hepatitis C: making the best of limited options.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Predictive Value of Tests; Prognosis; Ribavirin | 2000 |
[Hepatitis C--standard therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Survival Rate; Treatment Outcome | 2000 |
Adverse effects and other safety aspects of the hepatitis C antivirals.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2000 |
Pre- and post-transplant treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 2000 |
Treatment of hepatitis C with interferon and ribavirin.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 2000 |
Antiviral therapy for patients with chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2000 |
Treatment of chronic hepatitis C virus infection in patients with cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Ribavirin | 2000 |
Hepatitis C virus kinetics.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Mathematical Computing; Models, Biological; Models, Statistical; Ribavirin; RNA, Viral | 2000 |
Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.
Topics: Alanine Transaminase; Antiviral Agents; Black or African American; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Iron; Liver; Recurrence; Ribavirin; RNA, Viral | 2000 |
Management of recurrent hepatitis C after liver transplantation: a concise review.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Prognosis; Ribavirin; RNA, Viral; Secondary Prevention | 2000 |
Further evolution of hepatitis C treatment: individualized therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2000 |
Hepatitis C in African Americans: summary of a workshop.
Topics: Antiviral Agents; Black or African American; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver Neoplasms; Liver Transplantation; Prevalence; Ribavirin; Substance Abuse, Intravenous; United States; Veterans | 2000 |
[Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)].
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Polymorphism, Genetic; Ribavirin; RNA, Viral | 2000 |
Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Retreatment; Ribavirin | 2001 |
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; United Kingdom | 2000 |
Current treatment strategies for chronic hepatitis B and C.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Life Style; Recombinant Proteins; Ribavirin; Treatment Outcome; Vaccination | 2001 |
Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Failure | 2001 |
Should patients with chronic hepatitis C who have normal ALT levels be treated?
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Endpoint Determination; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin; Treatment Outcome | 2001 |
Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Kidney disease in patients with chronic hepatitis C.
Topics: Antigen-Antibody Complex; Antiviral Agents; Disease Progression; Glomerulonephritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2001 |
[Therapy of chronic hepatitis C].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2000 |
[Treatment of pretransplant and posttransplant viral cirrhosis].
Topics: Antiviral Agents; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Virus Replication | 2001 |
Overview of interferon therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 1999 |
Hepatitis C viral dynamics.
Topics: Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; Humans; Interferons; Ribavirin | 1999 |
Combination treatment with interferon and ribavirin for chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 1999 |
Cost-effectiveness of combined interferon and ribavirin versus interferon alone.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 1999 |
Current and future treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunoglobulins; Immunotherapy; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Catalytic; Virus Replication | 2001 |
Transplantation for chronic hepatitis B and C: strategies for prevention and treatment of recurrent disease.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 2001 |
[Chronic hepatitis--new therapeutic options].
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Lamivudine; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2001 |
Current and future therapies of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunization, Passive; Immunologic Factors; IMP Dehydrogenase; Interferon-alpha; Phenylurea Compounds; Ribavirin; RNA, Viral | 2001 |
Hepatitis C virus infection: 10 years after the discovery of the virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prevalence; Ribavirin; Risk Factors | 2001 |
What is (cost) effective in patients with chronic hepatitis C virus infection?
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2001 |
A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Switzerland; Treatment Outcome | 2001 |
[Antiviral therapy for patients with chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA | 2001 |
[Chronic viral hepatitis C: current therapy and perspectives].
Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Hepatitis C, Chronic; Interferons; Recurrence; Ribavirin | 2001 |
[PEG-interferons: significance for the treatment of viral hepatitis B and C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2001 |
[Recent progress and prospective view of chronic hepatitis C research].
Topics: Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Ribavirin | 2001 |
[Treatment of chronic hepatitis C patients complicated with the other disease].
Topics: Collagen Diseases; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2001 |
[Combination therapy of IFN and ribavirin].
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2001 |
[Present status of clinical trials on long-acting IFNs preparations (PEG-IFN alpha 2a, alpha 2b, IFN alpha-minipellet)].
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2001 |
[Future outlook for treatment of chronic hepatitis C: IFN + ribavirin combination therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2001 |
[Prognosis of chronic hepatitis C with regard to the aim of treatment].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin | 2001 |
Treatment of viral hepatitis--2001.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Hepatic granulomas in chronic hepatitis C.
Topics: Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Ribavirin; Risk Assessment; Treatment Outcome | 2001 |
Management of hepatitis C in HIV-infected persons.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Disease Transmission, Infectious; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Neoplasms; Recurrence; Ribavirin | 2001 |
Hepatitis C: a concise review.
Topics: Adult; Aged; Antiviral Agents; Child; Clinical Trials as Topic; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Viral Vaccines | 2001 |
Advances in therapy for chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Patient Compliance; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2001 |
Management of interferon therapy nonresponders.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Ribavirin; RNA, Viral; Ursodeoxycholic Acid | 2001 |
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Morbidity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk | 2001 |
Treatment of chronic hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Ribavirin | 2001 |
[Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Cost-Benefit Analysis; Diagnosis, Differential; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2001 |
Chronic hepatitis C: current status and rationale for antiviral therapy.
Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2001 |
Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2001 |
Concise review of the management of hepatitis C.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Factors | 2001 |
Treatment of chronic hepatitis C: lessons from human immunodeficiency virus dynamics.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV-1; Humans; Interferon-alpha; Ribavirin | 2001 |
Experimental and emerging therapies for chronic hepatitis C virus infection.
Topics: Animals; Antiviral Agents; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
[Chronic hepatitis C].
Topics: Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin | 2002 |
Hepatitis C virus infection: an overview.
Topics: Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Models, Genetic; Ribavirin; RNA, Viral | 2001 |
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2002 |
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Topics: Adjuvants, Immunologic; Amino Acid Sequence; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mood Disorders; Recombinant Proteins; Ribavirin | 2002 |
Bullet points: new topics in HIV/AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Lipids; Protease Inhibitors; Ribavirin | 2002 |
Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin | 2002 |
[Treatment of chronic hepatitis C with pegylated alpha-interferons].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
Mechanisms of action of ribavirin in antiviral therapies.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Mutagenesis; Ribavirin; RNA Viruses; T-Lymphocytes; Virus Replication | 2001 |
Developments in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sarcoidosis | 2002 |
The treatment of chronic hepatitis C not responding to interferon.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2002 |
New therapies for the treatment of chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Catalytic | 2002 |
Present treatment expectations and risks of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2002 |
[Treatment of chronic hepatitis C. Combined treatment in naive patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2000 |
[Treatment of chronic hepatitis C relapse].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferons; Recombinant Proteins; Recurrence; Ribavirin | 2000 |
[Treatment of chronic hepatitis C in patients not responding to interferon].
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 2000 |
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin | 2002 |
[Treatment strategies for viral hepatitis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin | 2002 |
Treatment of chronic hepatitis C infection with cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Ribavirin | 2002 |
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2002 |
Genetically modified interferon: is there a consensus yet?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Recombinant Proteins; Ribavirin | 2002 |
[Treatment of chronic hepatitis C in patients with HIV-coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
[Antiviral treatment of chronic hepatitis C in interferon nonresponders].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 2002 |
[Chronic hepatitis C: initial treatment in patients without previous treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Treatment of chronic hepatitis C in cirrhosis of the liver].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2002 |
Advances in treatment of chronic hepatitis C: 'pegylated' interferons.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Topics: Animals; Antiviral Agents; Circular Dichroism; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Isomerism; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Ribavirin with or without alpha interferon for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin | 2002 |
[Interferon-induced paranoid psychosis. Review of the literature and case report].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Paranoid Disorders; Recombinant Proteins; Ribavirin | 2002 |
Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Ribavirin | 2002 |
[Therapy of hepatitis C].
Topics: Antiviral Agents; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
1239 trial(s) available for ribavirin and Chronic Hepatitis C
| Article | Year |
|---|---|
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors | 2004 |
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.
Topics: Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Treatment Outcome; Valine | 2022 |
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; COVID-19; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pandemics; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides | 2022 |
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2023 |
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tablets; Treatment Outcome; Valine | 2020 |
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.
Topics: Adult; Catechin; Daclizumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Random Allocation; Ribavirin; Sofosbuvir; Standard of Care; Sustained Virologic Response; Tablets; Treatment Outcome; Viral Load | 2019 |
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study.
Topics: Antiviral Agents; Dietary Supplements; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Vitamin D | 2020 |
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2020 |
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2020 |
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutation; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2020 |
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan | 2021 |
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Longitudinal Studies; Male; Neutrophils; Recurrence; Ribavirin; Sofosbuvir; T-Lymphocytes; Transcriptome; Treatment Outcome | 2020 |
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Patient-Centered Care; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pilot Projects; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response | 2021 |
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult | 2021 |
Epigenetic scars of CD8
Topics: 2-Naphthylamine; Anilides; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Chromatin; Cyclopropanes; Epigenesis, Genetic; Hepacivirus; Hepatitis C, Chronic; High Mobility Group Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunologic Memory; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2021 |
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Uracil; Viral Load | 2017 |
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2017 |
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2017 |
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
Topics: Adolescent; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome | 2017 |
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Self Administration; Substance Abuse, Intravenous; Viral Load | 2017 |
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate | 2017 |
Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2018 |
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine | 2017 |
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2018 |
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2018 |
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
Topics: Antiviral Agents; Carbamates; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial.
Topics: Darbepoetin alfa; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome | 2017 |
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Egypt; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Ribavirin | 2018 |
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2018 |
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Asia, Eastern; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Ribavirin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2018 |
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2018 |
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
Topics: Adult; Aged; Antiviral Agents; Asian People; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult | 2018 |
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir | 2018 |
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine | 2018 |
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Republic of Belarus; Ribavirin; Ritonavir; Russia; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2018 |
A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2018 |
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
Topics: Antiviral Agents; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin | 2018 |
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome | 2018 |
[In process].
Topics: Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin | 2016 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2018 |
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Topics: Antiviral Agents; Benzimidazoles; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kupffer Cells; Liver; Parenchymal Tissue; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Taiwan; Valine; Viral Nonstructural Proteins | 2019 |
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters.
Topics: Antiviral Agents; Apolipoproteins; Fatty Liver; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Lipids; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome | 2019 |
Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
Topics: Adult; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Severity of Illness Index; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult | 2019 |
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Uridine; Young Adult | 2019 |
Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2019 |
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine | 2019 |
RNA editing blood biomarkers for predicting mood alterations in HCV patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Deaminase; Adult; Aged; Antiviral Agents; Biomarkers; Depression; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA Editing | 2019 |
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2013 |
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2013 |
Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Longitudinal Studies; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; United States | 2013 |
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Guanosine Monophosphate; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retreatment; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Role of statins in the treatment of chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2012 |
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Topics: Adult; Albumins; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Pulmonary Diffusing Capacity; Radiography, Thoracic; Recombinant Proteins; Ribavirin; Spirometry | 2013 |
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load | 2013 |
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate | 2013 |
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Topics: Adult; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Nonstructural Proteins | 2013 |
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
Topics: Adult; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2013 |
The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
Topics: Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Turkey; Viral Load | 2013 |
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.
Topics: Antiviral Agents; Base Sequence; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Molecular Sequence Data; Mutation; Prospective Studies; Ribavirin | 2013 |
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mucous Membrane; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Skin Pigmentation | 2013 |
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load | 2013 |
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Topics: Aged; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis | 2014 |
Sofosbuvir for previously untreated chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.
Topics: Adult; Aged; Antiviral Agents; Community Health Centers; Community Health Services; Delivery of Health Care; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Ontario; Patient Care Team; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome; Young Adult | 2013 |
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2013 |
Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, Protein; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
Topics: Adolescent; Adult; Antiviral Agents; Drug Monitoring; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Vitamin D; Young Adult | 2013 |
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2013 |
Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors | 2013 |
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.
Topics: Adult; Aged; Antiviral Agents; Calcifediol; Cell Line, Tumor; Cytokines; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Hepatitis C, Chronic; Hepatocytes; Humans; Immunity, Cellular; Immunologic Factors; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory; Th1 Cells; Treatment Outcome | 2013 |
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.
Topics: Adult; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genotype; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Time Factors; Viral Load | 2013 |
Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.
Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Young Adult | 2013 |
Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Ribavirin | 2013 |
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Electroporation; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care; T-Lymphocytes; Vaccines, DNA; Viral Hepatitis Vaccines; Viral Load | 2013 |
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Peptide Hydrolases; Polyethylene Glycols; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viremia; Young Adult | 2013 |
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2013 |
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.
Topics: Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Taiwan; Time Factors; Treatment Outcome | 2014 |
Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
Topics: Aged; Antiviral Agents; Biopsy, Needle; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Integration | 2014 |
Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.
Topics: Adult; Antiviral Agents; Body Temperature; Chemokine CXCL10; Female; Fever; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Topics: Antiviral Agents; Contraindications; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial.
Topics: Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Thiazoles | 2014 |
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
Topics: Adolescent; Adult; Aged; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Topics: Algorithms; Anemia; Antiviral Agents; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Asian People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome | 2014 |
Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Betaine; Carnitine; Chromatography, Liquid; Drug Therapy, Combination; Female; Glycine; Hepatitis C, Chronic; Humans; Interferons; Male; Metabolomics; Middle Aged; Polyethylene Glycols; Principal Component Analysis; Ribavirin; Tandem Mass Spectrometry; Treatment Outcome; Tryptophan; Viral Load | 2013 |
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
[Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Topics: Adult; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Anxiety; Data Interpretation, Statistical; Depression; Drug Therapy, Combination; Female; Health Status Indicators; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Patient Outcome Assessment; Placebos; Psychometrics; Quality of Life; Reproducibility of Results; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Topics: Adult; Antiviral Agents; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Ribavirin; Saudi Arabia | 2013 |
Predictors of consent to pharmacogenomics testing in the IDEAL study.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin; Sex Characteristics; Treatment Outcome; Young Adult | 2013 |
Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Spleen; Splenectomy; Thrombocytopenia; Treatment Outcome | 2014 |
Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Drug Administration Schedule; Drug Dosage Calculations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Metabolic Clearance Rate; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin; Severity of Illness Index | 2013 |
Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
Topics: Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load; Viral Nonstructural Proteins | 2014 |
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir | 2014 |
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
[Predicting side effects of the treatment of chronic hepatitis with peginterferon alpha-2A with ribaverin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins | 2013 |
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.
Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2014 |
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin.
Topics: Adult; Africa, Central; Aged; Antiviral Agents; Belgium; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.
Topics: Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome | 2013 |
Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.
Topics: Amino Acid Sequence; Base Sequence; Demography; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Kinetics; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Ribavirin; Risk Factors; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2013 |
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Topics: Drug Therapy, Combination; Female; Filtration; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome | 2013 |
Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Mutation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2014 |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Viral Load | 2013 |
Addicts with chronic hepatitis C: difficult to reach, manage or treat?
Topics: Adult; Antiviral Agents; Cooperative Behavior; Drug Therapy, Combination; Drug Users; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Italy; Male; Medication Adherence; Middle Aged; Patient Care Team; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Time Factors; Treatment Outcome | 2013 |
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Nausea; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.
Topics: Adult; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure | 2014 |
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2014 |
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Health; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2014 |
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult | 2014 |
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2014 |
Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Factor Analysis, Statistical; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Minnesota; Musculoskeletal Pain; Psychiatric Status Rating Scales; Reproducibility of Results; Ribavirin; Self Report; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome; Virginia; Young Adult | 2014 |
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Topics: Adult; Aged; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2013 |
Hepatitis C viral infection among prisoners.
Topics: Adult; Age Distribution; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Polyethylene Glycols; Prisoners; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Tattooing; Treatment Outcome | 2013 |
HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Cells, Cultured; Cuba; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunity, Cellular; Immunity, Humoral; Immunization Schedule; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Vaccines, DNA; Viral Hepatitis Vaccines | 2014 |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Topics: Administration, Oral; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; RNA, Viral; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2014 |
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2014 |
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2014 |
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Purines; Pyridazines; Quinolines; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2014 |
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pilot Projects; Pioglitazone; Retreatment; Ribavirin; RNA, Viral; Thiazolidinediones; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Efficiency; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2015 |
Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.
Topics: Adult; Antiviral Agents; Area Under Curve; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Viral Core Proteins | 2014 |
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Sulfonamides; Young Adult | 2014 |
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vaccines, DNA; Viral Vaccines | 2014 |
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome; United States | 2014 |
Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
Topics: Antiviral Agents; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Prospective Studies; Ribavirin; Silybin; Silymarin | 2014 |
A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2014 |
Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Prognosis; Ribavirin; Serum Amyloid A Protein; Treatment Outcome; Young Adult | 2014 |
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Vitamin D; Vitamins | 2014 |
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine | 2014 |
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Failure | 2014 |
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Topics: Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Splenectomy; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.
Topics: Adjuvants, Immunologic; Antibodies, Neutralizing; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon-alpha; Polyethylene Glycols; Polysorbates; Recombinant Proteins; Ribavirin; RNA, Viral; Squalene; Treatment Outcome; Vaccines, Synthetic; Viral Hepatitis Vaccines; Viral Load | 2014 |
PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
Topics: Antiviral Agents; Cell Count; Cell Degranulation; Cell Differentiation; Cytokines; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2014 |
[Individualization of antiviral treatment of chronic hepatitis].
Topics: Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Caproates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication; Young Adult | 2013 |
Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
Topics: Administration, Oral; Adolescent; Age Factors; Antiviral Agents; Biomarkers; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Pichia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Tertiary Care Centers; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisons; Recombinant Proteins; Ribavirin | 2014 |
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Valine | 2014 |
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Topics: Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Topics: Adult; Anemia; Antiviral Agents; Cell Count; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2015 |
Peginterferon α-2a and rivabirin in the treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Bangladesh; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Ribavirin; Treatment Failure; Young Adult | 2014 |
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclohexanols; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiophenes; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2014 |
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Topics: Acrylates; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Contraindications; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Virus Replication | 2014 |
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome | 2014 |
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome | 2014 |
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
Topics: 2-Naphthylamine; Antiviral Agents; Biological Assay; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Oligopeptides; Polyethylene Glycols; Proline; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Uracil; Viral Load | 2015 |
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isomerism; Male; Middle Aged; Oligopeptides; Ribavirin | 2014 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Middle Aged; Pilot Projects; Pioglitazone; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Thiazolidinediones; Viral Load | 2014 |
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate | 2014 |
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Registries; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoquinolines; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferons; Male; Patient Preference; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Uridine Monophosphate | 2014 |
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2015 |
Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Topics: Adult; Antiviral Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Topics: Adolescent; Adult; Aged; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Singapore; Treatment Outcome; Viral Load | 2015 |
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2015 |
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Young Adult | 2014 |
Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2014 |
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Ribavirin; Self Report; Simeprevir; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
Topics: Aged; Antiviral Agents; Citalopram; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Placebos; Ribavirin; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2014 |
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2014 |
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Virus Replication | 2015 |
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Topics: Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2015 |
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2015 |
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine | 2015 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2014 |
An interferon-free antiviral regimen for HCV after liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Ribavirin priming has no beneficial effects for chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Premedication; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.
Topics: Antiviral Agents; Appetite; Body Weight; Depression; Drug Therapy, Combination; Female; Genotype; Ghrelin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome; Weight Loss | 2014 |
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult | 2015 |
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
Topics: Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Simeprevir; Time Factors; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Treatment Outcome; United States; Viral Load; Viral Nonstructural Proteins | 2015 |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2015 |
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Menopause; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cardiovascular Diseases; Comorbidity; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Young Adult | 2015 |
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 an
Topics: Adolescent; Adult; Aged; Anemia; Depression; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Male; Middle Aged; Placebos; Ribavirin; Simeprevir; Treatment Outcome; Viral Load; Young Adult | 2015 |
A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
Topics: Adult; Antiviral Agents; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2015 |
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Topics: Acrylates; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Female; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Ribavirin; Thiazoles; Young Adult | 2015 |
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Young Adult | 2015 |
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Pilot Projects; Prognosis; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Topics: Aged; Antiviral Agents; Area Under Curve; beta 2-Glycoprotein I; Biomarkers; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2015 |
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles | 2015 |
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin | 2015 |
Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tacrolimus; Treatment Outcome; Young Adult | 2015 |
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Simeprevir; Treatment Outcome; Viral Load | 2015 |
The ARRIBA concept: adequate resorption of ribavirin.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Coinfection; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult | 2015 |
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine; Young Adult | 2015 |
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Body Weight; Erythrocytes; Female; Half-Life; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Models, Statistical; Oligopeptides; Phosphorylation; Population; Ribavirin; Sex Characteristics | 2015 |
Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2016 |
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C
Topics: Adolescent; Adult; Aged; Antiviral Agents; Data Collection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult | 2015 |
Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Topics: Administration, Ophthalmic; Aged; Antiviral Agents; Biomarkers; Calcifediol; Cholecalciferol; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxycholecalciferols; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Up-Regulation | 2015 |
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Topics: Adult; Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Ribavirin; Tandem Mass Spectrometry | 2015 |
Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; DNA, Circular; DNA, Viral; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load; Virus Integration; Virus Replication | 2015 |
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2015 |
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Analgesics, Opioid; Anilides; Antiviral Agents; Buprenorphine; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Methadone; Middle Aged; Opioid-Related Disorders; Proline; Retrospective Studies; Ribavirin; Sulfonamides; Uracil; Valine; Young Adult | 2015 |
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2015 |
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate; Young Adult | 2015 |
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients.
Topics: Adult; Antibodies, Neutralizing; Cost-Benefit Analysis; Drug Combinations; Egypt; Female; Genotype; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Young Adult | 2015 |
[Applying of recombinant interleukin-1β to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-1beta; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
Topics: Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Down-Regulation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2015 |
The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment.
Topics: Affective Symptoms; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Stress, Psychological | 2015 |
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load | 2015 |
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult | 2015 |
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Serum; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate | 2015 |
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Calcifediol; Cholecalciferol; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Vitamin D Deficiency; Vitamins | 2015 |
Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.
Topics: Adult; Aged; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin | 2015 |
Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.
Topics: Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2015 |
Interplay between vitamin D status and antiviral therapy among chronic hepatitis C Egyptian patients.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Vitamin D | 2015 |
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphocyte Count; Lymphopenia; Ribavirin | 2015 |
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
Topics: Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Recurrence; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2015 |
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study.
Topics: Adolescent; Adult; Case-Control Studies; Child; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
Topics: Aged; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Tertiary Prevention; Treatment Outcome | 2015 |
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Topics: Adult; Antiviral Agents; Cyclosporine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2015 |
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Bilirubin; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors; Simeprevir; Treatment Outcome | 2016 |
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin | 2015 |
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2015 |
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypoalbuminemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Thrombocytopenia; Treatment Outcome; Uracil; Valine; Young Adult | 2015 |
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2015 |
Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Deoxyguanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Metabolism Disorders; Leukocytes, Mononuclear; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
Topics: Adult; Aged; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Salvage Therapy; Sulfonamides; Treatment Outcome | 2016 |
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Double-Blind Method; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Thyroiditis, Autoimmune; Thyrotropin; Treatment Outcome; Young Adult | 2015 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Depressive Disorder, Major; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult | 2015 |
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir | 2015 |
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Topics: Adult; Age Factors; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; RNA, Viral; Scandinavian and Nordic Countries; Treatment Outcome | 2016 |
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Treatment Outcome; Valine | 2016 |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.
Topics: Adult; Antiparasitic Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Load | 2016 |
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2016 |
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin | 2015 |
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
Topics: Adult; Antiviral Agents; Biomarkers; Bone Remodeling; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2016 |
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Placebos; Proline; Quinolines; Ribavirin; Salvage Therapy; Thiazoles; Treatment Outcome | 2016 |
The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Ribavirin; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
Topics: Adult; Antiviral Agents; Body Weight; Diet; Directive Counseling; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Weight Loss | 2015 |
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Erythropoietin; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Peripheral lymphocyte subsets in chronic hepatitis C: Effects of 12 weeks of antiviral treatment with interferon-alpha plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; Treatment Outcome | 2016 |
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2016 |
Ocular Surface Changes With Sofosbuvir in Egyptian Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Dry Eye Syndromes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Tears | 2016 |
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; United States | 2016 |
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Gastroenterology; Genotype; Graft vs Host Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome; Viral Load; Young Adult | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 2016 |
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring.
Topics: Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Ribavirin | 2016 |
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Single-Blind Method; Time Factors; Treatment Outcome; Viral Load; Virus Internalization | 2016 |
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2016 |
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2016 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2016 |
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Elastase; Male; Middle Aged; Neutrophils; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Immunologic Factors; Interferon-alpha; Interferons; Leukocytes, Mononuclear; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles | 2016 |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2016 |
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-beta; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides | 2016 |
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Topics: Adult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Withholding Treatment | 2016 |
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Rapidity and Severity of Hemoglobin Decreasing Associated with Erythrocyte Inosine Triphosphatase Activity and ATP Concentration during Chronic Hepatitis C Treatment.
Topics: Adenosine Triphosphate; Adult; Aged; Antiviral Agents; Erythrocytes; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Pyrophosphatases; Ribavirin; Simeprevir | 2016 |
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Growth Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Topics: Acrylates; Adult; Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leucine; Male; Middle Aged; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Time Factors; Treatment Outcome; United States | 2016 |
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Young Adult | 2016 |
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
Topics: Adult; Alanine Transaminase; Anemia; Chemokine CXCL10; Dose-Response Relationship, Drug; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans | 2017 |
[In HIV-HCV co-infection check for drug interactions].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2016 |
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Young Adult | 2016 |
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Valine; Young Adult | 2016 |
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2016 |
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Topics: Adult; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
Topics: Adult; Antiviral Agents; Community Health Nursing; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2016 |
Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, Inte
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; International Cooperation; Male; Models, Theoretical; Outcome Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Research Design; Ribavirin; Sustained Virologic Response | 2016 |
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
Topics: Antiviral Agents; Benzofurans; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2016 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.
Topics: Adult; Aged; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Scavenger Receptors, Class B | 2016 |
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Precision Medicine; Ribavirin; Structure-Activity Relationship; Tablets; Viral Load | 2016 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine | 2016 |
Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
Topics: Antiviral Agents; Carrier Proteins; DNA, Viral; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Mutation, Missense; Polymorphism, Genetic; Ribavirin; Sequence Analysis, DNA; Simeprevir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2017 |
Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Interferon-alpha; Interleukins; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2016 |
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Young Adult | 2017 |
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2016 |
Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.
Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Oryza; Ribavirin; Viral Load; Viremia; Xylans | 2016 |
Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Vitamin D; Vitamins | 2016 |
Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.
Topics: Adult; Antioxidants; Antiviral Agents; Anxiety; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Psychiatric Status Rating Scales; Ribavirin; Silybin; Silymarin; Treatment Outcome; Work Performance | 2016 |
Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; North America; Oligopeptides; Phenotype; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome | 2018 |
Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Anxiety; China; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2016 |
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Topics: Acrylates; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Prognosis; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Viral Load; Young Adult | 2016 |
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Albumins; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Young Adult | 2017 |
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
Topics: Aged; Antiviral Agents; Cell Line; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transfection; Treatment Outcome; Viral Load; Viremia | 2017 |
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Leucine; Liver Function Tests; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult | 2017 |
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Ritonavir; Simeprevir; Sulfonamides; Valine | 2017 |
Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome; Work Performance | 2017 |
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Young Adult | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Tacrolimus; Treatment Outcome; Valine; Viral Load | 2017 |
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2008 |
[Efficacy of retherapy of chronic hepatitis C in children--own observation].
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Poland; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome; Viral Load | 2008 |
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome | 2008 |
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazolidinediones | 2008 |
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opportunistic Infections; Recombinant Proteins; Ribavirin | 2008 |
Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
[Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis].
Topics: Adult; Antiviral Agents; Biomarkers; Data Interpretation, Statistical; Drug Resistance; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-8; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2008 |
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome | 2008 |
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Therapy, Combination; Female; Forkhead Transcription Factors; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory; Th1 Cells; Treatment Outcome | 2008 |
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Topics: Administration, Oral; Adult; Albumins; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponde
Topics: Adult; Age Factors; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2008 |
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Self Administration; Substance Abuse, Intravenous; Treatment Outcome | 2008 |
[Depressive disorders and symptoms accompanying pegylated interferon alpha and ribavirin treatment of chronic hepatitis C patients].
Topics: Adult; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin | 2008 |
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Topics: Adult; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Carriers; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Incidence; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2008 |
Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; DNA Virus Infections; Drug Therapy, Combination; Female; Flaviviridae Infections; GB virus C; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Torque teno virus; Virus Diseases | 2008 |
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
Topics: Antioxidants; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Free Radical Scavengers; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silybum marianum; Silymarin; Time Factors; Treatment Outcome; Viral Load | 2008 |
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antiviral Agents; Diet; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Young Adult | 2008 |
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Blood Coagulation Disorders, Inherited; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2008 |
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Patient Selection; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Users; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Middle Aged; Ribavirin; Statistics as Topic | 2009 |
Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2009 |
[Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Antiviral Agents; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Polyethylene Glycols; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Superoxide Dismutase; Treatment Outcome | 2009 |
[Attention abnormalities in patients with chronic hepatitis C after pegylated interferon alpha and ribavirin treatment].
Topics: Antiviral Agents; Attention; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Topics: Adult; Antiparasitic Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
Topics: Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Motivation; Patient Acceptance of Health Care; Practice Patterns, Physicians'; Prospective Studies; Ribavirin; Statistics, Nonparametric | 2009 |
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Viral Load; White People; Young Adult | 2009 |
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Topics: Adult; Albumins; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2009 |
Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Child; Endemic Diseases; Female; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Mass Screening; Middle Aged; Prevalence; Ribavirin; Young Adult | 2009 |
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2009 |
Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Mass Index; Body Surface Area; Body Weight; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult | 2009 |
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins | 2009 |
Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Pharmacists; Pharmacy Service, Hospital; Polyethylene Glycols; Professional Role; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2009 |
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas.
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Topics: Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2009 |
Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2009 |
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
Topics: Antiviral Agents; Black or African American; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; White People | 2009 |
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2009 |
Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lenograstim; Liver; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Topics: Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure | 2009 |
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2009 |
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2009 |
High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Young Adult | 2009 |
CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Fibrosis; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Receptors, CCR5; Receptors, CXCR3; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology.
Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Topics: Adult; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; Genotype; Germany; Guidelines as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2009 |
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2009 |
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.
Topics: Age Factors; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome | 2009 |
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cholesterol, LDL; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oxidative Stress; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2009 |
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Vaccines, Subunit; Viral Hepatitis Vaccines; Young Adult | 2009 |
Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2009 |
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Nucleic Acid Amplification Techniques; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome; Vasculitis | 2009 |
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Body Mass Index; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Asian People; Black People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2009 |
Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Ribavirin; Risk Factors; Severity of Illness Index; Time; Treatment Outcome; Young Adult | 2009 |
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Treatment of a common problem in hemodialysis patients: is the juice worth the squeeze?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Renal Dialysis; Ribavirin; Saudi Arabia; Time Factors; Treatment Outcome | 2009 |
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2009 |
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load | 2010 |
Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
Topics: Antiviral Agents; Fatty Liver; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; CD11b Antigen; Chemotaxis, Leukocyte; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Macrophage-1 Antigen; Male; Middle Aged; Monocytes; Neutrophils; Phagocytosis; Polyethylene Glycols; Reactive Oxygen Species; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial.
Topics: Antiviral Agents; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Middle Aged; Phlebotomy; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin | 2009 |
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2009 |
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.
Topics: Adult; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Liver Diseases; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2009 |
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Middle Aged; Polyethylene Glycols; PPAR gamma; Recombinant Proteins; Ribavirin | 2009 |
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Biopsy; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opiate Substitution Treatment; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2009 |
Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazolidinediones; Young Adult | 2010 |
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Topics: Adult; Amantadine; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Logistic Models; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study.
Topics: 2',5'-Oligoadenylate Synthetase; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ketoprofen; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Treatment Outcome; Young Adult | 2009 |
No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Dosage Calculations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Logistic Models; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load; Young Adult | 2010 |
Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2010 |
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Topics: Adult; Chemokine CXCL10; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child Development; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; Demography; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Mutation; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
Ribavirin improves early responses to peginterferon through improved interferon signaling.
Topics: Adult; Aged; Antiviral Agents; Chemokine CXCL10; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Signal Transduction; Treatment Outcome | 2010 |
Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
Topics: Aged; Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Base Sequence; Cryoglobulinemia; DNA Primers; Drug Therapy, Combination; Female; Genes, Immunoglobulin Heavy Chain; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; RNA, Viral; Treatment Outcome | 2010 |
Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Delayed-Action Preparations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Telaprevir for previously treated chronic HCV infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Exanthema; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Failure; Viral Load; Young Adult | 2010 |
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Dropouts; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
An intervention to prevent symptoms associated with hepatitis C: a pilot study.
Topics: Antiviral Agents; Attitude to Health; Drug Therapy, Combination; Exercise Test; Exercise Therapy; Fatigue; Feasibility Studies; Female; Hepatitis C, Chronic; Home Care Services; Humans; Interferon-alpha; Male; Massachusetts; Middle Aged; Nursing Assessment; Nursing Evaluation Research; Pilot Projects; Quality of Life; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Walking | 2010 |
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; RNA, Viral; Treatment Outcome | 2010 |
Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2010 |
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Case-Control Studies; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antioxidants; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Mitochondria, Liver; Organophosphorus Compounds; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Ubiquinone; Viral Load | 2010 |
Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Retreatment; Ribavirin; RNA, Viral; Viral Load | 2010 |
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; United States | 2010 |
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Treatment Outcome; United States; Virus Replication | 2010 |
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Topics: Adult; Albumins; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Topics: Adult; Aged; Albumins; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
Topics: Adult; Anemia, Hypochromic; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Ferritins; Hematinics; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
Topics: Antiviral Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Hydrocortisone; Immunologic Factors; Interferon-alpha; Male; Psychiatric Status Rating Scales; Ribavirin; Time Factors | 2011 |
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Topics: Adult; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2010 |
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load; Viral Nonstructural Proteins | 2010 |
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].
Topics: Acridines; Adolescent; Adult; Antioxidants; Antiviral Agents; DNA; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Luminol; Male; Phthalazines; Quality of Life; Ribavirin; Risk Assessment; Succinates; Young Adult | 2010 |
Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
Topics: Adolescent; Adult; Anemia, Hemolytic; Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Creatinine; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypercholesterolemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Triglycerides; Viral Load; Young Adult | 2010 |
[Clinical significance of leukopenia and neutropenia patients with chronic hepatitis "C" in the various regimes antiretroviral therapy].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Male; Middle Aged; Moscow; Neutropenia; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2010 |
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
[Individualized respond guidance treatment of chronic hepatitis C with combination of peginterferon α-2a and ribavirin].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2010 |
von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Ribavirin; von Willebrand Factor | 2010 |
A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Topics: Antiviral Agents; Depression; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Psychotherapy; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2010 |
Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2010 |
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Seizures; Treatment Outcome | 2011 |
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Topics: Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; New Zealand; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; United States; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2010 |
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2011 |
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Topics: Adolescent; Adult; Aged; Antibodies, Neutralizing; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2010 |
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2010 |
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
Topics: Adult; Alanine Transaminase; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse.
Topics: Adult; Antiviral Agents; Arthralgia; Betaine; Diarrhea; Drug Therapy, Combination; Fatigue; Female; Gastrointestinal Agents; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; S-Adenosylmethionine; Time Factors; Treatment Outcome | 2010 |
Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.
Topics: Adult; Antiviral Agents; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Racial Groups; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load | 2011 |
[The virological response in prolonged therapy of chronic hepatitis C with low-dose peginterferon alpha-2a].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carrier Proteins; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2011 |
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Proteomics; Recombinant Proteins; Ribavirin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome | 2011 |
Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Australia; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome | 2011 |
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2011 |
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Topics: Adult; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2011 |
The role of patient religiosity in the evaluation and treatment outcomes for chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Illness Behavior; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Observational Studies as Topic; Patient Acceptance of Health Care; Patient Satisfaction; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Religion and Medicine; Religion and Psychology; Retrospective Studies; Ribavirin; Sex Factors; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2013 |
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2011 |
[Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C].
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Topics: Activities of Daily Living; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pakistan; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Kinetics; Models, Biological; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2011 |
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Prevalence; Ribavirin; Severity of Illness Index; Vitamin D; Vitamin D Deficiency | 2011 |
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Topics: Adult; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors | 2011 |
Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue.
Topics: Antiviral Agents; Depression; Drug Therapy, Combination; Fatigue; Hepatitis C, Chronic; Humans; Hydrocortisone; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Interleukin-6; Lymphocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polyethylene Glycols; Protein Processing, Post-Translational; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors | 2011 |
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Topics: Adolescent; Adult; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Coffee; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load | 2011 |
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia; Young Adult | 2011 |
Boceprevir for untreated chronic HCV genotype 1 infection.
Topics: Adult; Anemia; Antiviral Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Boceprevir for previously treated chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Europe, Eastern; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2011 |
Population pharmacokinetics and exposure-response of albinterferon alfa-2b.
Topics: Adolescent; Adult; Aged; Albumins; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Logistic Models; Male; Middle Aged; Models, Biological; Ribavirin; Tissue Distribution; Young Adult | 2012 |
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
Topics: Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
Topics: Anemia; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genomic Structural Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2011 |
Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2011 |
Telaprevir for retreatment of HCV infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Serine Proteinase Inhibitors; Viral Load; Young Adult | 2011 |
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Single-Blind Method; Treatment Outcome | 2011 |
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2011 |
Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2011 |
Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Pakistan; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Area Under Curve; Demography; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2011 |
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Young Adult | 2011 |
Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome | 2011 |
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome | 2011 |
Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2012 |
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial.
Topics: Adult; Antiviral Agents; Asian; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2011 |
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
Topics: Adult; Antiviral Agents; Cell Polarity; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; STAT4 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2012 |
Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Epidemiologic Methods; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2011 |
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
Topics: Acetylcarnitine; Adult; Dietary Supplements; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2011 |
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Thiazoles; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Chelation Therapy; Drug Therapy, Combination; Female; Greece; Hepatitis C, Chronic; Homozygote; Humans; Interferon alpha-2; Interferon-alpha; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transfusion Reaction; Treatment Outcome | 2011 |
The early on-treatment perihepatic lymph node response predicts sustained viral response of anti-hepatitis C virus therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Diseases; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Ultrasonography; Viral Load; Young Adult | 2011 |
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2011 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders; Creatine; Frontal Lobe; Hepatitis C, Chronic; Humans; Inositol; Interferons; Magnetic Resonance Spectroscopy; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Ribavirin; Surveys and Questionnaires | 2012 |
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Longitudinal Studies; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2012 |
[Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Topics: Adolescent; Antiviral Agents; Causality; Child; Child, Preschool; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases | 2011 |
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.
Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Topics: Adult; Age Factors; Antiviral Agents; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors | 2012 |
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
Topics: Adipokines; Adult; Chitinase-3-Like Protein 1; Disease Progression; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin | 2012 |
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.
Topics: Adult; Antiviral Agents; Carnitine; Dietary Supplements; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.
Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Computational Biology; Depression; Drug Therapy, Combination; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Longitudinal Studies; Male; Microarray Analysis; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Severity of Illness Index | 2012 |
[Efficacy of interferon alpha with ribavirin for treatment of chronic Hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Young Adult | 2011 |
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypolipidemic Agents; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Selective Serotonin Reuptake Inhibitors; Sertraline; Simvastatin; Singapore; United States | 2011 |
Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Neural Networks, Computer; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Reproducibility of Results; Ribavirin; ROC Curve; Sensitivity and Specificity | 2011 |
A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Salvage Therapy; Thalidomide; Treatment Outcome; Viral Load; Viremia | 2011 |
Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Kinetics; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
Topics: Adjuvants, Immunologic; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Safety; Treatment Outcome | 2012 |
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
Topics: Adolescent; Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin Diseases; Treatment Outcome; Withholding Treatment | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Valine | 2012 |
A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2012 |
Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; Data Mining; Drug Dosage Calculations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; RNA, Viral; Viral Load | 2012 |
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferon-alpha; International Cooperation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Sex Characteristics; Treatment Outcome | 2012 |
Insulin resistance impairs viral dynamics independently of ethnicity or genotypes.
Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spain; Treatment Outcome; Viral Load; White People | 2012 |
Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2012 |
Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients.
Topics: Adult; Aged; Antibodies, Antinuclear; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
Topics: Adult; Aged; Albumins; Antiviral Agents; Cholesterol; Chromatography, Gas; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lanosterol; Lipid Metabolism; Male; Mass Spectrometry; Middle Aged; Oxidative Stress; Pilot Projects; Prognosis; Ribavirin; Risk Assessment; Severity of Illness Index; Signal Transduction; Statistics, Nonparametric; Treatment Outcome | 2012 |
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Topics: Adult; Albumins; Antiviral Agents; Cohort Studies; Coinfection; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin | 2012 |
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thiazolidinediones; Treatment Outcome | 2012 |
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
Topics: Adolescent; Anemia; Antiviral Agents; Child; Child, Preschool; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Young Adult | 2012 |
Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis.
Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastric Emptying; Gastroparesis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Morpholines; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2012 |
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2012 |
Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; China; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Treatment Outcome; Viral Proteins; Young Adult | 2012 |
Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
Topics: Adipokines; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2012 |
Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytosis | 2012 |
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Young Adult | 2012 |
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Male; Metformin; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Statistics, Nonparametric | 2012 |
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Models, Biological; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Viral Load | 2012 |
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Internationality; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
Topics: Adult; Antiviral Agents; Biological Availability; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Hepatitis C treatment outcomes in Australian clinics.
Topics: Adult; Antiviral Agents; Australia; Body Mass Index; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2012 |
Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Purine-Nucleoside Phosphorylase; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load | 2012 |
Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment.
Topics: Adult; Antiviral Agents; Attitude to Health; Cohort Studies; Comorbidity; Comprehension; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interview, Psychological; Male; Middle Aged; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic; Patient Selection; Recombinant Proteins; Ribavirin; Treatment Refusal | 2012 |
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
Topics: Antiviral Agents; Chi-Square Distribution; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kaplan-Meier Estimate; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure | 2012 |
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Topics: Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load | 2012 |
Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2012 |
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Menopause; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Young Adult | 2012 |
Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.
Topics: Adjuvants, Pharmaceutic; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Recombinant Proteins; Ribavirin; RNA, Viral; Selective Estrogen Receptor Modulators | 2012 |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome | 2012 |
Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Estonia; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Viral Load | 2012 |
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Confidence Intervals; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2013 |
[Efficacy of combined immunocorrection in the treatment of chronic viral hepatitis C].
Topics: Acridines; Adult; Antigen-Antibody Complex; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon Inducers; Interferon-alpha; Leukocytes, Mononuclear; Lymphocyte Count; Macrophages; Male; Meglumine; Middle Aged; Phagocytosis; Ribavirin; Succinates; T-Lymphocytes; Treatment Outcome; Young Adult | 2012 |
Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Severity of Illness Index; Thrombocytopenia; Time; Treatment Outcome | 2013 |
Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment.
Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2012 |
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors | 2012 |
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
[Study on retreatment of CHC patients with initial treatment failure].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Viral Load; Young Adult | 2012 |
Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; France; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
[Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].
Topics: Adolescent; Adult; Antiviral Agents; Blood Donors; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Transfusion Reaction; Treatment Outcome; Viral Load; Young Adult | 2012 |
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tretinoin; Viral Load | 2013 |
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).
Topics: Adult; Antiviral Agents; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Exploratory study of oral combination antiviral therapy for hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; Ritonavir; RNA, Viral; Viral Load; Viral Nonstructural Proteins | 2013 |
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins | 2013 |
In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection.
Topics: Adult; Antiviral Agents; Clonal Anergy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Ribavirin; Time Factors | 2013 |
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Canada; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2013 |
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Nonstructural Proteins | 2013 |
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon Regulatory Factors; Interferon-alpha; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Transcriptome; Treatment Outcome; Viral Load | 2014 |
Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ki-1 Antigen; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Failure; Treatment Outcome | 2002 |
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2002 |
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Tuberculin | 2002 |
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2002 |
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2002 |
Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin.
Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2002 |
Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2002 |
High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2002 |
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.
Topics: Adjuvants, Immunologic; Antiviral Agents; CD4-Positive T-Lymphocytes; CD40 Ligand; Cells, Cultured; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Lymphocyte Activation; Male; Middle Aged; Mitogens; Monocytes; Recurrence; Ribavirin; RNA, Viral; Viral Core Proteins | 2002 |
Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Pilot Projects; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2002 |
Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2002 |
High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2002 |
The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.
Topics: Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load | 2003 |
[Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or a relapse with a previous interferon treatment. Long term follow-up].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2002 |
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Germany; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Survival Analysis | 2003 |
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Care; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Safety; Treatment Outcome | 2003 |
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virolo
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Time Factors | 2002 |
Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 2002 |
Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2003 |
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation.
Topics: Alanine Transaminase; Antiviral Agents; B-Lymphocytes; Base Sequence; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Drug Therapy, Combination; Female; Genes, bcl-2; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Translocation, Genetic; Treatment Outcome | 2003 |
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.
Topics: Abatacept; Adult; Antigens, CD; Antigens, Differentiation; Antiviral Agents; CTLA-4 Antigen; Female; Genetic Linkage; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoconjugates; Interferon-alpha; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribavirin; Time Factors | 2003 |
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2003 |
T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Case-Control Studies; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Drug Administration Schedule; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Viral Load | 2003 |
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Nonstructural Proteins | 2003 |
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2003 |
Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.
Topics: Adolescent; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2003 |
Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Failure | 2003 |
Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs.
Topics: Administration, Oral; Adult; Alanine Transaminase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pilot Projects; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2003 |
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Recombinant Proteins; Ribavirin | 2003 |
Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prognosis; Prospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Withholding Treatment | 2003 |
A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.
Topics: Antiviral Agents; Biological Assay; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Luciferases; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Tumor Cells, Cultured; Virus Replication | 2003 |
Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2003 |
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
Topics: Antiviral Agents; Biopsy; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral | 2003 |
Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Necrosis; Pilot Projects; Proteinuria; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2003 |
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Remission Induction; Ribavirin | 2003 |
High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.
Topics: Administration, Oral; Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2003 |
[Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in "real life"].
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin | 2003 |
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure | 2003 |
A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2003 |
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin | 2003 |
Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2003 |
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin | 2003 |
Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2003 |
First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Outcome | 2003 |
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Spain | 2003 |
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Belgium; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Netherlands; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2003 |
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load | 2003 |
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Treatment Outcome | 2003 |
Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interfer
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Kinetics; Male; Middle Aged; Monocytes; Myxovirus Resistance Proteins; Ribavirin; RNA, Viral; Time Factors | 2003 |
Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2004 |
Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; DNA Virus Infections; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Torque teno virus; Treatment Outcome | 2004 |
Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.
Topics: Adult; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia.
Topics: Adolescent; Adult; Antiviral Agents; Blood Coagulation Disorders; Double-Blind Method; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Transaminases | 2004 |
Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Ribavirin | 2004 |
A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
Topics: Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Recurrence; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2004 |
Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Efficiency; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2004 |
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
Topics: Adult; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2004 |
Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2004 |
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure | 2004 |
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2004 |
High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2004 |
Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2004 |
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection.
Topics: Adolescent; Adult; Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Leukocytes, Mononuclear; Middle Aged; Ribavirin | 2004 |
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione Disulfide; Glycogen Storage Disease Type I; Hemolysis; Hepatitis C, Chronic; Humans; In Vitro Techniques; Male; Maleates; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; Sulfhydryl Compounds | 2004 |
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Topics: Adult; Amantadine; Audiometry; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Sampling Studies; Severity of Illness Index | 2004 |
[Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].
Topics: Amantadine; Antiviral Agents; Autoantibodies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Islets of Langerhans; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Treatment Failure | 2004 |
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
Topics: Adult; Aged; Antiviral Agents; Drug Carriers; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferons; Iron; Liver; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load | 2004 |
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Socioeconomic Factors; White People | 2004 |
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
Topics: Adult; Aged; Antiviral Agents; Black or African American; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2004 |
Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2004 |
Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Solvents; Treatment Outcome | 2004 |
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance-Related Disorders; Treatment Outcome | 2004 |
Differences in treatment outcome for hepatitis C among ethnic groups.
Topics: Adult; Asian; Black or African American; Ethnicity; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome; White People | 2004 |
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 2004 |
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
Topics: Administration, Oral; Adult; Alanine Transaminase; Biopsy, Needle; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Drug Tolerance; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Safety | 2004 |
Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans | 2004 |
[Treatment with interferon and ribavirin of chronic hepatitis C in HIV-infected patients].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral | 2004 |
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleolus Organizer Region; Prospective Studies; Ribavirin; Silver Staining | 2004 |
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Austria; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Secondary Prevention; Treatment Failure; Treatment Outcome | 2004 |
Treatment of patients with HCV infection with or without liver biopsy.
Topics: Adult; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome | 2004 |
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome | 2004 |
[Peginterferon alpha-2b in patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome | 2004 |
Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2005 |
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication | 2004 |
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2004 |
Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Saudi Arabia; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; Salvage Therapy; Severity of Illness Index; Statistics, Nonparametric; Taiwan; Treatment Outcome; Viral Load | 2004 |
High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin.
Topics: Adult; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Female; Hemolysis; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Vitamin E | 2004 |
Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Liver; Liver Function Tests; Male; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2004 |
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hematologic Diseases; Hemorrhage; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2004 |
Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2005 |
Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.
Topics: Adult; Blood Platelets; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; von Willebrand Factor | 2005 |
Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
Topics: Adult; Aged; Antiviral Agents; Attitude to Health; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2005 |
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors | 2004 |
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.
Topics: Adult; Antiviral Agents; Anxiety; Depression; Drug Carriers; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Substance-Related Disorders; Time Factors; Treatment Outcome | 2005 |
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C.
Topics: Adult; Aged; Aging; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin | 2004 |
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Middle Aged; Patient Dropouts; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets | 2005 |
Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Saudi Arabia; Treatment Outcome | 2004 |
Peds-C.
Topics: Adolescent; Child; Child, Preschool; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2005 |
Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2005 |
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2005 |
Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Male; Placebos; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Epidermal Growth Factor; Female; Growth Substances; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet-Derived Growth Factor; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study).
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2005 |
Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection.
Topics: Adult; Antigens, CD; Antiviral Agents; Female; Hepatitis C, Chronic; HLA-DR Antigens; Humans; Interferon Type I; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors | 2005 |
Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.
Topics: Antiviral Agents; Automation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleic Acid Amplification Techniques; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2005 |
Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis | 2005 |
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia.
Topics: Adjuvants, Immunologic; Biopsy, Needle; Combined Modality Therapy; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interleukin-8; Leukapheresis; Male; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2005 |
Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Topics: Adolescent; Adult; Aged; Biopsy, Needle; Chi-Square Distribution; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Single-Blind Method; Taiwan; Time Factors; Treatment Outcome | 2005 |
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Amantadine; Biopsy, Needle; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2005 |
Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
Topics: Antiviral Agents; Body Weight; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
Topics: 2',5'-Oligoadenylate Synthetase; Adenosine Deaminase; Adult; Antiviral Agents; Black People; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; Genotype; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Myxovirus Resistance Proteins; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; White People | 2005 |
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin.
Topics: Adult; Drug Therapy, Combination; Female; Gluconates; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Zinc | 2005 |
Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2005 |
Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; Treatment Outcome | 2005 |
Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2005 |
Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Romania; Treatment Outcome | 2005 |
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; United Kingdom | 2006 |
Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial.
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Herbal Medicine; Humans; Liver Function Tests; Male; Middle Aged; Plant Extracts; Ribavirin; Th1 Cells; Th2 Cells; Viral Load | 2005 |
Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time; Transaminases | 2005 |
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Necrosis; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Treatment Outcome; Ursodeoxycholic Acid | 2005 |
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Circoviridae Infections; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2005 |
[An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C].
Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C.
Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Ribavirin; Treatment Outcome | 2005 |
Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; International Cooperation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load | 2005 |
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2005 |
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; RNA, Viral; Sample Size; Treatment Failure; Treatment Outcome | 2005 |
Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lebanon; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2005 |
Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin.
Topics: Adult; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Matrix Metalloproteinase 9; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1.
Topics: Adult; Aged; Antiviral Agents; Cell Proliferation; Combined Modality Therapy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukapheresis; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2005 |
High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokines, CXC; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome | 2005 |
Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Survival Analysis; Treatment Outcome | 2005 |
Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Cluster Analysis; Cytokines; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
Topics: Adult; Amantadine; Antiviral Agents; Drug Carriers; Drug Combinations; Drug Costs; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Black or African American; Drug Carriers; Drug Combinations; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2005 |
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2006 |
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Reference Standards; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients.
Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2006 |
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; ROC Curve; Severity of Illness Index; Single-Blind Method; Taiwan; Treatment Outcome | 2006 |
[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
Topics: Adult; Animals; Antiviral Agents; Base Sequence; Cell Line; Down-Regulation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Nucleic Acid Conformation; Protein Biosynthesis; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Viral Proteins | 2006 |
Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Species Specificity; Treatment Outcome; Viral Load | 2006 |
Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease-Free Survival; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ultrasonography | 2006 |
Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Vitamin E; Vitamins | 2006 |
Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2006 |
Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Topics: Adult; Aged; Antigen-Antibody Complex; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoprecipitation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2006 |
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Blood Glucose; Blood Pressure; Body Mass Index; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Syndrome; Metabolism; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Sex Factors; Triglycerides | 2006 |
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2006 |
Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Malaysia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2006 |
Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Deoxyguanosine; Dietary Supplements; Eicosapentaenoic Acid; Erythrocyte Membrane; Erythrocytes; Fatty Acids; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Phospholipids; Recombinant Proteins; Ribavirin | 2005 |
Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Antiviral Agents; Body Weight; Carnosine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Organometallic Compounds; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Zinc; Zinc Compounds | 2006 |
Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Prospective Studies; Research Design; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
[Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin | 2005 |
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2006 |
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral | 2006 |
Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sickness Impact Profile; Treatment Outcome | 2006 |
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2006 |
High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
Topics: Adult; Analysis of Variance; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; United Kingdom; Viral Load | 2006 |
[Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
Topics: Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; New England; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Fundus Oculi; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prevalence; Prospective Studies; Recombinant Proteins; Regression Analysis; Retinal Diseases; Retinal Hemorrhage; Ribavirin; Risk Factors; Time Factors | 2006 |
Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
[Sustained virological response in children with chronic hepatitis C treated with interferon alpha and ribavirin].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2006 |
Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferons; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin; RNA, Viral; Viremia | 2006 |
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Matched-Pair Analysis; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
Topics: Antiviral Agents; Black or African American; Black People; Blood Cell Count; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2006 |
Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eye Diseases; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Neovascularization; Ribavirin; Vascular Endothelial Growth Factor A | 2006 |
Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2006 |
Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, MHC Class II; Hepacivirus; Hepatitis B Antibodies; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunization Schedule; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Vaccines, Synthetic | 2006 |
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors | 2006 |
Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients.
Topics: alpha-Tocopherol; Ascorbic Acid; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Membrane; Female; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome | 2006 |
The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Marijuana Smoking; Middle Aged; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Substance-Related Disorders; Treatment Outcome; Viral Load | 2006 |
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Chemokines, CXC; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Topics: Adolescent; Adult; Aged; Antibodies; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gangliosides; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neural Conduction; Neurologic Examination; Peripheral Nervous System Diseases; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Statistics, Nonparametric; Sulfoglycosphingolipids; Time Factors | 2006 |
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine | 2006 |
Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin.
Topics: Adult; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2006 |
Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologi
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Analysis | 2006 |
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.
Topics: Adult; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Erythrocytes; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2006 |
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatic Veins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
Topics: Adult; Antiviral Agents; Blood Cell Count; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; P-Selectin; Polyethylene Glycols; Receptor, PAR-1; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
Topics: Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Prognosis; Ribavirin; RNA, Viral; ROC Curve; Survival Rate; Treatment Outcome | 2006 |
Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome; Vasculitis | 2006 |
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; White People | 2007 |
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2007 |
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Topics: Adult; Body Mass Index; Chemokine CXCL10; Chemokines, CXC; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome | 2006 |
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2006 |
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation; Antiviral Agents; CTLA-4 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Characteristics; T-Lymphocytes; Treatment Outcome | 2007 |
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Interferon-beta; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Ribavirin; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
Topics: Adult; Aged; Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins | 2007 |
Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; Down-Regulation; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lectins, C-Type; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteins; Receptors, Interleukin-7; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation | 2007 |
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Health Status; Health Surveys; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 2007 |
Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability.
Topics: Adult; Aged; Anemia, Hemolytic; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes; Hemorheology; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2007 |
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
[Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C].
Topics: Adult; Aged; Anemia; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Thyroiditis; Treatment Outcome; Viral Load | 2006 |
Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial.
Topics: Adult; Antiviral Agents; Blood Coagulation Disorders; Canada; Comorbidity; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Activation | 2006 |
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
Topics: Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Dietary Supplements; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Risk Factors; Statistics as Topic | 2007 |
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Topics: Adolescent; Adult; Antiviral Agents; Cell Nucleus; DNA; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin | 2007 |
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Count; Dendritic Cells; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance.
Topics: Adult; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
[A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2007 |
Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
Topics: Adult; Amantadine; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin | 2007 |
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.
Topics: Adult; Antiviral Agents; Black or African American; Drug Carriers; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Selection, Genetic; Tennessee; Treatment Failure; Viral Proteins | 2007 |
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
Topics: Adult; Antiviral Agents; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Maximum Tolerated Dose; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Topics: Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Ribavirin | 2007 |
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
Topics: Adult; Affect; Antiviral Agents; Cognition; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2007 |
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
Topics: Adult; Aged; Antiviral Agents; Cross-Over Studies; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutagenesis; Ribavirin; Time Factors; Viral Nonstructural Proteins; Viral Proteins | 2007 |
Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cells, Cultured; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Viral Load | 2007 |
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Biopsy, Needle; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Lamivudine; Leptin; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome | 2007 |
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
Topics: Adult; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Receptors, Tumor Necrosis Factor, Type II; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome; Viral Load | 2007 |
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Psychometrics; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Ribavirin; RNA, Viral | 2007 |
IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Substance-Related Disorders; Treatment Outcome | 2007 |
[The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Viral Load | 2007 |
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Zidovudine | 2007 |
Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.
Topics: Adult; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Methadone; Middle Aged; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Apoptosis; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Keratin-18; Kinetics; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Virus Replication | 2007 |
Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
Topics: Administration, Oral; Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Middle Aged; Odds Ratio; Patient Selection; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Ribavirin | 2007 |
Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Failure; United States; Viral Load | 2007 |
Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
Topics: Administration, Oral; Adult; Antiviral Agents; Buprenorphine; Comorbidity; Drug Therapy, Combination; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Norway; Opioid-Related Disorders; Patient Compliance; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Social Support; Substance Abuse, Intravenous | 2007 |
Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Carnosine; Dietary Supplements; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organometallic Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiobarbituric Acid Reactive Substances; Time Factors; Transaminases; Treatment Outcome; Vitamin E; Vitamins; Zinc; Zinc Compounds | 2007 |
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Spain; Treatment Outcome; Viral Load | 2007 |
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2007 |
Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Outcome | 2007 |
Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin.
Topics: Adult; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2007 |
Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.
Topics: Adult; Antiviral Agents; Biopsy; Case-Control Studies; Cluster Analysis; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Carnitine; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Ribavirin; Vitamin B Complex | 2008 |
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; Cohort Studies; Drug Therapy, Combination; Fatigue; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
Topics: Adolescent; Adult; Age Factors; Aged; Diabetes Complications; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Refusal; Viral Load | 2007 |
Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pediatrics; Placebos; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2007 |
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Risk Factors; Surveys and Questionnaires; Treatment Outcome | 2007 |
Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; China; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Patient Compliance; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Viral Load | 2008 |
Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Syria; Treatment Outcome; Viral Load | 2008 |
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.
Topics: Adult; Antiviral Agents; Canada; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome; Vasculitis | 2008 |
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Withholding Treatment; Zidovudine | 2008 |
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Topics: Adult; Anemia; Antiviral Agents; Darbepoetin alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Viremia | 2008 |
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study
Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Topics: Adult; Aged; Anemia; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2008 |
The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2008 |
Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C.
Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2008 |
Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2008 |
[Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
Topics: Actins; Adult; Antiviral Agents; Collagen Type III; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Liver; Liver Cirrhosis; Male; Middle Aged; Muscle, Smooth; Ribavirin; Treatment Outcome | 2008 |
Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Designer Drugs; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin | 2008 |
Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viremia | 2009 |
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.
Topics: Adult; Anorexia; Antiviral Agents; Cannabinoids; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Nausea; Retrospective Studies; Ribavirin; Treatment Outcome; Weight Loss | 2008 |
Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2008 |
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Therapy with interferon-alpha and ribavirin for chronic hepatitis C virus infection upregulates membrane HLA-ABC, CD86, and CD28 on peripheral blood mononuclear cells.
Topics: Adult; Aged; Antigens, Surface; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Up-Regulation | 2008 |
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome | 2008 |
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; Depression; Fatigue; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukin-6; Male; Middle Aged; Polymorphism, Genetic; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Serotonin Plasma Membrane Transport Proteins | 2009 |
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infections; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 1998 |
Ribavirin in hepatitis C related cryoglobulinemia.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Outcome; Viral Load | 1998 |
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Follow-Up Studies; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung; Male; Middle Aged; Recombinant Proteins; Remission, Spontaneous; Ribavirin; Sarcoidosis, Pulmonary; Skin; Time Factors; Tomography, X-Ray Computed | 1998 |
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Topics: Adolescent; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome | 1998 |
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 1998 |
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1998 |
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1998 |
Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nausea; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 1998 |
Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome | 1998 |
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
Topics: Adolescent; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 1998 |
r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.
Topics: Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 1999 |
[Opinion on interferon-ribavirin association in the primary treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Evaluation Studies as Topic; Hepatitis C, Chronic; Humans; Interferon-alpha; Placebos; Ribavirin | 1999 |
Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
Topics: Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 1999 |
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Topics: Adult; Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 1999 |
Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome | 1999 |
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome | 1999 |
Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Biopsy; Double-Blind Method; Drug Administration Routes; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Safety; Treatment Outcome | 1999 |
Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Surveys and Questionnaires; Treatment Outcome | 1999 |
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Statistics, Nonparametric | 1999 |
Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.
Topics: Antiviral Agents; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Necrosis; Ribavirin; Treatment Failure | 1999 |
Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 1999 |
Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Failure; Treatment Outcome | 1999 |
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 1999 |
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.
Topics: Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Quality of Life; Recombinant Proteins; Ribavirin | 1999 |
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Topics: Antiviral Agents; Combined Modality Therapy; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viremia | 1999 |
High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prevalence; Ribavirin | 1999 |
[Interferon-alpha plus ribavirin combination therapy in chronic hepatitis C].
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 1999 |
Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA Primers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunoblotting; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome | 1999 |
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
Topics: Adult; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 1999 |
Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Liver Function Tests; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin | 1999 |
Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Long-Term Care; Male; Middle Aged; Prognosis; Prospective Studies; Retreatment; Ribavirin; Spain; Statistics, Nonparametric; Treatment Failure; Treatment Outcome | 1999 |
Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 1999 |
Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antiviral Agents; Cost-Benefit Analysis; Daunorubicin; Doxorubicin; Hepatitis C, Chronic; Herpesvirus 8, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi | 1999 |
Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin.
Topics: Alanine Transaminase; Double-Blind Method; Hemoglobins; Hepatitis C, Chronic; Humans; Iron; Liver; Ribavirin; Siderosis | 2000 |
Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-10; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Viral Load | 2000 |
Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Lymph Nodes; Male; Middle Aged; Ribavirin; Treatment Outcome; Ultrasonography | 2000 |
Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiviral Agents; Biopsy, Needle; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2000 |
TT virus infection in patients with chronic hepatitis C virus infection--effect of primers, prevalence, and clinical significance. Hepatitis Interventional Therapy Group.
Topics: Adult; Antiviral Agents; DNA Virus Infections; DNA Viruses; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymerase Chain Reaction; Prevalence; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2000 |
Effect of interferon and ribavirin on HIV viral load.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Ribavirin; Viral Load | 2000 |
Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2000 |
Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
Topics: Adolescent; Adult; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ketoprofen; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral | 1999 |
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome; United States | 2000 |
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; RNA, Viral | 1999 |
Leucopenia is a side effect of combination therapy for hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Leukopenia; Male; Recombinant Proteins; Ribavirin | 2000 |
Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Recombinant Proteins; Ribavirin | 1999 |
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Amantadine; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral | 2000 |
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Saudi Arabia | 2000 |
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retreatment; Ribavirin; Treatment Outcome | 2000 |
Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2000 |
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Prospective Studies; Ribavirin; RNA, Viral | 2000 |
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Topics: Adult; Aged; Antiviral Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2000 |
Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Administration Routes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2000 |
A prospective and randomized study using ribavirin as monotherapy for the treatment of naïve patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2000 |
Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2000 |
Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure | 2000 |
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.
Topics: Adult; Aged; Antiviral Agents; Black People; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral | 2000 |
Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2000 |
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2000 |
Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Cause of Death; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Survival Rate; Time Factors; Treatment Outcome | 2000 |
[Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Topics: Adult; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2000 |
High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.
Topics: Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2000 |
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2000 |
Phase III Peg-Intron plus Rebetol results released.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2000 |
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Ribavirin; RNA, Viral | 2000 |
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Thyrotropin | 2001 |
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin | 2001 |
Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2001 |
Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Recurrence; Retreatment; Ribavirin; RNA, Viral | 2001 |
[Hepatitis C. Chances for treatment increase].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2001 |
Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Male; Middle Aged; Ribavirin; Time Factors; Viral Load; Virus Replication | 2001 |
Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Ribavirin; RNA, Viral | 2001 |
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone.
Topics: Adolescent; Adult; Analysis of Variance; Antiviral Agents; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Pilot Projects; Probability; Ribavirin; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2001 |
Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retreatment; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2001 |
Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2001 |
Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate.
Topics: Adult; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Ursodeoxycholic Acid | 2001 |
High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2001 |
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Molecular Sequence Data; Organization and Administration; Polymerase Chain Reaction; Probability; Prospective Studies; Reference Values; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2001 |
Factors influencing ribavirin-induced hemolysis.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Haptoglobins; Hemoglobins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors | 2001 |
Clearance kinetics of hepatitis C virus under different antiviral therapies.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors | 2001 |
A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome | 2001 |
A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Topics: Adult; Aged; Antiviral Agents; Blood; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Interferon-beta; Male; Middle Aged; Monocytes; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Inducers; Male; Middle Aged; Patient Dropouts; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2001 |
Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Topics: Administration, Oral; Adult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Probability; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Combinations; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
Topics: Alanine Transaminase; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors | 2001 |
Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Fibrosis; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Failure; Vascular Cell Adhesion Molecule-1 | 2001 |
[Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Poland; Ribavirin; Time Factors; Treatment Outcome | 2001 |
High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin | 2002 |
Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Infant; Interferon-alpha; Male; Ribavirin; Transfusion Reaction; Treatment Outcome; Viral Load | 2002 |
Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Ribavirin | 2002 |
Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine.
Topics: Adult; Amantadine; Antiviral Agents; Drug Synergism; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Sarcoidosis | 2002 |
Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2002 |
A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure | 2002 |
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha | 2002 |
Treatment of patients with chronic hepatitis C with normal liver enzymes.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load | 2002 |
A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Coagulation Disorders; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin | 2002 |
Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.
Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Transfusion Reaction | 2002 |
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2002 |
High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
Topics: Acute Disease; Acyltransferases; Adult; Aged; Antimetabolites; Antiviral Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2002 |
3749 other study(ies) available for ribavirin and Chronic Hepatitis C
| Article | Year |
|---|---|
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Topics: Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nitro Compounds; Recombinant Proteins; Replicon; Ribavirin; Thiazoles; Virus Replication | 2008 |
SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
Topics: Antiviral Agents; Cell Line, Tumor; Cyclophilin A; Diamide; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Molecular Conformation; Molecular Docking Simulation; Molecular Targeted Therapy; Structure-Activity Relationship; Surface Plasmon Resonance | 2020 |
Intracerebral haemorrhage and hepatitis C treatment.
Topics: Adult; Antiviral Agents; Australia; Cerebral Hemorrhage; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin | 2003 |
[Acute hepatitis C].
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2002 |
[The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type].
Topics: Adolescent; Antiviral Agents; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2006 |
Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Treatment Outcome | 2021 |
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Canada; Case-Control Studies; Female; Genome-Wide Association Study; Glycophorins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Prospective Studies; Pyrophosphatases; Receptors, Calcitriol; Ribavirin; Risk Assessment; Risk Factors | 2021 |
Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
Topics: Antiviral Agents; Cell Line; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir | 2021 |
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides | 2022 |
The use of antiviral drugs in children.
Topics: Adult; Antiviral Agents; Child; COVID-19; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Ribavirin; SARS-CoV-2 | 2022 |
An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.
Topics: Antiviral Agents; Artocarpus; Cell Line; Cyclosporine; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indonesia; Oligopeptides; Plant Extracts; Plant Leaves; Ribavirin | 2021 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Comment on "Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience".
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Ribavirin | 2021 |
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine | 2021 |
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project.
Topics: Aged; Antiviral Agents; Argentina; Carcinoma, Hepatocellular; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin | 2022 |
Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2021 |
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2022 |
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
Topics: Antiviral Agents; Canada; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome | 2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate | 2022 |
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014-2018).
Topics: Antiviral Agents; Emergency Service, Hospital; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2022 |
Deciphering the Significance of Plasma Chemokines as Prognostic Biomarkers in Pegylated IFN-Α-2a /Ribavirin-Treated Chronic Hepatitis C Genotype 4 Patients.
Topics: Antiviral Agents; Biomarkers; Chemokine CCL5; Chemokine CXCL10; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interleukin-8; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2022 |
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Ribavirin; Treatment Outcome | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
Topics: Antiviral Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Prospective Studies; Ribavirin; Ritonavir; Romania; Sulfonamides; Uracil; Valine | 2022 |
[The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus (Flaviviridae: Hepacivirus: Hepatitis С virus) NS4a antigen].
Topics: Antiviral Agents; Drug Therapy, Combination; Epitopes, B-Lymphocyte; Flaviviridae; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2022 |
Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Turkey | 2022 |
Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoprotein(a); Ribavirin; Sustained Virologic Response | 2022 |
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin | 2023 |
Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome | 2022 |
Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
Topics: Cohort Studies; Graves Disease; Hashimoto Disease; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Retrospective Studies; Ribavirin; Risk Factors | 2022 |
[Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Ritonavir; Treatment Outcome | 2022 |
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir | 2023 |
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir | 2022 |
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV.
Topics: Antiviral Agents; Brazil; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2023 |
Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis.
Topics: Adult; Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin | 2023 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
Topics: Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Treatment Outcome; Valine | 2023 |
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2023 |
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2023 |
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2023 |
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon.
Topics: Antiviral Agents; Cytokines; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukin-6; Interleukins; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2023 |
Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
Topics: Antiviral Agents; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Liver Cirrhosis; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2023 |
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome | 2023 |
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome | 2023 |
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2019 |
Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
Topics: Age Factors; Antiviral Agents; Benzimidazoles; British Columbia; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Lost to Follow-Up; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Topics: Analgesics, Opioid; Anilides; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Ribavirin; Sustained Virologic Response | 2020 |
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires | 2019 |
Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2020 |
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2019 |
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Treatment Outcome | 2020 |
New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2020 |
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2020 |
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
Topics: Carbamates; Drug Therapy, Combination; Egypt; Endpoint Determination; Gene Frequency; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mouth Neoplasms; Ribavirin; Taiwan | 2020 |
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Lost to Follow-Up; Male; Middle Aged; National Health Programs; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Inducible Nitric Oxide Synthase Polymorphism In Hepatitis C Patients Treated With Interferon Based-Treatment As A Predictor of Early Virological Response.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nitric Oxide Synthase Type II; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2019 |
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Young Adult | 2019 |
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; Viral Load | 2020 |
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C.
Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2020 |
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
Topics: Antiviral Agents; Cytokines; Fatty Acid-Binding Proteins; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney; Lipocalin-2; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2020 |
Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
Topics: Antiviral Agents; Carbamates; Cote d'Ivoire; Cross-Sectional Studies; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate | 2020 |
Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up?
Topics: Follow-Up Studies; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Ribavirin; Risk Factors | 2020 |
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
Topics: Adiponectin; Aged; Alanine Transaminase; Benzimidazoles; Blood Glucose; Carbamates; Cholesterol; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Insulin; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2020 |
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2020 |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
Topics: Adult; Antiviral Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2020 |
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine | 2020 |
C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle.
Topics: Adult; Antiviral Agents; Cell Line, Tumor; Female; Gene Knockout Techniques; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferons; Liver; Male; Middle Aged; Organelles; Replicon; Ribavirin; RNA-Binding Proteins; RNA, Viral; Treatment Outcome; Viral Replication Compartments; Virus Replication | 2020 |
Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; China; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; United States | 2020 |
Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Treatment Outcome | 2020 |
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin | 2020 |
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine; Young Adult | 2020 |
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine | 2020 |
Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Vietnam; Viral Load | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2020 |
The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Lactams, Macrocyclic; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Triglycerides; Valine | 2020 |
Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
Topics: Aged; Antibodies, Antinuclear; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Safety assessment of chronic hepatitis C treatment using h-FABP and 24-hour ECG Holter monitoring.
Topics: Antiviral Agents; Biomarkers; Electrocardiography, Ambulatory; Fatty Acid Binding Protein 3; Heart Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2020 |
Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
[Antiviral therapy of chronic hepatitis C: 30 years success story].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia | 2019 |
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Risk; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Triglycerides; Valine | 2020 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Patient Selection; Polyethylene Glycols; Retrospective Studies; Ribavirin; South Africa; Treatment Outcome | 2020 |
Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
Topics: Africa South of the Sahara; Antiviral Agents; Cote d'Ivoire; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir | 2020 |
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
Topics: Aged; Antiviral Agents; Brazil; Cohort Studies; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Ribavirin; Sustained Virologic Response | 2020 |
Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recombinant Proteins; Ribavirin; Treatment Outcome | 2020 |
Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; ROC Curve; South Africa; Sustained Virologic Response; Tertiary Care Centers | 2020 |
A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Pilot Projects; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2020 |
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome | 2021 |
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
Topics: Antiviral Agents; Bone Density; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2021 |
The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
Topics: Adult; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Valine | 2021 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2021 |
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir | 2020 |
Some concerns about "PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases".
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Programmed Cell Death 1 Receptor; Ribavirin | 2021 |
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2020 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
Topics: alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Interleukin-17; Recombinant Proteins; Ribavirin; Sofosbuvir | 2021 |
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Depression Disorders in Patients with Chronic Hepatitis C.
Topics: Antiviral Agents; Bosnia and Herzegovina; Buprenorphine; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Methadone; Ribavirin | 2020 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2021 |
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2021 |
Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Male; Middle Aged; Precipitating Factors; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Taiwan; Uracil; Valine | 2020 |
Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection.
Topics: Aged; Antiviral Agents; Female; Hemolysis; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Neutrophils; Phagocytosis; Prospective Studies; Ribavirin | 2021 |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2022 |
Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2022 |
Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients.
Topics: Antioxidants; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Kynurenic Acid; Kynurenine; Longitudinal Studies; Male; Middle Aged; ortho-Aminobenzoates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tryptophan | 2021 |
IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
Topics: Adult; Aged; Antibodies, Viral; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin E; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Nonstructural Proteins | 2021 |
A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Topics: Aged; Antiviral Agents; Brazil; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Transplant Recipients; Treatment Outcome | 2021 |
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
Topics: Anti-Retroviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Carbamazepine; Cell Membrane; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2021 |
The relevance between anti-rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection.
Topics: Antibodies, Antinuclear; Antiviral Agents; Genotype; Hepacivirus; Hepatitis Antibodies; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2021 |
[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients.
Topics: Antiviral Agents; Case-Control Studies; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-gamma; Killer Cells, Natural; Liver Transplantation; Phosphorylation; Ribavirin; Sofosbuvir; STAT1 Transcription Factor; STAT4 Transcription Factor; Time Factors; Treatment Outcome | 2021 |
Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.
Topics: Adult; Aged; Chemokine CXCL10; Cross-Sectional Studies; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Sustained Virologic Response; Young Adult | 2020 |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Ribavirin; Taiwan; Treatment Outcome | 2021 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins | 2021 |
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis.
Topics: Antiviral Agents; Coinfection; COVID-19; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Middle Aged; Plasmapheresis; Polyethylene Glycols; Positive-Strand RNA Viruses; Ribavirin; SARS-CoV-2; Treatment Outcome; Viral Load | 2021 |
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Black People; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Young Adult | 2021 |
Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retinal Diseases; Retrospective Studies; Ribavirin | 2021 |
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2021 |
Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey | 2021 |
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
Topics: Adult; Anilides; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2021 |
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Macrocyclic Compounds; Prevalence; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides | 2021 |
THE ROLE OF GALECTIN-9 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND ITS CONNECTION WITH THE TYPE OF THERAPY, THE DEGREE OF FIBROSIS, CLINICAL, LABORATORY, AUTOIMMUNE AND INTEGRATIVE INDICATORS.
Topics: Galectins; Hepatitis C, Chronic; Humans; Laboratories; Liver Cirrhosis; Ribavirin | 2021 |
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Treatment Outcome | 2021 |
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression.
Topics: Antiviral Agents; Cytokines; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Theoretical; Nonlinear Dynamics; Oligopeptides; Polyethylene Glycols; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2021 |
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
Topics: Analgesics; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Pharmacy; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Letter: sustained virological response and liver healing.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response | 2017 |
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine | 2017 |
Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea.
Topics: Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Prevalence; Prospective Studies; Psychiatric Status Rating Scales; Republic of Korea; Ribavirin; Sustained Virologic Response | 2017 |
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Fatal acute liver failure during Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Liver Failure, Acute; Ribavirin; Ritonavir | 2017 |
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Patient Preference; Prospective Studies; Ribavirin; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Refusal | 2017 |
Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medical Records; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult | 2017 |
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
Topics: Adult; Antiviral Agents; Asia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA Viruses; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation | 2017 |
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2018 |
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2017 |
IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2022 |
Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ireland; Male; Middle Aged; Oligopeptides; Proline; Propensity Score; Prospective Studies; Registries; Ribavirin; Treatment Outcome; Uncertainty | 2017 |
Reply to: "Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment".
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2017 |
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine | 2017 |
Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Topics: Adaptive Immunity; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2017 |
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\\ Sofosbuvir in HCV genotype IV.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Serine Proteases; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Failure | 2017 |
ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
Topics: Adult; Alleles; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2017 |
[Clinical timing and benefit of antiviral treatment for hepatitis C].
Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors; Treatment Outcome | 2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2017 |
The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.
Topics: Adult; Anemia; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Prognosis; Pyrophosphatases; Ribavirin | 2017 |
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Retrospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
Topics: Adult; Ambulatory Care; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; National Health Programs; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2017 |
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Ritonavir; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Treatment Failure; Valine | 2017 |
The Influence of Hepatitis C Virus Therapy on the DNA Base Excision Repair System of Peripheral Blood Mononuclear Cells.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cell Nucleus; Cyclopropanes; Deoxyuridine; DNA; DNA Breaks, Double-Stranded; DNA Glycosylases; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Therapy, Combination; Endonucleases; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lactams, Macrocyclic; Leukocytes, Mononuclear; Macrocyclic Compounds; Mitochondria; Molecular Mimicry; Primary Cell Culture; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferons; Isoquinolines; Kidney Transplantation; Male; Middle Aged; Prednisolone; Prospective Studies; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2017 |
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; RNA; RNA, Viral; Sustained Virologic Response; Treatment Outcome | 2017 |
Treatment of chronic Hepatitis C in Thalassemia major patients.
Topics: Adolescent; Adult; Anemia; Antiviral Agents; beta-Thalassemia; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; RNA, Viral; Sustained Virologic Response; Young Adult | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-Authors' reply.
Topics: Antiviral Agents; Child; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation.
Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
Topics: Anticoagulants; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Ribavirin; Sofosbuvir; Warfarin | 2017 |
Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Secondary Prevention; Transplant Recipients; Treatment Outcome | 2017 |
Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy.
Topics: Adult; Age Factors; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Risk Factors; Sex Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukins; Male; Middle Aged; Prospective Studies; Republic of Korea; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2018 |
Noninvasive serum models to predict significant liver related events in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin | 2017 |
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
The elderly and direct antiviral agents: Constraint or challenge?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2017 |
Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Ribavirin; Sustained Virologic Response | 2017 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Period; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Cytoplasmic rods and rings in ribavirin treatment.
Topics: Cytoplasm; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2017 |
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
Topics: Aged; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Egypt; Female; Glycated Hemoglobin; Glycemic Index; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Scandinavian and Nordic Countries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
Topics: Anemia, Hemolytic; Antiviral Agents; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotyping Techniques; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pharmacogenomic Testing; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome | 2017 |
Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
Topics: Alleles; Cohort Studies; Female; Genome-Wide Association Study; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Sustained Virologic Response | 2017 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Viremia; Virus Activation | 2018 |
The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2017 |
Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.
Topics: Aged; Antiviral Agents; B7-1 Antigen; B7-2 Antigen; Dendritic Cells; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome; Up-Regulation; Virus Replication | 2017 |
The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Logistic Models; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
Topics: Adult; Antiviral Agents; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Association of Interferon Alpha Receptor 1 with sustained virological response in hepatitis C and B co-infected patients.
Topics: Adult; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Prognosis; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger; RNA, Viral; Sustained Virologic Response | 2017 |
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
Topics: Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Withholding Treatment | 2017 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Proportional Hazards Models; Pyrrolidines; Ribavirin; Risk Factors; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Uric Acid | 2017 |
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2017 |
Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-15; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Scavenger Receptors, Class B; Sustained Virologic Response | 2017 |
Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.
Topics: Adult; Age Factors; Antiviral Agents; China; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Fees, Pharmaceutical; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Ribavirin; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Young Adult | 2017 |
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Young Adult | 2017 |
Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.
Topics: Cytoplasm; Hepatitis C, Chronic; Humans; Interferon-alpha; Mycophenolic Acid; Ribavirin | 2017 |
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-gamma; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2017 |
Interleukin 20 Gene Polymorphism (rs1518108) is not Associated with Sustained Virological Response in Iranian Patients with Hepatitis C Virus Infection.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Iran; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2017 |
Analysis of Hepatitis C Virus NS5A Region in Patients with Cirrhosis Using an Ultra-Deep Pyrosequencing Method.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation; Ribavirin; Viral Nonstructural Proteins | 2017 |
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
Topics: Antiviral Agents; Cholesterol; Drug Therapy, Combination; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipid Metabolism; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triglycerides | 2017 |
DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase.
Topics: Adenosine Triphosphate; Anemia; Antiviral Agents; Dehydroepiandrosterone; Erythrocytes; Glucosephosphate Dehydrogenase; Hemolysis; Hepatitis C, Chronic; Humans; Pentose Phosphate Pathway; Ribavirin | 2017 |
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Compassionate Use Trials; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Waiting Lists | 2018 |
A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Topics: Antiviral Agents; Developing Countries; District of Columbia; Genotype; Health Resources; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; India; Pilot Projects; Poverty; Ribavirin | 2017 |
Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Retrospective Studies; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2017 |
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2017 |
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Drug Therapy, Combination; Egypt; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrrolidines; Ribavirin; Serum Albumin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Topics: Adolescent; Antiviral Agents; Autoantibodies; Case-Control Studies; Child; Child, Preschool; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine | 2018 |
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult | 2017 |
High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Population Groups; Recombinant Proteins; Retrospective Studies; Ribavirin; Taiwan; Viral Load | 2017 |
Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFα α(Etanercept) Therapy.
Topics: Adult; Antiviral Agents; Etanercept; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Psoriasis; Ribavirin; RNA, Viral; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interleukin-17; Interleukin-22; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Protease Inhibitors; Ribavirin; Sustained Virologic Response; Th17 Cells | 2018 |
Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
The association of LMP7 and TAP2 gene polymorphisms with treatment response to interferon/ribavirin in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 3; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Ribavirin; Viral Load | 2017 |
Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Topics: alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Bone Morphogenetic Protein 7; Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: Lessons learned.
Topics: Antiviral Agents; Boston; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Care Team; Primary Health Care; Qualitative Research; Ribavirin | 2018 |
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine | 2017 |
Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin | 2017 |
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; Blood Transfusion; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response; Taiwan; Thalassemia; Viral Load; Young Adult | 2018 |
Association of
Topics: Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Retrospective Studies; Ribavirin | 2017 |
Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2017 |
Direct-acting antiviral agents in the treatment of chronic Hepatitis C - "Real-life" experience from an academic centre and two specialized clinical practices.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2018 |
Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2017 |
Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Receptors, KIR2DL3; Receptors, KIR3DL1; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2018 |
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load | 2018 |
Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Topics: Aged; Antiviral Agents; Austria; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Ribavirin; Sustained Virologic Response | 2018 |
The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response.
Topics: Amino Acid Sequence; Antigens, Viral; Antiviral Agents; Binding Sites; CD4-Positive T-Lymphocytes; Cell Proliferation; Gene Expression; Haplotypes; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; HLA-DQ beta-Chains; Humans; Immunity, Innate; Immunodominant Epitopes; Interferon-alpha; Lymphocyte Activation; Mutation; Polyethylene Glycols; Protein Binding; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2017 |
Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Heart Transplantation; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2017 |
The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Complications; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan | 2018 |
Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.
Topics: Adult; Affect; Aged; Antiviral Agents; Attention; Depression; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Memory, Episodic; Middle Aged; Prospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2017 |
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Virus Activation | 2018 |
Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Disease-Free Survival; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up.
Topics: Adult; Aged; Antimetabolites; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Obesity; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Weight Gain | 2017 |
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine | 2018 |
Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension; Incidence; Interferon-alpha; Male; Middle Aged; Retina; Retinal Diseases; Retinal Vessels; Retrospective Studies; Ribavirin; Risk Factors; Taiwan | 2018 |
Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Inflammation; Liver Transplantation; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate | 2018 |
HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lymphoma; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2018 |
Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno.
Topics: Antiviral Agents; Carbamates; Chile; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Public Health; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2017 |
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan; Tomography, X-Ray Computed; Treatment Failure | 2018 |
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
Topics: Adaptive Immunity; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunologic Memory; Interferon-alpha; Longitudinal Studies; Lymphocyte Activation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; T-Box Domain Proteins; Treatment Outcome | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Saudi Arabia; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Reply to: "'Who killed JR': Chronic hepatitis C or alcohol use disorders?"
Topics: Alcoholism; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2018 |
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Opiate Substitution Treatment; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load | 2018 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Spain; Treatment Outcome; Young Adult | 2018 |
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate | 2018 |
Factors Affecting the Virological Response Among Chronic Hepatitis C Virus Patients in Yemen.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Microbial Sensitivity Tests; Multivariate Analysis; Regression Analysis; Ribavirin; Yemen | 2018 |
NVR 3-778 Plus Pegylated Interferon-α Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2018 |
Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients.
Topics: Adult; Alleles; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Gene Expression; Gene Frequency; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin | 2018 |
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Valine | 2018 |
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Ribavirin; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2018 |
Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Case-Control Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prisoners; Ribavirin; Substance-Related Disorders | 2018 |
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antibodies, Viral; Antiviral Agents; Asian People; China; Disease Susceptibility; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sustained Virologic Response; T-Box Domain Proteins; Viral Core Proteins; Young Adult | 2018 |
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutant Proteins; Mutation, Missense; Prevalence; Ribavirin; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2018 |
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; gamma-Glutamyltransferase; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Prisoners; Prisons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoenzymes; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Recurrence; Ribavirin; Sulfonamides; Treatment Failure; Uracil; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2018 |
Interleukin-22 and Chemokine Interferon γ -Inducible-10 (IP-10) Levels in Chronic Hepatitis C Patients and Treatment Response to Pegylated Interferon and Ribavirin Therapy.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-22; Interleukins; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2017 |
Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Platelets; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2019 |
Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2018 |
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Topics: Aged; Antibodies; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Peptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Seroepidemiologic Studies; Sofosbuvir; Valine; Viral Load | 2018 |
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.
Topics: Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Sofosbuvir | 2018 |
Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prisons; Ribavirin; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Enzyme Induction; Female; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Pyrophosphatases; Ribavirin | 2018 |
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2018 |
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Diseases; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2018 |
Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Ribavirin; Survival Analysis; Sustained Virologic Response | 2018 |
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine | 2018 |
Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report.
Topics: Administration, Oral; Aged; Antibodies, Viral; Antiviral Agents; Diagnosis, Differential; DNA, Viral; Glucocorticoids; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Methylprednisolone; Pemphigoid, Bullous; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Association between
Topics: Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HLA-D Antigens; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2018 |
A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.
Topics: Antiviral Agents; Cohort Studies; Female; Genotyping Techniques; Hepatitis C, Chronic; Humans; Iran; Male; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2018 |
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2018 |
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis.
Topics: Adult; Anemia; Darbepoetin alfa; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Renal Dialysis; Ribavirin; Tacrolimus; Treatment Outcome | 2018 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2018 |
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
Topics: Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Ribavirin; Sofosbuvir; Time Factors | 2018 |
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
Topics: Antiviral Agents; Benzimidazoles; Blood Glucose; Carbamates; Diabetes Mellitus; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Black or African American; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Failure; Young Adult | 2018 |
Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Lupus Nephritis; Nephrotic Syndrome; Prednisolone; Remission Induction; Ribavirin; Sofosbuvir; Tacrolimus | 2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
[Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2017 |
Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China.
Topics: Adult; Alleles; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prevalence; Ribavirin | 2018 |
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report.
Topics: Antiviral Agents; Colchicine; Drug Therapy, Combination; Familial Mediterranean Fever; Female; Helicobacter Infections; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tubulin Modulators; Young Adult | 2018 |
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2018 |
Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults.
Topics: Aged; Aged, 80 and over; Anemia; Antiviral Agents; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2018 |
[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
Topics: Adolescent; Aged; Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2018 |
[Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2018 |
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Scleroderma, Localized; Skin; Sofosbuvir; Treatment Outcome | 2019 |
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt.
Topics: Antiviral Agents; Carbamates; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Editorial: retreatment of DAA-failures-no problem at all?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Echocardiography; Female; Genotype; Heart Ventricles; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pilot Projects; Polyethylene Glycols; Reproducibility of Results; Ribavirin; Sustained Virologic Response; Ventricular Dysfunction, Left | 2018 |
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2019 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medicaid; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate; Viral Load | 2018 |
Direct-acting antiviral drugs are triggers for psoriasis: report of three cases.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Symptom Flare Up; Valine | 2018 |
Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pharmacovigilance; Prospective Studies; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Valine | 2018 |
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2020 |
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Quinoxalines; Recurrence; Ribavirin; Serine Proteases; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2018 |
KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, KIR2DL2; Ribavirin; Risk Factors; Treatment Outcome | 2018 |
Identification of IL-10-secreting CD8
Topics: Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-10; Lymphocyte Activation; Male; Programmed Cell Death 1 Receptor; Ribavirin; RNA, Viral; T-Lymphocytes, Regulatory | 2018 |
Impact of Different Sources of Infection on Therapy Response in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Blood Transfusion; Bosnia and Herzegovina; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Iatrogenic Disease; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Transfusion Reaction; Treatment Outcome | 2018 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Outcome | 2018 |
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2018 |
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2019 |
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Findings from a large Asian chronic hepatitis C real-life study.
Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2018 |
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
Topics: Adult; Aged, 80 and over; Algorithms; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2019 |
Antidepressant effects of direct-acting antivirals against hepatitis C virus-Results from a pilot study.
Topics: Actigraphy; Adult; Aged; Antiviral Agents; Depression; Exercise; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Outcome; Tryptophan; Viral Load; Young Adult | 2018 |
Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Topics: Aged; Antiviral Agents; Chemokines; Cytokines; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Male; Middle Aged; Neutralization Tests; Polyethylene Glycols; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Viral Load | 2019 |
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2018 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwan | 2018 |
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Program Evaluation; Public Health; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
Topics: Aged; Antiviral Agents; Autoantibodies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2018 |
Acneiform eruptions: An unusual dermatological side effect of ribavirin.
Topics: Acneiform Eruptions; Adult; Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Male; Ribavirin | 2018 |
Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load; Young Adult | 2018 |
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2018 |
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Registries; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Treatment Outcome | 2019 |
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine | 2019 |
No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Geography; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine | 2019 |
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prisons; Retrospective Studies; Ribavirin; Taiwan; Viral Load | 2019 |
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India.
Topics: Adult; Dietary Supplements; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Viral Load; Vitamin D | 2018 |
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Users; Female; Genotype; Georgia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous | 2018 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Proline; Qualitative Research; Ribavirin; Ritonavir; RNA, Viral; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load | 2019 |
Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genetics, Population; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferons; Longitudinal Studies; Male; Middle Aged; Quasispecies; Ribavirin; Selection, Genetic; Young Adult | 2018 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Interferon alpha receptors and STAT1 as therapy predictors of a sustained virological response in hepatitis C/B co-infection.
Topics: Adult; Antibodies, Viral; Coinfection; Cross-Sectional Studies; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Receptor, Interferon alpha-beta; Recombinant Proteins; Retrospective Studies; Ribavirin; STAT1 Transcription Factor | 2018 |
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dyspepsia; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Burden of disease in patients with chronic hepatitis C in the Austrian REAL study.
Topics: Antiviral Agents; Austria; Cost of Illness; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome | 2019 |
Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antiviral Agents; Cardiovascular Diseases; Coronary Artery Bypass; Drug Therapy, Combination; Female; Heart Failure; Hepatitis C, Chronic; Humans; Incidence; Interferon Type I; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Protective Factors; Ribavirin; Stroke; Sustained Virologic Response | 2019 |
Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Topics: Antiviral Agents; Autoantibodies; Cohort Studies; Cytoskeleton; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2019 |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.
Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Taiwan; Treatment Failure; Viral Load | 2019 |
Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
Topics: Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2019 |
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
Topics: Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2019 |
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2018 |
Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response; Taiwan | 2019 |
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2019 |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome; Uridine Monophosphate | 2018 |
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Topics: Adult; Aged; Antiviral Agents; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response | 2018 |
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Ribavirin; Secondary Prevention; Sustained Virologic Response; Taiwan; Tertiary Prevention; Viral Load; Viremia | 2019 |
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lymphoma; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Taiwan | 2019 |
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral Therapy.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interleukin-17; Ribavirin; Sofosbuvir; Sustained Virologic Response; Th17 Cells; Treatment Outcome | 2018 |
Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response | 2019 |
Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Indonesia; Male; Medically Underserved Area; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retina; Ribavirin; Sofosbuvir; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Young Adult | 2019 |
Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2019 |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Costs; Drug Therapy, Combination; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon-alpha; Male; Medicare; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2019 |
Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Sustained Virologic Response; Time Factors; Treatment Outcome | 2019 |
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult | 2019 |
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2019 |
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Obesity; Prospective Studies; Ribavirin; Risk Factors; Sex Factors | 2019 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Recovery of Function; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load; Young Adult | 2019 |
Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens.
Topics: Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Monitoring, Physiologic; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response | 2019 |
Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C.
Topics: Antiviral Agents; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prospective Studies; Psychiatric Status Rating Scales; Ribavirin | 2019 |
The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy.
Topics: Antiviral Agents; Carbamates; Community Pharmacy Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Pharmacists; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sustained Virologic Response; Treatment Outcome | 2019 |
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2019 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2019 |
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Portugal; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult | 2019 |
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2022 |
Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Taiwan; Thyroid Diseases; Young Adult | 2019 |
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Leprosy; Male; Prevalence; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2019 |
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Leukemia, Myeloid, Acute; Male; Ribavirin; Treatment Outcome | 2019 |
Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Topics: Antiviral Agents; Diabetes Mellitus; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Veterans | 2020 |
Direct-acting antivirals and visceral leishmaniasis: a case report.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Antiviral Agents; Coinfection; Hepatitis C, Chronic; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Ribavirin; Sofosbuvir | 2019 |
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Topics: Carbamates; Chromatography, High Pressure Liquid; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Valine | 2019 |
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
[EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Ukraine; Uracil; Valine | 2019 |
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective.
Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Oligopeptides; Proline; Public Health Practice; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome | 2019 |
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Brazil; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Young Adult | 2019 |
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phylogeny; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2019 |
The association of hepatitis c virus infection status with serum glucose levels.
Topics: Adult; Antiviral Agents; Blood Glucose; Drug Therapy, Combination; Fasting; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2019 |
A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety.
Topics: Antiviral Agents; Anxiety; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin | 2019 |
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclopropanes; Hepatectomy; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Middle Aged; Neoplasm Recurrence, Local; Proline; Prospective Studies; Radiofrequency Ablation; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; Hepatitis E; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tenofovir; Treatment Outcome; Valine; Viral Load | 2020 |
Cluster of hepatitis C in a family: a twenty-year follow-up.
Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Family; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Needle Sharing; Ribavirin | 2019 |
Implications of soluble E-cadherin level of antiviral treatment in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cadherins; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Ribavirin; Viral Load | 2019 |
Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies.
Topics: Adult; Anemia; Antiviral Agents; Comorbidity; Delivery of Health Care, Integrated; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interprofessional Relations; Male; Middle Aged; Personality Disorders; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Sofosbuvir; Substance-Related Disorders | 2019 |
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International St
Topics: Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmaceutical Preparations; Ribavirin; Substance Abuse, Intravenous; Sustained Virologic Response | 2020 |
Effect of Combined HCV Therapy on Natural Killer Cell Activity.
Topics: Adult; Antiviral Agents; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 3; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Coinfection; Disease Progression; DNA, Mitochondrial; Europe; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk | 2019 |
Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2019 |
[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon.
Topics: Anemia; Antiviral Agents; Asian People; Drug Combinations; Female; Forecasting; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pyrophosphatases; Ribavirin | 2020 |
Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Transforming Growth Factor beta; Treatment Outcome; Valine; Viral Load | 2019 |
The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Papular Sarcoidosis of the Knees Following Treatment with Interferon Alpha and Ribavirin in a Woman with Hepatitis C.
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Knee; Middle Aged; Ribavirin; Sarcoidosis; Skin Diseases | 2019 |
[Pegylated intereferon hematological safety in comparison with standard].
Topics: Adult; Antiviral Agents; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
Topics: Antiviral Agents; Brazil; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2013 |
Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Pancreatitis; Panniculitis; Ribavirin; Skin | 2013 |
Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study.
Topics: Anti-Ulcer Agents; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatitis, Aphthous; Triazines | 2013 |
Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2013 |
Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Early Diagnosis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Polyethylene Glycols; Predictive Value of Tests; Pulmonary Surfactant-Associated Protein D; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Polymorphism, Genetic; Ribavirin; RNA, Viral; Viral Nonstructural Proteins | 2013 |
Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2013 |
Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Topics: Adipokines; Adiponectin; Adult; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Body Mass Index; Chi-Square Distribution; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Leptin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phenotype; Predictive Value of Tests; Ribavirin; Risk Factors; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load | 2013 |
Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
Topics: Adult; Antiviral Agents; Asian People; Case-Control Studies; DNA Primers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Autoantibodies in hepatitis C: red flag or bystander effect?
Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin | 2013 |
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2013 |
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Cardiovascular Diseases; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Practice Guidelines as Topic; Ribavirin; Young Adult | 2013 |
Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Topics: Adolescent; Age Factors; Antiviral Agents; Biomarkers; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
A comparison of modified directly observed therapy to standard care for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Viral Load | 2013 |
[Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
Topics: Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Autoantibodies; Autoantigens; Cyclophosphamide; Factor VIII; Glucocorticoids; Hematoma; Hemophilia A; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab | 2013 |
[Case report of the available of interhenotypic recombinant in chronic hepatitis C: the algorithm of individualization of the antiviral therapy].
Topics: 5' Untranslated Regions; Adult; Algorithms; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Mutation; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2013 |
The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
Topics: Antiviral Agents; Automation, Laboratory; Clinical Laboratory Techniques; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2013 |
Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
Topics: Adult; Antiviral Agents; Autoantibodies; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome | 2013 |
Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors | 2013 |
Boceprevir-based triple therapy for belgian liver transplant patients infected with hepatitis C virus: a preliminary experience.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2013 |
Sofosbuvir: the final nail in the coffin for hepatitis C?
Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Hepatitis C treatment: interferon free or interferon freer?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
Topics: Antibody-Dependent Cell Cytotoxicity; Antiviral Agents; Biomarkers; CD56 Antigen; GPI-Linked Proteins; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; Perforin; Polyethylene Glycols; Pore Forming Cytotoxic Proteins; Prospective Studies; Receptors, IgG; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Topics: Antiviral Agents; Autoantibodies; Carbon-Nitrogen Ligases; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Inclusion Bodies; Interferons; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Ribavirin; Staining and Labeling | 2013 |
Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin | 2013 |
District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Delivery of Health Care; Drug Therapy, Combination; England; Female; Hepatitis C, Chronic; Hospitals, District; Hospitals, General; Humans; Interferon-alpha; Male; Medical Audit; Nurse Clinicians; Patient Care Team; Patient Safety; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Standard of Care; Time Factors; Treatment Outcome | 2013 |
Anemia as a predictor of response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Quality-Adjusted Life Years; Recurrence; Ribavirin; Treatment Outcome | 2013 |
[Genetic polymorphisms of IL-28B are associated with sustained virologic response in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2012 |
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load | 2013 |
How cost-effective is hepatitis C virus treatment for people who inject drugs?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2013 |
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hashimoto Disease; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Islets of Langerhans; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitiligo; Young Adult | 2013 |
Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients.
Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Cohort Studies; Cross-Sectional Studies; Egypt; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Sex Factors; Viral Load | 2013 |
[Study on effect of intensive treatment for refractory chronic hepatitis C patients].
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Molecular Sequence Data; Nitro Compounds; Polyethylene Glycols; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Thiazoles; Treatment Failure; Viral Nonstructural Proteins | 2013 |
Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2013 |
Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2013 |
Hepatitis C treatment options improving.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Ribavirin; United States | 2013 |
IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Receptors, Cytokine; Retrospective Studies; Ribavirin; Treatment Failure | 2013 |
Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Socioeconomic Factors; Treatment Outcome | 2013 |
Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antiviral Agents; Anxiety; Cohort Studies; Depression; Drug Therapy, Combination; Fatigue; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; INDEL Mutation; Interferon-alpha; Interleukin-6; Middle Aged; Point Mutation; Polyethylene Glycols; Promoter Regions, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Serotonin; Serotonin Plasma Membrane Transport Proteins; White People | 2013 |
Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis.
Topics: Adult; Antiviral Agents; Delivery of Health Care, Integrated; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Opiate Substitution Treatment; Primary Health Care; Recombinant Proteins; Retrospective Studies; Ribavirin; Socioeconomic Factors; Substance-Related Disorders; Switzerland; Treatment Failure; Treatment Outcome | 2013 |
Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Middle Aged; Neutropenia; Opportunistic Infections; Prospective Studies; Ribavirin; Risk Assessment | 2013 |
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
Topics: Anemia; Erythropoietin; Escherichia coli; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-6; Ligands; Lipopolysaccharides; Monocytes; Phagocytosis; Reactive Oxygen Species; Receptors, Erythropoietin; Ribavirin; RNA, Messenger; Toll-Like Receptor 4 | 2013 |
Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2013 |
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
Topics: Aged; Aminoquinolines; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imiquimod; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Treatment Outcome | 2014 |
Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States | 2013 |
HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Saliva; Viral Load | 2014 |
HCV treatment--no more room for interferonologists?
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2013 |
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Body Mass Index; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recurrence; Ribavirin; RNA, Viral; Young Adult | 2013 |
Oral hyperpigmentation associated with interferon-alpha and ribavirin therapy for hepatitis C virus infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon-alpha; Middle Aged; Mouth Diseases; Ribavirin | 2014 |
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy | 2013 |
The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.
Topics: Adult; Antiviral Agents; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome | 2013 |
The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese.
Topics: Asian People; Drug Therapy, Combination; Female; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Linkage Disequilibrium; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; STAT6 Transcription Factor; Taiwan; Treatment Outcome | 2013 |
Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.
Topics: Adult; Antiviral Agents; Bias; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Treatment Outcome | 2013 |
[Respiratory function impairment during treatment of chronic hepatitis C with peginterferon alfa2 and ribavirin. Two cases presentation].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Young Adult | 2012 |
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transcriptome; Viral Load | 2014 |
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C].
Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Ribavirin; Treatment Outcome | 2013 |
[Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2013 |
Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2013 |
Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2013 |
The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Flow Cytometry; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Killer Cells, Natural; Linear Models; Liver; Lymphocyte Activation; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load | 2014 |
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Topics: Antibodies, Neutralizing; Culture Techniques; DNA, Recombinant; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mutation; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2013 |
Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
Topics: Adaptor Proteins, Signal Transducing; Antiviral Agents; DEAD Box Protein 58; DEAD-box RNA Helicases; Drug Resistance, Viral; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Receptors, Immunologic; Recombinant Proteins; Ribavirin; RNA, Messenger; Ubiquitin-Protein Ligases | 2013 |
Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Praziquantel; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Schistosomiasis; Schistosomicides; Time Factors; Treatment Outcome | 2013 |
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Registries; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
[Results of chronic hepatitis C treatment in a public hospital].
Topics: Antiviral Agents; Body Mass Index; Chile; Clinical Protocols; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hospitals, Public; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral | 2013 |
Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mathematical Concepts; Models, Biological; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2013 |
Energy dialogue technique in healing and health: relieving side effects and thyroid dysfunction in a male with hemophilia receiving pegylated interferon and ribavirin treatment for hepatitis C virus--an anecdotal case study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mind-Body Relations, Metaphysical; Ribavirin; Thyroid Diseases; Thyroid Gland | 2013 |
Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2014 |
Cognitive improvement after HCV eradication: Extending the benefits.
Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypophosphatemia; Interferons; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Ribavirin; Risk Factors; Tenofovir | 2013 |
SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin.
Topics: Adult; DNA Methylation; Drug Resistance, Viral; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2013 |
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Expectancy; Male; Middle Aged; Oligopeptides; Proline; Quality of Life; Ribavirin; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health | 2013 |
Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?".
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Pyrophosphatases; Ribavirin | 2013 |
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Pyrophosphatases; Ribavirin | 2013 |
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin | 2013 |
Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2013 |
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Thrombocytopenia; Young Adult | 2013 |
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL; Ribavirin; Treatment Outcome | 2013 |
[Predictive factors of response to peginterferon and ribavirin in Tunisians patients with chronic hepatitis C: report of 141 cases].
Topics: Adult; Aged; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Tunisia; Viral Load | 2013 |
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C.
Topics: Alleles; Antiviral Agents; Calcineurin Inhibitors; DNA; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C.
Topics: Adult; Anticoagulants; Antithrombin III; Blood Coagulation Tests; Case-Control Studies; Female; Fibrinogen; Hemostasis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Partial Thromboplastin Time; Polyethylene Glycols; Protein C; Protein S; Prothrombin Time; Recombinant Proteins; Ribavirin | 2013 |
Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Gene Frequency; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Young Adult | 2013 |
Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Blood Coagulation Disorders; Blood Transfusion; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transfusion Reaction; Young Adult | 2013 |
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Boceprevir for HCV in patients with HIV: where next?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.
Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Prognosis; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.
Topics: Adult; Aged; Alanine Transaminase; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; MicroRNAs; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serum | 2013 |
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.
Topics: Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Ribavirin; Risk Factors; Time Factors | 2013 |
Evidence that pulmonary vascular pathology explains the decline in lung function associated with interferon α based therapies for chronic hepatitis C virus.
Topics: Albumins; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Lung Diseases, Interstitial; Male; Polyethylene Glycols; Ribavirin | 2013 |
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
Topics: Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, DNA | 2013 |
Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Mass Spectrometry; Middle Aged; Multivariate Analysis; Proteome; Ribavirin; Sensitivity and Specificity; Taiwan; Treatment Outcome; Viral Load | 2015 |
HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Genotyping Techniques; Hepatitis C, Chronic; Histocompatibility Antigens Class I; HIV Infections; HLA-E Antigens; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.
Topics: Adult; Antiviral Agents; Cadherins; Chemokines; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Mental Disorders; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2012 |
Hepatitis C--an update.
Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
Topics: Adult; Age Factors; Antiviral Agents; Blood Platelets; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2013 |
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Severity of Illness Index; United States; Withholding Treatment | 2013 |
Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2013 |
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
Topics: Adult; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Premenopause; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sex Factors | 2013 |
Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin D; Vitamin D Deficiency; Vitiligo | 2013 |
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin | 2014 |
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Oligopeptides; Pilot Projects; Ribavirin; Treatment Outcome | 2013 |
Weight loss with interferon and ribavirin therapy in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chi-Square Distribution; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Treatment Outcome; Weight Loss | 2012 |
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Poisson Distribution; Prospective Studies; Ribavirin | 2013 |
Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Health Surveys; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Serotyping; Treatment Outcome | 2014 |
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2014 |
Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Aged; Antiviral Agents; Brazil; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2013 |
Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Phenotype; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Toll-Like Receptor 4; Treatment Outcome; Viral Load | 2013 |
Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children.
Topics: Adolescent; Alleles; Antiviral Agents; Child; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2013 |
Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
Topics: Antiviral Agents; Computational Biology; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Mathematical Concepts; Models, Biological; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Sofosbuvir-based interferon-free therapy for patients with HCV infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Chronic hepatitis C therapy: a rare complication revisited.
Topics: Administration, Cutaneous; Antiviral Agents; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Recombinant Proteins; Ribavirin | 2013 |
Liver histology of chronic hepatitis C patients who relapsed or not responded to conventional interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Treatment Failure | 2013 |
Relating serum GGT to ALT activity enhances its predictability on treatment outcome in chronic hepatitis C.
Topics: Antiviral Agents; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome | 2013 |
[Sofosbuvir: alternative in hepatitis C infection?].
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2013 |
Reply: To PMID 23258530.
Topics: Antiviral Agents; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Lymphocytes; Male; Middle Aged; Monocytes; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Protective Agents; Ribavirin; Transcription Factors | 2013 |
Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Ethnicity; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Pyrophosphatases; Ribavirin; Young Adult | 2013 |
Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Apolipoprotein B-100; Biomarkers; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Serum; Treatment Outcome; Young Adult | 2013 |
Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2013 |
Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide Synthase Type II; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome | 2013 |
Treatment of patients with dual hepatitis B and C: a step in the right direction.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.
Topics: Adult; Antiviral Agents; Bangladesh; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2013 |
Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.
Topics: Adult; Aged; Biopsy; Cross-Sectional Studies; Fatty Liver; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Failure; Ultrasonography; Young Adult | 2013 |
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin; Treatment Outcome | 2013 |
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment | 2013 |
Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C.
Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2013 |
Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C--authors' reply.
Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2013 |
Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2013 |
Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral--authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2013 |
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Topics: Animals; Antiviral Agents; Benzimidazoles; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Fluorenes; Haplorhini; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Inhibitory Concentration 50; Interferon-alpha; Protease Inhibitors; Purines; Pyridazines; Quinolines; Rats; Replicon; Ribavirin; Viral Nonstructural Proteins | 2014 |
Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse.
Topics: Adult; Antiviral Agents; Area Under Curve; Chromatography, Liquid; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Tandem Mass Spectrometry; Time Factors; Treatment Outcome | 2013 |
Sofosbuvir for previously untreated chronic hepatitis C infection.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2013 |
Sofosbuvir for previously untreated chronic hepatitis C infection.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2013 |
Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ribavirin; Risk Assessment; Risk Factors; Time Factors | 2013 |
Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
Topics: Adult; Antibodies; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Peptides; Pilot Projects; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.
Topics: Adult; Alleles; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome | 2013 |
[Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
Topics: Adult; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; Toll-Like Receptor 3; Toll-Like Receptor 4; Treatment Outcome; Young Adult | 2013 |
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2014 |
Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Time Factors; Treatment Outcome; Young Adult | 2014 |
Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.
Topics: Adult; Aged; Analysis of Variance; Apoptosis; Cytochromes c; Enzyme-Linked Immunosorbent Assay; Epitopes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Keratin-18; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric | 2014 |
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain | 2013 |
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Serum | 2014 |
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
Topics: Adult; Antiviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2013 |
[Clinical features of antiviral therapy-induced thyroid disease in patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Thyroid Diseases | 2013 |
[Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Real-Time Polymerase Chain Reaction; Ribavirin | 2013 |
[Sofosbuvir for hepatitis C - is brevity the soul of wit?].
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2013 |
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2014 |
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
Topics: Age Factors; Aged; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Matched-Pair Analysis; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2014 |
Relapse of hepatitis C in three immunocompetent patients achieved a sustained virological response following interferon-based antiviral therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2013 |
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
Topics: Adult; Antiviral Agents; Drug Interactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Withholding Treatment | 2013 |
Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Fluorouracil; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Microbial Sensitivity Tests; Mutation; Ribavirin; Viral Proteins; Virus Replication | 2013 |
A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hematoma, Subdural, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2013 |
Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors | 2014 |
Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis.
Topics: Antiviral Agents; Erythrocytes; Glycolysis; Hemolysis; Hepatitis C, Chronic; Humans; Oxidative Stress; Pentose Phosphate Pathway; Ribavirin | 2013 |
Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.
Topics: Antiviral Agents; Asthenia; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Viral Load | 2013 |
New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.
Topics: Antiviral Agents; Community Health Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Polyethylene Glycols; Proline; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials.
Topics: Deoxycytidine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
HCV, ribavirin, and anemia: a new dawn.
Topics: Anemia; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
[Conclusions].
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2013 |
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Treatment of chronic hepatitis C in injecting drug users--a 5-year follow-up.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Recurrence; Ribavirin; Serbia; Substance Abuse, Intravenous; Treatment Outcome | 2013 |
Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin.
Topics: Adult; Biomarkers, Pharmacological; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Immunotherapy; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2014 |
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukins; Male; Polymorphism, Genetic; Ribavirin; Treatment Failure | 2014 |
Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Calcitriol; Ribavirin; ROC Curve; Viral Load; Young Adult | 2013 |
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retinal Diseases; Ribavirin | 2014 |
Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Bone Marrow Cells; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Young Adult | 2013 |
Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; National Health Programs; Non-alcoholic Fatty Liver Disease; Psychiatric Status Rating Scales; Ribavirin; Risk Factors; Taiwan | 2015 |
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Selection; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
End of treatment response in chronic hepatitis C patients treated with interferon alpha and ribavirin.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.
Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load | 2014 |
Transcript analysis of P2X receptors in PBMCs of chronic HCV patients: an insight into antiviral treatment response and HCV-induced pathogenesis.
Topics: Adult; Antiviral Agents; Cytokines; Female; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Polyethylene Glycols; Protein Isoforms; Receptors, Purinergic P2X; Recombinant Proteins; Ribavirin | 2013 |
Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
[Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy].
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Postoperative Period; Ribavirin; Splenectomy; Treatment Outcome | 2013 |
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting | 2014 |
Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2013 |
Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation.
Topics: Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin | 2013 |
Vertical transmission of hepatitis C virus: a tale of multiple outcomes.
Topics: Antiviral Agents; Child; Coinfection; Evolution, Molecular; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Infectious; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin | 2013 |
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Resources; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Analysis | 2014 |
[Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2013 |
Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2014 |
Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Computational Biology; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Point Mutation; Ribavirin; Saudi Arabia; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins | 2014 |
Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2013 |
Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Severity of Illness Index; Young Adult | 2013 |
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.
Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2013 |
Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
Topics: Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Peptides, Cyclic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Neurocognitive function and dysfunction after hepatitis C therapy.
Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
Topics: Adult; Antiviral Agents; China; Cytokines; Enzyme-Linked Immunospot Assay; Female; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Polymorphism, Single Nucleotide; Ribavirin; Young Adult | 2014 |
Hepatitis C infection is very rarely treated among hemodialysis patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Prevalence; Proportional Hazards Models; Renal Dialysis; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 2014 |
Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
Topics: Adult; Antiviral Agents; Carrier Proteins; Drug Interactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Seizures; Viral Nonstructural Proteins | 2013 |
Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2014 |
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viremia | 2014 |
Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve; Viral Load | 2013 |
Interferon-free hepatitis C treatment: one pill to fit all?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin | 2014 |
Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.
Topics: Adult; Antiviral Agents; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Myxovirus Resistance Proteins; Osteopontin; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2013 |
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Retrospective Studies; Ribavirin; Young Adult | 2014 |
Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2014 |
Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Leukocytes, Mononuclear; Myxovirus Resistance Proteins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin | 2013 |
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Antiviral Agents; Cholestanetriol 26-Monooxygenase; Cytochrome P450 Family 2; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Vitamin D | 2013 |
Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
Topics: Administration, Oral; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2014 |
When do psychiatric side effects emerge during antiviral treatment of hepatitis C?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Referral and Consultation; Retrospective Studies; Ribavirin; Time Factors | 2013 |
Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult | 2013 |
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Topics: Adult; Antiviral Agents; Apoptosis; Caspase 8; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Ribavirin; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors | 2014 |
The dilemma for patients with chronic hepatitis C: treat now or warehouse?
Topics: Antiviral Agents; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors; Watchful Waiting | 2014 |
[Interferon-alpha toxicity and reversible bilateral optical neuropathy: a timely withdrawal of the drug].
Topics: Adult; Evoked Potentials, Visual; Factor VII Deficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Optic Neuritis; Polyethylene Glycols; Postoperative Complications; Reaction Time; Recombinant Proteins; Ribavirin; Vision Disorders | 2014 |
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Topics: Adult; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2014 |
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Limit of Detection; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Virus Replication | 2013 |
Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.
Topics: Adult; Animals; Antimicrobial Cationic Peptides; Antiviral Agents; Epidermal Growth Factor; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Hepcidins; Humans; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Phlebotomy; Renal Insufficiency, Chronic; Ribavirin; Virus Replication | 2014 |
Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2013 |
Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
Topics: Aged; Antiviral Agents; Cohort Studies; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Viral Load | 2013 |
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Metabolism, Inborn Errors; Middle Aged; Pyrophosphatases; Ribavirin; Treatment Outcome | 2013 |
Treatment of decompensated cirrhosis secondary to hepatitis C with antiviral therapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2014 |
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
Topics: Antiviral Agents; Efficiency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Uridine Monophosphate | 2014 |
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Liver Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Risk Factors | 2014 |
Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Weight Loss; Young Adult | 2013 |
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Hepatitis C treatment and alopecia totalis.
Topics: Alopecia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment | 2013 |
[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2013 |
Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Regulatory Factors; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Metallothionein; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation; Viral Load | 2014 |
Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome | 2014 |
Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study.
Topics: Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Inuit; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; White People | 2013 |
Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Japan; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Ribavirin | 2014 |
Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.
Topics: Antiviral Agents; Communication; Depression; Educational Status; Female; Hepatitis C, Chronic; Humans; Insurance, Health; Interferons; Interpersonal Relations; Male; Medication Adherence; Physician-Patient Relations; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Ribavirin; Self Efficacy | 2015 |
Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides | 2014 |
Telaprevir use in a chronic hepatitis C patient with hemophilia.
Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome | 2014 |
Sofosbuvir approved for chronic hepatitis C infection.
Topics: Drug Approval; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Young Adult | 2014 |
Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin | 2014 |
Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin | 2014 |
IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Interleukin-10; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Time for change: conventional interferon regimes should not be the standard of care for management of Pakistani genotype-3 in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Asian People; Body Mass Index; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Treatment Outcome | 2014 |
DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.
Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors | 2014 |
Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".
Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors | 2014 |
Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
Topics: Adult; Antiviral Agents; Base Sequence; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2014 |
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Viral Load; Viremia | 2014 |
Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection.
Topics: Aged; Antiviral Agents; Diagnostic Errors; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; United States; Vietnam; Viral Load | 2014 |
Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
Topics: Adult; Age Factors; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Pruritus; Recombinant Proteins; Ribavirin; Time Factors | 2014 |
Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antiviral Agents; Cell Differentiation; Chemokine CCL17; Chemokine CCL22; Chemokine CCL3; Chemokine CXCL11; Chemokine CXCL9; Hepacivirus; Hepatitis C, Chronic; Interferon-gamma; Interleukin-10; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Ribavirin; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha; Viral Nonstructural Proteins | 2014 |
Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Platelet Count; Polyethylene Glycols; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Remission Induction; Ribavirin | 2014 |
Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Topics: Blotting, Western; Body Mass Index; Cohort Studies; Cytokines; DNA Primers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-2; Interleukin-6; Leukocytes, Mononuclear; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins | 2015 |
[Treatment of infection due to hepatitis C virus in haemodialysis].
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2014 |
[The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients].
Topics: Antiviral Agents; DNA, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Standard of Care | 2013 |
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Treatment of chronic viral hepatitis C in children and adolescents: UK experience.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United Kingdom | 2014 |
Commentary: real-world triple therapy experience treating hepatitis C virus.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin | 2014 |
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin | 2014 |
Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
Topics: Alleles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prospective Studies; Ribavirin; Viral Load; Young Adult | 2015 |
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
Topics: Adult; Antiviral Agents; Decision Support Techniques; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Middle Aged; Models, Statistical; Prognosis; Ribavirin; Risk Assessment; Severity of Illness Index | 2014 |
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2014 |
Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Platelet Count; Receptors, Fc; Recombinant Fusion Proteins; Ribavirin; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2014 |
Hepatitis C genotype 3: a tough match for interferon-free regimens.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate | 2014 |
Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2013 |
Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mutation; Open Reading Frames; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2014 |
3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Esters; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphorus; Ribavirin; Time Factors; Treatment Outcome | 2014 |
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2014 |
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Treatment Outcome | 2014 |
Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Poverty; Recurrence; Retreatment; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Turkey; Viral Load | 2014 |
Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Living Donors; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Young Adult | 2014 |
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
Topics: Anemia; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Economic; Multicenter Studies as Topic; Oligopeptides; Outcome Assessment, Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2014 |
Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
Topics: Adult; Analysis of Variance; Antiviral Agents; Arginine; Cardiovascular Diseases; Chromatography, Liquid; Depression; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Nitric Oxide Synthase; Prospective Studies; Psychiatric Status Rating Scales; Regression Analysis; Ribavirin; Risk Factors; Time Factors | 2014 |
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load | 2014 |
Are statins a viable option for the treatment of infections with the hepatitis C virus?
Topics: Anticholesteremic Agents; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Virus Replication | 2014 |
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Risk Factors; Taiwan | 2014 |
Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glucocorticoids; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Middle Aged; Platelet Count; Polyethylene Glycols; Prednisolone; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2014 |
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Maintenance Chemotherapy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate; Time Factors | 2014 |
[Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; CD4-CD8 Ratio; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Young Adult | 2013 |
Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Diseases; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Survival Rate; Transplant Recipients; Treatment Outcome; Young Adult | 2014 |
Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2014 |
[MUW researcher of the month].
Topics: Austria; Awards and Prizes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; History, 21st Century; HIV Seropositivity; Humans; Interferons; Interleukins; Liver Cirrhosis; Precision Medicine; Ribavirin; Translational Research, Biomedical | 2014 |
Association of interleukin-10 polymorphisms with chronic hepatitis C virus infection in a case-control study and its effect on the response to combined pegylated interferon/ribavirin therapy.
Topics: Adult; Aged; Case-Control Studies; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome | 2015 |
Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Metabolic Syndrome; Pakistan; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2014 |
IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.
Topics: Antiviral Agents; Asian People; Case-Control Studies; Drug Therapy, Combination; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2014 |
Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
Topics: Adult; Aged; Antiviral Agents; Biological Availability; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; Young Adult | 2014 |
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome | 2014 |
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index | 2014 |
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Treatment Outcome | 2014 |
[Treatment of hepatitis C infection. A revolution should not hide another].
Topics: Antiviral Agents; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Risk Reduction Behavior | 2014 |
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Liver Cirrhosis; MicroRNAs; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Statistics, Nonparametric; Viral Load | 2014 |
Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Epistaxis; Esophageal and Gastric Varices; Feasibility Studies; Female; Gastrointestinal Hemorrhage; Gingival Hemorrhage; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia | 2014 |
Reply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools".
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.
Topics: Absorptiometry, Photon; Adult; Antiviral Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Case-Control Studies; Drug Therapy, Combination; Female; Femur Neck; Hepatitis C, Chronic; Humans; Interferon-alpha; Lumbar Vertebrae; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Receptors, Tumor Necrosis Factor, Type I; Recombinant Proteins; Ribavirin; Tumor Necrosis Factor Decoy Receptors; Young Adult | 2014 |
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; United States; Veterans | 2014 |
SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment.
Topics: Case-Control Studies; Female; Follow-Up Studies; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
The interaction of a single-nucleotide polymorphism with age on response to interferon-α and ribavirin therapy in female patients with hepatitis C infection.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2014 |
Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment.
Topics: Adult; Aged; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Indonesia; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2014 |
Letter to the editor.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin | 2014 |
De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.
Topics: Antiviral Agents; Common Variable Immunodeficiency; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Ribavirin; Young Adult | 2014 |
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2014 |
The price of good health.
Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cholesterol; Drug Therapy, Combination; False Positive Reactions; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Hypertriglyceridemia; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load; Viremia | 2015 |
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.
Topics: Adult; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pichia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyper-IgM Immunodeficiency Syndrome; Imidazoles; Immunoglobulin M; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Triple therapy for hepatitis C virus infection in patients receiving hemodialysis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin | 2014 |
Triple therapy for hepatitis C virus infection in patients receiving hemodialysis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin | 2014 |
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Cell Differentiation; Cell Proliferation; Erythroid Cells; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Topics: Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate | 2014 |
The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Triglycerides | 2014 |
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.
Topics: Adult; Aged; Aged, 80 and over; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral | 2014 |
Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium: a sub-analysis of the PROPHESYS study.
Topics: Adult; Aged; Antiviral Agents; Belgium; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C treatment outcome in relation to alcohol consumption and racial differences in southeastern Taiwan.
Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2015 |
Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil; Uridine Monophosphate | 2014 |
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Molecular Epidemiology; Prevalence; Recurrence; Ribavirin; Thailand; Treatment Outcome | 2014 |
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Topics: Adult; Antiviral Agents; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Thailand; Treatment Outcome | 2014 |
Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Male; Middle Aged; Myxovirus Resistance Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Treatment Failure; Tumor Necrosis Factor-alpha; Viral Load | 2014 |
Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Therapy of hepatitis C--back to the future.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Sulfonamides; Valine | 2014 |
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
Hepatitis C treatment in dialysis patients: is a new dawn approaching?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin | 2014 |
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2014 |
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost of Illness; End Stage Liver Disease; England; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Topics: Drug Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Young Adult | 2015 |
Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Skin Diseases; Treatment Outcome; Viral Load; Young Adult | 2014 |
Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment.
Topics: Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Polyethylene Glycols; Ribavirin; Signal Transduction; Treatment Failure | 2014 |
Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin | 2014 |
Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin.
Topics: Antifungal Agents; Antiviral Agents; Cryptococcus neoformans; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2014 |
Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment.
Topics: Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2015 |
Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-23; Leukocytes, Mononuclear; Male; Middle Aged; Receptor, Interferon alpha-beta; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Ribavirin; Serum Albumin | 2014 |
Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2015 |
My treatment approach to chronic hepatitis C virus.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2014 |
Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iran; Leukocytes, Mononuclear; Male; Middle Aged; Minor Histocompatibility Antigens; Polyethylene Glycols; Recombinant Proteins; Repressor Proteins; Ribavirin; Treatment Outcome; Tripartite Motif Proteins; Young Adult | 2014 |
Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?
Topics: Adult; Antiviral Agents; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Medical Tourism; Nephrectomy; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2014 |
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Chemokine CCL4; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-12 Subunit p35; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load; Viral Nonstructural Proteins | 2014 |
HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2014 |
Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Logistic Models; Polymorphism, Single Nucleotide; Receptors, KIR2DL2; Receptors, KIR2DL3; Ribavirin; Treatment Outcome | 2014 |
Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenectomy; Treatment Outcome | 2015 |
KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-B Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Receptors, KIR3DL1; Recombinant Proteins; Ribavirin; Viral Load | 2014 |
Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Ribavirin; Skin Neoplasms; Treatment Outcome | 2014 |
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Renal Insufficiency; Ribavirin | 2014 |
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Biopsy; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load | 2015 |
Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Coinfection; DNA, Viral; Egypt; Female; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2014 |
[Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Topics: Adult; Aged; Antiviral Agents; Cellulitis; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Parotitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sepsis; Staphylococcal Infections; Treatment Outcome; Withholding Treatment | 2015 |
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.
Topics: Adult; Aged; Amino Acids; Animals; Antiviral Agents; Cell Line, Tumor; Dietary Supplements; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Middle Aged; Multiprotein Complexes; Nutritional Status; Proto-Oncogene Proteins c-jun; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transforming Growth Factor beta | 2014 |
HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2014 |
Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Immunologic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Competence; Clinical Protocols; Drug Costs; Drug Discovery; Hepatitis C, Chronic; Humans; Interferons; Prevalence; Ribavirin; Viral Hepatitis Vaccines | 2014 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
[Management of side effects induced by antiviral therapy for chronic hepatitis infection].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hematinics; Hepatitis C, Chronic; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Treatment Outcome | 2013 |
Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin; Viral Load | 2014 |
rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Complement C3; Enzyme-Linked Immunosorbent Assay; Female; Gene Frequency; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Serum; Treatment Outcome; Young Adult | 2015 |
Reply to "Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment".
Topics: Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2015 |
You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin | 2014 |
Trace amounts of sporadically reappearing HCV RNA can cause infection.
Topics: Animals; Antiviral Agents; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Pan troglodytes; Phylogeny; Plasma; Ribavirin; RNA, Viral; T-Lymphocytes; Time Factors; Transfusion Reaction; Viremia | 2014 |
CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.
Topics: Adult; Anti-HIV Agents; Cell Proliferation; Coinfection; Female; Hepatitis A Virus Cellular Receptor 2; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Male; Membrane Proteins; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Outcome | 2014 |
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
Topics: Adult; Antiviral Agents; Base Sequence; Female; Genetic Heterogeneity; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2014 |
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Secondary Prevention; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
Topics: Adult; Alleles; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin | 2014 |
Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Polyethylene Glycols; Receptors, Pattern Recognition; Recombinant Proteins; Ribavirin; Toll-Like Receptors; Virus Replication | 2014 |
Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2014 |
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Female; Fluorescent Antibody Technique, Indirect; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferons; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Young Adult | 2014 |
Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Silybin; Silymarin | 2014 |
Delivery of treatment for hepatitis C virus infection in the primary care setting.
Topics: Adult; Antiviral Agents; Delivery of Health Care; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; New South Wales; Pilot Projects; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Plasma; Proline; Ribavirin; Treatment Failure; Viral Load; Viral Nonstructural Proteins; Young Adult | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Multivariate Analysis; National Health Programs; Polyethylene Glycols; Proline; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2014 |
Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
Topics: Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; PPAR gamma; Retrospective Studies; Ribavirin; RNA, Viral; Time; Treatment Outcome; Viral Load | 2014 |
Impact of antiviral treatment on survival in HCV-positive liver recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Poland; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult | 2014 |
Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Motivation; Patient Education as Topic; Polyethylene Glycols; Prisoners; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Spain; Time Factors; Treatment Outcome; Viral Load | 2014 |
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Topics: Aged; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Proline; Reproducibility of Results; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Can zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 4 infected Egyptian patients?
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult; Zinc | 2014 |
Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors | 2015 |
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Young Adult | 2015 |
Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Point Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2014 |
Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Complement C3; Complement C4; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Polyethylene Glycols; Ribavirin | 2014 |
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Young Adult | 2014 |
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2014 |
Reply: To PMID 23300053.
Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Viral Load | 2015 |
Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.
Topics: Adult; Antiviral Agents; Case-Control Studies; Chromosomes, Human, Pair 19; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2015 |
Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2014 |
Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors | 2015 |
IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome | 2014 |
[Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed | 2014 |
The role of IL-28, IFN-γ, and TNF-α in predicting response to pegylated interferon/ribavirin in chronic HCV patients.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Interferon-gamma; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kinetics; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Lung Diseases, Interstitial; Middle Aged; Remission Induction; Ribavirin | 2014 |
PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Vasculitis | 2015 |
Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy?
Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
Topics: Anilides; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2014 |
Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms.
Topics: Adenine Nucleotides; Algorithms; Antiviral Agents; Artificial Intelligence; Chi-Square Distribution; Computational Biology; Cytosine Nucleotides; Decision Support Techniques; Decision Trees; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine Nucleotides; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrogen; Interferons; Nucleotides; Oxygen; Patient Selection; Ribavirin; Treatment Outcome; Uracil Nucleotides | 2014 |
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.
Topics: Alanine Transaminase; Antiviral Agents; Cell Line; Cell Survival; Cohort Studies; Drug Therapy, Combination; Enzyme Activation; Fluoxetine; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; JNK Mitogen-Activated Protein Kinases; Microbial Sensitivity Tests; Polyethylene Glycols; PPAR gamma; PPAR-beta; Reactive Oxygen Species; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; STAT1 Transcription Factor | 2014 |
Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.
Topics: Age Factors; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load | 2014 |
Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection.
Topics: Amino Acid Substitution; Amino Acids; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Viral Core Proteins; White People | 2014 |
[Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Sarcoidosis on the injection sites following treatment of interferon-alpha and ribavirin for hepatitis C.
Topics: Aged; Antiviral Agents; Hepatitis C, Chronic; Humans; Injections; Interferon-alpha; Male; Ribavirin; Sarcoidosis; Sarcoidosis, Pulmonary; Skin Diseases | 2014 |
Treatment of hepatitis C with the earliest protease inhibitor-based therapy.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Ribavirin | 2014 |
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
A case of chronic hepatitis C patient of myocardial ischemia accompanied with interstitial pneumonia induced by pegylated interferon alpha-2a.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Myocardial Ischemia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population.
Topics: Adolescent; Adult; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Osteopontin; Pakistan; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult | 2014 |
[Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Open Reading Frames; Ribavirin; Treatment Outcome | 2014 |
[Cases of hepatitis C virus infection with 2i/2a recombination genotype in the Lanzhou area and effects of related genetic variations on interferon alpha response].
Topics: Angiogenesis Inhibitors; Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Open Reading Frames; Polyethylene Glycols; Recombinant Proteins; Recombination, Genetic; Ribavirin; Treatment Outcome | 2014 |
Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment.
Topics: Adult; Antiviral Agents; Cells, Cultured; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Young Adult | 2015 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis.
Topics: Anilides; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin | 2015 |
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Coinfection; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
Topics: Adult; Alleles; Antiviral Agents; Down-Regulation; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2014 |
Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2014 |
Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Uridine Monophosphate | 2014 |
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Protective Factors; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-27; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-α and ribavirin in chronic hepatitis C virus genotype 1 infection.
Topics: Alleles; Antiviral Agents; Female; Hepatitis C, Chronic; HLA-C Antigens; Homozygote; Humans; Interferon-alpha; Male; Polymorphism, Single Nucleotide; Ribavirin | 2015 |
Long-term growth outcomes in children treated for chronic hepatitis C.
Topics: Antiviral Agents; Body Height; Child; Female; Follow-Up Studies; Growth; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome | 2014 |
Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.
Topics: Antiviral Agents; Comorbidity; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Incidence; Insurance, Health; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin | 2014 |
[Thyrotoxicosis induced by interferonotherapy of chronic hepatitis C in a woman with Hashimoto's thyroiditis].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Thyrotoxicosis | 2014 |
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
Topics: Autophagy; Biological Transport; Biopsy; Cells, Cultured; Down-Regulation; Endoplasmic Reticulum Stress; Ethanol; Fatty Acids, Nonesterified; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Liver; Liver Cirrhosis; Receptor, Interferon alpha-beta; Receptors, Interferon; Ribavirin; Virus Replication | 2014 |
[A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin].
Topics: Acute Disease; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin; Young Adult | 2014 |
High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2015 |
IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Case-Control Studies; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2015 |
Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment.
Topics: Adult; Affect; Antiviral Agents; Cognition; Depression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Psychological Tests; Recombinant Proteins; Ribavirin; Viral Load | 2014 |
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Development of biodegradable nanoparticles for liver-specific ribavirin delivery.
Topics: Animals; Antiviral Agents; Biocompatible Materials; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Female; Galactans; Hep G2 Cells; Hepatitis C, Chronic; Humans; Lactic Acid; Liver; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polylysine; Polymers; Ribavirin | 2014 |
Nursing support increases the efficacy of interferon therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nurses, Community Health; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2014 |
Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Topics: Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Time Factors; Transplant Recipients; Treatment Outcome | 2015 |
Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Polymorphism, Genetic; Pyrophosphatases; Recurrence; Ribavirin | 2014 |
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Lipid Metabolism; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
Topics: Acute Disease; Allografts; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Middle Aged; Nephrectomy; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Renal Insufficiency, Chronic; Reoperation; Ribavirin; Risk Factors; Therapeutics; Time Factors | 2014 |
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Topics: Anemia; Antiviral Agents; Bilirubin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neutropenia; Prevalence; Pruritus; Ribavirin; Simeprevir | 2015 |
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Recurrence; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load | 2015 |
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antiviral Agents; Body Mass Index; Coinfection; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; Odds Ratio; Polymorphism, Single Nucleotide; Proteins; Ribavirin | 2014 |
Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; DNA; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptors, Interferon; Ribavirin; Viral Load; Young Adult | 2014 |
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
Topics: Acute Kidney Injury; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2015 |
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2015 |
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Topics: Antiviral Agents; Drug Monitoring; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Proline; Recombinant Proteins; Ribavirin; Signal Transduction; Treatment Outcome | 2014 |
[Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].
Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Polymorphisms of Toll-like receptors 2 and 4 in chronically infected hepatitis C patients from north-east Croatia.
Topics: Adult; Aged; Antiviral Agents; Croatia; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; RNA, Viral; Toll-Like Receptor 2; Toll-Like Receptor 4; Viral Load; Young Adult | 2015 |
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States; Veterans | 2015 |
Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Remission Induction; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Waiting Lists | 2015 |
Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?
Topics: Antiviral Agents; Continuity of Patient Care; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Eruptions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2014 |
Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
Topics: Adult; Aged; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index | 2015 |
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2014 |
[Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Methylprednisolone; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2015 |
A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Risk Factors; Taiwan; Young Adult | 2015 |
Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Chemokine CCL4; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2015 |
New kids on the block--step by step to an ideal HCV therapy.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides | 2015 |
Controlling hepatitis C with simeprevir.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides | 2015 |
Tuberculous peritonitis during pegylated interferon plus ribavirin combination therapy in a patient with chronic hepatitis C.
Topics: Aged; Antitubercular Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferons; Multimodal Imaging; Peritonitis, Tuberculous; Positron-Emission Tomography; Ribavirin; Tomography, X-Ray Computed | 2014 |
[Investigation of the association between paraoxonase-1 gene polymorphisms and response to therapy in chronic hepatitis C patients].
Topics: Adult; Aged; Antiviral Agents; Aryldialkylphosphatase; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
[Research of relationship between antiviral efficacy on chronic hepatitis C and the application time and dose of ribavirin].
Topics: Antiviral Agents; Female; Genotype; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.
Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Models, Economic; Oligopeptides; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Severity of Illness Index | 2014 |
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2015 |
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans | 2015 |
Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
[Ways of improving adherence on telaprevir-based therapy in patients with chronic HCV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Oligopeptides; Ribavirin | 2014 |
Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cohort Studies; Coinfection; Databases, Factual; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Taiwan; Tuberculosis; Young Adult | 2014 |
Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2015 |
[Is more expensive always better?].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2014 |
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Proline; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Study of pruritus in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Chemokine CCL17; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Pruritus; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment.
Topics: Antiviral Agents; Biomarkers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Turkey; Viral Load | 2014 |
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome | 2015 |
[Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
Topics: Antiviral Agents; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database.
Topics: Adolescent; Combined Modality Therapy; Databases, Factual; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Psychotherapy; Recombinant Proteins; Ribavirin; Self Report; Surveys and Questionnaires; Young Adult | 2015 |
Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Pulmonary; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Ribavirin | 2014 |
A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Models, Economic; Models, Theoretical; Practice Guidelines as Topic; Precision Medicine; Quality-Adjusted Life Years; Ribavirin | 2015 |
Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Uridine Monophosphate | 2015 |
Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Cost-effectiveness of screening for hepatitis C in Canada.
Topics: Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mass Screening; Middle Aged; Quality-Adjusted Life Years; Ribavirin | 2015 |
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin | 2015 |
Shorter treatments for hepatitis C: another step forward?
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2015 |
Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
Topics: Adult; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Severe cutaneous adverse reaction to telaprevir.
Topics: Anti-Inflammatory Agents; Clobetasol; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Middle Aged; Oligopeptides; Ribavirin; Stevens-Johnson Syndrome | 2015 |
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Lung Diseases, Interstitial; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load | 2015 |
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Male; Middle Aged; Mutation; Oligopeptides; Protease Inhibitors; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2015 |
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Ribavirin; Treatment Outcome | 2015 |
Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Topics: Antibodies, Neutralizing; Cohort Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Ribavirin; Treatment Outcome | 2015 |
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Diagnostic Techniques; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Plasma; Proline; Prospective Studies; Ribavirin; Treatment Failure | 2015 |
PHOTON-2: hope for patients with HIV and HCV co-infection?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients.
Topics: Adult; Cohort Studies; Female; Gene Frequency; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Linkage Disequilibrium; Logistic Models; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2015 |
The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection.
Topics: Adult; Alleles; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HLA-A Antigens; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Delayed hypersensitivity to ribavirin confirmed by provocation test.
Topics: Antiviral Agents; Drug Hypersensitivity; Female; Hepatitis C, Chronic; Humans; Hypersensitivity, Delayed; Middle Aged; Ribavirin | 2014 |
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Complications; Female; Follow-Up Studies; Forecasting; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors | 2015 |
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Topics: Adult; Aging; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Retreatment with peginterferon and ribavirin in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load; Virus Activation | 2015 |
Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
End-of-Treatment-Response in patients treated for hepatitis C virus with standard interferon and ribavirin based on viral load.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2015 |
Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2015 |
The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients.
Topics: Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2015 |
[Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia; Simeprevir; Sulfonamides | 2014 |
[Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience].
Topics: Acupuncture Therapy; Adult; Aged; Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Tattooing | 2015 |
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyponatremia; Interferon-alpha; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2015 |
Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Pyrophosphatases; Ribavirin; Thrombocytopenia; Treatment Outcome | 2015 |
[A new era in therapy of chronic hepatitis C].
Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
[New combination therapy increases chances of recovery].
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.
Topics: Benzazepines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Interferon-alpha; Isoquinolines; Male; Polyethylene Glycols; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides | 2015 |
Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Topics: Aged; Antiviral Agents; Chemokine CXCL10; Chemokine CXCL11; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2015 |
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Models, Econometric; Phenotype; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir | 2015 |
[Development of antiviral treatments for chronic hepatitis C].
Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2015 |
[Pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Ribavirin | 2015 |
[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides | 2015 |
[Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
[Natural human IFNβ and ribavirin combination therapy].
Topics: Aged; Depression; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-beta; Ribavirin; Thrombocytopenia | 2015 |
TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Toll-Like Receptor 3 | 2015 |
Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Blood Chemical Analysis; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
Topics: Adult; Alleles; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genome-Wide Association Study; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Evaluation of the frequency of the IL-28 polymorphism (rs8099917) in patients with chronic hepatitis C using Zip nucleic acid probes, Kerman, Southeast of Iran.
Topics: Adult; Alanine Transaminase; Anaplastic Lymphoma Kinase; Antibodies, Viral; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Iran; Male; Middle Aged; Nucleic Acid Probes; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2015 |
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Sex Factors; Thrombocytopenia; Treatment Outcome | 2015 |
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
Topics: Age Factors; Aged; Anemia; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyrophosphatases; Retrospective Studies; Ribavirin; Risk; Severity of Illness Index; Simeprevir; Viral Nonstructural Proteins | 2015 |
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; United States; Uridine Monophosphate; Young Adult | 2015 |
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients.
Topics: Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Spain; Tertiary Care Centers | 2015 |
Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Topics: Acute-Phase Proteins; Adult; Anti-HIV Agents; Aspartate Aminotransferases; Biomarkers; Carrier Proteins; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Kinetics; Lipopolysaccharide Receptors; Lipopolysaccharides; Male; Membrane Glycoproteins; Middle Aged; Retrospective Studies; Ribavirin; Solubility; Time Factors; Treatment Outcome | 2015 |
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.
Topics: Adult; Age Factors; Antiviral Agents; Diabetes Mellitus, Type 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome | 2015 |
Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Leukocyte Count; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Splenectomy; Survival Rate; Thrombocytopenia; Viral Load | 2015 |
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2015 |
Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Case-Control Studies; Female; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Logistic Models; Male; MicroRNAs; Polyethylene Glycols; Precision Medicine; Prognosis; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2015 |
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Topics: Antiviral Agents; Blotting, Western; Cation Transport Proteins; Chromatography, Liquid; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors; Treatment Outcome | 2015 |
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Oligopeptides; Phylogeny; Protease Inhibitors; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2015 |
High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Hepatic progenitor cells in children with chronic hepatitis C: correlation with histopathology, viremia, and treatment response.
Topics: Adolescent; Antiviral Agents; Cell Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Stem Cells; Treatment Outcome; Viral Load | 2015 |
Face skin hyperpigmentation during pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Biopsy; Drug Combinations; Drug Therapy, Combination; Face; Hepatitis C, Chronic; Humans; Hyperpigmentation; Injections, Subcutaneous; Interferon-alpha; Male; Melanocytes; Middle Aged; Ribavirin; Skin; Treatment Outcome | 2015 |
[Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
Topics: Anemia, Aplastic; Anti-Bacterial Agents; Antiviral Agents; Blood Component Transfusion; Drug Therapy, Combination; Filgrastim; Folic Acid; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisone; Ribavirin; Viremia; Vitamin B 12 | 2015 |
Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Male; Middle Aged; Military Medicine; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; United States; Veterans | 2015 |
Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Taiwan | 2015 |
Towards interferon-free treatment for all HCV genotypes.
Topics: Anilides; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir | 2015 |
IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Regulation; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Intracellular Signaling Peptides and Proteins; Liver; Male; MicroRNAs; Middle Aged; Ribavirin; Young Adult | 2015 |
Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thrombocytopenia; Withholding Treatment | 2015 |
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.
Topics: Cohort Studies; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Transcription, Genetic; Treatment Outcome | 2015 |
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients.
Topics: Antiviral Agents; Area Under Curve; Asian People; Biomarkers; Chi-Square Distribution; China; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10 Receptor beta Subunit; Interleukins; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myxovirus Resistance Proteins; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Cytokine; Receptors, Interferon; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load | 2015 |
Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Turkey | 2015 |
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Middle Aged; Pyrrolidines; Ribavirin; Treatment Failure; Valine; Viral Load; Viral Nonstructural Proteins | 2015 |
CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population.
Topics: Adult; Antiviral Agents; CD24 Antigen; China; Drug Combinations; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Therapeutics; Transcriptome | 2015 |
Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Neutropenia; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir | 2015 |
Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load | 2015 |
Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Markov Chains; Patient Acceptance of Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Severity of Illness Index; Sofosbuvir | 2015 |
Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Outcome | 2015 |
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Treatment Failure | 2015 |
Therapy: Retreatment of HCV infection in DAA nonresponders.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Uridine Monophosphate | 2015 |
Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C".
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Vitamin D | 2015 |
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Outcome Assessment, Health Care; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Simeprevir; State Medicine; United Kingdom | 2015 |
Evidence supporting a beneficial role of vitamin D in chronic hepatitis C.
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Vitamin D | 2015 |
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Spain; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; London; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2015 |
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2015 |
Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients.
Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Iran; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
Topics: Aged; Anemia, Aplastic; Antiviral Agents; Biopsy; Bone Marrow Examination; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Pancytopenia; Polyethylene Glycols; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome | 2015 |
Mannose-binding lectin in chronic hepatitis C in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Viral; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Metabolism, Inborn Errors; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; United Kingdom | 2015 |
The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Female; Genetic Association Studies; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Morocco; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2015 |
Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
Topics: Aged; Anemia; Antiviral Agents; Erythrocyte Transfusion; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Middle Aged; Mycophenolic Acid; Recurrence; Ribavirin; Simeprevir; Tacrolimus | 2015 |
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Protease Inhibitors; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.
Topics: Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lymphocytes; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Treatment Outcome | 2015 |
Hepatitis C in Arkansas: updates on epidemiology, testing and treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arkansas; Cross-Sectional Studies; Drug Costs; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult | 2015 |
Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antiviral Agents; Cohort Studies; Depressive Disorder, Major; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Norepinephrine; Prospective Studies; Ribavirin; Selective Serotonin Reuptake Inhibitors; Young Adult | 2016 |
IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Ribavirin; ROC Curve; Treatment Outcome; Viral Load; Young Adult | 2015 |
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Topics: Antiviral Agents; Clinical Decision-Making; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Spain; Treatment Outcome; Viral Load; Viremia | 2015 |
Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Kidney; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Valine; Viral Load; Viremia | 2015 |
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Tertiary Care Centers; Treatment Outcome; Viral Load | 2015 |
Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load | 2015 |
The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin | 2015 |
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Ribavirin | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Greece; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Markov Chains; Models, Econometric; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2015 |
The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
Topics: Adult; Antiviral Agents; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2015 |
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Withholding Treatment | 2015 |
Leg ulcer as a manifestation of eosinophilic vasculitis in a patient with hepatitis C virus infection, medicated with pegylated interferon/ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eosinophilia; Hepatitis C, Chronic; Humans; Interferon-alpha; Leg Ulcer; Male; Ribavirin; Vasculitis | 2015 |
Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response.
Topics: Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA Stability; RNA, Viral; Time Factors; Treatment Outcome | 2015 |
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult | 2015 |
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Topics: Aged; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Japan; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
Topics: Antiviral Agents; Blotting, Western; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epigenomics; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Histone-Lysine N-Methyltransferase; Humans; Immunoprecipitation; Interferon-alpha; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Transfection; Viral Load; Virus Replication | 2016 |
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Healthcare Disparities; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Viral Load | 2015 |
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2015 |
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Propensity Score; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome | 2015 |
Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Toll-Like Receptor 4; Treatment Outcome; Young Adult | 2015 |
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Topics: Adult; Antiviral Agents; Australia; Canada; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load | 2015 |
Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Time Factors | 2015 |
Optimum predictors of therapeutic outcome in HCV patients in Pakistan.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Prognosis; Ribavirin; Treatment Outcome | 2016 |
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome | 2016 |
Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Pyrophosphatases; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2015 |
Disease burden of chronic hepatitis C among immigrants in Canada.
Topics: Antiviral Agents; Canada; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Therapy, Combination; Emigrants and Immigrants; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Markov Chains; Models, Theoretical; Polyethylene Glycols; Quality-Adjusted Life Years; Retrospective Studies; Ribavirin | 2015 |
PharmGKB summary: peginterferon-α pathway.
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States | 2015 |
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Spain; Thrombocytopenia; Treatment Outcome; Viral Load | 2015 |
Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort.
Topics: Adult; Aged; Antidepressive Agents; Antiviral Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Performance; Ribavirin | 2015 |
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
Topics: Adult; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2016 |
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams; Male; Polyethylene Glycols; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides | 2015 |
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors | 2015 |
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dendritic Cells; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome | 2015 |
Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Brazil; Case-Control Studies; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2015 |
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin; Spain; Treatment Outcome | 2015 |
Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Renal Dialysis; Ribavirin; Viral Load | 2015 |
Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
Topics: Antiviral Agents; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2015 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
Sleep disturbances in hepatitis C patients undergoing treatment: minisleep questionnaire as a screening tool.
Topics: Antiviral Agents; Case-Control Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sleep Wake Disorders; Surveys and Questionnaires | 2015 |
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?
Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People | 2016 |
Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; United States; United States Department of Veterans Affairs; Veterans | 2015 |
Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.
Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
Topics: Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Severity of Illness Index; Simeprevir | 2014 |
Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C.
Topics: Adult; Biomarkers, Pharmacological; Female; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Immunity, Innate; Immunotherapy; Interferon-alpha; Killer Cells, Natural; Liver; Male; Middle Aged; Mutation; Polymorphism, Genetic; Receptors, KIR; Ribavirin | 2016 |
The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.
Topics: Aged; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sensitivity and Specificity; Viral Core Proteins | 2015 |
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome | 2015 |
Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome; Tunisia; Viral Load | 2015 |
Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Republic of Korea; Ribavirin; Young Adult | 2016 |
[Evaluation of tolerance and efficacy of the treatment of chronic viral hepatitis C in homozygous sickle cell patients].
Topics: Adult; Anemia, Sickle Cell; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Treatment Outcome | 2015 |
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate | 2015 |
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Topics: Antiviral Agents; Asia; Asian People; Australia; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proline; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load; White People | 2015 |
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate | 2015 |
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine | 2015 |
Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
Topics: Antiviral Agents; Biomarkers; Carbamates; Cell Line, Tumor; Dendritic Cells; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Isoquinolines; Liver Transplantation; Prednisolone; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Renal Insufficiency, Chronic; Ribavirin; Risk Factors; Taiwan | 2015 |
HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients.
Topics: Adult; Antiviral Agents; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; Transcription, Genetic; Tumor Suppressor Protein p53; Young Adult | 2015 |
Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Mental Disorders; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Sex Factors | 2015 |
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides | 2015 |
Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2016 |
Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Personality Disorders; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Young Adult | 2015 |
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.
Topics: Antiviral Agents; Biomarkers; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Models, Statistical; Nonlinear Dynamics; Oligopeptides; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2015 |
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir | 2015 |
The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Inverse Agonism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response | 2015 |
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Young Adult | 2015 |
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain | 2015 |
An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Simeprevir; Treatment Outcome | 2015 |
Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Case-Control Studies; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Texas; Time Factors; Treatment Outcome | 2016 |
Interferon-free treatments against HCV are far from free.
Topics: Anilides; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir | 2015 |
Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Signal Transduction; Thailand; Treatment Outcome | 2015 |
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Opiate Substitution Treatment; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2015 |
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2016 |
Pharmacokinetics in hepatic impairment: Mind the protein binding.
Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2015 |
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin; Risk Factors | 2016 |
Reply to "Pharmacokinetics in hepatic impairment: Mind the protein binding".
Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2015 |
Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
Topics: Adult; Antiviral Agents; Asian People; Autoantibodies; Autoantigens; Biomarkers; Chemokine CXCL10; China; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Thyroid Diseases; Thyroid Gland; Time Factors; Treatment Outcome | 2015 |
Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood; Flow Cytometry; Hepatitis C, Chronic; Humans; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Liver; Longitudinal Studies; Middle Aged; Oligopeptides; Ribavirin; Young Adult | 2015 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Futility; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome | 2015 |
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin | 2016 |
Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2015 |
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Carriers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Oligopeptides; Patient Acuity; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.
Topics: Adult; Age Factors; Aged; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Recurrence; Ribavirin; Sequence Deletion; Viral Envelope Proteins; Viral Load; Viral Proteins | 2015 |
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2016 |
Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Germany; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
[Kinetics of Virus Load HCV-RNA in Blood Serum and Peripheral Mononuclear Cells in a Patient with Hepatocirrhosis and Chronic Virus Hepatitis C Termination Treated According to Noninterferon Treatment Scheme (Cycloferon + Ribavirin)].
Topics: Acridines; Antiviral Agents; Contraindications; Drug Substitution; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Viral Load | 2015 |
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
Topics: Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Biopsy; Child; Child, Preschool; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Iatrogenic Disease; Incidence; Infant; Interferon-alpha; Liver; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Topics: Adult; Aged; Ambulatory Care; Antiviral Agents; Community Health Centers; Delivery of Health Care; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; New South Wales; Opiate Substitution Treatment; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Treatment Outcome | 2016 |
[Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Military Medicine; Military Personnel; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjuste
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir | 2016 |
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2016 |
Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.
Topics: Aged; Aged, 80 and over; Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Male; Medically Underserved Area; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2016 |
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
[HCV Genotype Distribution in Southwest China and Its Influence on Patients' Response to Pegylated-interferon α-2a Plus Ribavirin Therapy].
Topics: Antiviral Agents; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report.
Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Male; Middle Aged; Remission Induction; Ribavirin | 2015 |
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Transplant Recipients; Transplantation, Homologous; Viral Load; Virus Replication | 2016 |
ROLE OF T REGULATORY CELLS IN CHRONIC HCV INFECTED EGYPTIAN PATIENTS AND THEIR IMPACT ON THE RESPONSE TO PEGYLATED INTERFERON THERAPY.
Topics: Antiviral Agents; Forkhead Transcription Factors; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory | 2015 |
Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Load | 2015 |
Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
Topics: Adult; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Genetic; Receptors, LDL; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome | 2015 |
Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
Topics: Adult; Antiviral Agents; Chemokine CXCL12; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Reply to Merli et al.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphopenia; Ribavirin | 2016 |
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphopenia; Ribavirin | 2016 |
Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Delivery of Health Care; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Diseases; Male; Middle Aged; Patient Acceptance of Health Care; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2016 |
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult | 2015 |
Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Monitoring; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Viral Load | 2015 |
[Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Uridine Monophosphate | 2015 |
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
Topics: Antiviral Agents; Carbamates; Chile; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Probability; Protease Inhibitors; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Thyroid Diseases; Thyroid Gland; Time Factors; Treatment Outcome | 2015 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load | 2015 |
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2016 |
Glucose abnormalities in Asian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome | 2015 |
Genetic predictors of the response to the treatment of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viremia | 2015 |
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States | 2016 |
Ribavirin Desensitization in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Desensitization, Immunologic; Drug Hypersensitivity; Female; Hepatitis C, Chronic; Humans; Ribavirin | 2015 |
Hepatitis C treatment at three Norwegian hospitals 2000-2011.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Norway; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2015 |
A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients.
Topics: Aged; Asian People; Biomarkers, Pharmacological; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2016 |
[Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin].
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Galectin 3; Glycosylation; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Protein Binding; Ribavirin | 2015 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Intraocular pressure rise in the course of peginterferon alpha-2a, ribavirin, and boceprevir therapy for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Gonioscopy; Hepatitis C, Chronic; Humans; Interferon-alpha; Intraocular Pressure; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Tonometry, Ocular; Viral Load; Visual Fields | 2015 |
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
Topics: Acidosis, Lactic; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.
Topics: Antiviral Agents; Coinfection; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin | 2016 |
High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Topics: Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Monocytes; Neoplasm Staging; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Time Factors | 2016 |
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; South Africa; Uridine Monophosphate | 2016 |
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Blood; China; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Selection, Genetic; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult | 2015 |
A local experience of treatment response in chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Body Mass Index; Developing Countries; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2016 |
Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HLA Antigens; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Ribavirin; RNA, Viral; Sequence Analysis, Protein; South Africa; Viral Core Proteins; Viral Nonstructural Proteins | 2016 |
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome | 2016 |
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Macrophages; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Staining and Labeling | 2016 |
Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression.
Topics: Adult; Antiviral Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Depression; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Receptor, Serotonin, 5-HT1A; Receptors, Glucocorticoid; Ribavirin; Tacrolimus Binding Proteins; Treatment Outcome; White People | 2016 |
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2016 |
Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C.
Topics: Antiviral Agents; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2016 |
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Pyrrolidines; Retreatment; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Sulfonamides; Sustained Virologic Response; TNF-Related Apoptosis-Inducing Ligand; Valine; Viral Load | 2017 |
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin; Treatment Outcome | 2016 |
Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
Topics: Adult; Aged; Ambulatory Care Facilities; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; Treatment Outcome; United States | 2016 |
Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
Topics: Aged; Antiviral Agents; Community Health Services; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.
Topics: Adult; Anion Transport Proteins; Antiporters; Antiviral Agents; China; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kruppel-Like Transcription Factors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Variants; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Thrombocytopenia; Time Factors; Treatment Outcome | 2016 |
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
[Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin; Skin Diseases | 2016 |
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2015 |
Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Janus Kinases; Leukocytes, Mononuclear; Logistic Models; Male; Middle Aged; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Taiwan; Up-Regulation | 2016 |
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
Topics: Adult; Antiviral Agents; Asian People; China; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2016 |
Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013.
Topics: Adolescent; Antiviral Agents; Asian People; Child; Child Health Services; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Medical Records; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome | 2016 |
IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Coinfection; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukin-15; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Viral Load | 2016 |
[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
Topics: Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
[Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].
Topics: Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2015 |
[Telaprevir, peginterferon and ribavirin therapy for chronic hepatitis C].
Topics: Anemia; Drug Combinations; Hepatitis C, Chronic; Humans; Interferons; Kidney Function Tests; Oligopeptides; Ribavirin | 2015 |
[A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection].
Topics: Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Ribavirin; Simeprevir | 2015 |
[Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].
Topics: Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Indoles; Interferons; Isoindoles; Lactams, Macrocyclic; Leucine; Proline; Ribavirin; Sulfonamides | 2015 |
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load; Young Adult | 2016 |
The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia.
Topics: Adult; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Serbia; Treatment Outcome; Viral Proteins | 2016 |
Statins can exert dual, concentration dependent effects on HCV entry in vitro.
Topics: Claudin-1; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Membrane Proteins; Membrane Transport Proteins; Polyethylene Glycols; Pravastatin; Receptors, LDL; Ribavirin | 2016 |
Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.
Topics: Adolescent; Adult; Antiviral Agents; Cytosol; Dideoxynucleosides; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Plasma; Prospective Studies; Ribavirin; Time Factors; Young Adult | 2016 |
Dynamic changes in CD45RA(-)Foxp3(high) regulatory T-cells in chronic hepatitis C patients during antiviral therapy.
Topics: Adult; Antiviral Agents; Female; Forkhead Transcription Factors; Hepatitis C, Chronic; Humans; Immunophenotyping; Interferon-alpha; Leukocyte Common Antigens; Male; Middle Aged; Ribavirin; T-Lymphocytes, Regulatory | 2016 |
Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Egypt; Female; Genetic Association Studies; Genotyping Techniques; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Thrombocytopenia; Young Adult | 2016 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Failure; Valine; Viral Load | 2016 |
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Viral Load | 2016 |
Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.
Topics: Adult; Alleles; Antiviral Agents; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.
Topics: 2',5'-Oligoadenylate Synthetase; Adenosine Deaminase; Adult; Alleles; Antiviral Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptors, Calcitriol; Ribavirin; RNA-Binding Proteins; Treatment Outcome; Viral Load; Vitamin D | 2016 |
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans | 2016 |
Chronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino Veterans.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Seroepidemiologic Studies; Treatment Outcome; Veterans | 2016 |
Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin | 2016 |
Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug--authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin | 2016 |
Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.
Topics: Anemia; Antiviral Agents; Computer Simulation; Dose-Response Relationship, Drug; Erythrocytes; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Models, Biological; Pyrophosphatases; Ribavirin | 2016 |
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Renal Dialysis; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-gamma; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Treatment Failure; Viral Load | 2016 |
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.
Topics: Adult; Antiviral Agents; Brazil; Female; Genome-Wide Association Study; Haplotypes; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Platelet Count; Receptors, KIR; Ribavirin; Thrombocytopenia | 2017 |
Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2016 |
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Simeprevir; Sustained Virologic Response; Treatment Outcome | 2016 |
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Theoretical; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Young Adult | 2016 |
Non-sustained ventricular tachycardia during treatment of genotype 3 chronic hepatitis C - a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Tachycardia, Ventricular | 2016 |
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
Topics: Adult; Antiviral Agents; beta-Thalassemia; Drug Therapy, Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2016 |
[EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].
Topics: Adult; Alkaline Phosphatase; Bilirubin; Female; gamma-Glutamyltransferase; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ursodeoxycholic Acid | 2015 |
No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2016 |
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry.
Topics: Aged; Antiviral Agents; Asian People; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Routes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
Topics: Adult; Aged; Alaska; Alaskan Natives; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Indians, North American; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome | 2016 |
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply.
Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2016 |
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir?
Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2016 |
Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
Topics: Antiviral Agents; Attitude of Health Personnel; China; Clinical Competence; Drug Therapy, Combination; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferons; Patient Education as Topic; Polyethylene Glycols; Practice Patterns, Physicians'; Ribavirin; Standard of Care; Treatment Outcome | 2016 |
Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
Topics: Amylases; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipase; Middle Aged; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Tomography, X-Ray Computed | 2016 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Topics: 2-Naphthylamine; Anilides; Antacids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Treatment of Dual Genotype Chronic Hepatitis C: Case Series.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome | 2016 |
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
Topics: Anemia, Hemolytic; Antiviral Agents; Bacteremia; Blood Component Transfusion; Catheter-Related Infections; Drug Therapy, Combination; Glomerulonephritis; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Renal Dialysis; Ribavirin; Staphylococcal Infections; Thrombocytopenia | 2017 |
Healing livers, saving lives: Hepatitis C screening in an era of cure.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2016 |
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Proportional Hazards Models; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Ultrasonography | 2016 |
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2016 |
[Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Sustained Virologic Response; Tandem Mass Spectrometry; Treatment Outcome; Viral Load | 2016 |
[Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Topics: Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunotherapy; Interferon-alpha; Male; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Standard of Care; Sustained Virologic Response; Treatment Outcome; Viral Load | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; CTLA-4 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load | 2016 |
Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37.
Topics: Adult; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; HLA-G Antigens; Humans; Interferon-alpha; Interleukin-1; Male; Ribavirin; Solubility; Treatment Outcome | 2016 |
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sustained Virologic Response; Time | 2016 |
A New Treatment for Chronic Hepatitis C.
Topics: Antiviral Agents; Benzofurans; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin | 2016 |
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Remission Induction; Retrospective Studies; Ribavirin; ROC Curve; Severity of Illness Index; Sustained Virologic Response; Time Factors; Treatment Outcome | 2016 |
Molecular assessment of vitamin D receptor polymorphism as a valid predictor to the response of interferon/ribavirin-based therapy in Egyptian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Combinations; Female; Gene Frequency; Haplotypes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Ribavirin; Sustained Virologic Response; Vitamin D; Young Adult | 2016 |
Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Young Adult | 2016 |
The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bosnia and Herzegovina; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Personality Inventory; Prospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Sex Distribution; Young Adult | 2016 |
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin | 2016 |
[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2016 |
[Autoimmune hepatitis and membranous glomerulonephritis under immune therapy in chronic hepatitis C].
Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2016 |
Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Fatigue; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Linear Models; Male; Middle Aged; Multivariate Analysis; Recovery of Function; Ribavirin; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Viral Load | 2016 |
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxychloroquine; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Unmasking of myasthenia gravis during pegylated Alfa 2 a interferon and ribavirin therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Myasthenia Gravis; Ribavirin | 2016 |
COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Ethiopia; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Treatment Outcome | 2016 |
Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
Topics: Abdomen; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Panniculitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin; Ultrasonography | 2016 |
[THE USE OF COMBINATION ANTIVIRAL THERAPY IN LIVER CIRRHOSIS HCV ETIOLOGY].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2015 |
Impact of TGF-β1 Gene Polymorphism (rs1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C.
Topics: Adult; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Polymorphism, Single Nucleotide; Ribavirin; Transforming Growth Factor beta1 | 2016 |
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure | 2016 |
Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Myasthenia Gravis; Polyethylene Glycols; Respiration, Artificial; Ribavirin; Thymoma; Thymus Neoplasms | 2016 |
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
[Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2].
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Treatment Failure | 2016 |
Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Tertiary Care Centers | 2016 |
Resurrection of response-guided therapy for sofosbuvir combination therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2016 |
Therapy: HCV drugs reduce transplantation need.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Ribavirin | 2016 |
IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2016 |
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2016 |
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
Topics: Adolescent; Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antiviral Agents; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; Humans; Immunophenotyping; Interferon-alpha; Lymphocyte Activation; Male; Membrane Glycoproteins; Middle Aged; Protease Inhibitors; Ribavirin; Serum; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Young Adult | 2016 |
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Topics: Aged; Antiviral Agents; Colitis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2016 |
Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; Thyroid Diseases; Thyroid Function Tests; Treatment Outcome; Viral Load; Young Adult | 2016 |
Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatitis E; Hepatitis, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Raynaud's phenomenon and bilateral olecranon bursitis co-existing in a patient with chronic hepatitis B and D treated with pegylated interferon.
Topics: Antiviral Agents; Bursitis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D; Humans; Interferon-alpha; Olecranon Process; Raynaud Disease; Recombinant Proteins; Ribavirin | 2016 |
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2017 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.
Topics: Adult; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Pharmacogenomic Variants; Phenotype; Pyrophosphatases; Ribavirin | 2017 |
Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment.
Topics: Algorithms; Antiviral Agents; Cost Control; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2017 |
FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Drug Therapy, Combination; Egypt; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve | 2016 |
Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Quality Control; Ribavirin | 2016 |
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States | 2016 |
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult | 2016 |
MONOCYTE CHEMOTACTIC PROTEIN AND RESPONSE TO PEGYLATED INTERFERON-ALPHA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 4.
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Chemokine CCL2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2016 |
Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin | 2016 |
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection.
Topics: 2-Naphthylamine; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Withholding Treatment | 2016 |
Regional Differences in Hepatitis C Treatment with Peginterferon and Ribavirin in Japan in Both Genotype 1 and Genotype 2: A Retrospective Cohort Study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin | 2016 |
From current status to optimization of HCV treatment: Recommendations from an expert panel.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies, Medical; Viral Load | 2016 |
Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Young Adult | 2016 |
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; England; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Ribavirin; Treatment Outcome | 2016 |
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
Topics: Antiviral Agents; Colitis, Ulcerative; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2016 |
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prescription Fees; Qualitative Research; Quality of Life; Recombinant Proteins; Ribavirin; Socioeconomic Factors; Taiwan | 2016 |
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2015 |
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir | 2016 |
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prospective Studies; Registries; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Interleukin-23; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Young Adult | 2016 |
Oral therapy approved for chronic HCV infection of all genotypes.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2016 |
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?".
Topics: Antiviral Agents; Diabetes Mellitus; Hepatitis C, Chronic; Humans; Ribavirin | 2016 |
Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome | 2016 |
Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome; Young Adult | 2016 |
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia.
Topics: Adult; Alcoholism; Antiviral Agents; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; Serbia; Sustained Virologic Response | 2016 |
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.
Topics: Aged; Antiviral Agents; Female; Gene Expression; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Toll-Like Receptor 4; Viral Load | 2016 |
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult | 2016 |
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.
Topics: Adult; Antiviral Agents; Austria; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Regression Analysis; Retrospective Studies; Ribavirin; ROC Curve; von Willebrand Factor | 2016 |
Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Latent Tuberculosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2016 |
Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2016 |
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Topics: Aged; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Practice Guidelines as Topic; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis | 2016 |
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Topics: Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Palliative Care; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thailand | 2016 |
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate | 2017 |
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Time Factors; Tissue Donors; Treatment Outcome; Uridine Monophosphate | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.
Topics: Antigens, Viral; Antiviral Agents; Automation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
[PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Topics: Adult; Antiviral Agents; Blood Group Antigens; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Recombinant Proteins; Reproducibility of Results; Ribavirin | 2016 |
Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Ribavirin; Tunisia | 2016 |
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Aspartate Aminotransferases; Blood Platelets; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan | 2016 |
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires | 2016 |
Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Sequence Analysis, RNA; Treatment Outcome | 2016 |
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.
Topics: Adult; Antiviral Agents; Colon; Cross-Sectional Studies; Egypt; Female; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon-alpha; Interferons; Interleukins; Intestinal Mucosa; Liver; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome; Viral Load; Young Adult | 2016 |
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proline; Quality of Life; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Principal Component Analysis; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2016 |
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult | 2016 |
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Republic of Korea; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response | 2016 |
Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Topics: Aged; Antiviral Agents; France; Hepacivirus; Hepatitis C, Chronic; Humans; Markov Chains; Mass Screening; Middle Aged; Public Health; Ribavirin | 2017 |
Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cardiovascular Diseases; Eligibility Determination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Netherlands; Neutropenia; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2016 |
The Role of IL28B Genotype in HCV-RNA Baseline Levels.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Retrospective Studies; Ribavirin; RNA, Viral; Viremia | 2016 |
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Failure; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Eruptive seborrheic keratoses secondary to telaprevir-related dermatitis.
Topics: Aged; Antiviral Agents; Drug Eruptions; Facial Dermatoses; Female; Hepatitis C, Chronic; Humans; Interferons; Keratosis, Seborrheic; Oligopeptides; Ribavirin | 2016 |
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2017 |
Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
Topics: Adolescent; Alleles; Antiviral Agents; Child; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Liver; Male; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Treatment Outcome; Viral Load | 2016 |
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins | 2017 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Body Composition Changes in Patients with Chronic Hepatitis C.
Topics: Absorptiometry, Photon; Adiposity; Adult; Antiviral Agents; Body Mass Index; Bone Density; Case-Control Studies; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipodystrophy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Smoking | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Female; Genotyping Techniques; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Time Factors; Young Adult | 2017 |
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
Topics: Aged; Anticoagulants; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans; Warfarin | 2016 |
Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Alleles; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Viral Core Proteins; White People; Young Adult | 2016 |
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2017 |
Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Association Studies; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult | 2017 |
Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Topics: Adult; Alopecia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult | 2016 |
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in HCV genotype IV infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Polymorphism, Genetic; Quinoxalines; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HLA-D Antigens; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult | 2016 |
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People | 2017 |
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Failure; Treatment Outcome | 2016 |
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Topics: Administration, Oral; Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir | 2017 |
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-10; Liver; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2017 |
Assessment of pro-inflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Serum; Sustained Virologic Response; Young Adult | 2016 |
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate | 2017 |
Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dehydroepiandrosterone; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult | 2017 |
Regression of hepatocellular carcinoma after treatment with Sofosbuvir - A case report.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Base Sequence; Carbamates; China; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA Helicases; Sequence Analysis, DNA; Serine Endopeptidases; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.
Topics: 2-Naphthylamine; Anilides; Anticoagulants; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Warfarin | 2017 |
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin | 2016 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2017 |
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome | 2017 |
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cognitive Dysfunction; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2017 |
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Treatment Outcome | 2016 |
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2017 |
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Topics: Adenosine Triphosphate; Anemia, Hemolytic; Female; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Male; Middle Aged; Nucleotides; Phenotype; Polymorphism, Single Nucleotide; Purines; Pyrophosphatases; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
Topics: Adult; Aged; Aged, 80 and over; Disease Management; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Limit of Detection; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Young Adult | 2017 |
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombination, Genetic; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2017 |
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; United States | 2017 |
Lichen Aureus associated with interferon-alfa plus ribavirin.
Topics: Antiviral Agents; Dermoscopy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichenoid Eruptions; Male; Middle Aged; Ribavirin | 2017 |
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Plant Lectins; Polyethylene Glycols; Protein Binding; Receptors, N-Acetylglucosamine; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult | 2016 |
Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients?
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mortality; Prognosis; Ribavirin; RNA, Viral; Survival Analysis; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dyspnea; Female; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Sarcoidosis, Pulmonary | 2017 |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides | 2016 |
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Topics: Adult; Aged; Cytokines; Drug Resistance, Viral; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Myxovirus Resistance Proteins; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Ubiquitins | 2017 |
Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Cuba; Female; Gene Frequency; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Vaccines, DNA; Viral Hepatitis Vaccines | 2017 |
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors | 2017 |
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2017 |
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin | 2017 |
Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2017 |
Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-α and Ribavirin Treatment in Chronic Hepatitis Patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Depression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-6; Longitudinal Studies; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Genetic; Prevalence; Recombinant Proteins; Ribavirin | 2016 |
Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult | 2017 |
The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases.
Topics: Antiviral Agents; Community Networks; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome | 2016 |
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
Topics: Alanine Transaminase; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Middle Aged; Phylogeny; Reassortant Viruses; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Failure | 2017 |
A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
Topics: Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2017 |
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
Topics: Antiviral Agents; Benzofurans; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Treatment Outcome | 2017 |
Pegylated interferon for hepatitis C virus infection in Down syndrome.
Topics: Antiviral Agents; Down Syndrome; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2017 |
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cohort Studies; Coinfection; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Regression Analysis; Retrospective Studies; Ribavirin; Risk Assessment; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sofosbuvir | 2017 |
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Belgium; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.
Topics: Absorptiometry, Photon; Adolescent; Age Factors; Bone Density; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome | 2017 |
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Cohort Studies; Female; Healthcare Disparities; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Young Adult | 2017 |
Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2017 |
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2017 |
Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Psychometrics; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2017 |
Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer? Authors' reply.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasms; Ribavirin | 2017 |
Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasms; Ribavirin | 2017 |
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load | 2017 |
Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antigens, Neoplasm; Antiviral Agents; Drug Monitoring; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Withholding Treatment | 2017 |
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
Topics: Aged; Alleles; Anemia; Antiviral Agents; Disease Susceptibility; Drug Therapy, Combination; Enzyme Activation; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Risk Factors; Severity of Illness Index | 2017 |
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome | 2017 |
Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Skin Diseases; Treatment Outcome; Viral Load | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2017 |
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2017 |
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepacivirus; Hepatitis; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Polyethylene Glycols; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Transaminases | 2017 |
Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.
Topics: Adult; Aged; Alleles; Anemia, Hemolytic; Antiviral Agents; Disease Susceptibility; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin | 2017 |
Single Nucleotide rs760370 Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon-Ribaviri
Topics: Adult; Alleles; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2017 |
Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
Topics: Aged; Ambulatory Care; Ambulatory Care Facilities; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2017 |
Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2017 |
Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory | 2017 |
Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ribavirin; Sofosbuvir; Spinal Cord Diseases; Viral Load | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2008 |
Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors.
Topics: Antiviral Agents; Drug Therapy, Combination; Factor VII; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2008 |
Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test.
Topics: Adult; Antiviral Agents; Breath Tests; Case-Control Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Longitudinal Studies; Male; Methionine; Middle Aged; Mitochondria, Liver; Mitochondrial Diseases; Oxidative Stress; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
[Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Function Tests; Prognosis; Protease Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Asian People; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2008 |
[Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2008 |
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
Topics: Aged; Antiviral Agents; Consensus Sequence; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2008 |
Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoradiometric Assay; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Core Proteins; Viral Load | 2008 |
Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.
Topics: Aged; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Treatment Outcome | 2009 |
Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin.
Topics: Algorithms; Antiviral Agents; Computational Biology; Decision Support Techniques; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; ROC Curve; Treatment Outcome | 2008 |
Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Ribavirin; Time Factors | 2008 |
Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2008 |
Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.
Topics: Aged; Antipsychotic Agents; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Mental Health Services; Middle Aged; Patient Care Team; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Schizophrenia; Schizophrenic Psychology | 2010 |
[Results of the treatment of chronic hepatitis C genotype 4--a comparative analysis with genotype 1].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2008 |
[Treatment of chronic viral hepatitis].
Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome | 2008 |
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
[Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin].
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
[Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy].
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome; Viral Load | 2007 |
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Topics: Adult; Antiviral Agents; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Risk Assessment; RNA, Viral; Spain; Treatment Failure; Viral Load | 2008 |
Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin | 2008 |
Occurrence of diffuse, poorly differentiated hepatocellular carcinoma during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2008 |
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Sequence Analysis, DNA; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication | 2008 |
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2008 |
Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin | 2008 |
Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
Topics: Adult; Aged; Antimicrobial Cationic Peptides; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger | 2008 |
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention | 2008 |
The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Compliance; Ribavirin; Substance Abuse, Intravenous; Switzerland; Treatment Outcome | 2008 |
Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin.
Topics: Aged; Antiviral Agents; Asian People; Creatinine; Cystatin C; Cystatins; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum; Statistics as Topic | 2008 |
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2008 |
A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.
Topics: Algorithms; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neural Networks, Computer; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2008 |
Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.
Topics: Adult; Antiviral Agents; Azathioprine; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Male; Middle Aged; Pancytopenia; Platelet Count; Retrospective Studies; Ribavirin; Risk Factors | 2008 |
Platelet-associated IgG for the diagnosis of immune thrombocytopaenic purpura during peginterferon alpha and ribavirin treatment for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Blood Platelets; Female; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombocytopenic; Recombinant Proteins; Ribavirin | 2008 |
Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study.
Topics: Antiviral Agents; Folic Acid; Hepacivirus; Hepatitis C, Chronic; Homocysteine; Humans; Interferon alpha-2; Interferon-alpha; Italy; Methylenetetrahydrofolate Dehydrogenase (NADP); Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Vitamin B 12 | 2009 |
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2008 |
Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
Topics: Antiviral Agents; Drug Administration Schedule; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Viral Load | 2008 |
Interferon-induced haemolytic anaemia in hepatitis C.
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin | 2008 |
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy.
Topics: Absorptiometry, Photon; Adult; Antiviral Agents; Bone and Bones; Bone Density; Collagen Type I; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteocalcin; Osteoporosis; Prospective Studies; Recombinant Proteins; Ribavirin | 2008 |
[Management of chronic hepatitis in 2008].
Topics: Antiviral Agents; Consensus Development Conferences as Topic; Disease Management; Hepatitis C, Chronic; Humans; Patient Care Team; Ribavirin | 2008 |
Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lichen Planus, Oral; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.
Topics: Antiviral Agents; Asian People; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2009 |
[Peginterferon alfa-2b and ribavirin-induced pure red cell aplasia during treatment of chronic hepatitis C treated by cyclosporin A with good response].
Topics: Administration, Inhalation; Antiviral Agents; Cyclosporine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin | 2008 |
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians.
Topics: Adult; Antiviral Agents; Canada; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indians, North American; Interferon alpha-2; Interferon-alpha; Inuit; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
[Cytokine assessment in untreated hepatitis C virus infected patients and during interferon alpha +ribavirine therapy].
Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Male; Monitoring, Physiologic; Ribavirin | 2008 |
Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients.
Topics: Adult; Aged; Antigens, Neoplasm; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin | 2008 |
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.
Topics: Affect; Antiviral Agents; Biomarkers; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Resistance, Multiple, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Treatment Failure; Viral Proteins | 2009 |
Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Patient Compliance; Ribavirin; Substance-Related Disorders; Treatment Outcome; Viral Load | 2009 |
[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2008 |
[Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2008 |
Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cell Count; Cryoglobulinemia; Drug Therapy, Combination; Female; Flow Cytometry; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Statistics, Nonparametric; T-Lymphocytes, Regulatory; Treatment Outcome; Vasculitis | 2008 |
Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection.
Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Thyroid Diseases | 2008 |
Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Viral Load | 2009 |
Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Erectile Dysfunction; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Ribavirin; Surveys and Questionnaires | 2008 |
Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy.
Topics: Adult; Antiviral Agents; Bacterial Proteins; Cefotaxime; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon Type I; Interferon-alpha; Male; Meningitis, Pneumococcal; Opportunistic Infections; Penicillin G; Pneumococcal Vaccines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Splenectomy | 2008 |
[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
Topics: Adult; Antiviral Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Young Adult | 2008 |
HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
Topics: Adult; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation.
Topics: Animals; Antibodies, Monoclonal; Cell Proliferation; Cells, Cultured; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; Interferon-alpha; Interleukin-18; Pentoxifylline; Phosphorylation; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Ribavirin; Serum; Signal Transduction | 2008 |
Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.
Topics: Alleles; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Ethnicity; Female; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Major Histocompatibility Complex; Male; Middle Aged; Models, Statistical; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemochromatosis; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Phlebotomy; Polyethylene Glycols; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin | 2008 |
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Treatment Outcome; Viral Load; Young Adult | 2008 |
Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy.
Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Prednisone; Recombinant Proteins; Ribavirin; Risk Assessment; Sweet Syndrome; Treatment Outcome | 2008 |
Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy.
Topics: Adolescent; Adult; Antiviral Agents; Buprenorphine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2009 |
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
[Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].
Topics: Acridines; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferon-alpha; Male; Quality of Life; Ribavirin; Surveys and Questionnaires | 2008 |
Genetic variability in the 5' UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection.
Topics: 5' Untranslated Regions; Antiviral Agents; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins | 2008 |
Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Arginine; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Impact of the novel hepatotropic viruslike agent NV-F during chronic hepatitis C virus infection.
Topics: Adult; Antibodies, Viral; Antigens, Viral; Antiviral Agents; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.
Topics: Adult; Aged; Asian People; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Mental Disorders; Middle Aged; Pilot Projects; Retrospective Studies; Ribavirin; Viral Load | 2008 |
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; France; Genotype; Health Care Surveys; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Odds Ratio; Patient Education as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Young Adult | 2009 |
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Ribavirin; Silymarin; Treatment Outcome; Weight Loss | 2008 |
Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.
Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Endoribonucleases; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Sensitivity and Specificity | 2009 |
A surprising hyperpigmentation of the gums and tongue.
Topics: Adult; Antiviral Agents; Female; Gingival Diseases; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases | 2008 |
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult | 2008 |
Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy.
Topics: Antiviral Agents; Bone Marrow; Bone Marrow Diseases; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancytopenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Thyroiditis | 2009 |
Interferon-alpha-associated presumed ocular sarcoidosis.
Topics: Adult; Aged; Antiviral Agents; Choroid Diseases; Drug Therapy, Combination; Female; Glucocorticoids; Granuloma; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Panuveitis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed | 2009 |
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; United States | 2009 |
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cameroon; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin.
Topics: Adult; Aged; Antioxidants; Antiviral Agents; Biomarkers; Case-Control Studies; Female; Folic Acid Deficiency; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron; Iron Deficiencies; Lipid Peroxidation; Male; Middle Aged; Nutritional Status; Oxidation-Reduction; Oxidative Stress; Ribavirin; Vitamin B 6 Deficiency; Vitamin B Complex; Vitamin B Deficiency; Young Adult | 2009 |
[Relationship between patient profile and feverishness developed during interferon-ribavirin combination therapy of chronic hepatitis C patients].
Topics: Adult; Aged; Aging; Antiviral Agents; Drug Therapy, Combination; Female; Fever; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Sex Characteristics | 2008 |
Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Treatment Outcome | 2008 |
Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient.
Topics: Antiviral Agents; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tinnitus; Vertigo | 2008 |
[Comparative efficiency and side effects of combined antiviral therapy of chronic hepatitis C].
Topics: Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2008 |
Interferon-induced thyroid dysfunction in chronic hepatitis C.
Topics: Adult; Case-Control Studies; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Thyroid Diseases; Thyroid Function Tests; Western Australia | 2009 |
Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.
Topics: Adult; Antibody Formation; Antiviral Agents; Capsid Proteins; Cell Proliferation; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoglobulin A; Interferon-alpha; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocytes; Up-Regulation; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2009 |
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viremia | 2009 |
SEN Virus infection in HIV/HCV coinfected patients.
Topics: Adult; Antiviral Agents; Comorbidity; DNA Virus Infections; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Torque teno virus; Virus Replication | 2008 |
"12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors | 2008 |
Adherence to hepatitis C virus therapy and early virologic outcomes.
Topics: Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2009 |
[Protocol for the antiviral therapy of chronic hepatitis C].
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2008 |
Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Blood; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
What is the safe duration of therapy for patients infected with HCV genotype 6?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2009 |
[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2008 |
[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation].
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tomography, X-Ray Computed | 2008 |
The evaluation of patients with hepatitis C living in rural California via telemedicine.
Topics: Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Poverty; Retrospective Studies; Ribavirin; Rural Population; Telemedicine | 2008 |
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral | 2009 |
Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
Topics: Adult; Antiviral Agents; Dialysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin.
Topics: Adult; Antiviral Agents; Chemokine CCL3; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Models, Genetic; Pilot Projects; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Messenger; STAT5 Transcription Factor; STAT6 Transcription Factor; Tumor Suppressor Proteins | 2009 |
[Anti-virus response and interferon, cytokine systems in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Peptide Fragments; Retrospective Studies; Ribavirin; Young Adult | 2008 |
Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Crohn Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Case-Control Studies; Diabetes Mellitus; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Ohio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Failure; Viral Load | 2009 |
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome | 2009 |
A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2009 |
Autoimmune thrombocytopenia related to chronic hepatitis C virus infection.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Platelet Membrane Glycoproteins; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2009 |
The effect of controlled therapy interruption in chronic HCV infection: enhanced host immune response? A hypothesis.
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Viral Load; Withholding Treatment | 2009 |
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2009 |
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2009 |
Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study.
Topics: Adult; Aged; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Autoimmunity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Ultrasonography; Young Adult | 2009 |
The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
Topics: Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin | 2009 |
Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antiviral Agents; Cells, Cultured; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Ribavirin; RNA, Viral; T-Lymphocytes; Tetraspanin 28; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glucose Tolerance Test; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Insulin Secretion; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Receptors, Tumor Necrosis Factor, Type II; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Viral Load | 2010 |
Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
Topics: Anemia, Pernicious; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitisC.
Topics: Aged; Antiviral Agents; Female; Fluorescein Angiography; Fundus Oculi; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Papilledema; Recombinant Proteins; Ribavirin; Visual Acuity | 2009 |
Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk; Thyroid Diseases; Thyroid Function Tests; Treatment Outcome; Young Adult | 2009 |
Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Ferritins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin; Treatment Outcome | 2009 |
Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2009 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polypharmacy; Recombinant Proteins; Ribavirin; Sensation Disorders; Thyroiditis, Autoimmune; Thyroxine | 2009 |
Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Asian People; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Insulin-Secreting Cells; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Viral Load | 2009 |
Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
Topics: Antiviral Agents; Diabetes Mellitus; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2009 |
[Lichenoid eruption in a patient with chronic hepatitis C virus infection treated with interferon and ribavirin].
Topics: Drug Eruptions; Drug Therapy, Combination; Female; Hand Dermatoses; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lichenoid Eruptions; Middle Aged; Recombinant Proteins; Ribavirin | 2009 |
Treating chronic hepatitis C in recovering opiate addicts: yes, we can.
Topics: Antiviral Agents; Buprenorphine; Drug Therapy, Combination; Drug Users; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Methadone; Narcotics; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Refusal to Treat; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; United States | 2009 |
Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Molecular Epidemiology; Molecular Sequence Data; Mutation; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins | 2009 |
Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load | 2009 |
Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.
Topics: Antiviral Agents; Drug Carriers; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin; Treatment Outcome | 2010 |
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.
Topics: Amino Acid Sequence; Antiviral Agents; DNA-Directed RNA Polymerases; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Protein Structure, Tertiary; Ribavirin; RNA, Viral; Sequence Alignment; Sequence Analysis, DNA; Viral Proteins | 2009 |
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Topics: Acute Disease; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Pancreatitis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
Topics: Adult; Antiviral Agents; Biopsy; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
[Case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during peginterferon/ribavirin combination therapy].
Topics: Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Middle Aged; Neutropenia; Pneumococcal Infections; Pneumococcal Vaccines; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Sepsis; Splenectomy | 2009 |
Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
Topics: Adolescent; Anemia; Antiviral Agents; Chelation Therapy; Deferoxamine; Ferritins; Hemoglobinopathies; Hemosiderosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Siderophores | 2009 |
Pruritic papules limited to tattooed skin.
Topics: Adult; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sarcoidosis; Skin; Skin Diseases; Tattooing | 2009 |
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
Topics: Adult; Albumins; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prisoners; Recombinant Proteins; Retrospective Studies; Rhode Island; Ribavirin; Treatment Outcome; White People; Young Adult | 2009 |
Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphangioleiomyomatosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Topics: Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Retinol-Binding Proteins, Plasma; Ribavirin; Severity of Illness Index; Viral Load | 2009 |
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions.
Topics: Adult; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-12; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2009 |
Autoimmune haemolytic anaemia due to chronic hepatitis C virus infection treated with prednisone, pegylated interferon and ribavirin.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin | 2009 |
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2009 |
When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2009 |
Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy.
Topics: Antiviral Agents; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Drug Carriers; Drug Therapy, Combination; G(M1) Ganglioside; Gait Disorders, Neurologic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Muscle Weakness; Plasmapheresis; Polyethylene Glycols; Polyradiculoneuropathy; Recombinant Proteins; Ribavirin | 2009 |
High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Romania; Severity of Illness Index; Time Factors; Transaminases; Treatment Outcome; Viral Load | 2009 |
Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antifungal Agents; Antiviral Agents; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Invasive Pulmonary Aspergillosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2009 |
Ribavirin in chronic hepatitis C: past and future.
Topics: Antiviral Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2009 |
[Prediction of response to peginterferon and ribavirin combination therapy using mutations in the HCV genome].
Topics: Amino Acid Sequence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viremia | 2009 |
[Management of chronic hepatitis C which failed to respond to previous treatment].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2009 |
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2009 |
Localized scleroderma (morphea) in a patient with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Scleroderma, Localized | 2009 |
An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
[Treatment of chronic hepatitis C in HIV-infected patients].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
Topics: Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure | 2009 |
Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
Topics: Adult; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Biomarkers; Cross-Sectional Studies; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Failure; Treatment Outcome | 2009 |
Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thyroid Diseases; Thyroid Function Tests | 2009 |
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
Topics: Adrenal Cortex Hormones; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Optic Nerve Diseases; Papilledema; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vision Disorders | 2009 |
Peginterferon alfa-2b and ribavirin in chronic hepatitis C relapse: new indication. For some patients.
Topics: Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Secondary Prevention; Viral Load | 2009 |
Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hyperpigmentation; Iatrogenic Disease; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Impact of pegylated interferon alpha and ribavirin therapy of chronic hepatitis C on peripheral blood and intrahepatic lymphocytes].
Topics: Adult; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Immunity, Cellular; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Young Adult | 2009 |
Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Apolipoproteins B; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Retrospective Studies; Ribavirin; Treatment Outcome | 2009 |
Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2009 |
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
Topics: Adult; Antiviral Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazolidinediones | 2009 |
Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Autoantibodies; Autoimmunity; CD8-Positive T-Lymphocytes; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferons; Kidney; Liver; Male; Microsomes; Middle Aged; Ribavirin; Young Adult | 2009 |
A step forward in therapy for hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load; White People | 2009 |
Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
Topics: Adolescent; Adult; Anemia, Hemolytic; Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferons; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome | 2009 |
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; White People | 2009 |
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Feasibility Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Spectrometry, Mass, Electrospray Ionization | 2009 |
Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity.
Topics: Adult; Antiviral Agents; Ethnicity; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2009 |
What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases | 2010 |
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2009 |
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; New Mexico; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; White People | 2009 |
Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-alpha2b using an "induction" approach with natural interferon-beta in difficult-to-treat chronic hepatitis C.
Topics: Adult; Cytokines; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serologic Tests; Transcriptional Activation; Treatment Outcome; Viral Load; Virulence | 2009 |
The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Asian People; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Viral Load | 2009 |
Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus.
Topics: Antiviral Agents; Costs and Cost Analysis; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results; Ribavirin | 2008 |
Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2009 |
[Eradication of hepatitis C virus after a 5-week treatment].
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Marked iron overload related to ribavirin and iron sulfate treatment in a patient with active viral C cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Ferrous Compounds; Hepatitis C, Chronic; Humans; Iron Overload; Middle Aged; Ribavirin | 2009 |
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2009 |
Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy.
Topics: Adult; Antiviral Agents; Cohort Studies; Cytokines; Depression; Female; Hepatitis C, Chronic; Humans; Interleukin-10; Interleukin-2; Interleukin-4; Interleukin-6; Male; Middle Aged; Quality of Life; Ribavirin; Tumor Necrosis Factor-alpha | 2009 |
Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study.
Topics: Adult; Antiviral Agents; Biomarkers; Cohort Studies; Denmark; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Models, Statistical; Prognosis; Ribavirin; Young Adult | 2009 |
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2009 |
Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery.
Topics: Adult; Antiviral Agents; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Ileostomy; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pouchitis; Recombinant Proteins; Ribavirin | 2009 |
[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia; Young Adult | 2009 |
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Viral Load; Viral Nonstructural Proteins; Young Adult | 2009 |
[Standards of treatment of the hepatitis C (June 2008)].
Topics: Antiviral Agents; Critical Pathways; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2009 |
Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2010 |
Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load; Young Adult | 2009 |
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Libido; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; White People | 2009 |
Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Metabolic Networks and Pathways; Mevalonic Acid; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2009 |
Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Diabetes Mellitus; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retrospective Studies; Ribavirin; Risk Factors | 2009 |
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Neutropenia; Ribavirin; Risk Factors; Thrombocytopenia | 2010 |
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin; Treatment Outcome | 2009 |
Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Treatment Failure; Viral Load | 2009 |
Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Myasthenia Gravis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Living with hepatitis C and treatment: the personal experiences of patients.
Topics: Adaptation, Psychological; Adult; Antiviral Agents; Attitude to Health; Cost of Illness; Drug Therapy, Combination; Family; Health Services Needs and Demand; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; New South Wales; Nursing Methodology Research; Qualitative Research; Quality of Life; Ribavirin; Self Disclosure; Social Isolation; Stereotyping; Surveys and Questionnaires | 2009 |
Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
[Interferon-related retinopathy in a man with chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retinal Diseases; Ribavirin | 2009 |
Peginterferon plus ribavirin over two years may be successful in patients with chronic hepatitis C and a very slow virologic response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Topics: Adult; Animals; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Rats; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
[Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2009 |
[Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyroiditis, Subacute; Viral Load | 2009 |
Interferon-induced thyroid dysfunction--not always transient.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thyroid Diseases; Time Factors | 2009 |
Telaprevir for chronic HCV infection.
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.
Topics: Adult; Aged; Antiviral Agents; Drug Tolerance; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Response to combination therapy in hepatitis virus C genotype 2 and 3.
Topics: Adult; Antimetabolites; Antiviral Agents; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Retrospective Studies; Ribavirin; Treatment Outcome | 2009 |
Forewarned is forearmed.
Topics: Antiviral Agents; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Etanercept; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon-alpha; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Ribavirin | 2010 |
A fatal case of phlegmonous colitis in chronic hepatitis C receiving combination interferon and ribavirin therapy.
Topics: Colitis; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2009 |
Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
Topics: Adult; Antiviral Agents; Black People; Egypt; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin.
Topics: Adult; Aged; Animals; Antiviral Agents; Biomarkers; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Toll-Like Receptor 3; Treatment Outcome | 2010 |
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult | 2009 |
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy.
Topics: Adolescent; Amino Acid Sequence; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult | 2009 |
Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Laparoscopy; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2010 |
Comment to "Treating chronic hepatitis C in recovering opiate addicts: yes, we can".
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Young Adult | 2009 |
Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: really safe and effective?
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Short-term treatment of Hepatitis C in heroin-dependent patients].
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Care Team; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Time Factors; Treatment Outcome | 2009 |
Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load | 2009 |
Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Female; Graves Disease; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
Topics: Antiphospholipid Syndrome; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Ribavirin; Sarcoidosis | 2009 |
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Interferon-alfa, interferon-lambda and hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Signal Transduction; Treatment Outcome | 2009 |
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Topics: Alleles; Antiviral Agents; Asian People; Chromosomes, Human, Pair 19; Drug Combinations; Female; Genome-Wide Association Study; Genome, Human; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2009 |
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Topics: Adult; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Gene Expression Regulation; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2009 |
Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
Topics: Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pleural Effusion; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2009 |
Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
Topics: Antiviral Agents; Binding Sites; Cell Line; Endoribonucleases; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Point Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; Viral Nonstructural Proteins; Virus Cultivation | 2010 |
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis.
Topics: Alanine Transaminase; Antitubercular Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tuberculosis, Pulmonary | 2009 |
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Failure | 2010 |
Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.
Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Failure; Viral Load | 2010 |
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Topics: Acute Disease; Adult; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Seroepidemiologic Studies; Substance-Related Disorders; Treatment Outcome | 2010 |
Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
[A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin | 2009 |
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholesterol; Cholesterol, LDL; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2009 |
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.
Topics: Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Prevalence; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States | 2009 |
Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy.
Topics: Adult; alpha 1-Antitrypsin; Amantadine; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Multicenter Studies as Topic; Netherlands; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; Treatment Outcome; Ursodeoxycholic Acid | 2009 |
Azathioprine plus ribavirin treatment and pancytopenia.
Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Crohn Disease; Drug Interactions; Hepatitis C, Chronic; Humans; Male; Pancytopenia; Ribavirin | 2009 |
Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2009 |
Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2010 |
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression.
Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin | 2010 |
Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Erythropoietin; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients.
Topics: Antigens, Neoplasm; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serpins; Statistics, Nonparametric | 2010 |
Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy; Splenomegaly; Thrombocytopenia; Treatment Outcome; Viral Load | 2010 |
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Receptors, KIR; Receptors, KIR2DL2; Receptors, KIR2DL3; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Topics: Adult; Antiviral Agents; CD56 Antigen; CD57 Antigens; Cell Degranulation; Chemokine CCL4; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Subsets; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Perforin; Receptors, Natural Killer Cell; Ribavirin; Tumor Necrosis Factor-alpha | 2009 |
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Statistics as Topic; Treatment Outcome; Tunisia; Viral Nonstructural Proteins | 2009 |
Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C.
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Effects of chronic hepatitis C infection on the treatment of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2010 |
Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
Topics: Antiviral Agents; Bacterial Infections; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Receptors, KIR; Receptors, KIR2DL2; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperinsulinism; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Hepatitis C treatment completion rates in routine clinical care.
Topics: Antiviral Agents; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; Veterans | 2010 |
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Dermatitis, Exfoliative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin | 2009 |
Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Blood Platelets; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors; Young Adult | 2010 |
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2009 |
Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viral Load; Viremia | 2009 |
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Biopsy; Cluster Analysis; Cytokines; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Profiling; Genotype; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Kupffer Cells; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Ubiquitins; Viral Load | 2010 |
Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.
Topics: Adult; Analysis of Variance; Antiviral Agents; Asian People; Cohort Studies; Confidence Intervals; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Compliance; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Treatment Outcome; White People | 2010 |
Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Heart Failure; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Treatment for chronic hepatitis C, more opportunity, more challenge].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
[Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2009 |
[The study of optimal treatment in patients with refractory chronic hepatitis C].
Topics: Administration, Cutaneous; Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Female; Gene Frequency; Haplotypes; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Taiwan; Treatment Outcome; Viral Load | 2010 |
Do differences in pegylation of interferon alfa matter?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Metformin, hepatitis C, and insulin resistance: sufficient evidence?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Efficiency of a combined peginterferon alpha-2a and ribavarin therapy in intravenous opiate substances abusers with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Morphine Dependence; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2009 |
Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region.
Topics: Adult; Aged; Amino Acid Substitution; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load | 2010 |
Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Exenatide; Fatty Liver; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Peptides; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Venoms; Viral Load | 2009 |
A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
Topics: Aged; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin.
Topics: Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2010 |
Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Blood; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolic Networks and Pathways; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2010 |
Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.
Topics: Adult; Antiviral Agents; Asian; Blood; California; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2009 |
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2010 |
What now? Responding to relapse in hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Nurse Practitioners; Patient Education as Topic; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Recurrence; Referral and Consultation; Ribavirin; Risk Factors; United States; Viral Load | 2007 |
A levitating tattoo in a hepatitis C patient on treatment.
Topics: Antiviral Agents; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pulmonary Disease, Chronic Obstructive; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases; Steroids; Tattooing; Treatment Outcome | 2010 |
Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Chemokine CCL11; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Plasma; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Hypertension; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retinal Diseases; Ribavirin; Risk Factors; Visual Acuity | 2009 |
Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
[A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C].
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
[Predictive value of virological response on sustained virological response in hepatitis C patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2010 |
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
Topics: Adult; Aged; Female; Genetic Variation; Genome-Wide Association Study; Genotype; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Failure | 2010 |
An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.
Topics: Antioxidants; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Resveratrol; Ribavirin; RNA, Viral; Stilbenes; Virus Replication; Xanthophylls | 2010 |
Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics.
Topics: Adult; Aged; Antiviral Agents; Female; Filtration; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Japan; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load | 2010 |
Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics as Topic; Treatment Outcome | 2010 |
HCV genetic elements determining the early response to peginterferon and ribavirin therapy.
Topics: Antiviral Agents; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation, Missense; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2010 |
Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C.
Topics: Aged; Antigens, CD; Antiviral Agents; Biopsy; Female; Flow Cytometry; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Ribavirin; Staining and Labeling; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2010 |
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2010 |
Towards predicting the therapeutic response in patients with hepatitis C.
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Predictive Value of Tests; Ribavirin | 2010 |
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention | 2010 |
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2010 |
Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b.
Topics: Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serum | 2010 |
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy.
Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Neoplasms; Ribavirin; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
Topics: Antimicrobial Cationic Peptides; Antiviral Agents; Cell Degranulation; Cytokines; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Count; Peptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2010 |
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Databases, Factual; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Scandinavian and Nordic Countries; Treatment Outcome; Young Adult | 2010 |
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Cholestanetriol 26-Monooxygenase; Cytochrome P450 Family 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Vitamin D | 2010 |
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome | 2010 |
Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Ribavirin; Young Adult | 2010 |
New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
Topics: Adult; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin | 2009 |
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Male; Methylprednisolone; Recombinant Proteins; Ribavirin; Tropicamide; Uveomeningoencephalitic Syndrome | 2010 |
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Chromosomes, Human, Pair 20; Europe; Genetic Variation; Genome-Wide Association Study; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Single Nucleotide; Pyrophosphatases; Racial Groups; Ribavirin; United States | 2010 |
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Uveomeningoencephalitic Syndrome | 2010 |
Ribavirin ante portas: uptake transporters into hepatocytes dissected.
Topics: Antiviral Agents; Equilibrative Nucleoside Transporter 1; Hepatitis C, Chronic; Hepatocytes; Humans; Ribavirin | 2010 |
Maintenance ribavirin monotherapy: the case for post-transplantation recurrent hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunocompromised Host; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2010 |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Topics: Antiviral Agents; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Serum; Severity of Illness Index; Treatment Outcome; Vitamin B 12 | 2011 |
Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?
Topics: Antiviral Agents; Biopsy; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Tolerance; Interferons; Liver; Ribavirin; T-Lymphocyte Subsets; Treatment Outcome | 2011 |
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2010 |
Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Metformin; Ribavirin | 2010 |
[Retreatment options for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral | 2009 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Treatment of recurrent hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
[Treatment of viral hepatitis in children].
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunization; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Expression of microRNA-155 precursor in peripheral blood mononuclear cells from Hepatitis C patients after antiviral treatment.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; MicroRNAs; Recombinant Proteins; Ribavirin; RNA Precursors; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Molecular Sequence Data; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins | 2010 |
[Hepatitis C: 15 years of life].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[Treatment of hepatitis C in children].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2005 |
[Chronic hepatitis C. First treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[Treatment of relapsers].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
[Treatment of cirrhotics].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
[Treatment of patients with normal liver aminotransferases].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases | 2005 |
Identifying HCV genotype 1 patients at risk of relapse.
Topics: Adult; Age Distribution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; White People | 2010 |
Sarcoidosis and hepatitis C: clinical description of 11 cases.
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Arthritis; Cohort Studies; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sarcoidosis; Treatment Outcome; Uveitis; Young Adult | 2010 |
A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Microalbuminuria in hepatitis C-genotype 4: effect of pegylated interferon and ribavirin.
Topics: Adult; Albumins; Albuminuria; Antiviral Agents; Case-Control Studies; Creatinine; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Insufficiency, Chronic; Ribavirin; Viral Load | 2010 |
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics as Topic; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Body Temperature; Data Interpretation, Statistical; Excipients; Female; Fever; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Predictive Value of Tests; Ribavirin | 2010 |
Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2010 |
Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; eIF-2 Kinase; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Protein Binding; Protein Interaction Domains and Motifs; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Evaluating treatment of hepatitis C for hemolytic anemia management.
Topics: Anemia, Hemolytic; Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Biological; Recombinant Proteins; Ribavirin | 2010 |
Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response.
Topics: Adult; Antiviral Agents; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2010 |
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.
Topics: Adult; Alcohol Drinking; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Socioeconomic Factors; Switzerland; Treatment Outcome; Viral Load | 2010 |
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Blood; DNA, Viral; Female; France; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prevalence; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin | 2010 |
Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serum | 2010 |
Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection.
Topics: Adolescent; Antiviral Agents; Female; Ferritins; Hepatitis C, Chronic; Humans; Male; Ribavirin; RNA, Viral; Thalassemia | 2010 |
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.
Topics: Analgesics, Opioid; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Medication Adherence; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Surveys and Questionnaires; Treatment Outcome | 2010 |
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Buprenorphine; Citalopram; Depression; Directly Observed Therapy; Drug Administration Schedule; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2010 |
Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2011 |
[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2010 |
Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C.
Topics: Adult; Aged; Antimicrobial Cationic Peptides; Antiviral Agents; Female; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Middle Aged; Polyethylene Glycols; Protein Precursors; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Topics: Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load; Viremia | 2010 |
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy.
Topics: Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferons; Ribavirin; Signal Transduction; Toll-Like Receptor 7; Treatment Failure | 2010 |
Focus. The impact of ribavirin treatment on spermatogenesis inpatients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Child; Hepatitis C, Chronic; Humans; Male; Ribavirin; Spermatogenesis; Spermatozoa | 2010 |
Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
Topics: Administration, Oral; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Virulence | 2010 |
Entering the new era of therapy for HBV and HCV infections.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.
Topics: Adult; Antiviral Agents; Asthenozoospermia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligospermia; Recombinant Proteins; Ribavirin; RNA, Viral; Semen; Spermatogenesis; Spermatozoa | 2010 |
Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
Topics: Adult; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antigens, Viral; Antiviral Agents; Apoptosis Regulatory Proteins; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytomegalovirus; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunologic Memory; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukocytes; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Young Adult | 2010 |
Outcome of a hepatitis C outbreak among patients in a pain management clinic.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Biopsy; Chi-Square Distribution; Cross Infection; Disease Outbreaks; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Oklahoma; Pain Clinics; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
Topics: Acute Disease; Antiviral Agents; Autopsy; Disease Progression; Fatal Outcome; Graft Rejection; Heart Transplantation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Time Factors; Transplantation, Homologous | 2010 |
Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Animals; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Mice; Mice, Transgenic; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Failure; Viral Core Proteins | 2010 |
Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cluster Analysis; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Homozygote; Humans; Interferon alpha-2; Interferon Regulatory Factors; Interferon-alpha; Interferons; Interleukins; Liver; Logistic Models; Male; Middle Aged; Odds Ratio; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Probability; Prognosis; Receptors, KIR2DL5; Receptors, Natural Killer Cell; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Statistics, Nonparametric; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes.
Topics: Adult; Antiviral Agents; Epitopes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Evasion; Interferons; Male; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2011 |
[Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
Topics: Adult; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
A comprehensive hepatitis C viral kinetic model explaining cure.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2010 |
Making the best of a bad situation: early chronic nosocomial HCV infection.
Topics: Age Factors; Antiviral Agents; Biopsy; Cross Infection; Disease Outbreaks; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Liver; Oklahoma; Pain Clinics; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Activation | 2010 |
Hepatitis C: not so indolent in survivors of pediatric cancer?
Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Neoplasms; Ribavirin; RNA, Messenger; Young Adult | 2010 |
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].
Topics: Acridines; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Quality of Life; Ribavirin | 2010 |
A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
Topics: Adult; Antigens, CD; Antigens, CD19; Antiviral Agents; B-Lymphocyte Subsets; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tetraspanin 28 | 2011 |
Amantadine for treatment of hepatitis C: time to say "enough is enough"?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2010 |
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Topics: Adolescent; Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Leukocyte Count; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Saudi Arabia | 2011 |
Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Phenotype; Polyethylene Glycols; Precision Medicine; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2010 |
Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Antiviral treatment of chronic hepatitis C in clinical routine.
Topics: Adult; Antiviral Agents; Austria; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2010 |
[Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2010 |
Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally.
Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV.
Topics: Administration, Cutaneous; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV-1; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
Topics: Adult; Cohort Studies; Drug Therapy, Combination; Exanthema; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunomodulation; Male; Middle Aged; Polyethylene Glycols; Retreatment; Ribavirin; Thymalfasin; Thymosin | 2010 |
Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.
Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Severity of Illness Index; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2010 |
T-cell responses at baseline and during therapy with peginterferon-alpha and ribavirin are not associated with outcome in chronic hepatitis C infected patients.
Topics: Adult; Antiviral Agents; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Outcome | 2010 |
Association of NKG2A with treatment for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; CD3 Complex; CD56 Antigen; Cell Count; Female; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily C; NK Cell Lectin-Like Receptor Subfamily K; Polyethylene Glycols; Receptors, KIR; Receptors, KIR2DL1; Receptors, KIR2DL3; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; T-Lymphocytes; Time Factors | 2010 |
The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Membrane Proteins; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2010 |
Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C.
Topics: Aged; Drug Carriers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Female; Flaviviridae Infections; GB virus C; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome | 2011 |
Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Polymorphism, Genetic; Protein Structure, Secondary; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2010 |
Hepatocyte growth factor and chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2010 |
Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus.
Topics: Adult; Aged; Antigens, CD; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; DEAD Box Protein 58; DEAD-box RNA Helicases; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Memory; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, Immunologic; Recombinant Proteins; Ribavirin; Toll-Like Receptors | 2010 |
Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Young Adult | 2010 |
Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
Topics: Antiviral Agents; Awareness; Drug Costs; Drug Therapy, Combination; Health Knowledge, Attitudes, Practice; Health Promotion; Health Services Accessibility; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Referral and Consultation; Ribavirin; Romania; Time Factors | 2010 |
Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Treatment Outcome; Viral Load | 2010 |
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prevalence; Prisoners; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; South Australia; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load | 2010 |
[Effectiveness of combined therapies using two types of peginterferon and ribavirin in treating chronic hepatitis C virus genotypes 1b/6a infections].
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2010 |
[Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Virus Activation | 2010 |
[Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin | 2010 |
[Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Insulin; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyroxine | 2010 |
[Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C].
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Ribavirin | 2010 |
Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
Topics: Adult; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Biopsy; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin | 2009 |
Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2010 |
Interferon-induced vitiligo in hepatitis C patients: a case series.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Vitiligo | 2010 |
Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins | 2010 |
Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors | 2010 |
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response.
Topics: Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cells, Cultured; Cytokines; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Neoplasms; Mice; Protease Inhibitors; Replicon; Ribavirin; RNA, Small Interfering; Ubiquitins; Viral Load; Virus Replication | 2010 |
Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.
Topics: Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Substance Withdrawal Syndrome | 2010 |
[Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2010 |
Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Bone Marrow; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Recombinant Proteins; Remission Induction; Ribavirin; Viral Core Proteins; Young Adult | 2010 |
An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cholecalciferol; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Vitamin D; Vitamin D Deficiency | 2011 |
Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load; Viremia | 2010 |
Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Retinal Hemorrhage; Ribavirin | 2010 |
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Cohort Studies; Elasticity; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype.
Topics: Adult; Aged; Alleles; Antiviral Agents; Female; Genetic Testing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; White People | 2011 |
[24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2010 |
[Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Bronchial Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins | 2010 |
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure | 2010 |
Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Monitoring; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Antibodies; HIV Core Protein p24; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Envelope Proteins; Viral Nonstructural Proteins | 2010 |
Associations between serum lipids and hepatitis C antiviral treatment efficacy.
Topics: Adult; Antiviral Agents; Black or African American; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Triglycerides; White People | 2010 |
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferons; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Viremia | 2010 |
Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carboxypeptidase B2; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Ribavirin; Time Factors; Tissue Plasminogen Activator | 2011 |
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome | 2010 |
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
Topics: Adult; Antiviral Agents; Drug Carriers; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Messenger; RNA, Viral; Tissue Donors; Treatment Outcome | 2010 |
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2010 |
Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
Topics: Antiviral Agents; Biflavonoids; Catechin; Cell Line, Tumor; Cinnamomum zeylanicum; Drugs, Chinese Herbal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Proanthocyanidins; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Internalization; Virus Replication | 2010 |
Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection.
Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Polyethylene Glycols; Receptors, Thyrotropin; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells | 2010 |
Dental problems delaying the initiation of interferon therapy for HCV-infected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatognathic Diseases | 2010 |
Chronic hepatitis C treatment in näive patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Management of hepatitis C virus infection in childhood.
Topics: Antiviral Agents; Asymptomatic Infections; Biopsy; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Thrombocytopenia | 2010 |
The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Signal Transduction | 2010 |
Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Eruptions; Drug Therapy, Combination; Dyspnea; Eosinophilia; Exanthema; Female; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2010 |
Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.
Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Middle Aged; Polymorphism, Genetic; Receptors, Tumor Necrosis Factor, Member 25; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
How sustained is sustained viral response in patients with hepatitis C virus infection?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Tables; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2010 |
Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Diuretics; Glomerulosclerosis, Focal Segmental; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2010 |
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin | 2010 |
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
Topics: Adult; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum; Viral Load | 2010 |
Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C.
Topics: Antigens, Viral; Antiviral Agents; Clinical Laboratory Techniques; Drug Monitoring; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins | 2011 |
Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.
Topics: Adolescent; Adult; Age Factors; Aged; alpha-Fetoproteins; Antiviral Agents; Data Mining; Decision Trees; Drug Carriers; Female; gamma-Glutamyltransferase; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2010 |
Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Health Status Indicators; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2011 |
Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
Topics: Adolescent; Antiviral Agents; Child; Cluster Analysis; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins | 2010 |
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.
Topics: Adolescent; Adult; Antiviral Agents; Chi-Square Distribution; Contraindications; Drug Therapy, Combination; Drug Users; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyendocrinopathies, Autoimmune; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome | 2010 |
Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Medication Adherence; Middle Aged; Ribavirin | 2010 |
Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Transcription, Genetic | 2010 |
Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case.
Topics: Antiviral Agents; Biopsy; Cholangiography; Cholestasis, Intrahepatic; Diagnosis, Differential; Drug Carriers; Early Diagnosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; RNA, Viral; Ultrasonography, Doppler | 2010 |
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection.
Topics: Adult; Angiopoietin-2; Antiviral Agents; Case-Control Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vascular Endothelial Growth Factor A; Viral Load | 2011 |
The next step for taribavirin.
Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2010 |
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
Topics: Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Serum lipid profile and chronic hepatitis C virus.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Romania; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins | 2011 |
Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Saudi Arabia; Severity of Illness Index | 2011 |
The smoldering epidemic. The number of new cases of hepatitis C is down, but millions are chronically infected and may not know it.
Topics: Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2010 |
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Case-Control Studies; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Italy; Kynurenine; Male; Middle Aged; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Serotonin; Time Factors; Treatment Outcome; Tryptophan | 2011 |
Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2011 |
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.
Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Evidence-Based Medicine; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, General; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Product Surveillance, Postmarketing; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; ROC Curve; Viral Load | 2010 |
The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Treatment uptake of patients with chronic hepatitis C: can we expect and do more?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2010 |
Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage.
Topics: Adult; Antiviral Agents; Cystic Fibrosis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver; Lung Transplantation; Male; Portal System; Ribavirin | 2010 |
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferons; Limit of Detection; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; T-Lymphocytes | 2011 |
Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cohort Studies; Comorbidity; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Netherlands; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2011 |
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
[Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equipment Design; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Patient Education as Topic; Patient Satisfaction; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2010 |
Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin.
Topics: Antibodies, Neutralizing; Antiviral Agents; Cell Line; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Cohort Studies; Denmark; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Epidemiologic Methods; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
Topics: Adult; Age Distribution; Comorbidity; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Ireland; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Quinolines; Recombinant Proteins; Ribavirin; Time Factors; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome | 2010 |
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
Topics: Adult; Antiviral Agents; China; Drug Evaluation; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
[Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-α and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pulmonary Embolism; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Schistosomiasis; Transaminases; Treatment Outcome | 2011 |
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2011 |
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.
Topics: Acetyltransferases; Adult; Antiviral Agents; Biopsy; Cytokines; Decision Support Techniques; Decision Trees; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Logistic Models; Male; Membrane Proteins; Middle Aged; Oxidoreductases Acting on CH-CH Group Donors; Phenotype; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Messenger; Switzerland; Transcription Factors; Treatment Outcome; Ubiquitins | 2011 |
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Base Sequence; Case-Control Studies; DNA Primers; Female; Gene Frequency; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
Topics: Aged; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load; Young Adult | 2012 |
Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children.
Topics: Alanine Transaminase; Child; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2012 |
Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Messenger; RNA, Viral; Treatment Outcome | 2011 |
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Topics: Aged; Alleles; Antiviral Agents; Data Mining; Decision Trees; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Japan; Logistic Models; Male; Middle Aged; Models, Biological; Mutation; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2011 |
The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients.
Topics: Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
Topics: Adult; Antiviral Agents; Arthritis, Psoriatic; Drug Therapy, Combination; Etanercept; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Latent Tuberculosis; Male; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Ribavirin | 2011 |
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytokines; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Myxovirus Resistance Proteins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Ubiquitins | 2011 |
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tissue Donors; Treatment Outcome | 2011 |
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
Topics: Antiviral Agents; Black People; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Models, Theoretical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; South America; Viral Load; White People | 2011 |
Treating hepatitis C: are children the same as adults?
Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2011 |
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation | 2011 |
An adult case with onset of celiac disease during chronic hepatitis C antiviral treatment.
Topics: Adult; Antiviral Agents; Celiac Disease; Female; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2010 |
Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA Splice Sites; Treatment Outcome; Young Adult | 2011 |
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.
Topics: Antiviral Agents; Chemokine CXCL10; Dipeptidyl Peptidase 4; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peptide Fragments; Polyethylene Glycols; Prognosis; Protein Array Analysis; Receptors, CXCR3; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Failure | 2011 |
IL28B-genotype testing now and in the era of direct-acting antiviral agents.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
Topics: Antiviral Agents; Body Mass Index; Cholesterol; Fatty Liver; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides; Viral Load | 2011 |
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy.
Topics: Antiviral Agents; Drug Monitoring; Hepatitis C, Chronic; Humans; Interferons; Molecular Diagnostic Techniques; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viremia; Virology | 2011 |
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Topics: Adenosine Triphosphate; Adenylosuccinate Synthase; Adolescent; Adult; Anemia; Antiviral Agents; Enzyme Activation; Erythrocytes; Genetic Variation; Genotype; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; In Vitro Techniques; Inosine Triphosphatase; Inosine Triphosphate; Pyrophosphatases; Ribavirin; Young Adult | 2011 |
Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV).
Topics: Adult; Antiviral Agents; Area Under Curve; Female; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon Type I; Leukocytes, Mononuclear; Male; Middle Aged; Phosphoproteins; Polyethylene Glycols; Protein Array Analysis; Proteomics; Recombinant Proteins; Regression Analysis; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Signal Transduction; Statistics, Nonparametric | 2011 |
Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
Topics: Antiviral Agents; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; MicroRNAs; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Audit of state-funded antiviral treatment for chronic hepatitis C in Qatar.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Qatar; Recombinant Proteins; Residence Characteristics; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.
Topics: Adult; Aged; Antiviral Agents; Asia; Asian People; Female; Gene Frequency; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life'.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Dropouts; Recombinant Proteins; Ribavirin | 2011 |
Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; In Situ Hybridization; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2011 |
IL28B: A new wager in the skyline of hepatitis C virus infection.
Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Complete atrio-ventricular block: a rare complication of interferon alpha therapy].
Topics: Adult; Antiviral Agents; Atrioventricular Block; Cooperative Behavior; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Hepatitis C, Chronic; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Pacemaker, Artificial; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Processing, Computer-Assisted | 2011 |
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.
Topics: Adult; Age Factors; Aged; Amino Acid Substitution; Antiviral Agents; Data Mining; Decision Trees; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Sex Factors; Time Factors; Viral Load; Viral Nonstructural Proteins | 2011 |
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin | 2011 |
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.
Topics: Adaptation, Biological; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyproteins; Ribavirin; Treatment Outcome | 2011 |
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
Topics: Adult; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
Topics: Drug Synergism; Guanosine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-7; Interferon-alpha; Interferon-Stimulated Gene Factor 3, gamma Subunit; NF-kappa B; Oxidoreductases Acting on CH-CH Group Donors; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Tumor Cells, Cultured | 2011 |
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
Topics: Adult; Black or African American; Chemokine CXCL10; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2011 |
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
Topics: Antiviral Agents; Cohort Studies; Data Mining; Decision Trees; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Core Proteins | 2011 |
[Therapy of chronic hepatitis C--virologic response monitoring].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2010 |
[Acute loss of vision during therapy of chronic hepatitis C].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Bevacizumab; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Interferon-alpha; Intravitreal Injections; Macular Edema; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin; Tomography, Optical Coherence; Vision, Low; Visual Acuity | 2011 |
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Sarcoid-related dacryoadenitis following treatment with interferon alpha and ribavarin for hepatitis C.
Topics: Aged; Antiviral Agents; Biopsy; Dacryocystitis; Diagnosis, Differential; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Prednisolone; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed | 2011 |
Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
Topics: Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2012 |
[A case with chronic hepatitis C who developed liver cirrhosis due to liver dysfunction caused by pegylated interferon plus ribavirin treatment despite negativity of serum HCV RNA, during therapy].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2011 |
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Echocardiography; Electrocardiography; Female; Genotype; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Troponin I | 2011 |
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Male; Medicaid; Medically Uninsured; Middle Aged; Nutrition Surveys; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2011 |
Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Topics: Adenine; Adult; Albuminuria; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2011 |
Treatment of chronic hepatitis C in Croatian war veterans: experiences from Croatian reference center for viral hepatitis.
Topics: Adult; Comorbidity; Croatia; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans; Veterans Health; Warfare | 2011 |
Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea.
Topics: Age Factors; Antiviral Agents; Asian People; Aspartate Aminotransferases; Biomarkers; Chi-Square Distribution; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Topics: Adult; Analysis of Variance; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Chi-Square Distribution; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Nicotinamide Phosphoribosyltransferase; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Taiwan; Treatment Outcome; Up-Regulation; Viral Load | 2011 |
Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
Topics: Adaptation, Psychological; Alcoholism; Antiviral Agents; Awareness; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Education as Topic; Problem Solving; Psychotherapy; Psychotherapy, Group; Recombinant Proteins; Recurrence; Ribavirin; Social Support; Substance Abuse, Intravenous; Suicidal Ideation | 2011 |
Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Predictive Value of Tests; Receptors, Tumor Necrosis Factor; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2011 |
Tongue hyperpigmentation during interferon therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Tongue Diseases | 2011 |
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; Genetic Association Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Membrane Transport Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2011 |
IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
Topics: Adult; Aged; Alleles; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Taiwan; Young Adult | 2011 |
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
Topics: Antiviral Agents; Blood Transfusion; Disease Progression; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Inpatients; Insurance Claim Review; Interferons; Male; Middle Aged; Outpatients; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Thrombocytopenia; United States | 2011 |
Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Area Under Curve; Decision Support Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Failure; Viral Load | 2011 |
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2011 |
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Leukocyte Count; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Hepatitis C virus: five-year follow-up of patients with sustained virological response.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2011 |
Five-year follow-up of patients with chronic C hepatitis and sustained virological response.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2011 |
Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Autoantibodies; Autoimmunity; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Poverty; Psoriasis; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune | 2011 |
IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
Topics: Adult; Aged; Antiviral Agents; Biomarkers, Pharmacological; Drug Therapy, Combination; Female; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Evaluation of selected laboratory markers of liver fibrosis in patients with chronic hepatitis type C].
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Biopsy; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Platelet Count; Ribavirin | 2010 |
The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B
Topics: Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genetic Testing; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome | 2011 |
Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.
Topics: Adult; Aged; Antiviral Agents; Chromatography, High Pressure Liquid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load | 2011 |
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Portal Pressure; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2011 |
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Survival Analysis; Treatment Outcome; United States; Viral Load | 2011 |
Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.
Topics: Amino Acid Substitution; Antiviral Agents; Biomarkers; Cytokines; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Viral Core Proteins | 2011 |
Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Systemic Vasculitis; Treatment Outcome | 2011 |
[Metabolic syndrome in patients with chronic hepatitis C genotype 1].
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Liver Cirrhosis; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2011 |
Tubo-ovarian abscess during therapy of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Abdominal Abscess; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oophoritis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Salpingitis | 2011 |
Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Factor IX; Factor VIII; Hemophilia A; Hemophilia B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure, Acute; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients.
Topics: Anemia; Antiviral Agents; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Viral Load | 2011 |
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cohort Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic.
Topics: Adolescent; Adult; Antiviral Agents; Female; Government Programs; Health Facilities; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Medically Underserved Area; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2011 |
A new era of hepatitis C therapy begins.
Topics: Anemia; Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2011 |
Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.
Topics: Antiviral Agents; Biopsy; CD4 Antigens; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Liver; Ribavirin; T-Lymphocytes, Regulatory | 2011 |
Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report.
Topics: Acute Disease; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Ibuprofen; Interferon alpha-2; Interferon-alpha; Pericarditis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment | 2011 |
Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Cell Line, Tumor; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Liver Cirrhosis; Male; Malnutrition; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Molecular Sequence Data; Multiprotein Complexes; Nutritional Status; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Proteins; Recombinant Proteins; Regression Analysis; Ribavirin; RNA Interference; RNA, Viral; Severity of Illness Index; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transaminases; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2011 |
[Inhibitors of hepatitis C virus--current standards and status of investigations].
Topics: Antiviral Agents; Clinical Trials as Topic; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Topics: Adult; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Viral Load; Vitamin D; Vitamin D Deficiency | 2011 |
Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element.
Topics: Cell Line, Tumor; Drug Synergism; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factors; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transcriptional Activation | 2011 |
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2011 |
[Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol].
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Drugs, Chinese Herbal; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medicine, Chinese Traditional; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Ribavirin; Social Planning; Young Adult | 2011 |
Has genetics eradicated the good old predictors of hepatitis C treatment response?
Topics: Antiviral Agents; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin | 2011 |
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Middle Aged; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed; Uveomeningoencephalitic Syndrome | 2011 |
Skeletal recovery from hepatitis C-associated osteosclerosis (HCAO) following antiviral treatment.
Topics: Antiviral Agents; Bone and Bones; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Osteosclerosis; Radiography; Recovery of Function; Ribavirin | 2011 |
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult | 2011 |
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Core Proteins; Young Adult | 2011 |
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
Topics: Amino Acid Substitution; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins | 2011 |
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2011 |
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral | 2011 |
Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2011 |
Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.
Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection.
Topics: Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; B-Cell Activating Factor; Cytokines; Hepatitis C, Chronic; Humans; Interferon Type I; Magnetic Resonance Imaging; Male; Middle Aged; Peptides, Cyclic; Recombinant Proteins; Ribavirin; Risk Factors | 2011 |
Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Body Mass Index; Dyspnea; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spirometry; Young Adult | 2011 |
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin | 2011 |
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
Chronic cough associated with interferon/ribavirin therapy for hepatitis C.
Topics: Antiviral Agents; Capsaicin; Cough; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reflex; Ribavirin; Sensory System Agents | 2011 |
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2011 |
Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C.
Topics: Aged; Antiviral Agents; Bone Marrow Cells; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin | 2011 |
High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukin-8; Male; Middle Aged; Pakistan; Reference Values; Ribavirin; Risk Factors; Treatment Failure; Viral Load; Young Adult | 2011 |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Apoptosis; Cross-Sectional Studies; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, Tumor Necrosis Factor, Type I; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Indicators of body composition as prognostic factors of efficiency of antiviral therapy for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Body Mass Index; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2011 |
[Extrahepatic manifestations in hepatitis C].
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.
Topics: Adult; Antigens, CD; Antiviral Agents; Biomarkers; Case-Control Studies; CD83 Antigen; China; Dendritic Cells; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Interleukin-10; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
Topics: Antiviral Agents; Chromosomes, Human, Pair 19; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2011 |
The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Ferritins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
First-line treatments for hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2011 |
[Tuberculous lymphadenitis after successful treatment of hepatitis C].
Topics: Adult; Antiviral Agents; Cytokines; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Latent Tuberculosis; Male; Mycobacterium tuberculosis; Opportunistic Infections; Pakistan; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tuberculosis, Lymph Node | 2011 |
Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efficacy of interferon-ribavirin therapy in chronic hepatitis C patients.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Health Status Indicators; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics as Topic; Th1 Cells; Th17 Cells; Time Factors; Viral Load; Young Adult | 2011 |
Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Vitamin D; Vitamin D Deficiency | 2011 |
A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Embolization, Therapeutic; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenic Artery; Thrombocytopenia; Treatment Outcome | 2011 |
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.
Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2011 |
[MiR-196a-2 gene polymorphism and the antiviral therapy of chronic hepatitis C].
Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; MicroRNAs; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
Topics: Amino Acid Substitution; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Load | 2011 |
Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taste Disorders | 2010 |
Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Pakistan; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2011 |
Vitamin D levels may explain the racial differences in response rates to antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Biomarkers; Black or African American; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Vitamin D; White People | 2011 |
Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
Topics: Adult; Antiviral Agents; Atherosclerosis; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
[Importance of medication adherence to peginterferon-ribavirin combination therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2011 |
Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-α and ribavirin treatment.
Topics: Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Saudi Arabia; Sequence Analysis, DNA; Viral Proteins | 2011 |
[Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antiviral Agents; Debridement; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin Ulcer | 2011 |
Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
Topics: Acute Disease; Antiviral Agents; Biomarkers; Drug Administration Schedule; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; False Negative Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Retinal nerve fibre layer defects associated with cotton-wool spots in patients with interferon retinopathy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intraocular Pressure; Middle Aged; Nerve Fibers; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Ganglion Cells; Ribavirin; Tomography, Optical Coherence; Visual Acuity; Visual Fields | 2012 |
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferons; Linkage Disequilibrium; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytopenia | 2011 |
Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Secondary Prevention | 2011 |
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.
Topics: Adult; Alleles; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; ROC Curve; Viral Load | 2011 |
Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2011 |
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Decision Trees; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Severity of Illness Index | 2011 |
Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2011 |
Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin.
Topics: Adult; Antiviral Agents; Education, Medical; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Nurses; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
The burden of HCV treatment in patients with inherited bleeding disorders.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Coagulation Disorders, Inherited; Cost of Illness; Depressive Disorder; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Surveys and Questionnaires; Young Adult | 2011 |
The adjuvant role of thyroxine in the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Thyroid Diseases; Thyroxine | 2012 |
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
Topics: Adult; Celiac Disease; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kinetics; Linkage Disequilibrium; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD40 Ligand; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Triglycerides; Viral Load | 2011 |
Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Denmark; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; CD56 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Leukocyte Immunoglobulin-like Receptor B1; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; Polyethylene Glycols; Receptors, IgG; Receptors, Immunologic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2011 |
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Linkage Disequilibrium; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2012 |
Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Alcohol Drinking; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Cost of Illness; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Outpatients; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2011 |
Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.
Topics: Antiviral Agents; Drug Synergism; Hepatitis C, Chronic; Humans; Interferon-alpha; Pilot Projects; Prospective Studies; Quinolines; Random Allocation; Ribavirin; Viral Load | 2012 |
Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Chronic Disease; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Receptors, LDL; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Spain; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
[Gene expression profiling in the first twelve weeks of treatment in chronic hepatitis C patients].
Topics: Adult; Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viremia | 2011 |
The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2011 |
[Therapy of hepatitis C: individualized approach to treatment].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins | 2011 |
Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling Proteins; Treatment Failure | 2011 |
Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR.
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin | 2011 |
Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.
Topics: Antiviral Agents; Body Mass Index; Cholesterol; Drug Monitoring; Female; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Risk Factors; Treatment Outcome; Triglycerides | 2011 |
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Theoretical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2011 |
Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Blood Glucose; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2011 |
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Mutation; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins | 2011 |
[Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study].
Topics: Adult; Antiviral Agents; Comorbidity; Contraindications; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Refusal to Treat; Ribavirin; Spain; Treatment Refusal | 2011 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin | 2011 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2011 |
Case 10-2011: Fever, confusion, and liver failure.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Liver Failure; Lymphohistiocytosis, Hemophagocytic; Middle Aged; Ribavirin | 2011 |
Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse.
Topics: Adult; Alcoholism; Antiviral Agents; Behavior, Addictive; Case-Control Studies; Cohort Studies; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Temperance; Time Factors; Treatment Outcome; Viral Load | 2012 |
Gaps in the achievement of effectiveness of HCV treatment in national VA practice.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs; Viremia | 2012 |
Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Case-Control Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Interleukin-10; Middle Aged; Outpatients; Polyethylene Glycols; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Tumor Necrosis Factor-alpha | 2011 |
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome | 2011 |
Diagnosing and treating hepatitis C virus infection.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; United States; Viral Load | 2011 |
[Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Exudates and Transudates; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Hemorrhage; Ribavirin | 2011 |
Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cause of Death; Chi-Square Distribution; Combined Modality Therapy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
[Retreatment with peginterferon alpha-2a plus ribavirin for chronic hepatitis C: a case report].
Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Eczema; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2012 |
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Creatinine; Drug Administration Schedule; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Topics: Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2011 |
Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2011 |
Education by a nurse increases the adherence to therapy in chronic hepatitis C patients.
Topics: Antiviral Agents; Education, Medical; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Polyethylene Glycols; Ribavirin | 2012 |
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine | 2012 |
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Young Adult | 2011 |
Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance.
Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Down-Regulation; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inducible T-Cell Co-Stimulator Ligand; Inducible T-Cell Co-Stimulator Protein; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-4; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; Viral Load | 2012 |
The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically.
Topics: Antiviral Agents; Blood; Brazil; Desiccation; Diagnostic Errors; Drug Monitoring; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Diagnostic Techniques; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Specimen Handling; Virology | 2012 |
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
Topics: Antiviral Agents; Asian People; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; White People | 2011 |
Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Filtration; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.
Topics: Adult; Antiviral Agents; Coffee; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2012 |
The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Th1 Cells; Treatment Outcome; Young Adult | 2011 |
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antiviral Agents; DEAD Box Protein 58; DEAD-box RNA Helicases; Drug Resistance, Viral; Female; Gene Expression; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Immunologic; Ribavirin; ROC Curve; Sensitivity and Specificity | 2012 |
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Needles; Polyethylene Glycols; Prevalence; Ribavirin; Risk Factors; Secondary Prevention; Substance-Related Disorders; Syringes; United Kingdom | 2012 |
Retinopathy associated with pegylated interferon and ribavirin causing permanent visual impairment in a patient with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Retinal Diseases; Ribavirin; Vision Disorders; Visual Acuity | 2011 |
A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).
Topics: Academic Medical Centers; Adult; Antiviral Agents; Canada; Efficiency; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Community; Humans; Interferon-alpha; Male; Middle Aged; Office Visits; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load; Work | 2011 |
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2011 |
[Minimization of endogenous intoxication syndrome by individual choice of drugs for therapy of chronic hepatitis].
Topics: Acridines; Adolescent; Antiviral Agents; Asymptomatic Infections; Biomarkers; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferon-alpha; Ribavirin; Treatment Outcome | 2011 |
[Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Poland; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Ribavirin; Sequence Alignment; Viral Envelope Proteins | 2011 |
HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Virus Replication | 2011 |
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Disease Progression; Drug Costs; Drug Therapy, Combination; Drug Utilization; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, KIR; Receptors, KIR2DL3; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2011 |
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Treatment of chronic hepatitis C in a patient with Fanconi anaemia.
Topics: Adult; Fanconi Anemia; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon-alpha; Phenotype; Ribavirin; Risk; Time Factors; Treatment Outcome; Viral Load | 2011 |
Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult | 2012 |
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Multivariate Analysis; Platelet Count; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome; Viral Load | 2012 |
Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue; Tongue Diseases | 2012 |
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Precision Medicine; Retrospective Studies; Ribavirin; Severity of Illness Index; Viral Load; Young Adult | 2012 |
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.
Topics: Aged; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Retrospective Studies; Ribavirin; Spain; Treatment Failure; Viral Load | 2011 |
The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2011 |
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kuwait; Logistic Models; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2011 |
Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Earache; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.
Topics: Antiviral Agents; Chile; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2011 |
[New triple therapy in chronic hepatitis C. Increased patient chances].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; RNA, Viral | 2011 |
Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Treatment Outcome | 2011 |
Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult | 2011 |
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Social Support; Treatment Outcome | 2011 |
Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Platelet Count; Prospective Studies; Ribavirin; Treatment Outcome | 2012 |
Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antiviral Agents; Clavulanic Acid; Drug Therapy, Combination; Granuloma, Foreign-Body; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mineral Oil; Penile Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2011 |
Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin.
Topics: Adult; Analysis of Variance; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Statistics, Nonparametric; Thyroid Function Tests; Thyroid Hormones; Thyroiditis; Thyroiditis, Autoimmune; Time Factors; Treatment Outcome; Ultrasonography | 2011 |
One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA Mutational Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Logistic Models; Male; Middle Aged; Mutation; Patient Selection; Phenotype; Polyethylene Glycols; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Virus Replication; Young Adult | 2012 |
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Viral Load; Viremia | 2011 |
Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Dendritic Cells; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Toll-Like Receptor 3; Treatment Outcome; Viral Load | 2011 |
Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukin-12 Subunit p40; Interleukin-18; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2011 |
Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-6; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Data Mining; Decision Trees; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Ribavirin; Risk Assessment; Risk Factors | 2012 |
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Topics: Adult; Antiviral Agents; Black or African American; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; White People | 2012 |
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Assessment | 2011 |
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Superinfection; Treatment Outcome | 2012 |
Interferon-free treatment regimens for hepatitis C: are we there yet?
Topics: Aminoisobutyric Acids; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Oligopeptides; Proline; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; Thiazoles | 2011 |
Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2012 |
Genetic variation of the IL-28B promoter affecting gene expression.
Topics: Dinucleotide Repeats; Gene Expression; Genetic Variation; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Molecular Sequence Data; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin | 2011 |
[Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C].
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Chile; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Topics: Adult; Aged; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Serotyping | 2012 |
[Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2011 |
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Topics: Aged; Antiviral Agents; Cohort Studies; Computer Simulation; Contraindications; Cost-Benefit Analysis; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Mass Screening; Middle Aged; Primary Health Care; Quality-Adjusted Life Years; Ribavirin; Sensitivity and Specificity; United States | 2012 |
Implications of rapid virological response in hepatitis C therapy in the US veteran population.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Veterans; Viral Load | 2012 |
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Topics: Animals; Clinical Trials as Topic; Drug Discovery; Genotype; Hepacivirus; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Interferon-alpha; Mice; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; Treatment Outcome; United Arab Emirates | 2011 |
Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Personality Inventory; Psychometrics; Ribavirin; Risk Factors; Young Adult | 2011 |
Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Virus Activation; Young Adult | 2011 |
Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia.
Topics: Adult; Aged; Antiviral Agents; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenic Artery; Thrombocytopenia; Treatment Outcome | 2011 |
Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?
Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Secondary Prevention; Time Factors; Viral Load | 2012 |
Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Fatty Liver; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2012 |
[Virus removal and eradication by double filtration plasmapheresis (DFPP)].
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Treatment of elderly patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Response to interferon therapy using mutations in the HCV-NS5A].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
[Prediction of response to peginterferon and ribavirin therapy for chronic hepatitis C analyzed by data mining method].
Topics: Data Mining; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C].
Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2011 |
Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Parasite Interactions; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Viral Load; Viral Nonstructural Proteins; Young Adult | 2012 |
IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.
Topics: Case-Control Studies; Female; Gene Frequency; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Racial Groups; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2012 |
Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome.
Topics: Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Cluster Analysis; Electrophoresis, Gel, Two-Dimensional; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Principal Component Analysis; Prognosis; Proteome; Proteomics; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Treatment Outcome | 2012 |
Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2012 |
Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2011 |
Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2011 |
Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors | 2012 |
Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome | 2012 |
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
Topics: Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load | 2012 |
Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Egypt; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Retinal Diseases; Retrospective Studies; Ribavirin; Risk Factors; Young Adult | 2012 |
IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Coinfection; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; ROC Curve; Viral Load; Young Adult | 2012 |
Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome; United Kingdom | 2012 |
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2011 |
Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients.
Topics: Adult; Aged; Body Mass Index; Female; Genotype; Hepatitis C, Chronic; Humans; Infectious Disease Medicine; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Risk Factors; Treatment Outcome | 2011 |
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil.
Topics: Adult; Antiviral Agents; Brazil; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2012 |
[Pegasys and ribavirin therapy in an elderly patient with chronic hepatitis C].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyrotoxicosis | 2012 |
Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cell Line; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Lopinavir; Male; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Saquinavir; Tissue Inhibitor of Metalloproteinase-2; United Kingdom; Viral Load | 2011 |
Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
Topics: Adult; Antioxidants; Antiviral Agents; Austria; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2012 |
Neutrophil function and apoptosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Topics: Adult; Antigens, CD; Antiviral Agents; Apoptosis; Cell Adhesion Molecules; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Reactive Oxygen Species; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
[Experience with ronkoleukin and alfaferon combination in complex chronic hepatitis C treatment].
Topics: Adult; Antigens, CD; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load | 2011 |
Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.
Topics: Amino Acid Sequence; Antiviral Agents; Computational Biology; Databases, Protein; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Expert Systems; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protein Structure, Tertiary; Recombinant Proteins; Ribavirin; Serbia; Viral Proteins | 2012 |
Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2012 |
Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
Topics: Adult; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retinal Artery Occlusion; Retinal Vein Occlusion; Ribavirin; Visual Acuity | 2012 |
[Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.
Topics: Asian People; Cell Nucleus; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Protein Transport; Recombinant Proteins; Ribavirin; STAT1 Transcription Factor; Treatment Outcome | 2011 |
Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α.
Topics: Adult; Aged; Antibodies, Neutralizing; Antiviral Agents; Chi-Square Distribution; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment.
Topics: Adipose Tissue; Adult; Antiviral Agents; Basal Metabolism; Body Fluid Compartments; Body Mass Index; Diet Records; Energy Intake; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Standard of Care; Statistics, Nonparametric; Weight Loss | 2012 |
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2012 |
Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; MicroRNAs; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin | 2012 |
Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin.
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Ribavirin | 2012 |
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approach.
Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2012 |
Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.
Topics: Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin | 2012 |
Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Ribavirin; Treatment Outcome | 2012 |
Optimal treatment duration for patients with HCV genotype 1 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Topics: Adult; Anemia; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Oseltamivir; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2012 |
CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.
Topics: Antiviral Agents; Biomarkers; Biopsy; Chemokine CCL5; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Leukocytes; Liver; Liver Cirrhosis; Microarray Analysis; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Signal Transduction; Toll-Like Receptor 3 | 2012 |
Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Serum; Treatment Outcome; Viral Load | 2012 |
Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Biopsy; Cells, Cultured; Female; Gene Expression; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Immunohistochemistry; Immunologic Factors; Interferons; Liver; Male; Middle Aged; Myxovirus Resistance Proteins; Ribavirin; Treatment Outcome | 2012 |
Treatment and follow up of children with chronic hepatitis C in Albania.
Topics: Administration, Oral; Adolescent; Albania; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2012 |
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2012 |
Current treatment options and response rates in children with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2012 |
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2012 |
Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Quality of Life; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2012 |
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
Topics: Administration, Oral; Anemia; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Taiwan | 2012 |
Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
Topics: Adult; Age Factors; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Observation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer; Viral Load | 2012 |
Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Conserved Sequence; eIF-2 Kinase; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Phosphorylation; Phylogeny; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Serum; Viral Envelope Proteins | 2012 |
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
Topics: Antiviral Agents; Blood Glucose; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA | 2012 |
Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alleles; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Testing; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Enkephalin, Methionine; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Receptors, Opioid, delta; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2012 |
Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Topics: Adult; Animals; Antiviral Agents; Autoantibodies; Cell Line; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organelles; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-6; Interleukin-9; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Treatment Failure; Viral Load | 2012 |
Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Immunoenzyme Techniques; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin | 2012 |
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; United Kingdom; Viral Load | 2012 |
The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Receptors, Calcitriol; Ribavirin; Treatment Outcome; Vitamin D | 2012 |
Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Romania; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment.
Topics: Adult; Antigens, CD; Antiviral Agents; B7-1 Antigen; B7-2 Antigen; CD83 Antigen; Dendritic Cells; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon-alpha; Male; Membrane Glycoproteins; Middle Aged; Myeloid Cells; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation; Young Adult | 2012 |
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Topics: Antiviral Agents; Cohort Studies; Down-Regulation; Female; Gene Expression Profiling; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Time Factors; Up-Regulation | 2012 |
Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
Topics: Antiviral Agents; Base Sequence; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Escherichia coli; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins; Young Adult | 2012 |
Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
Topics: Adult; Antiviral Agents; Diabetic Retinopathy; Diagnostic Techniques, Ophthalmological; Drug Monitoring; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Hypertension; Hypertensive Retinopathy; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
[Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome | 2011 |
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
Topics: Antiviral Agents; Apoptosis Regulatory Proteins; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Programmed Cell Death 1 Receptor; Ribavirin; Viral Load | 2012 |
HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
Topics: Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-gamma; Longitudinal Studies; Lymphocyte Activation; Male; Reference Values; Ribavirin; Sensitivity and Specificity; T-Cell Antigen Receptor Specificity | 2012 |
[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection.
Topics: Abducens Nerve Diseases; Adult; Antiviral Agents; Eye; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Muscle, Skeletal; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Young Adult | 2012 |
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Medication Adherence; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Treatment Outcome | 2012 |
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2012 |
Study for frequency and aetiology of lymphadenopathy during combination therapy for chronic hepatitis C (pegylated interferon alpha plus ribavirin) at a tertiary care hospital in Hyderabad.
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Diseases; Male; Middle Aged; Pakistan; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2011 |
The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Blood Glucose; Chi-Square Distribution; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prediabetic State; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Taiwan; Treatment Outcome; Viral Load | 2012 |
Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Topics: Adult; Bacteria; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Demography; Female; Fibrosis; Hepatitis C, Chronic; HIV Infections; HLA-DR Antigens; Humans; Interferon-alpha; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Solubility; Treatment Outcome | 2012 |
Agranulocytosis during treatment of chronic hepatitis C complicated by hyperthyreosis. Case reports.
Topics: Adult; Agranulocytosis; Antithyroid Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperthyroidism; Interferon alpha-2; Interferon-alpha; Methimazole; Middle Aged; Polyethylene Glycols; Propylthiouracil; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2012 |
Interferon-induced thyroiditis during treatment of chronic hepatitis C.
Topics: Age Factors; Algorithms; Antithyroid Agents; Antiviral Agents; Autoantibodies; Diagnosis, Differential; Drug Interactions; Female; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Risk Factors; Sex Factors; Thyroid Gland; Thyroiditis | 2012 |
HCV infection, HOMA index and sustained virological response: the step we need to take before moving forward.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Ribavirin | 2012 |
The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin | 2012 |
Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2012 |
The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.
Topics: Aged; Antiviral Agents; Blood Platelets; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Typing; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load; Virus Replication | 2012 |
[The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bacterial Infections; CD4-Positive T-Lymphocytes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferons; Leukocyte Count; Male; Middle Aged; Neutrophils; Opportunistic Infections; Ribavirin | 2012 |
[Current indications for triple therapy in hepatitis C virus infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Confidence Intervals; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Time Factors; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 9; Viral Load; Young Adult | 2012 |
Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?
Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Factors | 2012 |
Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Confidence Intervals; Donor Selection; End Stage Liver Disease; Female; Genetic Testing; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC).
Topics: Down-Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Peptide Elongation Factors; Peptide Initiation Factors; Polyethylene Glycols; Protein Biosynthesis; Recombinant Proteins; Ribavirin; Ribosomal Proteins; Ribosomes | 2012 |
Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2012 |
Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Mutation; Polymorphism, Genetic; Ribavirin; Sequence Analysis; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2012 |
NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Apoptosis; Case-Control Studies; Fas Ligand Protein; Female; Hepatic Stellate Cells; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Polyethylene Glycols; Recombinant Proteins; Ribavirin; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2012 |
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Topics: Aged; Analysis of Variance; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load | 2012 |
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
Topics: Antiviral Agents; Female; Gastrointestinal Hemorrhage; Hematoma; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoas Muscles; Recombinant Proteins; Ribavirin | 2012 |
[Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin].
Topics: Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Young Adult | 2012 |
The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Area Under Curve; Black or African American; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People | 2012 |
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Ribavirin; Thrombocytopenia; Young Adult | 2012 |
Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2012 |
[Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thyroid Diseases; Thyroid Gland; Treatment Outcome | 2012 |
Liver biopsy in chronic hepatitis C: the experience of 15 Italian wards of infectious diseases.
Topics: Adult; Antiviral Agents; Biopsy, Needle; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Hospital Units; Hospitals, Isolation; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Italy; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Surveys and Questionnaires; Treatment Outcome | 2012 |
B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha.
Topics: Age Factors; Antiviral Agents; Autoantibodies; Autoimmunity; B-Cell Activating Factor; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Peroxidase; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sex Factors; Thyroid Gland | 2012 |
Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.
Topics: Age Factors; Aged; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Secondary Prevention; United States | 2013 |
[Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hearing Disorders; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2012 |
[A study of the relationship between neutropenia and clinical infection risk during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2012 |
Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
Topics: Administration, Oral; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin | 2012 |
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Gene Knockdown Techniques; Gene Silencing; Hep G2 Cells; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Interferon-alpha; Male; Metformin; Mice; Mice, Obese; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-akt; Ribavirin; STAT1 Transcription Factor; Tumor Necrosis Factor-alpha; Vanadates | 2012 |
Chronic hepatitis C: treat or wait? Medical decision making in clinical practice.
Topics: Adult; Antiviral Agents; Cohort Studies; Decision Making; Female; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Practice Patterns, Physicians'; Prospective Studies; Recombinant Proteins; Refusal to Treat; Ribavirin; Surveys and Questionnaires; Treatment Refusal | 2012 |
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
Topics: Adult; Antiviral Agents; Cholesterol, LDL; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Should routine screening for celiac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C or not?
Topics: Celiac Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2012 |
Comparison of hepatitis C virus treatment between incarcerated and community patients.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Confidence Intervals; Databases, Factual; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Prisoners; Recombinant Proteins; Residence Characteristics; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2012 |
Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco.
Topics: Adult; Alleles; Base Sequence; Cohort Studies; DNA Primers; Hepatitis C, Chronic; Humans; Infant, Newborn; Interferons; Interleukins; Morocco; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin | 2012 |
Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin | 2012 |
The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
Topics: Alanine Transaminase; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2012 |
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Hepatitis C infection in childhood.
Topics: Antiviral Agents; Biopsy; Child; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Mass Screening; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin | 2012 |
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lipase; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Development of new IL28B genotyping method using Invader Plus assay.
Topics: Adult; Aged; Asian People; Female; Genetic Techniques; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Reagent Kits, Diagnostic; Ribavirin | 2012 |
Genetic factors and hepatitis C virus infection.
Topics: Antiviral Agents; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2012 |
Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Treatment Outcome | 2012 |
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load | 2012 |
IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome; Viral Load | 2012 |
New genetic discoveries and treatment for hepatitis C.
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Proline; Recombinant Proteins; Ribavirin | 2012 |
Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).
Topics: Adult; Aged; Anemia; Cohort Studies; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin | 2012 |
Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Prospective Studies; Ribavirin | 2012 |
Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Japan; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Open Reading Frames; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Scandinavian and Nordic Countries; Treatment Outcome | 2012 |
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Virology | 2012 |
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
Topics: Adult; Anemia; Antiviral Agents; Coinfection; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Ribavirin; Treatment Outcome | 2012 |
Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin; United States | 2013 |
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Vitamin D; Vitamin D-Binding Protein; Young Adult | 2012 |
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2012 |
Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Topics: Aged; Antiviral Agents; Area Under Curve; Cohort Studies; Confidence Intervals; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2012 |
Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leukocytes, Mononuclear; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Virology | 2012 |
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure | 2012 |
Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Antiviral Agents; Area Under Curve; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin | 2012 |
Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Lipoproteins, LDL; Liver Cirrhosis; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2012 |
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Is the end of chronic hepatitis C virus infection in sight?
Topics: Antiviral Agents; Drug Users; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2012 |
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Users; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Victoria | 2012 |
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biopsy; Blotting, Western; CD8-Positive T-Lymphocytes; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; Endopeptidases; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunohistochemistry; Interferon-alpha; Interferon-gamma; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Phosphorylation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; STAT1 Transcription Factor; Switzerland; Time Factors; Transcription, Genetic; Treatment Outcome; Ubiquitin Thiolesterase | 2012 |
Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Ribavirin; Serum; Treatment Outcome | 2012 |
Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Topics: 5' Untranslated Regions; Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins | 2012 |
Interferon-induced sarcoidosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis | 2011 |
Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2012 |
Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoassay; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins | 2012 |
Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia; Young Adult | 2012 |
Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2012 |
Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?
Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Egypt; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2012 |
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Treatment Outcome | 2012 |
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Viral Load | 2012 |
New approaches to the management of hepatitis C in haemophilia in 2012.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2012 |
Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.
Topics: Adult; Antiviral Agents; Computational Biology; Down-Regulation; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Molecular Diagnostic Techniques; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Up-Regulation | 2012 |
[Efficacy of peg interferon alpha-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients].
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Impact of ribavirin dose on retreatment of chronic hepatitis C patients.
Topics: Adult; Age Factors; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2012 |
Effect of discounting on estimation of benefits determined by hepatitis C treatment.
Topics: Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin | 2012 |
Changes in fasting plasma glucose levels with ribavirin and pegylated interferon treatment in normal and impaired glucose tolerant patients with chronic hepatitis C.
Topics: Antiviral Agents; Blood Glucose; Female; Glucose Intolerance; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2012 |
Successful desensitization to ribavirin in a patient with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Desensitization, Immunologic; Drug Hypersensitivity; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiobarbituric Acid Reactive Substances; Treatment Outcome | 2012 |
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index | 2012 |
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Topics: Adult; Aged; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon-alpha; Male; Middle Aged; Ribavirin; Silybin; Silymarin; Treatment Outcome; Viremia | 2012 |
Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
Topics: Alanine Transaminase; Anemia; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Hearing Loss, Sudden; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2012 |
[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2012 |
Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2012 |
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Aged; Calcifediol; Demography; Female; Gene Frequency; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Seasons; Treatment Outcome; Vitamin D; Young Adult | 2012 |
A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms.
Topics: Algorithms; Anemia; Antiviral Agents; Hemoglobins; Hepatitis C, Chronic; Humans; Models, Biological; Polymorphism, Genetic; Pyrophosphatases; Reproducibility of Results; Ribavirin | 2012 |
Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?
Topics: Antiviral Agents; Drug Synergism; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Peptide Chain Initiation, Translational; Ribavirin | 2012 |
Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2012 |
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cell Proliferation; Clone Cells; Female; Hepatitis C, Chronic; Humans; Interleukin-2; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells | 2012 |
Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Italy; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Predicted effects of treatment for HCV infection vary among European countries.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Mass Screening; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2012 |
Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.
Topics: Antiviral Agents; Black or African American; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Research Subjects; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Failure | 2012 |
A case of chronic hepatitis C with nephrotic diabetic nephropathy who achieved sustained viral remission by double-filtration plasmapheresis and interferon combination therapy.
Topics: Aged; Antiviral Agents; Combined Modality Therapy; Diabetic Nephropathies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Viral Load | 2012 |
Expression of IFNAR2 mRNA in peripheral blood mononuclear cells of patients with HCV infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger | 2012 |
Relationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin | 2012 |
Efficacy of pegylated interferon-alpha-2a plus ribavirin for patients aged at least 60 years with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Platelet Count; Receptors, Fc; Recombinant Fusion Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Thrombopoietin; Time Factors; Treatment Outcome | 2012 |
Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Mutation; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Decision Support Techniques; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Prognosis; Ribavirin; Treatment Outcome | 2012 |
Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2012 |
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Topics: Aged; Antiviral Agents; Cyclosporine; Disease Management; Drug Therapy, Combination; Everolimus; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Tacrolimus; Viral Load | 2012 |
Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Homocysteine; Humans; Hyperhomocysteinemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triglycerides; Young Adult | 2012 |
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Japan; Male; Middle Aged; Ribavirin; Treatment Outcome; Young Adult | 2012 |
HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; HLA-B15 Antigen; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA | 2012 |
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites.
Topics: Adenosine Monophosphate; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Glucuronosyltransferase; Hepatitis C, Chronic; Humans; Nucleotides; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Uridine; Uridine Diphosphate; Uridine Monophosphate | 2012 |
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Topics: Adult; Anti-Retroviral Agents; Cardiac Output; CD4 Lymphocyte Count; Coinfection; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Interferon-alpha; Liver; Liver Cirrhosis; Lung; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viremia | 2012 |
A new tool to study ribavirin-induced haemolysis.
Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Dipyridamole; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythrocytes; Glutathione; Hematologic Tests; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Poliovirus; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2013 |
Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.
Topics: Adaptive Immunity; Adult; Aged; Antiviral Agents; Chemokines; Cytokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.
Topics: Adult; Aged; Antibodies, Neutralizing; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutralization Tests; Ribavirin; Treatment Outcome | 2012 |
Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Proteins | 2012 |
[Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2012 |
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Liver Neoplasms; Male; Middle Aged; Patient Selection; Platelet Count; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2013 |
Correlation between HCV viraemia and splenic volume in chronic HCV infected patients: an Egyptian study.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organ Size; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spleen; Statistics, Nonparametric; Ultrasonography; Viral Load; Viremia | 2012 |
High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Palmitic Acid; Polymorphism, Single Nucleotide; Ribavirin; Virus Replication; Young Adult | 2012 |
[Changes of the serum adiponectin during treatment with peginterferon α-2a and ribavirin for chronic hepatitis C].
Topics: Adiponectin; Adolescent; Adult; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antiviral Agents; Cough; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2013 |
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors | 2013 |
Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients.
Topics: Acquired Immunodeficiency Syndrome; Alleles; Anti-HIV Agents; Antiviral Agents; Chromosomes, Human, Pair 6; Coinfection; Female; Genotype; Hepatitis C, Chronic; HIV-1; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
Topics: Antiviral Agents; Egypt; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Molecular Sequence Data; Predictive Value of Tests; Prognosis; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Ribavirin | 2012 |
IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Platelet Count; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Viral Load | 2012 |
SASLT practice guidelines: management of hepatitis C virus infection.
Topics: Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors; Saudi Arabia | 2012 |
Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Romania; Treatment Outcome | 2012 |
Treatment with Peg-IFNα2a/ribavirin and low-dose NSAID for patients with chronic hepatitis C and rheumatoid syndrome.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Rheumatic Diseases; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2013 |
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.
Topics: Adult; Aged; Antiviral Agents; Black or African American; Cross-Sectional Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Vitamin D; Young Adult | 2012 |
Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Forecasting; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2012 |
[Treatment of chronic hepatitis viral C: new associations].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
Topics: Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Ribavirin | 2012 |
Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C.
Topics: Alleles; Antiviral Agents; Asian People; Case-Control Studies; Chromosomes, Human, Pair 12; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Introns; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Polymorphism, Single Nucleotide; Polypeptide N-acetylgalactosaminyltransferase; Ribavirin; Transcription, Genetic; Treatment Outcome; Virus Replication | 2013 |
Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon-alpha; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Psychotherapy, Group; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection.
Topics: Antiviral Agents; Hepatitis C, Chronic; Hodgkin Disease; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Tomography, X-Ray Computed | 2012 |
Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
Topics: Adult; Antiviral Agents; Biomarkers; Carrier State; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Portugal; Prospective Studies; Ribavirin; Viral Load | 2013 |
Double filtration plasmapheresis could induce a favorable immune response for chronic hepatitis C therapy.
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Filtration; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult | 2012 |
A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Black People; Drug Therapy, Combination; Evolution, Molecular; Female; Genome, Human; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Phylogeny; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viral Nonstructural Proteins; White People; Young Adult | 2012 |
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
Combination effect of ribavirin and erythropoietin treatment on hemoglobin A1c in a diabetic patient with chronic hepatitis C.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin | 2012 |
Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
Topics: Antiviral Agents; Area Under Curve; Black or African American; Body Weight; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2012 |
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome | 2012 |
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
The kinetics of virological and biochemical responses in the treatment of chronic hepatitis C by dual antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2012 |
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2013 |
Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Biopsy; Female; Hepatitis C, Chronic; Hepatomegaly; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Recurrence; Ribavirin; Splenomegaly; von Willebrand Factor | 2013 |
Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Topics: Adult; Antiviral Agents; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin; Risk Factors | 2013 |
Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents?
Topics: Antiviral Agents; Contraindications; Etanercept; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon-alpha; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Ribavirin | 2013 |
Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
Topics: Adult; Antiviral Agents; Blood Glucose; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.
Topics: Adult; Aged; Antiviral Agents; Candidiasis, Oral; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lichen Planus, Oral; Male; Middle Aged; Polyethylene Glycols; Prevalence; Ribavirin; Salivary Glands; Serum Albumin; Steroids; Stomatitis; Treatment Outcome; Weight Loss | 2012 |
Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Cytokines; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interferons; Interleukins; Male; Mice; Mice, SCID; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index | 2013 |
The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors | 2013 |
Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.
Topics: Adult; Antiviral Agents; Cell Proliferation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interleukin-10; Male; Middle Aged; Ribavirin; RNA, Viral; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Virus Replication | 2012 |
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Laparoscopy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Severity of Illness Index; Spleen; Splenectomy; Treatment Outcome; Ubiquitins | 2012 |
Interferon-induced central retinal vein thrombosis.
Topics: Anticholesteremic Agents; Anticoagulants; Antiviral Agents; Dyslipidemias; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Retinal Vein Occlusion; Ribavirin; Treatment Outcome; Visual Acuity | 2012 |
A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-rib
Topics: Antiviral Agents; Brazil; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Sarcoidosis and chronic hepatitis C: a case report.
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Diseases; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Sarcoidosis, Pulmonary; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Cryoglobulinemia; Cryoglobulins; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Medical Futility; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2013 |
Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.
Topics: Adult; Aged; Antiviral Agents; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2013 |
Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quinolines; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nuclear Proteins; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome; Young Adult | 2013 |
Recurrence of hepatitis C virus infection during pityriasis rosea.
Topics: Adult; Antiviral Agents; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Interferon-alpha; Pityriasis Rosea; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Virus Activation | 2013 |
Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.
Topics: Adult; Antiviral Agents; Asian People; Chi-Square Distribution; Confidence Intervals; Drug Therapy, Combination; Female; Gene Frequency; GTP-Binding Protein beta Subunits; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome | 2012 |
None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.
Topics: Data Interpretation, Statistical; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Topics: Adult; Antiviral Agents; Australia; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Early Medical Intervention; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Victoria | 2013 |
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin D | 2013 |
[Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2012 |
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
Topics: Anemia; Antiviral Agents; Cohort Studies; Female; Genetic Association Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2013 |
Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Viral Load | 2013 |
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2012 |
Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.
Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sensitivity and Specificity | 2013 |
Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin | 2013 |
Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin | 2013 |
Diagnosis of inflammatory bowel disease in chronic hepatitis C patients treated with pegylated interferon and ribavirin: coincidence or consequence?
Topics: Adult; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin | 2013 |
[Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.
Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Regression Analysis; Retreatment; Retrospective Studies; Ribavirin; Risk Assessment; Survival Analysis; Treatment Outcome | 2013 |
IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Syria; Treatment Outcome; Viral Load | 2013 |
Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Vitamin D; Vitamin D Deficiency | 2013 |
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome | 2013 |
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Female; Genetic Testing; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Outcome | 2013 |
Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome | 2012 |
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Statistics, Nonparametric; Time Factors; Treatment Failure | 2012 |
[Lingual hyperpigmentation in a patient with chronic infection].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferons; Polyethylene Glycols; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Ribavirin; Tongue Diseases | 2013 |
From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond.
Topics: Animals; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2013 |
Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Retrospective Studies; Ribavirin; United States; United States Department of Veterans Affairs; Veterans | 2013 |
The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience.
Topics: Adult; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Reoperation; Ribavirin; Survival Rate; Treatment Outcome | 2012 |
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferons; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Psychopathology; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2013 |
Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Topics: 2',5'-Oligoadenylate Synthetase; Adolescent; Adult; Aged; Antiviral Agents; Child; Cytokines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphocytes; Male; Middle Aged; Prognosis; Ribavirin; RNA, Viral; Toll-Like Receptors; Treatment Outcome; Ubiquitins; Viral Load; Young Adult | 2013 |
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Contraindications; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2013 |
[The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Precision Medicine; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2012 |
Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
Topics: Adult; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Ribavirin; Substance-Related Disorders | 2013 |
Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Pyrophosphatases; Ribavirin; Treatment Failure | 2013 |
Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Attention; Cognition; Cognition Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Psychological Tests; Psychometrics; Recombinant Proteins; Reproducibility of Results; Ribavirin; Treatment Outcome | 2013 |
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2013 |
[Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
Topics: Adult; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2013 |
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.
Topics: Antibodies; Antigens, Neoplasm; Antiviral Agents; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Lectins; Liver Cirrhosis; Membrane Glycoproteins; Polyethylene Glycols; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin | 2013 |
Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; United Kingdom | 2013 |
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome | 2013 |
Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Arginase; Cell Count; Disease Progression; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Ribavirin; RNA, Viral; T-Lymphocytes; Young Adult | 2013 |
Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Portugal; Proline; Recombinant Proteins; Ribavirin | 2013 |
Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.
Topics: Adult; Alleles; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genes, MHC Class I; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome | 2013 |
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; CD36 Antigens; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Plasma; Ribavirin; Severity of Illness Index | 2013 |
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; RNA, Viral; Standard of Care; Treatment Outcome; Viral Load; Young Adult | 2013 |
[Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA | 2012 |
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Alanine Transaminase; Cohort Studies; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Proportional Hazards Models; Ribavirin | 2013 |
Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin | 2013 |
[What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Waiting Lists | 2013 |
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4.
Topics: Adult; Antiviral Agents; Case-Control Studies; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2013 |
Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C.
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
[Pegylated interferon sets a new standard. Better prognosis for hepatitis C infected patients].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy.
Topics: Antineoplastic Agents; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Forecasting; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Predictive Value of Tests; Ribavirin; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2002 |
Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases.
Topics: Biopsy, Needle; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases | 2002 |
Effect of induction therapy on Hepatitis C.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Hepatocytes; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Iron; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Ribavirin; Transferrin | 2002 |
Difficulties in conducting large-scale studies on rare diseases: the case for pediatric hepatitis C infection.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sample Size; Treatment Outcome | 2002 |
Urticarial vasculitis with asymptomatic chronic hepatitis C infection: response to doxepin, interferon-alfa, and ribavirin.
Topics: Adolescent; Antiviral Agents; Doxepin; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Histamine Antagonists; Humans; Interferon-alpha; Ribavirin; Urticaria; Vasculitis | 2002 |
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2002 |
Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; eIF-2 Kinase; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Myxovirus Resistance Proteins; Proteins; Recombinant Proteins; Ribavirin | 2002 |
Dynamics of HCV replication in patients with chronic hepatitis C during interferon and ribavirin combined therapy.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Ribavirin; Time Factors; Virus Replication | 2001 |
[Chronic hepatitis C virus infection: always treat!--Pro].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin | 2002 |
[Chronic hepatitis C virus infection: always treat!--Contra].
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin | 2002 |
Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
Topics: Antiviral Agents; Blood Sedimentation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2002 |
Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C virus infection refractory to alpha-interferon.
Topics: Antiviral Agents; Cyclophosphamide; Drug Resistance; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon Type I; Middle Aged; Nephrotic Syndrome; Recombinant Proteins; Ribavirin | 2002 |
A case study in hepatitis C disease progression: reaching out while searching for new clues.
Topics: Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Gland | 2002 |
Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Remission Induction; Ribavirin; Treatment Outcome; Viral Load | 2002 |
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2002 |
I favor therapy for hepatitis C virus recurrence after transplantation.
Topics: Acute Disease; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral | 2002 |
Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?
Topics: Antiviral Agents; Autoimmune Diseases; Autoimmunity; Drug Therapy, Combination; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thyroid Diseases; Thyroid Gland | 2002 |
Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Pilot Projects; Ribavirin; Treatment Outcome | 2002 |
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.
Topics: Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Logistic Models; Male; Models, Biological; Ribavirin | 2002 |
Weight loss in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Mitochondria; Ribavirin; Weight Loss | 2002 |
Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome.
Topics: Adult; Antiviral Agents; Asia, Southeastern; Asian People; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins | 2002 |
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Prevalence; Retrospective Studies; Ribavirin; United States; White People | 2002 |
Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Porphyria Cutanea Tarda; Ribavirin | 2002 |
[Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Alopecia areata during interferon alpha-2b/ribavirin therapy.
Topics: Alopecia Areata; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin | 2002 |
C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Promoter Regions, Genetic; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2002 |
Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin | 2002 |
Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.
Topics: Antimetabolites; Antiviral Agents; Apoptosis; Cell Division; Cells, Cultured; Cytokines; DNA; Hepacivirus; Hepatitis C, Chronic; Humans; Leukocytes, Mononuclear; Phytohemagglutinins; Protein Biosynthesis; Proteins; Ribavirin; RNA; RNA, Viral | 2003 |
Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Thalassemia; Time Factors | 2002 |
Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients.
Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin | 2002 |
[What therapy is meaningful in chronic hepatitis C and resection of hepatocellular carcinoma for recurrence prophylaxis?].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin | 2002 |
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis; Viremia | 2002 |
Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis.
Topics: Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure | 2002 |
Ribavirin quantification in combination treatment of chronic hepatitis C.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Treatment Outcome | 2003 |
Regression of splenic lymphoma after treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma, B-Cell; Ribavirin; RNA, Viral; Splenic Neoplasms | 2002 |
Listeria monocytogenes meningitis in a patient with chronic hepatitis C infection, treated by interferon alfa and ribavirin.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Listeria monocytogenes; Listeriosis; Meningitis; Ribavirin | 2003 |
Successfull response to alpha 2b interferon plus ribavirin associated with venesectomies in a patient with chronic hepatitis C and genetic hemochromatosis.
Topics: Antiviral Agents; Hemochromatosis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phlebotomy; Recombinant Proteins; Ribavirin | 2003 |
[Prospective study of combination of interferon-alpha with ribavirin for treatment of chronic hepatitis C in children].
Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin | 2001 |
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Treatment for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
[Pegylated interferon alpha-2a. Quality of life improves significantly during successful therapy].
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
[Chronic hepatitis C. A new chance with Consensus Interferon for patients with handicaps].
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Meta-Analysis as Topic; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Risk Factors; Time Factors; Viral Load | 2002 |
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Topics: Adult; Alcohol Drinking; Antidepressive Agents; Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medical Records; Mental Disorders; Methadone; Middle Aged; Patient Compliance; Patient Dropouts; Prospective Studies; Ribavirin; Risk Factors; Substance-Related Disorders | 2003 |
SEN virus infection in patients with chronic hepatitis C: preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin.
Topics: Adult; Antiviral Agents; DNA Viruses; DNA, Single-Stranded; DNA, Viral; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Virus Diseases | 2003 |
Treatment of chronic hepatitis C in a state correctional facility.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Prisons; Retrospective Studies; Rhode Island; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Summaries for patients. Treatment for hepatitis C virus infection among inmates.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Prisons; Retrospective Studies; Rhode Island; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Assessment of depression in patients with chronic hepatitis: effect of interferon treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Depression; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2002 |
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retina; Retinal Diseases; Ribavirin; Vision Disorders; Visual Fields | 2003 |
Characteristics of and current treatment options for hepatitis B and hepatitis C.
Topics: Adult; Antiviral Agents; Drug Combinations; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin | 2000 |
[ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Predictive Value of Tests; Recurrence; Ribavirin; ROC Curve | 2002 |
Erythematous maculopapular eruption due to ribavirin administration in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Parapsoriasis; Recombinant Proteins; Ribavirin | 2003 |
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Leukocytes, Mononuclear; Middle Aged; Oligonucleotide Array Sequence Analysis; Recombinant Proteins; Ribavirin; RNA, Messenger | 2003 |
Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Eukaryotic Initiation Factor-2; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Alignment; Viral Envelope Proteins; Viral Nonstructural Proteins | 2003 |
The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; RNA, Viral | 2003 |
Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2003 |
[Only 1 injection per week brings a 60% chance of healing. New therapy recommendations in chronic hepatitis C].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Support Systems, Clinical; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Quality of Life; Ribavirin; Sensitivity and Specificity | 2003 |
A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2003 |
Hemoglobinuria with ribavirin treatment.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hemoglobinuria; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index | 2003 |
Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2003 |
[Anterior uveitis in a patient treated with pegylated interferon and ribavirin].
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Uveitis | 2003 |
[Clinical response to etiotropic therapy of chronic viral hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Mannan-binding lectin and hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Ribavirin | 2003 |
Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2003 |
[Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin | 2003 |
Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Epitopes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2003 |
Combination therapy with interferon-alpha and ribavirin as immunomodulators in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Th1 Cells | 2003 |
Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Cytokines; Drug Therapy, Combination; eIF-2 Kinase; Female; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-8; Liver; Liver Diseases; Male; Myxovirus Resistance Proteins; Proteins; Recombinant Proteins; Ribavirin; RNA, Messenger; Ubiquitins; Up-Regulation | 2003 |
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Recombinant Proteins; Ribavirin | 2003 |
Paternal exposure to ribavirin: pregnancy and neonatal outcome.
Topics: Abnormalities, Drug-Induced; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fetus; Hepatitis C, Chronic; Humans; Infant, Newborn; Interferons; Male; Paternal Exposure; Pregnancy; Pregnancy Outcome; Ribavirin | 2003 |
[Antiviral treatment in liver cirrhosis due to hepatitis C virus].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Waiting Lists | 2003 |
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Eicosapentaenoic Acid; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
[Chronic viral hepatitis].
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Clinical Enzyme Tests; Diagnosis, Differential; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Time Factors | 2003 |
Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors.
Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
[Hepatitis C and tricholeukocyte leukemia: a fortuitous association? A case report].
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Ribavirin | 2003 |
Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Paternal Exposure; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin | 2003 |
High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2003 |
An heteroduplex mobility analysis assay based on capillary electrophoresis for the study of HCV quasispecies.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Electrophoresis, Capillary; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Heteroduplex Analysis; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Proteins | 2003 |
[Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment].
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2003 |
Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.
Topics: Adult; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Migraine Disorders; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2003 |
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2003 |
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.
Topics: Analgesics, Non-Narcotic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interleukin-2; Retreatment; Ribavirin; Treatment Outcome | 2003 |
Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Topics: Adipokines; Adult; Antiviral Agents; Biomarkers; Chitinase-3-Like Protein 1; Female; Glycoproteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Middle Aged; Peptide Fragments; Predictive Value of Tests; Procollagen; Ribavirin; RNA, Viral; Severity of Illness Index; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2003 |
Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2003 |
Management of hepatitis C.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Minnesota; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Topics: Antiviral Agents; Branched DNA Signal Amplification Assay; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferons; Reagent Kits, Diagnostic; Reproducibility of Results; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Viremia | 2003 |
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Liver Cirrhosis; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States | 2003 |
Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2003 |
The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Receptors, CCR5; Ribavirin | 2003 |
[Place of consensus type interferon alpha in the management of chronic type C hepatitis].
Topics: Antiviral Agents; Consensus; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Topics: Adult; Aging; Alleles; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class II; HLA-B Antigens; HLA-B44 Antigen; Humans; Interferons; Middle Aged; Multivariate Analysis; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2003 |
Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Point Mutation; Receptors, CCR5; Ribavirin | 2003 |
Reversal of cirrhosis: evidence-based medicine?
Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Hepatitis C infections. From diagnosis to treatment.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Saudi Arabia; Severity of Illness Index; Treatment Outcome | 2003 |
Hematologic disorders associated with hepatitis C virus infection and their management.
Topics: Antiviral Agents; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-11; Recombinant Proteins; Ribavirin; United States | 2003 |
Response of interferon alone and with ribavirin in patients of chronic hepatitis C.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Prospective Studies; Ribavirin | 2003 |
Hyperlipasemia associated with hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lipase; Liver Function Tests; Male; Middle Aged; Pancreatitis; Retrospective Studies; Ribavirin; Viral Load | 2003 |
Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin | 2003 |
Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Obesity; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure | 2003 |
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2003 |
High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2003 |
Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism.
Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Tumor Necrosis Factor-alpha | 2003 |
The effect of early treatment in children with chronic hepatitis.
Topics: Antiviral Agents; Child; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2003 |
Slow viral dynamics of hepatitis C virus genotype 4.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2003 |
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.
Topics: Adult; Aged; Antigens, CD; Antiviral Agents; B-Lymphocytes; CD5 Antigens; Down-Regulation; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Membrane Proteins; Middle Aged; Ribavirin; RNA, Viral; Tetraspanin 28 | 2003 |
Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
Topics: Adult; Antiviral Agents; Cell Division; Cells, Cultured; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; T-Lymphocytes, Cytotoxic; Viremia | 2003 |
Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2003 |
A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Virus Activation | 2003 |
The treatment of viral hepatitis, present and future.
Topics: Amantadine; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2003 |
Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2003 |
Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome | 2003 |
Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2003 |
[Chronic C virus infection management].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
[Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin].
Topics: Adult; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2003 |
Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease.
Topics: Adult; Celiac Disease; Diabetes Mellitus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Prognosis; Ribavirin; Risk Assessment | 2003 |
The role of specific CD4+ T helper cell response in the course of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; CD4 Antigens; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer | 2003 |
Anemia in the treatment of hepatitis C virus infection.
Topics: Anemia; Antiviral Agents; Epoetin Alfa; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
[Therapy with interferon alfa and ribavirin in patients with chronic hepatitis C and normal levels of alanine aminotransferase].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Retrospective Studies; Ribavirin | 2003 |
Antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Australia; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2003 |
Vertebral osteopenia due to bone marrow hyperplasia during interferon-alpha and ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Bone Diseases, Metabolic; Bone Marrow; Hepatitis C, Chronic; Humans; Hyperplasia; Interferon alpha-2; Interferon-alpha; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2003 |
Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Biopsy; CD8-Positive T-Lymphocytes; Cell Count; Cytokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral | 2003 |
Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2004 |
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
Topics: Anemia, Hemolytic; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Male; Prognosis; Ribavirin; Treatment Outcome | 2003 |
Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Cryoglobulinemia; Drug Resistance, Neoplasm; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; Vasculitis | 2003 |
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Tyranny of algorithms in the treatment of patients with hepatitis C.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Use of incomplete post-treatment data in the analysis of viral eradication studies.
Topics: Antiviral Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Statistical; Ribavirin; Viral Load | 2003 |
[Chronic hepatitis C. Chances of healing good as never before].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Recombinant Proteins; Ribavirin; Time Factors | 2003 |
[Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2003 |
Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Progress on the treatment of hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Purpura, Thrombocytopenic, Idiopathic; Ribavirin | 2004 |
[Treatment of hepatitis C in nonresponders to ribavirin and/or interferon].
Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 2004 |
[Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Autoimmune Diseases; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Islets of Langerhans; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Treatment of chronic hepatitis C in a state correctional facility.
Topics: Data Interpretation, Statistical; Hepatitis C, Chronic; Humans; Interferon-alpha; Prisons; Rhode Island; Ribavirin | 2004 |
Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.
Topics: 5' Untranslated Regions; Adult; Antiviral Agents; Base Sequence; Codon, Initiator; Drug Resistance, Viral; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Nucleic Acid Conformation; Point Mutation; Polymorphism, Genetic; Protein Biosynthesis; Recombinant Proteins; Regulatory Sequences, Nucleic Acid; Ribavirin; RNA, Viral | 2004 |
[Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2003 |
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2004 |
Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome | 2004 |
[Hemosiderosis in Chronic Hepatitis C: Should Venesection Precede Treatment with Interferon-alpha and Ribavirin?].
Topics: Antiviral Agents; Bloodletting; Combined Modality Therapy; Female; Hemochromatosis Protein; Hemosiderosis; Hepatitis B; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Male; Membrane Proteins; Mutation; Randomized Controlled Trials as Topic; Ribavirin | 2004 |
Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2004 |
Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; eIF-2 Kinase; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Phosphorylation; Point Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2003 |
Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Viral Load | 2004 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Ribavirin | 2004 |
Antiviral action of ribavirin in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osmolar Concentration; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2004 |
Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Antiviral Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Haloperidol; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lithium Carbonate; Long-Term Care; Male; Polyethylene Glycols; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin | 2004 |
Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin.
Topics: Adult; Antioxidants; Antiviral Agents; Biomarkers; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Function Tests; Male; Middle Aged; Nitric Oxide; Probability; Recombinant Proteins; Ribavirin; Sampling Studies; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2003 |
Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2004 |
[Successful treatment of chronic hepatitis C in hemophiliacs based on historical development of therapeutic protocols].
Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 2004 |
Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin | 2004 |
Should routine screening for coeliac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C?
Topics: Antiviral Agents; Celiac Disease; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2004 |
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases | 2004 |
The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.
Topics: Antibody Specificity; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2004 |
[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
Topics: Antiviral Agents; Autoimmunity; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2004 |
Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient.
Topics: Child; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ki-1 Antigen; Male; Ribavirin; Solubility; Treatment Outcome | 2004 |
Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.
Topics: Anemia; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocytes; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index | 2004 |
Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Nonstructural Proteins | 2004 |
Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C.
Topics: Antiviral Agents; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunity, Cellular; Male; Middle Aged; Phenotype; Receptors, Interleukin; Receptors, Interleukin-12; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Statistics, Nonparametric; Th1 Cells; Th2 Cells; Up-Regulation | 2004 |
Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2004 |
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2004 |
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Infections; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon-alpha; Lymphocyte Activation; Ribavirin; Th1 Cells | 2004 |
Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Viral Proteins | 2004 |
Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Dermatitis Herpetiformis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
[Therapeutic behaviour for a HCV+ patient].
Topics: Antiviral Agents; Biopsy; Contraindications; Critical Pathways; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferons; Liver; Ribavirin; Risk Factors | 2004 |
Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Division; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Viremia | 2004 |
Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Pilot Projects; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Homology, Amino Acid; Viral Nonstructural Proteins | 2004 |
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis C-autoimmune hepatitis overlap syndrome.
Topics: Adult; Antiviral Agents; Azathioprine; Drug Therapy, Combination; Female; Glucocorticoids; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Interferon-alpha; Prednisone; Recombinant Proteins; Remission Induction; Ribavirin; Syndrome | 2004 |
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects.
Topics: Antiviral Agents; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Research Design; Ribavirin | 2004 |
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Osmolar Concentration; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins | 2004 |
Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin; Treatment Failure | 2004 |
Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
Topics: Administration, Oral; Adult; Black or African American; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prisons; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Telemedicine; Treatment Outcome; Virginia; White People | 2004 |
Acute west nile virus in two patients receiving interferon and ribavirin for chronic hepatitis C.
Topics: Acute Disease; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Assessment; West Nile Fever; West Nile virus | 2004 |
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Biomarkers; Combined Modality Therapy; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunotherapy, Active; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Ribavirin; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Viral Load | 2004 |
Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Psychotherapy; Recombinant Proteins; Ribavirin | 2004 |
Presence of HCV RNA in hepatic tissue and effectiveness of treatment with interferon and ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load | 2003 |
Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2003 |
Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glutathione Transferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2004 |
High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
Topics: Adolescent; Adult; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Prisoners; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Risk Factors; RNA, Viral; Serotyping; Substance Abuse, Intravenous | 2004 |
Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins | 2004 |
Determination of ribavirin in human serum and plasma by capillary electrophoresis.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Cytidine; Electrophoresis, Capillary; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Interferon induced glomerular disease in a patient with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Nephrotic Syndrome; Ribavirin | 2003 |
Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Data Interpretation, Statistical; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
[Hepatitis C infection. Overweight virus carriers are more difficult to cure].
Topics: Antiviral Agents; Biological Availability; Body Weight; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Clearance Rate; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Lymphatic Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome; Ultrasonography | 2004 |
Tomato-based functional food as interferon adjuvant in HCV eradication therapy.
Topics: Antioxidants; Antiviral Agents; Biological Availability; Carotenoids; Drug Therapy, Combination; Female; Flavonoids; Hepatitis C, Chronic; Humans; Interferons; Male; Oxidative Stress; Ribavirin; Treatment Outcome; Vitamin E | 2004 |
SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration.
Topics: Adult; Antiviral Agents; DNA Virus Infections; DNA Viruses; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2004 |
[Observation on the efficacy and safety of Infergen combined with capsule ribavirin in treatment of hepatitis C patients].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load | 2004 |
Treatment of chronic hepatitis C in hemophilic patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 2004 |
Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection.
Topics: Biopsy, Fine-Needle; Blood Cells; CD3 Complex; CD8 Antigens; CD8-Positive T-Lymphocytes; Cell Count; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunohistochemistry; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
Topics: Antiviral Agents; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Ribavirin | 2004 |
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recombinant Proteins; Remission Induction; Ribavirin | 2004 |
Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Topics: Acute Kidney Injury; Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, IGA; Hematuria; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Capsid Proteins; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins | 2004 |
Determination of glycated hemoglobin in patients with advanced liver disease.
Topics: Antiviral Agents; Fructosamine; Glycated Hemoglobin; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2004 |
Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interleukin-12; Lymphocyte Activation; Male; Middle Aged; Ribavirin; RNA, Viral | 2004 |
FDA approves Hep C drugs.
Topics: Antiviral Agents; Drug Approval; Hepatitis C, Chronic; Humans; Ribavirin; United States; United States Food and Drug Administration | 2004 |
Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neural Networks, Computer; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2004 |
Treating hepatitis C in "difficult-to-treat" patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Treatment of hepatitis C virus infection in patients of northern India.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2004 |
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study.
Topics: Antiviral Agents; Biomarkers; Blood Platelets; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-13; Interleukin-8; Membrane Proteins; Middle Aged; P-Selectin; Polyethylene Glycols; Prostaglandin-Endoperoxide Synthases; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States; Viral Load | 2004 |
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.
Topics: Adult; Cataract; Color Vision Defects; Eye Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Vision Disorders | 2004 |
Cutaneous reactions to interferon and ribavirin.
Topics: Antiviral Agents; Dermatologic Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Treatment of chronic hepatitis C in blacks and non-Hispanic whites.
Topics: Antiviral Agents; Black or African American; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People | 2004 |
Treatment of chronic hepatitis C in blacks and non-Hispanic whites.
Topics: Antiviral Agents; Black or African American; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins; White People | 2004 |
Treatment response in HCV related chronic hepatitis.
Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Chronic hepatitis C and normal ALT: considerations for treatment.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Reference Values; Ribavirin; Severity of Illness Index; Treatment Outcome | 2004 |
Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.
Topics: Adult; Biomarkers; Cohort Studies; Confidence Intervals; Drug Therapy, Combination; Female; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Predictive Value of Tests; Probability; Prognosis; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Core Proteins | 2004 |
Hepatitis C infection associated with renal disease and chronic renal failure.
Topics: Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Female; Follow-Up Studies; Free Radical Scavengers; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Oxidation-Reduction; Peroxides; Predictive Value of Tests; Prognosis; Ribavirin; Time Factors | 2004 |
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
Topics: Antiviral Agents; Black or African American; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; False Negative Reactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases | 2004 |
Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2004 |
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin | 2004 |
Interferon-alpha-associated sarcoidosis responsive to infliximab therapy.
Topics: Antibodies, Monoclonal; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Infliximab; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis | 2004 |
[Progress in the treatment of hepatitis B and C co-infection in HIV patients].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate | 2004 |
[APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
[Eliminating the gray zone. What can be done in normal ALT values?].
Topics: AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Cutaneous vasculitis with undetectable cryoglobulinemia in chronic hepatitis C.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Skin Diseases; Vasculitis | 2004 |
[Chronic hepatitis and cirrhosis caused by C virus before and after liver transplantation. Report of one case].
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Viral Load | 2004 |
Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C.
Topics: Antiviral Agents; Aspartate Aminotransferases; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2004 |
The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Circoviridae; Circoviridae Infections; DNA, Viral; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Taiwan; Viremia | 2004 |
Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Peptides, Cyclic; Ribavirin; Somatostatin; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon Type I; Interferon-alpha; Italy; Longitudinal Studies; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Respiratory Tract Infections; Retrospective Studies; Ribavirin | 2004 |
[Bilateral AION after the combined therapy of hepatitis C with PEG-interferon alpha2B and ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Visual Acuity; Visual Fields | 2004 |
Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
Topics: Amantadine; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure; Treatment Outcome | 2004 |
Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer | 2004 |
Factors contributing to ribavirin-induced anemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
[Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon].
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia.
Topics: Adenosylhomocysteinase; Anemia; Animals; Antiviral Agents; Erythrocytes; Hepatitis C, Chronic; Humans; Models, Biological; Ribavirin; S-Adenosylhomocysteine; S-Adenosylmethionine; Statistics as Topic | 2004 |
Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2004 |
Virological response in post-partum treated chronic hepatitis C women with pegylated interferon-alpha plus ribavirin. A case-control study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Postpartum Period; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Generalized exfoliative dermatitis induced by interferon alfa.
Topics: Adult; Antiviral Agents; Dermatitis, Exfoliative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pruritus; Recombinant Proteins; Ribavirin | 2004 |
PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Thyroid Diseases; Treatment Outcome | 2004 |
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Viral Load | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Withdrawal Syndrome | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Amines; Antimanic Agents; Antiviral Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome | 2004 |
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Possible herbal treatment for C4HCV patients who are not suitable for interferon based treatment.
Topics: Antiviral Agents; Complementary Therapies; Genotype; Hepacivirus; Hepatitis C, Chronic; Herbal Medicine; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2004 |
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2004 |
How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions.
Topics: Antiviral Agents; Comorbidity; Depressive Disorder; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Viral Load | 2005 |
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Substance-Related Disorders; Treatment Failure; Treatment Outcome; Viral Load | 2005 |
Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
Topics: Antiviral Agents; Drug Therapy, Combination; Growth Substances; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2005 |
[Chronic hepatitis C with normal level of alanine-aminotransferase].
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Body Mass Index; Clinical Enzyme Tests; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Ribavirin; Time Factors | 2004 |
Treatment of chronic hepatitis C in children.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Analysis of quasispecies in the viral 5' untranslated region of hepatitis C virus to evaluate ribavirin mutagenic effect in patients receiving ribavirin and interferon-alfa.
Topics: 5' Untranslated Regions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2004 |
A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy.
Topics: Biopsy, Needle; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2005 |
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cells, Cultured; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Lymphocytes; Macrophages; Male; Middle Aged; Monocytes; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Virus Replication | 2005 |
Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medicine, Kampo; Middle Aged; Retrospective Studies; Ribavirin | 2004 |
Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retreatment; Ribavirin; Thymalfasin; Thymosin | 2004 |
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Memory; Middle Aged; Prospective Studies; Psychomotor Disorders; Psychomotor Performance; Reaction Time; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2005 |
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Time Factors; Treatment Failure | 2004 |
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2004 |
Polyarteritis nodosa after interferon treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyarteritis Nodosa; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin | 2005 |
Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression.
Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Ribavirin; Selective Serotonin Reuptake Inhibitors | 2005 |
Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
Topics: Adult; Antiviral Agents; Eczema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2005 |
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Successful treatment of resistant chronic hepatitis C virus infection with high dose pegylated interferon.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.
Topics: Adult; Antiviral Agents; Cohort Studies; Eligibility Determination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2005 |
Treatment of chronic hepatitis C in a patient with systemic lupus erythematosus.
Topics: Aged; Anemia; Antiviral Agents; Asthenia; Drug Therapy, Combination; Female; Headache; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Lupus Erythematosus, Systemic; Ribavirin | 2004 |
Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure | 2005 |
Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy.
Topics: Adult; Antiviral Agents; Female; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Humans; Ribavirin | 2005 |
[Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sjogren's Syndrome; Viral Load | 2005 |
Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.
Topics: Acute Disease; Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Topics: Adult; Aged; Antibodies, Antinuclear; Antibody Specificity; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Muscle, Smooth; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?
Topics: Adult; Antibody Specificity; Antiviral Agents; Autoantibodies; Child; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2005 |
Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Lymphocyte Activation; Male; Probability; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; T-Lymphocytes, Cytotoxic; Treatment Outcome; Viral Load | 2005 |
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
Topics: Alanine Transaminase; Antiviral Agents; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Alleles; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2005 |
Interferon-induced depression: prevalence and management.
Topics: Adult; Aged; Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prevalence; Prognosis; Review Literature as Topic; Ribavirin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT.
Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis, Alcoholic; Recombinant Proteins; Ribavirin | 2005 |
[Hepatitis C and HIV in Spanish prisons].
Topics: Adult; Antiviral Agents; Comorbidity; Female; Hepatitis C, Chronic; HIV Infections; HIV Seroprevalence; Hospitalization; Hospitals, Public; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prisoners; Prisons; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Spain; Substance Abuse, Intravenous | 2005 |
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viral Interference | 2005 |
News in hepatitis C: Report from the 39th annual meeting of the European Association for the Study of the Liver.
Topics: Antiviral Agents; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Societies, Scientific | 2005 |
[Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Time Factors | 2004 |
Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C.
Topics: Adult; Antiviral Agents; Blood Coagulation Factors; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin | 2005 |
Non-responders to previous treatment for hepatitis C.
Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2005 |
Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin | 2005 |
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2005 |
Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Myelin Sheath; Recombinant Proteins; Ribavirin; Schwann Cells; Self Tolerance; Substance Abuse, Intravenous | 2005 |
Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.
Topics: Adult; Antiviral Agents; Delayed-Action Preparations; Electroretinography; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ischemia; Male; Middle Aged; Photic Stimulation; Polyethylene Glycols; Reaction Time; Recombinant Proteins; Retinal Hemorrhage; Retinal Vessels; Retrospective Studies; Ribavirin; Vision Disorders; Visual Fields | 2005 |
Monitoring treatment response by the hepatitis C virus core antigen assay.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Reagent Kits, Diagnostic; Regression Analysis; Ribavirin; RNA, Viral; Viral Core Proteins | 2005 |
Treatment of chronic hepatitis C in Canadian prison inmates.
Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prisoners; Recombinant Proteins; Retrospective Studies; Ribavirin | 2005 |
Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Iron; Iron Overload; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Postoperative Complications; Ribavirin; Transferrin | 2005 |
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mutation; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins | 2005 |
Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
Topics: Age Factors; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome | 2005 |
Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders.
Topics: Adult; Antiviral Agents; Cost Savings; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2005 |
HCV clearance patterns in saliva and serum of patients with chronic HCV infection under interferon plus ribavirin therapy.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Saliva; Viral Load | 2005 |
Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Bayes Theorem; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocyte Count; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Biological; Retrospective Studies; Ribavirin | 2005 |
Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Bile Acids and Salts; Chi-Square Distribution; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2005 |
Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Ribavirin; Treatment Failure | 2005 |
Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
Topics: Adult; Antiviral Agents; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2005 |
Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2005 |
[Severe autoimmune neutropenia and thrombopenia associated with chronic C hepatitis: effect of antiviral therapy].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; DNA; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linkage Disequilibrium; Male; Mannose-Binding Lectin; Middle Aged; Multienzyme Complexes; Myxovirus Resistance Proteins; Osteopontin; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Retrospective Studies; Ribavirin; RNA, Viral; Sialoglycoproteins; Treatment Outcome | 2005 |
Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biopsy, Needle; Case-Control Studies; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Risk Factors | 2004 |
The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2beta and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Thyroid Function Tests; Thyrotoxicosis | 2005 |
Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin | 2005 |
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Topics: Adult; Cooperative Behavior; Cost-Benefit Analysis; Decision Making; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Models, Theoretical; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2005 |
Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy.
Topics: Adult; Antiviral Agents; Apoptosis; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Ribavirin | 2005 |
Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Topics: Adult; Amantadine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; France; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Alignment; Sequence Analysis, DNA; Viral Load | 2005 |
Pilot study of interferon gamma for chronic hepatitis C.
Topics: Antiviral Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Failure | 2005 |
T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Black People; CD4 Lymphocyte Count; Cell Proliferation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Phytohemagglutinins; Prospective Studies; Ribavirin; T-Lymphocytes; Viral Load; White People | 2005 |
Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C.
Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index | 2005 |
The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin.
Topics: Comorbidity; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load | 2005 |
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Retinal Detachment; Ribavirin; Treatment Outcome; Uveomeningoencephalitic Syndrome | 2006 |
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Erythropoiesis; Female; Hematopoiesis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Thrombopoiesis | 2005 |
Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Virulence | 2005 |
Tear function changes during interferon and ribavirin treatment in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Conjunctiva; Drug Therapy, Combination; Dry Eye Syndromes; Epithelial Cells; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lacrimal Apparatus; Male; Metaplasia; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Tears | 2005 |
Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus.
Topics: Adjuvants, Immunologic; Adult; Aged; Alanine Transaminase; Combined Modality Therapy; Drug Therapy, Combination; Female; Granulocytes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukapheresis; Male; Middle Aged; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2005 |
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.
Topics: Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2005 |
Interstitial pneumonia recurrence during chronic hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tomography, X-Ray Computed | 2005 |
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2005 |
Unilateral oculomotor nerve palsy induced by combination therapy of interferon-alpha2b and ribavirin.
Topics: Adult; Antiviral Agents; Diagnosis, Differential; Diplopia; Drug Therapy, Combination; Eye Movements; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Oculomotor Nerve Diseases; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2005 |
[Hypothyroid myopathy caused by interferon-alpha therapy for chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Muscular Diseases; Recombinant Proteins; Ribavirin | 2005 |
Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Radionuclide Imaging; Radiopharmaceuticals; Ribavirin; Sodium Pertechnetate Tc 99m; Thyroiditis | 2005 |
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2005 |
[Curative short term treatment of chronic viral C hepatitis].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Quaternary Ammonium Compounds; Recombinant Proteins; Ribavirin; RNA, Viral; Surface-Active Agents; Trimethyl Ammonium Compounds | 2005 |
Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Polyethylene Glycols; Ribavirin | 2005 |
A case report of pityriasis lichenoides in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Pityriasis Lichenoides; Ribavirin; Skin; Treatment Outcome | 2005 |
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Ribavirin | 2005 |
Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Acceptance of Health Care; Patient Selection; Ribavirin; Substance-Related Disorders; Treatment Outcome; United States; Veterans | 2005 |
Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hair; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferons; Male; Middle Aged; Ribavirin; Risk Assessment; Severity of Illness Index | 2005 |
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Molecular Sequence Data; Mutagens; Mutation; Ribavirin; Viral Load; Viral Nonstructural Proteins | 2005 |
Mutagenic effects of ribavirin in vivo.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutagens; Ribavirin; Viral Load | 2005 |
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2005 |
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viremia | 2005 |
Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Weight Loss | 2005 |
Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
[Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin | 2005 |
Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia | 2005 |
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neurotoxicity Syndromes; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
Topics: Antiviral Agents; Body Mass Index; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2005 |
Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic.
Topics: Ambulatory Care Facilities; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Education as Topic; Pharmacy Service, Hospital; Polyethylene Glycols; Professional Role; Recombinant Proteins; Ribavirin | 2005 |
Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan.
Topics: Aged; Antiviral Agents; Body Mass Index; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Male; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Treatment Refusal | 2006 |
Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Infarction; Interferon alpha-2; Interferon-alpha; Ischemia; Jejunum; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vasculitis | 2006 |
Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes.
Topics: Adult; Antiviral Agents; Eligibility Determination; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Acceptance of Health Care; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans; White People | 2005 |
[Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic hepatitis C].
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sarcoidosis, Pulmonary; Th1 Cells; Tomography, X-Ray Computed | 2005 |
Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Phylogeny; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2005 |
Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin | 2005 |
[The apoptosis of hepatic tissues in hepatitis C].
Topics: Adult; Antiviral Agents; Apoptosis; Biopsy, Needle; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Severity of Illness Index; Tumor Suppressor Protein p53 | 2005 |
[Neuropsychiatric disorders in HCV-infected people--own observations].
Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Poland; Psychiatric Status Rating Scales; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
[The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichen Planus, Oral; Male; Middle Aged; Ribavirin; Risk Factors; Salivary Gland Diseases; Time Factors | 2005 |
[Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin].
Topics: Adolescent; Antiviral Agents; B-Lymphocytes; Biomarkers; Case-Control Studies; Child; Child Welfare; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Leukocytes; Lymphocyte Subsets; Male; Monocytes; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors | 2005 |
[Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Child; Child Welfare; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia | 2005 |
[Complications in a patient with liver cirrhosis and HCV coinfection during treatment with peginterferon and ribavirin].
Topics: Adolescent; Antiviral Agents; Biliary Atresia; Child; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Transplantation; Polyethylene Glycols; Portasystemic Shunt, Transjugular Intrahepatic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2005 |
The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.
Topics: Adult; Alcohol Drinking; Antiviral Agents; Black People; Drug Therapy, Combination; Ethanol; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2005 |
Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia; Treatment Outcome | 2005 |
Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Inflammatory Bowel Diseases; Interferon-alpha; Male; Middle Aged; Ribavirin | 2005 |
The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Function Tests; Male; Middle Aged; Ribavirin | 2005 |
Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nevus; Recombinant Proteins; Ribavirin; Skin Neoplasms | 2005 |
No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.
Topics: Antiviral Agents; Chemokine CCL2; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Deletion | 2005 |
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
Topics: Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2005 |
Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Child; Cohort Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-12; Interleukin-6; Male; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2004 |
[Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2005 |
The effect of ribavirin on bone density in patients with chronic hepatitis C treated with interferon-ribavirin therapy.
Topics: Adolescent; Biomarkers; Bone and Bones; Bone Density; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lumbar Vertebrae; Male; Recombinant Proteins; Ribavirin | 2005 |
Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.
Topics: Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Cytokines; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Flow Cytometry; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors; Treatment Outcome | 2005 |
[Treatment for hepatitis C virus associated cryoglobulinemia with interferon alpha and ribavirin].
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2005 |
Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?
Topics: Adult; Antiviral Agents; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2006 |
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2006 |
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2005 |
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Uveomeningoencephalitic Syndrome | 2005 |
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2006 |
[Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2005 |
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report.
Topics: Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2005 |
Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals.
Topics: Antiviral Agents; Clinical Laboratory Information Systems; Clinical Laboratory Techniques; Clinical Trials as Topic; Data Interpretation, Statistical; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Selection; Pharmaceutical Preparations; Reference Values; Ribavirin; Sensitivity and Specificity | 2005 |
Treatment of hepatitis C virus infection in thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Biopsy, Needle; Bone Marrow Transplantation; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Mass Spectrometry; Polyethylene Glycols; Ribavirin; Thalassemia; Transfusion Reaction; Treatment Outcome; Viremia | 2005 |
Hemolytic anemia during 24 weeks of ribavirin and interferon-alpha2b combination therapy does not influence the cardiac function of patients with viral hepatitis C.
Topics: Anemia, Hemolytic; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Recombinant Proteins; Ribavirin | 2006 |
Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Erythrocyte Membrane; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipids; Male; Membrane Lipids; Middle Aged; Ribavirin; Thiobarbituric Acid Reactive Substances | 2005 |
[Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retinal Diseases; Retinal Hemorrhage; Ribavirin | 2005 |
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
What do patients consider when making decisions about treatment for hepatitis C?
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Decision Making; Female; Focus Groups; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Participation; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Refusal | 2005 |
[Retreatment of patients with chronic hepatitis C].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Retreatment; Ribavirin; Treatment Failure | 2005 |
[Treatment of viral hepatitis in children].
Topics: Child; Drug Therapy, Combination; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2005 |
[Treatment of chronic hepatitis C in patients with HIV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2005 |
A success story with chronic hepatitis C.
Topics: Antiviral Agents; Drug Carriers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
Topics: Adult; Alleles; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; White People | 2005 |
[Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists].
Topics: Adult; Antiviral Agents; Drug Combinations; Female; Gastroenterology; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Outcome Assessment, Health Care; Private Practice; Prognosis; Remote Consultation; Ribavirin; Treatment Outcome | 2006 |
Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2006 |
Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
Topics: Adult; Black People; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Skin; Tongue | 2006 |
Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
Topics: Alanine Transaminase; Antiviral Agents; Blood Preservation; Chromatography, High Pressure Liquid; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Half-Life; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2006 |
Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Cryoglobulins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Prospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2005 |
Hepatitis C virus genotype 5 in southern belgium: epidemiological characteristics and response to therapy.
Topics: Adult; Age Distribution; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Sex Distribution; Treatment Outcome | 2005 |
Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin.
Topics: Adult; Antiviral Agents; Cells, Cultured; Factor VII; Gene Expression; Hemophilia A; Hemophilia B; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Male; Middle Aged; Ribavirin; RNA, Messenger | 2006 |
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytokines; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Carriers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 1; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Depression, anemia and health-related quality of life in chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Depression; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Risk Factors; Surveys and Questionnaires | 2006 |
[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
Topics: Amantadine; Antiviral Agents; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatovirus; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Viral Load | 2005 |
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Thalidomide; Treatment Outcome | 2006 |
Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
Topics: Antiviral Agents; Autoantibodies; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Thyroid Diseases; Thyrotropin; Thyroxine | 2006 |
Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.
Topics: Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoproliferative Disorders; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
[Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus].
Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Clinical Trials as Topic; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Manitoba; Outcome Assessment, Health Care; Outpatient Clinics, Hospital; Recombinant Proteins; Ribavirin | 2006 |
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; TNF-Related Apoptosis-Inducing Ligand | 2006 |
Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis.
Topics: Acute Disease; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Radiography; Ribavirin; Severity of Illness Index; Tomography Scanners, X-Ray Computed; Tuberculosis, Pulmonary | 2006 |
[Psychological side effects during interferon-alpha therapy -- a case study].
Topics: Adult; Antiviral Agents; Asthenia; Combined Modality Therapy; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Psychoanalytic Therapy; Psychophysiologic Disorders; Recombinant Proteins; Retreatment; Ribavirin; Sick Role; Substance Withdrawal Syndrome | 2006 |
[Treatment of chronic hepatitis C in haemophilia patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexual Behavior; Sexually Transmitted Diseases, Viral; Treatment Outcome | 2006 |
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viremia | 2006 |
Pegylated interferon and ribavirin in haemodialysis patients.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polymerase Chain Reaction; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Assessment; RNA, Viral; Treatment Outcome | 2006 |
Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Receptors, Interferon; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome | 2006 |
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Fibroblast Growth Factor 2; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2006 |
[Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon].
Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis | 2005 |
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?
Topics: Adult; Aged; Antiviral Agents; Diet; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Hepatitis C treatment of veterans with psychiatric illness.
Topics: Antiviral Agents; Cohort Studies; Comorbidity; Contraindications; Dementia; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Prejudice; Ribavirin; Risk Factors; Substance-Related Disorders; Veterans | 2006 |
Significance of occult HBV infection in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Time Factors; Treatment Outcome | 2006 |
[Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Nucleic Acid Amplification Techniques; Ribavirin; RNA, Viral; Viral Core Proteins; Viral Load | 2006 |
Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?
Topics: Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2006 |
[Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients.
Topics: Chemical Fractionation; Chromatography, High Pressure Liquid; Drug Monitoring; Hepatitis C, Chronic; Humans; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Ultraviolet Rays | 2006 |
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
[Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients].
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Gland; Thyroid Hormones | 2006 |
Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Apoptosis; Aspartate Aminotransferases; Case-Control Studies; Drug Therapy, Combination; fas Receptor; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Interleukin-18; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric | 2006 |
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Black People; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Ribavirin; RNA, Viral; White People | 2006 |
[Acute pancreatitis in a hepatitis C positive patient following treatment with peginterferon alfa-2b and ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
Topics: Antiviral Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Follow-Up Studies; Hepatectomy; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferons; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Ribavirin; Risk Assessment; Severity of Illness Index | 2006 |
[The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia | 2006 |
[The role of STAT proteins in the regulation of the response to the interferone alpha therapy in chronic hepatitis C].
Topics: Antiviral Agents; Biopsy; Hepatitis C, Chronic; Humans; Interferon-alpha; Janus Kinase 1; Liver; Mitogen-Activated Protein Kinase 3; Protein Inhibitors of Activated STAT; Protein-Tyrosine Kinases; Ribavirin; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; STAT Transcription Factors; Suppressor of Cytokine Signaling Proteins; Viral Load | 2006 |
Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2006 |
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA; Time Factors | 2006 |
Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Pilot Projects; Polyethylene Glycols; Prognosis; Protein Kinases; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins | 2006 |
Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient?
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Disease Progression; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2006 |
Mild hepatitis C: treat or monitor.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2006 |
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organometallic Compounds; Peptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2006 |
Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors | 2006 |
Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2006 |
Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Sweden | 2006 |
[Therapy with peginterferon alfa in a patient with polyneuropathy caused by hepatitis C-associated vasculitis].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Neuritis; Neurologic Examination; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vasculitis | 2006 |
Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Cerebral Hemorrhage; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Matched-Pair Analysis; Quality of Life; Ribavirin | 2006 |
[Association of chronic hepatitis C and lichen planus--in two patients].
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichen Planus; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Skin | 2006 |
Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.
Topics: Aged; Alcohol Drinking; Antiviral Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Patient Selection; Probability; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2006 |
Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloproteases; Middle Aged; NF-kappa B; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2006 |
[Concomitant nodular goiter during IFN and ribavirin treatment of HCV: a case report].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Goiter, Nodular; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2006 |
Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
Topics: Antiviral Agents; Autoimmunity; Chronic Disease; Combined Modality Therapy; Diabetes Mellitus, Type 1; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.
Topics: Antiviral Agents; Autoimmune Diseases; Combined Modality Therapy; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Middle Aged; Pituitary Diseases; Recombinant Proteins; Ribavirin; Thyroid Hormones | 2006 |
[Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin].
Topics: Antiviral Agents; Hemochromatosis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin | 2006 |
[How to use viral genomic analysis in clinical practice: chronic hepatitis B and C].
Topics: Adult; Genome, Viral; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Severe thrombocytopenia with probable autoimmune mechanism associated with interferon therapy in a patient with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhagic Disorders; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Interferons; Male; Methylprednisolone; Platelet Transfusion; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Ribavirin | 2006 |
Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
Topics: Adjuvants, Immunologic; Antiviral Agents; Costs and Cost Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mexico; Polyethylene Glycols; Prospective Studies; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2006 |
Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cryoglobulinemia; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Peripheral Nervous System Diseases; Prednisolone; Remission Induction; Ribavirin; Rituximab | 2006 |
Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Viral Load | 2006 |
Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Markers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Proteome; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2006 |
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Antiviral Agents; Biopsy; Chi-Square Distribution; Female; France; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Logistic Models; Male; Retrospective Studies; Ribavirin; Severity of Illness Index | 2006 |
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Hematocrit; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Monte Carlo Method; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sweden | 2006 |
Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Topics: Antigen Presentation; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Activation; Plasma Cells; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Th1 Cells | 2006 |
Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Treatment Outcome; Viral Load | 2006 |
Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient.
Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2006 |
Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.
Topics: Antiviral Agents; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Interferon-alpha; Liver Regeneration; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Up-Regulation | 2006 |
Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2006 |
Clinical and therapeutic implications of hepatitis C virus compartmentalization.
Topics: Adult; Antiviral Agents; Cell Compartmentation; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2006 |
The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Taiwan; Thyroid Diseases; Thyroid Gland | 2006 |
[Primer treatment of acute and chronic hepatitis C].
Topics: Acute Disease; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2006 |
[The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2006 |
Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis.
Topics: Antiviral Agents; Biopsy; Body Mass Index; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure | 2006 |
Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin; Vision, Low; Visual Acuity | 2006 |
Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Behavior, Addictive; Cocaine-Related Disorders; Comorbidity; Drug Administration Schedule; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Male; Methadone; Middle Aged; Opioid-Related Disorders; Patient Care Planning; Recurrence; Ribavirin; Risk Assessment; Substance Abuse, Intravenous; Treatment Outcome | 2006 |
Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2006 |
Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Crohn Disease; Cross Infection; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Genetic predisposition of responsiveness to therapy for chronic hepatitis C.
Topics: Adult; Aged; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribavirin | 2006 |
Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Clone Cells; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2006 |
Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Cohort Studies; Combined Modality Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Alignment; Viral Load | 2006 |
Disappointing results of combination therapy for HCV?
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2006 |
Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Erythrocyte Indices; Female; Glycated Hemoglobin; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; L-Lactate Dehydrogenase; Male; Middle Aged; Reticulocyte Count; Retrospective Studies; Ribavirin | 2006 |
Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.
Topics: Alkaline Phosphatase; Animals; Antiviral Agents; Cell Differentiation; Cell Line; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Mice; Osteoblasts; Osteoclasts; Osteogenesis; RANK Ligand; Ribavirin | 2007 |
Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Biopsy; Cell Differentiation; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Keratin-19; Keratin-7; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stem Cells | 2006 |
Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.
Topics: Adult; Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lymphadenitis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Tuberculosis, Lymph Node | 2006 |
Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymorphism, Genetic; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2006 |
Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Topics: 5' Untranslated Regions; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Genetic Drift; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mutation; Phylogeny; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins; Viral Nonstructural Proteins | 2006 |
From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2006 |
Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.
Topics: Adult; Antiviral Agents; Danazol; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Interferon-alpha; Purpura, Thrombocytopenic, Idiopathic; Ribavirin | 2006 |
A government sponsored clinic for the evaluation and treatment of chronic hepatitis C in an underinsured population in Puerto Rico.
Topics: Adult; Algorithms; Antiviral Agents; Female; Health Facilities; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medically Uninsured; Middle Aged; Polyethylene Glycols; Public Assistance; Puerto Rico; Recombinant Proteins; Ribavirin | 2004 |
Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2004 |
CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Receptors, CCR5; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2006 |
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepatitis C, Chronic; Humans; Indians, North American; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin | 2006 |
Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
Topics: Adult; Antiviral Agents; Body Mass Index; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides | 2006 |
Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.
Topics: Adult; Antiviral Agents; Biopsy; Comorbidity; Drug Therapy, Combination; Fatal Outcome; Giant Cells; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals, Special; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Retrospective Studies; Ribavirin; RNA, Viral; Spain | 2006 |
[A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].
Topics: Antiviral Agents; Catheter Ablation; Colitis, Ulcerative; Drug Therapy, Combination; Hepatectomy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Structure, Secondary; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2007 |
2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2006 |
Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
Topics: Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Contraindications; Female; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Middle Aged; Peptide Fragments; Procollagen; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1 | 2006 |
Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Dendritic Cells; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunity, Cellular; Interferon-alpha; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic | 2006 |
Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?
Topics: Antiviral Agents; Dendritic Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic | 2006 |
Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.
Topics: Adult; Antiviral Agents; Calcitonin; Calcitonin Gene-Related Peptide; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Protein Precursors; Recombinant Proteins; Ribavirin | 2006 |
[A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
Topics: Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Blood Cell Count; Blood Platelets; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Quebec; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2006 |
Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.
Topics: Adolescent; Antiviral Agents; Autoantibodies; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon-alpha; Male; Ribavirin; Thyroid Gland; Thyroiditis, Autoimmune | 2006 |
Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
Topics: Antiviral Agents; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure | 2006 |
Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
Topics: Age Factors; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome | 2006 |
Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C.
Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; NFATC Transcription Factors; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Th1 Cells; Th2 Cells; Toll-Like Receptors; Treatment Outcome | 2006 |
Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Topics: Adult; Aging; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2006 |
T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretro
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Follow-Up Studies; Gene Rearrangement, T-Lymphocyte; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Common Antigens; Male; Polyethylene Glycols; Prospective Studies; Receptors, Antigen, T-Cell; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Thymus Gland; Treatment Outcome | 2006 |
A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.
Topics: Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2006 |
Treatment rates in patients with chronic hepatitis C after liver biopsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver; Male; Medicaid; Medicare; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2006 |
An artificial neural network approach to the drug efficacy of interferon treatments.
Topics: Aging; Algorithms; Antiviral Agents; Drug Therapy, Combination; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Neural Networks, Computer; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Sex Characteristics; Signal Transduction; Viral Load | 2006 |
Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Colitis, Ischemic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction?
Topics: Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferons; Iron; Membrane Proteins; Mutation; Ribavirin | 2006 |
Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
Topics: Analgesics, Opioid; Antiviral Agents; Australia; Hepatitis C, Chronic; Humans; Interferon-alpha; Methadone; Referral and Consultation; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous | 2007 |
Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels.
Topics: Acute Disease; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Transaminases | 2007 |
Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Ki-1 Antigen; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Th1 Cells; Th2 Cells; Treatment Outcome | 2006 |
Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan | 2006 |
Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Development of hepatocellular carcinoma (HCC) in peginterferon and ribavirin HCV-infected cirrhotic treated patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Autoimmunity; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2006 |
A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2006 |
Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Tolerance; Female; Glucosephosphate Dehydrogenase Deficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
The faster the better?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
[Virological response of chronic hepatitis C management with peg-interferon alpha-2b and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Prisoners; Prisons; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Spain; Substance Abuse, Intravenous; Treatment Outcome | 2006 |
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin; Treatment Refusal | 2007 |
Insulin resistance and hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Topics: Algorithms; Antiviral Agents; Cost-Benefit Analysis; Erythropoietin; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2006 |
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
Topics: Anemia; Cost-Benefit Analysis; Darbepoetin alfa; Decision Trees; Drug Therapy, Combination; Erythropoietin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Markov Chains; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Phylogeny; Ribavirin | 2007 |
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
Topics: Antiviral Agents; Brazil; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Liver Cirrhosis; Ribavirin; RNA, Viral; Viral Load | 2006 |
[Early virologic response value as predictive factor of sustained virologic response to treatment with interferon alpha-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection].
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
[Applicability of hepatitis C virus kinetics in patients co-infected with HIV].
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Treatment of chronic hepatitis C within a heroine-assisted treatment program].
Topics: Administration, Oral; Adult; Antiviral Agents; Buprenorphine; Cocaine-Related Disorders; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Heroin; Heroin Dependence; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Rehabilitation, Vocational; Ribavirin; Social Adjustment; Social Welfare; Substance Abuse, Intravenous | 2006 |
Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Signal Transduction; White People | 2007 |
Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Male; Middle Aged; Retrospective Studies; Ribavirin | 2006 |
[Changes of immunocytes in livers of chronic hepatitis C patients treated with IFN alpha-2b and ribavirin].
Topics: Adult; Aged; Antigens, CD; Antiviral Agents; CTLA-4 Antigen; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2006 |
[The importance of using ribavirin in treating chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2006 |
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Biopsy; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viral Load | 2007 |
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-gamma; Interleukin-10; Peptide Fragments; Ribavirin; RNA, Messenger; RNA, Viral; T-Lymphocytes; Viral Core Proteins; Viral Nonstructural Proteins | 2007 |
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Alanine Transaminase; Antimicrobial Cationic Peptides; Antiviral Agents; Aspartate Aminotransferases; Deoxyguanosine; DNA Adducts; DNA Damage; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Hepcidins; Humans; Interferons; Iron Overload; Liver; Male; Middle Aged; Oxidative Stress; Ribavirin | 2007 |
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience.
Topics: Adolescent; Adult; Antiviral Agents; Blood Coagulation Disorders; Combined Modality Therapy; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2007 |
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2007 |
Lichen aureus induced by interferon-alpha plus ribavirin.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichenoid Eruptions; Male; Ribavirin | 2007 |
Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
Topics: Antiviral Agents; Creatinine; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Transplantation; Leg Ulcer; Liver; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Pegylated interferon and ribavirin failures: is retreatment an option?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; Treatment Failure | 2007 |
Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies.
Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Activation | 2007 |
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
Topics: Adolescent; Adult; Aged; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Black People; Cell Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Protease Inhibitors; Recombinant Proteins; Reticulocytes; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors; Treatment Outcome; White People; Zidovudine | 2007 |
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
Topics: Antiviral Agents; Biomarkers; Down-Regulation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Up-Regulation | 2007 |
Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Quality of Life; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2007 |
A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Partial Thromboplastin Time; Polyethylene Glycols; Prothrombin Time; Recombinant Proteins; Ribavirin; RNA, Viral; Venous Thrombosis | 2006 |
Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Polyethylene Glycols; Prisons; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention | 2007 |
Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
Topics: 5' Untranslated Regions; Adolescent; Adult; Antiviral Agents; Egypt; Female; Genetic Heterogeneity; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Statistics as Topic; Treatment Outcome | 2007 |
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Survival Rate; Taiwan; Time Factors | 2006 |
Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Topics: Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases | 2007 |
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2006 |
Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
Topics: Adolescent; Antibodies, Viral; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Situ Hybridization, Fluorescence; Interferons; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2007 |
Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2007 |
Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.
Topics: Antiviral Agents; Black or African American; Chi-Square Distribution; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Middle Aged; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2007 |
Adult systemic cat scratch disease associated with therapy for hepatitis C.
Topics: Bartonella henselae; Cat-Scratch Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Recombinant Proteins; Ribavirin; Survival Analysis; Treatment Outcome; United States; Urban Health | 2007 |
Evaluation of a pharmacist-managed hepatitis C care clinic.
Topics: Adult; Ambulatory Care Facilities; Disease Management; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Polyethylene Glycols; Practice Guidelines as Topic; Professional Role; Quality of Health Care; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs | 2007 |
Treatment and retreatment in patients with chronic hepatitis C: 10 years clinical practice in a single centre.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin | 2007 |
Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study.
Topics: Adult; Antiviral Agents; Central Nervous System Diseases; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polyneuropathies; Recombinant Proteins; Ribavirin | 2007 |
Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.
Topics: Adaptation, Biological; Drug Synergism; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homeostasis; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Viral Load; Viral Proteins; Virus Replication | 2007 |
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome | 2007 |
[Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
[Protocol for the treatment of chronic viral hepatitis].
Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Myasthenia Gravis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
Topics: Adult; Antiviral Agents; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Monosaccharides; Mutagens; Mutation; Replicon; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Triazoles; Viral Nonstructural Proteins | 2007 |
[Cutaneous necrosis in patient with chronic hepatitis].
Topics: Adult; Antiviral Agents; Biopsy; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Necrosis; Recombinant Proteins; Ribavirin; Skin | 2007 |
Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series.
Topics: Amantadine; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2007 |
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Transcription, Genetic; Viremia | 2007 |
Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antiviral Agents; Bipolar Disorder; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Fluoxetine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamotrigine; Male; Middle Aged; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triazines; Viral Load | 2006 |
[Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Pancytopenia; Polyethylene Glycols; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Signal Transduction | 2007 |
Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
Topics: Adult; Antiviral Agents; Drug Eruptions; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[The peculiarities of the clinical picture and the effectiveness of antiviral therapy of chronic hepatitis related to alcohol consumption plus hepatitis C virus effect].
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hepatitis, Alcoholic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Ultrasonography | 2007 |
Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report.
Topics: Antipsychotic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin; Risperidone | 2006 |
Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Vitiligo | 2007 |
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
Topics: Adolescent; Adult; Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Quality of Life; Ribavirin; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2007 |
Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins | 2007 |
Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies.
Topics: Adjuvants, Immunologic; Antiviral Agents; Collagen; Cosmetic Techniques; Face; Female; Granuloma, Foreign-Body; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Polymethyl Methacrylate; Recombinant Proteins; Ribavirin | 2007 |
A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Black or African American; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Epitopes; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; T-Lymphocytes; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins; White People | 2007 |
Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Topics: Adult; Age Factors; Aged; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Up-Regulation; Viral Load | 2007 |
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.
Topics: Antibodies, Viral; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Viremia | 2007 |
Acute pancreatitis associated with the use of peginterferon.
Topics: Acute Disease; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Hepatitis C in pregnancy.
Topics: Female; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Ribavirin | 2007 |
Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Biological Evolution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Viral Nonstructural Proteins | 2007 |
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.
Topics: Adipocytes; Adult; Antiviral Agents; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Intra-Abdominal Fat; Liver Cirrhosis; Male; Middle Aged; Obesity; Recombinant Proteins; Ribavirin | 2007 |
The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genome, Viral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C.
Topics: Algorithms; Antiviral Agents; Biomarkers; Carrier Proteins; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Intracellular Signaling Peptides and Proteins; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins; Viral Proteins | 2007 |
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2007 |
Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy.
Topics: Adult; Antiviral Agents; Biopsy; Blood Component Removal; Diagnosis, Differential; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Ribavirin | 2007 |
[Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Topics: Agranulocytosis; Antiviral Agents; Bacteremia; Bone Marrow; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Mesenteric vein thrombosis and protein C and S deficiency in a patient with chronic hepatitis C on treatment with interferon and ribavirin].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Fatal Outcome; Gram-Negative Bacterial Infections; Hemoperitoneum; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pneumonia, Bacterial; Polyethylene Glycols; Protein C Deficiency; Protein S Deficiency; Recurrence; Respiration, Artificial; Ribavirin; Stenotrophomonas maltophilia; Thrombectomy; Thrombophilia; Venous Thrombosis | 2007 |
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?
Topics: Adolescent; Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; B7-2 Antigen; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Middle Aged; Ribavirin; Viral Load | 2007 |
Antiviral therapy effects upon hepatitis C cholestatic syndrome.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Cholestasis; Cholesterol; Drug Therapy, Combination; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucyl Aminopeptidase; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Syndrome | 2007 |
Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transaminases; Treatment Outcome | 2007 |
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Parasitic Diseases; Recombinant Proteins; Ribavirin; Schizophrenia, Paranoid; Treatment Outcome | 2007 |
Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection.
Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Disease Progression; Exons; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
Topics: Antibodies, Monoclonal; Antiviral Agents; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Infliximab; Interferons; Male; Middle Aged; Ribavirin | 2007 |
Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases; White People | 2007 |
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Topics: Age Factors; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrosis; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States; United States Department of Veterans Affairs | 2007 |
Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Venous Pressure; Viral Load; Virulence | 2007 |
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
[A case of peripheral facial nerve palsy with cryoglobulinemia and chronic thyroiditis occurring during interferon plus ribavirin therapy for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chronic Disease; Cryoglobulinemia; Facial Paralysis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Thyroiditis | 2007 |
Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Efficiency; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Markov Chains; Models, Economic; Quality of Life; Ribavirin; Treatment Outcome | 2007 |
Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Phosphorylation; Reverse Transcriptase Inhibitors; Ribavirin; Zidovudine | 2007 |
Chronic hepatitis C: viral clearance several months after discontinuation of therapy in two non-responders.
Topics: Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2007 |
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Neutralization Tests; Polyethylene Glycols; Polymorphism, Single-Stranded Conformational; Ribavirin; Viral Envelope Proteins | 2007 |
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2007 |
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eye Diseases; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Retinal Vein Occlusion; Ribavirin; Uveomeningoencephalitic Syndrome | 2007 |
The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
Topics: Aspartate Aminotransferases; Cohort Studies; Drug Therapy, Combination; Endpoint Determination; Female; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Species Specificity; Time Factors; Treatment Failure; Urban Population; Viral Load | 2007 |
Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load | 2007 |
Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Middle Aged; Ribavirin; Risk Factors | 2007 |
Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2007 |
Thymalfasin for the treatment of chronic hepatitis C infection.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2007 |
Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0.
Topics: Hepatitis C, Chronic; Humans; Interferons; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity | 2007 |
Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin | 2007 |
Bile acids promote the expression of hepatitis C virus in replicon-harboring cells.
Topics: Animals; Antiviral Agents; Bile Acids and Salts; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Antagonism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Interferon-gamma; Pregnenediones; Receptors, Cytoplasmic and Nuclear; Replicon; Ribavirin; Swine; Transcription Factors; Vesicular Exanthema of Swine; Vesicular exanthema of swine virus; Virus Replication | 2007 |
[Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin | 2007 |
Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Asian People; Body Mass Index; Canada; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2007 |
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
Topics: Antiviral Agents; Belgium; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2007 |
Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection.
Topics: Adult; Alberta; Antiviral Agents; DNA, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Recombinant Proteins; Ribavirin; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Growth Hormone; Hepatitis C, Chronic; Humans; Insulin-Like Growth Factor Binding Protein 1; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monosaccharides; Pituitary Function Tests; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome; Triazoles | 2007 |
Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Cohort Studies; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; International Cooperation; Male; Middle Aged; Ribavirin; Treatment Outcome | 2007 |
Antiviral therapy for cryoglobulinemic neuropathy: comment on the article by Saadoun et al.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin | 2007 |
Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Survival Rate | 2007 |
Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2007 |
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Cell Line; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2007 |
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Mucins; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin | 2007 |
Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Disease Progression; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Turner Syndrome | 2007 |
[Expression of toll-like receptors on blood leucocytes of children with chronic viral hepatitis C].
Topics: Adolescent; Antiviral Agents; Child; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes; Male; Ribavirin; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors | 2006 |
[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy, Needle; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2006 |
Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Ribavirin | 2007 |
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2007 |
Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cost Control; Decision Trees; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2007 |
The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2007 |
Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoriasis; Pyoderma Gangrenosum; Recombinant Proteins; Ribavirin | 2007 |
Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Topics: Adult; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Treatment with natural interferon (alfaferone) in clinical practice--our experience].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2007 |
Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Bilirubin; Child; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Ribavirin; Vascular Endothelial Growth Factor A | 2007 |
Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy.
Topics: Adult; Age Factors; Antiviral Agents; Brazil; DNA; Drug Therapy, Combination; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Polymorphism, Genetic; Receptor, Interferon alpha-beta; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Hepatitis C virus with normal transaminase levels.
Topics: Alanine Transaminase; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2007 |
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cell Line, Transformed; Drug Therapy, Combination; Female; Gene Expression Profiling; Genetic Markers; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Failure; Treatment Outcome | 2008 |
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Genetic Markers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Treatment Outcome | 2008 |
[Treatment of chronic hepatitis C: shorter treatment duration for genotype 2 or 3 infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2007 |
[Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2007 |
[A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin; Vasculitis | 2007 |
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Time Factors | 2008 |
Recommendations for the treatment of chronic hepatitis C infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon-alpha; Ribavirin | 2007 |
Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.
Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Myocardial Ischemia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index | 2008 |
Iron and hepatitis C: beginning to make sense.
Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Phlebotomy; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Failure; Treatment Outcome | 2007 |
[Two cases of pyogenic spondylitis with chronic hepatitis C during combination therapy of interferon alfa and ribavirin].
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Spondylitis; Staphylococcal Infections; Streptococcal Infections; Suppuration; Treatment Outcome; Viridans Streptococci | 2007 |
Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Myasthenia Gravis; Ribavirin | 2007 |
Response of combination therapy on viral load and disease severity in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load | 2008 |
Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia.
Topics: Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Kynurenine; Macrophages; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tryptophan | 2007 |
B-cell depletion in the treatment of mixed cryoglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lymphocyte Depletion; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome | 2007 |
Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment.
Topics: Antiviral Agents; Black or African American; Drug Tolerance; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Antiviral treatment of HCV-related cirrhosis.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Improved cognitive function as a consequence of hepatitis C virus treatment.
Topics: Adult; Antiviral Agents; Cognition Disorders; Cognitive Behavioral Therapy; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome | 2007 |
PEG-IFN, RBV dosing during chronic HCV re-treatment.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection?
Topics: Antiviral Agents; Gene Expression; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Topics: Aged; Anti-Allergic Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin Diseases | 2007 |
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferons; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Obesity; Ribavirin; Treatment Failure; Treatment Outcome | 2008 |
[A periappendiceal abscess during combination interferon and ribavirin treatment for chronic hepatitis C].
Topics: Abscess; Antiviral Agents; Appendix; Cecal Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Chi-Square Distribution; Depression; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Educational Status; Emigrants and Immigrants; Employment; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Prospective Studies; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2007 |
Summaries for patients. Sustained virologic response in hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; DNA Probes, HLA; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2008 |
Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Hepatitis C, Chronic; Humans; Ribavirin; Sensitivity and Specificity; Solid Phase Extraction | 2007 |
Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclooxygenase 1; Cyclooxygenase 2; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Prostaglandin-Endoperoxide Synthases; Recombinant Proteins; Ribavirin; RNA, Viral; Staining and Labeling; Treatment Outcome | 2007 |
[Chronic fatigue. IV--Assessment of a 40-year-old patient].
Topics: Adult; Anemia, Iron-Deficiency; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Fatigue Syndrome, Chronic; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Methadone; Narcotics; Opioid-Related Disorders; Ribavirin; Thyroid Function Tests | 2007 |
Introduction. Necroinflammation and the course of chronic hepatitis.
Topics: Antiviral Agents; Congresses as Topic; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Ribavirin posology, observance, and sustained virologic response.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Age Factors; Alanine Transaminase; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Mutation; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United Kingdom; Viremia | 2008 |
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transcription, Genetic; Treatment Outcome | 2008 |
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin | 2007 |
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Hospitals; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2008 |
Treating children with chronic hepatitis C after malignancy in a single center.
Topics: Adolescent; Adult; Antiviral Agents; Blood Component Transfusion; Child; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Infant; Interferons; Male; Neoplasms; Ribavirin | 2007 |
Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
Topics: Adult; Anger; Anti-Retroviral Agents; Antiviral Agents; Anxiety Disorders; Cross-Sectional Studies; Female; France; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Records; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2008 |
Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Antiviral Agents; Carbimazole; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Propranolol; Quadriplegia; Recombinant Proteins; Ribavirin; Thyroid Diseases; Time Factors; Treatment Outcome | 2008 |
[Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity | 2007 |
[Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
Topics: Antiviral Agents; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2008 |
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
[Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2007 |
Severe stomatitis complicating treatment with pegylated-interferon alpha-2a and ribavirin in an HCV-infected patient.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatitis | 2008 |
[Development of a myasthenia crisis during interferon treatment for chronic C hepatitis].
Topics: Aged; Antiviral Agents; Cholinesterase Inhibitors; Follow-Up Studies; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Male; Myasthenia Gravis; Mycophenolic Acid; Prednisone; Pyridostigmine Bromide; Ribavirin | 2007 |
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2008 |
[Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].
Topics: Antiviral Agents; Biopsy; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Health Status; Hepatitis C, Chronic; Humans; Insurance, Health; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Education as Topic; Prospective Studies; Quality of Life; Ribavirin; Self-Help Groups; Socioeconomic Factors; Surveys and Questionnaires; Time Factors | 2008 |
Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Topics: Adiponectin; Adult; Antiviral Agents; Biomarkers; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Tumor Necrosis Factor-alpha | 2008 |
[Protocol for the treatment of chronic viral hepatitis].
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Protocols; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
[Acute portal thrombosis in patients with hepatitis C treated with pegylated interferon and ribavirin].
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Portal Vein; Recombinant Proteins; Ribavirin; Thrombosis | 2008 |
Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.
Topics: Administration, Oral; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
[Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection].
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin | 2007 |
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
Topics: Adult; Age Factors; Aged; Antiviral Agents; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Interferon-ribavirin-associated ischemic colitis.
Topics: Antiviral Agents; Biopsy; Colitis, Ischemic; Colon; Colonoscopy; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2008 |
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
Topics: Ethnicity; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome; Viral Load; Weight Loss | 2008 |
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Vasculitis; Virus Replication | 2008 |
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine | 2007 |
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors | 2008 |
Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells | 2008 |
Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Uric Acid | 2008 |
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Basal Ganglia; Depression; Fatigue; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Psychiatric Status Rating Scales; Reaction Time; Regression Analysis; Ribavirin | 2008 |
Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Psychotropic Drugs; Recombinant Proteins; Retrospective Studies; Ribavirin | 2008 |
The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-alpha and ribavirin combined therapy for chronic hepatitis C patients.
Topics: Antigens, CD; Antiviral Agents; Asian People; Drug Resistance, Viral; Female; Genetic Markers; Genome, Human; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-15; Linkage Disequilibrium; Male; Microsatellite Repeats; Polymorphism, Single Nucleotide; Ribavirin; Taiwan; Tetraspanin 28 | 2008 |
[Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2007 |
PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Uric Acid; Viral Load | 2008 |
Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Genes, Reporter; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Luciferases; Mutation, Missense; Polymorphism, Genetic; Ribavirin; Transfection; Viral Nonstructural Proteins | 2008 |
[Evaluation of hepatitis C virus genotype and its influence on therapeutical respond on combined therapy with pegilated interferon A 2a (40)kD and ribavirin].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Epidemiologic Methods; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2008 |
Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?
Topics: Adult; Alanine Transaminase; Antiviral Agents; Blood Cell Count; Cohort Studies; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2008 |
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Viral Load | 2008 |
Artificially low HbA1c associated with treatment with ribavirin.
Topics: Antiviral Agents; Diabetes Mellitus; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Ribavirin | 2008 |
Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin E | 2008 |
Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
Topics: Antiviral Agents; Depressive Disorder; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Interferons; Liver Function Tests; Male; Ribavirin; Risk Assessment; Severity of Illness Index | 2008 |
[Diabetes mellitus during interferon therapy].
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
[Bacterial endocarditis in the course of sepsis in 7th month of treatment with peginterferon alfa and ribavirin in patient with chronic hepatitis C].
Topics: Antiviral Agents; Endocarditis, Bacterial; Escherichia coli; Escherichia coli Infections; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sepsis; Time Factors; Treatment Outcome | 2007 |
Tongue hyperpigmentation resulting from peginterferon alpha-2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.
Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pigmentation Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue; White People | 2008 |
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load | 2008 |
Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Ribavirin; RNA-Dependent RNA Polymerase; Selection, Genetic; Viral Nonstructural Proteins | 2008 |
[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2008 |
[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
[Acute pancreatitis during treatment for chronic viral hepatitis C].
Topics: Acute Disease; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-2; Kinetics; Male; Middle Aged; Models, Biological; Models, Theoretical; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load | 2008 |
Chronic genotype 4 hepatitis C.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2008 |
Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Treatment of chronic hepatitis C in haemodialysis patients requires more ribavirin.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome | 2008 |
Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome | 2008 |
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.
Topics: Adolescent; Adult; Aged; Area Under Curve; Black or African American; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Viral Load; White People | 2008 |
[Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome; Viral Load | 2007 |
Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.
Topics: Alleles; Antiviral Agents; Black or African American; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load; White People | 2008 |
Adverse skin reactions associated with hepatitis C treatment: comment.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2008 |
Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
Topics: Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
ADVANCE study begins enrollment.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
[Peginterferon alpha-2a and ribavirin for treating chronic hepatitis C patients with persistent normal aminotransferase levels].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Young Adult | 2008 |
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.
Topics: Adult; Antiviral Agents; Blood Glucose; Drug Administration Schedule; Fasting; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Homeostasis; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy.
Topics: Adult; Antiviral Agents; Case-Control Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Statistics, Nonparametric; Viral Load | 2008 |
Response-guided therapy: optimizing treatment now and in the future.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2008 |
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues.
Topics: Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2008 |
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Area Under Curve; Body Mass Index; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Middle Aged; Prothrombin Time; Ribavirin; RNA, Viral; Viral Load | 2008 |
Chronic hepatitis C genotype 2 or 3 short treatment.
Topics: Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
[Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience].
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2008 |
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation, Missense; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
Topics: Antiviral Agents; Biomarkers; Blotting, Western; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; ROC Curve | 2008 |
Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biopsy, Needle; Female; Forecasting; Genotype; Greece; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; California; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Epitopes; Female; Granzymes; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Perforin; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Nonstructural Proteins | 2008 |
Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
[Treatment of hepatitis C: therapeutic management].
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin | 2008 |
Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; CD4 Lymphocyte Count; Cyclosporine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tacrolimus; Treatment Outcome; Viral Load | 2008 |
Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia | 2008 |
Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; Time Factors | 1998 |
Ribavirin and immune thrombocytopenic purpura.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Purpura, Thrombocytopenic, Idiopathic; Ribavirin | 1998 |
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 1998 |
Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Viral Load | 1998 |
From the Food and Drug Administration.
Topics: Allergens; Antiviral Agents; Cisapride; Contraindications; Desensitization, Immunologic; Drug Labeling; Drug Therapy, Combination; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mammography; Piperidines; Poaceae; Pollen; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cytokines; Drug Interactions; Enzyme Activation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 1998 |
Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Combined Modality Therapy; Drug Resistance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1998 |
Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Evaluation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 1998 |
[Indications for combination interferon-ribavirin therapy in chronic hepatitis C].
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin; Treatment Outcome | 1998 |
Combination therapy for hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Viral Load | 1998 |
Combination therapy of chronic hepatitis C: an important step but not the final goal!
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome | 1998 |
Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 1998 |
Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Flaviviridae; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 1998 |
Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Viral Load | 1998 |
Amantadine in the treatment of patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral | 1998 |
Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.
Topics: Antiviral Agents; Carcinogens; Cells, Cultured; Cytokines; Cytotoxicity, Immunologic; Enterotoxins; Hepatitis C, Chronic; Humans; Lymphocyte Activation; Ribavirin; T-Lymphocytes; Tetradecanoylphorbol Acetate | 1999 |
Making end points meet.
Topics: Biomarkers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Survival Rate; Transaminases; Treatment Outcome; Viral Load | 1999 |
Combination therapy for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 1999 |
Photoallergic skin reaction to ribavirin.
Topics: Aged; Antiviral Agents; Dermatitis, Photoallergic; Female; Hepatitis C, Chronic; Humans; Ribavirin; Skin; Ultraviolet Rays | 1999 |
Interferon plus ribavirin for chronic hepatitis C.
Topics: Administration, Oral; Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1999 |
Hemolytic anemia and the treatment of chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 1999 |
Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 1999 |
Enhancing the response to interferon-alpha.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Biological; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi | 1999 |
Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Combined Modality Therapy; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Viral Nonstructural Proteins | 1999 |
[Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1999 |
The scientific challenge of hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patents as Topic; Recombinant Proteins; Replicon; Ribavirin; Viral Hepatitis Vaccines; Virus Cultivation | 1999 |
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins | 1999 |
Oral thymic extract to treat hepatitis C.
Topics: Antiviral Agents; Complementary Therapies; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Thymus Extracts | 1999 |
Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence.
Topics: Adult; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Treatment Outcome; Viral Nonstructural Proteins | 1999 |
Interferon plus ribavirin: a cautionary note.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Myocardial Infarction; Ribavirin | 1999 |
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Statistical; Probability; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Time Factors; United States | 1999 |
[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].
Topics: Adult; Antiviral Agents; Child; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 1999 |
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome | 2000 |
Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C: a preliminary report.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 1999 |
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Antiviral Agents; Common Variable Immunodeficiency; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin | 1999 |
Hepatitis C therapy in treatment-naïve patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral | 1999 |
Management of interferon relapsers.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin; RNA, Viral; Viral Load | 1999 |
Available options for treatment of interferon nonresponders.
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Phlebotomy; Ribavirin; Treatment Failure | 1999 |
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin | 1999 |
Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Binding Sites; Drug Therapy, Combination; eIF-2 Kinase; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Protein Structure, Secondary; Protein Structure, Tertiary; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Nonstructural Proteins | 2000 |
Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 1998 |
Doing battle with HCV.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; United States; Veterans | 2000 |
[Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; National Health Programs; Ribavirin | 2000 |
Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2000 |
[Horton's disease in the course of chronic hepatitis C].
Topics: Adrenal Cortex Hormones; Antiviral Agents; Arterial Occlusive Diseases; Drug Therapy, Combination; Female; Giant Cell Arteritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Radiography; Ribavirin; Temporal Arteries | 2000 |
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Anion Exchange Protein 1, Erythrocyte; Antiviral Agents; Carrier Proteins; Complement C3; Erythrocyte Membrane; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferons; K Cl- Cotransporters; Male; Middle Aged; Oxidative Stress; Reticulocyte Count; Ribavirin; Sodium-Potassium-Exchanging ATPase; Symporters | 2000 |
Severe strongyloidiasis during interferon plus ribavirin therapy for chronic HCV infection.
Topics: Adult; Animals; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Middle Aged; Ribavirin; Severity of Illness Index; Strongyloides stercoralis; Strongyloidiasis | 2000 |
Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2000 |
Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2000 |
[Hepatitis C. Saving the liver].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 1999 |
Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Psoriasis; Recurrence; Ribavirin | 2000 |
Decisions, decisions, decisions.
Topics: Antiviral Agents; Gastroenterology; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2000 |
Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon.
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prednisone; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2000 |
Needle-stick exposure in the health care setting: do not forget hepatitis C!
Topics: Acute Disease; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Health Personnel; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Needlestick Injuries; Netherlands; Primary Prevention; Ribavirin; Time Factors | 2000 |
[Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 1999 |
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Time Factors | 2000 |
[Treatment and prevention of hepatitis C].
Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin | 2000 |
Clinical utility of early viral load quantification.
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral | 2000 |
The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Recombinant Proteins; Ribavirin | 2000 |
Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2000 |
Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Thyroiditis, Subacute | 2000 |
Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2000 |
Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy.
Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Transaminases | 2000 |
Combination treatment for hepatitis C is not being given.
Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; United Kingdom | 2000 |
Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Topics: Adult; Anemia; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymerase Chain Reaction; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2000 |
Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.
Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Sweden; Viral Load | 2000 |
[Chronic viral hepatitis: guidelines for diagnosis and therapy. When to treat--when wait?].
Topics: Drug Monitoring; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin | 2000 |
Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients.
Topics: Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2000 |
Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Psychiatric Status Rating Scales; Psychotic Disorders; Recombinant Proteins; Ribavirin | 2000 |
Re: Khalili et al.--chronic Hepatitis C treatment in interferon nonresponders.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2000 |
Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.
Topics: Bone Density; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osteoporosis; Ribavirin | 2000 |
[Hepatitis C in Egypt, a iatrogenic epidemic].
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Glycyrrhetinic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Plant Extracts; Recombinant Proteins; Ribavirin | 2000 |
The response to interferon + ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race.
Topics: Adult; Antiviral Agents; Black People; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Retreatment; Ribavirin; White People | 2000 |
Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral | 2001 |
Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Outcome Assessment, Health Care; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C.
Topics: Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-2; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Time Factors | 2000 |
Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Viral Load | 2001 |
Nonresponse to interferon in chronic hepatitis C: re-treatment redux.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Viral Load | 2001 |
[Efficacy and safety of combination therapy with interferon-alpha and ribavirin in patients with chronic hepatitis C coinfected with human immunodeficiency virus].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2000 |
[Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection].
Topics: Adult; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Ribavirin; Risk Factors; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2000 |
Treating chronic Hepatitis C patients with psychiatric disorders: an uphill battle.
Topics: Clinical Trials as Topic; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Prognosis; Ribavirin; Risk Assessment | 2001 |
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Safety | 2001 |
[When standard therapy fails. New therapy options in chronic hepatitis C].
Topics: Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure | 2001 |
Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.
Topics: Alleles; Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genetic Variation; Haplotypes; Hepatitis C, Chronic; Heterozygote; Homozygote; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin | 2001 |
Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
Topics: Antiviral Agents; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2001 |
Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
Topics: Adult; Antiviral Agents; Celiac Disease; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2001 |
Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viremia | 2001 |
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; B-Lymphocytes; Cell Division; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Drug Therapy, Combination; Female; Gene Rearrangement; Genes, bcl-2; Hepatitis C, Chronic; Humans; Immunoglobulin Heavy Chains; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Ribavirin; Translocation, Genetic | 2001 |
Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral | 2001 |
Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome | 2001 |
Managing chronic hepatitis C acquired through intravenous drug use.
Topics: Adolescent; Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome | 2001 |
[Ribavirin in combination with interferon alpha-2b in the treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2001 |
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
Topics: Amino Acid Sequence; Antiviral Agents; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins; Viral Proteins; Viral Structural Proteins | 2001 |
Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha.
Topics: Adult; Antibodies; Antiviral Agents; Autoimmunity; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Risk | 2001 |
Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.
Topics: Adjuvants, Immunologic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Lymphocyte Activation; Male; Middle Aged; Ribavirin; Viral Load | 2001 |
Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Calculi; Male; Recombinant Proteins; Ribavirin; Uric Acid | 2001 |
Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Ribavirin approved for hepatitis C combination treatment.
Topics: Antiviral Agents; Drug Approval; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 1998 |
Hepatitis C virus and HIV co-infection: a sleeping giant wakes.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 1999 |
Interferon alfa down-regulates CD81 in patients with chronic hepatitis C.
Topics: Antigens, CD; Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Lymphocytes; Membrane Proteins; Ribavirin; RNA, Messenger; Tetraspanin 28 | 2001 |
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Biomarkers; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Ribavirin; RNA, Viral; Tumor Necrosis Factor-alpha; Viral Load | 2001 |
Treatment of chronic hepatitis C in hereditary spherocytosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Spherocytosis, Hereditary | 2001 |
Pegylated interferon (PEG-Intron) for chronic hepatitis C.
Topics: Antimetabolites; Antiviral Agents; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tablets | 2001 |
Effective antiviral treatment for hepatitis C virus-related chronic active hepatitis in haemophiliac patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2001 |
[Management of chronic hepatitis C infection in patients infected with the human immunodeficiency virus: from what we know to what we ignore].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin | 2001 |
Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lupus Coagulation Inhibitor; Middle Aged; Partial Thromboplastin Time; Recombinant Proteins; Ribavirin | 2001 |
Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Renal Dialysis; Ribavirin; RNA, Viral | 2001 |
Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome.
Topics: Adult; Female; Fertilization; Fetus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin | 2001 |
No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.
Topics: Adult; Antimetabolites; Female; Fertilization; Fetus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mutagenesis; Paternal Exposure; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin | 2001 |
Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pilot Projects; Recombinant Proteins; Renal Dialysis; Ribavirin | 2001 |
Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Prospective Studies; Ribavirin; Time Factors; Treatment Failure | 2001 |
Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sweden | 2001 |
Patterns of response during therapy with interferon and outcome of retreatment with interferon plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retreatment; Ribavirin | 2001 |
Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy.
Topics: Adult; Alanine Transaminase; Antipyrine; Antiviral Agents; Chi-Square Distribution; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; Triglycerides | 2001 |
Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Retrospective Studies; Ribavirin; Time Factors | 2001 |
Erythema dyschromicum perstans and hepatitis C virus infection.
Topics: Antiviral Agents; Erythema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pigmentation Disorders; Recombinant Proteins; Ribavirin | 2001 |
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Remission, Spontaneous; Retinal Diseases; Retinal Hemorrhage; Ribavirin; Treatment Outcome | 2001 |
Costs of hepatitis C.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Costs and Cost Analysis; Cross-Sectional Studies; Female; Health Expenditures; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Survival Rate; United States | 2001 |
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.
Topics: Adult; Aged; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Prospective Studies; Ribavirin; Viral Load | 2001 |
Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Lung Diseases, Interstitial; Male; Middle Aged; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2001 |
Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Emotions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interpersonal Relations; Male; Middle Aged; Patient Compliance; Personality; Psychometrics; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2001 |
Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Myasthenia Gravis; Ribavirin | 2001 |
Treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2001 |
High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Time Factors | 2001 |
Influence of three successive antiviral treatments on viral heterogeneity in nonresponder chronic hepatitis C patients.
Topics: Amino Acid Sequence; Antiviral Agents; Cloning, Molecular; Drug Therapy, Combination; Female; Genes, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Proteins | 2001 |
SEN and sensibility: interactions between newly discovered and other hepatitis viruses?
Topics: Antiviral Agents; DNA Virus Infections; DNA Viruses; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Recombinant Proteins; Ribavirin; Treatment Outcome | 2001 |
Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; DNA Primers; DNA Virus Infections; DNA Viruses; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome | 2001 |
Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; Female; Health Resources; Health Status; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sensitivity and Specificity | 2002 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Consensus Development Conferences as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Psychotic Disorders; Ribavirin | 2001 |
[Sarcoidosis during the treatment of hepatitis C by interferon-alpha and ribavirin: 2 cases].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases; Male; Middle Aged; Ribavirin; Sarcoidosis; Time Factors | 2001 |
Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viremia | 2001 |
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Topics: Antiviral Agents; Body Weight; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2001 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin | 2001 |
Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferons; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Ribavirin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2002 |
Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2002 |
[Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C].
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viremia | 2001 |
Prevalence of hepatitis C genotypes in Indian patients and their clinical significance.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Chi-Square Distribution; Child; Data Interpretation, Statistical; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; India; Interferons; Male; Middle Aged; Prevalence; Ribavirin; Sex Factors | 2001 |
[Serious side-effects of interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Jaundice; Male; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin | 2002 |
24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prospective Studies; Ribavirin; Risk Assessment; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load | 2002 |
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2002 |
Risk of HAART therapy in hepatitis C.
Topics: Antiretroviral Therapy, Highly Active; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk | 2002 |
Management of chronic hepatitis C--time for a change?
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.
Topics: Adult; Antiviral Agents; Biomarkers; Complement Activation; Complement C4; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.
Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sarcoidosis | 2002 |
[Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin | 2002 |
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Lymphotoxin-alpha; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Ribavirin; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2002 |
[Hepatitis C treatment without liver biopsy].
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral | 2002 |
Management of chronic hepatitis C.
Topics: Algorithms; Antiviral Agents; Disease Management; Hepatitis C, Chronic; Humans; Interferon-alpha; National Institutes of Health (U.S.); Practice Guidelines as Topic; Ribavirin; United States | 2001 |
Liver biopsy in hepatitis C: reassessing its role in 2001.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2002 |
Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2002 |
[Living donor liver transplantation in a patient with HIV].
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hemophilia B; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Ribavirin; Treatment Outcome | 2002 |
Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Logistic Models; Male; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2002 |
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Recombinant Proteins; Ribavirin | 2002 |
Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load | 2002 |
Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Safety | 2002 |
Approach to the patient with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Biopsy; Complementary Therapies; Contraindications; Diet; Disease Transmission, Infectious; Female; Health Behavior; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Insurance, Life; Interferons; Middle Aged; Prognosis; Ribavirin; Risk Factors; Spouses | 2002 |
The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Case-Control Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk; Thyroid Gland; Thyroid Hormones | 2002 |
SEN viruses and treatment response in chronic hepatitis C virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Respirovirus Infections; Ribavirin; Sendai virus | 2002 |
SEN viruses and treatment response in chronic hepatitis C virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Respirovirus Infections; Ribavirin; Sendai virus; Treatment Outcome | 2002 |
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Codon; Drug Resistance, Viral; Drug Therapy, Combination; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phosphorylation; Ribavirin; RNA, Viral; Sequence Homology, Amino Acid; Treatment Outcome; Viral Envelope Proteins | 2002 |
Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay.
Topics: Adult; Aged; Antiviral Agents; Drug Combinations; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2002 |
[Treatment of chronic hepatitis C].
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2002 |
High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Lack of evidence for ribavirin-induced bone loss.
Topics: Bone Density; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Osteoporosis; Ribavirin | 2002 |
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; HLA Antigens; Humans; Interferons; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Ribavirin | 2002 |
Production of interleukins 10 and 12 by activated peripheral blood monocytes/macrophages in patients suffering from chronic hepatitis C virus infection with respect to the response to interferon and ribavirin treatment.
Topics: Adult; Antiviral Agents; B7-1 Antigen; Carrier State; Drug Therapy, Combination; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukin-12; Macrophages; Male; Monocytes; Ribavirin | 2002 |
[Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Genotype; Hemochromatosis Protein; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Iron; Liver; Male; Membrane Proteins; Middle Aged; Mutation; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2002 |